FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Huang, YF
   Tok, TS
   Lu, CL
   Ko, HC
   Chen, MY
   Chen, SCC
AF Huang, Ya-Fang
   Tok, Teck-Siang
   Lu, Chin-Li
   Ko, Hsing-Ching
   Chen, Min-Yu
   Chen, Solomon Chih-Cheng
TI Relationship Between being Overweight and Iron Deficiency in Adolescents
SO PEDIATRICS AND NEONATOLOGY
LA English
DT Article
DE body mass index; ferritin; obese; serum iron
ID SERUM FERRITIN CONCENTRATIONS; OBESE CHILDREN; UNITED-STATES;
   PREVALENCE; ANEMIA; INFLAMMATION; AREA; SCHOOLGIRLS; WOMEN; GIRLS
AB Objective: Being overweight has been considered to be a risk factor of iron deficiency (ID). The objective of this study was to examine the relationship between being overweight and body iron status among Taiwanese adolescents.
   Methods: A total of 2099 adolescents (1327 female) aged 12-19 years from four middle schools and one college in southern Taiwan participated in this study. Data on sex, age, body weight, height, hemoglobin concentration, plasma ferritin (PF), and serum iron (SI) levels were collected. According to the age- and sex-specific body mass index (BMI) percentiles, the participants were divided into four weight groups: underweight (< 5th percentile), normal weight (5-84th percentile), overweight (85-94th percentile), and obese (>= 95th percentile). A multivariate logistic regression model was used to estimate the odds ratio (OR) and the 95% confidence interval (CI) for each factor.
   Results: The correlation coefficients of linear regression were positive for BMI hemoglobin and BMI PF, but negative for BMI SI. Compared with the normal-weight group, the obese group had a lower risk of PF level < 15 mu g/L with an OR (95% CI) of 0.51 (0.30-0.87) but a higher risk of SI < 60 mu g/dL with an OR (95% CI) of 1.78 (1.34-2.37). The percentages of low PF declined as BMI increased, but the percentages of low SI rose, from underweight to obesity groups.
   Conclusion: The relationship between being overweight and depleted iron store depends on which indicator is used to define the iron deficiency. Being overweight or obese would not be a risk factor of ID in adolescents, if ID were defined by PF rather than SI level. Copyright (C) 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
C1 [Huang, Ya-Fang] Pingtung Christian Hosp, Dept Clin Lab, Pingtung, Taiwan.
   [Tok, Teck-Siang] Pingtung Christian Hosp, Dept Pediat, Pingtung, Taiwan.
   [Lu, Chin-Li] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan.
   [Ko, Hsing-Ching; Chen, Min-Yu; Chen, Solomon Chih-Cheng] Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pediat, Chiayi 60002, Taiwan.
   [Chen, Solomon Chih-Cheng] Taipei Med Univ, Sch Med, Taipei, Taiwan.
RP Chen, MY (reprint author), Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pediat, 539 Zhongxiao Rd, Chiayi 60002, Taiwan.
EM cych00026@gmail.com; solomon.ccc@gmail.com
CR Lewis DK, 2007, T ROY SOC TROP MED H, V101, P613, DOI 10.1016/j.trstmh.2006.11.004
   Chouliaras GL, 2009, BLOOD CELL MOL DIS, V43, P163, DOI 10.1016/j.bcmd.2009.03.007
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Eicher-Miller HA, 2009, AM J CLIN NUTR, V90, P1358, DOI 10.3945/ajcn.2009.27886
   Akramipour R, 2008, HEMATOLOGY, V13, P352, DOI 10.1179/102453308X343383
   Vaucher P, 2012, CAN MED ASSOC J, V184, P1247, DOI 10.1503/cmaj.110950
   Gartner A, 2013, AM J CLIN NUTR, V98, P821, DOI 10.3945/ajcn.112.054551
   Halterman JS, 2001, PEDIATRICS, V107, P1381, DOI 10.1542/peds.107.6.1381
   Lin JD, 2010, RES DEV DISABIL, V31, P25, DOI 10.1016/j.ridd.2009.07.017
   Yang YJ, 2005, HELICOBACTER, V10, P249, DOI 10.1111/j.1523-5378.2005.00317.x
   Leenstra T, 2004, EUR J CLIN NUTR, V58, P681, DOI 10.1038/sj.ejcn.1601865
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Kurniawan YAI, 2006, ASIA PAC J CLIN NUTR, V15, P350
   Phiri KS, 2009, J CLIN PATHOL, V62, P1103, DOI 10.1136/jcp.2009.066498
   Shaw NS, 1996, J FORMOS MED ASSOC, V95, P692
   Sun AD, 2012, J ORAL PATHOL MED, V41, P500, DOI 10.1111/j.1600-0714.2011.01122.x
   Milman N, 2011, ANN HEMATOL, V90, P369, DOI 10.1007/s00277-010-1144-5
   McCann JC, 2007, AM J CLIN NUTR, V85, P931
   Ren Y, 2014, METALLOMICS, V6, P1709, DOI 10.1039/c4mt00127c
   Ramzi M, 2011, IRAN RED CRESCENT ME, V13, P128
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Beard JL, 2006, AM J CLIN NUTR, V84, P1498
   Ong KH, 2005, ANN ACAD MED SINGAP, V34, P437
   Haas JD, 2001, J NUTR, V131, p676S
   Brownlie T., 2001, J NUTR, V131, p688S
   Grantham-McGregor S, 2001, J NUTR, V131, p666S, DOI DOI 10.1053/J.SEMINHEMATOL.2009.06.002
   Grantham-McGregor S, 2001, J NUTR, V131, p649S
   Hsieh Pei-Lin, 2005, Nurs Health Sci, V7, P134, DOI 10.1111/j.1442-2018.2005.00218.x
   Kahlon Namrata, 2011, Indian J Physiol Pharmacol, V55, P53
   Patidar Shailendra, 2013, J Clin Neonatol, V2, P121, DOI 10.4103/2249-4847.119995
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   Uen WC, 2005, J INTERN MED, V16, P269
   WHO, 2011, SER FERR CONC ASS IR
   WHO/UNICEF/UNU, 2001, IR DEF AN ASS PREV C
   Zaribaf Fatemeh, 2014, J Educ Health Promot, V3, P15, DOI 10.4103/2277-9531.127586
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1875-9572
J9 PEDIATR NEONATOL
JI Pediatr. Neonatol.
PD DEC
PY 2015
VL 56
IS 6
BP 386
EP 392
DI 10.1016/j.pedneo.2015.02.003
PG 7
WC Pediatrics
SC Pediatrics
GA DA5QZ
UT WOS:000367858900006
PM 25987352
ER

PT J
AU Chen, Y
   Yin, HQ
   Liu, HL
   Xiu, L
   Peng, XY
AF Chen, Yue
   Yin, Hui-qing
   Liu, Hao-ling
   Xiu, Lei
   Peng, Xiao-yu
TI Hepcidin and iron metabolism in non-diabetic obese and type 2 diabetic
   rats
SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL
   SCIENCES
LA English
DT Article
DE non-diabetic obesity; type 2 diabetes; hepcidin; iron metabolism
ID INSULIN-RESISTANCE; INFLAMMATION; LIVER; RISK; HYPOFERREMIA; DEFICIENCY;
   FERRITIN; HYPOXIA; STORES; WOMEN
AB The aim of this study was to investigate the changes of iron levels and hepatic regulatory molecules expression involved in iron metabolism in non-diabetic obese/type 2 diabetic rat models. Male Wistar rats were divided into 3 groups: control group, non-diabetic obese group and type 2 diabetic group (n=20 each). The rats were evaluated physiologically and biochemically. The hepatic histopathological changes were observed using haematoxylin and eosin (HE) staining. The mRNA expression patterns of hepcidin, interleukin-6 (IL-6), hypoxia-inducible factor (HIF) and ferroportin (Fpn) in the rat liver in control group, non-diabetic obese group and type 2 diabetic group were analyzed by real-time RT-PCR. The protein expression patterns of hepcidin in liver of each group were further analyzed by immunohistochemistry and Western blotting. As compared with control group, the ferritin in non-diabetic obese group and type 2 diabetic group was increased significantly (P < 0.001). However, there was no significant difference in soluble transferring receptor (sTfR):ferritin ratio among the three groups (P > 0.05). The real-time RT-PCR, immunohistochemistry and Western blotting results all revealed that the expression levels of hepcidin in non-diabetic obese group and type 2 diabetic group were elevated significantly as compared with those in control group (P < 0.001). The expression levels of hepcidin mRNA between non-diabetic obese group and type 2 diabetic group showed no significant difference (P > 0.05). However, the protein expression levels of hepcidin in type 2 diabetic group were significantly higher than those in non-diabetic obese group (P < 0.05). Compared to control group, the expression levels of IL-6 mRNA in non-diabetic obese group and type 2 diabetic group were increased significantly and the expression levels of Fpn mRNA decreased (P < 0.05). However, the expression levels of HIF mRNA had no significant difference among three groups. It is suggested that iron metabolism is substantially disturbed in non-diabetic obese and type 2 diabetic rats probably by the abnormal expression of hepcidin in chronic inflammatory status. The increased hepcidin may restrain the iron release from the cells by affecting the expression of Fpn, which probably associates with the development of diabetic complication.
C1 [Chen, Yue; Yin, Hui-qing; Liu, Hao-ling; Xiu, Lei; Peng, Xiao-yu] Harbin Med Univ, Affiliated Hosp 1, Dept Endocrinol, Harbin 150001, Peoples R China.
RP Yin, HQ (reprint author), Harbin Med Univ, Affiliated Hosp 1, Dept Endocrinol, Harbin 150001, Peoples R China.
EM 439518016@qq.com; yinhuiqing2003@gmail.com
CR Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Lukic L, 2014, INT J ENV RES PUB HE, V11, P3586, DOI 10.3390/ijerph110403586
   Gao W, 2014, DIABETES VASC DIS RE, V11, P270, DOI 10.1177/1479164114533356
   Jalali MT, 2012, EUR REV MED PHARMACO, V16, P1441
   Prince OD, 2012, HAEMATOL-HEMATOL J, V97, P1648, DOI [10.3324/haematol.2011.053397, 10.3324/haematol.2012.053397]
   DIEHL AM, 1988, GASTROENTEROLOGY, V95, P1056
   Xiao HJ, 2013, INT J MED SCI, V10, P1412, DOI 10.7150/ijms.5630
   Ganz T, 2006, AM J PHYSIOL-GASTR L, V290, pG199, DOI 10.1152/ajpgi.00412.2005.
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Jehn ML, 2007, AM J EPIDEMIOL, V165, P1047, DOI 10.1093/aje/kwk093
   Kalantar-Zadeh K, 2005, J AM SOC NEPHROL, V16, P3070, DOI 10.1681/ASN.2005040423
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Donovan A, 2000, NATURE, V403, P776
   Nath B, 2012, HEPATOLOGY, V55, P622, DOI 10.1002/hep.25497
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Bao W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-119
   Dulal H P, 2014, Nepal Med Coll J, V16, P54
   Ivan DD, 2007, MOL BIOL CELL, V18, P2569
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511
   Rishi G, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150014
   Wang XH, 2015, REV ENDOCR METAB DIS, V16, P15, DOI 10.1007/s11154-014-9303-y
   [冼苏 XIAN Su], 2006, [基础医学与临床, Basic Medical Sciences and Clinics], V26, P621
NR 28
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672-0733
EI 1993-1352
J9 J HUAZHONG U SCI-MED
JI J. Huazhong Univ. Sci. Tech.-Med.
PD DEC
PY 2015
VL 35
IS 6
BP 851
EP 857
DI 10.1007/s11596-015-1517-z
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CY8DT
UT WOS:000366639700010
ER

PT J
AU Cepeda-Lopez, AC
   Melse-Boonstra, A
   Zimmermann, MB
   Herter-Aeberli, I
AF Cepeda-Lopez, Ana C.
   Melse-Boonstra, Alida
   Zimmermann, Michael B.
   Herter-Aeberli, Isabelle
TI In overweight and obese women, dietary iron absorption is reduced and
   the enhancement of iron absorption by ascorbic acid is one-half that in
   normal-weight women
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE inflammation; iron absorption; obesity; overweight; stable isotopes
ID CO-REBREATHING METHOD; REGULATORY HORMONE HEPCIDIN; TOTAL HEMOGLOBIN
   MASS; SERUM HEPCIDIN; STABLE-ISOTOPE; ADIPOSE-TISSUE; UNITED-STATES;
   DEFICIENCY; CHILDREN; ADOLESCENTS
AB Background: Iron deficiency is common in overweight and obese individuals. This deficiency may be due to adiposity-related inflammation that increases serum hepcidin and decreases dietary iron absorption. Because hepcidin reduces iron efflux from the basolateral enterocyte, it is uncertain whether luminal enhancers of dietary iron absorption such as ascorbic acid can be effective in overweight and obese individuals.
   Objective: In this study, we compared iron absorption from a meal with ascorbic acid (+AA) and a meal without ascorbic acid (-AA) in women in a normal-weight group (NW) with those in overweight and obese groups combined (OW/OB).
   Design: Healthy, nonanemic women [n = 62; BMI (in kg/m(2)): 18.5-39.9] consumed a stable-isotope-labeled wheat-based test meal -AA and a wheat-based test meal +AA (31.4 mg ascorbic acid). We measured iron absorption and body composition with the use of dual-energy X-ray absorptiometry, blood volume with the use of a carbon monoxide (CO)-rebreathing method, iron status, inflammation, and serum hepcidin.
   Results: Inflammatory biomarkers (all P < 0.05) and hepcidin (P = 0.08) were lower in the NW than in the OW/OB. Geometric mean (95% CI) iron absorptions in the NW and OW/OB were 19.0% (15.2%, 23.5%) and 12.9% (9.7%, 16.9%) (P = 0.049), respectively, from -AA meals and 29.5% (23.3%, 38.2%) and 16.6% (12.8%, 21.7%) (P = 0.004), respectively, from +AA meals. Median percentage increases in iron absorption for -AA to +AA meals were 56% in the NW (P < 0.001) and 28% in OW/OB (P = 0.006). Serum ferritin [R-2 = 0.22; beta = -0.17 (95% CI: -0.25, -0.09)], transferrin receptor [R-2 = 0.23; beta = 2.79 (95% CI: 1.47, 4.11)], and hepcidin [R-2 = 0.13; b = -0.85 (95% CI: -1.41, -0.28)] were significant predictors of iron absorption.
   Conclusions: In overweight and obese women, iron absorption is two-thirds that in normal-weight women, and the enhancing effect of ascorbic acid on iron absorption is one-half of that in normal-weight women. Recommending higher intakes of ascorbic acid (or other luminal enhancers of iron absorption) in obese individuals to improve iron status may have a limited effect.
C1 [Cepeda-Lopez, Ana C.; Melse-Boonstra, Alida] Wageningen Univ, Div Human Nutr, NL-6700 AP Wageningen, Netherlands.
   [Cepeda-Lopez, Ana C.] Univ Monterrey UDEM, Div Ciencias Salud, Monterrey, Mexico.
   [Zimmermann, Michael B.; Herter-Aeberli, Isabelle] Swiss Fed Inst Technol Zurich, Inst Food Nutr & Hlth, Human Nutr Lab, Zurich, Switzerland.
RP Cepeda-Lopez, AC (reprint author), Wageningen Univ, Div Human Nutr, NL-6700 AP Wageningen, Netherlands.
EM ana.cepeda@udem.edu
FU Swiss Foundation for Nutrition Research; Swiss Federal Institute of
   Technology Zurich; Unilever
FX Supported by the Swiss Foundation for Nutrition Research and the Swiss
   Federal Institute of Technology Zurich. AC-CL was supported by a grant
   provided by Unilever to the Wageningen University program Micronutrients
   and International Health.
CR Hamza RT, 2013, HORM RES PAEDIAT, V80, P11, DOI 10.1159/000351941
   Thankachan P, 2008, AM J CLIN NUTR, V87, P881
   WALMSLEY TA, 1992, J CLIN PATHOL, V45, P151, DOI 10.1136/jcp.45.2.151
   HOSAIN F, 1967, J CLIN INVEST, V46, P1, DOI 10.1172/JCI105501
   Cercamondi CI, 2010, AM J CLIN NUTR, V92, P1385, DOI 10.3945/ajcn.2010.30051
   CONRAD ME, 1968, GASTROENTEROLOGY, V55, P35
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Durussel J, 2013, EUR J SPORT SCI, V13, P68, DOI 10.1080/17461391.2011.606843
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Chung B, 2007, J NUTR, V137, P2366
   Gore CJ, 2006, MED SCI SPORT EXER, V38, P1187, DOI 10.1249/01.mss.0000222848.35004.41
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Moschonis G, 2012, BRIT J NUTR, V108, P710, DOI 10.1017/S0007114511005952
   Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Steiner T, 2011, MED SCI SPORT EXER, V43, P1735, DOI 10.1249/MSS.0b013e3182118760
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Chambers EC, 2006, J AM DIET ASSOC, V106, P680, DOI 10.1016/j.jada.2006.02.013
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Prommer N, 2007, EUR J APPL PHYSIOL, V100, P383, DOI 10.1007/s00421-007-0439-2
   Roe MA, 2005, AM J CLIN NUTR, V81, P814
   Baumgartner J, 2013, INT J OBESITY, V37, P24, DOI 10.1038/ijo.2012.145
   Demircioglu F, 2014, EUR J PEDIATR, V173, P947, DOI 10.1007/s00431-014-2268-8
   Mujica-Coopman MF, 2015, J TRACE ELEM MED BIO, V30, P215, DOI 10.1016/j.jtemb.2014.03.008
   Luciani N, 2011, OBESITY, V19, P1545, DOI 10.1038/oby.2011.12
   COOK JD, 1977, AM J CLIN NUTR, V30, P235
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Walczyk T, 1997, FRESEN J ANAL CHEM, V359, P445, DOI 10.1007/s002160050608
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   WENZEL BJ, 1962, LANCET, V2, P327
   Teucher B, 2004, INT J VITAM NUTR RES, V74, P403, DOI 10.1024/0300-9831.74.6.403
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Schmidt W, 2005, EUR J APPL PHYSIOL, V95, P486, DOI 10.1007/s00421-005-0050-3
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   MONSEN ER, 1988, J AM DIET ASSOC, V88, P786
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   BALLOT D, 1987, BRIT J NUTR, V57, P331, DOI 10.1079/BJN19870041
   Whitfield JB, 2003, BRIT J HAEMATOL, V120, P860, DOI 10.1046/j.1365-2141.2003.04224.x
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Huang H, 2009, BLOOD, V113, P3593, DOI 10.1182/blood-2008-08-173641
   BJORNRAS.E, 1974, NUTR METAB, V16, P94
   Cook J, 1980, IRON
   Gibson RS, 2005, PRINCIPLES NUTRIONAL
   HALLBERG L, 1989, AM J CLIN NUTR, V49, P140
   Hurrell R., 2010, AM J CLIN NUTR, V91, P1461, DOI DOI 10.3945/AJCN.2010.28674F
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   Tussing-Humphreys L, 2011, THESCIENTIFICWORLDJO, V11, P2197, DOI 10.1100/2011/634861
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   WHO, 2004, ASS IR STAT POP INCL
NR 59
TC 0
Z9 0
U1 3
U2 3
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC
PY 2015
VL 102
IS 6
BP 1389
EP 1397
DI 10.3945/ajcn.114.099218
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CX5BY
UT WOS:000365717300013
PM 26561622
ER

PT J
AU Zhao, L
   Zhang, X
   Shen, Y
   Fang, X
   Wang, Y
   Wang, F
AF Zhao, L.
   Zhang, X.
   Shen, Y.
   Fang, X.
   Wang, Y.
   Wang, F.
TI Obesity and iron deficiency: a quantitative meta-analysis
SO OBESITY REVIEWS
LA English
DT Review
DE Anaemia; hypoferraemia; iron deficiency; obesity
ID SERUM TRANSFERRIN RECEPTOR; BODY-MASS INDEX; INSULIN-RESISTANCE; CHRONIC
   DISEASE; OVERWEIGHT CHILDREN; REPRODUCTIVE AGE; TRACE-ELEMENTS; HEALTHY
   GROWTH; ADOLESCENTS; WOMEN
AB Hypoferraemia (i.e. iron deficiency) was initially reported among obese individuals several decades ago; however, whether obesity and iron deficiency are correlated remains unclear. Here, we evaluated the putative association between obesity and iron deficiency by assessing the concentration of haematological iron markers and the risks associated with iron deficiency in both obese (including overweight) subjects and non-overweight participants. We performed a systematic search in the databases PubMed and Embase for relevant research articles published through December 2014. A total of 26 cross-sectional and case-control studies were analysed, comprising 13,393 overweight/obese individuals and 26,621 non-overweight participants. Weighted or standardized mean differences of blood iron markers and odds ratio (OR) of iron deficiency were compared between the overweight/obese participants and the non-overweight participants using a random-effects model. Compared with the non-overweight participants, the overweight/obese participants had lower serum iron concentrations (weighted mean difference [WMD]: -8.37gdL(-1); 95% confidence interval [CI]: -11.38 to -5.36gdL(-1)) and lower transferrin saturation percentages (WMD: 2.34%, 95% CI: -3.29% to -1.40%). Consistent with this finding, the overweight/obese participants had a significantly increased risk of iron deficiency (OR: 1.31; 95% CI: 1.01-1.68). Moreover, subgroup analyses revealed that the method used to diagnose iron deficiency can have a critical effect on the results of the association test; specifically, we found a significant correlation between iron deficiency and obesity in studies without a ferritin-based diagnosis, but not in studies that used a ferritin-based diagnosis. Based upon these findings, we concluded that obesity is significantly associated with iron deficiency, and we recommend early monitoring and treatment of iron deficiency in overweight and obese individuals. Future longitudinal studies will help to test whether causal relationship exists between obesity and iron deficiency.
C1 [Zhao, L.; Fang, X.; Wang, F.] Zhejiang Univ, Sch Med, Sch Publ Hlth,Dept Nutr, Inst Nutr & Food Safety,Nutr Discovery Innovat Ct, Hangzhou 310058, Zhejiang, Peoples R China.
   [Zhao, L.; Wang, F.] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou 310058, Zhejiang, Peoples R China.
   [Zhang, X.; Shen, Y.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Wang, Y.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA.
   [Wang, F.] Zhengzhou Univ, Coll Publ Hlth, Nutr Discovery Innovat Inst, Dept Nutr, Zhengzhou 450052, Peoples R China.
RP Wang, F (reprint author), Zhejiang Univ, Sch Publ Hlth, Dept Nutr, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
EM fwang@zju.edu.cn
FU Ministry of Science and Technology of China [2011CB966203,
   2012BAD33B05]; Chinese National Natural Science Foundation [31225013,
   31330036, 31530034, 31401016]; Fundamental Research Funds for the
   Central Universities
FX We thank Dr Junxia Min, Dr Xiuyang Li and Dr Hongzhi Wu for their
   helpful comments regarding the manuscript. We are also grateful to the
   members of Dr Fudi Wang's laboratory for their support. This work was
   supported by research grants from the Ministry of Science and Technology
   of China (2011CB966203 and 2012BAD33B05 to FW), grants by the Chinese
   National Natural Science Foundation grants (31225013, 31330036 and
   31530034 to FW; 31401016 to LZ) and the Fundamental Research Funds for
   the Central Universities.
CR Altunoglu E, 2014, TURK J HEMATOL, V31, P61, DOI 10.4274/Tjh.2012.0187
   Hamza RT, 2013, HORM RES PAEDIAT, V80, P11, DOI 10.1159/000351941
   Karl JP, 2009, J AM COLL NUTR, V28, P37
   Markovic M, 2007, INT J LAB HEMATOL, V29, P341, DOI 10.1111/j.1365-2257.2006.00875.x
   FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Manios Y, 2013, J HUM NUTR DIET, V26, P470, DOI 10.1111/jhn.12025
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Moschonis G, 2012, BRIT J NUTR, V108, P710, DOI 10.1017/S0007114511005952
   Brotanek JM, 2008, ARCH PEDIAT ADOL MED, V162, P374, DOI 10.1001/archpedi.162.4.374
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   CUSTER EM, 1995, J LAB CLIN MED, V126, P88
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Suliburska J, 2013, EUR REV MED PHARMACO, V17, P2396
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Wetzel NC, 1941, J AMER MED ASSOC, V116, P1187
   Eftekhari MH, 2009, PUBLIC HEALTH NUTR, V12, P2377, DOI 10.1017/S1368980009005187
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Kordas K, 2013, J NUTR, V143, P175, DOI 10.3945/jn.112.167767
   SHIH YJ, 1990, J BIOL CHEM, V265, P19077
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   FAILLA ML, 1988, J NUTR, V118, P46
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Demircioglu F, 2014, EUR J PEDIATR, V173, P947, DOI 10.1007/s00431-014-2268-8
   FRICKER J, 1990, AM J CLIN NUTR, V52, P863
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Fanou-Fogny N, 2011, BRIT J NUTR, V105, P574, DOI 10.1017/S0007114510003776
   Tascilar ME, 2011, BIOL TRACE ELEM RES, V143, P188, DOI 10.1007/s12011-010-8878-8
   Hayashino Y, 2005, J EPIDEMIOL, V15, P235, DOI 10.2188/jea.15.235
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   FAHMY M, 1993, BIOCHEM J, V296, P175
   WENZEL BJ, 1962, LANCET, V2, P327
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   DALLMAN PR, 1980, AM J CLIN NUTR, V33, P86
   Revenga-Frauca J, 2009, J PHYSIOL BIOCHEM, V65, P415, DOI 10.1007/BF03185937
   AHLUWALIA N, 1995, AM J CLIN NUTR, V61, P590
   Azab SFA, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-20
   Chang JS, 2014, NUTRIENTS, V6, P3929, DOI 10.3390/nu6093929
   Chang JS, 2014, NUTRITION, V30, P1165, DOI 10.1016/j.nut.2014.02.021
   Cook J D, 1992, Nutr Res Rev, V5, P198, DOI 10.1079/NRR19920014
   delsGiudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102
   Ferrari M, 2015, EUR J CLIN NUTR, V69, P247, DOI 10.1038/ejcn.2014.154
   Ghadiri-Anari A, 2014, ISRN HEMATOL, V2014, P3
   Laillou A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110499
   R Development Core Team, 2012, R LANG ENV STAT COMP
   Skikne B, 2012, NUTR HEALTH SER, P251, DOI 10.1007/978-1-60327-485-2_13
   Tobias A, 1999, STATA TECH B, V47, P15
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   vansVeldhuisen DJ, 2011, NAT REV CARDIOL, V8, P485
   Wells G, 2000, NEWCASTLE OTTAWA SCA
NR 59
TC 0
Z9 0
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1467-7881
EI 1467-789X
J9 OBES REV
JI Obes. Rev.
PD DEC
PY 2015
VL 16
IS 12
BP 1081
EP 1093
DI 10.1111/obr.12323
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CX1GG
UT WOS:000365443900006
PM 26395622
ER

PT J
AU Heidari, B
   Hosseini, R
   Javadian, Y
   Bijani, A
   Sateri, MH
   Nouroddini, HG
AF Heidari, Behzad
   Hosseini, Reza
   Javadian, Yahya
   Bijani, Ali
   Sateri, Mohammad Hassan
   Nouroddini, Haj Ghorban
TI Factors affecting bone mineral density in postmenopausal women
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Bone mineral density; Postmenopausal; Menopause; Obesity; Physical
   activity; Education; Parity
ID RISK-FACTORS; PHYSICAL-ACTIVITY; OSTEOPOROTIC FRACTURES; ELDERLY-MEN;
   AGE; ASSOCIATION; PREVALENCE; PREVENTION; PARITY; COHORT
AB This study aimed to determine the relationship between bone mineral density (BMD) and demographic, biochemical, and clinical features according to BMD measurement sites. The results indicated that BMD correlates negatively with menopause duration, parity, and history of fractures but positively correlates with obesity, physical activity, education, and serum ferritin.
   Purpose/Introduction Osteoporosis (OP) is an important cause of morbidity and mortality in the elderly people. The impacts of various factors on bone mineral density (BMD) differ across diverse population. We hypothesized that the influences of factors which affect BMD vary according to BMD measurement sites. The aim of this study was to determine the relationship between BMD in the femoral neck (FN) and lumbar spine (LS) with some common clinical, demographic, and biochemical parameters in postmenopausal women.
   Methods In this cross-sectional case-control study, all postmenopausal women of the Amirkola Health and Ageing Project (AHAP) who performed bone densitometry were included. BMD at FN and LS was measured by DXA method. Data regarding clinical, demographic, and biochemical characteristics were provided. OP was diagnosed by the International Society for Clinical Densitometry criteria. Pearson correlation and multivariate regression analyses with simultaneous adjustment were performed to determine relationship.
   Results Five hundred thirty-seven women with mean age of 67.9 +/- 6.7 years and mean menopause duration (MD) of 15.8 +/- 5.1 years were studied. MD correlated negatively with FNBMD and LS-BMD g/cm(2) (r=-0.405, p=0.001 and r=-0.217, p=0.001). Body mass index (BMI) correlated positively with FN and LS-BMD g/cm(2) (r=0.397, p=0.001 and r=0.311, p=0.001). The association of MD with risk of FN-OP was stronger than LS-OP. Obesity and metabolic syndrome (MS) and higher serum ferritin reduced the risk of OP at both LS and FN similarly, whereas the impacts of parity, prior fracture, high level of education, and physical activity were significantly different across BMD measurement sites.
   Conclusion The results of this study indicated a significant association between OP and MD, obesity, parity, MS, history of fracture, serum ferritin, level of education, and physical activity. However, the direction and the strength of association varied across BMD measurement sites.
C1 [Heidari, Behzad; Javadian, Yahya; Sateri, Mohammad Hassan] Babol Univ Med Sci, Mobil Impairment Res Ctr, Babol Sar, Iran.
   [Heidari, Behzad] Babol Univ Med Sci, Rouhani Hosp, Dept Internal Med, Babol Sar, Iran.
   [Hosseini, Reza] Babol Univ Med Sci, Dept Social Med, Babol Sar, Iran.
   [Javadian, Yahya; Nouroddini, Haj Ghorban] Babol Univ Med Sci, Dept Physiotherapy, Babol Sar, Iran.
   [Heidari, Behzad; Hosseini, Reza; Javadian, Yahya; Bijani, Ali; Sateri, Mohammad Hassan; Nouroddini, Haj Ghorban] Amirkola Hosp, Dept Radiol, Amirkola, Iran.
RP Javadian, Y (reprint author), Babol Univ Med Sci, Mobil Impairment Res Ctr, Babol Sar, Iran.
EM javad835@yahoo.com
OI Bijani, Ali/0000-0003-2233-8726
CR Pluskiewicz W, 2014, J BONE MINER METAB, V32, P89, DOI 10.1007/s00774-013-0471-8
   Allali F, 2010, CLIN RHEUMATOL, V29, P1269, DOI 10.1007/s10067-010-1535-y
   Hannan MT, 2000, J BONE MINER RES, V15, P710, DOI 10.1359/jbmr.2000.15.4.710
   Schmitt NM, 2009, MATURITAS, V63, P34, DOI 10.1016/j.maturitas.2009.03.002
   Pinheiro MM, 2010, REV SAUDE PUBL, V44, P479, DOI 10.1590/s0034-89102010000300011
   Bliuc D, 2009, JAMA-J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Moayyeri A, 2008, ANN EPIDEMIOL, V18, P827, DOI 10.1016/j.annepidem.2008.08.007
   Hans D, 2006, J CLIN DENSITOM, V9, P15, DOI 10.1016/j.jocd.2006.05.003
   Bliuc D, 2015, OSTEOPOROS INT
   Colaianni Graziana, 2014, World J Orthop, V5, P242, DOI 10.5312/wjo.v5.i3.242
   Gosch M, 2012, Z GERONTOL GERIATR, V45, P450, DOI 10.1007/s00391-012-0374-7
   Hajian-Tilaki K, 2014, Diabetes Metab Syndr, V8, P170, DOI 10.1016/j.dsx.2014.04.012
   Hamalainen P, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-114
   HEIDARI B, 2005, ACTA MED IRAN, V43, P99
   Heidari B, 2014, CLIN EXP NEPHROL
   Heidari Behzad, 2012, Caspian J Intern Med, V3, P428
   Heidari Behzad, 2011, Caspian J Intern Med, V2, P205
   HEIDARI B, 2011, J INTERN MED, V2, P249
   Heidari B, 2013, J REPROD MED, V58, P389
   Heidari B., 2010, Eastern Mediterranean Health Journal, V16, P868
   Hosseini SR, 2014, INT J EPIDEMIOL, V43, P1393, DOI 10.1093/ije/dyt089
   Kennish L, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-8
   Kim BJ, 2013, OSTEOPOROSIS INT, V24, P2627, DOI 10.1007/s00198-013-2363-0
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198-005-1863-y
   Liu PY, 2014, ETHNIC DIS, V24, P356
   Maghraoui A, 2014, BMC ENDOCR DISORD, V14, P93
   Niranjan G, 2013, J CLIN DIAGN RES, V7, P1099, DOI [10.7860/JCDR/2013/5290.3056, DOI 10.7860/JCDR/2013/5290.3056]
   North American Menopause Society, 2006, MENOPAUSE, V13, P340
   Sadat-Ali M, 2005, SAUDI MED J, V26, P1588
   Shilbayeh S, 2003, OSTEOPOROSIS INT, V14, P929, DOI 10.1007/s00198-003-1458-4
   Svejme O, 2014, SCAND J MED SCI SPOR, V24, P159, DOI 10.1111/j.1600-0838.2012.01504.x
   TUPPURAINEN M, 1993, MATURITAS, V17, P89, DOI 10.1016/0378-5122(93)90004-2
   Wastesson JW, 2013, OSTEOPOROSIS INT, V24, P433, DOI 10.1007/s00198-012-1945-6
   Wee James, 2013, Arch Osteoporos, V8, P162, DOI 10.1007/s11657-013-0162-z
NR 34
TC 0
Z9 0
U1 8
U2 8
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862-3522
EI 1862-3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD DEC
PY 2015
VL 10
IS 1
AR 15
DI 10.1007/s11657-015-0217-4
PG 7
WC Endocrinology & Metabolism; Orthopedics
SC Endocrinology & Metabolism; Orthopedics
GA CN2ZI
UT WOS:000358291800015
PM 25972061
ER

PT J
AU Alam, F
   Memon, AS
   Fatima, SS
AF Alam, Faiza
   Memon, Abdul Shakoor
   Fatima, Syeda Sadia
TI Increased Body Mass Index may lead to Hyperferritinemia Irrespective of
   Body Iron Stores
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Obesity; Inflammation; Ferritin; Iron; CRP
ID C-REACTIVE PROTEIN; SERUM FERRITIN; PHYSICAL-ACTIVITY; OBESITY;
   INFLAMMATION; DEFICIENCY; WOMEN; HYPOFERREMIA; POPULATIONS; METABOLISM
AB Objective: Obesity causes subclinical inflammation which results in the secretion of various bioactive peptides that are key players in metabolic regulation of iron homeostasis. We sought to establish correlation of one such peptide (ferritin) with marker of subclinical inflammation (CRP) in various BMI.
   Methods: Total 150 subjects between the ages of 20-60 years were included in the cross-sectional study conducted at Basic Medical Sciences Institute, Jinnah Post Graduate Medical Centre, Karachi, Pakistan. Body Mass Index (BMI) was calculated by weight (kg)/height (m(2)). The given values were used as reference for Group A: normal weight (18.0-22.9 kg/m2), Group B: overweight (23.0-24.9 kg/m2), Group C: obese (> 25.0 kg/m2) according to South Asian criteria. Serum Iron, Total Iron Binding Capacity, serum Transferrin Saturation, serum Ferritin and C-reactive protein were measured by commercially available kits. ANNOVA with Tukey's minimum significant difference and Spearman Rho correlation were used considering p<0.05 significant.
   Results: The results identified an increased serum Ferritin and CRP in obese versus lean subjects (p < 0.001). BMI showed significantly positive correlation with serum CRP (r = 0.815; p-value < 0.01) and Ferritin (r = 0.584; p-value < 0.01). However, serum Iron levels and Transferrin saturation decreased in obese versus normal weight individuals (p < 0.001).
   Conclusion: This integrated new data reveals that individuals with high BMI had high levels of Serum Ferritin despite low levels of iron with high levels of C-reactive protein. This might be caused due to inflammatory conditions prevailing in the presence of increased adipose tissue.
C1 [Alam, Faiza; Fatima, Syeda Sadia] Aga Khan Univ, Dept Biol & Biomed Sci, Karachi 74800, Pakistan.
   [Memon, Abdul Shakoor] Jinnah Postgrad Med Ctr, Inst Basic Med Sci, Dept Physiol, Karachi, Pakistan.
RP Fatima, SS (reprint author), Aga Khan Univ, Dept Biol & Biomed Sci, Stadium Rd, Karachi 74800, Pakistan.
EM sadia.fatima@aku.edu
CR Alam F, 2014, J PAK MED ASSOC, V64, P1389
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Karl JP, 2009, J AM COLL NUTR, V28, P37
   Rocha VZ, 2009, NAT REV CARDIOL, V6, P399, DOI 10.1038/nrcardio.2009.55
   Broderstad AR, 2007, EUR J HAEMATOL, V79, P447, DOI 10.1111/j.1600-0609.2007.00929.x
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Shiwaku K, 2004, LANCET, V363, P1077, DOI 10.1016/S0140-6736(04)15856-X
   Gartner A, 2013, AM J CLIN NUTR, V98, P821, DOI 10.3945/ajcn.112.054551
   Eftekhari MH, 2009, PUBLIC HEALTH NUTR, V12, P2377, DOI 10.1017/S1368980009005187
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Brooks GC, 2010, AM J CARDIOL, V106, P56, DOI 10.1016/j.amjcard.2010.02.017
   McClung JP, 2008, J NUTR, V138, P1293
   Chen SB, 2009, OBES SURG, V19, P461, DOI 10.1007/s11695-008-9619-3
   Choi J, 2013, OBES REV, V14, P232, DOI 10.1111/obr.12003
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Zekanowska Ewa, 2011, Biotechnologia (Poznan), V92, P147
   Zimmermann MB, 2008, BRIT J NUTR, V99, pS2, DOI 10.1017/S000711450800679X
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Misra A, 2009, J Assoc Physicians India, V57, P163
   Wish JB, 2006, CLIN J AM SOC NEPHRO, V1, pS4, DOI 10.2215/CJN.01490506
   Cheng HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068675
   GARROW JS, 1985, INT J OBESITY, V9, P147
   Ghadiri-Anari A, 2014, INT SCHOLARLY RES NO, DOI [10.1155/2014/525312, DOI 10.1155/2014/525312]
   Gray LJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026464
   Ishor S, 2013, INT J MED MED SCI, V5, P546, DOI [10.5897/IJMMS2013.0991, DOI 10.5897/IJMMS2013.0991]
   Sharp PA, 2010, INT J VITAM NUTR RES, V80, P231, DOI 10.1024/0300-9831/a000029
   Singh SP, 2008, MED J ARMED FORCES I, V64, P350, DOI 10.1016/S0377-1237(08)80019-6
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   World Health Organization, 2008, WAIST CIRC WAISTH RA
NR 32
TC 0
Z9 0
U1 0
U2 0
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD NOV-DEC
PY 2015
VL 31
IS 6
BP 1521
EP 1526
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CY9OG
UT WOS:000366735600046
ER

PT J
AU Huth, C
   Beuerle, S
   Zierer, A
   Heier, M
   Herder, C
   Kaiser, T
   Koenig, W
   Kronenberg, F
   Oexle, K
   Rathmann, W
   Roden, M
   Schwab, S
   Seissler, J
   Stockl, D
   Meisinger, C
   Peters, A
   Thorand, B
AF Huth, Cornelia
   Beuerle, Simon
   Zierer, Astrid
   Heier, Margit
   Herder, Christian
   Kaiser, Thorsten
   Koenig, Wolfgang
   Kronenberg, Florian
   Oexle, Konrad
   Rathmann, Wolfgang
   Roden, Michael
   Schwab, Sigrid
   Seissler, Jochen
   Stoeckl, Doris
   Meisinger, Christa
   Peters, Annette
   Thorand, Barbara
TI Biomarkers of iron metabolism are independently associated with impaired
   glucose metabolism and type 2 diabetes: the KORA F4 study
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID SOLUBLE TRANSFERRIN RECEPTOR; HUMAN SERUM TRANSFERRIN;
   INSULIN-RESISTANCE; BODY IRON; STORES; RISK; FERRITIN; SENSITIVITY;
   SATURATION; MEN
AB Objective: Iron has been suggested to play a role in the etiology of type 2 diabetes mellitus (T2DM). Except for ferritin, evidence is sparse for other markers of iron metabolism that are regulated differently and might act through independent pathways. We therefore investigated the associations of serum ferritin, transferrin, soluble transferrin receptor (sTfR), transferrin saturation (TSAT), sTfR-to-log(10)ferritin (sTfR-F) index, and iron with impaired glucose metabolism (IGM/'prediabetes'), T2DM, and four continuous glucose and insulin traits.
   Design and methods: Data from 2893 participants of the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4 study (Germany) was investigated through regression analysis. The results were adjusted for socio-demographic, life-style, and obesity measures as well as metabolic, inflammatory, and other iron biomarkers following a step-wise approach. Non-linearity was tested by adding a non-linear spline component to the model.
   Results: Ferritin and transferrin were positively associated with IGM (fourth vs first sex-specific quartile: ferritin odds ratio (OR) = 2.08 (95% CI 1.43-3.04) and transferrin OR = 1.89 (95% CI 1.32-2.70)), T2DM (ferritin OR = 1.98 (95% CI 1.22-3.22) and transferrin OR = 2.42 (95% CI 1.54-3.81)), and fasting as well as 2-h glucose. TSAT (OR = 0.55 (95% CI 0.34-0.88)) and iron (OR = 0.61 (95% CI 0.38-0.97)) were inversely associated with T2DM, sTfR-F-index was inversely associated with IGM (OR = 0.67 (95% CI 0.48-0.95)). There was no strong evidence for non-linear relationships.
   Conclusions: The observed associations of several markers of iron metabolism with hyperglycemia and insulin resistance suggest that iron stores as well as iron-related metabolic pathways contribute to the pathogenesis of IGM and T2DM. Moreover, TSAT levels are decreased in T2DM patients.
C1 [Huth, Cornelia; Beuerle, Simon; Zierer, Astrid; Heier, Margit; Schwab, Sigrid; Stoeckl, Doris; Meisinger, Christa; Peters, Annette; Thorand, Barbara] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Epidemiol 2, D-85764 Neuherberg, Germany.
   [Huth, Cornelia; Stoeckl, Doris; Meisinger, Christa; Peters, Annette; Thorand, Barbara] German Ctr Diabet Res DZD, Partner Neuherberg, Germany.
   [Heier, Margit; Meisinger, Christa] Cent Hosp Augsburg, MONICA KORA Myocardial Infarct Registry, Augsburg, Germany.
   [Herder, Christian; Roden, Michael] Univ Dusseldorf, Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany.
   [Herder, Christian; Rathmann, Wolfgang; Roden, Michael] German Ctr Diabet Res DZD, Partner Dusseldorf, Germany.
   [Kaiser, Thorsten] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04109 Leipzig, Germany.
   [Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, D-89069 Ulm, Germany.
   [Kronenberg, Florian] Med Univ Innsbruck, Div Genet Epidemiol, Dept Med Genet Mol & Clin Pharmacol, A-6020 Innsbruck, Austria.
   [Oexle, Konrad] Tech Univ Munich, Klinikum Rechts Isar, Inst Human Genet, D-80290 Munich, Germany.
   [Rathmann, Wolfgang] Univ Dusseldorf, Inst Biometr & Epidemiol, German Diabet Ctr, Leibniz Ctr Diabet Res, Dusseldorf, Germany.
   [Roden, Michael] Univ Dusseldorf, Fac Med, Dept Endocrinol & Diabetol, Dusseldorf, Germany.
   [Seissler, Jochen] Klinikum Ludwig Maximilians Univ, Diabet Zentrum, Med Klin & Poliklin 4, Munich, Germany.
   [Seissler, Jochen] Univ Munich, Clin Cooperat Grp Diabet, Munich, Germany.
   [Seissler, Jochen] Helmholtz Zentrum Munchen, Munich, Germany.
RP Huth, C (reprint author), German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.
EM huth@helmholtz-muenchen.de
RI Kronenberg, Florian/B-1736-2008; Thorand, Barbara/B-5349-2014
OI Kronenberg, Florian/0000-0003-2229-1120; Thorand,
   Barbara/0000-0002-8416-6440
FU Helmholtz Zentrum Munchen, German Research Center for Environmental
   Health; German Federal Ministry of Education and Research; state of
   Bavaria; German Research Foundation (DFG) [RA 459/2-1]; Ministry of
   Science and Research of the State of North Rhine-Westphalia (MIWF NRW);
   German Federal Ministry of Health (BMG)
FX The Cooperative Health Research in the Region of Augsburg (KORA)
   research platform is financed by the Helmholtz Zentrum Munchen, German
   Research Center for Environmental Health, which is funded by the German
   Federal Ministry of Education and Research and by the state of Bavaria.
   The Diabetes Cohort Study was funded by a German Research Foundation
   project grant to W Rathmann (DFG; RA 459/2-1). The present investigation
   was supported in part by a grant from the German Federal Ministry of
   Education and Research to the German Center for Diabetes Research (DZD
   e.V.). This work was also supported by the Ministry of Science and
   Research of the State of North Rhine-Westphalia (MIWF NRW) and by the
   German Federal Ministry of Health (BMG).
CR Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Punnonen K, 1997, BLOOD, V89, P1052
   Wang HY, 2014, DIABETES, V63, P1506, DOI 10.2337/db13-1195
   Fernandez-Real JM, 2009, J CLIN ENDOCR METAB, V94, P982, DOI 10.1210/jc.2008-1211
   Skikne BS, 2011, AM J HEMATOL, V86, P923, DOI 10.1002/ajh.22108
   Silva AMN, 2014, BIOCHEM J, V461, P33, DOI 10.1042/BJ20140133
   Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   Aregbesola A, 2013, EUR J ENDOCRINOL, V169, P247, DOI 10.1530/EJE-13-0145
   Mainous AG, 2002, J FAM PRACTICE, V51, P933
   Montonen J, 2012, DIABETOLOGIA, V55, P2613, DOI 10.1007/s00125-012-2633-y
   Roumen C, 2008, DIABETIC MED, V25, P1478, DOI 10.1111/j.1464-5491.2008.02589.x
   Salonen JT, 1998, BRIT MED J, V317, P727
   Cheung CL, 2013, CLIN NUTR, V32, P1055, DOI 10.1016/j.clnu.2012.11.024
   Krebs M, 2005, DIABETES OBES METAB, V7, P621, DOI 10.1111/j.1463-1326.2004.00439.x
   Bacon BR, 2011, HEPATOLOGY, V54, P328, DOI 10.1002/hep.24330
   Vargas L, 1998, HORM METAB RES, V30, P113, DOI 10.1055/s-2007-978847
   Park RJ, 2015, DIABETIC MED, V32, P673, DOI 10.1111/dme.12643
   Fernandez-Real JM, 2007, DIABETES CARE, V30, P604, DOI 10.2337/dc06-1138
   Rathmann W, 2012, ANN MED, V44, P170, DOI 10.3109/07853890.2010.531759
   Rajpathak SN, 2009, DIABETES OBES METAB, V11, P472, DOI 10.1111/j.1463-1326.2008.00985.x
   Thomas MC, 2003, DIABETES CARE, V26, P1164, DOI 10.2337/diacare.26.4.1164
   Camaschella C, 2013, HEMATOL-AM SOC HEMAT, P1
   Ellervik C, 2011, DIABETES CARE, V34, P2256, DOI 10.2337/dc11-0416
   Mojiminiyi OA, 2008, NUTR METAB CARDIOVAS, V18, P559, DOI 10.1016/j.numecd.2007.07.007
   Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007
   Orban E, 2014, DIABETES-METAB RES, V30, P372, DOI 10.1002/dmrr.2506
   Fernandez-Real JM, 2009, INT J OBESITY, V33, P768, DOI 10.1038/ijo.2009.99
   Wlazlo N, 2013, DIABETES CARE, V36, P309, DOI 10.2337/dc12-0505
   Rumberger JM, 2004, DIABETES, V53, P2535, DOI 10.2337/diabetes.53.10.2535
   Gaffney-Stomberg E, 2012, CURR OPIN CLIN NUTR, V15, P605, DOI 10.1097/MCO.0b013e328357f63b
   Arija V, 2014, BRIT J NUTR, V112, P1896, DOI 10.1017/S0007114514002852
   Bonfils L, 2015, DIABETOLOGIA, V58, P523, DOI 10.1007/s00125-014-3469-4
   Herklotz R, 2010, SCHWEIZ MED FORUM, V10, P500
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Lee Hye-Ja, 2014, Osong Public Health Res Perspect, V5, P204, DOI 10.1016/j.phrp.2014.06.005
   Meisinger C, 2014, J DIABETES METABOLIS, P355, DOI [10.4172/2155-6156.1000335, DOI 10.4172/2155-6156.1000335]
   Mitchell TC, 2014, CURR DIABETES REP, V14, P488, DOI DOI 10.1007/S11892-014-0488-Y
   Ruckert IM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022932
   WHO, 1999, DEF DIAGN CLASS DI 1, P1
   Wlazlo N, 2015, ACTA DIABETOL, V52, P337, DOI 10.1007/s00592-014-0646-3
   Yeap BB, 2015, CLIN ENDOCRINOL, V82, P525, DOI 10.1111/cen.12529
NR 42
TC 0
Z9 0
U1 2
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD NOV
PY 2015
VL 173
IS 5
BP 643
EP 653
DI 10.1530/EJE-15-0631
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CV1NU
UT WOS:000364025800015
PM 26294793
ER

PT J
AU Iqbal, R
   Iqbal, SP
   Yakub, M
   Tareen, AK
   Iqbal, MP
AF Iqbal, Romaina
   Iqbal, Saleem Perwaiz
   Yakub, Mohsin
   Tareen, Asa Khan
   Iqbal, Mohammad Perwaiz
TI Major dietary patterns and risk of acute myocardial infarction in young,
   urban Pakistani population
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Acute myocardial infarction; Dietary patterns; Dietary records;
   Pakistani population
ID CARDIOVASCULAR-DISEASE RISK; CORONARY-HEART-DISEASE; RED MEAT;
   CONSUMPTION; ASSOCIATION; OBESITY; WOMEN
AB Objective: To investigate the role of dietary intake in the development of premature acute myocardial infarction (AMI) in a hospital-based Pakistani population in Karachi.
   Methods: In a case control study, 203 consecutive patients (146 males and 57 females) with their first AMI and age below 45 years were enrolled with informed consent. Similarly, 205 gender and age matched (within 3 years) healthy adults were also included as controls. Dietary intake of both cases and controls was assessed by using a simple 14-item food frequency questionnaire. Using factor analysis, 3 major dietary patterns- prudent dietary pattern, combination dietary pattern and western dietary pattern were identified. Fasting plasma/serum of both cases and controls were analyzed for homocysteine, folate, vitamin B12, blood Pb, ferritin, cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. ANOVA and conditional logistic regression were used to predict the association of dietary patterns with AMI.
   Results: Consumption of prudent diet, characterized by high consumption of legumes, vegetables, wheat, chicken and fruits, is protective against the risk of premature AMI. Moderate to high consumption of combination diet, characterized by high intake of eggs, fish, fruits, juices and coffee was associated with decreased risk of AMI. No association was observed between western diet, characterized by high intake of meat, fish and tea with milk and risk of AMI.
   Conclusions: Consumption of a prudent dietary pattern and a combination dietary pattern is protective against the risk of AMI in a Pakistani population.
C1 [Iqbal, Romaina; Iqbal, Saleem Perwaiz] New York Inst Technol, Coll Osteopath Med, Dept Community Hlth Sci, Old Westbury, NY 11568 USA.
   [Yakub, Mohsin] New York Inst Technol, Coll Osteopath Med, Dept Biol & Biomed Sci, Old Westbury, NY 11568 USA.
   [Tareen, Asa Khan] Natl Inst Cardiovasc Dis, Karachi, Pakistan.
   [Iqbal, Romaina; Yakub, Mohsin; Iqbal, Mohammad Perwaiz] Aga Khan Univ, Dept Biol & Biomed Sci, Karachi 74800, Pakistan.
RP Iqbal, MP (reprint author), Aga Khan Univ, Dept Biol & Biomed Sci, Stadium Rd, Karachi 74800, Pakistan.
EM perwaiz.iqbal@aku.edu
FU Pakistan Academy of Sciences/Higher Education Commission
FX Pakistan Academy of Sciences/Higher Education Commission.
CR Iqbal R, 2008, CIRCULATION, V118, P1929, DOI 10.1161/CIRCULATIONAHA.107.738716
   Lim JH, 2011, J KOREAN MED SCI, V26, P1201, DOI 10.3346/jkms.2011.26.9.1201
   Yakub M, 2010, J NUTR, V140, P1261, DOI 10.3945/jn.109.120477
   Ahmed J, 2013, E MEDITERR HEALTH J, V19, P242
   Zobairi SE, 1998, AUST NZ J OBSTET GYN, V38, P188, DOI 10.1111/j.1479-828X.1998.tb02999.x
   Grieger JA, 2012, J HUM NUTR DIET, V25, P75, DOI 10.1111/j.1365-277X.2011.01195.x
   Butt MS, 2009, J AOAC INT, V92, P1277
   Moshe G, 2013, J PEDIATR GASTR NUTR, V57, P722, DOI 10.1097/MPG.0b013e3182a80c42
   Hall JN, 2009, AM J PREV MED, V36, P402, DOI 10.1016/j.amepre.2009.01.029
   Kamath SK, 1999, AM J CLIN NUTR, V69, P621
   Jafary MH, 2007, PAK J MED SCI, V23, P485
   Javed I, 2012, PAK J MED SCI, V28, P143
   Fung TT, 2001, AM J CLIN NUTR, V73, P61
   Hu FB, 2000, AM J CLIN NUTR, V72, P912
   Panwar RB, 2011, INDIAN J MED RES, V134, P26
   Vyas A, 2003, J HUM NUTR DIET, V16, P327, DOI 10.1046/j.1365-277X.2003.00461.x
   Olaya GA, 2013, AM J CLIN NUTR, V98, P983, DOI 10.3945/ajcn.112.053595
   Field AP, 2005, DISCOVERING STAT USI
   Holmboe-Ottesen G, 2012, FOOD NUTR RES, P56, DOI [10.3402/fnr.v56i0.18891, DOI 10.3402/MR.V56I0.18891]
   Hunt JR, 2003, AM J CLIN NUTR, V78, p633S
   Iqbal MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067981
   Quadros E. V., 2000, CHEM ANAL SERIES, P311
   Willet WC, 1998, NUTR EPIDEMIOLOGY
NR 23
TC 0
Z9 0
U1 0
U2 0
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD SEP-OCT
PY 2015
VL 31
IS 5
BP 1213
EP 1218
DI 10.12669/pjms.315.7690
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CX1KU
UT WOS:000365455900038
ER

PT J
AU Aljwaid, H
   White, DL
   Collard, KJ
   Moody, AJ
   Pinkney, JH
AF Aljwaid, Husam
   White, Desley L.
   Collard, Keith J.
   Moody, A. John
   Pinkney, Jonathan H.
TI Non-transferrin-bound iron is associated with biomarkers of oxidative
   stress, inflammation and endothelial dysfunction in type 2 diabetes
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Obesity; Type 2 diabetes; Cardiovascular disease; Endothelial
   dysfunction; Non-transferrin-bound iron; Oxidative stress
ID CARDIOVASCULAR-DISEASE; CELL UNITS; PLASMA; ANEMIA; ERYTHROCYTES;
   MELLITUS; PROTEIN; OBESITY; QUANTIFICATION; DEFORMABILITY
AB Aims: To investigate the association between circulating non-transferrin-bound iron [NTBI], and markers of oxidative stress, endothelial function and inflammation in subjects with type 2 diabetes and non-diabetic subjects with varying degrees of obesity.
   Methods: Plasma NTBI was measured by HPLC, together with total iron, iron-binding capacity, transferrin saturation and soluble transferrin receptor, together with total and reduced ascorbate, malondialdehyde [MDA], E-selectin and high-sensitivity c-reactive protein [hs-CRP] in groups of 28 subjects with type 2 diabetes, 28 non-obese controls and 17 obese non-diabetic subjects.
   Results: Levels of NTBI were higher than controls in the diabetes group, but the total serum iron levels were lower. MDA levels were higher than controls in both the diabetes and obese groups, and this was associated with higher levels of oxidised ascorbate. hs-CRP levels were higher in both the diabetes and obese groups, and E-selectin was significantly higher in the diabetes group. There were strong positive correlations between HbA1c levels and NTBI [P < 0.01], HbA1c and E-selectin [P < 0.001] and NTBI and E-selectin [P < 0.02] in the diabetes group.
   Conclusion: These results support the hypothesis that iron-mediated oxidative stress may be a mechanism linking poor glycaemic control with vascular dysfunction in type 2 diabetes. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Aljwaid, Husam; Moody, A. John] Univ Plymouth, Sch Biol Sci, Fac Sci & Environm, Plymouth PL4 8AA, Devon, England.
   [White, Desley L.; Collard, Keith J.] Univ Plymouth, Fac Hlth & Human Sci, Sch Hlth Profess, Plymouth PL4 8AA, Devon, England.
   [Pinkney, Jonathan H.] Peninsula Sch Med, Ctr Biomed Res Translat & Stratified Med, Plymouth, Devon, England.
   [Pinkney, Jonathan H.] Peninsula Sch Dent, Ctr Biomed Res Translat & Stratified Med, Plymouth, Devon, England.
RP Collard, KJ (reprint author), Univ Plymouth, Link Labs, Food & Nutr Unit, Plymouth PL4 8AA, Devon, England.
EM husam.aljwaid@plymouth.ac.uk; desley.white@plymouth.ac.uk;
   keith.collard@plymouth.ac.uk; j.moody@plymouth.ac.uk;
   jonathan.pinkney@plymouth.ac.uk
FU Government of Iraq; Plymouth University Faculty of Health Dean's
   Scholarship
FX We would like to thank all the subjects for kindly participating in the
   study. The technical support of Liz Preston and Natalie Sweet is
   gratefully acknowledged. HA was supported by a doctoral bursary from the
   Government of Iraq. DLW was in receipt of a Plymouth University Faculty
   of Health Dean's Scholarship.
CR Adam FI, 2015, CHEM RES TOXICOL, V28, P604, DOI 10.1021/tx500377b
   Agarwal R, 2002, J CHROMATOGR B, V775, P121, DOI 10.1016/S1570-0232(02)00273-8
   Starodubtseva MN, 2008, B EXP BIOL MED+, V145, P99, DOI 10.1007/s10517-008-0036-3
   Diamantopoulos EJ, 2004, HORM METAB RES, V36, P142, DOI 10.1055/s-2004-814337
   KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035
   Rooyakkers TM, 2002, EUR J CLIN INVEST, V32, P9, DOI 10.1046/j.1365-2362.2002.0320s1009.x
   Sato Y, 2010, BIOL PHARM BULL, V33, P364
   Brissot P, 2012, BBA-GEN SUBJECTS, V1820, P403, DOI 10.1016/j.bbagen.2011.07.014
   Taher A, 2009, BRIT J HAEMATOL, V146, P569, DOI 10.1111/j.1365-2141.2009.07810.x
   Ganz T, 2009, SEMIN HEMATOL, V46, P387, DOI 10.1053/j.seminhematol.2009.06.001
   Resmi H, 2005, CELL BIOCHEM FUNCT, V23, P163, DOI 10.1027/cbf.1129
   Lee DH, 2006, DIABETES CARE, V29, P1090, DOI 10.2337/DC05-2471
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Zhang QB, 2011, J PROTEOME RES, V10, P3076, DOI 10.1021/pr200040j
   Maitra D, 2011, FREE RADICAL BIO MED, V51, P374, DOI 10.1016/j.freeradbiomed.2011.04.011
   Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102
   Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007
   HUBERT HB, 1983, CIRCULATION, V67, P968
   Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Collard K, 2014, BLOOD TRANSFUS-ITALY, V12, P210, DOI 10.2450/2013.0142-13
   Basuli D., 2014, FRONT PHARMACOL, V2014, P177
   Capeda-Lopez A. C., 2011, AM J CLIN NUTR, V93, P975
   Collard KJ, 2014, BLOOD TRANSFUS-ITALY, V12, P527, DOI 10.2450/2014.0271-13
   Dixon J R Jr, 1998, Qual Assur, V6, P65
   Goto T, 2013, INT J HEMATOL, V97, P125, DOI 10.1007/s12185-012-1252-1
   Kime R, 1996, CLIN SCI, V91, P633
   Lee DH, 2004, MED HYPOTHESES, V62, P442, DOI 10.1016/s0306-9877(03)00344-x
   Leoncini S, 2008, FREE RADICAL RES, V42, P716, DOI 10.1080/10715760802317655
   Porter JB, 2014, BRIT J HAEMATOL, V167, P692, DOI 10.1111/bjh.13081
   Riquelme B, 2005, J BIOCHEM BIOPH METH, V62, P131, DOI 10.1016/j.jbbm.2004.10.004
   Sasaki K, 2011, MOL MED REP, V4, P913, DOI 10.3892/mmr.2011.518
   Sulieman M, 2004, DIABETES CARE, V27, P2730, DOI 10.2337/diacare.27.11.2730
   TANNER LI, 1987, J BIOL CHEM, V262, P8975
   Van Campenhout A, 2006, FREE RADICAL BIO MED, V40, P1749, DOI 10.1016/j.freeradbiomed.2006.01.010
   Vinchi F, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00094
   Vinchi F., 2013, OXIDATIVE MED CELLUL, P1
   Waldvogel-Abramowski S, 2014, TRANSFUS MED HEMOTH, V41, P213, DOI 10.1159/000362888
   White D. L, 2013, ADV NUTR, V4, P404
   Zhang WJ, 2003, FREE RADICAL BIO MED, V34, P674, DOI 10.1016/S0891-5849(02)01375-8
NR 42
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD SEP-OCT
PY 2015
VL 29
IS 7
BP 943
EP 949
DI 10.1016/j.jdiacomp.2015.05.017
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CQ4UG
UT WOS:000360599500016
PM 26104728
ER

PT J
AU Weigert, R
   Dosch, NC
   Bacsik-Campbell, ME
   Guilbert, TW
   Coe, CL
   Kling, PJ
AF Weigert, R.
   Dosch, N. C.
   Bacsik-Campbell, M. E.
   Guilbert, T. W.
   Coe, C. L.
   Kling, P. J.
TI Maternal pregnancy weight gain and cord blood iron status are associated
   with eosinophilia in infancy
SO JOURNAL OF PERINATOLOGY
LA English
DT Article
ID CHILDHOOD ASTHMA; YOUNG-CHILDREN; RISK; LIFE; INNATE; DEFICIENCY;
   OBESITY; HYPOXEMIA; DIAGNOSIS; RESPONSES
AB OBJECTIVE: Allergic disease is multifactorial in origin. Because iron nutrition affects immune responses and maternal pregnancy weight gain impairs fetal iron delivery while increasing fetal demands for growth, the study examined maternal pregnancy weight gain, newborn iron status and an index of atopic disease, infant eosinophilia.
   STUDY DESIGN: Within a larger prospective study of healthy newborns at risk for developing iron deficiency anemia, umbilical cord iron indicators were compared to infant eosinophil counts.
   RESULT: Infants who developed eosinophilia exhibited higher cord reticulocyte-enriched zinc protoporphyrin/heme ratio, P < 0.05 and fewer cord ferritin values in the highest (best) quartile, P < 0.05. If cord ferritin was in the upper three quartiles, the negative predictive value for infant eosinophilia was 90%. High maternal pregnancy weight gain predicted infant eosinophil counts, P < 0.04, and contributed to cord ferritin predicting eosinophilia, P < 0.003.
   CONCLUSION: Poor fetal iron status may be an additional risk factor for infant eosinophilia.
C1 [Weigert, R.; Dosch, N. C.; Bacsik-Campbell, M. E.; Guilbert, T. W.; Kling, P. J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53715 USA.
   [Weigert, R.; Bacsik-Campbell, M. E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
   [Guilbert, T. W.] Univ Cincinnati, Cincinnati, OH USA.
   [Coe, C. L.] Univ Wisconsin, Harlow Ctr Biol Psychol, Madison, WI USA.
RP Kling, PJ (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, 202 S Pk St, Madison, WI 53715 USA.
EM pkling@pediatrics.wisc.edu
OI Guilbert, Theresa/0000-0002-6932-712X
FU University of Wisconsin Medical Student Shapiro Summer Research
   Fellowship; Cardiovascular Research Center Research Fellowship; UW
   Hilldale Undergraduate Research Fellowship; NIH (UW CTSA Program)
   [UL1TR000427]; Meriter Foundation; Wisconsin Partnership Collaborative
   Health Sciences Program Grant; Thrasher Research Fund
FX We thank the participating families, Meriter Hospital Birthing Center
   Staff, Sharon E Blohowiak, BS, MS; Daphne Q-D Pham, PhD; Anthony P
   Auger, PhD; Robert F Lemanske Jr, MD; and the Kling Laboratory Research
   Team. RW and MEB-C received fellowship support from the University of
   Wisconsin Medical Student Shapiro Summer Research and Cardiovascular
   Research Center Research Fellowships. NCD received grant support from
   the UW Hilldale Undergraduate Research Fellowship. PJK received grant
   support from NIH UL1TR000427 (UW CTSA Program), Meriter Foundation,
   Wisconsin Partnership Collaborative Health Sciences Program Grant and
   the Thrasher Research Fund. TWG and CLC have no relationships to declare
   for this manuscript.
CR Karakoc F, 2002, CLIN EXP ALLERGY, V32, P51, DOI 10.1046/j.0022-0477.2001.01273.x
   Spencer SJ, 2011, AM J PHYSIOL-ENDOC M, V300, pE11, DOI 10.1152/ajpendo.00516.2010
   Gentile M, 2010, EUR J CLIN NUTR, V64, P873, DOI 10.1038/ejcn.2010.69
   Baker RD, 2010, PEDIATRICS, V126, P1040, DOI 10.1542/peds.2010-2576
   Lowe A, 2011, J ALLERGY CLIN IMMUN, V128, P1107, DOI 10.1016/j.jaci.2011.08.025
   Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5
   Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020
   GEORGIEFF MK, 1992, AM J PHYSIOL, V262, pR485
   Shaheen SO, 2004, EUR RESPIR J, V24, P292, DOI 10.1183/09031936.04.00117803
   Jason J, 2001, CLIN EXP IMMUNOL, V126, P466, DOI 10.1046/j.1365-2249.2001.01707.x
   Phillips AK, 2014, J PERINATOL, V34, P513, DOI 10.1038/jp.2014.42
   Pedersen SE, 2011, PEDIATR PULM, V46, P1, DOI 10.1002/ppul.21321
   Halonen M, 2013, AM J RESP CRIT CARE, V188, P35, DOI 10.1164/rccm.201207-1265OC
   McLimore HM, 2013, J PEDIAT HEMATOL ONC, V35, P473, DOI 10.1097/MPH.0b013e3182707f2e
   Coe CL, 2007, PEDIATR RES, V61, P520, DOI 10.1203/pdr.0b013e318045be53
   Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403
   Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002
   Bowlus CL, 2003, AUTOIMMUN REV, V2, P73, DOI 10.1016/S1568-9972(02)00143-X
   Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892
   Siddappa AM, 2007, NEONATOLOGY, V92, P73, DOI 10.1159/000100805
   Saito I, 2003, CIRC J, V67, P323
   Blohowiak SE, 2008, PEDIATR RES, V64, P63, DOI 10.1203/PDR.0b013e31817328e5
   Bloom B, 2012, VITAL HLTH STAT, V2013, P1
   Committee to Reexamine the IOM Pregnancy Weight Guidelines, 2009, WEIGHT GAIN PREGN RE
   Guilbert TW, 2007, AM J RESP CRIT CARE, V176, P843, DOI 10.1164/rccm.200610-1507OC
   Just J, 2010, J ASTHMA, V47, P412, DOI 10.3109/02770900903584035
   Lesser KB, 2006, J PERINATOL, V26, P671, DOI 10.1038/sj.jp.7211600
   Lott DG, 2005, PEDIATRICS, V116, P414, DOI 10.1542/peds.2004-1601
   Lowe A, 2011, J ALLERGY CLIN IMMUN, V128, pe1101
   MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301
   Mbugi EV, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-162
   Nwaru BI, 2014, BRIT J NUTR, V112, P2018, DOI 10.1017/S0007114514003122
   Silvestri M, 2000, ANN ALLERG ASTHMA IM, V84, P426
   Sumino K, 2012, J ALLERGY CLIN IMMUN, V129, P1267, DOI 10.1016/j.jaci.2012.02.033
   Youroukova VF, 1998, J ASTHMA, V35, P489, DOI 10.3109/02770909809071002
NR 35
TC 0
Z9 0
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0743-8346
EI 1476-5543
J9 J PERINATOL
JI J. Perinatol.
PD AUG
PY 2015
VL 35
IS 8
BP 621
EP 626
DI 10.1038/jp.2015.21
PG 6
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA CN8IQ
UT WOS:000358684100018
PM 25836316
ER

PT J
AU Thatte, U
   Chiplunkar, S
   Bhalerao, S
   Kulkarni, A
   Ghungralkar, R
   Panchal, F
   Vetale, S
   Teli, P
   Kumbhar, D
   Munshi, R
AF Thatte, Urmila
   Chiplunkar, Shubhada
   Bhalerao, Supriya
   Kulkarni, Aditi
   Ghungralkar, Raman
   Panchal, Falguni
   Vetale, Shamal
   Teli, Pradeep
   Kumbhar, Dipti
   Munshi, Renuka
TI Immunological & metabolic responses to a therapeutic course of Basti in
   obesity
SO INDIAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE Basti; immunological markers; metabolic markers; obesity; Panchakarma
ID TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE; INSULIN-RESISTANCE;
   INTERLEUKIN-6; INFLAMMATION; METAANALYSIS; DISEASE
AB Background & objectives: Basti (medicated enema) is a popular Ayurvedic intervention recommended for obesity. However, there are no data to show whether any physiological or biochemical changes occur following this treatment. This study was conducted to identify the immunological and metabolic changes in obese individuals after a therapeutic course of basti.
   Methods: Thirty two obese individuals (18 and 60 yr) with a body mass index (BMI) >= 30 kg/m(2) who received a therapeutic course of 16 enemas (basti) followed by a specific diet and lifestyle regimen for a period of 32 days as their treatment for obesity, were enrolled in the study. Clinical examination, measurement of immune and metabolic markers were done before (S1), immediately after (S2) and 90 days after the completion of therapy (S3).
   Results: A significant reduction (p<0.001) in weight, BMI, upper arm and abdominal circumference was seen at S3, along with a decrease in serum interferon (IFN)-alpha (p<0.02), interleukin (IL)-6 (p<0.02) and ferritin (P<0.05) and increase in IgM levels (p<0.02). Peripheral blood lymphocytes (PBLs) stimulated with anti-CD3 monoclonal antibodies showed significant increase in reactive oxygen species (ROS) generation and calcium flux after Basti. All organ function tests revealed no changes.
   Interpretation & conclusions: Our study documents that a therapeutic course of basti modulates immune responses by regulating pro-inflammatory cytokines, immunoglobulins and functional properties of T-cells. These changes are associated with a reduction in the body weight which is maintained even after three months of treatment. the study also documents the safety of basti procedure.
C1 [Thatte, Urmila] Seth GS Med Coll, Dept Clin Pharmacol, Bombay 400012, Maharashtra, India.
   [Thatte, Urmila] King Edward Mem Hosp, Bombay, Maharashtra, India.
   [Chiplunkar, Shubhada; Vetale, Shamal; Teli, Pradeep] Tata Mem Hosp, Chiplunkar Lab, ACTREC, Mumbai, Maharashtra, India.
   [Bhalerao, Supriya; Panchal, Falguni; Kumbhar, Dipti; Munshi, Renuka] TNMC & BYL Nair Charitable Hosp, Dept Clin Pharmacol, Bombay, Maharashtra, India.
   [Kulkarni, Aditi; Ghungralkar, Raman] MA Podar Ayurved Hosp, Dept Kayachikitsa, Bombay, Maharashtra, India.
RP Thatte, U (reprint author), Seth GS Med Coll, Dept Clin Pharmacol, 1st Floor,MS Bldg, Bombay 400012, Maharashtra, India.
EM urmilathatte@gmail.com
CR BULL BS, 1993, J CLIN PATHOL, V46, P198
   Carr MC, 2004, J CLIN ENDOCR METAB, V89, P2601, DOI 10.1210/jc.2004-0432
   Ronti T, 2006, CLIN ENDOCRINOL, V64, P355, DOI 10.1111/j.1365-2265.2006.02474.x
   Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745
   Cartier A, 2008, J CLIN ENDOCR METAB, V93, P1931, DOI 10.1210/jc.2007-2191
   Li ZP, 2005, ANN INTERN MED, V142, P532
   Cartier A, 2009, AM J CLIN NUTR, V89, P1307, DOI 10.3945/ajcn.2008.27030
   Wang Y, 2007, EPIDEMIOL REV, V29, P6, DOI 10.1093/epirev/mxm007
   Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Walrand S, 2003, CLIN CHIM ACTA, V331, P103, DOI 10.1016/S0009-8981(03)00086-X
   Sell H, 2012, NAT REV ENDOCRINOL, V8, P709, DOI 10.1038/nrendo.2012.114
   Rucker D, 2007, BRIT MED J, V335, P1194, DOI 10.1136/bmj.39385.413113.25
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Bult MJF, 2008, EUR J ENDOCRINOL, V158, P135, DOI 10.1530/EJE-07-0145
   Kaplan LM, 2005, GASTROENTEROL CLIN N, V34, P91, DOI 10.1016/j.gtc.2004.12.002
   Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076
   Berghofer A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-200
   Böyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77
   Clement K, 2009, REV MED INTERNE, V30, P824, DOI 10.1016/j.revmed.2009.03.363
   Dandona P, 2004, REV ENDOCR METAB DIS, V5, P189, DOI 10.1023/B:REMD.0000032407.88070.0a
   Dhar Swati, 2010, Cancer Immun, V10, P10
   Furukawa S, 2004, J CLIN INVEST, V114, P752
   Kimmons JE, ASS BODY MASS INDEX
   Kobashi C, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-25
   Trikamaji AJ, 2001, SIDDHISHANA CHARAK S, P682
   Trikamaji AJ, 2001, SUTRASTHANA CHARAK S, P117
   Trikamaji AJ, 2001, SIDDHI STHANA CHARAK, P684
   Trikamaji AJ, 2001, SIDDHI STHANA CHARAK, P688
   VANDENBERGHE PA, 1990, J IMMUNOL METHODS, V127, P197, DOI 10.1016/0022-1759(90)90069-8
   Wadia P, 2005, ORAL ONCOL, V41, P175, DOI 10.1016/j.oraloncology.2004.08.007
   Zemel MB, 2002, J AM COLL NUTR, V21, p146S
NR 32
TC 0
Z9 0
U1 2
U2 2
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0971-5916
J9 INDIAN J MED RES
JI Indian J. Med. Res.
PD JUL
PY 2015
VL 142
BP 53
EP 62
DI 10.4103/0971-5916.162099
PG 10
WC Immunology; Medicine, General & Internal; Medicine, Research &
   Experimental
SC Immunology; General & Internal Medicine; Research & Experimental
   Medicine
GA CQ5NQ
UT WOS:000360652400009
PM 26261167
ER

PT J
AU Sanchez, AMM
   Pampillon, N
   Abaurre, M
   Omelanczuk, P
AF Magali Sanchez, Angela Maria
   Pampillon, Natalia
   Abaurre, Mariela
   Omelanczuk, Pablo
TI PRE-OPERATIVE IRON DEFICIENCY IN BARIATRIC SURGERY: DIAGNOSIS AND
   TREATMENT
SO NUTRICION HOSPITALARIA
LA Spanish
DT Article
DE Morbid obesity; Bariatric surgery; Iron deficiency; Anemia; Intravenous
   iron
ID Y GASTRIC BYPASS; MORBID-OBESITY; ANEMIA; HEPCIDIN; HYPOFERREMIA;
   MANAGEMENT; ABSORPTION; EXPRESSION
AB Introduction: chronic inflammation induced by obesity alters iron homeostasis leading to mild/moderate iron deficiency and anaemia. Between 14% and 43% of patients may suffer from iron deficiency without anaemia before surgery. The management of pen-operative iron deficiency improves patient outcome and quality of life. Under certain circumstances intravenous (IV) iron must be considered. IV iron (which may avoid iron blockage in enterocytes and macrophages) has turned out to be a safe and efficient alternative.
   Objetives: 1) To assess the prevalence of iron deficiency in morbidly obese patients candidates for bariatric surgery. 2) Assess whether supplementation of parenteral iron in iron-deficient patients is effective in preventing the decrease in hematocrit after surgery.
   Materials and methods: prospective, observational study which included 89 morbidly obese patients who underwent bariatric surgery. The population was divided according to whether or not patients had pre-op iron deficiency, and post-op evolution was analyzed. Iron-deficient patients were supplemented with 500 mg of intravenous (IV) carboximaltose and were evaluated post-op.
   Results: twenty-three patients (25.8%) presented pre-op iron deficiency pre-operatively while six (6.74%) had anemia. 74.2% (66 patients) had no iron deficiency. The group without iron deficiency at one month of surgery had the following laboratory values: Hematocrit: 41.30% +/- 3.77; hemoglobin: 13.64 g/l +/- 1.25 and transferrin saturation: 30.55 %. The patients with pre-op iron deficiency had the following values: Hematocrit: 40.40% +/- 3.03; hemoglobin: 13.40 g/l +/- 1.07; transferrin saturation: 15.50% +/- 4.18, and ferritin: 87.10 ng/ml +/- 81.23. Post-op hematocrit reduction was 38.40% +/- 3.17 (p: 0.034). In iron-deficient patients without IV iron supplementation (n=15), hematocrit and hemoglobin were 41.2% +/- 2.5 and 13.7 g/l +/- 0.9 respectively with post-op reduction (37.5% 3.4 and 12.3 g/l p < 0.05). IV iron supplementation in iron-deficient patients (n = 9) increased hemoglobin (13.5 g/l +/- 0.7), compared with the pre-op (12.8 g/l +/- 1.2; p: 0.05), as well as transferrin saturation and ferritin. One month after surgery there were no significant changes in hematocrit (pre-op: 39%, post-op: 40% p: > 0.05).
   Discussion: 1) Almost 26% of patients present pre-op iron deficiency. 2) Treatment with IV iron seems to be efficient to prevent hematocrit reduction and to improve iron metabolism in pre-op iron-deficient patients. In patients without iron deficiency, hematocrit and iron metabolism remain normal one month after surgery without the need for iron supplementation.
C1 [Magali Sanchez, Angela Maria; Pampillon, Natalia; Abaurre, Mariela; Omelanczuk, Pablo] Ctr Quirurg Obesidad, Mendoza, Argentina.
RP Sanchez, AMM (reprint author), Ctr Quirurg Obesidad, Olegario V Andrade 290, RA-5500 Capital Mendoza, Argentina.
EM ammagali@hotmail.com
CR Ganz T, 2007, J AM SOC NEPHROL, V18, P394, DOI 10.1681/ASN.2006070802
   Ernst B, 2009, OBES SURG, V19, P66, DOI 10.1007/s11695-008-9545-4
   Catalan V, 2007, OBES SURG, V17, P1464, DOI 10.1007/s11695-008-9424-z
   Gesquiere I, 2014, OBES SURG, V24, P56, DOI 10.1007/s11695-013-1042-8
   Chung B, 2007, J NUTR, V137, P2366
   Flancbaum L, 2006, J GASTROINTEST SURG, V10, P1033, DOI 10.1016/j.gassur.2006.03.004
   Puglisi MJ, 2008, J NUTR, V138, P2293, DOI 10.3945/jn.108.097188
   van der Beek ESJ, 2015, OBES SURG, V25, P818, DOI 10.1007/s11695-014-1456-y
   Salgado W, 2014, SURG OBES RELAT DIS, V10, P49, DOI 10.1016/j.soard.2013.06.012
   Thomas DW, 2013, BRIT J HAEMATOL, V161, P639, DOI 10.1111/bjh.12311
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Beris P, 2008, BRIT J ANAESTH, V100, P599, DOI 10.1093/bja/aen054
   Toh SY, 2009, NUTRITION, V25, P1150, DOI 10.1016/j.nut.2009.03.012
   Munoz M, 2009, NUTR HOSP, V24, P640, DOI 10.3305/nh.2009.24.6.4547
   Moize V, 2011, OBES SURG, V21, P1382, DOI 10.1007/s11695-011-0360-y
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Gasteyger C, 2008, AM J CLIN NUTR, V87, P1128
   Saltzman E, 2013, ANNU REV NUTR, V33, P183, DOI 10.1146/annurev-nutr-071812-161225
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Careaga M, 2014, SURG OBES R IN PRESS
   Coad J, 2014, SCAND J CLIN LAB INV, V74, P82, DOI 10.3109/00365513.2014.936694
   Gomez MM, 2005, NEFROLOGIA, V25, P9
   Muñoz M, 2004, Nutr Hosp, V19, P319
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   Varma S, 2008, SURG OBES RELAT DIS, V4, P715, DOI [10.1016/j.soard.2008.04.015, 10.1010/j.soard.2008.04.015]
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
NR 26
TC 0
Z9 0
U1 4
U2 4
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD JUL
PY 2015
VL 32
IS 1
BP 75
EP 79
DI 10.3305/nh.2015.32.1.8871
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CM7AB
UT WOS:000357841700012
ER

PT J
AU Fussner, LA
   Heimbach, JK
   Fan, C
   Dierkhising, R
   Coss, E
   Leise, MD
   Watt, KD
AF Fussner, Lynn A.
   Heimbach, Julie K.
   Fan, Chun
   Dierkhising, Ross
   Coss, Elizabeth
   Leise, Michael D.
   Watt, Kymberly D.
TI Cardiovascular disease after liver transplantation: When, What, and Who
   Is at Risk
SO LIVER TRANSPLANTATION
LA English
DT Article
ID SERUM TROPONIN LEVELS; METABOLIC SYNDROME; ASSOCIATION; TACROLIMUS;
   EVENTS; CYCLOSPORINE; PREVALENCE; PREDICTION; RECIPIENTS; MORTALITY
AB The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence of obesity and metabolic syndrome (MS), define the cumulative incidence of CVD, and characterize risk factors associated with these comorbidities after LT. A retrospective review of 455 consecutive LT recipients from 1999 to 2004 with an 8- to 12-year follow-up was performed. Obesity increased from 23.8% (4 months) to 40.8% (3 years) after LT. Increase in body mass index predicted MS at 1 year after LT (odds ratio, 1.1; P < 0.001, per point). CVD developed in 10.6%, 20.7%, and 30.3% of recipients within 1, 5, and 8 years, respectively. Age, diabetes, hypertension, glomerular filtration rate < 60 mL/minute, prior CVD, ejection fraction < 60%, left ventricular hypertrophy, and serum troponin (TN) > 0.07 ng/mL were associated with CVD on univariate analysis. Age (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.01-1.06; P = 0.019), diabetes (HR, 1.78; 95% CI, 1.09-2.92; P = 0.022), prior history of CVD (HR, 2.46; 95% CI, 1.45-4.16; P < 0.001), and serum TN > 0.07 ng/mL (HR, 1.98; 95% CI, 1.23-3.18; P = 0.005) were independently associated with CVD in the long term. Smoking history (ever), sex, hyperlipidemia, and serum ferritin levels were not predictive of CVD. Tacrolimus use versus noncalcineurin-based immunosuppression (HR, 0.26; 95% CI, 0.14-0.49; P < 0.001) was associated with reduced risk of CVD but not versus cyclosporine (HR, 0.67; 95% CI, 0.30-1.49; P = 0.322). CVD is common after LT. Independent of MS, more data are needed to identify nonconventional risk factors and biomarkers like serum TN. Curbing weight gain in the early months after transplant may impact MS and subsequent CVD in the long term. Liver Transpl 21:889-896, 2015. (c) 2015 AASLD.
C1 [Fussner, Lynn A.; Coss, Elizabeth; Leise, Michael D.; Watt, Kymberly D.] Mayo Clin, Transplant Ctr, Dept Internal Med, Rochester, MN 55905 USA.
   [Heimbach, Julie K.] Mayo Clin, Transplant Ctr, Dept Surg, Rochester, MN 55905 USA.
   [Fan, Chun; Dierkhising, Ross] Mayo Clin, Transplant Ctr, Div Biomed Stat & Informat, Rochester, MN 55905 USA.
   [Leise, Michael D.; Watt, Kymberly D.] Mayo Clin, Transplant Ctr, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA.
RP Watt, KD (reprint author), Mayo Clin, Transplant Ctr, Div Gastroenterol & Hepatol, CH 10,200 First St Southwest, Rochester, MN 55905 USA.
EM watt.kymberly@mayo.edu
CR Laryea M, 2007, LIVER TRANSPLANT, V13, P1109, DOI 10.1002/lt.21126
   Ford ES, 2004, DIABETES CARE, V27, P2444, DOI 10.2337/diacare.27.10.2444
   Watt KDS, 2010, AM J TRANSPLANT, V10, P1420, DOI 10.1111/j.1600-6143.2010.03126.x
   Richards J, 2005, TRANSPLANT INT, V18, P461, DOI 10.1111/j.1432-2277.2004.00067.x
   Fouad TR, 2009, TRANSPLANTATION, V87, P763, DOI 10.1097/TP.0b013e318198d734
   Laish I, 2011, LIVER TRANSPLANT, V17, P15, DOI 10.1002/lt.22198
   Johnston SD, 2002, TRANSPLANTATION, V73, P901, DOI 10.1097/00007890-200203270-00012
   Pateron D, 1999, HEPATOLOGY, V29, P640, DOI 10.1002/hep.510290332
   Piscaglia F, 1999, HEPATOLOGY, V30, P58, DOI 10.1002/hep.510300112
   Bianchi G, 2008, LIVER TRANSPLANT, V14, P1648, DOI 10.1002/lt.21588
   Canzanello VJ, 1998, LIVER TRANSPLANT SUR, V4, P328
   Braun S, 2004, ATHEROSCLEROSIS, V174, P105, DOI 10.1016/j.atherosclerosis.2004.01.011
   Buglioni A, 2015, HYPERTENSION, V65, P45, DOI 10.1161/HYPERTENSIONAHA.114.03936
   Coss E, 2011, LIVER TRANSPLANT, V17, P23, DOI 10.1002/lt.22140
   GADANO A, 1995, HEPATOLOGY, V22, P458, DOI 10.1016/0270-9139(95)90566-9
   Rouyer O, 2009, CLIN TRANSPLANT, V23, P897, DOI 10.1111/j.1399-0012.2009.01013.x
   Safadi A, 2009, CIRCULATION, V120, P1189, DOI 10.1161/CIRCULATIONAHA.108.847178
   Seibert F, 2011, TRANSPL INT, V24, P708, DOI 10.1111/j.1432-2277.2011.01265.x
   Tepperman ED, 2011, J HEART LUNG TRANSPL, V30, P583, DOI 10.1016/j.healun.2010.11.022
   Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600
   Watt KDS, 2010, LIVER TRANSPLANT, V16, P990, DOI 10.1002/lt.22102
NR 21
TC 4
Z9 4
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2015
VL 21
IS 7
BP 889
EP 896
DI 10.1002/lt.24137
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA CL5QF
UT WOS:000357014100007
PM 25880971
ER

PT J
AU Gangarapu, V
   Ince, AT
   Baysal, B
   Kayar, Y
   Kilic, U
   Gok, O
   Uysal, O
   Senturk, H
AF Gangarapu, Venkatanarayana
   Ince, Ali Tuzun
   Baysal, Birol
   Kayar, Yusuf
   Kilic, Ulkan
   Gok, Ozlem
   Uysal, Omer
   Senturk, Hakan
TI Efficacy of rifaximin on circulating endotoxins and cytokines in
   patients with nonalcoholic fatty liver disease
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE endotoxins; gut microbiota; lipopolysaccharides; nonalcoholic fatty
   liver disease; rifaximin
ID GUT MICROBIOTA; INSULIN-RESISTANCE; METABOLIC SYNDROME; HEPATIC
   STEATOSIS; OBESITY; STEATOHEPATITIS; INTERLEUKIN-10; INFLAMMATION;
   ASSOCIATION; ALCOHOL
AB ObjectiveRecent studies have suggested that endotoxin-induced cytokines play an important role in nonalcoholic fatty liver disease (NAFLD). Rifaximin is a nonabsorbable antibiotic that might act on Gram-negative bacteria, thereby inhibiting endotoxin proinflammatory cytokine production in patients with NAFLD. Our aim was to investigate the efficacy of rifaximin on NAFLD.MethodsForty-two patients with biopsy-proven NAFLD [15 steatosis, 27 nonalcoholic steatohepatitis (NASH)] were included in this prospective, open-label, observational cohort study. BMI and serum aspartate aminotransferase, alanine aminotransferase (ALT), gamma glutamyl transferase, lipid profile, ferritin, C-reactive protein, glucose, insulin, homeostatic model assessment as well as endotoxin, serum Toll-like receptor 4 (TlR4), interleukin-1 (IL-1), IL-6, IL-10, IL-12, and tumor necrosis factor- (TNF-) levels were measured before and after a 28-day administration of rifaximin (1200mg/daily). Results were analyzed using nonparametric Wilcoxon signed-rank tests.ResultsA mild reduction in the mean BMI (32.36.9 vs. 31.9 +/- 6.8, P=0.02) and a significant reduction in the endotoxin (0.9 +/- 0.34 vs. 0.8 +/- 0.13, P=0.03) and IL-10 (4.08 +/- 0.9 vs. 3.73 +/- 0.7, P=0.006) levels in the NASH group were noted. A significant reduction was observed in serum aspartate aminotransferase (50.4 +/- 39 vs. 33 +/- 14, P=0.01), ALT (72 +/- 48 vs. 45.2 +/- 26.3, P=0.0001), gamma glutamyl transferase (52 +/- 33 vs. 41.2 +/- 21.1, P=0.02), LDL (137 +/- 34 vs. 127 +/- 27.5, P=0.03), and ferritin (142 +/- 214 vs. 89.3 +/- 123, P=0.0001) in the NASH group, but only in ALT (50.4 +/- 26 vs. 35.5 +/- 23.25, P=0.01), and ferritin (73.6 +/- 83 vs. 55 +/- 76, P=0.004) levels decreased significantly in the steatosis group. Treatment with rifaximin did not exert a significant effect on serum levels of TLR-4, IL-1, IL-6, IL-12, or TNF- in either group.ConclusionIn NAFLD and especially in NASH, short-term administration of rifaximin appears to be safe and effective.
C1 [Gangarapu, Venkatanarayana; Ince, Ali Tuzun; Baysal, Birol; Kayar, Yusuf; Senturk, Hakan] Istanbul Medipol Univ, Fac Med, Dept Gastroenterol, Istanbul, Turkey.
   [Kilic, Ulkan; Gok, Ozlem] Istanbul Medipol Univ, Fac Med, Dept Med Biol, Istanbul, Turkey.
   [Uysal, Omer] Bezmialem Vakif Univ, Fac Med, Dept Biostat, TR-34093 Istanbul, Turkey.
RP Senturk, H (reprint author), Bezmialem Vakif Univ, Gastroenterol Clin, Adnan Menderes Bulvari, TR-34093 Istanbul, Turkey.
EM drhakansenturk@yahoo.com
FU Scientific Research Project Council of the Bezmialem Vakif University
   (BAP) [6.2013/4]
FX This work is supported by the Scientific Research Project Council of the
   Bezmialem Vakif University (BAP No. 6.2013/4)
CR Angulo P, 2014, CLIN GASTROENTEROL H, V12
   Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634
   DRENICK EJ, 1982, GASTROENTEROLOGY, V82, P535
   Cheung O, 2010, CURR OPIN GASTROEN, V26, P202, DOI 10.1097/MOG.0b013e328337b0c4
   Wagnerberger S, 2012, BRIT J NUTR, V107, P1727, DOI 10.1017/S0007114511004983
   Xu RY, 2012, J CLIN BIOCHEM NUTR, V50, P72, DOI 10.3164/jcbn.11-38
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Crews FT, 2006, ALCOHOL CLIN EXP RES, V30, P720, DOI 10.1111/j.1530-0277.2006.00084.x
   Bajaj JS, 2011, GASTROENTEROLOGY, V140, P478, DOI 10.1053/j.gastro.2010.08.061
   Jenkins DJA, 2005, METABOLISM, V54, P103, DOI 10.1016/j.metabol.2004.07.019
   Bergheim I, 2008, J HEPATOL, V48, P983, DOI 10.1016/j.jhep.2008.01.035
   Mouzaki M, 2013, HEPATOLOGY, V58, P120, DOI 10.1002/hep.26319
   Hu KC, 2014, WORLD J GASTROENTERO, V20, P7718, DOI 10.3748/wjg.v20.i24.7718
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a
   Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008
   Vlachogiannakos J, 2009, ALIMENT PHARM THER, V29, P992, DOI 10.1111/j.1365-2036.2009.03958.x
   Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001
   Mandrekar P, 2009, J HEPATOL, V50, P1258, DOI 10.1016/j.jhep.2009.03.007
   Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   Raman M, 2013, CLIN GASTROENTEROL H, V11, P868, DOI 10.1016/j.cgh.2013.02.015
   Thuy S, 2008, J NUTR, V138, P1452
   Kalambokis GN, 2012, LIVER INT, V32, P467, DOI 10.1111/j.1478-3231.2011.02650.x
   Esposito K, 2003, J CLIN ENDOCR METAB, V88, P1055, DOI 10.1210/jc.2002-021437
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Cintra DE, 2008, J HEPATOL, V48, P628, DOI 10.1016/j.jhep.2007.12.017
   GILLIS JC, 1995, DRUGS, V49, P467, DOI 10.2165/00003495-199549030-00009
   Kim CH, 2011, METABOLISM, V60, P414, DOI 10.1016/j.metabol.2010.03.007
   Rivera CA, 2007, J HEPATOL, V47, P571, DOI 10.1016/j.jhep.2007.04.019
   Kanuri G, 2015, LIVER INT, V35, P562, DOI 10.1111/liv.12442
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   van Exel E, 2002, DIABETES, V51, P1088, DOI 10.2337/diabetes.51.4.1088
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   Farhadi A, 2008, LIVER INT, V28, P1026, DOI 10.1111/j.1478-3231.2008.01723.x
   Bajaj JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060042
   Calcaterra Valeria, 2009, Acta Biomed, V80, P117
   Cameron RG, 1999, CLIN BIOCHEM, V32, P579, DOI 10.1016/S0009-9120(99)00058-2
   Cobbold JF, 2013, GUT, V62, pA92, DOI 10.1136/gutjnl-2013-304907.203
   Fernandes J, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.23
   Flamm Steven L, 2011, Therap Adv Gastroenterol, V4, P199, DOI 10.1177/1756283X11401774
   Hebbard L, 2011, NAT REV GASTRO HEPAT, V8, P34, DOI 10.1038/nrgastro.2010.191
   Koo HL, 2010, CURR OPIN GASTROEN, V26, P17, DOI 10.1097/MOG.0b013e328333dc8d
   Meli R, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00177
   Rosette C, 2013, INT J ANTIMICROB AG, V42, P182, DOI 10.1016/j.ijantimicag.2013.04.020
NR 47
TC 1
Z9 1
U1 5
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0954-691X
EI 1473-5687
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD JUL
PY 2015
VL 27
IS 7
BP 840
EP 845
DI 10.1097/MEG.0000000000000348
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CK9VV
UT WOS:000356588500012
PM 26043290
ER

PT J
AU Alwan, NA
   Cade, JE
   McArdle, HJ
   Greenwood, DC
   Hayes, HE
   Simpson, NAB
AF Alwan, Nisreen A.
   Cade, Janet E.
   McArdle, Harry J.
   Greenwood, Darren C.
   Hayes, Helen E.
   Simpson, Nigel A. B.
TI Maternal iron status in early pregnancy and birth outcomes: insights
   from the Baby's Vascular health and Iron in Pregnancy study
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Iron; Birth weight; Preterm birth; Pregnancy
ID DEFICIENCY ANEMIA; TRANSFERRIN RECEPTOR; PRETERM DELIVERY; INCREASED
   RISK; BRITISH WOMEN; WEIGHT; MORTALITY; CHILDREN; DISEASE; OBESITY
AB Fe deficiency anaemia during early pregnancy has been linked with low birth weight and preterm birth. However, this evidence comes mostly from studies measuring Hb levels rather than specific measures of Fe deficiency. The present study aimed to examine the association between maternal Fe status during the first trimester of pregnancy, as assessed by serum ferritin, transferrin receptor and their ratio, with size at birth and preterm birth. In the Baby VIP (Baby's Vascular health and Iron in Pregnancy) study, we recruited 362 infants and their mothers after delivery in Leeds, UK. Biomarkers were measured in maternal serum samples previously obtained in the first trimester of pregnancy. The cohort included sixty-four (18 %) small for gestational age (SGA) babies. Thirty-three babies were born preterm (9 %; between 34 and 37 weeks). First trimester maternal Fe depletion was associated with a higher risk of SGA (adjusted OR 2.2, 95% CI 1.1, 4.1). This relationship was attenuated when including early pregnancy Hb in the model, suggesting it as a mediator (adjusted OR 1.6, 95% CI 0.8, 3.2). For every 10 g/l increase in maternal Hb level in the first half of pregnancy the risk of SGA was reduced by 30% (adjusted 95% CI 0, 40 %); levels below 110 g/l were associated with a 3-fold increase in the risk of SGA (95% CI 1.0, 9.0). There was no evidence of association between maternal Fe depletion and preterm birth (adjusted OR 1.5, 95% 0.6, 3.8). The present study shows that depleted Fe stores in early pregnancy are associated with higher risk of SGA.
C1 [Alwan, Nisreen A.] Univ Southampton, Acad Unit Primary Care & Populat Sci, Southampton Gen Hosp, Fac Med, Southampton SO16 6YD, Hants, England.
   [Cade, Janet E.] Univ Leeds, Sch Food Sci & Nutr, Nutr Epidemiol Grp, Leeds LS2 9JT, W Yorkshire, England.
   [McArdle, Harry J.; Hayes, Helen E.] Univ Aberdeen, Rowett Inst Nutr & Hlth, Aberdeen, Scotland.
   [Greenwood, Darren C.] Univ Leeds, Div Biostat, Leeds, W Yorkshire, England.
   [Simpson, Nigel A. B.] Univ Leeds, Div Womens & Childrens Hlth, Leeds, W Yorkshire, England.
RP Alwan, NA (reprint author), Univ Southampton, Acad Unit Primary Care & Populat Sci, Southampton Gen Hosp, Fac Med, Southampton SO16 6YD, Hants, England.
EM n.a.alwan@soton.ac.uk
RI Greenwood, Darren/C-3220-2008; Alwan, Nisreen/A-5081-2014
OI Greenwood, Darren/0000-0001-7035-3096; Alwan,
   Nisreen/0000-0002-4134-8463
FU Wellcome Trust Research Training Fellowship [WT87789]; Scottish
   Government's Rural and Environment Science and Analytical Services;
   Cerebra
FX N. A. A. was funded by a Wellcome Trust Research Training Fellowship
   (WT87789). H. J. M. and H. E. H. are supported by the Scottish
   Government's Rural and Environment Science and Analytical Services. N.
   A. B. S. is supported by Cerebra.
CR Allen LH, 2000, AM J CLIN NUTR, V71, P1280
   Alwan NA, 2010, P NUTR SOC, V69, pE592
   Alwan NA, 2011, HUM REPROD, V26, P911, DOI 10.1093/humrep/der005
   Baynes RD, 1996, CLIN BIOCHEM, V29, P209, DOI 10.1016/0009-9120(96)00010-K
   Lone FW, 2004, TROP MED INT HEALTH, V9, P486, DOI 10.1111/j.1365-3156.2004.01222.x
   Allen J, 1998, CLIN CHEM, V44, P35
   Scanlon KS, 2000, OBSTET GYNECOL, V96, P741, DOI 10.1016/S0029-7844(00)00982-0
   GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x
   Mei ZG, 2011, AM J CLIN NUTR, V93, P1312, DOI 10.3945/ajcn.110.007195
   Worwood M, 1997, CLIN CHIM ACTA, V259, P3, DOI 10.1016/S0009-8981(96)06488-1
   Cook JD, 2005, BEST PRACT RES CL HA, V18, P319, DOI 10.1016/j.beha.2004.08.022
   Skikne BS, 2008, AM J HEMATOL, V83, P872, DOI 10.1002/ajh.21279
   Bondevik GT, 2001, ACTA OBSTET GYN SCAN, V80, P402
   Gardosi J, 2004, SEMIN PERINATOL, V28, P33, DOI 10.1053/j.semperi.2003.12.002
   Lawn JE, 2004, LANCET, V364, P399, DOI 10.1016/S0140-6736(04)16783-4
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Beard JL, 2008, J NUTR, V138, P2534
   Howie GJ, 2009, J PHYSIOL-LONDON, V587, P905, DOI 10.1113/jphysiol.2008.163477
   Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728
   [Anonymous], 2001, IR DEF AN ASS PREV C
   Alwan NA, 2010, BJOG-INT J OBSTET GY, V117, P821, DOI 10.1111/j.1471-0528.2010.02549.x
   SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985
   Zimmermann MB, 2008, BRIT J NUTR, V99, pS2, DOI 10.1017/S000711450800679X
   Brion MJA, 2008, AM J CLIN NUTR, V88, P1126
   Barbin B, 1990, ANN TROP MED PARASIT, V84, P11
   BARKER DJP, 1995, BRIT MED J, V311, P171
   BEARD JL, 1994, AM J CLIN NUTR, V59, p502S
   Bergmann RL, 2002, EUR J OBSTET GYN R B, V102, P155, DOI 10.1016/S0301-2115(01)00609-1
   Colomer J, 1990, Paediatr Perinat Epidemiol, V4, P196, DOI 10.1111/j.1365-3016.1990.tb00638.x
   Gluckman P, 2006, BMJ-BRIT MED J
   James WPT, 2000, FOOD NUTR BULL, V21, P1
   Kilbride J, 1999, INT J EPIDEMIOL, V28, P461, DOI 10.1093/ije/28.3.461
   McMahon L. P., 2010, OBSTETRIC MED, V3, P17
   NICE, 2008, ANT CAR ROUT CAR HLT
   Rasmussen KM, 2001, J NUTR, V131, p590S
   Remacle C, 2011, AM J CLIN NUTR, V94, p1846S, DOI 10.3945/ajcn.110.001651
   Ribot B, 2012, HUM REPROD, V27, P1260, DOI 10.1093/humrep/des026
   RICHARDSON DK, 1993, PEDIATRICS, V91, P969
   Royal College of Obstetricians and Gynaecologists, 2013, SMALL FOR GEST AG FE, V31
   Ruivard M, 2000, AM J CLIN NUTR, V21, P837
   Schluchter MD, 2008, MULTIVAR BEHAV RES, V43, P268, DOI 10.1080/00273170802034877
   SCHOLL TO, 1994, AM J CLIN NUTR, V59, p492S
   Scholl TO, 2005, AM J CLIN NUTR, V81, p1218S
   Scholl TO, 1994, AM J CLIN NUTR S, V59, p500S
   WHO, 2010, MICR DEF
   WHO, 2011, SER FERR CONC ASS IR
   Zhou LM, 1998, AM J EPIDEMIOL, V148, P998
NR 47
TC 0
Z9 0
U1 6
U2 6
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUN 28
PY 2015
VL 113
IS 12
BP 1985
EP 1992
DI 10.1017/S0007114515001166
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CM7PR
UT WOS:000357887800016
PM 25946517
ER

PT J
AU Tijerina-Saenz, A
   Martinez-Garza, NE
   Ramirez-Lopez, E
   Solis-Perez, E
   Martinez-Baez, AZ
AF Tijerina-Saenz, Alexandra
   Martinez-Garza, Nancy E.
   Ramirez-Lopez, Erik
   Solis-Perez, Elizabeth
   Martinez-Baez, Adbel Z.
TI Iron status and dietary intakes of iron in normal-weight and obese young
   Mexican women
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Obesity; Body fat; Iron status; Dietary intake; Women
ID MENSTRUATING WOMEN; REPRODUCTIVE AGE; SERUM IRON; DEFICIENCY;
   INFLAMMATION; FERRITIN; ANEMIA; HEALTH; CYCLE; CITY
AB Introduction: obesity is reported to be a predictor of iron deficiency. In Mexico, 45.5 % of women older than 20 years have obesity, and the prevalence of anemia is 10.2 % in women 20 to 29 years.
   Objective: to investigate the relation between body mass index (BMI), percentage of body fat (% BF), dietary intakes and iron status of healthy normal-weight and obese young women.
   Methods: a total of 86 women [normal-weight (n = 46) and obese (n = 40)] completed the study. Intakes were evaluated by an 8-day food-record. Anthropometrics and blood collection (hemoglobin, hematocrit, ferritin and transferrin) were done on the luteal phase of menstrual cycle; menstrual characteristics were also reported. Iron status was determined according to stages of iron depletion. T-test and Mann-Whitney U test were used to compare groups' variables. Pearson correlation was used to determine relationships between variables. An odds ratio (OR) analysis was used to measure the association of BMI, % BF and dietary intakes with iron status.
   Results: biomarkers of iron were similar between groups. There was a positive correlation between % BF and ferritin (r = 0.222; p = 0.032). Similar intakes and menstrual periods may be the reason of similar iron status. BMI, % BF or dietary intakes were not independent contributors to stages of iron depletion.
   Conclusion: guidance on dietary intakes is suggested for this population to avoid future iron deficiency complications.
C1 [Tijerina-Saenz, Alexandra; Martinez-Garza, Nancy E.; Ramirez-Lopez, Erik; Solis-Perez, Elizabeth; Martinez-Baez, Adbel Z.] UANL, Fac Salud Publ & Nutr FaSPyN, CINSP, Monterrey, NL, Mexico.
RP Tijerina-Saenz, A (reprint author), Col Mitras Ctr, Dr Eduardo Aguirre Pequeno & Yuriria, Monterrey 66455, NL, Mexico.
EM alexandra.tijerinas@uanl.mx
FU Support Program for Scientific and Technological Research (PAICYT, for
   its Spanish abbreviation) - UANL
FX This work was supported by the Support Program for Scientific and
   Technological Research (PAICYT, for its Spanish abbreviation) sponsored
   by the UANL.
CR Aigner E, 2014, NUTRIENTS, V6, P3587, DOI 10.3390/nu6093587
   Alves-Pereira R, 2010, CAD SAUDE PUBLICA, V26, P2101
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Lazarevich I, 2013, NUTR HOSP, V28, P1892, DOI [10.3305/nutr hosp.v28in06.6873, 10.3305/nh.2013.28.6.6873]
   Kordas K, 2013, J NUTR, V143, P175, DOI 10.3945/jn.112.167767
   Chambers EC, 2006, J AM DIET ASSOC, V106, P680, DOI 10.1016/j.jada.2006.02.013
   FRICKER J, 1990, AM J CLIN NUTR, V52, P863
   Fanou-Fogny N, 2011, BRIT J NUTR, V105, P574, DOI 10.1017/S0007114510003776
   [Anonymous], BOD FAT RANG STAND A
   Casanueva E, 2003, ANN NUTR METAB, V47, P60, DOI 10.1159/000069276
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Gallagher D, 2000, AM J CLIN NUTR, V72, P694
   Milman N, 1998, ANN HEMATOL, V77, P13, DOI 10.1007/s002770050405
   Dale JC, 2002, AM J CLIN PATHOL, V117, P802, DOI 10.1309/2YT4-CMP3-KYW7-9RK1
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Bryant M, 2006, BRIT J NUTR, V96, P888, DOI 10.1017/BJN20061931
   Bourges H, 2008, RECOMENDACIONES INGE, P188
   Cairo Romilda Castro de Andrade, 2014, NUTR HOSP, V29, P1240
   Cook J, 1999, Arch Latinoam Nutr, V49, p11S
   Horvath JDC, 2014, NUTR HOSP, V29, P292, DOI 10.3305/nh.2014.29.2.7053
   Duport N, 2003, EUR J CLIN NUTR, V57, P1169, DOI 10.1038/sj.ejcn.1601669
   Elizondo LL, 2011, TERAPIA NUTR MED GIN, P79
   Gutierrez J.P., 2012, ENCUESTA NACL SALUD
   KIM I, 1993, AM J CLIN NUTR, V58, P705
   Andrews Guzmán Mónica, 2014, Nutr Hosp, V30, P577, DOI 10.3305/nh.2014.30.3.7647
   Perez EM, 2009, AM J CLIN NUTR, V89, p946S
   Thompson FE, 2013, NUTR PREVENTION TREA, P5, DOI DOI 10.1016/B978-0-12-391884-0.00001-9
   World Health Organization, 2014, GLOB DAT BOD MASS IN
NR 29
TC 0
Z9 0
U1 7
U2 7
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD JUN
PY 2015
VL 31
IS 6
BP 2412
EP 2418
DI 10.3305/nh.2015.31.6.8687
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CK0KV
UT WOS:000355895000010
PM 26040346
ER

PT J
AU Guglielmi, V
   D'Adamo, M
   Bellia, A
   Ciotto, RT
   Federici, M
   Lauro, D
   Sbraccia, P
AF Guglielmi, V.
   D'Adamo, M.
   Bellia, A.
   Ciotto, R. T.
   Federici, M.
   Lauro, D.
   Sbraccia, P.
TI Iron status in obesity: An independent association with metabolic
   parameters and effect of weight loss
SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
LA English
DT Article
DE Obesity; Ferritin; Iron status
ID FATTY LIVER-DISEASE; INSULIN-RESISTANCE; SERUM FERRITIN; INFLAMMATION;
   HYPOFERREMIA; SENSITIVITY; HEPCIDIN; INDEXES; STORES; ADULTS
AB Background and aims: Growing evidence has shown that ferritin concentrations are associated with obesity and insulin resistance, and with nonalcoholic fatty liver disease. However, it is unclear whether ferritin is simply an inflammatory marker, or it may directly contribute to the pathogenesis of obesity-related metabolic alterations. The aim of our study was to investigate the independent associations of ferritin levels with metabolic parameters in overweight/obese subjects before and after hypocaloric diet-induced weight changes.
   Methods and results: A sample study of 48 premenopausal, 39 postmenopausal women and 50 men was retrospectively analyzed. Clinical, bioimpedentiometry and biochemical data from baseline evaluations and after 3, 6 and 12 months of hypocaloric diet were collected. In the whole sample study, the baseline values of ferritin concentrations were positively correlated with body mass index (BMI) (r = 0.21, p < 0.05) and mass body fat (MBF) (r = 0.26, p < 0.05), whereas the serum iron level was negatively correlated with MBF (r = -0.29, p < 0.05). In premenopausal women, BMI-adjusted ferritin concentrations were negatively associated with high-density lipoprotein-cholesterol and positively related with triglycerides and aspartate aminotransferase. Moreover, the quantitative ferritin reduction at 12 months was positively associated with the relative reduction of BMI (r = 0.34, p < 0.05). Finally, the association between changes of alanine aminotransferase and ferritin levels at 12 months from baseline turned out to be independent of respective BMI changes (beta = 0.31, p < 0.05).
   Conclusion: In obesity, ferritin, putatively entailing increased iron storage, is independently associated with lipid derangements and transaminase levels, and the association with the latter persists after weight changes. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Guglielmi, V.; D'Adamo, M.; Bellia, A.; Ciotto, R. T.; Federici, M.; Lauro, D.; Sbraccia, P.] Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy.
   [Guglielmi, V.; D'Adamo, M.; Ciotto, R. T.; Sbraccia, P.] Univ Hosp Policlin Tor Vergata, Obes Ctr, Rome, Italy.
RP Sbraccia, P (reprint author), Univ Roma Tor Vergata, Dept Syst Med, Via Montpellier 1, I-00133 Rome, Italy.
EM sbraccia@med.uniroma2.it
OI Lauro, Davide/0000-0002-8597-4415; FEDERICI, MASSIMO/0000-0003-4989-5194
FU Ministero dell'Universita e della Ricerca [prot. 2010329EKE_003]
FX We gratefully acknowledge the assistance of Dr. Eva Tola and Dr.
   Samantha Santelli, dietitians, in planning dietary regimens and
   counseling patients. This work was supported by a grant from the
   Ministero dell'Universita e della Ricerca (prot. 2010329EKE_003).
CR Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Fernandez-Real JM, 2014, LANCET DIABETES ENDO, V2, P513, DOI 10.1016/S2213-8587(13)70174-8
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Ramalho R, 2009, OBES SURG, V19, P915, DOI 10.1007/s11695-009-9848-0
   Whaley-Connell A, 2011, REV CARDIOVASC MED, V12, P21, DOI 10.3909/ricm0555
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Kong WN, 2014, BIOL TRACE ELEM RES, V160, P258, DOI 10.1007/s12011-014-0051-3
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   Ahmed U, 2012, WORLD J GASTROENTERO, V18, P4651, DOI 10.3748/wjg.v18.i34.4651
   Dongiovanni P, 2013, AM J PATHOL, V182, P2254, DOI 10.1016/j.ajpath.2013.02.019
   Moreno-Navarrete JM, 2010, INT J OBESITY, V34, P240, DOI 10.1038/ijo.2009.242
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   Schweiger C, 2010, OBES SURG, V20, P193, DOI 10.1007/s11695-009-0008-3
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007
   Sesti G, 2013, NUTR METAB CARDIOVAS, V23, P1182, DOI 10.1016/j.numecd.2013.01.006
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Wlazlo N, 2013, DIABETES CARE, V36, P309, DOI 10.2337/dc12-0505
   Festa M, 2000, J BIOL CHEM, V275, P36708, DOI 10.1074/jbc.M004988200
   Rumberger JM, 2004, DIABETES, V53, P2535, DOI 10.2337/diabetes.53.10.2535
   Beard J, 1997, AM J CLIN NUTR, V66, P104
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   Gastaldelli A, 2009, OBES SURG, V19, P80, DOI 10.1007/s11695-008-9690-9
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Kilani N, 2014, NUTR METAB CARDIOVAS, V24, pE28, DOI 10.1016/j.numecd.2014.04.018
   Machado M, 2006, LIVER INT, V26, P1159, DOI 10.1111/j.1478-3231.2006.01394.x
   Manousou P, 2011, LIVER INT, V31, P730, DOI 10.1111/j.1478-3231.2011.02488.x
   Rodriguez-Rodriguez E, 2007, ANN NUTR METAB, V51, P367, DOI 10.1159/000107680
   Tao H, 2014, NUTR METAB CARDIOVAS, V24, pE11, DOI 10.1016/j.numecd.2013.04.012
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
NR 36
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0939-4753
EI 1590-3729
J9 NUTR METAB CARDIOVAS
JI Nutr. Metab. Carbiovasc. Dis.
PD JUN
PY 2015
VL 25
IS 6
BP 541
EP 547
DI 10.1016/j.numecd.2015.02.012
PG 7
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition
   & Dietetics
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism;
   Nutrition & Dietetics
GA CJ0GL
UT WOS:000355153700004
PM 25843660
ER

PT J
AU Ledesma, M
   Hurtado-Roca, Y
   Leon, M
   Giraldo, P
   Pocovi, M
   Civeira, F
   Guallar, E
   Ordovas, JM
   Casasnovas, JA
   Laclaustra, M
AF Ledesma, Marta
   Hurtado-Roca, Yamilee
   Leon, Montserrat
   Giraldo, Pilar
   Pocovi, Miguel
   Civeira, Fernando
   Guallar, Eliseo
   Maria Ordovas, Jose
   Antonio Casasnovas, Jose
   Laclaustra, Martin
TI Association of Ferritin Elevation and Metabolic Syndrome in Males.
   Results from the Aragon Workers' Health Study (AWHS)
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; CARDIOVASCULAR RISK-FACTORS;
   INSULIN-RESISTANCE SYNDROME; KOREAN NATIONAL-HEALTH; C-REACTIVE PROTEIN;
   BETA-CELL FUNCTION; SERUM FERRITIN; HEREDITARY HEMOCHROMATOSIS;
   GENERAL-POPULATION; OXIDATIVE STRESS
AB Context: Ferritin concentration is associated with metabolic syndrome, but the possibility of a nonlinear association has never been explored.
   Objective: This study aimed to examine the relationship between serum ferritin levels and the metabolic syndrome in Spanish adult males.
   Design: This was a cross-sectional analysis of baseline data from the Aragon Workers' Health Study.
   Setting: Healthy workers from a factory were studied during their annual checkup.
   Participants: Spanish male adults (n = 3386) between the ages of 19 and 65 years participated. We excluded participants with ferritin > 500 mu g/L, ferritin < 12 mu g/L, or C-reactive protein > 10 mg/L.
   Main Outcome Measure: Metabolic syndrome was defined according to the 2009 consensus definition from the Joint Interim Statement of several international societies.
   Results: Metabolic syndrome prevalence was 27.1%. We found a positive association between elevated iron stores, measured as serum ferritin concentration, and metabolic syndrome and its criteria. Participants within the highest serum ferritin quintile had a higher risk than those in the lowest quintile for central obesity (odds ratio [OR], 1.88; 95% confidence interval [CI], 1.46-2.42), hypertriglyceridemia (OR, 2.15; 95% CI, 1.69-2.74), and metabolic syndrome (OR, 1.92; 95% CI, 1.48-2.49). The association was nonlinear and occurred at serum ferritin concentrations > 100 mu g/L (similar to 33th percentile). Ferritin was also associated with insulin resistance, measured by homeostatic model assessment-insulin resistance (HOMA-IR) (P trend < .001).
   Conclusions: Our findings suggest that serum ferritin is significantly associated with metabolic syndrome and its criteria (especially central obesity and hypertriglyceridemia), suggesting that ferritin could be an early marker of metabolic damage in the development of metabolic syndrome.
C1 [Ledesma, Marta; Leon, Montserrat; Giraldo, Pilar; Pocovi, Miguel; Civeira, Fernando; Antonio Casasnovas, Jose] Inst Aragones Ciencias Salud, Zaragoza 50009, Spain.
   [Hurtado-Roca, Yamilee; Maria Ordovas, Jose; Laclaustra, Martin] Spanish Natl Ctr Cardiovasc Res, Dept Epidemiogy Atherothrombosis & Imaging, Madrid 28029, Spain.
   [Giraldo, Pilar] CIBERER, Zaragoza 50009, Spain.
   [Guallar, Eliseo] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Dept Epidemiol, Baltimore, MD 21205 USA.
   [Guallar, Eliseo] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Dept Med, Baltimore, MD 21205 USA.
   [Laclaustra, Martin] Univ Autonoma Madrid, Sch Med, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain.
   [Laclaustra, Martin] St Louis Univ, Dept Epidemiol, St Louis, MO 63104 USA.
RP Ledesma, M (reprint author), Ctr Nacl Invest Cardiovasc, Dept Epidemiogy Atherothrombosis & Imaging, C Melchor Fernandez Almagro 3, Madrid 28029, Spain.
EM mlaclaustra@cnic.es
RI Laclaustra, Martin/C-6709-2015
OI Laclaustra, Martin/0000-0003-3963-0846
FU Instituto Aragones de Ciencias de la Salud (I+CS); Spanish National
   Center for Cardiovascular Research (Centro Nacional de Investigaciones
   Cardiovasculares); Instituto de Salud Carlos III [FIS CP08/00112,
   PI10/00021, PI14/00009]; Peruvian government [088-FINCyT-BDE-2014]; FIS
   [PI12/01703, PI12/01434]
FX The Aragon Workers' Health Study is funded by Instituto Aragones de
   Ciencias de la Salud (I+CS) and the Spanish National Center for
   Cardiovascular Research (Centro Nacional de Investigaciones
   Cardiovasculares). M.La. was supported in part by Grants FIS CP08/00112,
   PI10/00021, and PI14/00009 from the Instituto de Salud Carlos III.
   Y.H.-R. was supported by Scholarship NO. 088-FINCyT-BDE-2014 from the
   Peruvian government. M.P. was supported by FIS PI12/01703. M.Leo. was
   supported by FIS PI12/01434.
CR Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Mateo-Gallego R, 2010, METABOLISM, V59, P154, DOI 10.1016/j.metabol.2009.06.021
   Wu JP, 2014, ARCH MED RES, V45, P251, DOI 10.1016/j.arcmed.2014.03.004
   Park SK, 2012, DIABETES CARE, V35, P2521, DOI 10.2337/dc12-0543
   Yoo KD, 2012, CLIN ENDOCRINOL, V77, P233, DOI 10.1111/j.1365-2265.2011.04248.x
   Lee BK, 2011, METABOLISM, V60, P1416, DOI 10.1016/j.metabol.2011.02.008
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   COOK JD, 1974, AM J CLIN NUTR, V27, P681
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Halle M, 1997, ATHEROSCLEROSIS, V128, P235, DOI 10.1016/S0021-9150(96)05994-1
   McClain DA, 2006, DIABETOLOGIA, V49, P1661, DOI 10.1007/s00125-006-0200-0
   LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Tamakoshi K, 2003, INT J OBESITY, V27, P443, DOI 10.1038/sj.ijo.0802260
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Laclaustra M, 2007, NUTR METAB CARDIOVAS, V17, P125, DOI 10.1016/j.numecd.2006.10.005
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Parola M, 2011, ANTIOXID REDOX SIGN, V15, P461, DOI 10.1089/ars.2010.3848
   Cooksey RC, 2004, ENDOCRINOLOGY, V145, P5305, DOI 10.1210/en.2004-0392
   Kim CH, 2011, METABOLISM, V60, P414, DOI 10.1016/j.metabol.2010.03.007
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   DAVIS RJ, 1986, J BIOL CHEM, V261, P8708
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Crownover BK, 2013, AM FAM PHYSICIAN, V87, P183
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Moreno-Navarrete JM, 2014, DIABETES CARE, V37, P1092, DOI 10.2337/dc13-1602
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Wessling-Resnick M, 2010, ANNU REV NUTR, V30, P105, DOI 10.1146/annurev.nutr.012809.104804
   Casanova-Esteban P, 2011, METABOLISM, V60, P830, DOI 10.1016/j.metabol.2010.07.035
   Casasnovas JA, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-45
   Kaur J., 2014, CARDIOL RES PRACT, V2014, DOI 10.1155/2014/943162.
   Vagu C, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.13136
   Wood MJ, 2012, HEPATOLOGY, V56, P904, DOI 10.1002/hep.25720
NR 37
TC 0
Z9 0
U1 1
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2015
VL 100
IS 5
BP 2081
EP 2089
DI 10.1210/jc.2014-4409
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CM4QG
UT WOS:000357669000065
PM 25695891
ER

PT J
AU Vazquez-Lopez, MA
   Ibanez-Alcalde, M
   Lendinez-Molinos, F
   Ruiz-Sanchez, AM
   Galera-Martinez, R
   Garcia-Garcia, E
   Parron-Carreno, T
   Bonillo-Perales, A
AF Vazquez-Lopez, Maria A.
   Ibanez-Alcalde, Mercedes
   Lendinez-Molinos, Francisco
   Ruiz-Sanchez, Ana M.
   Galera-Martinez, Rafael
   Garcia-Garcia, Emilio
   Parron-Carreno, Tesifon
   Bonillo-Perales, Antonio
TI Reference Values of Serum Transferrin Receptor and sTfR/Log Ferritin
   Index in Healthy Adolescents
SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
LA English
DT Article
DE healthy adolescents; iron deficiency; serum transferrin receptor; serum
   transferrin receptor/log ferritin index; serum erythropoietin
ID FUNCTIONAL IRON-DEFICIENCY; REFERENCE LIMITS; REFERENCE INTERVALS;
   DIAGNOSIS; CHILDREN; OBESITY; AGE; PREVALENCE; ANEMIA; HYPOFERREMIA
AB Adolescence is a period of increased iron requirements, which impact on iron status. The purpose of this research is to determine the reference intervals for serum transferrin receptor (sTfR) and sTfR/log ferritin index (sTfR-F index) in healthy adolescents, and their relation with iron parameters and erythropoiesis. A total of 253 healthy adolescents without overweight, aged 12 to 16 years, were selected in a cross-sectional study. Hemoglobin, red cell indices, reticulocyte hemoglobin content (rHb), reticulocytes, ferritin, transferrin saturation, erythrocyte protoporphirin, erythropoietin, C-reactive protein, sTfR, and sTfR-F index were measured. Changes in erythropoiesis and iron status in the age interval were observed and analyzed, and linear multiple regression was applied to identify the factors that determine the variability of sTfR and sTfR-F index. Mean values for sTfR and sTfR-F index were 1.32 +/- 0.3 mg/L (95% CI, 1.3-1.36) and 0.9 +/- 0.25 (95% CI, 0.87-0.93). The reference intervals were 0.84 to 1.97 mg/L and 0.51 to 1.44, respectively. sTfR and sTfR-F index values were significantly higher in boys (1.39 +/- 0.3 vs. 1.23 +/- 0.26 mg/L, P < 0.0001 and 0.93 +/- 0.37 vs. 0.86 +/- 0.22, P < 0.04) and decreased with age (P < 0.0001 and 0.04, respectively). No changes were recorded in erythropoietin. Age, sex, pubertal status, and ferritin predicted 24.1% of sTfR variability and age, sex, pubertal status, transferrin saturation, rHb, erythrocytes, and reticulocytes predicted 15% of sTfR-F index variability.
C1 [Vazquez-Lopez, Maria A.; Ibanez-Alcalde, Mercedes; Lendinez-Molinos, Francisco; Ruiz-Sanchez, Ana M.; Galera-Martinez, Rafael; Garcia-Garcia, Emilio; Parron-Carreno, Tesifon; Bonillo-Perales, Antonio] Torrecardenas Hosp, Dept Pediat, Almeria, Spain.
RP Vazquez-Lopez, MA (reprint author), Plaza Castillo 10, Carboneras 04140, Almeria, Spain.
EM mavazquezl59@gmail.com
CR Abrams SA, 2013, IRON REQUIREMENTS IR
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Punnonen K, 1997, BLOOD, V89, P1052
   Castel R, 2012, CLIN CHEM LAB MED, V50, P1343, DOI 10.1515/cclm-2011-0594
   Skikne BS, 2011, AM J HEMATOL, V86, P923, DOI 10.1002/ajh.22108
   Thomas C, 2002, CLIN CHEM, V48, P1066
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Thorpe SJ, 2010, CLIN CHEM LAB MED, V48, P815, DOI 10.1515/CCLM.2010.167
   [Anonymous], 2008, AN PEDIATR
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Thomas DW, 2013, BRIT J HAEMATOL, V161, P639, DOI 10.1111/bjh.12311
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Thomas C, 2006, MED ONCOL, V23, P23, DOI 10.1385/MO:23:1:23
   Ferrari M, 2011, EUR J CLIN NUTR, V65, P340, DOI 10.1038/ejcn.2010.279
   Merkel D, 2005, J ADOLESCENT HEALTH, V37, P220, DOI 10.1016/j.jadohealth.2004.08.029
   SKIKNE BS, 1990, BLOOD, V75, P1870
   Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   CHISOLM JJ, 1975, CLIN CHEM, V21, P1669
   Choi JW, 1999, CLIN CHEM, V45, P1562
   Danise P, 2008, INT J LAB HEMATOL, V30, P306, DOI 10.1111/j.1751-553X.2007.00960.x
   Garcia-Garcia E, 2012, EUR J ENDOCRINOL, V167, P387, DOI 10.1530/EJE-12-0267
   Infusino I, 2010, AM J CLIN PATHOL, V138, P642
   KIVIVUORI SM, 1993, PEDIATR RES, V34, P297, DOI 10.1203/00006450-199309000-00011
   Kratovil T, 2007, CLIN CHIM ACTA, V380, P222, DOI 10.1016/j.cca.2007.02.012
   Lin WM, 2006, BR J NUTR, V96, P1134
   Matsuda A, 2002, HAEMATOLOGIA, V32, P225, DOI 10.1163/15685590260461048
   Ooi CL, 2009, WORLD J PEDIATR, V5, P122, DOI 10.1007/s12519-009-0024-3
   Raya G, 2001, CLIN CHEM LAB MED, V39, P1162, DOI 10.1515/CCLM.2001.183
   Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1
   Majem LS, 2003, MED CLIN-BARCELONA, V121, P725
   Speeckaert M, 2011, CRIT REV CLIN LAB SC, V47, P213
   Suominen P, 2001, CLIN CHEM, V47, P935
   Takala TI, 2003, CLIN CHEM LAB MED, V41, P203, DOI 10.1515/CCLM.2003.033
   Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd, P212
   Vazquez MA, 2006, J PEDIAT HEMATOL ONC, V28, P809
   Vázquez Lopez Maria Angeles, 2006, Haematologica, V91, P264
   WHO/CDC, 2007, ASS IR STAT POP REP, V2nd
NR 38
TC 0
Z9 0
U1 3
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1077-4114
EI 1536-3678
J9 J PEDIAT HEMATOL ONC
JI J. Pediatr. Hematol. Oncol.
PD MAY
PY 2015
VL 37
IS 4
BP 274
EP 280
PG 7
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA CG5AR
UT WOS:000353301600022
PM 25354256
ER

PT J
AU Lazarou, C
   Matalas, AL
AF Lazarou, Chrystalleni
   Matalas, Antonia-Leda
TI Breakfast intake is associated with nutritional status, Mediterranean
   diet adherence, serum iron and fasting glucose: the CYFamilies study
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Breakfast intake; Mediterranean diet; Obesity; Serum iron
ID BODY-MASS INDEX; CARDIOMETABOLIC RISK-FACTORS; PHYSICAL-ACTIVITY;
   SCHOOL-CHILDREN; LIFE-STYLE; NUTRIENT INTAKE; SKIPPING BREAKFAST;
   AFRICAN-AMERICAN; FOOD-CONSUMPTION; ADOLESCENTS
AB Objective: To assess the association of breakfast intake with Mediterranean diet adherence, physical activity levels, obesity, selected cardiovascular risk markers and Fe status.
   Design: Cross-sectional study. BMI, body fat percentage and waist circumference were assessed. Physical activity was assessed using a pedometer and diet quality was evaluated by applying the KIDMED index. Blood tests to assess blood lipids, high-sensitivity C-reactive protein, fasting glucose, serum Fe and ferritin, as well as Hb, were performed.
   Setting: Primary-school children of the Troodos mountainous area in Cyprus.
   Subjects: Eighty-three Cypriot children (mean age 9.2 (SD 1.7) years).
   Results: Compared with breakfast skippers, regular breakfast eaters were 40 % more likely to have a KIDMED score higher by one point on average (OR=1.41; 95 % CI 1.08, 1.84) after accounting for obesity levels and other confounders. Breakfast skippers, on the other hand, were by about 14 % more likely to have a body fat percentage value higher by one unit, as well as higher values for both BMI and waist circumference. The relationship was significantly strengthened when combining body fat percentage and waist circumference into a composite variable (OR = 0.20; 95 % CI 0.06, 0.69). Fasting glucose was inversely correlated to breakfast intake in descriptive analyses, whereas serum Fe was positively correlated to breakfast intake after considering age, gender and diet quality. The latter relationship disappeared, however, after considering physical activity levels.
   Conclusions: Cypriot children who take breakfast regularly exhibit a higher adherence to the Mediterranean diet and have higher serum Fe concentrations and lower BMI, waist circumference, body fat percentage and fasting glucose levels, compared with children who skip breakfast. Public health professionals, educators and parents should prioritize on actions that will motivate children to regularly eat breakfast.
C1 [Lazarou, Chrystalleni] Cyprus Food & Nutr Museum, CY-2417 Ekgomi Nicosia, Cyprus.
   [Matalas, Antonia-Leda] Harokopio Univ, Dept Dietet & Nutr, Athens, Greece.
RP Lazarou, C (reprint author), Cyprus Food & Nutr Museum, 5 Christianas Christofidou St, CY-2417 Ekgomi Nicosia, Cyprus.
EM stalolaz@logosnet.cy.net
FU Cyprus Research Promotion Foundation; Vouros Chemicals' Company
FX Financial support: The study was supported by Cyprus Research Promotion
   Foundation and Vouros Chemicals' Company. Cyprus Research Promotion
   Foundation and Vouros Chemicals' Company had no role in the design,
   analysis or writing of this article.
CR Affenito SG, 2005, J AM DIET ASSOC, V105, P938, DOI 10.1016/j.jada.2005.03.003
   American Heart Association (n.d.), CHILDR CHOL
   Godin G, 2005, AM J HEALTH PROMOT, V20, P20
   Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C
   Hoyland A, 2009, NUTR RES REV, V22, P220, DOI 10.1017/S0954422409990175
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Niemeier HM, 2006, J ADOLESCENT HEALTH, V39, P842, DOI 10.1016/j.jadohealth.2006.07.001
   Cahill LE, 2013, CIRCULATION, V128, P337, DOI 10.1161/CIRCULATIONAHA.113.001474
   Dubois L, 2009, PUBLIC HEALTH NUTR, V12, P19, DOI 10.1017/S1368980008001894
   Keski-Rahkonen A, 2003, EUR J CLIN NUTR, V57, P842, DOI 10.1038/sj.ejcn.1601618
   Woodruff SJ, 2008, BODY IMAGE, V5, P404, DOI 10.1016/j.bodyim.2008.04.006
   Savva SC, 2000, INT J OBESITY, V24, P1453, DOI 10.1038/sj.ijo.0801401
   Timlin MT, 2007, NUTR REV, V65, P268, DOI 10.1301/nr.2007.jun.268-281
   [Anonymous], 2013, BREAKFAST IS BEST CA
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Veugelers PJ, 2005, CAN J PUBLIC HEALTH, V96, P212
   Bel-Serrat S, 2013, PEDIATR OBES, V8, P225, DOI 10.1111/j.2047-6310.2012.00107.x
   Farshchi HR, 2005, AM J CLIN NUTR, V81, P388
   Hirschman J, 2013, PUBLIC HEALTH NUTR, V16, P982, DOI 10.1017/S1368980012004144
   Kontogianni MD, 2010, J AM DIET ASSOC, V110, P215, DOI 10.1016/j.jada.2009.10.035
   Mekary RA, 2013, AM J CLIN NUTR, V98, P436, DOI 10.3945/ajcn.112.057521
   Utter J, 2007, J AM DIET ASSOC, V107, P570, DOI 10.1016/j.jada.2007.01.010
   Smith KJ, 2010, AM J CLIN NUTR, V92, P1316, DOI 10.3945/ajcn.2010.30101
   Lazarou C, 2010, CLIN NUTR, V29, P779, DOI 10.1016/j.clnu.2010.05.001
   Loucaides CA, 2004, HEALTH EDUC RES, V19, P138, DOI 10.1093/her/cyg014
   Sjoberg A, 2003, EUR J CLIN NUTR, V57, P1569, DOI 10.1038/sj.ejcn.1601726
   Hallstrom L, 2013, PUBLIC HEALTH NUTR, V16, P1296, DOI 10.1017/S1368980012000973
   Moreno LA, 2007, CURR OPIN CLIN NUTR, V10, P336, DOI 10.1097/MCO.0b013e3280a94f59
   Astbury NM, 2011, J NUTR, V141, P1381, DOI 10.3945/jn.110.128645
   Albertson A, 2003, J AM DIET ASSOC, V103, P1613, DOI [10.1016/j.jada.2003.09.020, 10.1016/S0002-8223(03)01363-4]
   Mariscal-Arcas M, 2009, PUBLIC HEALTH NUTR, V12, P1408, DOI 10.1017/S1368980008004126
   Szajewska H, 2010, CRIT REV FOOD SCI, V50, P113, DOI 10.1080/10408390903467514
   McCarthy HD, 2006, INT J OBESITY, V30, P598, DOI 10.1038/sj.ijo.0803232
   Serra-Majem L, 2003, EUR J CLIN NUTR, V57, pS35, DOI 10.1038/sj.ejcn.1601812
   Croezen S, 2009, EUR J CLIN NUTR, V63, P405, DOI 10.1038/sj.ejcn.1602950
   Deshmukh-Taskar P, 2013, PUBLIC HEALTH NUTR, V16, P2073, DOI 10.1017/S1368980012004296
   di Giuseppe R, 2012, NUTR METAB CARDIOVAS, V22, P347, DOI 10.1016/j.numecd.2010.07.006
   Firore H, 2006, J AM DIET ASSOC, V106, P55
   Grivetti L. E., 1997, Nutrition Today, V32, P164, DOI 10.1097/00017285-199707000-00007
   Hanes S, 1984, Am J Clin Nutr, V40, P390
   Heymsfield S. B., 2005, HUMAN BODY COMPOSITI
   Lazarou C, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-147
   Lazarou C, 2012, COMPUT METH PROG BIO, V108, P706, DOI 10.1016/j.cmpb.2011.12.011
   Lazarou C, 2010, EUR J PUBLIC HEALTH, V20, P70, DOI 10.1093/eurpub/ckp093
   Matalas A-L, 2012, TIME FOOD EVERYDAY M, P237
   Moore L, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-258
   Nicklas TA, 2000, J ADOLESCENT HEALTH, V27, P314, DOI 10.1016/S1054-139X(00)00113-0
   Nicklas TA, 1998, AM J CLIN NUTR S, V67, p757S
   Ortega RM, 1998, J AM COLL NUTR, V17, P19
   Radzikowski J, 1984, Am J Clin Nutr, V40, P454
   Rampersaud GC, 2005, J AM DIET ASSOC, V105, P743, DOI 10.1016/j.jada.2005.02.007
   RESNICOW K, 1991, J SCHOOL HEALTH, V61, P81
   Ruxton CHS, 1997, BRIT J NUTR, V78, P199, DOI 10.1079/BJN19970140
   SAMPSON AE, 1995, J NATL MED ASSOC, V87, P195
   Sandercock GRH, 2010, EUR J CLIN NUTR, V64, P1086, DOI 10.1038/ejcn.2010.145
   Sese MA, 2012, APPETITE, V59, P140, DOI 10.1016/j.appet.2012.04.011
   USDA U.S. Department of Health and Human Ser-vices, 2010, REP DIET GUID ADV CO
   Vereecken C, 2009, INT J PUBLIC HLTH S, V54, P180
   Yiagkou V, 2011, HELLEN J NUTR DIET, V2, P87
NR 59
TC 1
Z9 1
U1 2
U2 7
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD MAY
PY 2015
VL 18
IS 7
BP 1308
EP 1316
DI 10.1017/S1368980014001967
PG 9
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA CF0NB
UT WOS:000352239800020
PM 25287356
ER

PT J
AU Glass, LM
   Dickson, RC
   Anderson, JC
   Suriawinata, AA
   Putra, J
   Berk, BS
   Toor, A
AF Glass, Lisa M.
   Dickson, Rolland C.
   Anderson, Joseph C.
   Suriawinata, Arief A.
   Putra, Juan
   Berk, Brian S.
   Toor, Arifa
TI Total Body Weight Loss of >= 10 % Is Associated with Improved Hepatic
   Fibrosis in Patients with Nonalcoholic Steatohepatitis
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Fibrosis
ID FATTY LIVER-DISEASE; BARIATRIC SURGERY; RISK-FACTORS; OUTCOMES; TRIAL
AB Background Given the rising epidemics of obesity and metabolic syndrome, nonalcoholic steatohepatitis (NASH) is now the most common cause of liver disease in the developed world. Effective treatment for NASH, either to reverse or prevent the progression of hepatic fibrosis, is currently lacking.
   Aim To define the predictors associated with improved hepatic fibrosis in NASH patients undergoing serial liver biopsies at prolonged biopsy interval.
   Methods This is a cohort study of 45 NASH patients undergoing serial liver biopsies for clinical monitoring in a tertiary care setting. Biopsies were scored using the NASH Clinical Research Network guidelines. Fibrosis regression was defined as improvement in fibrosis score >= 1 stage. Univariate analysis utilized Fisher's exact or Student's t test. Multivariate regression models determined independent predictors for regression of fibrosis.
   Results Forty-five NASH patients with biopsies collected at a mean interval of 4.6 years (+/- 1.4) were included. The mean initial fibrosis stage was 1.96, two patients had cirrhosis and 12 patients (26.7 %) underwent bariatric surgery. There was a significantly higher rate of fibrosis regression among patients who lost >= 10 % total body weight (TBW) (63.2 vs. 9.1 %; p = 0.001) and who underwent bariatric surgery (47.4 vs. 4.5 %; p = 0.003). Factors such as age, gender, glucose intolerance, elevated ferritin, and A1AT heterozygosity did not influence fibrosis regression. On multivariate analysis, only weight loss of >= 10 % TBW predicted fibrosis regression [OR 8.14 (CI 1.08-61.17)].
   Conclusion Results indicate that regression of fibrosis in NASH is possible, even in advanced stages. Weight loss of >= 10 % TBW predicts fibrosis regression.
C1 [Glass, Lisa M.; Dickson, Rolland C.; Berk, Brian S.; Toor, Arifa] Dartmouth Hitchcock Med Ctr, Gastroenterol Sect, Lebanon, NH 03756 USA.
   [Glass, Lisa M.] Univ Michigan Hlth Syst, Div Gastroenterol & Hepatol, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA.
   [Dickson, Rolland C.] Geisel Sch Med Dartmouth, Dept Med, Lebanon, NH USA.
   [Dickson, Rolland C.] Dartmouth Hitchcock Med Ctr, Dept Hepatol, Lebanon, NH 03756 USA.
   [Anderson, Joseph C.] Geisel Sch Med Dartmouth, Gastroenterol Sect, Lebanon, NH USA.
   [Suriawinata, Arief A.; Putra, Juan] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03756 USA.
   [Berk, Brian S.] St Lukes Clin, Gastroenterol, Twin Falls, ID USA.
RP Dickson, RC (reprint author), Dartmouth Hitchcock Med Ctr, Dept Hepatol, One Med Ctr Dr, Lebanon, NH 03756 USA.
EM rcdickson3@gmail.com
CR Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Argo CK, 2009, J HEPATOL, V51, P371, DOI 10.1016/j.jhep.2009.03.019
   Finkelstein EA, 2012, AM J PREV MED, V42, P563, DOI 10.1016/j.amepre.2011.10.026
   Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x
   Dixon JB, 2004, HEPATOLOGY, V39, P1647, DOI 10.1002/hep.20251
   Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929
   Harrison SA, 2009, HEPATOLOGY, V49, P80, DOI 10.1002/hep.22575
   Mathurin P, 2009, GASTROENTEROLOGY, V137, P532, DOI 10.1053/j.gastro.2009.04.052
   McCullough AJ, 2006, J CLIN GASTROENTEROL, V40, pS17
   Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762
   Bedogni G, 2005, HEPATOLOGY, V42, P44, DOI 10.1002/hep.20734
   Kok KF, 2007, NETH J MED, V65, P160
   Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
   Furuya CK, 2007, J GASTROEN HEPATOL, V22, P510, DOI 10.1111/j.1440-1746.2007.04833.x
   Charlton MR, 2011, GASTROENTEROLOGY, V141, P1249, DOI 10.1053/j.gastro.2011.06.061
   Mummadi RR, 2008, CLIN GASTROENTEROL H, V6, P1396, DOI 10.1016/j.cgh.2008.08.012
   Younossi ZM, 2011, HEPATOLOGY, V53, P1874, DOI 10.1002/hep.24268
   Pagadala MR, 2012, CLIN LIVER DIS, V16, P487, DOI 10.1016/j.cld.2012.05.006
   Liu XL, 2007, OBES SURG, V17, P486, DOI 10.1007/s11695-007-9086-2
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Tendler D, 2007, DIGEST DIS SCI, V52, P589, DOI 10.1007/s10620-006-9433-5
   Promrat K, 2010, HEPATOLOGY, V51, P121, DOI 10.1002/hep.23276
   Huang MA, 2005, AM J GASTROENTEROL, V100, P1072, DOI 10.1111/j.1572-0241.2005.41334.x
   Chavez-Tapia NC, 2010, COCHRANE DB SYST REV, V20
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   Mattar SG, 2005, ANN SURG, V242, P610, DOI 10.1097/01.sla.0000179652.07502.3f
NR 26
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD APR
PY 2015
VL 60
IS 4
BP 1024
EP 1030
DI 10.1007/s10620-014-3380-3
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CI0YC
UT WOS:000354464900035
PM 25354830
ER

PT J
AU Garcia-Valdes, L
   Campoy, C
   Hayes, H
   Florido, J
   Rusanova, I
   Miranda, MT
   McArdle, HJ
AF Garcia-Valdes, L.
   Campoy, C.
   Hayes, H.
   Florido, J.
   Rusanova, I.
   Miranda, M. T.
   McArdle, H. J.
TI The impact of maternal obesity on iron status, placental transferrin
   receptor expression and hepcidin expression in human pregnancy
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
ID DEFICIENCY ANEMIA; CHRONIC DISEASE; FETAL-GROWTH; WEIGHT-GAIN; CORD
   BLOOD; BODY IRON; IN-VIVO; SERUM; WOMEN; HYPOXIA
AB BACKGROUND: Obesity is associated with decreased iron status, possibly due to a rise in hepcidin, an inflammatory protein known to reduce iron absorption. In animals, we have shown that maternal iron deficiency is minimised in the foetus by increased expression of placental transferrin receptor (pTFR1), resulting in increased iron transfer at the expense of maternal iron stores.
   OBJECTIVE: This study examines the effect of obesity during pregnancy on maternal and neonatal iron status in human cohorts and whether the placenta can compensate for decreased maternal iron stores by increasing pTFR1 expression.
   SUBJECTS/METHODS: A total of 240 women were included in this study. One hundred and fifty-eight placentas (Normal: 90; Overweight: 37; Obese: 31) were collected at delivery. Maternal iron status was measured by determining serum transferrin receptor (sTFR) and ferritin levels at 24 and 34 weeks and at delivery. Hepcidin in maternal and cord blood was measured by ELISA and pTFR1 in placentas by western blotting and real-time RT-PCR.
   RESULTS: Low iron stores were more common in obese women. Hepcidin levels (ng ml(-1)) at the end of the pregnancy were higher in obese than normal women (26.03 +/- 12.95 vs 18.00 +/- 10.77, P < 0.05). Maternal hepcidin levels were correlated with maternal iron status (sTFR r = 0.2 P = 0.025), but not with neonatal values. mRNA and protein levels of pTFR1 were both inversely related to maternal iron status. For mRNA and all women, sTFR r = 0.2 P = 0.044. Ferritin mRNA levels correlated only in overweight women r = -0.5 P = 0.039 with hepcidin (r = 0.1 P = 0.349), irrespective of maternal body mass index (BMI).
   CONCLUSIONS: The data support the hypothesis that obese pregnant women have a greater risk of iron deficiency and that hepcidin may be a regulatory factor. Further, we show that the placenta responds to decreased maternal iron status by increasing pTFR1 expression.
C1 [Garcia-Valdes, L.; Hayes, H.; McArdle, H. J.] Univ Aberdeen, Rowett Inst Nutr & Hlth, Aberdeen AB21 9SB, Scotland.
   [Garcia-Valdes, L.; Campoy, C.; Rusanova, I.] Univ Granada, Sch Med, Dept Paediat, Granada, Spain.
   [Florido, J.] Univ Granada, Sch Med, Dept Obstet & Gynaecol, Granada, Spain.
   [Miranda, M. T.] Univ Granada, Sch Med, Dept Biostat, Granada, Spain.
RP McArdle, HJ (reprint author), Univ Aberdeen, Rowett Inst Nutr & Hlth, Greenburn Rd, Aberdeen AB21 9SB, Scotland.
EM h.mcardle@abdn.ac.uk
OI Rusanova, Iryna/0000-0002-3640-7350
FU Spanish Government Innovation, Science and Company Ministry (PREOBE)
   [P06-CTS-02341]; Scottish Government (Rural and Environmental Scientific
   and Analytical Services (RESAS); Alfonso Martin Escudero Foundation
FX We thank the families participating in the study, and clinicians and
   personnel from the hospital who provided invaluable assistance and
   support. This work was supported by Spanish Government Innovation,
   Science and Company Ministry (Excellence project P06-CTS-02341 (PREOBE)
   and Scottish Government (Rural and Environmental Scientific and
   Analytical Services (RESAS). Dr Luz Garcia Valdes gratefully
   acknowledges support from the Alfonso Martin Escudero Foundation.
CR American College of Obstetricians and Gynecologists, 2008, OBSTET GYNECOL, V112, P201, DOI 10.1097/AOG.0b013e3181809c0d
   Walsh T, 2011, CLIN CHEM LAB MED, V49, P1225, DOI 10.1515/CCLM.2011.187
   FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385
   O'Brien KO, 2003, AM J CLIN NUTR, V77, P924
   Punnonen K, 1997, BLOOD, V89, P1052
   Khatun R, 2003, PLACENTA, V24, P870, DOI 10.1016/S0143-4004(03)00138-3
   Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147
   Paiva AD, 2003, CLIN CHIM ACTA, V334, P197, DOI 10.1016/S0009-8981(03)00237-7
   Baker RD, 2010, PEDIATRICS, V126, P1040, DOI 10.1542/peds.2010-2576
   Mei ZG, 2011, AM J CLIN NUTR, V93, P1312, DOI 10.3945/ajcn.110.007195
   Aranceta J, 2001, EUR J CLIN NUTR, V55, P430, DOI 10.1038/sj.ejcn.1601189
   Young ME, 2012, J NUTR, V142, P33, DOI 10.3945/jn.111.145961
   Akesson A, 1998, AM J CLIN NUTR, V68, P1241
   Zamudio S, 2006, PLACENTA, V27, P49, DOI 10.1016/j.placenta.2004.12.010
   Bhutta ZA, 2008, LANCET, V371, P186, DOI 10.1016/S0140-6736(08)60116-6
   Gambling L, 2009, AM J PHYSIOL-REG I, V296, pR1063, DOI 10.1152/ajpregu.90793.2008
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Higgins L, 2011, PLACENTA, V32, P1, DOI 10.1016/j.placenta.2010.09.019
   Phillips AK, 2014, J PERINATOL, V34, P513, DOI 10.1038/jp.2014.42
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Young MF, 2010, PLACENTA, V31, P1010, DOI 10.1016/j.placenta.2010.08.009
   CARRIAGA MT, 1991, AM J CLIN NUTR, V54, P1077
   Wallace JM, 2012, PLACENTA, V33, P611, DOI 10.1016/j.placenta.2012.05.006
   Choi JW, 2000, CLIN CHEM, V46, P725
   Nohr EA, 2005, OBSTET GYNECOL, V106, P250, DOI 10.1097/01.AOG.0000172422.81496.57
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Catalano PM, 2007, OBSTET GYNECOL, V110, P743, DOI 10.1097/01.AOG.0000284990.84982.ba
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Santacruz A, 2010, BRIT J NUTR, V104, P83, DOI 10.1017/S0007114510000176
   SKIKNE BS, 1990, BLOOD, V75, P1870
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142
   Aranceta J, 2004, OBESIDAD RIESGO CARD, P125
   CDC, 1998, MMWR-MORBID MORTAL W, V47, P1
   Chelchowska M, 2008, GINEKOL POL, V79, P754
   Dao MC, 2012, J PERINATOL, V33, P177
   Duffy EM, 2010, PUBLIC HEALTH NUTR, V13, P331, DOI 10.1017/S1368980009991054
   Ervasti M, 2009, EUR J OBSTET GYN R B, V147, P161, DOI 10.1016/j.ejogrb.2009.08.012
   Gambling L, 2011, AM J CLIN NUTR, V94, p1903S, DOI 10.3945/ajcn.110.000885
   Gambling L, 2001, BIOCHEM J, V356, P883, DOI 10.1042/0264-6021:3560883
   Gambling L, 2002, BIOL REPROD, V66, P516, DOI 10.1095/biolreprod66.2.516
   Georgieff MK, 2007, AM J CLIN NUTR, V85, p614S
   Iannotti LL, 2005, J NUTR, V135, P2572
   KELLY AM, 1978, BRIT J OBSTET GYNAEC, V85, P338, DOI 10.1111/j.1471-0528.1978.tb14890.x
   LAURIER D, 1992, INT J OBESITY, V16, P565
   Lewis RM, 2013, ANN NUTR METAB, V63, P208, DOI 10.1159/000355222
   Li YQ, 2008, EUR J OBSTET GYN R B, V140, P48, DOI 10.1016/j.ejogrb.2008.02.012
   Mando C, 2010, PLACENTA, V32, P44
   [Organisation WH WHO], 1992, PREV AN WOM TAB AV I
   Rehu M, 2010, EUR J HAEMATOL, V85, P345, DOI 10.1111/j.1600-0609.2010.01479.x
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   van Santen S, 2012, CLIN CHEM LAB MED, V14, P1
   Yu ZB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061627
NR 56
TC 1
Z9 1
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD APR
PY 2015
VL 39
IS 4
BP 571
EP 578
DI 10.1038/ijo.2015.3
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA CF4XO
UT WOS:000352557500004
PM 25614087
ER

PT J
AU Oh, S
   Shida, T
   Yamagishi, K
   Tanaka, K
   So, R
   Tsujimoto, T
   Shoda, J
AF Oh, Sechang
   Shida, Takashi
   Yamagishi, Kazumasa
   Tanaka, Kiyoji
   So, Rina
   Tsujimoto, Takehiko
   Shoda, Junichi
TI Moderate to Vigorous Physical Activity Volume Is an Important Factor for
   Managing Nonalcoholic Fatty Liver Disease: A Retrospective Study
SO HEPATOLOGY
LA English
DT Article
ID WEIGHT-LOSS; OXIDATIVE STRESS; EXERCISE; OBESITY; INFLAMMATION;
   PREVENTION; NAFLD; STRATEGIES; GUIDELINES; MANAGEMENT
AB Recently, the beneficial effects of increased physical activity (PA) on nonalcoholic fatty liver disease (NAFLD) in obese subjects were reported. However, the optimal strength and volume of PA in lifestyle modification to improve NAFLD pathophysiology and be recommended as an appropriate management of this condition are unclear. The primary goal of this retrospective study was to estimate the beneficial effects of a varying volume of moderate to vigorous intensity PA (MVPA) on the improvement of NAFLD. A total of 169 obese, middle-aged men were enrolled in a 12-week weight reduction program through lifestyle modification consisting of dietary restrictions plus aerobic exercise. Among these obese subjects, 40 performed MVPA for <150 minwk(-1), 42 performed MVPA for 150-250 minwk(-1), and 87 performed MVPA for >250 minwk(-1). The subjects in the MVPA 250 minwk(-1) group, in comparison with those in the MVPA <250 minwk(-1) group, showed significantly attenuated levels of hepatic steatosis (-31.8% versus -23.2%). This attenuation was likely independent of the detectable weight reduction. MVPA for 250 minwk(-1) in comparison with that for <150 minwk(-1) led to a significant decrease in the abdominal visceral adipose tissue severity (-40.6% versus -12.9%), levels of ferritin (-13.6% versus +1.5%), and lipid peroxidation (-15.1% versus -2.8%), and a significant increase in the adiponectin levels (+17.1% versus +5.6%). In association with these changes, the gene expression levels of sterol regulatory element-binding protein-1c and carnitine palmitoyltransferase-1 in peripheral blood mononuclear cells also significantly decreased and increased, respectively. Conclusion: MVPA for 250 minwk(-1) as part of lifestyle management improves NAFLD pathophysiology in obese men. The benefits seem to be acquired through reducing inflammation and oxidative stress levels and altering fatty acid metabolism. (Hepatology 2015;61:1205-1215)
C1 [Oh, Sechang; Shoda, Junichi] Univ Tsukuba, Fac Med, Div Clin Med, Tsukuba, Ibaraki 3058575, Japan.
   [Shida, Takashi] Univ Tsukuba, Grad Sch Comprehens Human Sci, Doctoral Programs Med Sci, Tsukuba, Ibaraki 3058575, Japan.
   [Yamagishi, Kazumasa] Univ Tsukuba, Div Publ Hlth Med, Fac Med, Tsukuba, Ibaraki 3058575, Japan.
   [Tanaka, Kiyoji; So, Rina; Tsujimoto, Takehiko] Univ Tsukuba, Fac Hlth & Sports Sci, Div Sports Med, Tsukuba, Ibaraki 3058575, Japan.
RP Shoda, J (reprint author), Univ Tsukuba, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
EM shodaj@md.tsukuba.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [24390488, 25282212, 25282172, 25293278, 26282191, 26293297, 26670109]
FX Supported in part by Grants-in-Aid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science and Technology, Japan
   (nos. 24390488,25282212, 25282172, 25293278, 26282191, 26293297, and
   26670109).
CR Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Oh S, 2014, METAB SYNDR RELAT D, V12, P290, DOI 10.1089/met.2013.0143
   Farrell GC, 2007, J GASTROEN HEPATOL, V22, P775, DOI 10.1111/j.1440-1746.2007.05002.x
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   Rector RS, 2011, J APPL PHYSIOL, V111, P1828, DOI 10.1152/japplphysiol.00384.2011
   Madan K, 2006, J CLIN GASTROENTEROL, V40, P930, DOI 10.1097/01.mcg.0000212608.59090.08
   Kumahara H, 2004, BRIT J NUTR, V91, P235, DOI 10.1079/BJN20031033
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Eguchi Y, 2012, J GASTROENTEROL, V47, P586, DOI 10.1007/s00535-012-0533-z
   Sasso M, 2010, ULTRASOUND MED BIOL, V36, P1825, DOI 10.1016/j.ultrasmedbio.2010.07.005
   Sandrin L, 2003, ULTRASOUND MED BIOL, V29, P1705, DOI 10.1016/j.ultrasmedbio.2003.07.001
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129
   Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001
   Shin S, 2009, EUR J PHARMACOL, V620, P138, DOI 10.1016/j.ejphar.2009.08.022
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   Rector RS, 2008, WORLD J GASTROENTERO, V14, P185, DOI 10.3748/wjg.14.185
   Day CP, 2006, CLIN MED, V6, P19
   Kanazawa M, 2005, WORLD REV NUTR DIET, V94, P1, DOI 10.1159/000088200
   Finelli C, 2013, WORLD J GASTROENTERO, V19, P802, DOI 10.3748/wjg.v19.i6.802
   Hallsworth K, 2011, GUT, V60, P1278, DOI 10.1136/gut.2011.242073
   Donnelly JE, 2009, MED SCI SPORT EXER, V41, P459, DOI 10.1249/MSS.0b013e3181949333
   Harrison SA, 2007, GUT, V56, P1760, DOI 10.1136/gut.2006.112094
   Oh S, 2013, MED SCI SPORT EXER, V45, P2214, DOI 10.1249/MSS.0b013e31829afc33
   Kistler KD, 2011, AM J GASTROENTEROL, V106, P460, DOI 10.1038/ajg.2010.488
   Finelli C, 2012, WORLD J GASTROENTERO, V18, P6790, DOI 10.3748/wjg.v18.i46.6790
   Bae JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046819
   BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
   Bouwens M, 2010, AM J CLIN NUTR, V91, P208, DOI 10.3945/ajcn.2009.28586
   Johnson NA, 2012, SEMIN LIVER DIS, V32, P65, DOI 10.1055/s-0032-1306427
   Kim SY, 2010, KAPHED, V49, P419
   Lemasters JJ, 2009, LIVER BIOL PATHOBIOL, P511, DOI 10.1002/9780470747919.ch33
   PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402
   StsGeorge A, 2009, HEPATOLOGY, V50, P68
   Tomita K, 2008, HEPATOLOGY, V48, P458, DOI 10.1002/hep.22365
NR 36
TC 7
Z9 7
U1 5
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD APR
PY 2015
VL 61
IS 4
BP 1205
EP 1215
DI 10.1002/hep.27544
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CE8NM
UT WOS:000352099700017
PM 25271091
ER

PT J
AU Ferrer, R
   Pardina, E
   Rossell, J
   Baena-Fustegueras, JA
   Lecube, A
   Balibrea, JM
   Caubet, E
   Gonzalez, O
   Vilallonga, R
   Fort, JM
   Peinado-Onsurbe, J
AF Ferrer, Roser
   Pardina, Eva
   Rossell, Joana
   Antonio Baena-Fustegueras, Juan
   Lecube, Albert
   Maria Balibrea, Jose
   Caubet, Enric
   Gonzalez, Oscar
   Vilallonga, Ramon
   Manuel Fort, Jose
   Peinado-Onsurbe, Julia
TI Haematological parameters and serum trace elements in "healthy" and
   "unhealthy" morbidly obese patients before and after gastric bypass
SO CLINICAL NUTRITION
LA English
DT Article
DE Healthy obese; Dyslipidemia; Diabetes; Haematology; Haemostasis;
   Bariatric surgery
ID METABOLICALLY NORMAL OBESITY; BARIATRIC SURGERY; IRON-DEFICIENCY;
   INFLAMMATION; PROFILE
AB Background & aims: We have investigated the differences in plasma parameters and serum trace elements between "healthy" and unhealthy morbidly obese patients before and after Roux-en-Y gastric bypass surgery.
   Methods: A group of 32 morbidly obese patients undergoing bariatric surgery were divided into three groups. Group 1 subjects were free of dyslipidemia and type II diabetes mellitus (defined as "healthy" obese, DM-DL-; Group 2 subjects had only the presence of dyslipidemia (DM-DL+), while group 3 patients demonstrated the presence of both (DM + DL+). In all patients, we studied haematological, haemostasis, anaemia, coagulation plasma and trace elements parameters before and 1, 6 and 12 months after gastric bypass surgery.
   Results: We found significant differences in some haematological parameters, including haemostasis (e.g., T-Quick, p = 0.0048) and coagulation (e.g., ATIII and PAI-1, p = 0.001 and p < 0.0001, respectively) and in anaemia parameters (e.g., folate, cobalamin and transferrin, p = 0.0002, p < 0.0001 and p = 0.0001, respectively) but also in serum trace elements between the groups. However, the response to bariatric surgery was similar in the three groups.
   Conclusion: Any healthy morbid obese subject is really metabolically "unhealthy" because he or she has many other haematologic or serum abnormalities that are often not included in the criteria for the definition of "healthy" in these obese subjects. (C) 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
C1 [Pardina, Eva; Rossell, Joana; Peinado-Onsurbe, Julia] Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain.
   [Antonio Baena-Fustegueras, Juan] Arnau de Vilanova Univ Hosp UdL, Surg Unit, Madrid, Spain.
   [Lecube, Albert] Arnau de Vilanova Univ Hosp UdL, Endocrinol & Nutr Dept, Madrid, Spain.
   [Lecube, Albert] Inst Salud Carlos III, UAB, VHIR, Diabet & Metab Res Unit, Madrid, Spain.
   [Lecube, Albert] Inst Salud Carlos III, CIBER Diabet & Enfermedades Metab CIBERDEM, Madrid, Spain.
   [Ferrer, Roser] Univ Autonoma Barcelona, Hosp Univ Vall DHebron, Biochemistiy Dept, E-08193 Barcelona, Spain.
   [Maria Balibrea, Jose; Caubet, Enric; Gonzalez, Oscar; Vilallonga, Ramon; Manuel Fort, Jose] Univ Autonoma Barcelona, Hosp Univ Vall DHebron, Endocrinol Surg Unit, E-08193 Barcelona, Spain.
RP Peinado-Onsurbe, J (reprint author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Diagonal 643, E-08028 Barcelona, Spain.
EM jpeinado@ub.edu
OI VILALLONGA, RAMON/0000-0001-9333-2765
FU Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III of
   the Spanish Ministry for Health and Consumer Affairs [PI070079,
   PI11/01159]
FX This research has received funding from the Fondo de Investigacion
   Sanitaria del Instituto de Salud Carlos III of the Spanish Ministry for
   Health and Consumer Affairs (PI070079 and PI11/01159).
CR Vallianou NG, 2010, MED SCI MONITOR, V16, pCR56
   Pardina E, 2009, OBES SURG, V19, P608, DOI 10.1007/s11695-009-9827-5
   Aguilar-Salinas CA, 2008, J CLIN ENDOCR METAB, V93, P4075, DOI 10.1210/jc.2007-2724
   Karelis AD, 2005, J CLIN ENDOCR METAB, V90, P4145, DOI 10.1210/jc.2005.0482
   [Anonymous], 1988, STAND ANTHR MEAS AIR
   Pataky Z, 2010, INT J OBESITY, V34, pS18, DOI 10.1038/ijo.2010.235
   Vaya A, 2011, CLIN HEMORHEOL MICRO, V48, P247, DOI 10.3233/CH-2011-1417
   Phillips CM, 2013, J CLIN ENDOCR METAB, V98, pE1610, DOI 10.1210/jc.2013-2038
   Wiewiora M, 2006, CLIN HEMORHEOL MICRO, V34, P499
   Pardina E, 2009, OBES SURG, V19, P894, DOI 10.1007/s11695-008-9739-9
   Wiewiora M, 2014, CLIN HEMORHEOL MICRO, V56, P101, DOI 10.3233/CH-2012-1642
   Meigs JB, 2006, J CLIN ENDOCR METAB, V91, P2906, DOI 10.1210/jc.2006-0594
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Wildman RP, 2011, OBESITY, V19, P1482, DOI 10.1038/oby.2010.332
   Sola E, 2007, OBESITY, V15, P2128, DOI 10.1038/oby.2007.253
   Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011
   Barbarroja N, 2010, BIOCHEM J, V430, P141, DOI 10.1042/BJ20100285
   LEDEVEHAT C, 1992, DIABETES METAB, V18, P43
   GREEN R, 1989, BLOOD CELLS, V15, P481
   Livingston EH, 2007, ARCH SURG-CHICAGO, V142, P919, DOI 10.1001/archsurg.142.10.919
   Bougle D, 2009, DAIRY SCI TECHNOL, V89, P213, DOI 10.1051/dst/2009010
   Cameron AJ, 2012, INT J OBESITY, V36, P164, DOI 10.1038/ijo.2011.57
   Chen M, 2013, BIOMED RES INT, V2013, P1
   Hamalainen P, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-116
   Lobo JC, 2010, BIOL TRACE ELEM RES, V135, P16, DOI 10.1007/s12011-009-8504-9
   Pardina E, 2012, OBESITY, V20, P1048, DOI 10.1038/oby.2011.361
   Pardina E, 2010, OBES SURG, V20, P623, DOI 10.1007/s11695-010-0103-5
   Pardina E, 2012, OBES SURG, V22, P131, DOI 10.1007/s11695-011-0546-3
   Pataky Z, 2011, Rev Med Suisse, V7, P692
   Soverini V, 2010, OBES SURG, V20, P295, DOI 10.1007/s11695-009-9999-z
   Valensi P, 1996, INT J OBESITY, V20, P814
   WYSOCKI M, 1991, ATHEROSCLEROSIS, V88, P21, DOI 10.1016/0021-9150(91)90253-Y
NR 32
TC 0
Z9 0
U1 2
U2 7
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0261-5614
EI 1532-1983
J9 CLIN NUTR
JI Clin. Nutr.
PD APR
PY 2015
VL 34
IS 2
BP 276
EP 283
DI 10.1016/j.clnu.2014.04.003
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CE6QM
UT WOS:000351963000018
PM 24792189
ER

PT J
AU Sanal, MG
AF Sanal, Madhusudana Girija
TI Biomarkers in nonalcoholic fatty liver disease-the emperor has no
   clothes?
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Nonalcoholic fatty liver disease; Biomarkers; Fibrosis; Cirrhosis;
   Steatohepatitis; Liver biopsy
ID BIOCHEMICAL MARKERS; HEPATITIS-C; PREDICTING FIBROSIS;
   LIPID-PEROXIDATION; DIAGNOSTIC-VALUE; STEATOHEPATITIS; NAFLD; FIBROTEST;
   SYSTEM; TESTS
AB Fatty liver is present in over ten percentage of the world population and it is a growing public health problem. Nonalcoholic fatty liver disease (NAFLD) is not a single disease, but encompasses a spectrum of diseases of different etiologies. It is difficult to find highly specific and sensitive diagnostic biomarkers when a disease is very complex. Therefore, we should aim to find relevant prognostic markers rather than accurate diagnostic markers which will help to minimize the frequency of liver biopsies to evaluate disease progression. There are several biomarker panels commercially available, however, there is no clear evidence that more sophisticated panels are better compared to simple criteria such as, presence of diabetes over five years, metabolic syndrome, obesity, obstructive sleep apnea, aspartate transaminase/alanine transaminase (ALT) ratio > 0.8 or ferritin levels > 1.5 times normal in patients with over six month history of raised ALT and/or ultrasonological evidence of fat in the liver. Currently the biomarker panels are not a replacement for a liver biopsy. However the need and benefit of liver biopsy in NAFLD is questionable because there is no convincing evidence that biopsy and detailed staging of NAFLD improves the management of NAFLD and benefits the patient. After all there is no evidence based treatment for NAFLD other than management of lifestyle and components of "metabolic syndrome".
C1 Albert Einstein Coll Med, Bronx, NY 10461 USA.
RP Sanal, MG (reprint author), Albert Einstein Coll Med, Room 323,Ullmann Bldg,1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM sanalmg@gmail.com
FU IIP fellowship, Albert Einstein College of Medicine, New York, through
   generosity of the Gruss Lipper Family Foundation
FX Supported by IIP fellowship (2013-2014), Albert Einstein College of
   Medicine, New York, through the generosity of the Gruss Lipper Family
   Foundation.
CR Chitturi S, 2007, J GASTROEN HEPATOL, V22, P778, DOI 10.1111/j.1440-1746.2007.05001.x
   Ratziu V, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-6
   Adler M, 2008, HEPATOLOGY, V47, P762, DOI 10.1002/hep.22085
   Chalasani N, 2004, AM J GASTROENTEROL, V99, P1497, DOI 10.1111/j.1572-0241.2004.30159.x
   [Anonymous], 2003, PTX3 pentraxin 3, long, Patent No. 6631330
   Wieckowska A, 2008, AM J GASTROENTEROL, V103, P1372, DOI 10.1111/j.1572-0241.2007.01774.x
   Dalle-Donne I, 2006, CLIN CHEM, V52, P601, DOI 10.1373/clinchem.2005.061408
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   Yesilova Z, 2005, AM J GASTROENTEROL, V100, P850, DOI 10.1111/j.1572-0241.2005.41500.x
   Shah AG, 2009, CLIN GASTROENTEROL H, V7, P1104, DOI 10.1016/j.cgh.2009.05.033
   Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008
   Musso G, 2011, ANN MED, V43, P617, DOI 10.3109/07853890.2010.518623
   Matsuda M, 2013, OBES RES CLIN PRACT, V7, pE330, DOI 10.1016/j.orcp.2013.05.004
   Feldstein AE, 2010, J LIPID RES, V51, P3046, DOI 10.1194/jlr.M007096
   Nobili V, 2009, GASTROENTEROLOGY, V136, P160, DOI 10.1053/j.gastro.2008.09.013
   Fielding CA, 2014, IMMUNITY, V40, P40, DOI 10.1016/j.immuni.2013.10.022
   Castera L, 2013, NAT REV GASTRO HEPAT, V10, P666, DOI 10.1038/nrgastro.2013.175
   Schuppan D, 2013, J CLIN INVEST, V123, P1887, DOI 10.1172/JCI66028
   Ji JL, 2009, FEBS LETT, V583, P759, DOI 10.1016/j.febslet.2009.01.034
   Patel K, 2014, CURR OPIN GASTROEN, V30, P253, DOI 10.1097/MOG.0000000000000059
   Alisi A, 2011, LAB INVEST, V91, P283, DOI 10.1038/labinvest.2010.166
   Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
   Imbert-Bismut F, 2004, CLIN CHEM LAB MED, V42, P323, DOI 10.1515/CCLM.2004.058
   Harrison SA, 2008, GUT, V57, P1441, DOI 10.1136/gut.2007.146019
   Yamada H, 2013, CLIN CHIM ACTA, V424, P99, DOI 10.1016/j.cca.2013.05.021
   de Alwis NMW, 2008, J HEPATOL, V48, pS104, DOI 10.1016/j.jhep.2008.01.009
   Parkes J, 2011, J VIRAL HEPATITIS, V18, P23, DOI 10.1111/j.1365-2893.2009.01263.x
   Venugopal SK, 2010, AM J PHYSIOL-GASTR L, V298, pG101, DOI 10.1152/ajpgi.00220.2009
   Palekar NA, 2006, LIVER INT, V26, P151, DOI 10.1111/j.1478-3231.2005.01209.x
   Cheung O, 2008, HEPATOLOGY, V48, P1810, DOI 10.1002/hep.22569
   Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Ruffillo G, 2011, J HEPATOL, V54, P160, DOI 10.1016/j.jhep.2010.06.028
   Lok ASF, 2005, HEPATOLOGY, V42, P282, DOI 10.1002/hep.20772
   Cusi K, 2014, J HEPATOL, V60, P167, DOI 10.1016/j.jhep.2013.07.042
   Sanchez-Gomez FJ, 2013, BIOL CHEM, V394, P1263, DOI 10.1515/hsz-2013-0150
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Vallet-Pichard A, 2006, HEPATOLOGY, V44, P769, DOI 10.1002/hep.21334
   Cales P, 2009, J HEPATOL, V50, P165, DOI 10.1016/j.jhep.2008.07.035
   Cales P, 2005, HEPATOLOGY, V42, P1373, DOI 10.1002/hep.20935
   Poynard T, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-34
   Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540
   Sebastiani G, 2011, ALIMENT PHARM THER, V34, P1202, DOI 10.1111/j.1365-2036.2011.04861.x
   Cermelli S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023937
   Hsieh Yung-Yu, 2009, Chang Gung Med J, V32, P614
   Lee HH, 2010, J KOREAN MED SCI, V25, P67, DOI 10.3346/jkms.2010.25.1.67
   NashTest, NASHTEST IS DIAGN NO
   Parsian H, 2013, CLIN APPL NONINVASIV
   Pearce Steven G, 2013, Biomark Res, V1, P7, DOI 10.1186/2050-7771-1-7
   Sanal MG, 2008, WORLD J GASTROENTERO, V14, P831, DOI 10.3748/wjg.14.831
   Sanal M G, 2011, Minerva Gastroenterol Dietol, V57, P419
   Thampanitchawong P, 1999, WORLD J GASTROENTERO, V5, P301
   Vizzutti F, 2009, ANN HEPATOL, V2, P89
NR 52
TC 3
Z9 3
U1 4
U2 4
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAR 21
PY 2015
VL 21
IS 11
BP 3223
EP 3231
DI 10.3748/wjg.v21.i11.3223
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CD5YQ
UT WOS:000351165100009
PM 25805928
ER

PT J
AU Motadi, SA
   Mbhenyane, XG
   Mbhatsani, HV
   Mabapa, NS
   Mamabolo, RL
AF Motadi, Selekane Ananias
   Mbhenyane, Xikombiso G.
   Mbhatsani, Hlekani V.
   Mabapa, Ngoako S.
   Mamabolo, Ramoteme L.
TI Prevalence of iron and zinc deficiencies among preschool children ages 3
   to 5 y in Vhembe district, Limpopo province, South Africa
SO NUTRITION
LA English
DT Article
DE Iron deficiency; Overweight; Preschool children; Stunting; Zinc
   deficiency
ID DEVELOPING-COUNTRIES; MALAWIAN CHILDREN; OLD CHILDREN; ORAL IRON;
   OVERWEIGHT; SUPPLEMENTATION; CHILDHOOD; OBESITY; ABSORPTION; NUTRITION
AB Objectives: Children under the age of 5 y constitute the most vulnerable group for iron and zinc deficiencies and their nutritional status is a sensitive indicator of community health and nutrition. The aim of this study was to determine the prevalence of zinc and iron deficiency among preschool children aged 3 to 5 y in Vhembe district, Limpopo province, South Africa.
   Methods: This study included 349 preschool children recruited from two municipalities of Vhembe district, Limpopo province, South Africa. Municipalities were purposively selected and simple random sampling was used to choose children. Body weight and height were measured using standard techniques. Serum zinc, iron, ferritin, transferrin saturation, transferrin and C-reactive protein levels were also assessed, as were hemoglobin levels.
   Results: The prevalence of wasting, stunting, and underweight was 1.4%, 18.6%, and 0.3%, respectively; whereas 20.9% of the children were overweight and 9.7% were obese. The prevalence of zinc deficiency was 42.6% and anemia was 28%; both were higher in girls than in boys. When using serum ferritin and transferrin saturation 7 (2%) of the children had iron-deficiency anemia. Combined iron and zinc deficiencies using ferritin was found in 8 (2.3%) of the children; when using transferrin saturation these deficiencies were found in 42 (12%) of the children.
   Conclusions: Iron and zinc deficiencies as well as anemia, accompanied by high prevalence of stunting; and overweight and obesity, were common in preschool children. The results observed here call for interventions to combat the escalating problem of child malnutrition in the form of nutritional education for mothers and food handlers at preschools to ensure food diversification in these children. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Motadi, Selekane Ananias; Mbhatsani, Hlekani V.; Mabapa, Ngoako S.; Mamabolo, Ramoteme L.] Univ Venda, Sch Hlth Sci, Dept Nutr, Thohoyandou, South Africa.
   [Mbhenyane, Xikombiso G.] Univ Stellenbosch, Fac Med & Hlth Sci, Dept Interdisciplinary Hlth Sci, ZA-7600 Stellenbosch, South Africa.
RP Motadi, SA (reprint author), Univ Venda, Sch Hlth Sci, Dept Nutr, Thohoyandou, South Africa.
EM selekane.motadi@univen.ac.za
FU University of Venda; South African National Research Foundation
FX The authors acknowledge the University of Venda and the South African
   National Research Foundation for their financial assistance toward
   conducting the study. Furthermore, the authors acknowledge the mothers
   and guardians of the children, their children, and staff members at the
   preschools for their participation and cooperation, not forgetting the
   nursing staff that assisted during blood collection. Any opinions,
   findings and conclusions or recommendations expressed in this article
   are those of the authors and the NRF does not accept any liability in
   regard thereto.
CR Baughcum AE, 2001, J DEV BEHAV PEDIATR, V22, P391
   Stoltzfus RJ, 2000, J NUTR, V130, P1724
   Gibson RS, 2006, P NUTR SOC, V65, P51, DOI 10.1079/PNS2005474
   Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301
   Brown KH, 2002, AM J CLIN NUTR, V75, P1062
   SANDSTROM B, 1985, J NUTR, V115, P411
   Dehghani SM, 2011, IRAN RED CRESCENT ME, V13, P4
   Baughcum AE, 2000, PEDIATRICS, V106, P1380, DOI 10.1542/peds.106.6.1380
   Dietz WH, 1998, PEDIATRICS, V101, P518
   Baumgartner J, 2013, INT J OBESITY, V37, P24, DOI 10.1038/ijo.2012.145
   Maret W, 2006, J TRACE ELEM MED BIO, V20, P3, DOI 10.1016/j.jtemb.2006.01.006
   Manary MJ, 2002, AM J CLIN NUTR, V75, P1057
   [Anonymous], 2005, NAT FOOD CONS SURV F
   Tatala S, 1998, AM J CLIN NUTR, V68, P171
   Samie A, 2009, J HEALTH POPUL NUTR, V27, P739
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Black RE, 2003, J NUTR, V133, P1485
   Wu Ann Chen, 2002, Pediatr Rev, V23, P171, DOI 10.1542/pir.23-5-171
   Cole CR, 2010, AM J CLIN NUTR, V91, P1027, DOI 10.3945/ajcn.2009.28089
   Crosby, ZINC DIAGN TESTS 200
   Dhansay MA, 2007, S AFRICAN J CLIN NUT
   Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4
   Taheri F, 2009, IRAN J PEDIATR, V19, P135
   Kruger Marita, 1996, Food and Nutrition Bulletin, V17, P11
   Kruger R, 2003, PUBLIC HEALTH NUTR, V6, P217, DOI 10.1079/PHN2002419
   Labadarios D., 2008, FOLATE IRON VITAMIN, P202
   Labadarios D, 2005, S AFRICAN J CLIN NUT, V21, P245
   Manary MJ, 2000, J NUTR, V130, P2959
   McLean E, WORLDWIDE PREVALENCE
   Mittal Poonam C, 2006, Rural Remote Health, V6, P385
   Momoh A, 2012, S AFRICA INT J CUR F, V4, P129
   Nel JH, 2002, REP S AFR FOOD CONS
   Nolunkcwe B., CHILD NUTR STATUS HO
   Oelofse A, 2002, PUBLIC HEALTH NUTR, V5, P290
   Samie A, 2010, AFR J BIOTECHNOL, V9, P7157
   Samuel FO, 2010, PREVALENCE ZINC DEFI
   Sreedhar B, 2004, BIOCHEM BIOPH RES CO, V318, P992, DOI 10.1016/j.bbrc.2004.04.132
   Stewart A, 2011, INT STANDARDS ANTHR, P114
   Tanaka M, 2002, ACTA OTO-LARYNGOL, V122, P134, DOI 10.1080/00016480260046526
   Torbjorn L, 2004, AM J CLIN NUTR, V80, P729
   Uchida T, 2000, CHEM PHARM BULL, V48, P1843
   UNICEF, 2006, PROGR REP CHILDR NUT
   Vieria AC, 2007, J PEDIAT, V83, P370
   Walker CF, 2005, AM J CLIN NUTR, V82, P5
   Wamani Henry, 2007, BMC Pediatr, V7, P17, DOI 10.1186/1471-2431-7-17
   WHO, 2001, IR DEF AN ASS PREV C
   World Health Organization, 1989, PREV CONTR IR DEF AN
   Zere E, 2003, J HEALTH POPUL NUTR, V21, P205
NR 48
TC 0
Z9 0
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD MAR
PY 2015
VL 31
IS 3
BP 452
EP 458
DI 10.1016/j.nut.2014.09.016
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CC3RT
UT WOS:000350267800006
PM 25701334
ER

PT J
AU Yegin, ZA
   Iyidir, OT
   Demirtas, C
   Suyani, E
   Yetkin, I
   Pasaoglu, H
   Ilhan, C
   Sucak, GT
AF Yegin, Z. A.
   Iyidir, O. T.
   Demirtas, C.
   Suyani, E.
   Yetkin, I.
   Pasaoglu, H.
   Ilhan, C.
   Sucak, G. T.
TI The interplay among iron metabolism, endothelium and inflammatory
   cascade in dysmetabolic disorders
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Iron overload; Ferritin; Metabolic syndrome; Diabetes mellitus;
   Osteopontin; Hepcidin
ID INSULIN-RESISTANCE; OSTEOPONTIN; PREVALENCE; ASSOCIATION; OBESITY;
   ADULTS
AB Purpose Metabolic syndrome (MetS) is considered as a proinflammatory and prothrombotic state with atherogenic risk factors including dyslipidemia, obesity and glucose intolerance. Oxidative stress is a unifying basis of several disorders including diabetes mellitus (DM) and MetS. We therefore designed this cross-sectional study to investigate the potential interaction among iron metabolism, inflammation and endothelial plexus in MetS and DM patients.
   Methods A total of 62 patients [median age 54 (23-76) years; male/female 16/46] and 18 healthy controls [median age 38 (30-64) years; male/female 6/12] were included in the study. Patient population was classified as MetS (n = 30) and DM (n = 32).
   Results Leukocyte count (p = 0.002) and osteopontin (OPN) levels (p = 0.008) were significantly higher, while C-reactive protein (CRP) (p = 0.056) and IL-6 (p = 0.059) represented a relative increase in the patient group. Leptin, endothelin 1 (ET1), hepcidin, nitric oxide synthase (NOS), erythrocyte sedimentation rate (ESR), iron, transferrin saturation (TS) and ferritin levels were not significantly different between the patient and control groups. Endothelin 1 was found to be higher in the DM group compared to MetS group (p = 0.15, p = 0.049). Leukocyte count, leptin, hepcidin, OPN, NOS, IL-6, ESR, CRP, iron, TS and ferritin levels were not different between DM and MetS groups. A positive correlation was demonstrated between leptin and OPN (p = 0.001, r = 0.360), ferritin and hepcidin (p < 0.01, r = 0.633), IL-6 and CRP (p = 0.023, r = 0.319), leptin and NOS (p = 0.005, r = 0.309) and OPN and NOS (p < 0.001, r = 0.803). There was a negative correlation between hepcidin and NOS (p = 0.009, r = -0.289). When the study cohort was divided into two particular groups based on median ferritin and hepcidin levels, hepcidin (p = 0.002), ALT (p = 0.001) and LDL (p = 0.049) levels were higher in the high-ferritin group. Nitric oxide synthase levels (p = 0.033) were lower, whereas ferritin levels (p = 0.004) were higher in the high-hepcidin group.
   Conclusion Mechanisms involved in the vicious circle of MetS including inflammation, endothelial vasculature and iron metabolism remain to be elucidated. The role of iron metabolism in this complex interaction should be confirmed with further studies.
C1 [Yegin, Z. A.; Suyani, E.; Ilhan, C.; Sucak, G. T.] Gazi Univ, Fac Med, Dept Hematol, Ankara, Turkey.
   [Iyidir, O. T.; Yetkin, I.] Gazi Univ, Fac Med, Dept Endocrinol, Ankara, Turkey.
   [Demirtas, C.; Pasaoglu, H.] Gazi Univ, Fac Med, Dept Biochem, Ankara, Turkey.
RP Yegin, ZA (reprint author), Gazi Univ, Fac Med, Dept Hematol, Ankara, Turkey.
EM zeyneparzuyegin@gmail.com
CR Vykoukal D, 2011, J VASC SURG, V54, P819, DOI 10.1016/j.jvs.2011.01.003
   Valenti L, 2011, NUTR METAB CARDIOVAS, V21, P568, DOI 10.1016/j.numecd.2010.01.003
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Kang HT, 2012, CLIN CHIM ACTA, V413, P636, DOI 10.1016/j.cca.2011.12.011
   Valenti L, 2011, ARTERIOSCL THROM VAS, V31, P683, DOI 10.1161/ATVBAHA.110.214858
   Mateo-Gallego R, 2010, METABOLISM, V59, P154, DOI 10.1016/j.metabol.2009.06.021
   Guzik TJ, 2006, J PHYSIOL PHARMACOL, V57, P505
   Duvnjak L, 2009, J PHYSIOL PHARMACOL, V60, P19
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Tesauro M, 2011, ACTA PHYSIOL, V203, P279, DOI 10.1111/j.1748-1716.2011.02290.x
   Datz C, 2013, EUR J CLIN INVEST, V43, P215, DOI 10.1111/eci.12032
   Uede T, 2011, PATHOL INT, V61, P265, DOI 10.1111/j.1440-1827.2011.02649.x
   Cho GJ, 2011, MENOPAUSE, V18, P1120, DOI 10.1097/gme.0b013e318217e172
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Campia U, 2012, BRIT J PHARMACOL, V165, P561, DOI 10.1111/j.1476-5381.2011.01661.x
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Arredondo M, 2011, BIOL TRACE ELEM RES, V143, P625, DOI 10.1007/s12011-010-8895-7
   Berezin AE, 2013, ATHEROSCLEROSIS, V229, P475, DOI 10.1016/j.atherosclerosis.2013.06.003
   Freixenet N, 2011, DIABETES RES CLIN PR, V91, pE33, DOI 10.1016/j.diabres.2010.10.003
   Houschyar KS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-54
   Javanmard SH, 2012, MOL BIOL REP, V39, P3355, DOI 10.1007/s11033-011-1105-7
   Komorowski J, 2011, CYTOKINE, V55, P56, DOI 10.1016/j.cyto.2011.03.020
   Le Guenno G, 2007, DIABETES RES CLIN PR, V77, P363, DOI 10.1016/j.diabres.2007.02.004
   Levesque J, 2008, J NUTRIGENET NUTRIGE, V1, P100, DOI 10.1159/000112457
   Martinelli N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048250
   Piperno A, 2004, LIVER INT, V24, P471, DOI 10.1111/j.1478-3231.2004.0988.x
   Rasic-Milutinovic Z, 2007, INTERNAL MED, V46, P945, DOI 10.2169/internalmedicine.46.0092
   Stepien E, 2011, CLIN BIOCHEM, V44, P826, DOI 10.1016/j.clinbiochem.2011.04.016
   Yilmaz Y, 2012, ALIMENT PHARM THER, V36, P815, DOI 10.1111/apt.12046
NR 29
TC 1
Z9 1
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1720-8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD MAR
PY 2015
VL 38
IS 3
BP 333
EP 338
DI 10.1007/s40618-014-0174-6
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CC9IB
UT WOS:000350681200007
PM 25245337
ER

PT J
AU Wang, XH
   Fang, XX
   Wang, FD
AF Wang, Xinhui
   Fang, Xuexian
   Wang, Fudi
TI Pleiotropic actions of iron balance in diabetes mellitus
SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
LA English
DT Article
DE Iron homeostasis; Diabetes; Insulin secretion; Insulin resistance;
   Inflammation; Hypoxia
ID STIMULATED INSULIN-SECRETION; SERUM TRANSFERRIN RECEPTOR; HEME
   OXYGENASE-1 GENE; PANCREATIC BETA-CELLS; BODY IRON; HEREDITARY
   HEMOCHROMATOSIS; THALASSEMIA MAJOR; COBALT PROTOPORPHYRIN;
   CLINICAL-ASPECTS; CHRONIC DISEASE
AB As an essential element, iron plays a central role in many physiological processes, including redox balance, inflammation, energy metabolism, and environment sensing. Perturbations in iron homeostasis are associated with several conditions, including hyperglycemia and diabetes, both of which have been studied in patients and animal models. To clarify the pleiotropic role of iron homeostasis in diabetes development, the early studies on diseases with iron-overload, studies on clinical iron depletion therapies, associations between iron-related genetic polymorphisms and diabetes, and etiological mechanisms underlying iron perturbations-impaired insulin secretion and insulin sensitivity were carefully reviewed and discussed. Hereditary hemochromatosis, transfusion-dependent thalassemia, and excess heme iron intake can increase the risk of developing diabetes. Genetically modified mice and mice fed a high-iron diet present with discrepant phenotypes due to differences in tissue iron distribution. Moreover, several genetic polymorphisms related to iron homeostasis have been associated with the risk of developing diabetes. Tightly controlled iron metabolism is essential for insulin secretion and insulin sensitivity, and iron overload in pancreatic islets alters reactive oxygen species (ROS) generation, as well as hypoxia-inducible factor-1 alpha (HIF-1 alpha) stability and adenosine triphosphate (ATP) synthesis, thereby impairing the function and viability of beta-cells. Decreased levels of adiponectin, macrophage-mediated inflammation, and ROS-mediated liver kinase B1 (LKB1)/adenosine monophosphate-activated protein kinase (AMPK) activation can contribute to iron overload-induced insulin resistance, whereas iron deficiency could also participate in obesity-related inflammation, hypoxia, and insulin resistance. Because iron homeostasis is closely correlated with many metabolic processes, future studies are needed in order to elucidate the finely tuned network among iron homeostasis, carbohydrate and lipid metabolism, inflammation, and hypoxia.
C1 [Wang, Xinhui; Fang, Xuexian; Wang, Fudi] Zhejiang Univ, Sch Med, Sch Publ Hlth, Dept Nutr,Res Ctr Nutr & Hlth,Inst Nutr & Food Sa, Hangzhou 310058, Zhejiang, Peoples R China.
   [Wang, Fudi] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou 310058, Zhejiang, Peoples R China.
RP Wang, FD (reprint author), Zhejiang Univ, Sch Med, Sch Publ Hlth, Dept Nutr,Res Ctr Nutr & Hlth,Inst Nutr & Food Sa, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
EM fwang@zju.edu.cn
FU Chinese National Natural Science Foundation [31225013, 31330036,
   31030039]; Distinguished Professorship Program from Zhejiang University
FX This work was supported by the Chinese National Natural Science
   Foundation (grant numbers 31225013, 31330036, and 31030039 to F.W.).
   This work was also supported by the Distinguished Professorship Program
   from Zhejiang University (to F.W.). We are also grateful to the members
   of the Wang laboratory for their encouragement and helpful comments.
CR Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   Odegaard JI, 2013, SCIENCE, V339, P172, DOI 10.1126/science.1230721
   Burgess A, 2010, HYPERTENSION, V56, P1124, DOI 10.1161/HYPERTENSIONAHA.110.151423
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Gerber PA, 2014, DIABETOLOGIA, V57, P1635, DOI 10.1007/s00125-014-3266-0
   Chan KKL, 2009, BJOG-INT J OBSTET GY, V116, P789, DOI 10.1111/j.1471-0528.2008.02014.x
   Jais A, 2014, CELL, V158, P25, DOI 10.1016/j.cell.2014.04.043
   Bullo M, 2012, AM J CLIN NUTR, V95, P249, DOI 10.3945/ajcn.111.016642
   Hansen JB, 2012, CELL METAB, V16, P449, DOI 10.1016/j.cmet.2012.09.001
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Pi JB, 2007, DIABETES, V56, P1783, DOI 10.2337/db06-1601
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0
   Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187
   Huang JY, 2013, FASEB J, V27, P2845, DOI 10.1096/fj.12-216929
   Buysschaert M, 1997, DIABETES METAB, V23, P308
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   NIEDERAU C, 1994, ADV EXP MED BIOL, V356, P293
   Zheng JY, 2008, MOL CELL BIOCHEM, V319, P153, DOI 10.1007/s11010-008-9888-0
   Qi L, 2005, DIABETES, V54, P3567, DOI 10.2337/diabetes.54.12.3567
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Wang XH, 2014, ANTIOXID REDOX SIGN, V20, P191, DOI 10.1089/ars.2013.5361
   Li M, 2008, DIABETES, V57, P1526, DOI 10.2337/db07-1764
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Salonen JT, 1998, BRIT MED J, V317, P727
   Chambers EC, 2006, J AM DIET ASSOC, V106, P680, DOI 10.1016/j.jada.2006.02.013
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Gan W, 2012, AM J CLIN NUTR, V95, P626, DOI 10.3945/ajcn.111.025684
   Vogiatzi MG, 2009, BRIT J HAEMATOL, V146, P546, DOI 10.1111/j.1365-2141.2009.07793.x
   Cheng K, 2010, J CLIN INVEST, V120, P2171, DOI 10.1172/JCI35846
   Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5
   Kunutsor SK, 2013, DIABETES-METAB RES, V29, P308, DOI 10.1002/dmrr.2394
   Liu XF, 2013, UNIVERSITAS-TAIWAN, V40, P1
   Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Rajpathak SN, 2009, DIABETES OBES METAB, V11, P472, DOI 10.1111/j.1463-1326.2008.00985.x
   Shan Y, 2006, FASEB J, V20, P2651, DOI 10.1096/fj.06-6346fje
   Mleczko-Sanecka K, 2010, BLOOD, V115, P2657, DOI 10.1182/blood-2009-09-238105
   Huang JY, 2011, DIABETES, V60, P80, DOI 10.2337/db10-0593
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Marsella M, 2014, HEMATOL ONCOL CLIN N, V28, P703, DOI 10.1016/j.hoc.2014.04.004
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Johnson AMF, 2013, CELL, V152, P673, DOI 10.1016/j.cell.2013.01.041
   Berdoukas V, 2011, EXPERT REV HEMATOL, V4, P17, DOI [10.1586/ehm.10.74, 10.1586/EHM.10.74]
   Ashcroft FM, 2012, CELL, V148, P1160, DOI 10.1016/j.cell.2012.02.010
   Sullivan JL, 2007, EXP BIOL MED, V232, P1014, DOI 10.3181/0703-MR-54
   WENZEL BJ, 1962, LANCET, V2, P327
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007
   Donovan A, 2000, NATURE, V403, P776
   Nicolai A, 2009, HYPERTENSION, V53, P508, DOI 10.1161/HYPERTENSIONAHA.108.124701
   Orban E, 2014, DIABETES-METAB RES, V30, P372, DOI 10.1002/dmrr.2506
   Aigner E, 2013, J NUTR BIOCHEM, V24, P112, DOI 10.1016/j.jnutbio.2012.02.017
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   SKIKNE BS, 1990, BLOOD, V75, P1870
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Borgna-Pignatti C, 2011, EXPERT REV HEMATOL, V4, P353, DOI [10.1586/ehm.11.29, 10.1586/EHM.11.29]
   Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6
   Forman HJ, 2010, ANN NY ACAD SCI, V1203, P35, DOI 10.1111/j.1749-6632.2010.05551.x
   Bao W, 2010, AM J EPIDEMIOL, V172, P631, DOI 10.1093/aje/kwq162
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Koliaraki V, 2011, ADV EXP MED BIOL, V780, P101, DOI 10.1007/978-1-4419-5632-3_9
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Silvestri L, 2008, CELL METAB, V8, P502, DOI 10.1016/j.cmet.2008.09.012
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Hunnicutt J, 2014, J NUTR, V144, P359, DOI 10.3945/jn.113.185124
   Bao W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-119
   Chan KK, 2009, BJOG, V116, P97
   COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63
   De Sanctis Vincenzo, 2013, Curr Diabetes Rev, V9, P332
   DESANCTIS V, 1985, POSTGRAD MED J, V61, P963
   DYMOCK IW, 1972, AM J MED, V52, P203, DOI 10.1016/0002-9343(72)90070-8
   Facchini FS, 1998, DIABETES CARE, V21, P2190
   Fernandez-Real JM, 2010, EUR J CLIN INVEST, V40, P600, DOI 10.1111/j.1365-2362.2010.02306.x
   Galanello R, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-11
   Gutierrez-Aguilar R, 2007, DIABETES METAB, V33, P372, DOI 10.1016/j.diabet.2007.06.002
   Hanot V, 1896, Br Med J, V1, P206
   Hanot V, 1886, ARCH PHYS NORM PATHO, V7, P50
   He MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040919
   Hudson DM, 2010, AM J PHYSIOL-GASTR L, V298, pG425, DOI 10.1152/ajpgi.00453.2009
   Juanola-Falgarona M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076433
   Katchunga Philippe Bianga, 2013, Diabetes Metab Syndr, V7, P112, DOI 10.1016/j.dsx.2013.02.017
   Koch RO, 2003, HISTOL HISTOPATHOL, V18, P1095
   Wilson Carol, 2012, Nat Rev Endocrinol, V8, P696, DOI [10.1038/nrendo.2012.196, 10.1038/nrendo.2012.185]
   Nikonorov AA, 2014, J TRACE ELEM MED BIO
   Opie E L, 1899, J Exp Med, V4, P279, DOI 10.1084/jem.4.3-4.279
   O'Sullivan EP, 2008, DIABETES RES CLIN PR, V81, P316, DOI 10.1016/j.diabres.2008.05.001
   RAHIER J, 1987, DIABETOLOGIA, V30, P5, DOI 10.1007/BF01788899
   Rodriguez A, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-379
   Tarasov A, 2004, DIABETES, V53, pS113, DOI 10.2337/diabetes.53.suppl_3.S113
   Trousseau A, 1865, CLIN MED HOTEL PARIS, V2, P663
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
   Utzschneider KM, 2014, J DIABETES COMPLICAT, V28, P177, DOI 10.1016/j.jdiacomp.2013.11.007
   Villar E, 2011, J DIABETES COMPLICAT, V25, P237, DOI 10.1016/j.jdiacomp.2011.03.003
   Zhao ZX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041641
NR 97
TC 2
Z9 2
U1 13
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1389-9155
EI 1573-2606
J9 REV ENDOCR METAB DIS
JI Rev. Endocr. Metab. Disord.
PD MAR
PY 2015
VL 16
IS 1
BP 15
EP 23
DI 10.1007/s11154-014-9303-y
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CC6RD
UT WOS:000350493800002
PM 25520048
ER

PT J
AU Wendt, AS
   Jefferds, ME
   Perrine, CG
   Halleslevens, P
   Sullivan, KM
AF Wendt, Amanda S.
   Jefferds, Maria E.
   Perrine, Cria G.
   Halleslevens, Patricia
   Sullivan, Kevin M.
TI Obese women less likely to have low serum ferritin, Nicaragua
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Obesity; Serum ferritin; Iron deficiency; Inflammation; alpha(1)-Acid
   glycoprotein
ID ACUTE-PHASE RESPONSE; C-REACTIVE PROTEIN; IRON-DEFICIENCY; SUBCLINICAL
   INFLAMMATION; OVERWEIGHT CHILDREN; REPRODUCTIVE AGE; PREVALENCE; ANEMIA;
   HYPOFERREMIA; ADOLESCENTS
AB Objective: To examine the association between overweight and obesity and serum ferritin among women of reproductive age (15-49 years) in Nicaragua, considering the effect of a1-acid glycoprotein (AGP), a marker of inflammation.
   Design: We analysed data from the 2004-05 Nicaraguan Integrated Surveillance System for Nutrition Interventions. Three logistic regression models were analysed with low serum ferritin (< 15 mu g/l) as the dependent variable: (i) overweight or obese status and covariates; (ii) model 1 plus AGP; and (iii) model 1 restricted to only women with normal AGP levels (<= 1.0 g/l).
   Setting: Nicaragua.
   Subjects: Included in this analysis were 832 non-pregnant mother/caregivers (15-49 years) surveyed in 2004-2005.
   Results: In the sample, prevalence of overweight and obesity was 31.8 % and 19.2 %, respectively, and 27.6 % had low serum ferritin. In model 1, the adjusted OR of low serum ferritin was 0.74 (95 % CI 0.52, 1.05) for overweight women and 0.42 (95 % CI 0.26, 0.65) for obese women. In model 2, AGP was significantly independently associated with low serum ferritin (adjusted OR = 0.56, 95 % CI 0.34, 0.92) while the adjusted OR for overweight and obesity were largely unchanged. Excluding women with elevated AGP did not appreciably affect the relationship between overweight or obesity and low serum ferritin (model 3).
   Conclusions: Overall, in this population of reproductive-age women, obese women were less likely to have low serum ferritin levels, and this was independent of inflammation as measured by AGP.
C1 [Wendt, Amanda S.] Emory Univ, Laney Grad Sch, Grad Div Biol & Biomed Sci, Nutr & Hlth Sci Program, Atlanta, GA 30322 USA.
   [Jefferds, Maria E.; Perrine, Cria G.; Sullivan, Kevin M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA.
   [Halleslevens, Patricia] Minist Hlth, Managua, Nicaragua.
   [Sullivan, Kevin M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Wendt, AS (reprint author), Emory Univ, Laney Grad Sch, Grad Div Biol & Biomed Sci, Nutr & Hlth Sci Program, 1599 Clifton Rd NE Room 6-426, Atlanta, GA 30322 USA.
EM awendt@emory.edu
FU T-32 Reproductive, Perinatal, Pediatric Predoctoral Fellowship through
   the National Institutes of Health [2T32HD052460]
FX This research received no specific grant from any funding agency in the
   public, commercial or not-for-profit sectors. The primary author was
   supported by a T-32 Reproductive, Perinatal, Pediatric Predoctoral
   Fellowship through the National Institutes of Health (Grant #
   2T32HD052460). The findings and conclusions in this report are those of
   the authors and do not necessarily represent the official position of
   the US Centers for Disease Control and Prevention.
CR Ahmed F, 2008, ASIA PAC J CLIN NUTR, V17, P40
   Allen LH, 2000, AM J CLIN NUTR, V71, p1280S
   Shafique S, 2007, INT J EPIDEMIOL, V36, P449, DOI 10.1093/ije/dyl306
   Karl JP, 2009, J AM COLL NUTR, V28, P37
   Thurnham DI, 2003, LANCET, V362, P2052, DOI 10.1016/S0140-6736(03)15099-4
   Mendez MA, 2005, AM J CLIN NUTR, V81, P714
   Caballero B, 2007, EPIDEMIOL REV, V29, P1, DOI 10.1093/epirev/mxm012
   Fernald LC, 2007, EUR J CLIN NUTR, V61, P623, DOI 10.1038/sj.ejcn.1602558
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Moschonis G, 2012, BRIT J NUTR, V108, P710, DOI 10.1017/S0007114511005952
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Timpson NJ, 2011, INT J OBESITY, V35, P300, DOI 10.1038/ijo.2010.137
   Farr SA, 2008, ENDOCRINOLOGY, V149, P2628, DOI 10.1210/en.2007-1722
   Maachi M, 2004, INT J OBESITY, V28, P993, DOI 10.1038/sj.ijo.0802718
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Satia JA, 2010, APPL PHYSIOL NUTR ME, V35, P219, DOI 10.1139/H10-007
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Kordas K, 2013, J NUTR, V143, P175, DOI 10.3945/jn.112.167767
   Northrop-Clewes CA, 2008, ANN CLIN BIOCHEM, V45, P18, DOI 10.1258/acb.2007.007167
   HALLBERG L, 1993, BRIT J HAEMATOL, V85, P787, DOI 10.1111/j.1365-2141.1993.tb03225.x
   Baumgartner J, 2013, INT J OBESITY, V37, P24, DOI 10.1038/ijo.2012.145
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Fanou-Fogny N, 2011, BRIT J NUTR, V105, P574, DOI 10.1017/S0007114510003776
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   Thurnham DI, 2005, P NUTR SOC, V64, P502, DOI 10.1079/PNS2005468
   BAYNES R, 1986, SCAND J CLIN LAB INV, V46, P695, DOI 10.3109/00365518609083733
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Stevens GA, 2013, LANCET GLOB HEALTH, V1, pE16, DOI 10.1016/S2214-109X(13)70001-9
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Feelders RA, 1998, EUR J CLIN INVEST, V28, P520
   FINCH CA, 1986, WESTERN J MED, V145, P657
   Greenberg Andrew S, 2006, Am J Clin Nutr, V83, p461S
   Kung'u JK, 2009, J NUTR, V139, P2124, DOI 10.3945/jn.108.104026
   Means RT, 2004, BLOOD REV, V18, P219, DOI 10.1016/S0268-960X9(03)00066-3
   Ministerio de Salud Nicaragua, 2008, SIST INT VIG INT NUT
   Stevens GA, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-22
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   US Centers for Disease Control and Prevention, 2012, 2 US CDCP NAT CTR EN
   WHO, 1995, WHO TECHN REP SER
   WHO, 2001, IR DEF AN ASS PREV C
   World Health Organization, 2003, WHO TECHN REP SER, V916
   World Health Organization, 2012, TRAIN COURS CHILD GR
   World Health Organization/Centers for Disease Control and Prevention, 2005, ASS IR STAT POP REP
NR 47
TC 0
Z9 0
U1 1
U2 3
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD MAR
PY 2015
VL 18
IS 4
BP 736
EP 741
DI 10.1017/S1368980014000755
PG 6
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA CB6TW
UT WOS:000349760600021
PM 24848519
ER

PT J
AU Lau, K
   Baumeister, SE
   Lieb, W
   Meffert, PJ
   Lerch, MM
   Mayerle, J
   Volzke, H
AF Lau, K.
   Baumeister, S. E.
   Lieb, W.
   Meffert, P. J.
   Lerch, M. M.
   Mayerle, J.
   Voelzke, H.
TI The combined effects of alcohol consumption and body mass index on
   hepatic steatosis in a general population sample of European men and
   women
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID FATTY LIVER-DISEASE; CARBOHYDRATE-DEFICIENT TRANSFERRIN; METABOLIC
   SYNDROME; BINGE DRINKING; RISK-FACTORS; PREVALENCE; HEALTH; ADULTS
AB Background
   Research on the association between alcohol consumption and hepatic steatosis revealed conflictive results.
   Aim
   To investigate the associations between average daily alcohol consumption and binge drinking with hepatic steatosis, and to analyse combined effects of average daily alcohol consumption and binge drinking with body mass index (BMI) on hepatic steatosis.
   Methods
   Data from the population-based Study of Health in Pomerania (SHIP) conducted in north-east Germany comprising 4009 adults were used. Alcohol consumption was assessed by self-report. Serum carbohydrate-deficient transferrin (CDT) was analysed as biomarker for alcohol consumption. Hepatic steatosis was diagnosed by ultrasonography.
   Results
   Analyses revealed a dose-response relationship between average daily alcohol consumption and hepatic steatosis in men starting with a consumption of 20 g of alcohol per day [adjusted odds ratio (OR) compared to abstainers 1.53; 95% confidence interval (CI) 1.15-2.05]. Using CDT as alternative exposure variable confirmed these results. Binge drinking was associated with hepatic steatosis in men (adjusted OR of binge drinkers compared to nonbinge drinkers 1.36, 95% CI 1.06-1.74). The likelihood of having hepatic steatosis increased in men and women with increasing levels of average daily alcohol consumption in combination with overweight or obesity. Similarly, binge drinking in combination with overweight or obesity enhanced the likelihood of having hepatic steatosis.
   Conclusions
   Overweight or obesity substantially enhanced the effect of high levels of average daily alcohol consumption and binge drinking on hepatic steatosis in the present study population. This finding underlines the necessity to screen for multiple risk factors in the prevention of hepatic steatosis.
C1 [Lau, K.; Baumeister, S. E.; Meffert, P. J.; Voelzke, H.] Univ Med Greifswald, Inst Community Med, Greifswald, Germany.
   [Lau, K.] Univ Med Ctr Hamburg Eppendorf, Dept Psychosomat Med & Psychotherapy, Hamburg, Germany.
   [Lau, K.] Schon Clin Hamburg Eilbek, Hamburg, Germany.
   [Lieb, W.] Univ Med Ctr Kiel, Inst Epidemiol, Kiel, Germany.
   [Lerch, M. M.; Mayerle, J.] Univ Med Greifswald, Dept Med A, Greifswald, Germany.
RP Lau, K (reprint author), Univ Med Ctr Hamburg Eppendorf UKE, Dept Psychosomat Med & Psychotherapy, Martinistr 52, D-20246 Hamburg, Germany.
EM k.lau@uke.de
RI Lieb, Wolfgang/C-1990-2012
FU German Federal Ministry of Education and Research (BMBF) [01ZZ96030,
   01ZZ0701]; BMBF [03IS2061A]
FX SHIP is part of the Community Medicine Net
   (http://medizin.uni-greifs-wald.de/icm) of the University of Greifswald
   funded by grants from the German Federal Ministry of Education and
   Research (BMBF, grant 01ZZ96030, 01ZZ0701) and the network 'Greifswald
   Approach to Individualized Medicine (GANI_MED)' which is funded by the
   BMBF (grant 03IS2061A). The assistance of field workers, study
   physicians, ultrasound technicians, interviewers and computer assistants
   in the collection of data is gratefully acknowledged.
CR Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x
   White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067
   Bellentani S, 2000, ANN INTERN MED, V132, P112
   Hiramine Y, 2011, J GASTROENTEROL, V46, P519, DOI 10.1007/s00535-010-0336-z
   Nishioji K, 2015, J GASTROENTEROL, V50, P95, DOI 10.1007/s00535-014-0948-9
   Desquilbet L, 2010, STAT MED, V29, P1037, DOI 10.1002/sim.3841
   Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70
   Baumeister SE, 2005, GESUNDHEITSWESEN, V67, P39, DOI 10.1055/s-2004-813829
   Alatalo PI, 2008, AM J CLIN NUTR, V88, P1097
   Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
   Gunji T, 2009, AM J GASTROENTEROL, V104, P2189, DOI 10.1038/ajg.2009.361
   Hamaguchi M, 2012, WORLD J GASTROENTERO, V18, P156, DOI 10.3748/wjg.v18.i2.156
   Morini L, 2011, THER DRUG MONIT, V33, P654, DOI 10.1097/FTD.0b013e318232950f
   Ruhl CE, 2005, CLIN GASTROENTEROL H, V3, P1260, DOI 10.1016/S1542-3565(05)00743-3
   Shen Z, 2010, EUR J GASTROEN HEPAT, V22, P820, DOI 10.1097/MEG.0b013e3283328b86
   de Araujo Souza Monica Rodrigues, 2012, Arquivos de Gastroenterologia, V49, P89, DOI 10.1590/S0004-28032012000100015
   Mathurin P, 2009, GUT, V58, P613, DOI 10.1136/gut.2007.145573
   Moriya A, 2011, ALIMENT PHARM THER, V33, P378, DOI 10.1111/j.1365-2036.2010.04520.x
   Arndt T, 2001, CLIN CHEM, V47, P13
   Buhringer G, 2000, ALKOHOLKONSUM ALKOHO
   Caballeria L, 2007, BMC GASTROENTEROL, V7, DOI 10.1186/1471-230X-7-41
   De Vries JHM, 1999, HLTH ISSUES RELATED, P27
   Fagan KJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-97
   Volzke H, 2010, INT J EPIDEMIOL, V40, P294
   WHO, 2000, WHO TECHN REP SER, V894
   World Health Organization, 2000, INT GUID MON ALC CON
   Yamada T, 2010, DIGEST DIS SCI, V55, P176, DOI 10.1007/s10620-008-0693-0
NR 27
TC 3
Z9 4
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAR
PY 2015
VL 41
IS 5
BP 467
EP 476
DI 10.1111/apt.13067
PG 10
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA CA2IF
UT WOS:000348731400007
PM 25588768
ER

PT J
AU Tang, Q
   Liu, ZF
   Tang, Y
   Tan, AH
   Gao, Y
   Lu, Z
   Wang, QY
   Chen, YC
   Wu, CL
   Zhang, HY
   Yang, XB
   Mo, ZN
AF Tang, Qin
   Liu, Zhenfang
   Tang, Yan
   Tan, Aihua
   Gao, Yong
   Lu, Zheng
   Wang, Qiuyan
   Chen, Yingchun
   Wu, Chunlei
   Zhang, Haiying
   Yang, Xiaobo
   Mo, Zengnan
TI High serum ferritin level is an independent risk factor for metabolic
   syndrome in a Chinese male cohort population
SO DIABETOLOGY & METABOLIC SYNDROME
LA English
DT Article
DE Metabolic syndrome; Serum ferritin; Central obesity; Hypertension;
   Triglycerides; High-density lipoprotein cholesterol
ID BODY IRON STORES; INSULIN-RESISTANCE; KOREAN MEN; ASSOCIATION; OBESITY;
   HYPERTENSION; TRANSFERRIN; CANCER; ADULTS; WOMEN
AB Background: Elevated serum ferritin levels have been reported to contribute to metabolic syndrome (MetS). We examined the association of serum ferritin levels with the development of MetS in a representative sample of Chinese male adult population.
   Method: The data came from the 2009-2013 Fangchenggang Area Males Health and Examination Survey (FAMHES). We combined a cross-sectional study of 2417 males and a longitudinal study of 857 males who participated in the FAMHES.
   Result: The serum ferritin level of MetS was higher than that of nonMetS (median and percentiles 25-75: 447.4 (294.1-612.4) vs. 302.4 (215.0-435.8) ng/ml, p < 0.01). A positive correlation between ferritin concentrations and blood pressure (Systolic BP: R = 0.110, Diastolic BP: R = 0.158), waist circumference (R = 0.333), fasting glucose (R = 0.089), triglyceride (R = 0.315) and low high-density lipoprotein cholesterol (R = 0.130) was significant (all p < 0.001). Compared with the level of ferritin in the group with no MetS component, the group with all five MetS components had a higher ferritin level (554.7 (340.1-606.4) vs. 274.2 (198.2-384.4) ng/ml). The odd radio (OR) was higher for MetS in the highest ferritin quartile (OR = 2.29, 95% CI = 1.47-3.54) compared with the lowest ferritin quartile after adjustment for multi-factors. After 4-year follow up, 79 subjects newly diagnosed with MetS in 857 cohort male participants in 2013. Compared with the lowest ferritin quartile, the RR of the highest ferritin quartile was 2.55 (95% CI = 1.30-5.00) after multiple adjustments (p < 0.01).
   Conclusion: Our findings confirm that the serum ferritin level is associated with the independent components of MetS, and elevated ferritin level is an independent risk factor for MetS development in the Chinese male population during the 4-year follow-up period.
C1 [Tang, Qin; Tang, Yan; Tan, Aihua; Gao, Yong; Lu, Zheng; Wang, Qiuyan; Chen, Yingchun; Wu, Chunlei; Zhang, Haiying; Yang, Xiaobo; Mo, Zengnan] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning 530021, Guangxi, Peoples R China.
   [Tang, Qin; Tang, Yan; Wang, Qiuyan; Chen, Yingchun; Yang, Xiaobo; Mo, Zengnan] Guangxi Key Lab Genom & Personalized Med, Nanning 530021, Guangxi, Peoples R China.
   [Tang, Qin; Tang, Yan; Wang, Qiuyan; Chen, Yingchun; Yang, Xiaobo; Mo, Zengnan] Guangxi Collaborat Innovat Ctr Genom & Personaliz, Nanning 530021, Guangxi, Peoples R China.
   [Liu, Zhenfang] Guangxi Med Univ, Affiliated Hosp 1, Hematol Dept, Nanning 530021, Guangxi, Peoples R China.
   [Tan, Aihua] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Chemotherapy, Nanning 530021, Guangxi, Peoples R China.
   [Lu, Zheng; Mo, Zengnan] Guangxi Med Univ, Affiliated Hosp 1, Inst Urol & Nephrol, Nanning 530021, Guangxi, Peoples R China.
   [Zhang, Haiying; Yang, Xiaobo] Guangxi Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Environm Hlth, Nanning 530021, Guangxi, Peoples R China.
RP Yang, XB (reprint author), Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning 530021, Guangxi, Peoples R China.
EM yxbo21021@163.com
FU Guangxi Science Fund for Distinguished Young Scholars [2012jjFA40011];
   Guangxi science and technology development project [1355007-1]; Program
   for New Century Excellent Talents in University [NCET-12-0653]; National
   Natural Science Foundations of China [81260130, 81460159]
FX This study was funded by Guangxi Science Fund for Distinguished Young
   Scholars (2012jjFA40011); Guangxi science and technology development
   project (1355007-1); Program for New Century Excellent Talents in
   University (NCET-12-0653); and National Natural Science Foundations of
   China (81260130 and 81460159).
CR Abril-Ulloa V, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-483
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Park SK, 2014, ENDOCR J, V61, P215, DOI 10.1507/endocrj.EJ13-0173
   Tan AH, 2011, METABOLISM, V60, P1186, DOI 10.1016/j.metabol.2011.01.002
   Mateo-Gallego R, 2010, METABOLISM, V59, P154, DOI 10.1016/j.metabol.2009.06.021
   Park SK, 2012, DIABETES CARE, V35, P2521, DOI 10.2337/dc12-0543
   Chang JS, 2013, ASIA PAC J CLIN NUTR, V22, P400, DOI 10.6133/apjcn.2013.22.3.07
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Zwart SR, 2013, AM J CLIN NUTR, V98, P217, DOI 10.3945/ajcn.112.056465
   Montonen J, 2012, DIABETOLOGIA, V55, P2613, DOI 10.1007/s00125-012-2633-y
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Ishino K, 2013, CANCER LETT, V334, P56, DOI 10.1016/j.canlet.2012.10.012
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Cooksey RC, 2004, ENDOCRINOLOGY, V145, P5305, DOI 10.1210/en.2004-0392
   Gao Y, 2012, UROLOGY, V79, P194, DOI 10.1016/j.urology.2011.07.1399
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Li YQ, 2014, INT J ENV RES PUB HE, V11, P2899, DOI 10.3390/ijerph110302899
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   Eckel RH, 2010, LANCET, V375, P181, DOI 10.1016/S0140-6736(09)61794-3
   Onat A, 2013, EUR J CLIN INVEST, V43, P1129, DOI 10.1111/eci.12150
   Onat A, 2010, J CLIN LIPIDOL, V4, P89, DOI 10.1016/j.jacl.2010.02.005
   Fairweather-Tait SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083047
   Giudice A, 2014, J GASTROINTEST LIVER, V23, P73
   Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198
   Han LL, 2014, MOL NUTR FOOD RES, V58, P2189, DOI 10.1002/mnfr.201400088
   Harris EL, 2007, ARCH INTERN MED, V167, P722, DOI 10.1001/archinte.167.7.722
   Kim MK, 2012, AM J HYPERTENS, V25, P492, DOI 10.1038/ajh.2011.241
   Li J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074168
   LIU Z, 2013, IEEE PULSE, V4, P10
   Milman N, 2001, EUR J HAEMATOL, V66, P115, DOI 10.1034/j.1600-0609.2001.00312.x
   Puntarulo Susana, 2005, Molecular Aspects of Medicine, V26, P299, DOI 10.1016/j.mam.2005.07.001
   Sengsuk Chintana, 2014, Indian J Clin Biochem, V29, P298, DOI 10.1007/s12291-013-0376-2
   Suarez-Ortegon MF, 2012, BIOL TRACE ELEM RES, V145, P283, DOI 10.1007/s12011-011-9192-9
   WOLFF SP, 1993, BRIT MED BULL, V49, P642
   Yang T, 2013, ENDOCRINE, V43, P351, DOI 10.1007/s12020-012-9743-7
NR 39
TC 1
Z9 1
U1 4
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-5996
J9 DIABETOL METAB SYNDR
JI Diabetol. Metab. Syndr.
PD FEB 24
PY 2015
VL 7
AR 11
DI 10.1186/s13098-015-0004-9
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CC3MV
UT WOS:000350254500001
PM 25741386
ER

PT J
AU Yamano, N
   Ikeda, Y
   Sakama, M
   Izawa-Ishizawa, Y
   Kihira, Y
   Ishizawa, K
   Miyamoto, L
   Tomita, S
   Tsuchiya, K
   Tamaki, T
AF Yamano, Noriko
   Ikeda, Yasumasa
   Sakama, Minoru
   Izawa-Ishizawa, Yuki
   Kihira, Yoshitaka
   Ishizawa, Keisuke
   Miyamoto, Licht
   Tomita, Shuhei
   Tsuchiya, Koichiro
   Tamaki, Toshiaki
TI A Long-Term High-Fat Diet Changes Iron Distribution in the Body,
   Increasing Iron Accumulation Specifically in the Mouse Spleen
SO JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY
LA English
DT Article
DE iron/spleen/diet; high fat/diabetes mellitus; type 2/DMT1 protein (iron
   transporter)
ID OXIDATIVE STRESS; FERRITIN LEVELS; ABSORPTION; STORES; OBESE; RATS;
   HEMOCHROMATOSIS; SPLENECTOMY; ASSOCIATION; EXPRESSION
AB Although iron is an essential trace metal, its presence in excess causes oxidative stress in the human body. Recent studies have indicated that iron storage is a risk factor for type 2 diabetes mellitus. Dietary iron restriction or iron chelation ameliorates symptoms of type 2 diabetes in mouse models. However, whether iron content in the body changes with the development of diabetes is unknown. Here, we investigated the dynamics of iron accumulation and changes in iron absorption-related genes in mice that developed obesity and diabetes by consuming a high-fat diet (FIFD-fed mice). HFD-fed mice (18-20 wk) were compared with control mice for hematologic features, serum ferritin levels, and iron contents in the gastrocnemius muscle, heart, epididymal fat, testis, liver, duodenum, and spleen. In addition, the spleen was examined histologically. Iron absorption-related gene expression in the liver and duodenum was also examined. Hemoglobin and serum ferritin levels were increased in HFD-fed mice. The HFD-fed mice showed iron accumulation in the spleen, but not in the heart or liver. Increased percentages of the splenic red pulp and macrophages were observed in HFD-fed mice and iron accumulation in the spleen was found mainly in the splenic red pulp. The HFD-fed mice also showed decreased iron content in the duodenum. The mRNA expression of divalent metal transporter-1 (DMT-1), an iron absorption-related gene, was elevated in the duodenum of HFD-fed mice. These results indicate that iron accumulation (specifically accumulation in the spleen) is enhanced by the development of type 2 diabetes induced by HFD.
C1 [Yamano, Noriko; Ikeda, Yasumasa; Izawa-Ishizawa, Yuki; Kihira, Yoshitaka; Tamaki, Toshiaki] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Pharmacol, Tokushima 7708503, Japan.
   [Sakama, Minoru] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Radiol Sci, Tokushima 7708503, Japan.
   [Ishizawa, Keisuke; Miyamoto, Licht; Tsuchiya, Koichiro] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med Pharmacol, Tokushima 7708503, Japan.
   [Tomita, Shuhei] Tottori Univ, Fac Med, Div Mol Pharmacol, Yonago, Tottori 6838503, Japan.
RP Yamano, N (reprint author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Pharmacol, Tokushima 7708503, Japan.
EM yamanori@tokushima-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX The authors thank Yoshimi Bando, M.D., Ph.D. for advice on histology.
   This work was supported by Grants for the Regional Innovation Cluster
   Program from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan (to T.T.).
CR Anderson GJ, 1999, LANCET, V353, P2089, DOI 10.1016/S0140-6736(99)00113-0
   Kremastinos DT, 2011, CIRCULATION, V124, P2253, DOI 10.1161/CIRCULATIONAHA.111.050773
   Tajima S, 2012, AM J PHYSIOL-ENDOC M, V302, pE77, DOI 10.1152/ajpendo.00033.2011
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Gulec S, 2014, AM J PHYSIOL-GASTR L, V307, pG397, DOI 10.1152/ajpgi.00348.2013
   Fernandez-Real JM, 2009, J CLIN ENDOCR METAB, V94, P982, DOI 10.1210/jc.2008-1211
   Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499
   Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6
   Petroianu A, 2008, J GASTROEN HEPATOL, V23, pE221, DOI 10.1111/j.1440-1746.2007.05263.x
   Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, pE1236, DOI 10.1152/ajpendo.00022.2010
   Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353
   Kunutsor SK, 2013, DIABETES-METAB RES, V29, P308, DOI 10.1002/dmrr.2394
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Castellani RJ, 2012, BIOFACTORS, V38, P133, DOI 10.1002/biof.1010
   Aso Y, 2010, DIABETES RES CLIN PR, V90, P250, DOI 10.1016/j.diabres.2010.09.008
   Ganz T, 2013, PHYSIOL REV, V93, P1721, DOI 10.1152/physrev.00008.2013
   Lin L, 2007, BLOOD, V110, P2182, DOI 10.1182/blood-2007-04-087593
   Fleming RE, 1999, P NATL ACAD SCI USA, V96, P3143, DOI 10.1073/pnas.96.6.3143
   Inoue M, 2012, HEPATOL RES, V42, P203, DOI 10.1111/j.1872-034X.2011.00914.x
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Mills SE, 2006, HISTOLOGY PATHOLOGIS, P786
   Paulo DNS, 2009, MICROSURG, V29, P154, DOI 10.1002/micr.20568
NR 23
TC 0
Z9 0
U1 2
U2 5
PU CENTER ACADEMIC PUBL JAPAN
PI TOKYO
PA 2-4-16 YAYOI, BUNKYO-KU, TOKYO, 113-0032, JAPAN
SN 0301-4800
EI 1881-7742
J9 J NUTR SCI VITAMINOL
JI J. Nutr. Sci. Vitaminol.
PD FEB
PY 2015
VL 61
IS 1
BP 20
EP 27
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CC7ID
UT WOS:000350540000004
PM 25994136
ER

PT J
AU Hubler, MJ
   Peterson, KR
   Hasty, AH
AF Hubler, Merla J.
   Peterson, Kristin R.
   Hasty, Alyssa H.
TI Iron homeostasis: a new job for macrophages in adipose tissue?
SO TRENDS IN ENDOCRINOLOGY AND METABOLISM
LA English
DT Review
DE iron; adipose tissue; inflammation; macrophage
ID NONALCOHOLIC FATTY LIVER; INSULIN-RESISTANCE; SERUM FERRITIN; METABOLIC
   SYNDROME; HEPCIDIN EXPRESSION; ADIPOCYTE DIFFERENTIATION; OBESITY; MICE;
   ADIPONECTIN; RISK
AB Elevated serum ferritin and increased cellular iron concentrations are risk factors for diabetes; however, the etiology of this association is unclear. Metabolic tissues such as pancreas, liver, and adipose tissue (AT), as well as the immune cells resident in these tissues, may be involved. Recent studies demonstrate that the polarization status of macrophages has important relevance to their iron-handling capabilities. Furthermore, a subset of macrophages in AT have elevated iron concentrations and a gene expression profile indicative of iron handling, a capacity diminished in obesity. Because iron overload in adipocytes increases systemic insulin resistance, iron handling by AT macrophages may have relevance not only to adipocyte iron stores but also to local and systemic insulin sensitivity.
C1 [Hubler, Merla J.; Hasty, Alyssa H.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
   [Peterson, Kristin R.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA.
   [Hasty, Alyssa H.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN 37212 USA.
RP Hasty, AH (reprint author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
EM alyssa.hasty@vanderbilt.edu
OI Hasty, Alyssa/0000-0001-7302-8045
FU National Institute of General Medical Studies for the Vanderbilt
   Medical-Scientist Training Program [T32 GM07347]; National Institutes of
   Health (NIH) National Research Service Award [F30 DK103438]; T32
   Training in Pharmacological Sciences grant [T32 GM007628]; VA Merit
   award [101 BX002195]; NIH [DK095456]; American Heart Association
   Established Investigator Award [12EIA827]
FX M.J.H. was supported by a T32 GM07347 from the National Institute of
   General Medical Studies for the Vanderbilt Medical-Scientist Training
   Program, and is currently supported by an individual National Institutes
   of Health (NIH) National Research Service Award (F30 DK103438). K.R.P.
   is supported by a T32 Training in Pharmacological Sciences grant (T32
   GM007628). A.H.H. is supported by VA Merit award 101 BX002195, NIH grant
   DK095456, and an American Heart Association Established Investigator
   Award (12EIA827). We would like to thank W. Reid Bolus for creating
   Figure 2.
CR Boyle JJ, 2009, AM J PATHOL, V174, P1097, DOI 10.2353/ajpath.2009.080431
   Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   DRAPIER JC, 1993, EMBO J, V12, P3643
   Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Ganz T, 2012, J INNATE IMMUN, V4, P446, DOI 10.1159/000336423
   Jais A, 2014, CELL, V158, P25, DOI 10.1016/j.cell.2014.04.043
   Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Winer S, 2012, IMMUNOL CELL BIOL, V90, P755, DOI 10.1038/icb.2011.110
   Orozco LD, 2007, CIRC RES, V100, P1703, DOI 10.1161/CIRCRESAHA.107.151720
   Kusminski CM, 2012, TRENDS ENDOCRIN MET, V23, P435, DOI 10.1016/j.tem.2012.06.004
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825
   Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631
   Chang JS, 2013, ASIA PAC J CLIN NUTR, V22, P400, DOI 10.6133/apjcn.2013.22.3.07
   Murdolo G, 2013, BIOCHIMIE, V95, P585, DOI 10.1016/j.biochi.2012.12.014
   Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138
   Sierra-Filardi E, 2010, IMMUNOBIOLOGY, V215, P788, DOI 10.1016/j.imbio.2010.05.020
   Sindrilaru A, 2011, J CLIN INVEST, V121, P985, DOI 10.1172/JCI44490
   Trujillo ME, 2006, ENDOCR REV, V27, P762, DOI 10.1210/er.2006-0033
   Haap M, 2003, ANN INTERN MED, V139, P869
   Levi S, 2009, BBA-GEN SUBJECTS, V1790, P629, DOI 10.1016/j.bbagen.2008.09.008
   Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, pE1236, DOI 10.1152/ajpendo.00022.2010
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767
   Etzerodt A, 2010, J LEUKOCYTE BIOL, V88, P1201, DOI 10.1189/jlb.0410235
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X
   Kim S, 2000, J BIOL CHEM, V275, P6220, DOI 10.1074/jbc.275.9.6220
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353
   Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653
   Gotardo EMF, 2013, J NUTR SCI VITAMINOL, V59, P454, DOI 10.3177/jnsv.59.454
   Hosogai N, 2007, DIABETES, V56, P901, DOI 10.2337/db06-0911
   Dongiovanni P, 2013, AM J PATHOL, V182, P2254, DOI 10.1016/j.ajpath.2013.02.019
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Tsuchiya H, 2013, METABOLISM, V62, P62, DOI 10.1016/j.metabol.2012.06.008
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Valenti L, 2010, J HEPATOL, V53, P927, DOI [10.1016/j.jhep.2010.05.023, 10.1016/j.jhep.2010.06.010]
   Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027
   Bugianesi E, 2004, HEPATOLOGY, V39, P179, DOI 10.1002/hep.20023
   Kohyama M, 2009, NATURE, V457, P318, DOI 10.1038/nature07472
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Nemeth E, 2009, ACTA HAEMATOL-BASEL, V122, P78, DOI 10.1159/000243791
   Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007
   Moreno-Navarrete JM, 2014, DIABETOLOGIA, V57, P1957, DOI 10.1007/s00125-014-3298-5
   Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752
   Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62
   Ku BJ, 2009, DIS MARKERS, V27, P303, DOI 10.3233/DMA-2009-0676
   Morris DL, 2013, DIABETES, V62, P2762, DOI 10.2337/db12-1404
   Moreno-Navarrete JM, 2014, DIABETES CARE, V37, P1092, DOI 10.2337/dc13-1602
   Finn AV, 2012, J AM COLL CARDIOL, V59, P166, DOI 10.1016/j.jacc.2011.10.852
   Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008
   Wlazlo N, 2013, DIABETES CARE, V36, P309, DOI 10.2337/dc12-0505
   Sporrer D, 2009, EUR J CLIN INVEST, V39, P671, DOI 10.1111/j.1365-2362.2009.02170.x
   Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847
   Recalcati S, 2010, EUR J IMMUNOL, V40, P824, DOI 10.1002/eji.200939889
   Nishimura S, 2007, DIABETES, V56, P1517, DOI 10.2337/db06-1749
   Rumberger JM, 2004, DIABETES, V53, P2535, DOI 10.2337/diabetes.53.10.2535
   Cho CH, 2007, CIRC RES, V100, pE47, DOI 10.1161/01.RES.0000259564.92792.93
   Bari MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101327
   Basuli D, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00117
   Bones G., 2013, CIRC RES, V113, P1196
   Cairo G, 2006, GENES NUTR, V1, P25, DOI 10.1007/BF02829934
   Chung J, 2011, NUTR RES, V31, P915, DOI 10.1016/j.nutres.2011.09.014
   Coma G., 2010, HAEMATOLOGICA, V95, P1814, DOI DOI 10.3324/HAEMAT01.2010.023879
   CORHAY JL, 1992, EUR RESPIR J, V5, P804
   Galleano Monica, 2004, Molecular Aspects of Medicine, V25, P141, DOI 10.1016/j.mam.2004.02.015
   Hill AA, 2014, IMMUNOL REV, V262, P134, DOI 10.1111/imr.12216
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Lakhal S, 2011, J BIOL CHEM, V286, P4090, DOI 10.1074/jbc.M110.173096
   McDonald SD, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3428
   Mehta V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057573
   Orr JS, 2013, DIABETES, V63, P421
   Ponugoti B, 2012, EXP DIABETES RES, DOI 10.1155/2012/939751
   Salgia RJ, 2015, CLIN LIVER DIS, V19, P187, DOI 10.1016/j.cld.2014.09.011
   SHODEN ARNE, 1962, AMER JOUR PATHOL, V40, P671
   Thomsen JH, 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/523652
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Wlazlo N., 2014, ACTA DIABETOL
   Wu XG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044622
NR 88
TC 3
Z9 3
U1 2
U2 10
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1043-2760
J9 TRENDS ENDOCRIN MET
JI Trends Endocrinol. Metab.
PD FEB
PY 2015
VL 26
IS 2
BP 101
EP 109
DI 10.1016/j.tem.2014.12.005
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CB6HZ
UT WOS:000349729400006
PM 25600948
ER

PT J
AU Ferrari, M
   Cuenca-Garcia, M
   Valtuena, J
   Moreno, LA
   Censi, L
   Gonzalez-Gross, M
   Androutsos, O
   Gilbert, CC
   Huybrechts, I
   Dallongeville, J
   Sjostrom, M
   Molnar, D
   De Henauw, S
   Gomez-Martinez, S
   de Moraes, ACF
   Kafatos, A
   Widhalm, K
   Leclercq, C
AF Ferrari, M.
   Cuenca-Garcia, M.
   Valtuena, J.
   Moreno, L. A.
   Censi, L.
   Gonzalez-Gross, M.
   Androutsos, O.
   Gilbert, C. C.
   Huybrechts, I.
   Dallongeville, J.
   Sjostrom, M.
   Molnar, D.
   De Henauw, S.
   Gomez-Martinez, S.
   de Moraes, A. C. F.
   Kafatos, A.
   Widhalm, K.
   Leclercq, C.
CA HELENA Study Grp
TI Inflammation profile in overweight/obese adolescents in Europe: an
   analysis in relation to iron status
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID C-REACTIVE PROTEIN; BODY-MASS INDEX; NUTRITION EXAMINATION SURVEY; 3RD
   NATIONAL-HEALTH; ADIPOSE-TISSUE; OBESE CHILDREN; ANTHROPOMETRIC
   MEASUREMENTS; NUTRIENT-DENSITY; DIETARY-INTAKE; NORMAL-WEIGHT
AB BACKGROUND/OBJECTIVES: The objectives of this study were to investigate the relationship between inflammatory parameters (CRP, c-reactive protein; AGP, alpha 1-acid glycoprotein), iron status indicators (SF, serum ferritin; sTfR, soluble transferrin receptor) and body mass index (BMI) z-score, fat-free mass (FFM) and fat mass (FM) in European adolescents. Differences in intake for some nutrients (total iron, haem and non-haem iron, vitamin C, calcium, proteins) were assessed according to BMI categories, and the association of nutrient intakes with BMI z-score, FM and FFM was evaluated.
   METHODS: A total of 876 adolescents participating in the Healthy Lifestyle in Europe by Nutrition in Adolescence-Cross Sectional Study were included in the study sample.
   RESULTS: Mean CRP values (standard error; s.e.) were significantly higher in overweight/obese adolescents (1.7 +/- 0.3 and 1.4 +/- 0.3 mg/l in boys and girls, respectively) than in thin/normal-weight adolescents (1.1 +/- 0.2 and 1.0 +/- 0.1 mg/l in boys and girls, respectively) (P < 0.05). For boys, mean SF values (s.e.) were significantly higher in overweight/obese adolescents (46.9 +/- 2.7 mu g/l) than in thin/normal-weight adolescents (35.7 +/- 1.7 mu g/l) (P < 0.001), whereas median sTfR values did not differ among BMI categories for both boys and girls. Multilevel regression analyses showed that BMI z-score and FM were significantly related to CRP and AGP (P < 0.05). Dietary variables did not differ significantly among BMI categories, except for the intake of vegetable proteins, which, for boys, was higher in thin/normal-weight adolescents than in overweight/obese adolescents (P < 0.05).
   CONCLUSIONS: The adiposity of the European adolescents was sufficient to cause chronic inflammation but not sufficient to impair iron status and cause iron deficiency.
C1 [Ferrari, M.; Valtuena, J.; Censi, L.; Leclercq, C.] Food & Nutr Res Ctr, Agr Res Council, CRA NUT, I-00178 Rome, Italy.
   [Cuenca-Garcia, M.] Univ Granada, Sch Med, Dept Med Physiol, Granada, Spain.
   [Valtuena, J.; Gonzalez-Gross, M.] Univ Politecn Madrid, ImFine Res Grp, Dept Hlth & Human Performance, Fac Ciencias Actividad Fis & Deporte INEF, Madrid, Spain.
   [Moreno, L. A.; de Moraes, A. C. F.] Univ Zaragoza, EU Ciencias Salud, GENUD Growth Exercise Nutr & Dev Res Grp, Zaragoaza, Spain.
   [Gonzalez-Gross, M.] Univ Bonn, Dept Nutr & Food Sci Nutr Physiol, Bonn, Germany.
   [Androutsos, O.] Harakopio Univ, Dept Nutr & Dietet, Athens, Greece.
   [Gilbert, C. C.] Campden BRI, Dept Consumer & Sensory Sci, Chipping Campden, Glos, England.
   [Huybrechts, I.] Int Agcy Res Canc, Dietary Exposure Assessment Grp, F-69372 Lyon, France.
   [Dallongeville, J.] Univ Lille Nord France, Inst Pasteur Lille, INSERM, U744, Lille, France.
   [Sjostrom, M.] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden.
   [Molnar, D.] Univ Pecs, Dept Paediat, Pecs, Hungary.
   [De Henauw, S.] Univ Ghent, Dept Publ Hlth, Univ Hosp, B-9000 Ghent, Belgium.
   [De Henauw, S.] Univ Coll Ghent, Dept Nutr & Dietet, Fac Hlth Care Vesalius, Ghent, Belgium.
   [Gomez-Martinez, S.] Spanish Council Sci Res CSIC, Dept Metab & Nutr, Immunonutr Res Grp, Madrid, Spain.
   [de Moraes, A. C. F.] Univ Sao Paulo, Sch Med, Postgrad Program Sci, Dept Prevent Med, Sao Paulo, Brazil.
   [Kafatos, A.] Univ Crete, Sch Med, Dept Social Med, Prevent Med & Nutr Clin, Iraklion, Greece.
   [Widhalm, K.] Private Med Univ Salzburg, Div Clin Nutr, Dept Paediat & Adolescents Med, Salzburg, Austria.
RP Ferrari, M (reprint author), Food & Nutr Res Ctr, Agr Res Council, Via Ardeatina 546, I-00178 Rome, Italy.
EM marika.ferrari@entecra.it
RI gottrand, frederic/G-7370-2015; 
OI gottrand, frederic/0000-0002-5290-0436; Azzini,
   Elena/0000-0002-1971-1668
FU European Community Sixth RTD Framework Programme [FOOD-CT-2005-007034];
   Spanish Ministry of Education [AGL2007-29784-E/ALI, AP-2005-3827,
   AP-2008-03806]; Universidad Politecnica de Madrid; Sao Paulo Research
   Foundation - FAPESP [proc. 2011/11137-1, proc. 2011/20662-2]; CNPq
   (National Counsel of Technological and Scientific Development); CAPES
   (Coordination of Improvement of Higher Education Personnel) [proc.
   007/2012]
FX The HELENA Study has taken place with the financial support of the
   European Community Sixth RTD Framework Programme (Contract
   FOOD-CT-2005-007034). Additional support was obtained from the Spanish
   Ministry of Education (AGL2007-29784-E/ALI; AP-2005-3827;
   AP-2008-03806). Jara Valtuena was financially supported by the
   Universidad Politecnica de Madrid. Augusto Cesar F. de Moraes was given
   scholarship from Sao Paulo Research Foundation - FAPESP (proc.
   2011/11137-1 and 2011/20662-2). Luis A. Moreno was given scholarship of
   visiting professor from Brazilian government by Science without Borders
   Program by CNPq (National Counsel of Technological and Scientific
   Development) and CAPES (Coordination of Improvement of Higher Education
   Personnel) (proc. 007/2012). The content of this article reflects only
   the authors' views, and the European Community is not liable for any use
   that may be made of the information contained therein. We thank all
   adolescents who participated in the study. We also thank Lorenza Mistura
   for her assistance in the statistical analysis.
CR Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
   Moreno LA, 2002, EUR J CLIN NUTR, V56, P1208, DOI 10.1038/sj.ejcn.1601493
   Aeberli I, 2007, SWISS MED WKLY, V137, P424
   SLAUGHTER MH, 1988, HUM BIOL, V60, P709
   Manios Y, 2013, J HUM NUTR DIET, V26, P470, DOI 10.1111/jhn.12025
   TANNER JM, 1976, ARCH DIS CHILD, V51, P170
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Moschonis G, 2012, BRIT J NUTR, V108, P710, DOI 10.1017/S0007114511005952
   Moreno LA, 2008, INT J OBESITY, V32, pS4, DOI 10.1038/ijo.2008.177
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   van Dielen FMH, 2001, INT J OBESITY, V25, P1759, DOI 10.1038/sj.ijo.0801825
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Maachi M, 2004, INT J OBESITY, V28, P993, DOI 10.1038/sj.ijo.0802718
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Vereecken CA, 2008, INT J OBESITY, V32, pS26, DOI 10.1038/ijo.2008.180
   Northrop-Clewes CA, 2008, ANN CLIN BIOCHEM, V45, P18, DOI 10.1258/acb.2007.007167
   [Anonymous], 2001, DIETARY REFERENCE IN, P290
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   FAILLA ML, 1988, J NUTR, V118, P46
   Vereecken CA, 2005, EUR J CLIN NUTR, V59, P658, DOI 10.1038/sj.ejcn.1602124
   Nagy E, 2008, INT J OBESITY, V32, pS58, DOI 10.1038/ijo.2008.184
   Warnberg J, 2006, AM J CLIN NUTR, V84, P505
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Trayhurn P, 2005, BIOCHEM SOC T, V33, P1078
   Day CP, 2006, GASTROENTEROLOGY, V130, P207, DOI 10.1053/j.gastro.2005.11.017
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Stang J, 2000, J AM DIET ASSOC, V100, P905, DOI 10.1016/S0002-8223(00)00262-5
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   Kant AK, 2003, ARCH PEDIAT ADOL MED, V157, P789, DOI 10.1001/archpedi.157.8.789
   Ford ES, 2001, J PEDIATR-US, V138, P486, DOI 10.1067/mpd.2001.112898
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Erhardt JG, 2004, J NUTR, V134, P3127
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Beghin L, 2008, INT J OBESITY, V32, pS12, DOI 10.1038/ijo.2008.179
   Béghin Laurent, 2012, Arch Public Health, V70, P14, DOI 10.1186/0778-7367-70-14
   Beguin Y., 2004, CLIN CHIM ACTA, V329, P9
   BENEDEK IH, 1984, BRIT J CLIN PHARMACO, V18, P941
   Bogdański Paweł, 2006, Pol Merkur Lekarski, V21, P12
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   HALLBERG L, 1981, AM J CLIN NUTR, V34, P2242
   Haubrock J, 2010, ARCH PUBLIC HLTH, V68, P14
   Knowles J, 2013, BRIT J NUTR, V110, P2285, DOI 10.1017/S000711451300158X
   Mena NP, 2008, AM J PHYSIOL-GASTR L, V294, P192
   Pardo A, 2007, PSICOTHEMA, V19, P308
   Visser M, 2001, PEDIATRICS, V107, P1
NR 51
TC 2
Z9 2
U1 8
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD FEB
PY 2015
VL 69
IS 2
BP 247
EP 255
DI 10.1038/ejcn.2014.154
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CB2CH
UT WOS:000349433800018
PM 25205319
ER

PT J
AU Marin, FA
   Rasera, I
   Leite, CVD
   de Oliveira, MRM
AF Marin, Flavia Andreia
   Rasera Junior, Irineu
   de Souza Leite, Celso Vieira
   Marques de Oliveira, Maria Rita
TI Ferritin in hypertensive and diabetic women before and after bariatric
   surgery
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Ferritin; Inflammation; Obesity; Comorbidities; Bariatric surgery
ID Y GASTRIC BYPASS; INSULIN-RESISTANCE; IRON-DEFICIENCY; CHRONIC DISEASE;
   OBESITY; ANEMIA; INFLAMMATION; PREVALENCE; METABOLISM; ABSORPTION
AB In addition to its important role as marker of iron stores, serum ferritin is a marker of systemic inflammation, and obesity has been associated with chronic inflammation.
   Objective: To verify, six months after surgery, the effect of bariatric surgery on the serum ferritin of women who were hypertensive, diabetic, or comorbidity free before surgery.
   Sample and methods: This retrospective study included 200 women aged 20 to 45 years, with a body mass index (BMI) equal to or greater than 35 kg/m(2), submitted to Roux-en-Y gastric bypass (RYGB). Seventy of these women were hypertensive, forty had type 2 diabetes (T2D), and ninety were comorbidity free (CF). They were assessed before and six months after surgery. Anthropometric, laboratory (serum ferritin and hemoglobin), and comorbidity-related data were collected from their medical records.
   Results: Before surgery, women with comorbidities were older, the hypertensives had higher BMI, and the diabetics had higher serum ferritin levels than the CF women. The study comorbidities had resolved in 68% of the hypertensive women and 86% of the diabetic women six months after RYGB. Also at this time, the serum ferritin of hypertensive women decreased from 110.1 +/- 86.3 to 88.7 +/- 80.5 ng/dL and of diabetic women, from 164.8 +/- 133.4 to 101.2 +/- 97.7 ng/dL (p<0.05); hemoglobin also decreased in hypertensive and CF women (p>0.05).
   Conclusion: High ferritin in premenopausal obese women was associated with the main obesity-related comorbidities, and these comorbidities determined the reduction of serum ferritin after bariatric surgery.
C1 [Marin, Flavia Andreia; Marques de Oliveira, Maria Rita] Univ Estadual Paulista, Fac Ciencias Farmaceut UNESP FcFar, Programa Posgrad Alimentos & Nutr Ciencias Nutr, Araraquara, SP, Brazil.
   [Rasera Junior, Irineu] Hosp Fornecedores de Cana, Ctr Gastroenterol & Cirurgia Obesidade Clin Baria, Piracicaba, SP, Brazil.
   [Rasera Junior, Irineu; de Souza Leite, Celso Vieira] Univ Estadual Paulista, Fac Med, Botucatu, SP, Brazil.
   [Marques de Oliveira, Maria Rita] Univ Estadual Paulista, Inst Biociencias, Botucatu, SP, Brazil.
RP de Oliveira, MRM (reprint author), Univ Estadual Paulista UNESP, Inst Biociencias, Curso Nutr, Dist Rubiao Jr S-N,Cx Postal 510, BR-18618000 Botucatu, SP, Brazil.
EM mrmolive@ibb.unesp.br
FU Fundacao de Amparo Pesquisa do Estado de Silo Paulo - FAPESP (Sao Paulo
   State Research Support Foundation); Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq (National Council for Scientific and
   Technological Development)
FX This study was sponsored by Fundacao de Amparo Pesquisa do Estado de
   Silo Paulo - FAPESP (Sao Paulo State Research Support Foundation) and
   the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq
   (National Council for Scientific and Technological Development).
CR Aarts EO, 2012, J OBES, V2012, DOI DOI 10.1155/2012/193705
   Abril-Ulloa V, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-483
   Ponikowska B, 2013, DIABETES CARE, V36, P4147, DOI 10.2337/dc13-0528
   Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724
   Gesquiere I, 2014, OBES SURG, V24, P56, DOI 10.1007/s11695-013-1042-8
   [Anonymous], 1983, STAT B METROP LIVE F, V64, P3
   Kang HT, 2012, CLIN CHIM ACTA, V413, P636, DOI 10.1016/j.cca.2011.12.011
   Vargas-Ruiz AG, 2008, OBES SURG, V18, P288, DOI 10.1007/s11695-007-9310-0
   Gartner A, 2013, AM J CLIN NUTR, V98, P821, DOI 10.3945/ajcn.112.054551
   Blume CA, 2012, OBES SURG, V22, P1676, DOI 10.1007/s11695-012-0696-y
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Andrews M, 2012, BIOL TRACE ELEM RES, V149, P1, DOI 10.1007/s12011-012-9389-6
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Ruz M, 2009, AM J CLIN NUTR, V90, P527, DOI 10.3945/ajcn.2009.27699
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Gasteyger C, 2008, AM J CLIN NUTR, V87, P1128
   Martinez-Garcia MA, 2009, DIABETES CARE, V32, P1525, DOI 10.2337/dc09-0420
   Bremer AA, 2013, J OBES, V2013, DOI [DOI 10.1155/2013/393192, 10.1155/2013/393192]
   Chen H., 2013, PLOS ONE, V8, P1
   Drygalski AV, 2011, SURG OBES RELAT DIS, V7, P151
   Gastaldelli A, 2009, OBES SURG, V19, P80, DOI 10.1007/s11695-008-9690-9
   International Federation for the Surgery of Obesity [IFSO], 2001, WEBS PAT SEL BAR SUR
   Kim C, 2012, J WOMENS HEALTH, V21, P872, DOI 10.1089/jwh.2012.3549
   Mechanick JI, 2013, OBESITY, V21, P1
   Pontiroli AE, 2013, NUTR HOSP, V28, P104, DOI 10.3305/nh.2013.28.sup2.6720
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   WHO, 2011, SER FERR CONC ASS IR
   WHO, 2001, IR DEF AN ASS PREV C
NR 29
TC 0
Z9 0
U1 1
U2 3
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD FEB
PY 2015
VL 31
IS 2
BP 666
EP 671
DI 10.3305/nh.2015.31.2.7629
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CA3SD
UT WOS:000348825500017
ER

PT J
AU Ramsay, ES
   Lerman, MA
AF Ramsay, Elaine S.
   Lerman, Melissa A.
TI How to use the erythrocyte sedimentation rate in paediatrics
SO ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION
LA English
DT Article
ID CHILDREN; ESR
AB The erythrocyte sedimentation rate (ESR) has become a ubiquitously used technique in medicine as a marker of systemic illness. The test involves placing anticoagulated whole blood into an upright test tube and monitoring the rate at which red blood cells (RBC) fall over time. Negative charges keep RBC from sticking together. If this charge is neutralised, RBC stack into chains, or rouleaux, and fall more rapidly. ESR can be measured with a variety of tests: Westergren and modified Westergren; Wintrobe; micro-ESR. The Westergren is the most commonly used method of performing the ESR. Technical factors, such as temperature, time from specimen collection, tube orientation and vibration, can affect the results. RBC size, shape and concentration impact the ESR. Plasma characteristics are also important determinants of the ESR. Other factors that can change ESR include age, sex, race, medications and disease states, such as obesity, hypofibrinogenaemia and congestive heart failure. Other acute-phase reactants besides the ESR include C-reactive protein, fibrinogen, complement, ferritin, plasma viscosity, serum amyloid A and albumin. When clinical suspicion for infection or inflammation is low, a normal ESR can reassure that there is no active disease. The slow rise (48 h) and fall of the ESR relative to other acute-phase reactants may make it superior for monitoring inflammation in more chronic conditions. In conjunction with physical findings and other laboratory values, the ESR value can be used to screen for disease or disease complications, aid in disease diagnosis or assess disease activity or response to therapy.
C1 [Ramsay, Elaine S.; Lerman, Melissa A.] Childrens Hosp Philadelphia, Dept Rheumatol, Philadelphia, PA 19104 USA.
RP Ramsay, ES (reprint author), Childrens Hosp Philadelphia, Dept Rheumatol, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM RamsayE@email.chop.edu
CR Abbag FI, 2007, ANN SAUDI MED, V27, P175
   Breda L, 2010, SEMIN ARTHRITIS RHEU, V40, P53, DOI 10.1016/j.semarthrit.2008.12.001
   Kesmarky G, 2008, CLIN HEMORHEOL MICRO, V39, P243, DOI 10.3233/CH-2008-1088
   Caird MS, 2006, J BONE JOINT SURG AM, V88A, P1251, DOI 10.2106/JBJS.E.00216
   Saadeh C, 1998, SOUTHERN MED J, V91, P220
   SOX HC, 1986, ANN INTERN MED, V104, P515
   REINHART WH, 1995, EUR J CLIN INVEST, V25, P523, DOI 10.1111/j.1365-2362.1995.tb01739.x
   Jou JM, 2011, INT J LAB HEMATOL, V33, P125, DOI 10.1111/j.1751-553X.2011.01302.x
   BEDELL SE, 1985, AM J MED, V78, P1001, DOI 10.1016/0002-9343(85)90224-4
   BOTTIGER LE, 1967, BRIT MED J, V2, P85
   Brigden M, 1998, POSTGRAD MED, V103, P72
   Brigden M, 1998, Postgrad Med, V103, P257
   Cassidy JT, 2011, TXB PEDIAT RHEUMATOL, P244
   Ciccone MM, 2011, EUR J CARDIOV PREV R, V18, P831, DOI 10.1177/1741826711398180
   DAWSON JB, 1960, BRIT MED J, V1, P1697
   LASCARI AD, 1972, PEDIATR CLIN N AM, V19, P1113
   Long SS, 2012, LONG PRINCIPLES PRAC, P1400
   McPherson RA, 2011, MCPHERSON HENRYS CLI, P519
   Murray RDB, 2012, HARPERS ILLUSTRATED, P583
   Osei-Bimpong A, 2007, HEMATOLOGY, V12, P353, DOI 10.1080/10245330701340734
   Ray G R, 1973, Natl Cancer Inst Monogr, V36, P315
NR 21
TC 1
Z9 2
U1 1
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1743-0585
EI 1743-0593
J9 ARCH DIS CHILDHOOD-E
JI Arch. Dis. Childhood-Educ. Pract. Ed.
PD FEB
PY 2015
VL 100
IS 1
BP 30
EP 36
DI 10.1136/archdischild-2013-305349
PG 7
WC Pediatrics
SC Pediatrics
GA AZ5QX
UT WOS:000348276000009
PM 25205237
ER

PT J
AU Adediran, A
   Uche, E
   Akinbami, A
   Dada, A
   Wakama, T
   Damulak, D
   Ajibola, S
   Okwegbuna, O
AF Adediran, Adewumi
   Uche, Ebele
   Akinbami, Akinsegun
   Dada, Akin
   Wakama, Tamunomieibi
   Damulak, Dapus
   Ajibola, Sarah
   Okwegbuna, Oluwakemi
TI Hemoglobin and Ferritin Concentrations in Subjects with Metabolic
   Syndrome
SO NUTRITION AND METABOLIC INSIGHTS
LA English
DT Article
DE metabolic syndrome; ferritin; insulin resistance; dyslipidemia
ID SERUM FERRITIN; CARDIOVASCULAR-DISEASE; IRON STORES; INSULIN
   SENSITIVITY; HEART-DISEASE; MEN; POPULATION; RESISTANCE; RISK
AB BACKGROUND: Metabolic syndrome (MetS), a clinical condition characterized by insulin resistance, glucose intolerance, dyslipidemia, hypertension, and obesity, has been linked with raised levels of serum ferritin (Sfr) concentrations.
   OBJECTIVES: This study was carried out to compare hemoglobin (Hb) and Sfr concentrations in patients with MetS, regular donors and first-time donors.
   MATERIALS AND METHODS: A total of 102 subjects who were between 18 and 60 years were enrolled for the study. They were divided into three groups. The first group (n = 20) was made up of 5 males and 15 females, all who met the criteria that define MetS. The second group (n = 52; M = 34, F = 18) were regular donors, while the last group (n = 30; M = 16, F = 14) were first-time donors or those who had not donated before. Following an overnight fast, 20 mL of venous blood was drawn from each subject. About 5 mL of this was put into sodium ethylenediaminetetraacetate (EDTA) specimen bottles for the full blood count parameters with Sysmex KX-21N hematology analyzer (made in Japan). The remaining 15 mL had serum separated for Sfr assay using enzyme-linked immunosorbent assay (ELISA) with a commercial assay kit manufactured by Teco Diagnostics.
   RESULTS: Significant difference was found in the mean Sfr concentration of subjects with MetS (163 +/- 136.92 ng/mL) and regular donors (41.46 +/- 40.33 ng/mL), P = 0.001. The mean Sfr concentrations of subjects with MetS (163 +/- 136.92 ng/mL) were also higher than that of first-time donors (102.46 +/- 80.26 ng/mL), but it was not statistically significant, P = 0.053. The Hb concentrations of the three groups were not significantly different.
   CONCLUSION: Sfr concentrations of regular donors were lower than that of subjects with MetS and first-time donors. The difference between regular donors and subjects with MetS was statistically significant. However, there is no significant difference in the Hb concentrations in the three groups. MetS is not associated with anemia or hyperferritinemia.
C1 [Adediran, Adewumi] Univ Lagos, Dept Haematol & Blood Transfus, Coll Med, Lagos, Nigeria.
   [Uche, Ebele; Akinbami, Akinsegun] Lagos State Univ, Dept Haematol & Blood Transfus, Teaching Hosp, Lagos, Nigeria.
   [Dada, Akin] Lagos State Univ, Dept Med, Teaching Hosp, Lagos, Nigeria.
   [Wakama, Tamunomieibi] Natl Hosp, Dept Haematol & Blood Transfus, Abuja, Nigeria.
   [Damulak, Dapus] Univ Jos, Teaching Hosp, Dept Haematol & Blood Transfus, Jos, Nigeria.
   [Ajibola, Sarah] Babcock Univ, Ben Carson Sch Med, Dept Haematol, Ilisan Remo, Ogun State, Nigeria.
   [Okwegbuna, Oluwakemi] Univ Lagos, Dept Haematol & Blood Transfus, Teaching Hosp, Lagos, Nigeria.
RP Adediran, A (reprint author), Univ Lagos, Dept Haematol & Blood Transfus, Coll Med, Lagos, Nigeria.
EM adediranadewumi@yahoo.comPaper
CR Adediran A, 2013, J BLOOD MED, V4, P1
   Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Vallianou NG, 2010, MED SCI MONITOR, V16, pCR56
   Isomaa B, 2003, LIFE SCI, V73, P2395, DOI 10.1016/S0024-3205(03)00646-5
   Swaminathan S, 2007, DIABETES CARE, V30, P1926, DOI 10.2337/dc06-2625
   LEGGETT BA, 1990, CLIN CHEM, V36, P1350
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Wood RJ, 2004, AGEING RES REV, V3, P355, DOI 10.1016/j.arr.2004.04.002
   Kapoor D, 2005, CLIN ENDOCRINOL, V63, P239, DOI 10.1111/j.1365-2265.2005.02299.x
   Whaley-Connell A, 2011, REV CARDIOVASC MED, V12, P21, DOI 10.3909/ricm0555
   Galan P, 2006, PUBLIC HEALTH NUTR, V9, P70, DOI 10.1079/PHN2005826
   WITTE DL, 1991, CLIN CHEM, V37, P484
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Novak M, 2013, J HUM HYPERTENS, V27, P56, DOI 10.1038/jhh.2011.106
   [Anonymous], 2011, J BIOTECHNOL COMP BI
   Poulsen P, 2001, DIABETOLOGIA, V44, P537, DOI 10.1007/s001250051659
   Datz C, 2013, EUR J CLIN INVEST, V43, P215, DOI 10.1111/eci.12032
   Perez-Torres I, 2011, CURR TOP MED CHEM, V11, P1694
   Wang C, 2011, DIABETES CARE, V34, P1669, DOI 10.2337/dc10-2339
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   WALTERS GO, 1973, J CLIN PATHOL, V26, P770, DOI 10.1136/jcp.26.10.770
   Lao TT, 2001, DIABETIC MED, V18, P218, DOI 10.1046/j.1464-5491.2001.00453.x
   Malik S, 2004, CIRCULATION, V110, P1245, DOI 10.1161/01.CIR.0000140677.20606.0E
   Reaven G, 2002, CIRCULATION, V106, P286, DOI 10.1161/01.CIR.0000019884.36724.D9
   Beigh Seerat Hussain, 2012, Bioinformation, V8, P613, DOI 10.6026/97320630008613
   Ghadiri-Anari A, 2014, ISRN HEMATOL, V2014, P3
   Hamalainen P, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-116
   Hayden M R, 1998, Mo Med, V95, P213
   Houschyar KS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-54
   Liu Fang, 2003, Zhonghua Yi Xue Za Zhi, V83, P1317
   Park YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085068
NR 32
TC 0
Z9 0
U1 1
U2 1
PU LIBERTAS ACAD
PI AUCKLAND
PA PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND
SN 1178-6388
J9 NUTR METAB INSIGHTS
JI Nutr. Metab. Insights
PY 2015
VL 8
BP 15
EP 19
DI 10.4137/NMI.S23302
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CZ2IU
UT WOS:000366929100003
PM 26056471
ER

PT J
AU Jin, YL
   He, LP
   Chen, Y
   Fang, Y
   Yao, YS
AF Jin, Yuelong
   He, Lianping
   Chen, Yi
   Fang, Yun
   Yao, Yingshui
TI Association between serum ferritin levels and metabolic syndrome: an
   updated meta-analysis
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Ferritin; metabolic syndrome; meta-analysis
ID IRON; RISK; HEALTH
AB It is definite that the serum iron level has a positive correlation with the risk of obesity. However, the association between increased serum ferritin levels and the metabolic syndrome still remains controversial. The purpose of this meta-analysis is to confirm the association between serum ferritin levels and metabolic syndrome. We searched PubMed and the China National Knowledge Infrastructure (CNKI) for relevant articles that assessed the association between serum ferritin levels and metabolic syndrome and were published between 2006 and 2014. Review Manage 5.3 software was used to collect and analysis the data cited in the ultimately selected papers. The variance was exhibited using the forest plot and the heterogeneity among studies was examined using the I-2 index. We use the funnel plot to evaluate the publication bias. Cross-sectional study, case-control study and prospective cohort study met our inclusion criteria including data from a total of 4,797 participants. The pooled odds ratio (OR) for the metabolic syndrome comparing the highest and lowest category of ferritin levels was 1.20 (95% CI: 0.69, 1.71; I-2 = 96%). The meta-analysis demonstrates that elevated ferritin levels are positive aassociated with metabolic syndrome.
C1 [Jin, Yuelong; He, Lianping; Fang, Yun; Yao, Yingshui] Wannan Med College, Sch Publ Hlth, Wuhu 241002, Anhui, Peoples R China.
   [Chen, Yi] Wannan Med Coll, Sch Clin Med, Wuhu 241002, Anhui, Peoples R China.
RP Yao, YS (reprint author), Wannan Med College, Sch Publ Hlth, 22 Rd Wenchangxi, Wuhu 241002, Anhui, Peoples R China.
EM yingshui-yao@163.com
FU Wannan Medical key scientific research projects Eng-agement Fund
   [WK2014Z05]; Anhui Provincial Natural Science Foundation [1308085MH135];
   National Training Programs of Innovation and Entrepreneurship for
   Undergraduates [201510368035]; Provincial Natural Science Research
   Project of Anhui Colleges [KJ2014A265]
FX This research was supported by Wannan Medical key scientific research
   projects Eng-agement Fund (WK2014Z05), the Anhui Provincial Natural
   Science Foundation (1308085MH135), National Training Programs of
   Innovation and Entrepreneurship for Undergraduates (201510368035), and
   Provincial Natural Science Research Project of Anhui Colleges
   (KJ2014A265).
CR Abril-Ulloa V, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-483
   Chen H, 2012, BIOL TRACE ELEM RES, V147, P67, DOI 10.1007/s12011-011-9306-4
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   SAYERS MH, 1994, AM J HEMATOL, V47, P194, DOI 10.1002/ajh.2830470309
   Otto MCD, 2012, J NUTR, V142, P526, DOI 10.3945/jn.111.149781
   Choi KM, 2005, METABOLISM, V54, P1510, DOI 10.1016/j.metabol.2005.05.018
   Yoon JH, 2012, CLIN CHEM LAB MED, V50, P2057, DOI 10.1515/cclm-2011-0928
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Vardanyan Z, 2012, BIOCHEM BIOPH RES CO, V417, P541, DOI 10.1016/j.bbrc.2011.11.159
   Rajpathak SN, 2009, DIABETES OBES METAB, V11, P472, DOI 10.1111/j.1463-1326.2008.00985.x
   Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031
   El-Aty Mahmoud Abd, 2014, Sultan Qaboos Univ Med J, V14, pe460
   Han LL, 2014, MOL NUTR FOOD RES, V58, P2189, DOI 10.1002/mnfr.201400088
   Iwanaga Suketaka, 2014, Obes Res Clin Pract, V8, pe201, DOI 10.1016/j.orcp.2013.01.003
   Jeon Yeon Jin, 2013, Ann Pediatr Endocrinol Metab, V18, P141, DOI 10.6065/apem.2013.18.3.141
   Lee Hye-Ja, 2014, Osong Public Health Res Perspect, V5, P204, DOI 10.1016/j.phrp.2014.06.005
   Li Y, 2006, CHIN J LAB DIAGN, V10, P1331
   Lin QH, 2010, MODERN PRACTICAL MED, V22, P630
   Mendonca FM, 2015, METABOLISM, V64, P182, DOI 10.1016/j.metabol.2014.10.008
   Sekine S, 2015, TOXICOL APPL PHARM, V282, P237, DOI 10.1016/j.taap.2014.12.004
   Tang L., 2007, ZHEJIANG MED J, V29, P1331
   Xiao Xincai, 2011, Wei Sheng Yan Jiu, V40, P32
   Yegin ZA, 2015, J ENDOCRINOL INVEST, V38, P333, DOI 10.1007/s40618-014-0174-6
   Yu Y, 2015, NUTR RES PRACT, V9, P199, DOI 10.4162/nrp.2015.9.2.199
NR 24
TC 0
Z9 0
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 8
BP 13317
EP 13322
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CW8TJ
UT WOS:000365271900161
PM 26550259
ER

PT J
AU Weng, TC
   Chang, CH
   Dong, YH
   Chang, YC
   Chuang, LM
AF Weng, Ting-Chia
   Chang, Chia-Hsuin
   Dong, Yaa-Hui
   Chang, Yi-Cheng
   Chuang, Lee-Ming
TI Anaemia and related nutrient deficiencies after Roux-en-Y gastric bypass
   surgery: a systematic review and meta-analysis
SO BMJ OPEN
LA English
DT Article
ID WEIGHT-LOSS MAINTENANCE; BARIATRIC SURGERY; IRON-DEFICIENCY; NUTRITIONAL
   DEFICIENCIES; MORBID-OBESITY; FOLLOW-UP; ACID-SECRETION; DIETARY-INTAKE;
   RISK-FACTORS; TRENDS
AB Objective: To obtain a pooled risk estimate on the long-term impact of anaemia and related nutritional deficiencies in patients receiving Roux-en-Y gastric bypass (RYGB) surgery.
   Design: Systematic review and meta-analysis.
   Data sources: MEDLINE, EMBASE and Cochrane databases were searched to identify English reports published before 16 May 2014.
   Eligibility criteria: Articles with case numbers >100, follow-up period >12 months, and complete data from both before and after surgery were selected. Outcomes of interest were changes in baseline measurements of proportion of patients with anaemia, by haemoglobin, haematocrit, ferritin, iron, vitamin B-12 and folate levels.
   Data collection and analysis: Two reviewers independently reviewed data and selected six prospective and nine retrospective studies with a total of 5909 patients. A random effect model with inverse variance weighting was used to calculate summary estimates of outcomes at 6, 12, 24 and 36 months postoperatively.
   Results: Proportion of patients with anaemia was 12.2% at baseline, which, respectively, increased to 20.9% and 25.9% at 12 and 24 months follow-up, consistent with decreases in haemoglobin and haematocrit levels. Although the serum iron level did not change substantially after surgery, the frequency of patients with ferritin deficiency increased from 7.9% at baseline to 13.4% and 23.0% at 12 and 24 months, respectively, postoperation. Vitamin B-12 deficiency increased from 2.3% at baseline to 6.5% at 12 months after surgery in those subjects receiving RYGB. There was no obvious increase in folate deficiency.
   Conclusions: RYGB surgery is associated with an increased risk of anaemia and deficiencies of iron and vitamin B-12, but not folate. Ferritin is more sensitive when serum iron level is within normal range.
C1 [Weng, Ting-Chia; Chang, Chia-Hsuin; Chuang, Lee-Ming] Natl Taiwan Univ, Coll Med, Dept Med, Taipei, Taiwan.
   [Chang, Chia-Hsuin; Chang, Yi-Cheng; Chuang, Lee-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
   [Chang, Chia-Hsuin; Chuang, Lee-Ming] Natl Taiwan Univ, Coll Publ Hlth, Inst Prevent Med, Taipei 10764, Taiwan.
   [Dong, Yaa-Hui] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
   [Chang, Yi-Cheng] Natl Taiwan Univ, Grad Inst Med Genom & Prote, Taipei 10764, Taiwan.
RP Chuang, LM (reprint author), Natl Taiwan Univ, Coll Med, Dept Med, Taipei, Taiwan.
EM leeming@ntu.edu.tw
CR Aarts EO, 2012, J OBES, V2012, DOI DOI 10.1155/2012/193705
   Ernst B, 2009, OBES SURG, V19, P66, DOI 10.1007/s11695-008-9545-4
   Gletsu-Miller N, 2013, ADV NUTR, V4, P506, DOI 10.3945/an.113.004341
   Avgerinos DV, 2010, WORLD J GASTROENTERO, V16, P1867, DOI 10.3748/wjg.v16.i15.1867
   Clifton PM, 2008, NAT CLIN PRACT GASTR, V5, P672, DOI 10.1038/ncpgasthep1283
   Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603
   Cummings DE, 2004, J CLIN ENDOCR METAB, V89, P2608, DOI 10.1210/jc.2004-0433
   Cintra W, 2012, INFLAMMATION, V35, P316, DOI 10.1007/s10753-011-9321-9
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Gesquiere I, 2014, OBES SURG, V24, P56, DOI 10.1007/s11695-013-1042-8
   Madan AK, 2006, OBES SURG, V16, P603, DOI 10.1381/096089206776945057
   Green R, 2012, HEMATOL-AM SOC HEMAT, P492, DOI 10.1182/asheducation-2012.1.492
   Flancbaum L, 2006, J GASTROINTEST SURG, V10, P1033, DOI 10.1016/j.gassur.2006.03.004
   Moize V, 2013, J ACAD NUTR DIET, V113, P400, DOI 10.1016/j.jand.2012.11.013
   AVINOAH E, 1992, SURGERY, V111, P137
   Mechanick JI, 2013, OBESITY, V21, pS1, DOI 10.1002/oby.20461
   Salgado W, 2014, SURG OBES RELAT DIS, V10, P49, DOI 10.1016/j.soard.2013.06.012
   Cable CT, 2011, SURG OBES RELAT DIS, V7, P134, DOI 10.1016/j.soard.2010.10.013
   Cabrera EJ, 2010, OBES SURG, V20, P42, DOI 10.1007/s11695-009-9988-2
   Fried M, 2014, OBES SURG, V24, P42, DOI 10.1007/s11695-013-1079-8
   Levinson R, 2013, OBES SURG, V23, P992, DOI 10.1007/s11695-013-0922-2
   Morinigo R, 2007, DIABETES CARE, V30, P1906, DOI 10.2337/dc07-0189
   Santry HP, 2005, JAMA-J AM MED ASSOC, V294, P1909, DOI 10.1001/jama.294.15.1909
   Blume CA, 2012, OBES SURG, V22, P1676, DOI 10.1007/s11695-012-0696-y
   von Drygalski A, 2011, SURG OBES RELAT DIS, V7, P151, DOI 10.1016/j.soard.2010.04.008
   Blackburn GL, 2009, OBESITY, V17, P842, DOI 10.1038/oby.2008.578
   Goddard AF, 2011, GUT, V60, P1309, DOI 10.1136/gut.2010.228874
   SMITH CD, 1993, ANN SURG, V218, P91, DOI 10.1097/00000658-199307000-00014
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Ikramuddin S, 2013, JAMA-J AM MED ASSOC, V309, P2240, DOI 10.1001/jama.2013.5835
   Ziegler O, 2009, DIABETES METAB, V35, P544, DOI 10.1016/S1262-3636(09)73464-0
   Toh SY, 2009, NUTRITION, V25, P1150, DOI 10.1016/j.nut.2009.03.012
   Majumder S, 2013, SURG OBES RELAT DIS, V9, P1013, DOI 10.1016/j.soard.2013.04.017
   Malone M, 2008, ANN PHARMACOTHER, V42, P1851, DOI 10.1345/aph.1L321
   BEHRNS KE, 1994, DIGEST DIS SCI, V39, P315, DOI 10.1007/BF02090203
   Rojas P, 2011, OBES SURG, V21, P561, DOI 10.1007/s11695-011-0368-3
   Salameh BS, 2010, EXPERT REV GASTROENT, V4, P217, DOI [10.1586/egh.09.67, 10.1586/EGH.09.67]
   Maggard MA, 2005, ANN INTERN MED, V142, P547
   Moize V, 2011, OBES SURG, V21, P1382, DOI 10.1007/s11695-011-0360-y
   Ledoux S, 2014, ANN SURG, V259, P1104, DOI 10.1097/SLA.0000000000000249
   Aasheim ET, 2008, AM J CLIN NUTR, V87, P362
   Malinowski SS, 2006, AM J MED SCI, V331, P219, DOI 10.1097/00000441-200604000-00009
   Sarwer DB, 2011, SURG OBES RELAT DIS, V7, P644, DOI 10.1016/j.soard.2011.06.016
   von Drygalski A, 2009, NUTR CLIN PRACT, V24, P217, DOI 10.1177/0884533609332174
   Dallal RM, 2012, SURG OBES RELAT DIS, V8, P164, DOI 10.1016/j.soard.2011.02.006
   Marinella MA, 2008, SOUTH MED J, V101, P1024, DOI 10.1097/SMJ.0b013e31817cf7b7
   Shinogle JA, 2005, OBES RES, V13, P2202, DOI 10.1038/oby.2005.273
   Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3
   Gasteyger C, 2008, AM J CLIN NUTR, V87, P1128
   Bal B, 2010, NAT REV GASTRO HEPAT, V7, P320, DOI 10.1038/nrgastro.2010.60
   Chen MY, 2013, BIOMED RES INT, DOI 10.1155/2013/205467
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   Buchwald H, 2013, OBES SURG, V23, P427, DOI 10.1007/s11695-012-0864-0
   Balsiger BM, 2000, MAYO CLIN PROC, V75, P673
   Fujioka K, 2005, DIABETES CARE, V28, P481, DOI 10.2337/diacare.28.2.481
   Svetkey LP, 2008, JAMA-J AM MED ASSOC, V299, P1139, DOI 10.1001/jama.299.10.1139
   Gletsu-Miller N, 2012, INT J OBESITY, V36, P328, DOI 10.1038/ijo.2011.159
   Jauregui-Lobera I, 2013, NUTRIENTS, V5, P1595, DOI 10.3390/nu5051595
   Chang SH, 2014, JAMA SURG, V149, P275, DOI 10.1001/jamasurg.2013.3654
   Brolin R E, 1998, J Gastrointest Surg, V2, P436, DOI 10.1016/S1091-255X(98)80034-6
   Clements RH, 2006, AM SURGEON, V72, P203
   Clements RH, 2006, AM SURGEON, V72, P1196
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Obinwanne KM, 2014, J AM COLL SURGEONS, V218, P246, DOI 10.1016/j.jamcollsurg.2013.10.023
   Poitou BC, 2007, DIABETES METAB, V33, P13
   Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622
   Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1
NR 67
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 7
AR e006964
DI 10.1136/bmjopen-2014-006964
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA CU4FH
UT WOS:000363482000009
PM 26185175
ER

PT J
AU Choma, SSR
   Alberts, M
   Modjadji, SEP
AF Choma, Solomon Simon Ramphai
   Alberts, Marianne
   Modjadji, Sewela Elizabeth Perpetua
TI Conflicting effects of BMI and waist circumference on iron status
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Iron status; Iron deficiency; Iron overload; BMI; Waist circumference;
   Obesity
ID BODY-FAT DISTRIBUTION; ADIPOSE-TISSUE; OVERWEIGHT CHILDREN; SERUM IRON;
   DEFICIENCY; OBESE; WOMEN; INFLAMMATION; ADOLESCENTS; EXPRESSION
AB The association between obesity and iron status has a long history and is still receiving attention. However comparative analysis of the association between general obesity (BMI) and visceral obesity (waist circumference) with iron status has not been extensively researched. The aim of the present study is thus to determine if body mass index and waist circumference have the same correlation with iron status. One thousand one hundred and thirty people (225 men and 905 women) aged 30 years and above participated in this study. Anthropometric parameters, haemoglobin, iron and total iron binding capacity concentrations were measured using standard methods. Percentage transferrin saturation was calculated and ferritin concentrations were measured using an enzyme linked immunosorbent assay. Obese or overweight women had significantly lower iron and transferrin saturation concentration when compared to non-obese women. In contrast, women with high waist circumference had comparable plasma iron and transferrin saturation to women with normal waist circumference. Partial correlation analysis and linear regression analysis showed that BMI is negatively and significantly associated with plasma iron, transferrin saturation, Hb and ferritin concentration, whilst waist circumference is positively but insignificantly associated with plasma iron, transferrin saturation, Hb and ferritin concentration. Binary regression analysis showed that obese or overweight people are more likely to have iron deficiency, whilst those with raised waist circumference are more likely to have iron overload. Multivariate analysis showed that body mass index is negatively and significantly associated with low iron status, while waist circumference is positively and insignificantly associated with iron status. This is supported by a comparison of plasma iron, transferrin saturation and ferritin concentrations in participants with high body mass index and normal waist circumference and participants with normal body mass index and high waist circumference to those participants having normal body mass index and normal waist circumference. The present study suggests that in women body mass index is associated with low plasma iron, transferrin saturation and ferritin concentrations, while waist circumference is associated with high plasma iron, transferrin saturation and ferritin concentrations. (C) 2015 Published by Elsevier GmbH.
C1 [Choma, Solomon Simon Ramphai; Alberts, Marianne; Modjadji, Sewela Elizabeth Perpetua] Univ Limpopo, Dept Med Sci Publ Hlth & Hlth Promot, Fac Hlth Sci, Sovenga, Polokwane, South Africa.
RP Choma, SSR (reprint author), Univ Limpopo, Dept Med Sci Publ Hlth & Hlth Promot, Fac Hlth Sci, Private Bag X1106, Sovenga, Polokwane, South Africa.
EM Solomon.Choma@ul.ac.za; Marianne.Alberts@ul.ac.za;
   Perpetua.Modjadji@ul.ac.za
FU Norwegian Universities Committee for Development Research and Education
   (NUFU); Medical Research Council of South Africa
FX The authors acknowledge the Norwegian Universities Committee for
   Development Research and Education (NUFU) and the Medical Research
   Council of South Africa for funding this research. We further
   acknowledge all stakeholders (participants, traditional chiefs, nurses
   and fieldworkers) who were responsible for the success of this research.
CR Kesa H, 2005, PUBLIC HEALTH, V119, P294, DOI 10.1016/j.puhe.2004.08.010
   Neymotin F, 2011, OBESITY, V19, P191, DOI 10.1038/oby.2010.112
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Moschonis G, 2012, BRIT J NUTR, V108, P710, DOI 10.1017/S0007114511005952
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Zeba AN, 2012, PUBLIC HEALTH NUTR, V15, P2210, DOI 10.1017/S1368980012000729
   Gartner A, 2013, AM J CLIN NUTR, V98, P821, DOI 10.3945/ajcn.112.054551
   Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631
   Nikonorov AA, 2015, J TRACE ELEM MED BIO, V30, P207, DOI 10.1016/j.jtemb.2014.05.005
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Aderibigbe OR, 2011, CARDIOVASC J AFR, V22, P249, DOI 10.5830/CVJA-2011-015
   Chambers EC, 2006, J AM DIET ASSOC, V106, P680, DOI 10.1016/j.jada.2006.02.013
   Linder K, 2004, J LIPID RES, V45, P148, DOI 10.1194/jlr.M300256-JLR200
   FAILLA ML, 1988, J NUTR, V118, P46
   Becker C, 2015, J TRACE ELEM MED BIO, V30, P195, DOI 10.1016/j.jtemb.2014.10.011
   [Anonymous], 2011, J BIOTECHNOL COMPUT
   Fanou-Fogny N, 2011, BRIT J NUTR, V105, P574, DOI 10.1017/S0007114510003776
   DERIDDER CM, 1992, INT J OBESITY, V16, P443
   Alberts M, 1999, S AFR MED J, V89, P851
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   WENZEL BJ, 1962, LANCET, V2, P327
   Vidal H, 2001, ANN MED, V33, P547, DOI 10.3109/07853890108995965
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Dusserre E, 2000, BBA-MOL BASIS DIS, V1500, P88, DOI 10.1016/S0925-4439(99)00091-5
   Prinsloo J, 2011, EXP CLIN ENDOCR DIAB, V119, P599, DOI 10.1055/s-0031-1280801
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Munoz M, 2011, J CLIN PATHOL, V64, P287, DOI 10.1136/jcp.2010.086991
   FRIEDMAN BM, 1990, S AFR MED J, V78, P301
   Cancello R., 2006, INT J OBSTET GYNECOL, V113, P1141
   Chang B., 2007, J NUTR, V137, P2366
   Choma S.S.R., 2007, S AFR J CLIN NUTR, V20, P62
   Crowther NJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048883
   Hoebel S., 2013, J ENDOCRINOL METAB D, V18, P88
   Russell CD, 1998, AM J PHYSIOL-ENDOC M, V275, pE507
   Steyn N. P., 2001, SAJCN - South African Journal of Clinical Nutrition, V14, P140
   Van Harmelen V, 1998, DIABETES, V47, P913, DOI 10.2337/diabetes.47.6.913
   World Health Organisation, 2008, WAIST CIRC WAIST HIP
   Zariwala M.G., 2014, END ABSTR, V34, P255
NR 42
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PY 2015
VL 32
BP 73
EP 78
DI 10.1016/j.jtemb.2015.06.003
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA CS9AC
UT WOS:000362380200011
PM 26302915
ER

PT J
AU Buffler, M
   Becker, C
   Windisch, W
   Schumann, K
AF Buffler, M.
   Becker, C.
   Windisch, W.
   Schuemann, K.
TI Inflammation neither increases hepatic hepcidin nor affects intestinal
   Fe-59-absorption in two murine models of bowel inflammation, hemizygous
   TNF Delta ARE/+ and homozygous IL-10(-/-) mice
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Inflammation; Hepcidin; Iron-absorption; TNF Delta ATE/+-mice;
   IL-10(-/-)-mice
ID IRON-METABOLISM; HOMEOSTATIC MECHANISMS; DISEASE; SUPPLEMENTATION;
   TRANSPORTER; ACTIVATION; MALARIA; OBESITY; METAL; PCR
AB Hepcidin-synthesis was reported to be stimulated by inflammation. In contrast, hepcidin synthesis was inhibited by TNF alpha and serum hepcidin was low. To elucidate these contradictions, we compare data on hepcidin expression, on iron absorption and homoeostasis and markers of inflammation between two murine models of intestinal inflammation and corresponding wild-types as determined by standard methods.
   In TNF Delta ARE/+ and IL-10(-/-)-mice hepatic hepcidin expression and protein content was significantly lower than in corresponding wild-types. However, Fe-59 whole-body retention showed no difference between knock-outs and corresponding wild-types 7d after gavage, in neither strain. Compared to wild-types, body weight, hepatic non-haem iron content, hemoglobin and hematocrit were significantly decreased in TNF Delta ARE/+ mice, while erythropoiesis increased. These differences were not seen in IL-10(-/-) mice. Duodenal IL-6 and TNF alpha content increased significantly in TNF Delta ARE/+ mice, while ferritin-H decreased along with hepatic hepcidin expression, ferritin L, and non-haem iron. In IL-10(-/-) mice, these changes were less marked or missing for non-haem iron. Duodenal ferritin-L and ferroportin increased significantly, while HFE decreased.
   Our results corroborate the conflicting combination of low hepcidin with inflammation and without increased intestinal iron absorption. Speculating on underlying mechanism, decreased hepcidin may result from stimulated erythropoiesis. Unaltered intestinal iron-absorption may compromise between the stimulation by increased erythropoiesis and inhibition by local and systemic inflammation. The findings suggest intense interaction between counterproductive mechanisms and ask for further research. (C) 2015 Elsevier GmbH. All rights reserved.
C1 [Buffler, M.; Becker, C.; Windisch, W.] Tech Univ Munich, Chair Anim Nutr, TUM Sch Life Sci, D-80290 Munich, Germany.
   [Schuemann, K.] Tech Univ Munich, Res Ctr Nutr & Food Sci ZIEL, TUM Sch Life Sci, D-80290 Munich, Germany.
RP Becker, C (reprint author), Tech Univ Munich, Chair Anim Nutr, TUM Sch Life Sci, D-80290 Munich, Germany.
EM christiane.becker@wzw.tum.de
FU Hildegard-Grunow Foundation, Munich, Germany
FX We thank Prof. Kollias [29] and Dr. Balish for making TNF<SUP>Delta
   ARE</SUP> and IL-10<SUP>-/-</SUP> mice available to us. The study was
   sponsored by the Hildegard-Grunow Foundation, Munich, Germany.
CR Sellon RK, 1998, INFECT IMMUN, V66, P5224
   Vanoaica L, 2010, CELL METAB, V12, P273, DOI 10.1016/j.cmet.2010.08.003
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Wang LJ, 2012, INFLAMM BOWEL DIS, V18, P112, DOI 10.1002/ibd.21675
   Wang LJ, 2009, J CLIN INVEST, V119, P3322, DOI 10.1172/JCI39939
   Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Lee PL, 2009, ANNU REV PATHOL-MECH, V4, P489, DOI 10.1146/annurev.pathol.4.110807.092205
   Brugger D, 2014, ARCH ANIM NUTR, V68, P73, DOI 10.1080/1745039X.2014.898392
   Oustamanolakis P, 2011, EUR J GASTROEN HEPAT, V23, P262, DOI 10.1097/MEG.0b013e328343b885
   Becker C, 2015, J TRACE ELEM MED BIO, V30, P202, DOI 10.1016/j.jtemb.2014.10.012
   SCHUMANN K, 1990, DIGESTION, V46, P35
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Becker C, 2015, J TRACE ELEM MED BIO, V30, P195, DOI 10.1016/j.jtemb.2014.10.011
   Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2
   Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028
   Schumann K, 2001, ANN NUTR METAB, V45, P91, DOI 10.1159/000046713
   FINCH CA, 1978, P SOC EXP BIOL MED, V159, P335
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Schumann K, 2010, J TRACE ELEM MED BIO, V24, P58, DOI 10.1016/j.jtemb.2009.10.002
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Brasse-Lagnel C, 2011, GASTROENTEROLOGY, V140, P1261, DOI 10.1053/j.gastro.2010.12.037
   Silvestri L, 2008, CELL METAB, V8, P502, DOI 10.1016/j.cmet.2008.09.012
   Schumann K, 2013, FOOD NUTR BULL, V34, P349
   Nairz M, 2010, CELL MICROBIOL, V12, P1691, DOI 10.1111/j.1462-5822.2010.01529.x
   Wessling-Resnick M, 2010, ANNU REV NUTR, V30, P105, DOI 10.1146/annurev.nutr.012809.104804
   Huang H, 2009, BLOOD, V113, P3593, DOI 10.1182/blood-2008-08-173641
   Arnold J, 2009, EUR J GASTROEN HEPAT, V21, P335, DOI 10.1097/MEG.0b013e32830e2885
   Beard J., 2015, IRON HDB NUTROTIONAL
   Shanmugam NKN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038136
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
NR 31
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PY 2015
VL 32
BP 162
EP 167
DI 10.1016/j.jtemb.2015.07.003
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA CS9AC
UT WOS:000362380200020
PM 26302924
ER

PT J
AU Hirakawa, M
   Arase, Y
   Amakawa, K
   Ohmoto-Sekine, Y
   Ishihara, M
   Shiba, M
   Ogawa, K
   Okuda, C
   Jinno, T
   Kato, H
   Tsuji, H
   Hashimoto, M
   Yamamoto, T
   Arimoto, S
   Hara, S
AF Hirakawa, Miharu
   Arase, Yasuji
   Amakawa, Kazuhisa
   Ohmoto-Sekine, Yuki
   Ishihara, Makiko
   Shiba, Masato
   Ogawa, Kyoko
   Okuda, Chikao
   Jinno, Toyohisa
   Kato, Hisahito
   Tsuji, Hiroyuki
   Hashimoto, Mitsuyo
   Yamamoto, Takashi
   Arimoto, Satao
   Hara, Shigeko
TI Relationship between Alcohol Intake and Risk Factors for Metabolic
   Syndrome in Men
SO INTERNAL MEDICINE
LA English
DT Article
DE alcohol intake; blood pressure; plasma glucose; triglyceride; HDL
   cholesterol; metabolic syndrome
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; SERUM FERRITIN;
   CONSUMPTION; INSULIN; DISEASE; EPIDEMIOLOGY; ASSOCIATION; OBESITY;
   ADULTS
AB Objective The precise relationship between alcohol intake and metabolic syndrome (MetS) is still unclear, and the results from previous studies have been inconclusive. Thus, we examined the effect of alcohol intake on the risk of MetS in men in order to gain more information on a potential relationship.
   Methods This study included 22,349 men who were divided into four groups according to their average alcohol intake [non-, light (less than 20 g ethanol/day), heavy (equal or more than 20 g and less than 60 g ethanol/day) and very heavy (equal and greater than 60 g ethanol/day) drinkers]. We measured each subject's body mass index (BMI), waist circumference and blood pressure (BP) and conducted a blood test to obtain a complete blood count and biochemical panel. These results were used to obtain the MetS prevalence. Additionally, fatty liver was diagnosed using abdominal ultrasonography.
   Results Light drinkers had smaller waist circumferences. Heavy and very heavy drinkers had larger waist circumferences, a higher BMI, a higher BP, higher fasting plasma glucose levels, higher triglycerides (TG) levels and higher high-density lipoprotein (HDL) cholesterol levels while they had lower low-density lipoprotein cholesterol levels than nondrinkers. The prevalence of high BP, hyperglycemia and high TG was significantly higher in heavy and very heavy drinkers than in nondrinkers. The prevalence of low HDL cholesterol levels decreased with an increase in alcohol consumption. The prevalence of MetS was significantly lower in light drinkers and higher in very heavy drinkers compared with nondrinkers.
   Conclusion Alcohol intake significantly influences the risk of MetS in men. A significant association was seen between an alcohol intake of 60 g/day or higher and the prevalence of MetS.
C1 [Hirakawa, Miharu; Arase, Yasuji; Amakawa, Kazuhisa; Ohmoto-Sekine, Yuki; Ishihara, Makiko; Shiba, Masato; Ogawa, Kyoko; Okuda, Chikao; Jinno, Toyohisa; Kato, Hisahito; Tsuji, Hiroyuki; Hashimoto, Mitsuyo; Yamamoto, Takashi; Arimoto, Satao; Hara, Shigeko] Toranomon Gen Hosp, Hlth Management Ctr, Tokyo, Japan.
RP Hirakawa, M (reprint author), Toranomon Gen Hosp, Hlth Management Ctr, Tokyo, Japan.
EM ZXC00701@nifty.ne.jp
CR Aneja Jitender, 2013, Indian J Psychol Med, V35, P190, DOI 10.4103/0253-7176.116253
   Baik I, 2008, AM J CLIN NUTR, V87, P1455
   [Anonymous], 2005, NIHON NAIKA GAKKAI Z, V94, P794
   Goude D, 2002, CLIN SCI, V102, P345, DOI 10.1042/CS20010188
   Sumida Y, 2011, J GASTROENTEROL, V46, P257, DOI 10.1007/s00535-010-0305-6
   Wakabayashi I, 2012, GERONTOLOGY, V58, P24, DOI 10.1159/000323080
   Halle M, 1997, ATHEROSCLEROSIS, V128, P235, DOI 10.1016/S0021-9150(96)05994-1
   LELBACH WK, 1975, ANN NY ACAD SCI, V252, P85, DOI 10.1111/j.1749-6632.1975.tb19146.x
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Freiberg MS, 2004, DIABETES CARE, V27, P2954, DOI 10.2337/diacare.27.12.2954
   MARMOT MG, 1994, BRIT MED J, V308, P1263
   Goldberg IJ, 2001, CIRCULATION, V103, P472
   Yoon YS, 2004, AM J CLIN NUTR, V80, P217
   Lazarus R, 1997, AM J EPIDEMIOL, V145, P909
   Eckel RH, 2010, LANCET, V375, P181, DOI 10.1016/S0140-6736(09)61794-3
   Hatonen KA, 2012, AM J CLIN NUTR, V96, P44, DOI 10.3945/ajcn.111.031682
   Tsugane S, 2012, J GASTROEN HEPATOL, V27, P121, DOI 10.1111/j.1440-1746.2011.07021.x
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Rimm EB, 1999, BRIT MED J, V319, P1523
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Kim CH, 2010, METABOLISM, V60, P414
   LELBACH WK, 1967, ACTA HEPATO-SPLENOL, V14, P9
   Li J, 2013, PLOS ONE, V8, P1
   Urashima M., 2005, JMAJ - Japan Medical Association Journal, V48, P441
NR 25
TC 0
Z9 0
U1 3
U2 3
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2015
VL 54
IS 17
BP 2139
EP 2145
DI 10.2169/internalmedicine.54.2736
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA CQ9MI
UT WOS:000360938700007
PM 26328637
ER

PT J
AU Hughes, EA
   Patel, JV
   Bredow, Z
   Gill, PS
   Chackathayil, J
   Agaoglu, ES
   Flinders, P
   Mirrielees, R
AF Hughes, Elizabeth A.
   Patel, Jeetesh V.
   Bredow, Zosia
   Gill, Paramjit S.
   Chackathayil, Julia
   Agaoglu, Elif S.
   Flinders, Paul
   Mirrielees, Rebecca
TI Ferritin as a Risk Factor for Glucose Intolerance amongst Men and Women
   Originating from the Indian Subcontinent
SO INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; THALASSEMIA MAJOR; APOLIPOPROTEIN-B; IRON
   STORES; TOLERANCE; PREVALENCE; INSULIN; POPULATIONS; THERAPY; CHINESE
AB Background. Serum ferritin predicts the onset of diabetes; however, this relationship is not clear amongst South Asians, a population susceptible to glucose intolerance and anaemia. Objective. This study tests whether ferritin levels reflect glucose tolerance in South Asians, independent of lifestyle exposures associated with Indian or British residence. Methods. We randomly sampled 227 Gujaratis in Britain (49.8 (14.4) years, 50% men) and 277 contemporaries living in Gujarati villages (47.6 (11.8) years, 41% men). Both groups underwent a 75 g oral-glucose-tolerance test. We evaluated lifestyle parameters with standardised questionnaires and conducted comprehensive clinical and lab measurements. Results. Across sites, the age-adjusted prevalence of diabetes was 9.8%. Serum ferritin was higher amongst diabetics (P = 0.005), irrespective of site, gender, and central obesity (P <= 0.02), and was associated with fasting and postchallenge glucose, anthropometry, blood pressure, triglycerides, and nonesterified fatty acids (P < 0.001). Diabetes was less in those with low ferritin (< 20 mg/mL), P < 0.008, and risk estimate = 0.35 (95% CI 0.15-0.81), as were blood pressure and metabolic risk factors. On multivariate analysis, diabetes was independently associated with ferritin (P = 0.001) and age (P < 0.001). Conclusion. Ferritin levels are positively associated with glucose intolerance in our test groups, independent of gender and Indian or UK lifestyle factors.
C1 [Hughes, Elizabeth A.; Patel, Jeetesh V.] Univ Birmingham, Sandwell & West Birmingham Hosp NHS Trust, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England.
   [Patel, Jeetesh V.; Bredow, Zosia; Agaoglu, Elif S.; Flinders, Paul; Mirrielees, Rebecca] Univ Nottingham, Sch Med, Nottingham NG7 2UH, England.
   [Gill, Paramjit S.; Chackathayil, Julia] Univ Birmingham, Primary Care Clin Sci, Birmingham B15 2TT, W Midlands, England.
RP Patel, JV (reprint author), Univ Birmingham, Sandwell & West Birmingham Hosp NHS Trust, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England.
EM jeeteshp@gmail.com
FU British Heart Foundation (London, UK)
FX This research was supported by the British Heart Foundation (London,
   UK).
CR Jiang R, 2004, AM J CLIN NUTR, V79, P70
   Farmaki K, 2006, BRIT J HAEMATOL, V134, P438, DOI 10.1111/j.1365-2141.2006.06203.x
   Patel JV, 2006, ATHEROSCLEROSIS, V185, P297, DOI 10.1016/j.atherosclerosis.2005.06.005
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Jehn ML, 2007, AM J EPIDEMIOL, V165, P1047, DOI 10.1093/aje/kwk093
   Kim CH, 2011, METABOLISM, V60, P414, DOI 10.1016/j.metabol.2010.03.007
   DMOCHOWSKI K, 1993, J CLIN ENDOCR METAB, V77, P478, DOI 10.1210/jc.77.2.478
   NIEDERAU C, 1984, DIABETOLOGIA, V26, P441
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Olivieri NF, 1997, BLOOD, V89, P739
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Ren Y, 2004, DIABETES CARE, V27, P622, DOI 10.2337/diacare.27.2.622
   Qi L, 2007, DIABETES CARE, V30, P101, DOI 10.2337/dc06-1686
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Cade JE, 2005, AM J CLIN NUTR, V82, P813
   CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108
   CRUICKSHANK JK, 1991, LANCET, V338, P842, DOI 10.1016/0140-6736(91)91501-K
   DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390
   Fischbacher C, 2001, BRIT MED J, V322, P958, DOI 10.1136/bmj.322.7292.958
   Hevi S, 2003, J BIOL CHEM, V278, P31924, DOI 10.1074/jbc.M303081200
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Juanola-Falgarona M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076433
   Patel JV, 2005, DIABETES CARE, V28, P1505, DOI 10.2337/diacare.28.6.1505
   RAMAIYA KL, 1995, DIABETIC MED, V12, P904
   Rashid KA, 2002, J BIOL CHEM, V277, P22010, DOI 10.1074/jbc.M112448200
   VERMA NPS, 1986, BRIT MED J, V293, P423
   WHO Study Group, 1985, WHO TECHNICAL REPORT, V727
   Yamamoto M, 2007, J GASTROEN HEPATOL, V22, P498, DOI 10.1111/j.1440-1746.2006.04548.x
NR 28
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-8337
EI 1687-8345
J9 INT J ENDOCRINOL
JI Int. J. Endocrinol.
PY 2015
AR 924387
DI 10.1155/2015/924387
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CP8MR
UT WOS:000360148500001
ER

PT J
AU Feldman, A
   Aigner, E
   Weghuber, D
   Paulmichl, K
AF Feldman, Alexandra
   Aigner, Elmar
   Weghuber, Daniel
   Paulmichl, Katharina
TI The Potential Role of Iron and Copper in Pediatric Obesity and
   Nonalcoholic Fatty Liver Disease
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID SERUM FERRITIN CONCENTRATION; REGULATORY HORMONE HEPCIDIN;
   TRACE-ELEMENTS; CELLULAR IRON; DIETARY IRON; TRANSFERRIN SATURATION;
   OVERWEIGHT CHILDREN; INSULIN-RESISTANCE; ADIPOSE-TISSUE; NORMAL-WEIGHT
AB Obesity is a rapidly growing health problem and is paralleled by a multitude of comorbidities, including nonalcoholic fatty liver disease (NAFLD). NAFLD has become the most common chronic liver disease in both adults and children. The current understanding of NAFLD is still fragmentary. While simple steatosis is characterized by the interplay between excessive free fatty acid accumulation and hepatic insulin resistance, the progression to NASH has been related to oxidative stress and a proinflammatory state with dysbalanced adipokine, cytokine levels, and endotoxin-mediated immune response. In addition, oxidative stress has been suggested to play a central role for the sequelae leading to NASH. Trace elements are critical in regulatory, immunologic, and antioxidant functions resulting in protection against inflammation and peroxidation and consequently against the known comorbidities of obesity. Disruptions of the metal detoxification processes located in the liver are plausibly related to NAFLD development via oxidative stress. Perturbations of iron and copper (Cu) homeostasis have been shown to contribute to the pathogenesis of NAFLD. This review presents current data from pediatric studies. In addition, data from adult studies are summarized where clinical relevance may be extrapolated to pediatric obesity and NAFLD.
C1 [Feldman, Alexandra; Aigner, Elmar] Paracelsus Med Univ, Dept Med 1, A-5020 Salzburg, Austria.
   [Feldman, Alexandra; Aigner, Elmar; Weghuber, Daniel; Paulmichl, Katharina] Paracelsus Med Univ, Obes Res Unit, A-5020 Salzburg, Austria.
   [Weghuber, Daniel; Paulmichl, Katharina] Paracelsus Med Univ, Dept Pediat, A-5020 Salzburg, Austria.
RP Weghuber, D (reprint author), Paracelsus Med Univ, Obes Res Unit, Mullner Hauptstr 48, A-5020 Salzburg, Austria.
EM d.weghuber@salk.at
FU PMU-Forschungsforderungsfonds [E-13/17/086-AIG]; European Commission
   [279153]
FX Elmar Aigner is supported by PMU-Forschungsforderungsfonds
   (E-13/17/086-AIG). Daniel Weghuber and Katharina Paulmichl would like to
   acknowledge support by a grant from the European Commission (FP7
   Contract 279153, Beta-JUDO).
CR Aigner E, 2014, NUTRIENTS, V6, P3587, DOI 10.3390/nu6093587
   ALOTHMAN AA, 1992, J NUTR, V122, P1199
   ALOTHMAN AA, 1993, P SOC EXP BIOL MED, V204, P97
   Klevay LM, 2011, J TRACE ELEM MED BIO, V25, P204, DOI 10.1016/j.jtemb.2011.08.146
   Sharp P, 2004, P NUTR SOC, V63, P563, DOI 10.1079/PNS2004386
   Vajro P, 2012, J PEDIATR GASTR NUTR, V54, P700, DOI 10.1097/MPG.0b013e318252a13f
   Aeberli I, 2007, SWISS MED WKLY, V137, P424
   Tessari P, 2009, NUTR METAB CARDIOVAS, V19, P291, DOI 10.1016/j.numecd.2008.12.015
   Ganz T, 2005, CELL METAB, V1, P155, DOI 10.1016/j.cmet.2005.02.005
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Chung B, 2007, J NUTR, V137, P2366
   Mims MP, 2005, HEMATOLOGY, V10, P339, DOI 10.1080/10245330500093419
   Moschonis G, 2012, BRIT J NUTR, V108, P710, DOI 10.1017/S0007114511005952
   Nobili V, 2013, J PEDIATR GASTR NUTR, V56, P370, DOI 10.1097/MPG.0b013e31827aced4
   Spruss A, 2009, J NUTR BIOCHEM, V20, P657, DOI 10.1016/j.jnutbio.2009.05.006
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Song M, 2012, J HEPATOL, V56, P433, DOI 10.1016/j.jhep.2011.05.030
   Suliburska J, 2013, EUR REV MED PHARMACO, V17, P2396
   Schwimmer JB, 2006, PEDIATRICS, V118, P1388, DOI 10.1542/peds.2006-1212
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   HALLIWELL B, 1984, BIOCHEM J, V219, P1
   Lee PL, 2009, ANNU REV PATHOL-MECH, V4, P489, DOI 10.1146/annurev.pathol.4.110807.092205
   Weismuller TJ, 2011, HEPATOLOGY, V54, P2114, DOI 10.1002/hep.24635
   Sorrentino P, 2009, J HEPATOL, V50, P351, DOI 10.1016/j.jhep.2008.09.011
   Eftekhari MH, 2009, PUBLIC HEALTH NUTR, V12, P2377, DOI 10.1017/S1368980009005187
   Piperno A, 1998, HAEMATOLOGICA, V83, P447
   Aigner E, 2010, AM J GASTROENTEROL, V105, P1978, DOI 10.1038/ajg.2010.170
   Gehrke SG, 2003, BLOOD, V102, P371, DOI 10.1182/blood-2002-11-3610
   Feldstein AE, 2009, GUT, V58, P1538, DOI 10.1136/gut.2008.171280
   Walker NM, 2010, HEPATOLOGY, V51, P1683, DOI 10.1002/hep.23537
   Kohgo Y, 2008, INT J HEMATOL, V88, P7, DOI 10.1007/s12185-008-0120-5
   Ganz T, 2009, SEMIN HEMATOL, V46, P387, DOI 10.1053/j.seminhematol.2009.06.001
   Lima SCVC, 2006, BIOL TRACE ELEM RES, V114, P19, DOI 10.1385/BTER:114:1:19
   Baumgartner J, 2013, INT J OBESITY, V37, P24, DOI 10.1038/ijo.2012.145
   Corey KE, 2014, CLIN LIVER DIS, V18, P1, DOI 10.1016/j.cld.2013.09.019
   Wei YZ, 2008, WORLD J GASTROENTERO, V14, P193, DOI 10.3748/wjg.14.193
   Demircioglu F, 2014, EUR J PEDIATR, V173, P947, DOI 10.1007/s00431-014-2268-8
   Datz C, 2013, EUR J CLIN INVEST, V43, P215, DOI 10.1111/eci.12032
   Aigner E, 2010, EUR J CLIN INVEST, V40, P155, DOI 10.1111/j.1365-2362.2009.02238.x
   Tascilar ME, 2011, BIOL TRACE ELEM RES, V143, P188, DOI 10.1007/s12011-010-8878-8
   Gong LY, 2014, J PEDIATR-US, V164, P795, DOI 10.1016/j.jpeds.2013.12.004
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Manco M, 2011, J HEPATOL, V55, P647, DOI 10.1016/j.jhep.2010.12.007
   HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Aigner E, 2008, GASTROENTEROLOGY, V135, P680, DOI 10.1053/j.gastro.2008.04.007
   Ferrari M, 2011, EUR J CLIN NUTR, V65, P340, DOI 10.1038/ejcn.2010.279
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Tan TCH, 2013, LAB INVEST, V93, P1295, DOI 10.1038/labinvest.2013.121
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Valenti L, 2010, GASTROENTEROLOGY, V138, P905, DOI 10.1053/j.gastro.2009.11.013
   Falzacappa MVV, 2007, BLOOD, V109, P353, DOI 10.1182/blood-2006-07-033969
   Brunt EM, 2010, NAT REV GASTRO HEPAT, V7, P195, DOI 10.1038/nrgastro.2010.21
   Ponka P, 1998, SEMIN HEMATOL, V35, P35
   Kulaksiz H, 2008, J ENDOCRINOL, V197, P241, DOI 10.1677/JOE-07-0528
   Azab SFA, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-20
   Cayir Y, 2014, BIOL TRACE ELEM RES, V160, P155, DOI 10.1007/s12011-014-0038-0
   HALLBERG L, 1981, ANNU REV NUTR, V1, P123, DOI 10.1146/annurev.nu.01.070181.001011
   JACOBS P, 1971, BLOOD-J HEMATOL, V37, P220
   Korolnek T, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00126
   LAITINEN R, 1989, J AM COLL NUTR, V8, P400
   Moya D, 2014, FASEB J, V28
   Mujica-Coopman M. F., 2014, J TRACE ELEMENTS MED
   Nairz M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00152
   NEWMAN R, 1982, TRENDS BIOCHEM SCI, V7, P397, DOI 10.1016/0968-0004(82)90184-0
   Petrak J, 2005, INT J BIOCHEM CELL B, V37, P1173, DOI 10.1016/j.biocel.2004.12.007
   Prohaska JR, 2003, EXP BIOL MED, V228, P959
   Scheiber Ivo, 2013, Met Ions Life Sci, V13, P359, DOI 10.1007/978-94-007-7500-8_11
   Schuschke DA, 2009, INFLAMMATION, V32, P333, DOI 10.1007/s10753-009-9140-4
   Schwinnner JB, 2005, HEPATOLOGY, V42, P641, DOI 10.1002/hep.20842
   Tussing-Humphreys L, 2011, THESCIENTIFICWORLDJO, V11, P2197, DOI 10.1100/2011/634861
   van de Wier B, 2013, FEBS LETT, V587, P2461, DOI 10.1016/j.febslet.2013.06.019
   Yilmaz Y, 2012, ALIMENT PHARM THER, V36, P815, DOI 10.1111/apt.12046
   Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X
NR 77
TC 0
Z9 0
U1 7
U2 7
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 287401
DI 10.1155/2015/287401
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CO5YS
UT WOS:000359235000001
ER

PT J
AU Wei, D
   Chen, T
   Li, J
   Gao, Y
   Ren, Y
   Zhang, XX
   Yu, HL
   Tian, HM
AF Wei, Dong
   Chen, Tao
   Li, Jie
   Gao, Yun
   Ren, Yan
   Zhang, Xiangxun
   Yu, Hongling
   Tian, Haoming
TI Association of Serum Gamma-Glutamyl Transferase and Ferritin with the
   Metabolic Syndrome
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Article
ID INSULIN-RESISTANCE SYNDROME; INTERNATIONAL DIABETES FEDERATION;
   MIDDLE-AGED MEN; SYNDROME DESIR; WOMEN; RISK; DEFINITION;
   GLUTAMYLTRANSFERASE; TRANSPEPTIDASE; POPULATION
AB Aim. To investigate the relationship among GGT, ferritin, and the risk of metabolic syndrome. Methods. A total of 1024 eligible individuals of the Chinese Yi ethnic group were enrolled in this cross-sectional study. The presence of metabolic syndrome was determined using the revised NCEP-ATP III and CDS criteria. Odds ratios for the metabolic syndrome and its components for different groups based on the levels of GGT and ferritin were calculated using multiple logistic regressions. Results. Serum GGT and ferritin concentrations were significantly higher in subjects with metabolic syndrome compared to those without metabolic syndrome in both genders (p < 0.05). Serum GGT was positively correlated with ferritin (p < 0.05). The risk of the metabolic syndrome was significantly higher in female subjects who had elevated GGT and ferritin levels (p < 0.05). Furthermore, the increased risk of having each of the metabolic syndrome components (overweight or obesity, hypertriglyceridemia, hypertension, hyperglycemia, and insulin resistance) was also observed in those subjects after adjustment for possible confounders (p < 0.05). Conclusions. These data indicate that GGT and ferritin synergistically correlate with the risk of the metabolic syndrome, suggesting that they could potentially be used as predictive biomarkers for the metabolic syndrome.
C1 [Wei, Dong; Chen, Tao; Gao, Yun; Ren, Yan; Tian, Haoming] Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu 610041, Peoples R China.
   [Wei, Dong] Second Peoples Hosp Chengdu, Dept Endocrinol & Metab, Chengdu 610017, Peoples R China.
   [Li, Jie] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15224 USA.
   [Zhang, Xiangxun; Yu, Hongling; Tian, Haoming] Sichuan Univ, West China Hosp, Lab Endocrinol & Metab, Chengdu 610041, Peoples R China.
RP Tian, HM (reprint author), Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu 610041, Peoples R China.
EM hmtian999@126.com
FU Chinese National Natural Science Foundation for the Youth [81100572];
   Health Department of Sichuan Province [100011]; Chengdu Health Bureau
   [0905]
FX The authors acknowledge the residents and nurses of Department of
   Endocrinology of the First People's Hospital of Liangshan Yi Autonomy
   Prefecture for their diligent work on collecting demographic data and
   blood samples. This study was supported by Chinese National Natural
   Science Foundation for the Youth (Grant 81100572), Health Department of
   Sichuan Province (Grant 100011), and Chengdu Health Bureau (Grant 0905).
CR Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Chen T, 2010, DIABETES RES CLIN PR, V90, P352, DOI 10.1016/j.diabres.2010.09.017
   Pham NM, 2013, METABOLISM, V62, P561, DOI 10.1016/j.metabol.2012.07.025
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Lee DH, 2004, FREE RADICAL RES, V38, P535, DOI 10.1080/10715760410001694026
   Turgut O, 2011, J ATHEROSCLER THROMB, V18, P177
   Andre P, 2007, DIABETES CARE, V30, P2355, DOI 10.2337/dc07-0440
   Ren Y, 2004, DIABETES CARE, V27, P622, DOI 10.2337/diacare.27.2.622
   Targher G, 2010, CLIN CHEM LAB MED, V48, P147, DOI 10.1515/CCLM.2010.031
   Stoutenberg M, 2013, BRIT J NUTR, V110, P901, DOI 10.1017/S0007114512005764
   Bataller-Sifre R, 2011, REV ESP ENFERM DIG, V103, P586, DOI 10.4321/s1130-01082011001100006
   Churilla James R, 2014, Diabetes Metab Syndr, V8, P119, DOI 10.1016/j.dsx.2014.04.001
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Hamalainen P, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-114
   Han LL, 2014, MOL NUTR FOOD RES, V58, P2189, DOI 10.1002/mnfr.201400088
   Iciek M, 2007, BBA-MOL CELL RES, V1773, P201, DOI 10.1016/j.bbamcr.2006.10.013
   Im Ho-Jin, 2014, Korean J Fam Med, V35, P173, DOI 10.4082/kjfm.2014.35.4.173
   Kunutsor SK, 2015, INT J CLIN PRACT, V69, P136, DOI 10.1111/ijcp.12507
   Metabolic Syndrome Study Cooperation Group of Chinese Diabetes Society, 2004, CHIN J DIAB, V12, P156
   Ryu S, 2010, METABOLISM, V59, P683, DOI 10.1016/j.metabol.2009.08.024
   Wakabayashi I, 2014, ALCOHOL CLIN EXP RES, V38, P1689, DOI 10.1111/acer.12425
NR 25
TC 1
Z9 1
U1 3
U2 3
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2015
AR 741731
DI 10.1155/2015/741731
PG 10
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CM1XM
UT WOS:000357473900001
ER

PT J
AU Mujica-Coopman, MF
   Brito, A
   de Romana, DL
   Pizarro, F
   Olivares, M
AF Fernanda Mujica-Coopman, Maria
   Brito, Alex
   Lopez de Romana, Daniel
   Pizarro, Fernando
   Olivares, Manuel
TI Body mass index, iron absorption and iron status in childbearing age
   women
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Obesity; Body mass index; Iron absorption; Hemoglobin; Women
ID NUTRITION TRANSITION; SERUM IRON; OBESITY; DEFICIENCY; BIOAVAILABILITY;
   INFLAMMATION; ZINC; HYPOFERREMIA; CHILDREN; HEPCIDIN
AB Background: The prevalence of obesity has-increased at an alarming rate worldwide. Some studies have observed an association between iron (Fe) deficiency (ID) and obesity, however more research is needed.
   Objective: To assess whether body mass index (BMI) is associated with both Fe absorption and Fe status.
   Methods: A cross sectional sample of 318 Chilean childbearing age women was studied. The women received either a single dose of 0.5 mg of Fe (n =137, group 1) or 3 mg of Fe plus ascorbic acid (1:2 molar ratio) (n =181, group 2), both as FeSO4 with labeled radioisotopes. Fe absorption was assessed through radio Fe erythrocyte incorporation. Fe status was determined by hemoglobin (Hb), mean corpuscular volume, serum Fe, total iron binding capacity, transferrin saturation, erythrocyte Zn protoporphyrin and serum ferritin (SF).
   Results: 29%, 47% and 24% of the women were classified as normal, overweight or obese, respectively. Fe absorption was significantly lower in obese women (p < 0.05). In group 1, the geometric mean and range +/- 1 SD of the percentage of Fe absorption for normal-weight women was 32.9% vs. 19.7% in obese. For group 2, this percentage was 36% vs. 30%, respectively (2-way ANOVA: BMI classification and Fe dose p < 0.05; interaction p = 034). Although Fe absorption was lower in obese women, they had higher SF (p < 0.01) and Hb (p < 0.05) concentrations.
   Conclusion: Although we did not observe a relationship between BMI and Fe status, obese women displayed lower Fe absorption compared with overweight and normal weight women, possibly due to subclinical inflammation associated with obesity. (C) 2014 Elsevier GmbH. All rights reserved.
C1 [Fernanda Mujica-Coopman, Maria; Brito, Alex; Lopez de Romana, Daniel; Pizarro, Fernando; Olivares, Manuel] Univ Chile, Inst Nutr & Food Technol, Micronutrients Lab, Santiago, Chile.
   [Brito, Alex] Univ Calif Davis, USDA, Western Human Nutr Res Ctr, Davis, CA 95616 USA.
   [Lopez de Romana, Daniel] Micronutrient Initiat, Ottawa, ON, Canada.
RP Olivares, M (reprint author), Av El Libano 5524, Santiago 7830490, Chile.
EM molivare@inta.uchile.cl
RI Brito, Alex/I-2858-2013
OI Brito, Alex/0000-0002-6212-8814
FU Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) Chile
   [1950242, 1040879, 1070665]
FX The study was partially supported by grants from Fondo Nacional de
   Desarrollo Cientifico y Tecnologico (FONDECYT) Chile #. 1950242,
   1040879, 1070665.
CR Aaeribigbe O, 2014, CRIT REV FOOD SCI NU, V54, P553
   Olivares M, 2007, NUTR RES, V27, P279, DOI 10.1016/j.nutres.2007.04.006
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Hertrampf E, 2003, J NUTR, V133, P3166
   Olivares M, 2007, BIOL TRACE ELEM RES, V117, P7, DOI 10.1007/BF02698079
   Walter T, 2003, J NUTR, V133, P3158
   Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x
   NADLER SB, 1962, SURGERY, V51, P224
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   [Anonymous], 2003, ENC NAC SAL CHIL
   Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824
   Datz C, 2013, EUR J CLIN INVEST, V43, P215, DOI 10.1111/eci.12032
   EAKINS JD, 1966, INT J APPL RADIAT IS, V17, P391, DOI 10.1016/0020-708X(66)90065-2
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   [Anonymous], 2008, WORLDW PREV AN 1993
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Zekanowska Ewa, 2011, Biotechnologia (Poznan), V92, P147
   Beard JL, 2006, AM J CLIN NUTR, V84, P1498
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   FISCHER DS, 1964, CLIN CHEM, V10, P21
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Bothwell TH, 1962, IRON METABOLISM
   Centers for Disease Control, 1998, MMWR, V47
   de Romana DL, 2008, NUTRITION, V24, P957, DOI 10.1016/j.nut.2008.04.007
   Food and Agriculture Organization of the United Nations, 2006, FAO FOOD NUTR PAP, V84, P1
   Hintze K, 2011, ADV HEMATOL, V2011, P1
   International Anemia Consultative Group, 1985, MEAS IR STAT REP INT
   Olivares M, 2007, NUTRITION, V23, P296, DOI 10.1016/j.nut.2006.04.014
   Olivares M, 2010, BIOL TRACE ELEM RES, V136, P180, DOI 10.1007/s12011-009-8536-1
   Olivares M, 1997, J NUTR, V127, P1407
   Olivares M, 2007, NUTRITION, V23, P292, DOI 10.1016/j.nut.2007.01.006
   Olivares M, 1999, NUTR RES, V19, P179, DOI 10.1016/S0271-5317(98)00182-1
   Pizarro F, 1998, ARCH LATINOAM NUTR, V48, P25
   Popkin BM, 2004, NUTR REV, V62, P140, DOI 10.1301/nr.2004.jul.S140-S143
   Razak F, 2013, PLOS MED, V10, P1
   Rebolledo A Annabella, 2005, Rev. chil. nutr., V32, P118, DOI 10.4067/S0717-75182005000200006
   SCHEER JC, 1981, AM J CLIN NUTR, V34, P2748
   Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1
   Tomkins A, 2003, J NUTR, V133, P1649
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   WHO, 2000, WHO TECHN REP SER, P894
NR 46
TC 7
Z9 7
U1 4
U2 7
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PY 2015
VL 30
BP 215
EP 219
DI 10.1016/j.jtemb.2014.03.008
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA CE4LL
UT WOS:000351802000034
PM 24813452
ER

PT J
AU Khanbhai, M
   Dubb, S
   Patel, K
   Ahmed, A
   Richards, T
AF Khanbhai, M.
   Dubb, S.
   Patel, K.
   Ahmed, A.
   Richards, T.
TI The prevalence of iron deficiency anaemia in patients undergoing
   bariatric surgery
SO OBESITY RESEARCH & CLINICAL PRACTICE
LA English
DT Article
DE Anaemia; Iron deficiency; Obesity; Bariatric surgery
ID GASTRIC BYPASS; HEMOGLOBIN LEVEL; CANCER-PATIENTS; MORBID-OBESITY;
   MORTALITY; OUTCOMES; HYPOFERREMIA; OVERWEIGHT; COHORT; TRENDS
AB As bariatric surgery rates continue to climb, anaemia will become an increasing concern. We assessed the prevalence of anaemia and length of hospital stay in patients undergoing bariatric surgery. Prospective data (anaemia [haemoglobin <12 g/dL], haematinics and length of hospital stay) was analysed on 400 hundred patients undergoing elective laparoscopic bariatric surgery. Results from a prospective database of 1530 patients undergoing elective general surgery were used as a baseline. Fifty-seven patients (14%) were anaemic pre-operatively, of which 98% were females. Median MCV (fL) and overall median ferritin (mu g/L) was lower in anaemic patients (83 vs. 86, p = 0.001) and (28 vs. 61, p < 0.0001) respectively. In the elective general surgery patients, prevalence of anaemia was similar (14% vs. 16%) but absolute iron deficiency was more common in those undergoing bariatric surgery; microcytosis p < 0.0001, ferritin <30 p < 0.0001. Mean length of stay (days) was increased in the anaemic compared to in the non-anaemic group (2.7 vs. 1.9) and patients who were anaemic immediately post-operatively, also had an increased length of stay (2.7 vs. 1.9), p < 0.05. Absolute iron deficiency was more common in patients undergoing bariatric surgery. In bariatric patients with anaemia there was an overall increased length of hospital stay. (C) 2013 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
C1 [Khanbhai, M.; Richards, T.] UCL, London WC1E 6BT, England.
   [Dubb, S.; Patel, K.; Ahmed, A.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.
RP Khanbhai, M (reprint author), Div Surg & Interventional Sci, 4th Floor,Med Sch Bldg,74 HuntleyStreet, London WC1E 6AU, England.
EM mustafa.khanbhai@doctors.org.uk
CR ALVAREZCORDERO R, 1992, OBES SURG, V2, P87, DOI 10.1381/096089292765560619
   AMARAL JF, 1985, ANN SURG, V201, P186, DOI 10.1097/00000658-198502000-00009
   Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187
   Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.2009.2014
   Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643
   Brolin RE, 2002, J GASTROINTEST SURG, V6, P195, DOI 10.1016/S1091-255X(01)00022-1
   Glance LG, 2011, ANESTHESIOLOGY, V114, P283, DOI 10.1097/ALN.0b013e3182054d06
   Santry HP, 2005, JAMA-J AM MED ASSOC, V294, P1909, DOI 10.1001/jama.294.15.1909
   Ludwig H, 2004, EUR J CANCER, V40, P2293, DOI 10.1016/j.ejca.2004.06.019
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   [Anonymous], 1991, ANN INTERNAL MED, V115, P956
   Trus TL, 2005, SURG ENDOSC, V19, P616, DOI 10.1007/s00464-004-8827-8
   Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Freedman DM, 2006, INT J OBESITY, V30, P822, DOI 10.1038/sj.ijo.0803193
   Brolin RE, 2002, J GASTROINTESTINAL S, V6, P204
   Dunne JR, 2002, AM SURGEON, V68, P582
   E.R.P. Programme, 2010, DEL ENH REC HELP PAT
   Littlewood TJ, 2001, SEMIN ONCOL, V28, P49, DOI 10.1053/sonc.2001.25397
   Marinella MA, 1999, NEW ENGL J MED, V341, P60, DOI 10.1056/NEJM199907013410117
   Napolitano LM, 2005, SURG CLIN N AM, V85, P1215, DOI 10.1016/j.suc.2005.10.012
   REINHOLD RB, 1994, J AM COLL NUTR, V13, P326
   Shander Aryeh, 2004, Am J Med, V116 Suppl 7A, p58S
   Tampellini M, 2006, BRIT J CANCER, V95, P13, DOI 10.1038/sj.bjc.6603204
   Thomas G, 2001, SEMIN ONCOL, V28, P60, DOI 10.1053/sonc.2001.25400
NR 25
TC 1
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1871-403X
EI 1878-0318
J9 OBES RES CLIN PRACT
JI Obes. Res. Clin. Pract.
PD JAN-FEB
PY 2015
VL 9
IS 1
BP 45
EP 49
DI 10.1016/j.orcp.2013.12.004
PG 5
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA CB2NH
UT WOS:000349463900006
PM 25660174
ER

PT J
AU Citelli, M
   Fonte-Faria, T
   Nascimento-Silva, V
   Renovato-Martins, M
   Silva, R
   Luna, AS
   da Silva, SV
   Barja-Fidalgo, C
AF Citelli, Marta
   Fonte-Faria, Thais
   Nascimento-Silva, Vany
   Renovato-Martins, Mariana
   Silva, Raphael
   Luna, Aderval Severino
   da Silva, Simone Vargas
   Barja-Fidalgo, Christina
TI Obesity Promotes Alterations in Iron Recycling
SO NUTRIENTS
LA English
DT Article
DE hepcidin; ferroportin; ER stress; obesity; iron; bioavailability
ID OVERWEIGHT CHILDREN; ADIPOSE-TISSUE; FATTY LIVER; HEPCIDIN; DEFICIENCY;
   EXPRESSION; CELLS; MACROPHAGES; METABOLISM; ERYTHROPHAGOCYTOSIS
AB Hepcidin is a key hormone that induces the degradation of ferroportin (FPN), a protein that exports iron from reticuloendothelial macrophages and enterocytes. The aim of the present study was to experimentally evaluate if the obesity induced by a high-fat diet (HFD) modifies the expression of FPN in macrophages and enterocytes, thus altering the iron bioavailability. In order to directly examine changes associated with iron metabolism in vivo, C57BL/6J mice were fed either a control or a HFD. Serum leptin levels were evaluated. The hepcidin, divalent metal transporter-1 (DMT1), FPN and ferritin genes were analyzed by real-time polymerase chain reaction. The amount of iron present in both the liver and spleen was determined by flame atomic absorption spectrometry. Ferroportin localization within reticuloendothelial macrophages was observed by immunofluorescence microscopy. Obese animals were found to exhibit increased hepcidin gene expression, while iron accumulated in the spleen and liver. They also exhibited changes in the sublocation of splenic cellular FPN and a reduction in the FPN expression in the liver and the spleen, while no changes were observed in enterocytes. Possible explanations for the increased hepcidin expression observed in HFD animals may include: increased leptin levels, the liver iron accumulation or endoplasmic reticulum (ER) stress. Together, the results indicated that obesity promotes changes in iron bioavailability, since it altered the iron recycling function.
C1 [Citelli, Marta; Silva, Raphael] Univ Estado Rio de Janeiro, Inst Nutr, Dept Nutr Basica & Expt, BR-21941590 Rio De Janeiro, RJ, Brazil.
   [Fonte-Faria, Thais; Nascimento-Silva, Vany; Renovato-Martins, Mariana; da Silva, Simone Vargas; Barja-Fidalgo, Christina] Univ Estado Rio de Janeiro, Inst Biol Roberto Alcantara Gomes, BR-20551030 Rio De Janeiro, RJ, Brazil.
   [Luna, Aderval Severino] Univ Estado Rio de Janeiro, Inst Quim, BR-20551030 Rio De Janeiro, RJ, Brazil.
RP Citelli, M (reprint author), Univ Estado Rio de Janeiro, Inst Nutr, Dept Nutr Basica & Expt, BR-21941590 Rio De Janeiro, RJ, Brazil.
EM martacitelli@gmail.com; thaisfaria09@gmail.com; vanysilva@hotmail.com;
   m_renovatomartins@yahoo.com.br; raphasilva02@gmail.com; asluna@uerj.br;
   si_vargas@oi.com.br; barja-fidalgo@uerj.br
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). The authors are
   grateful to Michelle Parvatiyar for her English language review and to
   Genilson Rodrigues da Silva and Diego Barros Batista for their excellent
   technical assistance.
CR Aigner E, 2014, NUTRIENTS, V6, P3587, DOI 10.3390/nu6093587
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Orr JS, 2014, DIABETES, V63, P421, DOI 10.2337/db13-0213
   Citelli M, 2012, BIOL TRACE ELEM RES, V149, P64, DOI 10.1007/s12011-012-9397-6
   Chung B, 2007, J NUTR, V137, P2366
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Chaston T, 2008, GUT, V57, DOI 10.1136/gut.2007.131722
   Shi YG, 2003, ENDOCR REV, V24, P91, DOI 10.1210/er.2002-0018
   Shi YG, 1998, MOL CELL BIOL, V18, P7499
   Arruda SF, 2009, NUTRITION, V25, P472, DOI 10.1016/j.nut.2008.11.030
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Wahlang B, 2013, J NUTR BIOCHEM, V24, P1587, DOI 10.1016/j.jnutbio.2013.01.009
   Ahmed U, 2013, NUTR RES, V33, P126, DOI 10.1016/j.nutres.2012.11.012
   Mujica-Coopman MF, 2015, J TRACE ELEM MED BIO, V30, P215, DOI 10.1016/j.jtemb.2014.03.008
   Harding HP, 1999, NATURE, V397, P271
   Vecchi C, 2009, SCIENCE, V325, P877, DOI 10.1126/science.1176639
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Delaby C, 2008, BIOCHEM J, V411, P123, DOI 10.1042/BJ20071474
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008
   Nascimento-Silva V, 2007, THROMB HAEMOSTASIS, V97, P88, DOI 10.1160/TH06-06-0315
   Burke RM, 2014, NUTRIENTS, V6, P4093, DOI 10.3390/nu6104093
   Chung J, 2011, NUTR RES, V31, P915, DOI 10.1016/j.nutres.2011.09.014
   Fischer-Posovszky P, 2007, HORM METAB RES, V39, P314, DOI 10.1055/s-2007-976539
   Gregorio B.M., 2010, AM J OBSTET GYNECOL, V203, P1, DOI DOI 10.1016/J.AJ0G.2010.06.042)
   HEUFF G, 1994, J IMMUNOL METHODS, V174, P61, DOI 10.1016/0022-1759(94)90010-8
   Knutson MD, 2003, BLOOD, V102, P4191, DOI 10.1182/blood-2003-04-1250
   Le Guenno G, 2007, DIABETES RES CLIN PR, V77, P363, DOI 10.1016/j.diabres.2007.02.004
   Akiyama M, 2013, DIABETES, V62, P2439, DOI 10.2337/db12-1747
   Oliveira SJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006618
   Pierre N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065061
   Sonnweber T, 2012, J NUTR BIOCHEM, V23, P1600, DOI 10.1016/j.jnutbio.2011.10.013
NR 34
TC 0
Z9 0
U1 2
U2 6
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JAN
PY 2015
VL 7
IS 1
BP 335
EP 348
DI 10.3390/nu7010335
PG 14
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AZ7ML
UT WOS:000348402900020
PM 25569627
ER

PT J
AU Andrews, M
   Soto, N
   Arredondo-Olguin, M
AF Andrews, Monica
   Soto, Nestor
   Arredondo-Olguin, Miguel
TI Association between ferritin and hepcidin levels and inflammatory status
   in patients with type 2 diabetes mellitus and obesity
SO NUTRITION
LA English
DT Article
DE Ferritin; Hepcidin; Inflammation; Diabetes; Obesity
ID TOLL-LIKE RECEPTORS; BODY IRON STORES; INSULIN-RESISTANCE; HUMAN
   MONOCYTES; HEALTHY WOMEN; RISK; EXPRESSION; RETINOL-BINDING-PROTEIN-4;
   METABOLISM; STRESS
AB Objective: The aim of this study was to determine the association between iron parameters and inflammation in obese individuals with and without type 2 diabetes mellitus (T2DM).
   Methods: We studied 132 obese individuals (OB), 60 individuals with T2DM, 106 obese individuals with T2DM (T2DOB), and 146 controls (C). All of were men aged >30 y. Biochemical, iron nutrition, and oxidative stress parameters were determined. Peripheral mononuclear cells were isolated and total RNA was extracted to quantify tumor necrosis factor (TNF)-alpha, nuclear factor (NF)-kB, interleukin (IL)-6, toll-like receptor (TLR)-2/4 and hepcidin by quantitative reverse transcription polymerase chain reaction.
   Results: OB, T2DM, and T2DOB individuals had higher ferritin, retinol-binding protein 4, and thiobarbituric acid reactive substance (TBAR) levels than controls. T2DOB and T2DM individuals showed high high-sensitivity C-reactive protein (hsCRP) levels and OB with and without 12DM had elevated levels of serum hepcidin. Heme oxygenase activity was high in OB and T2DM and there were no differences observed in superoxide dismutase and glutathione parameters. A correlation between TBARS and ferritin in T2DOB was observed (r = 0.31; P < 0.006). Multiple linear regression analysis showed an association between diabetes and obesity with ferritin, TBARS, and hsCRP levels. The upper quartiles of ferritin, TBARS and hepcidin showed an adjusted odd ratio for T2DM of 1.782, 2.250, and 4.370, respectively. TNF-alpha, IL-6, hepcidin, NF-kB, TLR-2/4 mRNA abundances were increased in T2DM and T2DOB.
   Conclusion: Elevated hsCRP and hepcidin levels, and increased gene expression of TNF-alpha, IL-6, NF-kB, and TLR-2/4 in patients with diabetes, obesity, or both exacerbate and perpetuate the insulin resistance and inflammatory state. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Andrews, Monica; Arredondo-Olguin, Miguel] Univ Chile, Micronutrient Lab, Inst Nutr & Food Technol INTA, Santiago, Chile.
   [Soto, Nestor] Hosp San Borja Arriaran, Endocrinol & Diabet Unit, Santiago, Chile.
RP Arredondo-Olguin, M (reprint author), Univ Chile, Micronutrient Lab, Inst Nutr & Food Technol INTA, Santiago, Chile.
EM marredon@inta.uchile.cl
FU Fondo Nacional de Desarrolio Cientifico y Tecnologico, Chile [1110080]
FX This study was supported by grant No. 1110080 from Fondo Nacional de
   Desarrolio Cientifico y Tecnologico, Chile. MA was responsible for the
   study design; data collection, analysis, and interpretation; and
   drafting the manuscript. NS was responsible for management of the field
   site, management of patients with diabetes, data collection, and
   analysis. MAO designed the study, assisted in the data analysis and
   interpretation and drafting the manuscript. None of the authors declared
   a personal or any financial conflict of interest.
CR Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862
   Ganz T, 2011, ANNU REV MED, V62, P347, DOI [10.1146/annurev-med-050109-142444, 10.1146/annurev-rned-050109-142444]
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/01.CIR.0000012489.17433.31
   Fernandez-Real JM, 2008, DIABETES, V57, P1918, DOI 10.2337/db08-0041
   Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018
   Lee BK, 2011, METABOLISM, V60, P1416, DOI 10.1016/j.metabol.2011.02.008
   Jonas JC, 2003, DIABETOLOGIA, V46, P1234, DOI 10.1007/s00125-003-1174-9
   Dasu MR, 2011, AM J PHYSIOL-ENDOC M, V300, pE145, DOI 10.1152/ajpendo.00490.2010
   Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898
   Hulsmans M, 2012, CURR ATHEROSCLER REP, V14, P264, DOI 10.1007/s11883-012-0237-0
   Li M, 2008, DIABETES, V57, P1526, DOI 10.2337/db07-1764
   Vitseva OI, 2008, OBESITY, V16, P932, DOI 10.1038/oby.2008.25
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Ibrahim MM, 2010, OBES REV, V11, P11, DOI 10.1111/j.1467-789X.2009.00623.x
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   Dasu MR, 2008, DIABETES, V57, P3090, DOI 10.2337/db08-0564
   Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Jehn ML, 2007, AM J EPIDEMIOL, V165, P1047, DOI 10.1093/aje/kwk093
   Theurl I, 2008, BLOOD, V111, P2392, DOI 10.1182/blood-2007-05-090019
   Rajpathak SN, 2009, DIABETES OBES METAB, V11, P472, DOI 10.1111/j.1463-1326.2008.00985.x
   Miller LS, 2007, J IMMUNOL, V179, P6933
   Leibowitz G, 2010, DIABETES OBES METAB, V12, P66, DOI 10.1111/j.1463-1326.2010.01280.x
   Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102
   Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031
   Lipinski B, 2011, OXID MED CELL LONGEV, DOI 10.1155/2011/809696
   Wong VWS, 2014, AM J GASTROENTEROL, V109, P589, DOI 10.1038/ajg.2014.1
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Stefan N, 2007, DIABETES CARE, V30, P1173, DOI 10.2337/dc06-2342
   Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Boni-Schnetzler M, 2009, ENDOCRINOLOGY, V150, P5218, DOI 10.1210/en.2009-0543
   Arredondo M, 2007, AM J CLIN NUTR, V86, P1347
   Bakhai A, 2008, QJM-INT J MED, V101, P767, DOI 10.1093/qjmed/hcn066
   Coimbra S, 2013, OBES REV, V14, P771, DOI 10.1111/obr.12057
   D'Archivio M, 2011, EUR J CLIN INVEST, V42, P70
   Derbent AU, 2013, J MATERN-FETAL NEO M, V26, P1112, DOI 10.3109/14767058.2013.770462
   Fisher DS, 1964, CLIN CHEM, V10, P21
   Fleming RE, 2008, J MOL MED-JMM, V86, P491, DOI 10.1007/s00109-008-0349-8
   Gavi S, 2007, J CLIN ENDOCR METAB, V92, P1886, DOI 10.1210/jc.2006-1815
   Hernandez C, 2005, DIABETIC MED, V22, P97, DOI 10.1111/j.1464-5491.2004.01331.x
   Jiang F, 2011, DIABETES RES CLIN PR, V93, P1
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Lee JW, 2007, OBESITY, V15, P2225, DOI 10.1038/oby.2007.264
   Pae Hyun-Ock, 2009, Immune Netw, V9, P12, DOI 10.4110/in.2009.9.1.12
   Puntarulo Susana, 2005, Molecular Aspects of Medicine, V26, P299, DOI 10.1016/j.mam.2005.07.001
NR 53
TC 3
Z9 3
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD JAN
PY 2015
VL 31
IS 1
BP 51
EP 57
DI 10.1016/j.nut.2014.04.019
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AX1CJ
UT WOS:000346685600007
PM 25441587
ER

PT J
AU Dogan, K
   Aarts, EO
   Koehestanie, P
   Betzel, B
   Ploeger, N
   de Boer, H
   Aufenacker, TJ
   van Laarhoven, KJHM
   Janssen, IMC
   Berends, FJ
AF Dogan, Kemal
   Aarts, Edo O.
   Koehestanie, Parweez
   Betzel, Bark
   Ploeger, Nadine
   de Boer, Hans
   Aufenacker, Theo J.
   van Laarhoven, Kees J. H. M.
   Janssen, Ignace M. C.
   Berends, Frits J.
TI Optimization of Vitamin Suppletion After Roux-En-Y Gastric Bypass
   Surgery Can Lower Postoperative Deficiencies A Randomized Controlled
   Trial
SO MEDICINE
LA English
DT Article
ID BARIATRIC SURGERY; NUTRITIONAL DEFICIENCIES; BILIOPANCREATIC DIVERSION;
   METABOLIC COMPLICATIONS; SLEEVE GASTRECTOMY; IRON-ABSORPTION;
   LIFE-STYLE; OBESITY; SUPPLEMENTATION; CONSEQUENCES
AB Iron, vitamin B12, and folic acid deficiencies are among the most common deficiencies occurring after laparoscopic Roux-en-Y gastric bypass (LRYGB). The present study evaluates the effectiveness of a specially designed multivitamin supplement (WLS Forte, Fit-ForMe, Rotterdam, the Netherlands) specifically developed for LRYGB patients.
   A triple-blind, randomized, 12-month study was conducted comparing WLS forte with a standard multivitamin supplement (sMVS) containing approximately 100% of the recommended daily allowance (RDA) for iron, vitamin B12, and folic acid. WLS Forte contains vitamin B12 14000% RDA, iron 500% RDA, and folic acid 300% RDA.
   In total, 148 patients (74 in each group) underwent a LRYGB procedure. Baseline characteristics were similar for both groups. Per protocol analysis demonstrated that sMVS treatment was associated with a decline in ferritin (-24.4 +/- 70.1mg/L) and vitamin B12 (-45.9 +/- 150.3 pmol/L) over 12 months, whereas in WLS Forte patients, ferritin remained stable (+3.2 +/- 93.2 mu g/L) and vitamin B12 increased significantly (+55.1 +/- 144.2 pmol/L). The number of patients developing ferritin or vitamin B12 deficiency was significantly lower with WLS Forte compared with sMVS (P<0.05). Iron deficiency (ID) was reduced by 88% after WLS Forte compared with sMVS. Adverse events related to supplement use did not occur.
   An optimized multivitamin supplement is safe and reduces the development of iron and vitamin B12 deficiencies after LRYGB.
C1 [Dogan, Kemal; Aarts, Edo O.; Koehestanie, Parweez; Betzel, Bark; Aufenacker, Theo J.; Janssen, Ignace M. C.; Berends, Frits J.] Rijnstate Hosp, Dept Surg, NL-6800 TA Arnhem, Netherlands.
   [de Boer, Hans] Rijnstate Hosp, Dept Internal Med, NL-6800 TA Arnhem, Netherlands.
   [van Laarhoven, Kees J. H. M.] Radboud Univ Nijmegen, Dept Surg, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
RP Dogan, K (reprint author), Rijnstate Hosp, Dept Surg, Postal 1190,POB 9555, NL-6800 TA Arnhem, Netherlands.
EM dogan_kemal@hotmail.com
RI Laarhoven, C.J.H.M./H-8065-2014
CR Aarts EO, 2012, J OBES, V2012, DOI DOI 10.1155/2012/193705
   Aasheim ET, 2012, SURG OBES RELAT DIS, V8, P169, DOI 10.1016/j.soard.2011.01.038
   Angrisani L, 2007, SURG OBES RELAT DIS, V3, P32
   Fish E, 2010, J SURG RES, V164, P198, DOI 10.1016/j.jss.2010.06.029
   Mason ME, 2005, GASTROENTEROL CLIN N, V34, P25, DOI 10.1016/j.gtc.2004.12.008
   Goldner WS, 2009, OBES SURG, V19, P173, DOI 10.1007/s11695-008-9680-y
   Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724
   Brolin RE, 2002, J GASTROINTEST SURG, V6, P195, DOI 10.1016/S1091-255X(01)00022-1
   Ruz M, 2011, AM J CLIN NUTR, V94, P1004, DOI 10.3945/ajcn.111.018143
   Vargas-Ruiz AG, 2008, OBES SURG, V18, P288, DOI 10.1007/s11695-007-9310-0
   de Campos CD, 2008, OBES SURG, V18, P386, DOI 10.1007/s11695-007-9393-7
   Moize V, 2013, J ACAD NUTR DIET, V113, P400, DOI 10.1016/j.jand.2012.11.013
   Rhode BM, 1996, AM J CLIN NUTR, V63, P103
   Edholm D, 2013, SURG OBES RELAT DIS, V9, P708, DOI 10.1016/j.soard.2012.02.011
   Aasheim ET, 2009, AM J CLIN NUTR, V90, P15, DOI 10.3945/ajcn.2009.27583
   Decker GA, 2007, AM J GASTROENTEROL, V102, P2571, DOI 10.1111/j.1572-0241.2007.01421.x
   Alvarez-Leite JI, 2004, CURR OPIN CLIN NUTR, V7, P569, DOI 10.1097/00075197-200409000-00010
   Parkes E, 2006, AM J MED SCI, V331, P207, DOI 10.1097/00000441-200604000-00007
   Blume CA, 2012, OBES SURG, V22, P1676, DOI 10.1007/s11695-012-0696-y
   Ruz M, 2012, AM J CLIN NUTR, V96, P810, DOI 10.3945/ajcn.112.039255
   Flores L, 2010, OBES SURG, V20, P738, DOI 10.1007/s11695-010-0138-7
   Aarts E, 2011, EUR J ENDOCRINOL, V164, P827, DOI 10.1530/EJE-10-1126
   [Anonymous], 1991, ANN INTERN MED, V115, P956
   Bloomberg RD, 2005, OBES SURG, V15, P145, DOI 10.1381/0960892053268264
   Davies DJ, 2007, OBES SURG, V17, P1150, DOI 10.1007/s11695-007-9208-x
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Aills L, 2008, SURG OBES RELAT DIS, V4, pS73, DOI 10.1016/j.soard.2008.03.002
   Rojas P, 2011, OBES SURG, V21, P561, DOI 10.1007/s11695-011-0368-3
   Johnson JM, 2006, ANN SURG, V243, P701, DOI 10.1097/01.sla.0000216773.47825.c1
   Maggard MA, 2005, ANN INTERN MED, V142, P547
   Malinowski SS, 2006, AM J MED SCI, V331, P219, DOI 10.1097/00000441-200604000-00009
   Angrisani L, 2007, SURG OBES RELAT DIS, V3, P127, DOI 10.1016/j.soard.2006.12.005
   Ruz M, 2009, AM J CLIN NUTR, V90, P527, DOI 10.3945/ajcn.2009.27699
   Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Gudzune KA, 2013, OBES SURG, V23, P1581, DOI 10.1007/s11695-013-0919-x
   Buchwald H, 2013, OBES SURG, V23, P427, DOI 10.1007/s11695-012-0864-0
   van Groningen L, 2010, EUR J ENDOCRINOL, V162, P805, DOI 10.1530/EJE-09-0932
   Brolin RE, 1999, OBES SURG, V9, P150, DOI 10.1381/096089299765553395
   Brolin RE, 2002, J GASTROINTEST SURG, V6, P4
   Brolin R E, 1998, J Gastrointest Surg, V2, P436, DOI 10.1016/S1091-255X(98)80034-6
   Brolin RE, 1998, ARCH SURG-CHICAGO, V133, P740, DOI 10.1001/archsurg.133.7.740
   Carlin Arthur M, 2006, Surg Obes Relat Dis, V2, P638, DOI 10.1016/j.soard.2006.09.003
   Coupaye M, 2009, OBES SURG, V19, P56, DOI 10.1007/s11695-008-9571-2
   Elliot Kelly, 2003, Crit Care Nurs Q, V26, P133
   Hultdin J, 2005, INT J CANCER, V113, P819, DOI 10.1002/ijc.20646
   Johnson JM, 2006, ANN SURG, V243, P4
   Matrana MR, 2009, SOUTH MED J, V102, P1025, DOI 10.1097/SMJ.0b013e3181b62614
   Navarro M, 2003, J AM COLL NUTR, V22, P124
   Signori C, 2010, OBES SURG, V20, P949, DOI 10.1007/s11695-010-0178-z
   Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622
   Skroubis G, 2002, OBES SURG, V12, P551, DOI 10.1381/096089202762252334
   Xanthakos SA, 2006, CURR OPIN CLIN NUTR, V9, P489, DOI 10.1097/01.mco.0000232913.07355.cf
NR 53
TC 0
Z9 0
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV
PY 2014
VL 93
IS 25
AR e169
DI 10.1097/MD.0000000000000169
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AU4DJ
UT WOS:000345559000011
PM 25437032
ER

PT J
AU Castillo, RF
   Gallegos, RF
   Serrano, MAA
   Negrillo, AMN
   Perez, CFN
   Alfonso, AIQ
AF Fernandez Castillo, Rafael
   Fernandez Gallegos, Ruth
   Alvarez Serrano, Maria Adelaida
   Nunez Negrillo, Ana Maria
   Navarro Perez, Carmen Flores
   Quero Alfonso, Angel I.
TI ASSESSMENT OF NUTRITIONAL STATUS IN RENAL TRANSPLANT PATIENTS DURING 5
   YEARS OF FOLLOW-UP
SO NUTRICION HOSPITALARIA
LA Spanish
DT Article
DE Renal Transplantation; Obesity; Obesity Degree; Malnutrition; Body Mass
   Index
ID POSTTRANSPLANT WEIGHT-GAIN; BODY-MASS INDEX; GRAFT FUNCTION;
   RISK-FACTORS; RECIPIENTS; KIDNEY; OBESITY; DIALYSIS; INFLAMMATION;
   EVOLUTION
AB Introduction: Weight gain and malnutrition after kidney transplantation is common and the resulting overweight and obesity is associated with serious health complications. By contrast, the prevalence of malnutrition in patients with renal transplantation and its impact on the outcome of kidney transplantation is underestimated.
   Objectives: The aim of this study was to evaluate the nutritional status of renal transplant patients and determine if the five-year follow-up, these patients undergo alterations that suggest nutritional deterioration.
   Methods: The sample consisted of 119 renal transplant patients who attended for five years post-transplant consultation. All patients measurements of total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides and ferritin (Ft) were performed. and anthropometric measurements were made of weight, height and BMI. Patients were divided into three groups according to GFR Group 1: <60 mL / min, Group 2: 89-60 mL / min Group 3: >= 90 mL / min.
   Results: The weight and BMI tended to decrease in group 3 while increasing in the other groups. A decrease in total cholesterol, HDL, LDL, Triglycerides and Ferritin less pronounced in group 3 occurs.
   Conclusions: After five years you can see a significant reduction in nutritional biochemical parameters in general, likewise the nutritional status is closely related, and is directly proportional to the function of the graft.
C1 [Fernandez Castillo, Rafael; Alvarez Serrano, Maria Adelaida; Nunez Negrillo, Ana Maria; Navarro Perez, Carmen Flores; Quero Alfonso, Angel I.] Univ Granada, Fac Ciencias Salud, Dept Enfermeria, Granada, Spain.
   [Fernandez Gallegos, Ruth] Hosp Univ Virgen de las Nieves, Serv Nefrol, Unidad Hemodialisis, Granada, Spain.
RP Castillo, RF (reprint author), Univ Granada, Fac Ciencias Salud, Campus Ceuta,C Cortadura Valle SN, Ceuta 51001, Spain.
EM rafaelfernandez@ugr.es
RI Castillo, Rafael/H-2178-2013
OI Castillo, Rafael/0000-0002-1814-5254
CR Ahmadpoor P, 2009, TRANSPL P, V41, P2820, DOI 10.1016/j.transproceed.2009.07.018
   Alexander JW, 2007, NUTR CLIN PRACT, V22, P16, DOI 10.1177/011542650702200116
   Jezior D, 2007, TRANSPL P, V39, P2772, DOI 10.1016/j.transproceed.2007.09.001
   Ducloux D, 2005, AM J TRANSPLANT, V5, P2922, DOI 10.1111/j.1600-6143.2005.01104.x
   Sharif A, 2008, TRANSPLANTATION, V85, P353, DOI 10.1097/TP.0b013e3181605ebf
   Heaf J, 2004, J RENAL NUTR, V14, P20, DOI 10.1053/j.jm.2003.09.005
   Guida B, 2007, NEPHROL DIAL TRANSPL, V22, P3304, DOI 10.1093/ndt/gfm345
   Lamb KE, 2011, AM J TRANSPLANT, V11, P450, DOI 10.1111/j.1600-6143.2010.03283.x
   Martins C, 2004, TRANSPLANT P, V36, P1650, DOI 10.1016/j.transproceed.2004.06.065
   Segev DL, 2011, AM J TRANSPLANT, V11, P652, DOI 10.1111/j.1600-6143.2011.03471.x
   Armstrong KA, 2005, NEPHROLOGY, V10, P405, DOI 10.1111/j.1440-1797.2005.00406.x
   Schutz T, 2012, NUTRITION, V28, P378, DOI 10.1016/j.nut.2011.07.019
   Kalantar-Zadeh K, 2001, AM J KIDNEY DIS, V38, P1343, DOI 10.1053/ajkd.2001.29250
   Kovesdy CP, 2009, AM J CLIN NUTR, V90, P407, DOI 10.3945/ajcn.2008.27390
   Dalrymple LS, 2012, NAT REV NEPHROL, V8, P258, DOI 10.1038/nrneph.2012.63
   El Haggan W, 2006, TRANSPLANT P, V38, P3517, DOI 10.1016/j.transproceed.2006.10.121
   Gill JS, 2007, KIDNEY INT, V71, P442, DOI 10.1038/sj.ki.5002072
   Habedank D, 2009, NEPHROL DIAL TRANSPL, V24, P3854, DOI 10.1093/ndt/gfp433
   Harada H, 2006, CLIN TRANSPLANT, V20, P26, DOI 10.1111/j.1399-0012.2006.00546.x
   Harada H, 2012, TRANSPL P, V44, P672, DOI 10.1016/j.transproceed.2011.12.010
   Leeuwen MTv, 2011, BMJ-BRIT MED J, V11, pc570
   Lopez MM, 2006, TRANSPL IMMUNOL, V17, P31, DOI 10.1016/j.trim.2006.09.018
   Malluche HH, 2010, NAT REV NEPHROL, V6, P32, DOI 10.1038/nrneph.2009.192
   Mantoo Sonali, 2007, Saudi J Kidney Dis Transpl, V18, P382
   Marcen R, 2007, TRANSPL P, V39, P2205, DOI 10.1016/j.transproceed.2007.07.072
   Moreau K, 2006, J RENAL NUTR, V16, P291, DOI 10.1053/j.jrn.2006.04.026
   Rettkowski O, 2007, TRANSPL P, V39, P1416, DOI 10.1016/j.transproceed.2006.11.031
   Souza GC, 2008, J RENAL NUTR, V18, P479, DOI 10.1053/j.jrn.2008.05.008
   Torres MRSG, 2007, TRANSPL P, V39, P443, DOI 10.1016/j.transproceed.2007.01.044
NR 29
TC 0
Z9 0
U1 1
U2 6
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD NOV
PY 2014
VL 30
IS 5
BP 1130
EP 1134
DI 10.3305/nh.2014.30.5.7696
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AT6OO
UT WOS:000345058900019
ER

PT J
AU Hamalainen, P
   Saltevo, J
   Kautiainen, H
   Mantyselka, P
   Vanhala, M
AF Hamalainen, Paivi
   Saltevo, Juha
   Kautiainen, Hannu
   Mantyselka, Pekka
   Vanhala, Mauno
TI Serum ferritin levels and the development of metabolic syndrome and its
   components: a 6.5-year follow-up study
SO DIABETOLOGY & METABOLIC SYNDROME
LA English
DT Article
DE Metabolic syndrome; Ferritin; Obesity
ID BODY IRON STORES; NUTRITION EXAMINATION SURVEY; INSULIN-RESISTANCE
   SYNDROME; KOREAN NATIONAL-HEALTH; RISK; MEN; WOMEN; ASSOCIATION;
   POPULATION; OBESITY
AB Background: The aim of this study was to investigate the relationship between changes in serum ferritin concentrations and the development of metabolic syndrome (MetS) and its components over a 6.5 year follow-up period in Finnish adults.
   Methods: Adults born in Pieksamaki, Finland, in 1942, 1947, 1952, 1957, and 1962 (n = 1294) were invited to health checkups between 1997 and 1998 and 2003 and 2004. All of the required variables for both checkups were available from 691 (53%) subjects (289 men and 402 women). MetS was defined by the National Cholesterol Education Program criteria.
   Results: During the 6.5-year follow-up period, 122 (18%) subjects developed incident cases of MetS. Increases in serum ferritin levels were significantly higher in both women and men with incident MetS compared with women and men without MetS (p = 0.04, p = 0.03). Also, serum ferritin levels increased significantly less in women in whom the criteria for MetS resolved during the follow-up period (p = 0.01). Increases in serum ferritin levels were significantly lower in women in whom the glucose criterion for MetS resolved, and higher in women for whom the waist criterion developed (p = 0.01 and p < 0.001, respectively). Serum ferritin levels decreased significantly more in men in whom the triglyceride criterion for MetS resolved during the follow-up period (p = 0.01). There was a clear and significant correlation between change in serum ferritin level and change in waist circumference both in men and women (p < 0.001, p < 0.01). In addition, correlations between change in serum ferritin level and change in plasma triglyceride as well as glucose levels were strongly positive in men (p < 0.001). There was negative correlation between change in serum ferritin and plasma high density cholesterol level both in men and women.
   Conclusions: Increases in serum ferritin over a 6,5 year period are associated with development of MetS in both men and women. Whereas, lower increases in serum ferritin over the same timeframe are associated with resolution of hypertriglyceridemia in men and hyperglycemia in women. Increases in waist circumference was positively correlated with increases in serum ferritin in both men and women.
C1 [Hamalainen, Paivi] Tampere Univ Hosp, Dept Internal Med, Tampere 33521, Finland.
   [Saltevo, Juha] Cent Finland Cent Hosp, Dept Internal Med, Jyvaskyla, Finland.
   [Kautiainen, Hannu; Vanhala, Mauno] Cent Finland Cent Hosp, Unit Family Practice, Jyvaskyla, Finland.
   [Kautiainen, Hannu; Mantyselka, Pekka; Vanhala, Mauno] Univ Eastern Finland, Unit Primary Hlth Care, Kuopio, Finland.
   [Mantyselka, Pekka; Vanhala, Mauno] Kuopio Univ Hosp, Unit Primary Hlth Care, SF-70210 Kuopio, Finland.
RP Hamalainen, P (reprint author), Tampere Univ Hosp, Dept Internal Med, Teiskontie 35, Tampere 33521, Finland.
EM Paivi.O.Hamalainen@uta.fi
CR Opara EC, 2004, J INVEST MED, V52, P19, DOI 10.2310/6650.2004.12362
   Moller DE, 2005, ANNU REV MED, V56, P45, DOI 10.1146/annurev.med.56.082103.104751
   Kang HT, 2012, CLIN CHIM ACTA, V413, P636, DOI 10.1016/j.cca.2011.12.011
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Park SK, 2012, DIABETES CARE, V35, P2521, DOI 10.2337/dc12-0543
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   Aregbesola A, 2013, EUR J ENDOCRINOL, V169, P247, DOI 10.1530/EJE-13-0145
   Yao DC, 2005, FREE RADICAL BIO MED, V39, P1385, DOI 10.1016/j.freeradbiomed.2005.07.015
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Yoo KD, 2012, CLIN ENDOCRINOL, V77, P233, DOI 10.1111/j.1365-2265.2011.04248.x
   Lee BK, 2011, METABOLISM, V60, P1416, DOI 10.1016/j.metabol.2011.02.008
   Montonen J, 2012, DIABETOLOGIA, V55, P2613, DOI 10.1007/s00125-012-2633-y
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Petersen KF, 2007, P NATL ACAD SCI USA, V104, P12587, DOI 10.1073/pnas.0705408104
   Rajpathak SN, 2009, DIABETES OBES METAB, V11, P472, DOI 10.1111/j.1463-1326.2008.00985.x
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Hotamisligil GS, 2000, INT J OBESITY, V24, pS23
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Winterbourn CC, 1995, TOXICOL LETT, V82-3, P969, DOI 10.1016/0378-4274(95)03532-X
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Merono T, 2011, EUR J CLIN INVEST, V41, P479, DOI 10.1111/j.1365-2362.2010.02429.x
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Ashraf AP, 2010, DIABETOLOGY METAB SY, V2
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   Gillum RF, 2001, INT J OBESITY, V25, P628, DOI 10.1038/sj.ijo.0801590
   Hamalainen P, 2012, CARDIOVASC DIABETOL, V11
   Houschyar KS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-54
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Martinelli N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048250
   Milnam N, 1996, INT J HEMATOL, V63, P103
   Ryoo JH, 2011, DIABETES-METAB RES, V27, P597, DOI 10.1002/dmrr.1211
   Salomaa V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010100
NR 39
TC 2
Z9 2
U1 2
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-5996
J9 DIABETOL METAB SYNDR
JI Diabetol. Metab. Syndr.
PD OCT 26
PY 2014
VL 6
AR 114
DI 10.1186/1758-5996-6-114
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AS9HY
UT WOS:000344555100001
PM 25371712
ER

PT J
AU Chang, JS
   Li, YL
   Lu, CH
   Owaga, E
   Chen, WY
   Chiou, HY
AF Chang, Jung-Su
   Li, Yu-Ling
   Lu, Chiou-Han
   Owaga, Eddy
   Chen, Wei-Yu
   Chiou, Hung-Yi
TI Interleukin-10 as a potential regulator of hepcidin homeostasis in
   overweight and obese children: A cross-sectional study in Taiwan
SO NUTRITION
LA English
DT Article
DE Hepcidin; IL-10; Iron deficiency; Obese children; Taiwan
ID IRON-DEFICIENCY; METABOLIC SYNDROME; SERUM FERRITIN; C/EBP-ALPHA;
   ADOLESCENTS; EXPRESSION; ANEMIA; TRANSCRIPTION; HEPATOCYTES; ASSOCIATION
AB Objective: A sharp increase in the prevalence of obesity and a decline in iron deficiency in children was observed between the two consecutive Nutrition and Health Surveys in Taiwan. The aim of this study was to evaluate the distribution of hepcidin in relation to nutritional status in children.
   Methods: 648 children ages 7 to 13 y living in Taipei and New Taipei City were enrolled in this study. Parameters for obesity, iron status, and inflammatory markers were evaluated.
   Results: There were no differences in the prevalence of iron deficiency and iron depletion between normal and overweight/obese children. A V-sharp hepcidin distribution curve was seen in normal weight children and overweight/obese boys. Serum hepcidin levels remained stable in overweight/obese girls during transition from childhood to teenager. Overweight/obese children had increased serum nitric oxide (NO) and interleukin (IL)-1 beta but decreased IL-10 concentration compared with normal weight children. A strong inverse relationship was found between IL-10 and body mass index (BMI; odds ratio (OR), 0.86, 95% confidence interval [CI], 0.83-0.89). By contrast, positive correlations were observed between BMI and IL-1 beta (OR, 1.60; 95% CI, 1.29-1.98); and between BMI and NO (OR, 1.04, 95% Cl, 1.02-1.07). Multivariate linear regression analysis showed serum hepcidin was significantly correlated with IL-10 (beta = 0.26, P < 0.0001).
   Conclusions: Our results raise the possibility that IL-10 may play a role in iron homeostasis. Decreased circulating IL-10 concentration may temporary protect young overweight/obese girls against the development of iron deficiency. However, long-term decrease in hepcidin concentration may increase the risk for iron overload in overweight/obese children. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Chang, Jung-Su; Lu, Chiou-Han; Owaga, Eddy] Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Nutr & Hlth Sci, Taipei, Taiwan.
   [Li, Yu-Ling; Chiou, Hung-Yi] Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Publ Hlth, Taipei, Taiwan.
   [Chen, Wei-Yu] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei, Taiwan.
   [Chen, Wei-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan.
RP Chiou, HY (reprint author), Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Publ Hlth, Taipei, Taiwan.
EM hychiou@tmu.edu.tw
FU Taipei Medical University [102 TMU-TMUH-16]; National Science Council
   Taiwan [NSC102-2320-B-038-013]
FX J-S Chang was supported by a grant from the Taipei Medical University
   (102 TMU-TMUH-16) and the National Science Council Taiwan
   (NSC102-2320-B-038-013). J-SC conceptualized and designed the study,
   drafted the initial manuscript, and approved the final manuscript as
   submitted. Y-LL supervised sample collection at four sites and carried
   out the initial analyses. EO contributed to the initiation of the
   project and supervision of recruitment. C-HL participated in the iron
   biochemistry analysis. W-YC contributed to the optimization of protocols
   and preparation and examination of cytokines measurements. H-YC
   critically reviewed the manuscript and approved the final manuscript as
   submitted. The authors have no financial relationships relevant to this
   article to disclose.
CR Miura K, 2008, HEPATOLOGY, V48, P1420, DOI 10.1002/hep.22486
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Lee P, 2004, P NATL ACAD SCI USA, V101, P9263, DOI 10.1073/pnas.0403108101
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Chang JS, 2013, ASIA PAC J CLIN NUTR, V22, P400, DOI 10.6133/apjcn.2013.22.3.07
   Goodnough JB, 2012, HEPATOLOGY, V56, P291, DOI 10.1002/hep.25615
   Troutt JS, 2012, CLIN CHEM, V58, P1225, DOI 10.1373/clinchem.2012.186866
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Tan CE, 2004, DIABETES CARE, V27, P1182, DOI 10.2337/diacare.27.5.1182
   [Anonymous], 2001, JAMA, V285, P2486
   Kemna EHJM, 2008, BLOOD CELL MOL DIS, V40, P339, DOI 10.1016/j.bcmd.2007.10.002
   Pinto JP, 2008, BLOOD, V111, P5727, DOI 10.1182/blood-2007-08-106195
   Shaw NS, 1996, J FORMOS MED ASSOC, V95, P692
   Arslan N, 2010, INDIAN PEDIATR, V47, P829, DOI 10.1007/s13312-010-0142-y
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   COOK JD, 1976, BLOOD, V48, P449
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Choi SO, 2007, BIOCHEM BIOPH RES CO, V356, P312, DOI 10.1016/j.bbrc.2007.02.137
   Pan WH, 2008, OBES REV, V9, P22, DOI 10.1111/j.1467-789X.2007.00434.x
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Chang JS, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-123
   Chang JS, 2014, PUBLIC HEALTH NUTR, V17, P1498, DOI 10.1017/S1368980013001596
   Gardenghi S, 2010, HEMATOL ONCOL CLIN N, V24, P1089, DOI 10.1016/j.hoc.2010.08.003
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   Wang L SN, IRON STATUS TAIWANES
NR 26
TC 1
Z9 1
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD OCT
PY 2014
VL 30
IS 10
BP 1165
EP 1170
DI 10.1016/j.nut.2014.02.021
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AP5KB
UT WOS:000342117000011
PM 25194615
ER

PT J
AU Augustine, LF
   Nair, KM
   Rao, SF
   Rao, MV
   Ravinder, P
   Balakrishna, N
   Laxmaiah, A
   Vazir, S
AF Augustine, Little Flower
   Nair, Krishnapillai Madhavan
   Rao, Sylvia Fernandez
   Rao, Mendu Vishnuvardhana
   Ravinder, Punjal
   Balakrishna, Nagalla
   Laxmaiah, Avula
   Vazir, Shahnaz
TI Adolescent Life-Event Stress in Boys Is Associated with Elevated IL-6
   and Hepcidin but Not Hypoferremia
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Article
DE hepcidin; adolescents; inflammation; India; path analysis; IL-6; iron;
   stress
ID C-REACTIVE PROTEIN; PSYCHOLOGICAL STRESS; IRON-DEFICIENCY; SKINFOLD
   THICKNESS; INTERLEUKIN-6; INFLAMMATION; FERRITIN; RECEPTOR; OBESITY;
   PLASMA
AB Objective: The link between stress-related increases in inflammatory markers, hepcidin, and iron status are poorly understood, especially in developing countries like India. The aim of the study was to examine the relationship between adolescent life-event stress (ALES), inflammatory markers, and its association with hepcidin and biomarkers of iron status among adolescent boys.
   Methods: Data pertaining to a subsample of 145 participants from a cross-sectional, school-based study recruiting 370 adolescent boys aged 15-19years, from 5 schools in Hyderabad, India, were analyzed. Stress was assessed using the ALES scale, psychological distress by the General Health Questionnaire-2 (GHQ-12), and approach and avoidance coping using the Coping Strategies Scale. Biomarkers of iron and concentrations of other micronutrients, hepcidin, IL-6 and C-reactive protein (CRP) in plasma were analyzed. Data were subjected to regression, path analyses, and analysis of covariance (ANCOVA).
   Results: ALES was a significant predictor of interleukin (IL)-6 (beta = 0.196, p = 0.012), CRP (beta = 0.217, p = 0.010), and log hepcidin (beta = 0.228, p = 0.006). Hepcidin correlated significantly (p < 0.001) with IL-6 (r = 0.344) and CRP (r = 0.370) but not with the biomarkers of iron status. Path analysis showed that the model had an acceptable fit, with a root mean square error of approximation of 0.019, 90% confidence interval (CI) of 0.00-0.074, comparative fit index of 0.988, chi-square p = 0.393, and chi-square/df of 1.053.
   Conclusions: Adolescent life-event stress is associated with elevated IL-6 and hepcidin concentration but not hypoferremia. These findings may help in iron supplementation programs for tackling anemia.
C1 [Augustine, Little Flower; Nair, Krishnapillai Madhavan; Ravinder, Punjal] Indian Council Med Res, Natl Inst Nutr, Div Micronutrient Res, Hyderabad 500007, Andhra Pradesh, India.
   [Nair, Krishnapillai Madhavan; Rao, Sylvia Fernandez; Rao, Mendu Vishnuvardhana; Balakrishna, Nagalla; Laxmaiah, Avula; Vazir, Shahnaz] Indian Council Med Res, Natl Inst Nutr, Hyderabad 500007, Andhra Pradesh, India.
RP Nair, KM (reprint author), Indian Council Med Res, Natl Inst Nutr, Hyderabad 500007, Andhra Pradesh, India.
EM nairthayil@gmail.com
FU University Grants Commission, New Delhi; Indian Council of Medical
   Research, New Delhi
FX The fellowship received by LFA from University Grants Commission, New
   Delhi, and the funding received from the Indian Council of Medical
   Research, New Delhi, is gratefully acknowledged.
CR Aggarwal Shilpa, 2007, Indian J Psychiatry, V49, P96, DOI 10.4103/0019-5545.33255
   Laxmaiah A, 2007, OBESITY, V15, P1384, DOI 10.1038/oby.2007.165
   Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100
   Morozink JA, 2010, HEALTH PSYCHOL, V29, P626, DOI 10.1037/a0021360
   Detivaud L, 2005, BLOOD, V106, P746, DOI 10.1182/blood-2004-12-4855
   Vanoaica L, 2010, CELL METAB, V12, P273, DOI 10.1016/j.cmet.2010.08.003
   Steptoe A, 2001, CLIN SCI, V101, P185, DOI 10.1042/CS20010038
   Wians FH, 2001, AM J CLIN PATHOL, V115, P112
   Ferrucci L, 2010, BLOOD, V115, P3810, DOI 10.1182/blood-2009-02-201087
   Cook DG, 2000, ATHEROSCLEROSIS, V149, P139, DOI 10.1016/S0021-9150(99)00312-3
   ZANNONI V, 1974, BIOCHEM MED METAB B, V11, P41, DOI 10.1016/0006-2944(74)90093-3
   Augustine LF, 2011, INDIAN J MED RES, V134, P61
   Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0
   Warnberg J, 2007, BRIT J NUTR, V98, pS116, DOI 10.1017/S0007114507839614
   Hohaus S, 2010, J CLIN ONCOL, V28, P2538, DOI 10.1200/JCO.2009.27.6873
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   Zhao M, 2008, BIOCHEM BIOPH RES CO, V373, P90, DOI 10.1016/j.bbrc.2008.05.166
   Shariatpanaahi MV, 2007, EUR J CLIN NUTR, V61, P532, DOI 10.1038/sj.ejcn.1602542
   Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028
   Sharma S, 2008, CLIN CANCER RES, V14, P3262, DOI 10.1158/1078-0432.CCR-07-4153
   Shah YM, 2009, CELL METAB, V9, P152, DOI 10.1016/j.cmet.2008.12.012
   McCann JC, 2007, AM J CLIN NUTR, V85, P931
   Jones SA, 1999, J EXP MED, V189, P599, DOI 10.1084/jem.189.3.599
   Nair KM, 2009, INDIAN J MED RES, V130, P634
   BIERI JG, 1979, AM J CLIN NUTR, V32, P2143
   Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3
   YOUNG DS, 1987, ANN INTERN MED, V106, P114
   Wei CL, 2008, INT J HEMATOL, V88, P52, DOI 10.1007/s12185-008-0105-4
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   DURNIN JVG, 1967, BRIT J NUTR, V21, P681, DOI 10.1079/BJN19670070
   Romeo RD, 2006, ANN NY ACAD SCI, V1094, P202, DOI 10.1196/annals.1376.022
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Cohen S, 1999, PSYCHOSOM MED, V61, P175
   Rangan AM, 1998, J AM COLL NUTR, V17, P351
   Arun Priti, 2009, Indian J Med Sci, V63, P281, DOI 10.4103/0019-5359.55112
   Bandyopadhyay G, 1988, Int J Soc Psychiatry, V34, P130, DOI 10.1177/002076408803400207
   Bansal Vivek, 2009, Ind Psychiatry J, V18, P43, DOI 10.4103/0972-6748.57859
   Chen JB, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-83
   Cherian S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004030
   Craig J, 2007, OCCUPATIONAL MED, V57, P79
   Goldberg D. P., 1988, USERS GUIDE GEN HLTH
   HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4
   International Institute for Population Sciences and Macro International, 2007, NAT FAM HLTH SURV NF
   International Institute for Population Sciences and ORC Macro, 2000, NAT FAM HLTH SURV NF
   International Nutritional Anemia Consultative Group, 1985, MEAS IR STAT REP INA
   Mohan Viswanathan, 2010, J Diabetes Sci Technol, V4, P158
   PAWASHE AB, 1987, CLIN CHIM ACTA, V163, P119, DOI 10.1016/0009-8981(87)90041-6
   Siri W., 1961, TECHNIQUES MEASURING, P223
   Srivastava AK, 2001, MANUAL COPING STRATE
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   WHO, 2008, FOOD NUTR BULL, V29, pS238
   World Health Organisation, 2008, WAIST CIRC WAIST HIP
NR 52
TC 0
Z9 0
U1 1
U2 5
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0731-5724
EI 1541-1087
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD SEP 3
PY 2014
VL 33
IS 5
BP 354
EP 362
DI 10.1080/07315724.2013.875417
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AS6TS
UT WOS:000344395700002
PM 25302670
ER

PT J
AU Guzman, MA
   Olguin, MA
AF Andrews Guzman, Monica
   Arredondo Olguin, Miguel
TI Association between ferritin, high sensitivity c-reactive protein
   (hsCRP) and relative abundance of Hepcidin mRNA with the risk of type 2
   diabetes in obese subjects
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Inflammatory cytokines; Iron; Hepcidin; Ferritin; Obesity
ID INSULIN-RESISTANCE; OXIDATIVE STRESS; IRON STORES; ANTIOXIDANT STATUS;
   METABOLIC SYNDROME; GLUCOSE REGULATION; BODY IRON; IN-VIVO;
   INFLAMMATION; INTERLEUKIN-6
AB Obesity and Type 2 diabetes mellitus share a strong pro-inflammatory profile. It has been observed that iron is a risk factor in the development of type 2 diabetes. The aim of this study was to evaluate the relationship between iron nutritional status and inflammation with the risk of type 2 diabetes development in obese subjects. We studied 30 obese men with type 2 diabetes (OBDM); 30 obese subjects without diabetes (OB) and 30 healthy subjects (Cu). We isolated peripheral mononuclear cells (PMCs) and challenged them with high Fe concentrations. Total mRNA was isolated and relative abundance of TNF-alpha, IL-6 and hepcidin were determined by qPCR. Iron status, biochemical, inflammatory and oxidative stress parameters were also characterized. OBDM and OB patients showed increased hsCRP levels compared to the Cn group. OBDM subjects showed higher levels of ferritin than the Cu group. TNF-alpha and IL-6 mRNA relative abundances were increased in OBDM PMCs treated with high/Fe. Hepcidin mRNA was increased with basal and high iron concentration. We found that the highest quartile of ferritin was associated with an increased risk of type 2 diabetes when it was adjusted to BMI and HOMA-IR; this association was independent of the inflammatory status. The highest level of hepcidin gene expression also showed a trend of increased risk of diabetes, however it was not significant. Levels of hsCRP over 2 mg/L showed a significant trend of increasing the risk of diabetes. In conclusion, iron may stimulate the expression of pro-inflammatory genes (TNF-alpha and IL-6), and both hepcidin and ferritin gene expression levels could be a risk factor for the development of type 2 diabetes. Subjects that have an increased cardiovascular risk also have a major risk to develop type 2 diabetes, which is independent of the BMI and insulin resistance state.
C1 [Andrews Guzman, Monica; Arredondo Olguin, Miguel] Univ Chile, INTA, Lab Micronutriente, Santiago, Chile.
RP Guzman, MA (reprint author), Univ Chile, Inst INTA, El Libano 5524, Santiago, Chile.
EM monica.andrews@gmail.com
FU Diabetes and Endocrinology Society of Chile (SOCHED); FONDECYT [1085173,
   1110080]
FX This research was supported by the Diabetes and Endocrinology Society of
   Chile (SOCHED) and FONDECYT No 1085173 and 1110080.
CR Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Atli T, 2004, ARCH GERONTOL GERIAT, V39, P269, DOI 10.1016/j.archger.2004.04.065
   Zhang XL, 2010, BBA-GEN SUBJECTS, V1800, P1262, DOI 10.1016/j.bbagen.2010.08.005
   Ganz T, 2011, ANNU REV MED, V62, P347, DOI [10.1146/annurev-med-050109-142444, 10.1146/annurev-rned-050109-142444]
   Swaminathan S, 2007, DIABETES CARE, V30, P1926, DOI 10.2337/dc06-2625
   Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822
   Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167
   Fernandez-Real JM, 2009, J CLIN ENDOCR METAB, V94, P982, DOI 10.1210/jc.2008-1211
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Song FF, 2007, CLIN SCI, V112, P599, DOI 10.1042/CS20060323
   You SA, 2005, CLIN CHIM ACTA, V357, P1, DOI 10.1016/j.cccn.2005.02.001
   Jiang F, 2011, DIABETES RES CLIN PR, V93, P43, DOI 10.1016/j.diabres.2011.03.028
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Salonen JT, 1998, BRIT MED J, V317, P727
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Torisu T, 2007, GENES CELLS, V12, P143, DOI 10.1111/j.1365-2443.2007.01044.x
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Jehn ML, 2007, AM J EPIDEMIOL, V165, P1047, DOI 10.1093/aje/kwk093
   Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200
   Sabio G, 2008, SCIENCE, V322, P1539, DOI 10.1126/science.1160794
   Jomova K, 2010, MOL CELL BIOCHEM, V345, P91, DOI 10.1007/s11010-010-0563-x
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Yeh ETH, 2005, CLIN CARDIOL, V28, P408, DOI 10.1002/clc.4960280905
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Buyukkocak S, 2000, J ENDOCRINOL INVEST, V23, P228
   Dasu M. R., 2010, AM J PHYSIOL-ENDOC M, V300, pE145, DOI 10.1152/ajpendo.00490.2010
   Fleming RE, 2008, J MOL MED-JMM, V86, P491, DOI 10.1007/s00109-008-0349-8
   Halliwell B., 2001, DRUGS AGING, V18, P865
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Pearson TA, 2003, CIRCULATION, V107, P449
   Pinto JP, 2010, IMMUNOLOGY, V130, P217, DOI 10.1111/j.1365-2567.2009.03226.x
   STITH RD, 1994, CIRC SHOCK, V44, P210
   Zafon C, 2009, OBES REV, V11, P322
NR 38
TC 0
Z9 0
U1 0
U2 10
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD SEP
PY 2014
VL 30
IS 3
BP 577
EP 584
DI 10.3305/nh.2014.30.3.7647
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AQ7AC
UT WOS:000342964000015
ER

PT J
AU Aigner, E
   Feldman, A
   Datz, C
AF Aigner, Elmar
   Feldman, Alexandra
   Datz, Christian
TI Obesity as an Emerging Risk Factor for Iron Deficiency
SO NUTRIENTS
LA English
DT Review
DE iron deficiency; obesity; insulin resistance; hepcidin
ID Y GASTRIC BYPASS; FATTY LIVER-DISEASE; BARIATRIC SURGERY;
   ADIPOSE-TISSUE; WEIGHT-LOSS; SERUM HEPCIDIN; OVERWEIGHT CHILDREN; SLEEVE
   GASTRECTOMY; NUTRITIONAL-STATUS; METABOLIC SYNDROME
AB Iron homeostasis is affected by obesity and obesity-related insulin resistance in a many-facetted fashion. On one hand, iron deficiency and anemia are frequent findings in subjects with progressed stages of obesity. This phenomenon has been well studied in obese adolescents, women and subjects undergoing bariatric surgery. On the other hand, hyperferritinemia with normal or mildly elevated transferrin saturation is observed in approximately one-third of patients with metabolic syndrome (MetS) or nonalcoholic fatty liver disease (NAFLD). This constellation has been named the dysmetabolic iron overload syndrome (DIOS). Both elevated body iron stores and iron deficiency are detrimental to health and to the course of obesity-related conditions. Iron deficiency and anemia may impair mitochondrial and cellular energy homeostasis and further increase inactivity and fatigue of obese subjects. Obesity-associated inflammation is tightly linked to iron deficiency and involves impaired duodenal iron absorption associated with low expression of duodenal ferroportin (FPN) along with elevated hepcidin concentrations. This review summarizes the current understanding of the dysregulation of iron homeostasis in obesity.
C1 [Aigner, Elmar; Feldman, Alexandra] Paracelsus Med Univ, Dept Med 1, A-5020 Salzburg, Austria.
   [Aigner, Elmar; Datz, Christian] Paracelsus Med Univ, Obes Res Unit, A-5020 Salzburg, Austria.
   [Datz, Christian] Gen Hosp, Dept Internal Med, A-5110 Oberndorf, Austria.
RP Aigner, E (reprint author), Paracelsus Med Univ, Dept Med 1, Mullner Hauptstr 48, A-5020 Salzburg, Austria.
EM e.aigner@salk.at; a.feldman@salk.at; c.datz@kh-obdf.salzburg.at
FU PMU-Forschungsforderungsfonds [E-13/17/086-AIG]; SPAR Austria
FX Elmar Aigner is supported by PMU-Forschungsforderungsfonds
   (E-13/17/086-AIG). Support from SPAR Austria to Christian Datz is
   gratefully acknowledged.
CR Aktas G, 2014, Clin Ter, V165, pe87, DOI 10.7471/CT.2014.1688
   Ernst B, 2009, OBES SURG, V19, P66, DOI 10.1007/s11695-008-9545-4
   Shander A, 2012, BRIT J ANAESTH, V109, P55, DOI 10.1093/bja/aes139
   Baptista V, 2013, CURR OPIN GASTROEN, V29, P684, DOI 10.1097/MOG.0b013e3283651af2
   Gesquiere I, 2014, OBES SURG, V24, P56, DOI 10.1007/s11695-013-1042-8
   Manios Y, 2013, J HUM NUTR DIET, V26, P470, DOI 10.1111/jhn.12025
   Noto H, 2013, J DIABETES INVEST, V4, P225, DOI 10.1111/jdi.12068
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Santos J, 2014, SCAND J SURG, V103, P21, DOI 10.1177/1457496913490467
   Lefebvre P, 2014, SURG OBES RELAT DIS, V10, P540, DOI 10.1016/j.soard.2013.10.003
   Flancbaum L, 2006, J GASTROINTEST SURG, V10, P1033, DOI 10.1016/j.gassur.2006.03.004
   Vulpe CD, 1999, NAT GENET, V21, P195
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Mechanick JI, 2013, OBESITY, V21, pS1, DOI 10.1002/oby.20461
   Ramalho R, 2009, OBES SURG, V19, P915, DOI 10.1007/s11695-009-9848-0
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Fried M, 2014, OBES SURG, V24, P42, DOI 10.1007/s11695-013-1079-8
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Ozata M, 2002, CLIN BIOCHEM, V35, P627, DOI 10.1016/S0009-9120(02)00363-6
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Ruz M, 2012, AM J CLIN NUTR, V96, P810, DOI 10.3945/ajcn.112.039255
   Patel SRH, 2013, SURG OBES RELAT DIS, V9, P482, DOI 10.1016/j.soard.2013.01.015
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   Ganz T, 2009, SEMIN HEMATOL, V46, P387, DOI 10.1053/j.seminhematol.2009.06.001
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Munoz M, 2009, NUTR HOSP, V24, P640, DOI 10.3305/nh.2009.24.6.4547
   Mujica-Coopman MF, 2015, J TRACE ELEM MED BIO, V30, P215, DOI 10.1016/j.jtemb.2014.03.008
   Datz C, 2013, EUR J CLIN INVEST, V43, P215, DOI 10.1111/eci.12032
   Aigner E, 2010, EUR J CLIN INVEST, V40, P155, DOI 10.1111/j.1365-2362.2009.02238.x
   Lear SA, 2014, CAN MED ASSOC J, V186, P258, DOI 10.1503/cmaj.131090
   Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028
   Gong LY, 2014, J PEDIATR-US, V164, P795, DOI 10.1016/j.jpeds.2013.12.004
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Cusi K, 2010, CURR DIABETES REP, V10, P306, DOI 10.1007/s11892-010-0122-6
   DePaoli AM, 2014, J ENDOCRINOL, V223, pT71, DOI 10.1530/JOE-14-0258
   Gehrer S, 2010, OBES SURG, V20, P447, DOI 10.1007/s11695-009-0068-4
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Barisani D, 2008, J HEPATOL, V49, P123, DOI 10.1016/j.jhep.2008.03.011
   Damms-Machado A, 2012, OBES SURG, V22, P881, DOI 10.1007/s11695-012-0609-0
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   Ruivard M, 2009, J HEPATOL, V50, P1219, DOI 10.1016/j.jhep.2009.01.029
   WENZEL BJ, 1962, LANCET, V2, P327
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Low S, 2009, ANN ACAD MED SINGAP, V38, P57
   Alexandrou A, 2014, SURG OBES RELAT DIS, V10, P262, DOI 10.1016/j.soard.2013.07.014
   Schwenger KJP, 2014, WORLD J GASTROENTERO, V20, P1712, DOI 10.3748/wjg.v20.i7.1712
   Aigner E, 2008, GASTROENTEROLOGY, V135, P680, DOI 10.1053/j.gastro.2008.04.007
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008
   Kulaksiz H, 2008, J ENDOCRINOL, V197, P241, DOI 10.1677/JOE-07-0528
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   Beard J, 1997, AM J CLIN NUTR, V66, P104
   Coupaye M, 2009, OBES SURG, V19, P56, DOI 10.1007/s11695-008-9571-2
   DiToro A, 1997, BIOL TRACE ELEM RES, V57, P97
   Flehmig G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099785
   Hallet J, 2014, TRANSFUS MED REV, V28, P205, DOI 10.1016/j.tmrv.2014.05.004
   HARJU E, 1988, JPEN-PARENTER ENTER, V12, P282, DOI 10.1177/0148607188012003282
   Korolnek T, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00126
   Marambio A, 2014, WORLD J GASTROENTERO, V20, P6534, DOI 10.3748/wjg.v20.i21.6534
   Matak P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059538
   Mather KJ, 2014, BEST PRACT RES CL EN, V28, P107, DOI 10.1016/j.beem.2013.06.008
   Myint PK, 2014, HEART, V100, P1613, DOI 10.1136/heartjnl-2014-305816
   Nairz M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00152
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   Shi ZM, 2005, J ADOLESCENT HEALTH, V37, P313, DOI 10.1016/j.jadohealth.2004.10.013
   Skroubis G, 2014, OBES SURG, V24, P197, DOI 10.1007/s11695-013-1081-1
   Sonnweber T, 2012, J NUTR BIOCHEM, V23, P1600, DOI 10.1016/j.jnutbio.2011.10.013
   Tussing-Humphreys L, 2011, THESCIENTIFICWORLDJO, V11, P2197, DOI 10.1100/2011/634861
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   Wu Lindsay E, 2014, Mol Metab, V3, P465, DOI 10.1016/j.molmet.2014.02.005
NR 80
TC 11
Z9 12
U1 5
U2 21
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD SEP
PY 2014
VL 6
IS 9
BP 3587
EP 3600
DI 10.3390/nu6093587
PG 14
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AQ6EW
UT WOS:000342903700013
PM 25215659
ER

PT J
AU Chang, JS
   Chen, YC
   Owaga, E
   Palupi, KC
   Pan, WH
   Bai, CH
AF Chang, Jung-Su
   Chen, Yi-Chun
   Owaga, Eddy
   Palupi, Khairizka Citra
   Pan, Wen-Harn
   Bai, Chyi-Huey
TI Interactive Effects of Dietary Fat/Carbohydrate Ratio and Body Mass
   Index on Iron Deficiency Anemia among Taiwanese Women
SO NUTRIENTS
LA English
DT Article
DE iron deficiency anemia; dietary fat and carbohydrate; overweight and
   obesity; Taiwanese female
ID METABOLIC SYNDROME; REPRODUCTIVE AGE; OBESE CHILDREN; SERUM FERRITIN;
   UNITED-STATES; HIGH-FAT; OVERWEIGHT; HEPCIDIN; ADULTS; HYPOFERREMIA
AB Whether being overweight or obese is associated with increased risk of iron deficiency anemia (IDA) remains controversial. We evaluated the dietary intakes and risk for IDA in relation to body mass index (BMI). One thousand two hundred and seventy-four females aged 19 years, enrolled in the third Nutrition and Health Survey in Taiwan (NAHSIT) 2005-2008, were selected. Half of the women were either overweight (24.0%) or obese (25.3%). The overall prevalence of anemia, iron deficiency and IDA among adult women was 19.5%, 8.6% and 6.2%. BMI showed a protective effect on IDA: overweight (odds ratio, OR: 0.365 (0.181-0.736)) and obese (OR: 0.480 (0.259-0.891)) when compared with normal weight. Univariate analysis identified increased IDA risk for overweight/obese women who consumed higher dietary fat but lower carbohydrate (CHO) (OR: 10.119 (1.267-80.79)). No such relationship was found in IDA women with normal weight (OR: 0.375 (0.036-4.022)). Analysis of interaction(s) showed individuals within the highest BMI tertile (T3) had the lowest risk for IDA and the risk increased with increasing tertile groups of fat/CHO ratio; OR 0.381 (0.144-1.008; p = 0.051), 0.370 (0.133-1.026; p = 0.056) and 0.748 (0.314-1.783; p = 0.513); for T1, T2 and T3, respectively. In conclusion, a protective effect of BMI on IDA may be attenuated in women who had increased fat/CHO ratio.
C1 [Chang, Jung-Su; Chen, Yi-Chun; Palupi, Khairizka Citra] Taipei Med Univ, Coll Publ Hlth & Nutr, Sch Nutr & Hlth Sci, Taipei 110, Taiwan.
   [Owaga, Eddy] Dedan Kimathi Univ Technol, Inst Food & Bioresources Technol, Nyeri 10100, Kenya.
   [Pan, Wen-Harn] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
   [Bai, Chyi-Huey] Taipei Med Univ, Coll Med, Dept Publ Hlth, Taipei 110, Taiwan.
RP Bai, CH (reprint author), Taipei Med Univ, Coll Med, Dept Publ Hlth, 250 Wu Hsing St, Taipei 110, Taiwan.
EM susanchang@tmu.edu.tw; yichun@tmu.edu.tw; eowaga@yahoo.co.uk;
   khairizka.citra@gmail.com; pan@ibms.sinica.edu.tw; baich@tmu.edu.tw
FU Department of Health in Taiwan [DOH94-FS-6-4];  [102TMU-TMUH-16]; 
   [NSC102-2320-B-038-013];  [MOST 103-2314-B-038-033-MY3]
FX We express our sincere appreciation to the study participants. We also
   thank staff from the Research Center for Humanities and Social Sciences,
   Center for Survey Research, Academia Sinica, and directors of Wen-Han
   Pan and Su-Hao Tu. Data analyzed in this paper were obtained from "The
   Third Nutrition and Health Survey in Taiwan (NAHSIT 2005-2008, Adults)",
   which was sponsored by the Department of Health in Taiwan
   (DOH94-FS-6-4). Jung-Su Chang was supported by grant 102TMU-TMUH-16 and
   NSC102-2320-B-038-013. Chyi-Huey Bai was supported by grant MOST
   103-2314-B-038-033-MY3.
CR Karl JP, 2009, J AM COLL NUTR, V28, P37
   Goris AHC, 2000, AM J CLIN NUTR, V71, P130
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Neymotin F, 2011, OBESITY, V19, P191, DOI 10.1038/oby.2010.112
   Wu SJ, 2011, ASIA PAC J CLIN NUTR, V20, P251
   Chang JS, 2013, ASIA PAC J CLIN NUTR, V22, P400, DOI 10.6133/apjcn.2013.22.3.07
   Markovic TP, 2009, MED J AUSTRALIA, V190, P149
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Eckhardt CL, 2008, EUR J CLIN NUTR, V62, P238, DOI 10.1038/sj.ejcn.1602727
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Kordas K, 2013, J NUTR, V143, P175, DOI 10.3945/jn.112.167767
   Tan CE, 2004, DIABETES CARE, V27, P1182, DOI 10.2337/diacare.27.5.1182
   [Anonymous], 2001, JAMA, V285, P2486
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Fanou-Fogny N, 2011, BRIT J NUTR, V105, P574, DOI 10.1017/S0007114510003776
   Tsuchiya H, 2013, METABOLISM, V62, P62, DOI 10.1016/j.metabol.2012.06.008
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Pan WH, 2011, ASIA PAC J CLIN NUTR, V20, P238
   Pan WH, 2008, OBES REV, V9, P22, DOI 10.1111/j.1467-789X.2007.00434.x
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Andrews NC, 2004, J CLIN INVEST, V113, P1251, DOI 10.1172/JCI200421441
   Kozai D, 2014, MOL PHARMACOL, V85, P175, DOI 10.1124/mol.113.088864
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Chang JS, 2014, PUBLIC HEALTH NUTR, V17, P1498, DOI 10.1017/S1368980013001596
   Chung J, 2011, NUTR RES, V31, P915, DOI 10.1016/j.nutres.2011.09.014
   deGonzague B, 1999, J AM DIET ASSOC, V99, P710, DOI 10.1016/S0002-8223(99)00170-4
   Gartner A, 2014, J NUTR, V144, P87, DOI 10.3945/jn.113.178285
   Jackson KA, 2008, EUR J CLIN NUTR, V62, P537, DOI 10.1038/sj.ejcn.1602740
   Sonnweber T, 2012, J NUTR BIOCHEM, V23, P1600, DOI 10.1016/j.jnutbio.2011.10.013
   World Hhealth Organization, 2000, THW AS PAC PERS RED
NR 34
TC 1
Z9 1
U1 1
U2 6
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD SEP
PY 2014
VL 6
IS 9
BP 3929
EP 3941
DI 10.3390/nu6093929
PG 13
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AQ6EW
UT WOS:000342903700032
PM 25255383
ER

PT J
AU Lander, RL
   Bailey, KB
   Lander, AG
   Alsaleh, AA
   Costa-Ribeiro, HC
   Mattos, AP
   Barreto, DL
   Houghton, LA
   Morison, IM
   Williams, SM
   Gibson, RS
AF Lander, Rebecca L.
   Bailey, Karl B.
   Lander, Alastair G.
   Alsaleh, Abdulmonem A.
   Costa-Ribeiro, Hugo C.
   Mattos, Angela P.
   Barreto, Danile L.
   Houghton, Lisa A.
   Morison, Ian M.
   Williams, Sheila M.
   Gibson, Rosalind S.
TI Disadvantaged pre-schoolers attending day care in Salvador, Northeast
   Brazil have a low prevalence of anaemia and micronutrient deficiencies
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Anaemia; Micronutrient deficiencies; Predictors; Pre-schoolers;
   Disadvantaged; Northeast Brazil
ID NUTRITION EXAMINATION SURVEY; SERUM ZINC CONCENTRATIONS;
   IRON-DEFICIENCY; SUBCLINICAL INFLAMMATION; NATIONAL-HEALTH;
   UNITED-STATES; RISK-FACTORS; FOLIC-ACID; CHILDREN; PLASMA
AB Objective: To examine the micronutrient status of disadvantaged pre-schoolers from Northeast Brazil, following the introduction of pro-poor policies, by assessing the prevalence of anaemia and micronutrient deficiencies and the role of sociodemographic factors, genetic Hb disorders and parasitic infections.
   Design: In a cross-sectional study, data on sociodemographic status, health, growth, genetic Hb disorders, parasites and nutrient supply from day-care meals were obtained. Fasting blood samples were collected and analysed for Hb, serum ferritin, transferrin receptor, folate, vitamin B-12, retinol, Zn and Se.
   Setting: Seven philanthropic day-care centres serving urban slums in Salvador, Northeast Brazil.
   Subjects: Pre-schoolers aged 3-6 years from disadvantaged households.
   Results: Of the 376 sampled children, 94% were of black or mixed race; 33% and 29% had at least one genetic Hb disorder and intestinal parasite, respectively. Stunting and underweight were <= 5%; 14% were overweight. Day-care centres supplied micronutrient-dense meals and snacks each weekday. Less than 10% of pre-schoolers had anaemia and micronutrient deficiencies. Predictors (P<0.05) of Hb were a 3.7 thalassaemia, Se and retinol (but not ferritin). Micronutrient predictors (P<0.05) were: elevated alpha(1)-glycoprotein for ferritin, Hb AS and BMI Z-score >1 for transferrin receptor, Zn and elevated alpha(1)-glycoprotein for retinol, sex and helminths for Se, helminths for vitamin B-12, and Giardia intestinalis infection for serum folate.
   Conclusions: Impaired growth, anaemia and micronutrient deficiencies were uncommon among these disadvantaged pre-schoolers attending day care. A range of interventions including provision of micronutrient-dense, fortified day-care meals, deworming and vitamin A supplementation likely contributed to improved micronutrient status, suggesting expanded coverage of these programmes.
C1 [Lander, Rebecca L.; Bailey, Karl B.; Lander, Alastair G.; Houghton, Lisa A.; Gibson, Rosalind S.] Univ Otago, Dept Human Nutr, Dunedin, New Zealand.
   [Alsaleh, Abdulmonem A.; Morison, Ian M.] Univ Otago, Dept Pathol, Dunedin, New Zealand.
   [Costa-Ribeiro, Hugo C.; Mattos, Angela P.; Barreto, Danile L.] Hosp Univ Prof Edgard Santos, Fima Lifshitz Res Unit, Salvador, BA, Brazil.
   [Williams, Sheila M.] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand.
RP Gibson, RS (reprint author), Univ Otago, Dept Human Nutr, POB 56, Dunedin, New Zealand.
EM rosalind.gibson@otago.ac.nz
RI Houghton, Lisa/F-5305-2011; Morison, Ian/A-1236-2008
OI Houghton, Lisa/0000-0002-2276-6205; Morison, Ian/0000-0003-3616-0025
FU University of Otago
FX Sources of funding: The work was funded in part by the University of
   Otago Research Fund, but the Board administering the Fund had no role in
   the design of the study, the data analysis or the writing of this
   article.
CR ALLEN LH, 1995, AM J CLIN NUTR, V62, P1013
   Alsaleh A, 2011, THESIS U OTAGO
   Thurnham DI, 2003, LANCET, V362, P2052, DOI 10.1016/S0140-6736(03)15099-4
   Zemel BS, 2002, AM J CLIN NUTR, V75, P300
   Fung EB, 2010, ANN NY ACAD SCI, V1202, P188, DOI 10.1111/j.1749-6632.2010.05578.x
   Antunes MML, 2010, CAD SAUDE PUBLICA, V26, P1642, DOI 10.1590/S0102-311X2010000800017
   Tan ASC, 2001, BLOOD, V98, P250, DOI 10.1182/blood.V98.1.250
   Ballew C, 2001, AM J CLIN NUTR, V73, P586
   Troen AM, 2006, J NUTR, V136, P189
   Fishman SM, 2000, PUBLIC HEALTH NUTR, V3, P125, DOI 10.1017/S1368980000000173
   Hotz C, 2003, AM J CLIN NUTR, V78, P756
   Lander RL, 2012, CAD SAUDE PUBLICA, V28, P2177, DOI 10.1590/S0102-311X2012001100017
   Mostert V, 2003, FEBS LETT, V541, P85, DOI 10.1016/S0014-5793(03)00309-0
   Pfeiffer CM, 2007, AM J CLIN NUTR, V86, P718
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   Nagababu E, 2003, BBA-GEN SUBJECTS, V1620, P211, DOI 10.1016/S0304-4165(02)00537-8
   Thurnham DI, 2005, P NUTR SOC, V64, P502, DOI 10.1079/PNS2005468
   Thomson CD, 2004, EUR J CLIN NUTR, V58, P391, DOI 10.1038/sj.ejcn.1601800
   Assuncao MCF, 2012, PUBLIC HEALTH NUTR, V15, P1796, DOI 10.1017/S1368980012003047
   Barreto ML, 2010, ENVIRON HEALTH PERSP, V118, P1637, DOI 10.1289/ehp.1002058
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   SMITH JC, 1979, CLIN CHEM, V25, P1487
   SOLOMONS NW, 1993, PARASITOLOGY, V107, pS19
   Prado MS, 2003, EPIDEMIOL INFECT, V131, P899, DOI 10.1017/S0950268803001018
   Molloy AM, 1997, METHOD ENZYMOL, V281, P43
   Assis Ana Marlúcia O, 2004, Cad Saude Publica, V20, P1633, DOI 10.1590/S0102-311X2004000600022
   Bain BJ, 2006, HAEMOGLOBINOPATHY DIAGNOSIS, 2ND EDITION, P1, DOI 10.1002/9780470988787
   Brazil Ministry of Health, 2007, DEF MICR CAD AT BAS
   COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63
   de Benoist Bruno, 2008, Food Nutr Bull, V29, pS238
   de Pee S, 2002, J NUTR S9, V132, P2895
   dos Reis JC, 2007, DIGEST DIS SCI, V52, P1253, DOI 10.1007/s10620-006-9288-9
   Gibson R., 2005, PRINCIPLES NUTR ASSE
   Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4
   INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATISTICA, 2010, CENS 2010
   Issler RMS, 1996, REV SAUDE PUBL, V30, P506, DOI 10.1590/S0034-89101996000600003
   JACOBSON BE, 1988, CLIN CHEM, V34, P709
   Jordão Regina Esteves, 2009, Rev. paul. pediatr., V27, P90, DOI 10.1590/S0103-05822009000100014
   Khademi R, 2006, IRAN J PARASITOL, V1, P47
   Lander R, 2012, THESIS U OTAGO
   Martins MC, 2004, REV SAUDE PUBL, V38, P537, DOI [10.1590/S0034-89102004000400009, 10.1590/s0034-89102004000400009]
   Muller N, 2005, INT J PARASITOL, V35, P1339, DOI 10.1016/j.ijpara.2005.07.008
   Munoz EC, 2000, AM J CLIN NUTR, V71, P789
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   Paiva Adriana de Azevedo, 2006, Cad. Saúde Pública, V22, P1979
   Smith AD, 2010, AM J CLIN NUTR, V91, P1408, DOI 10.3945/ajcn.2010.29238
   Sousa MC, 2001, CLIN DIAGN LAB IMMUN, V8, P258, DOI 10.1128/CDLI.8.2.258-265.2001
   TAMURA T, 1994, BIOL TRACE ELEM RES, V41, P165, DOI 10.1007/BF02917226
   The United Nations Children's Fund (UNICEF), 2012, CHILDR URB WORLD STA
   Thurlow RA, 2005, AM J CLIN NUTR, V82, P380
   THURNHAM DI, 1988, CLIN CHEM, V34, P377
   Vieira ACF, 2007, J PEDIAT, V83, P370, DOI [10.2223/JPED.1680, 10.1590/S0021-75572007000500014]
   WHO, 2001, IR DEF AN ASS PREV C
   WHO Multicentre Growth Reference Study Group, 2006, ACTA PAEDIATR, V450, P76, DOI DOI 10.1080/08035320500495548
   World Health Organization/Centers for Disease Control and Prevention, 2007, ASS IR STAT POP
NR 55
TC 0
Z9 0
U1 0
U2 11
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD SEP
PY 2014
VL 17
IS 9
BP 1984
EP 1992
DI 10.1017/S1368980013002310
PG 9
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA AM8YY
UT WOS:000340166800010
PM 24008015
ER

PT J
AU Maitland, RA
   Seed, PT
   Briley, AL
   Homsy, M
   Thomas, S
   Pasupathy, D
   Robson, SC
   Nelson, SM
   Sattar, N
   Poston, L
AF Maitland, R. A.
   Seed, P. T.
   Briley, A. L.
   Homsy, M.
   Thomas, S.
   Pasupathy, D.
   Robson, S. C.
   Nelson, S. M.
   Sattar, N.
   Poston, L.
CA UPBEAT Trial Consortium
TI Prediction of gestational diabetes in obese pregnant women from the UK
   Pregnancies Better Eating and Activity (UPBEAT) pilot trial
SO DIABETIC MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; RISK-FACTORS; INFLAMMATORY MEDIATORS;
   ADIPONECTIN LEVELS; MATERNAL OBESITY; MELLITUS; GLUCOSE; WEIGHT;
   OVERWEIGHT; OUTCOMES
AB Aim To examine the prediction of gestational diabetes in obese women using routine clinical measures and measurement of biomarkers related to insulin resistance in the early second trimester.
   Methods A total of 117 obese pregnant women participating in a pilot trial of a complex intervention of dietary advice and physical activity were studied. Blood samples were obtained at recruitment (15(+0)-17(+6) weeks' gestation) and demographic, clinical history and anthropometric measures recorded. The biomarkers analysed were plasma lipids (HDL cholesterol, LDL cholesterol, triglycerides), high-sensitivity C-reactive protein, alanine transaminase, aspartate transaminase, ferritin, fructosamine, insulin, adiponectin, tissue plasminogen activator, interleukin-6, visfatin and leptin. Univariate and logistic regression analyses were performed to determine independent predictors and area under the receiver-operating curve was calculated for the model.
   Results Of the 106 participants included in the analysis, 29 (27.4%) developed gestational diabetes. Participants with gestational diabetes were older (P = 0.002), more often of parity >= 2, had higher systolic (P = 0.02) and diastolic blood pressure (P = 0.02) and were more likely to be black (P = 0.009). Amongst the blood biomarkers measured, plasma adiponectin alone remained independently associated with gestational diabetes in adjusted models (P = 0.002). The area under the receiver-operating curve for clinical factors alone (0.760) increased significantly (area under the curve 0.834, chi-square statistic (1) = 4.00, P = 0.046) with the addition of adiponectin.
   Conclusions A combination of routinely measured clinical factors and adiponectin measured in the early second trimester in obese women may provide a useful approach to the prediction of gestational diabetes. Validation in a large prospective study is required to determine the usefulness of this algorithm in clinical practice. (Clinical Trial Registry No: ISRCTN89971375)
C1 [Maitland, R. A.; Seed, P. T.; Homsy, M.; Pasupathy, D.; Poston, L.] Kings Coll London, Div Womens Hlth, Womens Hlth Acad Ctr, London WC2R 2LS, England.
   [Maitland, R. A.; Seed, P. T.; Homsy, M.; Pasupathy, D.; Poston, L.] St Thomas Hosp, Kings Hlth Partners, London, England.
   [Briley, A. L.; Thomas, S.] Guys & St Thomas NHS Fdn Trust, London, England.
   [Robson, S. C.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Nelson, S. M.] Univ Glasgow, Sch Med, Glasgow, Lanark, Scotland.
   [Sattar, N.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
RP Maitland, RA (reprint author), Kings Coll London, Div Womens Hlth, Womens Hlth Acad Ctr, London WC2R 2LS, England.
EM rahat.maitland@kcl.ac.uk
OI Nelson, Scott/0000-0002-9099-3047; Seed, Paul/0000-0001-7904-7933
FU National Institute for Health Research (NIHR) [RP-0407-10452]; Guy's and
   St. Thomas' Charity [251983]; UK Chief Scientist Office; Scottish
   Government Health Directorates, Edinburgh, UK; Tommy's Charity, UK
   [1060508]
FX This paper presents independent research funded by the National
   Institute for Health Research (NIHR) under the Programme Grants for
   Applied Research funding stream (Ref: RP-0407-10452). The views
   expressed are those of the author(s) and not necessarily those of the
   NHS, the NIHR or the Department of Health. The study was also supported
   by Guy's and St. Thomas' Charity; Reg Charity 251983, the UK Chief
   Scientist Office, the Scottish Government Health Directorates,
   Edinburgh, UK and Tommy's Charity; Reg Charity 1060508, UK.
CR Miyazaki T, 2003, HEART, V89, P663, DOI 10.1136/heart.89.6.663
   Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6
   Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799
   Barakat R, 2012, BRIT J SPORT MED, V46, P656, DOI 10.1136/bjsports-2011-090009
   Li SS, 2009, JAMA-J AM MED ASSOC, V302, P179, DOI 10.1001/jama.2009.976
   Oostdam N, 2012, BJOG-INT J OBSTET GY, V119, P1098, DOI 10.1111/j.1471-0528.2012.03366.x
   Hedderson MM, 2013, DIABETES CARE, V36, P3930, DOI 10.2337/dc13-0389
   Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140-6736(02)09335-2
   Chu SY, 2007, DIABETES CARE, V30, P2070, DOI 10.2337/dc06-2559a
   Fraser A, 2012, CIRCULATION, V125, P1367, DOI 10.1161/CIRCULATIONAHA.111.044784
   Akolekar R, 2013, FETAL DIAGN THER, V33, P8, DOI 10.1159/000341264
   Lacroix M, 2013, DIABETES CARE, V36, P1577, DOI 10.2337/dc12-1731
   Lowe LP, 2010, J CLIN ENDOCR METAB, V95, P5427, DOI 10.1210/jc.2010-1662
   Heslehurst N, 2010, INT J OBESITY, V34, P420, DOI 10.1038/ijo.2009.250
   Savvidou M, 2010, DIABETES, V59, P3017, DOI 10.2337/db10-0688
   Athukorala C, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-56
   Ferreira AFA, 2011, CLIN CHEM, V57, P609, DOI 10.1373/clinchem.2010.159806
   Sattar N, 2008, DIABETOLOGIA, V51, P926, DOI 10.1007/s00125-008-0954-7
   Retnakaran R, 2004, DIABETES CARE, V27, P799, DOI 10.2337/diacare.27.3.799
   Nanda S, 2011, PRENATAL DIAG, V31, P135, DOI 10.1002/pd.2636
   Aye ILMH, 2013, PLACENTA, V34, pS40, DOI 10.1016/j.placenta.2012.11.024
   Dodd JM, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-79
   Gobl C, 2012, DIABETOLOGIA, V55, P3173, DOI 10.1007/s00125-012-2726-7
   Gueuvoghlanian-Silva BY, 2012, AM J REPROD IMMUNOL, V67, P241, DOI 10.1111/j.1600-0897.2011.01090.x
   Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848
   Poston L, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-148
   Scott D A, 2002, Health Technol Assess, V6, P1
   Thangaratinam S, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2088
   Walsh J, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-16
NR 29
TC 3
Z9 3
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD AUG
PY 2014
VL 31
IS 8
BP 963
EP 970
DI 10.1111/dme.12482
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AN5XT
UT WOS:000340666600012
PM 24798080
ER

PT J
AU Gibson, RS
   Bailey, KB
   Williams, S
   Houghton, L
   Costa-Ribeiro, HC
   Mattos, AP
   Barreto, DL
   Lander, RL
AF Gibson, R. S.
   Bailey, K. B.
   Williams, S.
   Houghton, L.
   Costa-Ribeiro, H. C.
   Mattos, A. P.
   Barreto, D. L.
   Lander, R. L.
TI Tissue iron deficiency and adiposity-related inflammation in
   disadvantaged preschoolers from NE Brazil
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID SERUM HEPCIDIN; OBESITY; CHILDREN; ABSORPTION; FORTIFICATION;
   HYPOFERREMIA; LEPTIN; ANEMIA; GROWTH; WOMEN
AB BACKGROUND/OBJECTIVES: Earlier we reported an association between iron deficiency and overweight in Brazilian preschoolers. Here, we investigate whether this is the result of adipose-related inflammation.
   SUBJECTS/METHODS: Fasting serum C-reactive protein, alpha-1-acid glycoprotein (AGP), hepcidin, interleukin-6 (IL-6) and leptin, together with two iron biomarkers (serum ferritin and transferrin receptor (sTfR)), were measured in 364 disadvantaged preschoolers with a mean BMIZ (standardised Z-score for BMI) of 0.015, aged 3-6 years and attending day care in Salvador, Brazil. The role of genetic haemoglobin (Hb) disorders, intestinal parasites and dietary iron supply (calculated from serving sizes of 20 weekday menus) were also examined.
   RESULTS: Forty-eight children (13%) were overweight (BMIZ >1). Prevalence of tissue iron deficiency (sTfR >113.3 nmol/l; 30.6 vs 12.5%; P=0.002) and chronic inflammation (AGP >25 mu mol/l; 19 vs 10%; P=0.025) were higher in overweight than in normal-weight children. From multiple regression, BMIZ was a positive predictor of log serum sTfR, ferritin and leptin, but not of log hepcidin or IL-6. Instead, major positive predictors of log hepcidin were log IL-6, followed by an elevated AGP and sex (male), whereas for log IL-6 elevated AGP was the only significant predictor. Besides BMIZ, sex (female) was also a major positive predictor of leptin. Heterozygous variant of sickle cell Hb (n=20), but not helminths, was also a positive predictor of log sTfR. Median dietary iron supply (mg/day) was above the WHO Recommended Nutrient Intake assuming moderate bioavailability and appeared adequate.
   CONCLUSIONS: The role of adiposity-related inflammation in tissue iron deficiency should be considered even when the prevalence of overweight is relatively low.
C1 [Gibson, R. S.; Bailey, K. B.; Houghton, L.; Lander, R. L.] Univ Otago, Dept Human Nutr, Dunedin 9015, New Zealand.
   [Williams, S.] Univ Otago, Dept Prevent & Social Med, Dunedin 9015, New Zealand.
   [Costa-Ribeiro, H. C.; Mattos, A. P.; Barreto, D. L.] Hosp Univ Prof Edgard Santos, Fima Lifshitz Res Unit, Salvador, BA, Brazil.
RP Gibson, RS (reprint author), Univ Otago, Dept Human Nutr, POB 56, Dunedin 9015, New Zealand.
EM rosalind.gibson@otago.ac.nz
RI Houghton, Lisa/F-5305-2011
OI Houghton, Lisa/0000-0002-2276-6205
FU University of Otago Research Fund; Department of Human Nutrition,
   University of Otago, Performance-Based Research Fund
FX The study received financial support from the University of Otago
   Research Fund and the Department of Human Nutrition, University of
   Otago, Performance-Based Research Fund.
CR Ganz T, 2008, BLOOD, V112, P4292, DOI [10.1182/blood-2008-02-139915, 10.1182/blood-2008-02139915]
   Rechavi G, 2008, CURR MOL MED, V8, P646, DOI 10.2174/156652408786241401
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Hickey MS, 1996, BIOCHEM MOL MED, V59, P1, DOI 10.1006/bmme.1996.0056
   Lander RL, 2012, CAD SAUDE PUBLICA, V28, P2177, DOI 10.1590/S0102-311X2012001100017
   Monteiro CA, 2002, PUBLIC HEALTH NUTR, V5, P105, DOI 10.1079/PHN2001281
   Kroot JJC, 2009, HAEMATOL-HEMATOL J, V94, P1748, DOI 10.3324/haematol.2009.010322
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Assuncao MCF, 2012, PUBLIC HEALTH NUTR, V15, P1796, DOI 10.1017/S1368980012003047
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Beard JL, 2007, J NUTR, V137, P1741
   Hillman R. S., 2005, HEMATOLOGY CLIN PRAC
   Lander RL, 2013, PUB HLTH NUTR, V5, P1
   Matthew R, 1975, AGR HDB, V102, P891
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   United States Department of Agriculture (USDA), 2007, USDA TABL NUTR RET F
   Van Gaal LF, 1999, INT J OBESITY, V23, P29, DOI 10.1038/sj.ijo.0800792
   WHO Multicentre Growth Reference Study Group, 2006, ACTA PAEDIATR, V450, P76, DOI DOI 10.1080/08035320500495548
   World Health Organization and Food and Agriculture Organization of the United Nations, 2004, VIT MIN REQ HUM NUTR
   Wright VJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000433
NR 29
TC 1
Z9 1
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD AUG
PY 2014
VL 68
IS 8
BP 887
EP 891
DI 10.1038/ejcn.2014.83
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AN0XV
UT WOS:000340308200006
PM 24824017
ER

PT J
AU Ehx, G
   Gerin, S
   Mathy, G
   Franck, F
   Oliveira, HC
   Vercesi, AE
   Sluse, FE
AF Ehx, Gregory
   Gerin, Stephanie
   Mathy, Gregory
   Franck, Fabrice
   Oliveira, Helena C. F.
   Vercesi, Anibal E.
   Sluse, Francis E.
TI Liver proteomic response to hypertriglyceridemia in human-apolipoprotein
   C-III transgenic mice at cellular and mitochondrial compartment levels
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
ID TRIGLYCERIDE-RICH LIPOPROTEINS; IN-GEL ELECTROPHORESIS; FERRITIN
   MESSENGER-RNA; NONALCOHOLIC STEATOHEPATITIS; OXIDATIVE STRESS; APO-CIII;
   METABOLIC SYNDROME; FATTY LIVER; IRON; TRANSPORT
AB Background: Hypertriglyceridemia (HTG) is defined as a triglyceride (TG) plasma level exceeding 150 mg/dl and is tightly associated with atherosclerosis, metabolic syndrome, obesity, diabetes and acute pancreatitis. The present study was undertaken to investigate the mitochondrial, sub-mitochondrial and cellular proteomic impact of hypertriglyceridemia in the hepatocytes of hypertriglyceridemic transgenic mice (overexpressing the human apolipoproteinC-III).
   Methods: Quantitative proteomics (2D-DIGE) analysis was carried out on both "low-expressor" (LE) and "high-expressor" (HE) mice, respectively exhibiting moderate and severe HTG, to characterize the effect of the TG plasma level on the proteomic response.
   Results: The mitoproteome analysis has revealed a large-scale phenomenon in transgenic mice, i.e. a general down-regulation of matricial proteins and up-regulation of inner membrane proteins. These data also demonstrate that the magnitude of proteomic changes strongly depends on the TG plasma level. Our different analyses indicate that, in HE mice, the capacity of several metabolic pathways is altered to promote the availability of acetyl-CoA, glycerol-3-phosphate, ATP and NADPH for TG de novo biosynthesis. The up-regulation of several cytosolic ROS detoxifying enzymes has also been observed, suggesting that the cytoplasm of HTG mice is subjected to oxidative stress. Moreover, our results suggest that iron over-accumulation takes place in the cytosol of HE mice hepatocytes and may contribute to enhance oxidative stress and to promote cellular proliferation.
   Conclusions: These results indicate that the metabolic response to HTG in human apolipoprotein C-III overexpressing mice may support a high TG production rate and that the cytosol of hepatocytes is subjected to an important oxidative stress, probably as a result of FFA over-accumulation, iron overload and enhanced activity of some ROS-producing catabolic enzymes.
C1 [Ehx, Gregory; Gerin, Stephanie; Mathy, Gregory; Franck, Fabrice; Sluse, Francis E.] Univ Liege, Dept Life Sci, Lab Bioenerget B22, B-4000 Liege, Belgium.
   [Oliveira, Helena C. F.] Univ Estadual Campinas, Inst Biol, Dept Fisiol & Biofis, BR-13083887 Campinas, SP, Brazil.
   [Vercesi, Anibal E.] Univ Estadual Campinas UNICAMP, Fac Ciencias Med, Dept Patol Clin, BR-13083 Sao Paulo, Brazil.
RP Sluse, FE (reprint author), Univ Liege, Dept Life Sci, Lab Bioenerget B22, Blvd rectorat 27, B-4000 Liege, Belgium.
EM f.sluse@ulg.ac.be
RI Oliveira, Helena/C-1343-2013; OCRC, FAPESP/K-1312-2015
OI OCRC, FAPESP/0000-0003-4596-1043
FU Fond de la Recherche Fondamentale et Collective grant [FRFC 2.4597.11];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/50400-0]; FRS-FNRS
FX This work was supported by a Fond de la Recherche Fondamentale et
   Collective grant (FRFC 2.4597.11) and by the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) - grant #2011/50400-0. GE and
   SG are recipients of FRS-FNRS doctoral fellowships. FF is a Research
   Director of the FRS-FNRS. We would like to thank Dr. Luciane Alberici
   for providing us with biological samples and Dr. Pierre Leprince and
   Prof. Edwin de Pauw for providing us with access to proteomic and mass
   spectrometry platforms.
CR Alberici LC, 2011, J BIOENERG BIOMEMBR, V43, P19, DOI 10.1007/s10863-011-9326-y
   Alberici LC, 2003, J BIOENERG BIOMEMBR, V35, P451, DOI 10.1023/A:1027343915452
   Amaral MEC, 2002, HORM METAB RES, V34, P21, DOI 10.1055/s-2002-19962
   Alberici LC, 2006, GASTROENTEROLOGY, V131, P1228, DOI 10.1053/j.gastro.2006.07.021
   MacGarvey NC, 2012, AM J RESP CRIT CARE, V185, P851, DOI 10.1164/rccm.201106-1152OC
   Mann CJ, 1997, J BIOL CHEM, V272, P31348, DOI 10.1074/jbc.272.50.31348
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   WINDLER E, 1985, J LIPID RES, V26, P556
   ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484
   HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996
   Shevchenko A, 1996, BIOCHEM SOC T, V24, P893
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7
   Knowles MR, 2003, PROTEOMICS, V3, P1162, DOI 10.1002/pmic.200300437
   Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601
   Koek GH, 2011, CLIN CHIM ACTA, V412, P1297, DOI 10.1016/j.cca.2011.04.013
   Marouga R, 2005, ANAL BIOANAL CHEM, V382, P669, DOI 10.1007/s00216-005-3126-3
   Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.213585100
   Piao CS, 2010, PHARMACOL RES, V61, P342, DOI 10.1016/j.phrs.2009.11.009
   HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802
   MAEDA N, 1994, J BIOL CHEM, V269, P23610
   Alberici LC, 2009, FREE RADICAL BIO MED, V47, P1432, DOI 10.1016/j.freeradbiomed.2009.08.013
   Salerno AG, 2007, INT J OBESITY, V31, P1586, DOI 10.1038/sj.ijo.0803646
   Zhang YKJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059122
   REAVEN GM, 1994, J LIPID RES, V35, P820
   Haynes CM, 2013, TRENDS CELL BIOL, V23, P311, DOI 10.1016/j.tcb.2013.02.002
   Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeadbiomed.2005.02.026
   Callister SJ, 2006, J PROTEOME RES, V5, P277, DOI 10.1021/pr050300l
   Lee HY, 2011, HEPATOLOGY, V54, P1650, DOI 10.1002/hep.24571
   Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814
   GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713
   Cardoso AR, 2010, BBA-BIOENERGETICS, V1797, P832, DOI 10.1016/j.bbabio.2009.12.017
   Reid AE, 2001, GASTROENTEROLOGY, V121, P710, DOI 10.1053/gast.2001.27126
   Krawczyk M, 2010, BEST PRACT RES CL GA, V24, P695, DOI 10.1016/j.bpg.2010.08.005
   Jong MC, 2001, J LIPID RES, V42, P1578
   AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066
   WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711
   Douette P, 2005, J PROTEOME RES, V4, P2024, DOI 10.1021/pr050187z
   Thomas A, 2012, PROTEOMICS, V12, P1437, DOI 10.1002/pmic.201100628
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008
   ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514
   Raisanen SR, 1999, FASEB J, V13, P513
   Mackenzie EL, 2008, ANTIOXID REDOX SIGN, V10, P997, DOI [10.1089/ars.2007.1893, 10.1089/ars.007.1893]
   Caldwell SH, 2009, HEPATOLOGY, V49, P1888, DOI 10.1002/hep.22851
   Dansen TB, 2001, IUBMB LIFE, V51, P223
   Fodor IK, 2005, BIOINFORMATICS, V21, P3733, DOI 10.1093/bioinformatics/bti612
   Li Lei O, 2010, Mol Endocrinol, V24, P657, DOI 10.1210/me.2009-0152
   Mathy G, 2006, J PROTEOME RES, V5, P339, DOI 10.1021/or050346e
   Mathy G, 2008, BBA-BIOENERGETICS, V1777, P1072, DOI 10.1016/j.bbabio.2008.04.042
   Ng DS, 2004, J BIOL CHEM, V279, P7636, DOI 10.1074/jbc.M309439200
   Petrak J, 2007, AM J PHYSIOL-GASTR L, V292, pG1490, DOI 10.1152/ajpgi.00455.2006
   SHOULDERS CC, 1991, ATHEROSCLEROSIS, V87, P239, DOI 10.1016/0021-9150(91)90026-Y
   SOTTOCAS.GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   TOSKES PP, 1990, GASTROENTEROL CLIN N, V19, P783
   Zheng J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-251
NR 56
TC 0
Z9 0
U1 1
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD JUL 21
PY 2014
VL 13
AR 116
DI 10.1186/1476-511X-13-116
PG 16
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA AM0DF
UT WOS:000339512800001
PM 25047818
ER

PT J
AU Cortese, S
   Angriman, M
AF Cortese, Samuele
   Angriman, Marco
TI Attention-Deficit/Hyperactivity Disorder, Iron Deficiency, and Obesity:
   Is There a Link?
SO POSTGRADUATE MEDICINE
LA English
DT Article
DE ADHD; iron; obesity; inflammation
ID RESTLESS LEGS SYNDROME; OF-THE-LITERATURE; HYPERACTIVITY DISORDER;
   OVERWEIGHT CHILDREN; SERUM FERRITIN; EMPIRICAL-EVIDENCE; GROWTH
   DEFICITS; SYMPTOM RATINGS; CHRONIC DISEASE; WEIGHT-LOSS
AB The exact etiopathophysiology of attention-deficit/hyperactivity disorder (ADHD) remains elusive, likely because of its phenotypic heterogeneity. Given the involvement of iron in neurocognitive and behavioral functions, iron deficiency (ID) has been suggested as a possible etiopathophysiological factor in a subsample of individuals with ADHD. Most studies assessing ID in ADHD have focused on serum ferritin, a marker of peripheral iron status. Results from these studies are mixed, and the largest studies failed to find a significant association between ADHD and low serum ferritin levels. However, serum ferritin may be influenced by several conditions, including inflammatory status. Increasing evidence, especially from epidemiological studies, points to a significant association between ADHD and obesity. Interestingly, obesity is associated with a chronic inflammatory status, characterized by ID with normal-to-high serum ferritin levels. This article reviews the literature on iron status in ADHD and on the relationship between ADHD and obesity; discusses a possible link among ADHD, ID, and obesity; and proposes that comorbid obesity contributes to ID, via chronic inflammation, in a subsample of individuals with ADHD. Thus, the comorbidity between ADHD and obesity suggests moving beyond serum ferritin levels and assessing the molecular pathways of chronic inflammation that lead to ID in individuals with ADHD and obesity. In turns, this may pave the way for novel treatment strategies for cognitive and behavioral dysfunctions related to ID in ADHD.
C1 [Cortese, Samuele] Univ Verona, Child Neuropsychiat Unit, GB Rossi Hosp, Dept Life Sci & Reprod, I-37100 Verona, Italy.
   [Cortese, Samuele] NYU, Phyllis Green & Randolph Cowen Inst Pediat Neuros, Ctr Child Study, Langone Med Ctr, New York, NY USA.
   [Angriman, Marco] Cent Hosp Bolzano, Dept Pediat, Child Neurol & Neurorehabil Unit, Bolzano, Italy.
RP Cortese, S (reprint author), Osped GB Rossi, Unita Autonoma Neuropsichiatria Infantile, Piazzale Ludovico Antonio Scuro 12, I-37134 Verona, Italy.
EM samuele.cortese@gmail.com
FU European Union Commission (Marie Curie Actions, International Outgoing
   Fellowships for Career Development) [253103]
FX Samuele Cortese, MD, was supported by a grant from the European Union
   Commission (Marie Curie Actions, International Outgoing Fellowships for
   Career Development, grant No. 253103).
CR Adisetiyo V, 2012, 20 ANN M SOC MAGN RE
   Altfas JR, 2002, BMC PSYCHIATRY, V2, DOI 10.1186/1471-244X-2-9
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Jensen JH, 2006, MAGN RESON MED, V55, P1350, DOI 10.1002/mrm.20907
   Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006
   Spencer TJ, 2006, J AM ACAD CHILD PSY, V45, P527, DOI 10.1097/01.chi.0000205710.01690.d4
   Cortese S, 2013, PEDIATRICS, V131, pE1731, DOI 10.1542/peds.2012-0540
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Menegassi M, 2010, REV BRAS PSIQUIATR, V32, P132, DOI 10.1590/S1516-44462009005000008
   Braet C, 2007, EUR CHILD ADOLES PSY, V16, P473, DOI 10.1007/s00787-007-0623-2
   Chung B, 2007, J NUTR, V137, P2366
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Calarge C, 2010, J CHILD ADOL PSYCHOP, V20, P495, DOI 10.1089/cap.2010.0053
   Kieling C, 2008, CHILD ADOL PSYCH CL, V17, P285, DOI 10.1016/j.chc.2007.11.012
   Worwood M, 1997, CLIN CHIM ACTA, V259, P3, DOI 10.1016/S0009-8981(96)06488-1
   Cortese S, 2012, EXPERT REV NEUROTHER, V12, P1227, DOI [10.1586/ern.12.116, 10.1586/ERN.12.116]
   Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2
   Anderson SE, 2006, AMBUL PEDIATR, V6, P297, DOI 10.1016/j.ambp.2006.06.002
   Biederman J, 2003, PEDIATRICS, V111, P1010, DOI 10.1542/peds.111.5.1010
   Cortese S, 2008, MED HYPOTHESES, V71, P770, DOI 10.1016/j.mehy.2008.06.017
   Sever Y, 1997, NEUROPSYCHOBIOLOGY, V35, P178, DOI 10.1159/000119341
   Cortese S, 2012, WORLD J BIOL PSYCHIA, V13, P223, DOI 10.3109/15622975.2011.570376
   Oner P, 2007, TOHOKU J EXP MED, V213, P269, DOI 10.1620/tjem.213.269
   Cortese S, 2008, MED HYPOTHESES, V70, P12, DOI 10.1016/j.mehy.2007.04.036
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Oner O, 2008, PEDIATR INT, V50, P40, DOI 10.1111/j.1442-200X.2007.02496.x
   Spencer TJ, 1996, J AM ACAD CHILD PSY, V35, P1460, DOI 10.1097/00004583-199611000-00014
   Konofal E, 2004, ARCH PEDIAT ADOL MED, V158, P1113, DOI 10.1001/archpedi.158.12.1113
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Allen RP, 2007, MOVEMENT DISORD, V22, pS440, DOI 10.1002/mds.21607
   Baumgartner J, 2013, INT J OBESITY, V37, P24, DOI 10.1038/ijo.2012.145
   Agranat-Meged AN, 2005, INT J EAT DISORDER, V37, P357, DOI 10.1002/eat.20096
   Hassapidou M, 2006, OBESITY, V14, P855, DOI 10.1038/oby.2006.99
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Konofal E, 2007, SLEEP MED, V8, P711, DOI 10.1016/j.sleep.2007.04.022
   Millichap JG, 2006, PEDIATR NEUROL, V34, P200, DOI 10.1016/j.pediatrneurol.2005.09.001
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Verrotti A, 2012, ACTA PAEDIATR, V101, pe416, DOI 10.1111/j.1651-2227.2012.02768.x
   Swanson J, 2006, J AM ACAD CHILD PSY, V45, P1304, DOI 10.1097/01.chi.0000235075.25038.5a
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Retz W, 2012, EXPERT REV NEUROTHER, V12, P1241, DOI [10.1586/ern.12.109, 10.1586/ERN.12.109]
   Simon V, 2009, BRIT J PSYCHIAT, V194, P204, DOI 10.1192/bjp.bp.107.048827
   Cortese S, 2013, BRIT J PSYCHIAT, V203, P24, DOI 10.1192/bjp.bp.112.123299
   Cortese S, 2010, POSTGRAD MED, V122, P88, DOI 10.3810/pgm.2010.09.2205
   WENZEL BJ, 1962, LANCET, V2, P327
   Erermis S, 2004, PEDIATR INT, V46, P296, DOI 10.1111/j.1442-200x.2004.01882.x
   Faraone SV, 2006, PSYCHOL MED, V36, P159, DOI 10.1017/S003329170500471X
   DRAYER B, 1986, AM J ROENTGENOL, V147, P103
   Donfrancesco R, 2013, J ATTEN DISORD, V17, P347, DOI 10.1177/1087054711430712
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Pagoto SL, 2009, OBESITY, V17, P539, DOI 10.1038/oby.2008.587
   Zimmermann MB, 2008, BRIT J NUTR, V99, pS2, DOI 10.1017/S000711450800679X
   Mustillo S, 2003, PEDIATRICS, V111, P851, DOI 10.1542/peds.111.4.851
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   SKIKNE BS, 1990, BLOOD, V75, P1870
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942
   Ptacek R, 2009, NEUROENDOCRINOL LETT, V30, P377
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   Chen MH, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-161
   Coimbra S, 2013, OBES REV, V14, P771, DOI 10.1111/obr.12057
   Cortese Samuele, 2012, Curr Top Behav Neurosci, V9, P199, DOI 10.1007/7854_2011_154
   Cortese S, 2005, SLEEP, V28, P1007
   Cortese S, 2009, EUR CHILD ADOLES PSY, V18, P393, DOI 10.1007/s00787-009-0746-8
   Cortese S, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-286
   Curtin Carol, 2005, BMC Pediatr, V5, P48, DOI 10.1186/1471-2431-5-48
   Davis Caroline, 2006, Eat Behav, V7, P266, DOI 10.1016/j.eatbeh.2005.09.006
   Faraone SV, 2005, J CHILD ADOL PSYCHOP, V15, P191, DOI 10.1089/cap.2005.15.191
   Fleming JP, 2005, EAT WEIGHT DISORD-ST, V10, P10
   Genizi J, 2013, J HEADACHE PAIN, V14, P1, DOI 10.1186/1129-2377-14-54
   Gottfried RJ, 2013, J CHILD ADOL PSYCHOP, V23, P91, DOI 10.1089/cap.2012.0001
   Holtkamp K, 2004, INT J OBESITY, V28, P685, DOI 10.1038/sj.ijo.0802623
   Hubel R, 2006, Eat Weight Disord, V11, P139
   Juneja M, 2010, INDIAN PEDIATR, V47, P955, DOI 10.1007/s13312-010-0160-9
   Kiddie J. Y., 2010, INT J PEDIAT
   Konofal E, 2005, ANN NEUROL, V58, P341, DOI 10.1002/ana.20562
   Lozoff B, 2006, NUTR REV, V64, pS34, DOI 10.1301/nr.2006.may.S34-S43
   Oner O, 2010, CHILD PSYCHIAT HUM D, V41, P441, DOI 10.1007/s10578-010-0178-1
   Oner P, 2008, CHILD PSYCHIAT HUM D, V39, P323, DOI 10.1007/s10578-007-0095-0
   Oner P, 2012, PEDIATR INT, V54, P688, DOI 10.1111/j.1442-200X.2012.03664.x
   Pagoto SL, 2010, EAT WEIGHT DISORD-ST, V15, pE166
   Parisi P, 2010, J PEDIATR ENDOCR MET, V23, P1133, DOI 10.1515/jpem.2010.178
   Romanos Marcel, 2013, Atten Defic Hyperact Disord, V5, P313, DOI 10.1007/s12402-013-0108-8
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   World Health Organization UNICEF United Nations University, IR DEF AN ASS PREV C
   Yang RW, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-133
NR 91
TC 1
Z9 1
U1 1
U2 6
PU JTE MULTIMEDIA
PI WEST CONSHOHOCKEN
PA 18 ELIZABETH ST, STE 110, WEST CONSHOHOCKEN, PA 19428 USA
SN 0032-5481
EI 1941-9260
J9 POSTGRAD MED
JI Postgrad. Med.
PD JUL
PY 2014
VL 126
IS 4
BP 155
EP 170
DI 10.3810/pgm.2014.07.2793
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA AZ6FH
UT WOS:000348313900015
PM 25141253
ER

PT J
AU Siddique, A
   Nelson, JE
   Aouizerat, B
   Yeh, MM
   Kowdley, KV
AF Siddique, Asma
   Nelson, James E.
   Aouizerat, Bradley
   Yeh, Matthew M.
   Kowdley, Kris V.
CA NASH Clinical Res Network
TI Iron Deficiency in Patients With Nonalcoholic Fatty Liver Disease Is
   Associated With Obesity, Female Gender, and Low Serum Hepcidin
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE NASH CRN; BMI; NAFLD; Nutrition; Ferroportin; Inflammation
ID ADIPOSE-TISSUE; UNITED-STATES; IN-VIVO; EXPRESSION; TRANSCRIPTION;
   HYPOFERREMIA; POPULATION; ANEMIA
AB BACKGROUND & AIMS: Iron deficiency is often observed in obese individuals. The iron regulatory hormone hepcidin is regulated by iron and cytokines interleukin (IL) 6 and IL1 beta. We examine the relationship between obesity, circulating levels of hepcidin, and IL6 and IL1 beta, and other risk factors in patients with nonalcoholic fatty liver disease (NAFLD) with iron deficiency.
   METHODS: We collected data on 675 adult subjects (> 18 years old) enrolled in the Nonalcoholic Steato-hepatitis Clinical Research Network. Subjects with transferrin saturation < 20% were categorized as iron deficient, whereas those with transferrin saturation 20% were classified as iron normal. We assessed clinical, demographic, anthropometric, laboratory, dietary, and histologic data from patients, and serum levels of hepcidin and cytokines IL6 and IL1 beta. Univariate and multivariate analysis were used to identify risk factors for iron deficiency.
   RESULTS: One-third of patients (231 of 675; 34%) were iron deficient. Obesity, diabetes, and metabolic syndrome were more common in subjects with iron deficiency (P < .01), compared with those that were iron normal. Serum levels of hepcidin were significantly lower in subjects with iron deficiency (61 +/- 45 vs 81 +/- 51 ng/mL; P < .0001). Iron deficiency was significantly associated with female gender, obesity, increased body mass index and waist circumference, presence of diabetes, lower alcohol consumption, black or American Indian/Alaska Native race (P <= .018), and increased levels of IL6 and IL1 beta (6.6 vs 4.8 for iron normal, P <= .0001; and 0.45 vs 0.32 for iron normal, P <= .005).
   CONCLUSIONS: Iron deficiency is prevalent in patients with NAFLD and associated with female gender, increased body mass index, and nonwhite race. Serum levels of hepcidin were lower in iron-deficient subjects, reflecting an appropriate physiologic response to decreased circulating levels of iron, rather than a primary cause of iron deficiency in the setting of obesity and NAFLD.
C1 [Siddique, Asma; Nelson, James E.; Kowdley, Kris V.] Virginia Mason Med Ctr, Inst Digest Dis, Liver Ctr Excellence, Seattle, WA 98101 USA.
   [Nelson, James E.; Kowdley, Kris V.] Virginia Mason Med Ctr, Benaroya Res Inst, Seattle, WA 98101 USA.
   [Aouizerat, Bradley] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA.
   [Aouizerat, Bradley] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
   [Yeh, Matthew M.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
RP Kowdley, KV (reprint author), 1201 9th Ave, Seattle, WA 98101 USA.
EM Kris.kowdley@vmmc.org
OI Sirlin, Claude/0000-0002-6639-9072
FU National Institute of Diabetes and Digestive and Kidney Diseases
   [U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734,
   U01DK061737, U01DK061738, U01DK061730, U01DK061713]; National Institute
   of Child Health and Human Development. Several clinical centers;
   National Center for Advancing Translational Sciences [UL1TR000439,
   UL1TR000077, UL1TR000436, UL1TR000150, UL1TR000424, UL1TR000006,
   UL1TR000448, UL1TR000040, UL1TR000100, UL1TR000004, UL1TR000423,
   UL1TR000058, UL1TR000067, UL1TR000454]; Intramural Research Program of
   the National Cancer Institute
FX The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) is
   supported by the National Institute of Diabetes and Digestive and Kidney
   Diseases (grants U01DK061718, U01DK061728, U01DK061731, U01DK061732,
   U01DK061734, U01DK061737, U01DK061738, U01DK061730, and U01DK061713) and
   the National Institute of Child Health and Human Development. Several
   clinical centers use support from the National Center for Advancing
   Translational Sciences in conduct of NASH CRN Studies (grants
   UL1TR000439, UL1TR000077, UL1TR000436, UL1TR000150, UL1TR000424,
   UL1TR000006, UL1TR000448, UL1TR000040, UL1TR000100, UL1TR000004,
   UL1TR000423, UL1TR000058, UL1TR000067, and UL1TR000454). This work was
   supported in part by the Intramural Research Program of the National
   Cancer Institute.
CR Ganz T, 2008, BLOOD, V112, P4292, DOI [10.1182/blood-2008-02-139915, 10.1182/blood-2008-02139915]
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Dawson DA, 2005, ALCOHOL CLIN EXP RES, V29, P844, DOI 10.1097/01.ALC.0000164374.32229.A2
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Harrison-Findik DD, 2006, J BIOL CHEM, V281, P22974, DOI 10.1074/jbc.M602098200
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Theurl I, 2011, HAEMATOL-HEMATOL J, V96, P1761, DOI 10.3324/haematol.2011.048926
   Darshan D, 2009, BIOMETALS, V22, P77, DOI 10.1007/s10534-008-9187-y
   Cohen JC, 2011, SCIENCE, V332, P1519, DOI 10.1126/science.1204265
   WENZEL BJ, 1962, LANCET, V2, P327
   Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102
   Darshan D, 2010, HAEMATOL-HEMATOL J, V95, P1660, DOI 10.3324/haematol.2010.022426
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Lasocki S, 2008, CRIT CARE MED, V36, P2388, DOI 10.1097/CCM.0b013e31818103b9
   Nelson JE, 2012, HEPATOLOGY, V56, P1730, DOI 10.1002/hep.25856
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   Stadlmayr A, 2011, J INTERN MED, V270, P41, DOI 10.1111/j.1365-2796.2011.02377.x
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Costa-Matos L, 2012, EUR J GASTROEN HEPAT, V24, P1158, DOI 10.1097/MEG.0b013e328355cfd0
   Nelson JE, 2011, HEPATOLOGY, V53, P448, DOI 10.1002/hep.24038
   Chung M, 2012, AGENCY HEALTHCARE RE
   Harris RJ, 2004, ARCH DIS CHILD, V89, P154, DOI 10.1136/adc.2003.019703
   Ioannou GN, 2007, CLIN GASTROENTEROL H, V5, P624, DOI 10.1016/j.cgh.2007.01.008
   Neuschwander-Tetri Brent A, 2010, Hepatology, V52, P913, DOI 10.1002/hep.23784
   Schrier SL, 2012, UPTODATE
   Tussing-Humphreys L, 2011, THESCIENTIFICWORLDJO, V11, P2197, DOI 10.1100/2011/634861
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
NR 29
TC 1
Z9 1
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JUL
PY 2014
VL 12
IS 7
BP 1170
EP 1178
DI 10.1016/j.cgh.2013.11.017
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AK4WX
UT WOS:000338426100022
PM 24269922
ER

PT J
AU Demircioglu, F
   Gorunmez, G
   Dagistan, E
   Goksugur, SB
   Bekdas, M
   Tosun, M
   Kizildag, B
   Kismet, E
AF Demircioglu, Fatih
   Gorunmez, Gokhan
   Dagistan, Emine
   Goksugur, Sevil Bilir
   Bekdas, Mervan
   Tosun, Mehmet
   Kizildag, Betul
   Kismet, Erol
TI Serum hepcidin levels and iron metabolism in obese children with and
   without fatty liver: case-control study
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article
DE Fatty liver; Obesity; Children; Hepcidin; Iron metabolism
ID INSULIN-RESISTANCE; ADIPOSE-TISSUE; INFLAMMATION; DEFICIENCY; ANEMIA;
   ADOLESCENTS; DISEASE; HYPOFERREMIA; ASSOCIATION; ABSORPTION
AB Hepcidin is a regulator of iron balance that is increased in obesity. It reduces the absorption of iron, reduces the transfer of iron from macrophages to the plasma and/or prevents mobilisation of stored iron. Obese patients with non-alcoholic fatty liver disease (NAFLD) demonstrate adipokine and cytokine release promoting inflammatory response. We aimed to analyse the hepcidin levels and iron metabolism in obese children with and without NAFLD and non-obese healthy controls. The study population consisted of 110 children aged 7-18 years in three groups: 50 obese patients without NAFLD, 30 obese patients with NAFLD, and 30 non-obese healthy controls. Serum hepcidin, ferritin, and iron levels, iron-binding capacity, lipid profile, and liver function tests were measured, and hepatic ultrasonography was performed in all participants. Obese patients' white blood cell counts, total cholesterol, triglyceride levels, and homeostatic model assessment of insulin resistance (HOMA-IR) were significantly higher than those of the control group. Iron-binding capacity was significantly higher in obese patients without NAFLD compared with obese patients with NAFLD (p = 0.002). Hepcidin levels were not significantly different between obese patients and the control group. However, hepcidin levels in obese patients with NAFLD were significantly higher than those in obese patients without NAFLD (p < 0.001). Conclusions: Hepcidin levels were significantly higher in obese children with NAFLD than those without NAFLD. Obese children with NAFLD should receive attention regarding iron metabolism disorders. Serum hepcidin could be a marker of iron metabolism status and NAFLD in these groups of patients.
C1 [Demircioglu, Fatih; Kismet, Erol] Abant Izzet Baysal Univ, Div Pediat Hematol Oncol, Dept Pediat, Fac Med, TR-14280 Golkoy, Bolu, Turkey.
   [Gorunmez, Gokhan; Goksugur, Sevil Bilir; Bekdas, Mervan] Abant Izzet Baysal Univ, Dept Pediat, Fac Med, TR-14280 Golkoy, Bolu, Turkey.
   [Dagistan, Emine; Kizildag, Betul] Abant Izzet Baysal Univ, Dept Radiol, Fac Med, TR-14280 Golkoy, Bolu, Turkey.
   [Tosun, Mehmet] Abant Izzet Baysal Univ, Dept Biochem, Fac Med, TR-14280 Golkoy, Bolu, Turkey.
RP Demircioglu, F (reprint author), Abant Izzet Baysal Univ, Div Pediat Hematol Oncol, Dept Pediat, Fac Med, TR-14280 Golkoy, Bolu, Turkey.
EM fatih_demircioglu@yahoo.com
FU scientific research fund from the Abant Izzet Baysal University
FX This research was supported by the scientific research fund from the
   Abant Izzet Baysal University.
CR Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020
   Turlin B, 2001, AM J CLIN PATHOL, V116, P263
   Baynes RD, 1996, CLIN BIOCHEM, V29, P209, DOI 10.1016/0009-9120(96)00010-K
   Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298
   Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4
   Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Tilg H, 2002, J IMMUNOL, V169, P2204
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Dunn LL, 2007, TRENDS CELL BIOL, V17, P93, DOI 10.1016/j.tcb.2006.12.003
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Zhang XL, 2013, BIOL CHEM, V394, P231, DOI 10.1515/hsz-2012-0217
   Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Senates E, 2011, METAB SYNDR RELAT D, V9, P287, DOI 10.1089/met.2010.0121
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Mehta K, 2002, NUTR REV, V60, P289, DOI 10.1301/002966402320387224
   Chang JS, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-123
   Dao MC, 2013, ADV NUTR, V4, P602, DOI 10.3945/an.113.004424
   Haluzik M, 2004, PHYSIOL RES, V53, P123
   Kuczmarski RJ, 2002, VITAL HLTH STAT, V11, P1
   Lee Sang Hyub, 2010, Korean J Hepatol, V16, P288, DOI 10.3350/kjhep.2010.16.3.288
   Moafi Alireza, 2011, Int J Prev Med, V2, P280
   Poskitt EM, 1995, CLIN PAEDIAT ENDOCRI, P210
   QUINN SF, 1985, AM J ROENTGENOL, V145, P753
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   van der Aa MP, 2014, CLIN PEDIATR, V53, P337, DOI 10.1177/0009922813509480
   Vuppalanchi R, 2013, OBESITY SILVER SPRIN, DOI [10.1002/oby.20403, DOI 10.1002/OBY.20403]
NR 31
TC 4
Z9 4
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6199
EI 1432-1076
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
PD JUL
PY 2014
VL 173
IS 7
BP 947
EP 951
DI 10.1007/s00431-014-2268-8
PG 5
WC Pediatrics
SC Pediatrics
GA AK1ZZ
UT WOS:000338219600013
PM 24500395
ER

PT J
AU Phillips, AK
   Roy, SC
   Lundberg, R
   Guilbert, TW
   Auger, AP
   Blohowiak, SE
   Coe, CL
   Kling, PJ
AF Phillips, A. K.
   Roy, S. C.
   Lundberg, R.
   Guilbert, T. W.
   Auger, A. P.
   Blohowiak, S. E.
   Coe, C. L.
   Kling, P. J.
TI Neonatal iron status is impaired by maternal obesity and excessive
   weight gain during pregnancy
SO JOURNAL OF PERINATOLOGY
LA English
DT Article
ID DIABETIC MOTHERS; FETAL IRON; ZINC PROTOPORPHYRIN/HEME; BIRTH-WEIGHT;
   TRANSFERRIN SATURATION; DEFICIENCY ANEMIA; GESTATIONAL-AGE; INFANTS;
   INFLAMMATION; WOMEN
AB OBJECTIVE: Maternal iron needs increase sixfold during pregnancy, but obesity interferes with iron absorption. We hypothesized that maternal obesity impairs fetal iron status. STUDY DESIGN: Three hundred and sixteen newborns with risk factors for infantile iron deficiency anemia (IDA) were studied to examine obesity during pregnancy and neonatal iron status. Erythrocyte iron was assessed by cord blood hemoglobin (Hb), zinc protoporphyrin/heme (ZnPP/H) and reticulocyte-ZnPP/H, and storage iron by serum ferritin. RESULT: Women with body mass index (BMI) >= 30 kg m(-2), as compared with non-obese women, delivered larger offspring with higher reticulocyte-ZnPP/H and lower serum ferritin concentrations (P < 0.05 for both). With increasing BMI, the estimated body iron was relatively lower (mg kg(-1)) and the ratio of total Hb-bound iron (mg) per total body iron (mg) increased. Maternal diabetes compromised infant iron status, but multivariate analysis demonstrated that obesity was an independent predictor. CONCLUSION: Obesity during pregnancy and excessive weight gain are independent risk factors for iron deficiency in the newborn.
C1 [Phillips, A. K.; Roy, S. C.; Lundberg, R.; Guilbert, T. W.; Blohowiak, S. E.; Kling, P. J.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53715 USA.
   [Phillips, A. K.; Roy, S. C.; Lundberg, R.; Guilbert, T. W.; Blohowiak, S. E.; Kling, P. J.] Univ Wisconsin, Meriter Hosp, Madison, WI 53715 USA.
   [Phillips, A. K.; Guilbert, T. W.; Blohowiak, S. E.; Kling, P. J.] Univ Wisconsin, Dept Pediat, Madison, WI USA.
   [Auger, A. P.; Coe, C. L.] Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA.
   [Coe, C. L.] Univ Wisconsin, Harlow Ctr Biol Psychol, Madison, WI 53706 USA.
RP Kling, PJ (reprint author), Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, 202 South Pk St, Madison, WI 53715 USA.
EM pkling@pediatrics.wisc.edu
OI Guilbert, Theresa/0000-0002-6932-712X
FU University of Wisconsin Shapiro Research Program; University of
   Wisconsin Cardiovascular Research Center; Meriter Foundation; Wisconsin
   Partnership Collaborative Health Sciences Program Grant; NIH [1
   ULRR026011 UW CTSA]; Thrasher Research Fund; UW Graduate School
   Competition
FX We thank the participating families, Meriter Hospital Birthing Center
   Staff, Meriter Hospital Blood Bank, Deb Krumpos (RN), Sue Shafranski
   (RN), Patricia Green-Sotos (RN), Melinda E Chen (BS), Beth A Fischer
   (PhD), Jens Eichman (PhD), Chong Zhang, Vidya Sridhar (MBBS), Brian R
   Pisula (BS), Murray L Katcher (MD, PhD), Daphne Pham (PhD) and members
   of the Kling Laboratory Research Team. This work was supported by
   University of Wisconsin Shapiro Research Program (SCR), University of
   Wisconsin Cardiovascular Research Center (SCR), Meriter Foundation
   (PJK), Wisconsin Partnership Collaborative Health Sciences Program Grant
   (PJK), NIH 1 ULRR026011 UW CTSA, Thrasher Research Fund (PJK), UW
   Graduate School Competition (PJK).
CR Alexander G R, 1999, Matern Child Health J, V3, P225, DOI 10.1023/A:1022381506823
   Lozoff B, 2006, AM J CLIN NUTR, V84, P1412
   O'Brien KO, 2003, AM J CLIN NUTR, V77, P924
   Gentile M, 2010, EUR J CLIN NUTR, V64, P873, DOI 10.1038/ejcn.2010.69
   Baker RD, 2010, PEDIATRICS, V126, P1040, DOI 10.1542/peds.2010-2576
   Schmatz M, 2010, J PERINATOL, V30, P441, DOI 10.1038/jp.2009.182
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Georgieff MK, 2002, J PEDIATR-US, V141, P405, DOI 10.1067/mpd.2002.127090
   WIDNESS JA, 1981, J CLIN INVEST, V67, P637, DOI 10.1172/JCI110078
   [Anonymous], 2009, WEIGHT GAIN PREGNANC
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Siddappa AM, 2004, PEDIATR RES, V55, P1034, DOI 10.1203/01.pdr.0000127021.38207.62
   GEORGIEFF MK, 1992, AM J PHYSIOL, V262, pR485
   Rao R, 2007, SEMIN FETAL NEONAT M, V12, P54, DOI 10.1016/j.siny.2006.10.007
   Rebouche CJ, 2004, J BIOCHEM BIOPH METH, V58, P239, DOI 10.1016/j.jbbm.2003.11.003
   Kasper DC, 2009, NEONATOLOGY, V95, P164, DOI 10.1159/000153101
   Gambling L, 2009, AM J PHYSIOL-REG I, V296, pR1063, DOI 10.1152/ajpregu.90793.2008
   Nold JL, 2004, PEDIATR CLIN N AM, V51, P619, DOI 10.1016/j.pcl.2004.01.003
   GEORGIEFF MK, 1990, J PEDIATR-US, V117, P455, DOI 10.1016/S0022-3476(05)81097-2
   Dao MC, 2013, J PERINATOL, V33, P177, DOI 10.1038/jp.2012.81
   Ullrich C, 2005, JAMA-J AM MED ASSOC, V294, P924, DOI 10.1001/jama.294.8.924
   Muller KF, 2012, J PEDIATR-US, V160, P949, DOI 10.1016/j.jpeds.2011.12.030
   McLimore HM, 2013, J PEDIAT HEMATOL ONC, V35, P473, DOI 10.1097/MPH.0b013e3182707f2e
   Clark SF, 2008, NUTR CLIN PRACT, V23, P128, DOI 10.1177/0884533608314536
   ARBUCKLE TE, 1993, OBSTET GYNECOL, V81, P39
   Thorsdottir I, 2003, EUR J CLIN NUTR, V57, P505, DOI 10.1038/sj.ejcn.1601594
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Siddappa AM, 2007, NEONATOLOGY, V92, P73, DOI 10.1159/000100805
   Saito I, 2003, CIRC J, V67, P323
   Beard JL., 1994, AM J CLIN NUTR S, V59, p502S
   Beard JL, 1994, AM J CLIN NUTR, V59, p508S
   Blohowiak SE, 2008, PEDIATR RES, V64, P63, DOI 10.1203/PDR.0b013e31817328e5
   Bradley J, 2004, AM J PHYSIOL-REG I, V287, pR894, DOI 10.1152/ajpregu.00525.2003
   Cogswell ME, 2003, J NUTR, V133, p1974S
   Committee on Obstetric Practice, 2013, OBSTET GYNECOL, V549, P213
   Fomon S, 1993, IRON NUTR NORMAL INF, P239
   Kleven KJ, 2007, NEONATOLOGY, V92, P91, DOI 10.1159/000100807
   Lesser KB, 2006, J PERINATOL, V26, P671, DOI 10.1038/sj.jp.7211600
   Lott DG, 2005, PEDIATRICS, V116, P414, DOI 10.1542/peds.2004-1601
   Lozoff B, 2006, NUTR REV, V64, pS72
   Lozoff Betsy, 2006, Semin Pediatr Neurol, V13, P158, DOI 10.1016/j.spen.2006.08.004
   Lozoff B, 2006, NUTR REV, V64, P34, DOI 10.1301/nr.2006.may.S34-S43
   SAARINEN UM, 1977, J PEDIATR-US, V91, P875, DOI 10.1016/S0022-3476(77)80880-9
   SIIMES MA, 1979, AM J CLIN NUTR, V32, P2295
   Wisconsin Association for Perinatal Care Prenatal Testing Committee, 2011, LAB TEST PREGN
NR 45
TC 5
Z9 5
U1 2
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0743-8346
EI 1476-5543
J9 J PERINATOL
JI J. Perinatol.
PD JUL
PY 2014
VL 34
IS 7
BP 513
EP 518
DI 10.1038/jp.2014.42
PG 6
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA AK2CK
UT WOS:000338226300004
PM 24651737
ER

PT J
AU Gibson, RS
   Heath, ALM
   Szymlek-Gay, EA
AF Gibson, Rosalind S.
   Heath, Anne-Louise M.
   Szymlek-Gay, Ewa A.
TI Is iron and zinc nutrition a concern for vegetarian infants and young
   children in industrialized countries?
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article; Proceedings Paper
CT 6th International Congress on Vegetarian Nutrition (ICVN)
CY FEB 24-26, 2013
CL Loma Linda Univ, Loma Linda, CA
SP Loma Linda Univ Hlth, Kelloggs, Calif Walnut Commiss, Silk, Lifestyle Med Inst Sanitarium Hlth & Wellbeing, LifeLong Hlth, Int Nut & Dried Fruit Council
HO Loma Linda Univ
ID CONSUMING CONTROLLED LACTOOVOVEGETARIAN; MULTIPLE MICRONUTRIENT
   DEFICIENCIES; AGED 7-11 YEARS; PRESCHOOL-CHILDREN; COMPLEMENTARY FOODS;
   DIETARY-INTAKE; UNITED-STATES; INOSITOL PHOSPHATES; FEEDING PRACTICES;
   OMNIVOROUS DIETS
AB Well-planned vegetarian diets are considered adequate for all stages of the life cycle, despite limited data on the zinc status of vegetarians during early childhood. The bioavailability of iron and zinc in vegetarian diets is poor because of their higher content of absorption inhibitors such as phytate and polyphenols and the absence of flesh foods. Consequently, children as well as adult vegetarians often have lower serum ferritin concentrations than omnivores, which is indicative of reduced iron stores, despite comparable intakes of total iron; hemoglobin differences are small and rarely associated with anemia. However, data on serum zinc concentrations, the recommended biomarker for identifying population groups at elevated risk of zinc deficiency, are sparse and difficult to interpret because recommended collection and analytic procedures have not always been followed. Existing data indicate no differences in serum zinc or growth between young vegetarian and omnivorous children, although there is some evidence of low serum zinc concentrations in vegetarian adolescents. Some vegetarian immigrants from underprivileged households may be predisposed to iron and zinc deficiency because of nondietary factors such as chronic inflammation, parasitic infections, overweight, and genetic hemoglobin disorders. To reduce the risk of deficiency, the content and bioavailability of iron and zinc should be enhanced in vegetarian diets by consumption of fortified cereals and milk, by consumption of leavened whole grains, by soaking dried legumes before cooking and discarding the soaking water, and by replacing tea and coffee at meals with vitamin C rich drinks, fruit, or vegetables. Additional recommended practices include using fermented soy foods and sprouting at least some of the legumes consumed. Fortified foods can reduce iron deficiency, but whether they can also reduce zinc deficiency is less certain. Supplements may be necessary for vegetarian children following very restricted vegan diets.
C1 [Gibson, Rosalind S.; Heath, Anne-Louise M.] Univ Otago, Dept Human Nutr, Dunedin 9054, New Zealand.
   [Szymlek-Gay, Ewa A.] Deakin Univ, Sch Exercise & Nutr Sci, Ctr Phys Act & Nutr Res, Burwood, Australia.
RP Gibson, RS (reprint author), Univ Otago, Dept Human Nutr, POB 56, Dunedin 9054, New Zealand.
EM rosalind.gibson@otago.ac.nz
RI Heath, Anne-Louise/C-8337-2013
CR Mangels AR, 2003, J AM DIET ASSOC, V103, P748, DOI 10.1053/jada.2003.50142
   Sandberg AS, 1999, AM J CLIN NUTR, V70, P240
   Cardenas VM, 2006, AM J EPIDEMIOL, V163, P127, DOI 10.1093/aje/kwj018
   TURNLUND JR, 1984, AM J CLIN NUTR, V40, P1071
   Hurrell RF, 2004, INT J VITAM NUTR RES, V74, P445, DOI 10.1024/0300-9831.74.6.445
   Chung CS, 2008, AM J CLIN NUTR, V87, P1224
   Gibson SA, 1999, PUBLIC HEALTH NUTR, V2, P521, DOI 10.1017/S1368980099000701
   Minihane AM, 1998, AM J CLIN NUTR, V68, P96
   Taylor A, 2004, BIOL TRACE ELEM RES, V97, P197, DOI 10.1385/BTER:97:3:197
   Miller LV, 2007, J NUTR, V137, P135
   Gibson RS, 2006, P NUTR SOC, V65, P160, DOI 10.1079/PNS2006489
   BOREL MJ, 1991, AM J CLIN NUTR, V54, P729
   Hambidge KM, 2008, J NUTR, V138, P2363, DOI 10.3945/jn.108.093823
   Hunt JR, 2000, AM J CLIN NUTR, V71, P94
   Devaney B, 2004, J AM DIET ASSOC, V104, pS14, DOI 10.1016/j.jada.2003.10.022
   Gibson RS, 1998, EUR J CLIN NUTR, V52, P764, DOI 10.1038/sj.ejcn.1600645
   SANDSTROM B, 1992, J TRACE ELEM ELECT H, V6, P99
   Armah CN, 2008, J NUTR, V138, P873
   Petry N, 2010, J NUTR, V140, P1977, DOI 10.3945/jn.110.125369
   SANDSTROM B, 1989, J NUTR, V119, P48
   DONOVAN UM, 1995, J AM COLL NUTR, V14, P463
   Hess SY, 2007, FOOD NUTR BULL, V28, pS403
   Villalpando S, 2006, J NUTR, V136, P2633
   Kirby M, 2009, PEDIATR CLIN N AM, V56, P1085, DOI 10.1016/j.pcl.2009.07.003
   Hunt JR, 2008, AM J CLIN NUTR, V87, P1336
   Butte NF, 2010, J AM DIET ASSOC, V110, pS27, DOI 10.1016/j.jada.2010.09.004
   Jebb SA, 2004, PUBLIC HEALTH NUTR, V7, P461, DOI 10.1079/PHN2003539
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   Briefel RR, 2004, ANNU REV NUTR, V24, P401, DOI 10.1146/annurev.nutr.23.011702.073349
   Teucher B, 2004, INT J VITAM NUTR RES, V74, P403, DOI 10.1024/0300-9831.74.6.403
   Szymlek-Gay EA, 2009, AM J CLIN NUTR, V90, P1541, DOI 10.3945/ajcn.2009.27588
   de Benoist B, 2007, FOOD NUTR BULL, V28, pS480
   Karr M, 1996, AUST NZ J PUBL HEAL, V20, P618, DOI 10.1111/j.1467-842X.1996.tb01076.x
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Kimmons JE, 2005, J NUTR, V135, P444
   Gibson RS, 2009, MATERN CHILD NUTR, V5, P260, DOI 10.1111/j.1740-8709.2008.00179.x
   Arsenault JE, 2003, AM J CLIN NUTR, V78, P1011
   BINDRA GS, 1986, NUTR RES, V6, P475, DOI 10.1016/S0271-5317(86)80101-4
   Brown KH, 2007, INT J VITAM NUTR RES, V77, P174, DOI 10.1024/0300-9831.77.3.174
   Brown KH, 2009, FOOD NUTR BULL, V30, pS144
   Brown K.H., 2004, FOOD NUTR BULL, V25, pS99
   BRUNE M, 1989, AM J CLIN NUTR, V49, P542
   [Centers for Disease Control and Prevention World Health Organization], 2007, ASS IR STAT POP INCL
   DAGNELIE PC, 1994, EUR J CLIN NUTR, V48, pS103
   Dewey Kathryn G., 2003, Food and Nutrition Bulletin, V24, P5
   EARLEY A, 1990, ARCH DIS CHILD, V65, P610
   Eichler K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-506
   Fairweather-Tait SJ, 2004, P NUTR SOC, V63, P519, DOI 10.1079/PNS2004394
   Fernandes SMR, 2008, J CLIN GASTROENTEROL, V42, P152, DOI 10.1097/01.mcg.0000248007.62773.3a
   Food and Nutrition Board, 2001, DIET REF INT VIT A V
   Food and Nutrition Board Institute of Medicine, 2000, DIET REF INT APPL DI
   Fox MK, 2004, J AM DIET ASSOC, V104, pS22, DOI 10.1016/j.jada.2003.10.026
   Fox MK, 2006, J AM DIET ASSOC, V106, pS66, DOI 10.1016/j.jada.2005.09.042
   Gibson RS, 2001, BRIT J NUTR, V86, P71, DOI 10.1079/BJN2001370
   Grantham-McGregor S, 2001, J NUTR, V131, p649S
   Heath ALM, 2002, ASIA PAC J CLIN NUTR, V11, P251, DOI 10.1046/j.1440-6047.2002.00313.x
   Hebbelinck M, 1999, AM J CLIN NUTR, V70, p579S
   Hotz C, 2001, EUR J CLIN NUTR, V55, P841, DOI 10.1038/sj.ejcn.1601239
   Hunt JR, 1998, AM J CLIN NUTR, V67, P421
   Hunt JR, 2009, AM J CLIN NUTR, V89, P839, DOI 10.3945/ajcn.2008.27175
   Hunt JR, 1999, AM J CLIN NUTR, V69, P944
   Hurrell RF, 2000, BRIT J NUTR, V84, P903
   Jalla S, 2002, J PEDIATR GASTR NUTR, V34, P35, DOI 10.1097/00005176-200201000-00009
   Lander R, 2010, PUBLIC HEALTH NUTR, V13, P1304, DOI 10.1017/S1368980009991856
   Le HT, 2007, ASIA PAC J CLIN NUTR, V16, P716
   Leung SSF, 2001, J PAEDIATR CHILD H, V37, P247, DOI 10.1046/j.1440-1754.2001.00647.x
   LONNERDAL B, 1988, AM J CLIN NUTR, V48, P1301
   Mangels AR, 2001, J AM DIET ASSOC, V101, P670, DOI 10.1016/S0002-8223(01)00169-9
   Messina V, 2003, CAN J DIET PRACT RES, V64, P82, DOI 10.3148/64.2.2003.82
   Morgan EJ, 2010, J NUTR, V140, P2221, DOI 10.3945/jn.109.120717
   Nathan I, 1996, BRIT J NUTR, V75, P533, DOI 10.1079/BJN19960157
   Nathan I, 1997, EUR J CLIN NUTR, V51, P20, DOI 10.1038/sj.ejcn.1600354
   OCONNELL JM, 1989, PEDIATRICS, V84, P475
   Prynne CJ, 1999, PUBLIC HEALTH NUTR, V2, P537, DOI 10.1017/S1368980099000725
   RONA RJ, 1987, J EPIDEMIOL COMMUN H, V41, P233, DOI 10.1136/jech.41.3.233
   ROSSANDERHULTEN L, 1991, AM J CLIN NUTR, V54, P152
   SABATE J, 1991, EUR J CLIN NUTR, V45, P51
   SABATE J, 1990, AM J DIS CHILD, V144, P1159
   SANDERS TAB, 1981, J HUM NUTR, V35, P349
   SANDERS TAB, 1992, J HUM NUTR DIET, V5, P11, DOI 10.1111/j.1365-277X.1992.tb00129.x
   Sazawal S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012167
   SIEGENBERG D, 1991, AM J CLIN NUTR, V53, P537
   Siekmann JH, 2003, J NUTR, V133, p3972S
   Skinner JD, 1997, J AM DIET ASSOC, V97, P496, DOI 10.1016/S0002-8223(97)00129-6
   Thane CW, 2000, J HUM NUTR DIET, V13, P149, DOI 10.1046/j.1365-277X.2000.00227.x
   Thane CW, 2003, PUBLIC HEALTH NUTR, V6, P485, DOI 10.1079/PHN2002455
   WHO, 2001, IR DEF AN ASS PREV C
   World Health Organization and Food and Agriculture Organization of the United Nations, 2004, VIT MIN REQ HUM NUTR
   Yen CE, 2008, NUTR RES, V28, P430, DOI 10.1016/j.nutres.2008.03.012
NR 89
TC 1
Z9 1
U1 18
U2 56
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUL
PY 2014
VL 100
IS 1
SU S
BP 459S
EP 468S
DI 10.3945/ajcn.113.071241
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AJ7FI
UT WOS:000337862200023
PM 24871479
ER

PT J
AU Zhang, FF
   Rodday, AM
   Kelly, MJ
   Must, A
   MacPherson, C
   Roberts, SB
   Saltzman, E
   Parsons, SK
AF Zhang, Fang Fang
   Rodday, Angie Mae
   Kelly, Michael J.
   Must, Aviva
   MacPherson, Cathy
   Roberts, Susan B.
   Saltzman, Edward
   Parsons, Susan K.
TI Predictors of Being Overweight or Obese in Survivors of Pediatric Acute
   Lymphoblastic Leukemia (ALL)
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE hyperferritinemia; hyperbilirubinemia; Epstein-Barr virus; Epstein-Barr
   virus-associated hemophagocytic lymphohistiocytosis
ID LONG-TERM SURVIVORS; BODY-MASS-INDEX; CHILDHOOD-CANCER SURVIVOR; ADULT
   SURVIVORS; BLOOD-PRESSURE; US CHILDREN; PREVALENCE; ADOLESCENTS; LEPTIN;
   RISK
AB Background Despite several advances in the treatment of Epstein-Barr virus (EBV) in recent years, patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) do not always show satisfactory outcomes. We here conducted a nationwide survey in Japan to identify prognostic factors of EBV-HLH in children with this disease in an effort to improve the management and the outcomes of these patients. Procedure Between January 2003 and June 2008, we enrolled 98 children younger than 18 years of age who were diagnosed with EBV-HLH. We then studied the clinical characteristics and laboratory findings at the time of diagnosis with the aim to identify prognostic factors for EBV-HLH. Results The mean age of onset of EBV-HLH was 3.9 +/- 2.8 years. Most of our patients presented with fever, hepatosplenomegaly, lymphadenopathy, and hemophagocytosis of bone marrow. Sixty-two percent of patients showed T cell clonality, and 97% had EBV infection in either T or natural killer cells. Most patients (60%) were treated with a multi-agent chemotherapeutic regimen, including corticosteroid, etoposide, and cyclosporine. After initial treatment, 90.3% of patients were in remission, and 7 patients (8.2%) experienced recurrence of EBV infection. Among several prognostic factors, patients with both hyperbilirubinemia (>1.8 mg/dl) and hyperferritinemia (>20,300 ng/ml) at the time of diagnosis had significantly poorer outcomes than those with low serum bilirubin and ferritin levels. Conclusions These findings suggest that the therapeutic strategy for children with EBV-HLH could be tailored according to the laboratory findings at diagnosis. Pediatr Blood Cancer 2014;61:1257-1262. (c) 2014 Wiley Periodicals, Inc.
C1 [Zhang, Fang Fang] Tufts Univ, Friedman Sch Nutr Sci & Policy, Dept Nutr Sci, Boston, MA 20111 USA.
   [Zhang, Fang Fang; Roberts, Susan B.; Saltzman, Edward] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 20111 USA.
   [Rodday, Angie Mae; Parsons, Susan K.] Tufts Univ, Sch Med, Dept Med, Boston, MA 20111 USA.
   [Rodday, Angie Mae; Parsons, Susan K.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA.
   [Kelly, Michael J.; Parsons, Susan K.] Tufts Univ, Sch Med, Dept Pediat, Boston, MA 20111 USA.
   [Kelly, Michael J.; MacPherson, Cathy] Tufts Med Ctr, Floating Hosp Children, Div Pediat Hematol Oncol, Boston, MA USA.
   [Must, Aviva] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 20111 USA.
RP Zhang, FF (reprint author), Tufts Univ, Friedman Sch Nutr Sci & Policy, Dept Nutr Sci, 150 Harrison Ave, Boston, MA 20111 USA.
EM fang_fang.zhang@tufts.edu
FU Catalyst; Tufts Clinical and Translational Science Award; National
   Center for Research Resources [UL1 RR025752]; National Center for
   Advancing Translational Sciences, the National Institutes of Health [UL1
   TR000073]; Boston Nutrition Obesity Research Center [P30DK46200]
FX Grant sponsor: Catalyst; Grant sponsor: Tufts Clinical and Translational
   Science Award; Grant sponsor: National Center for Research Resources;
   Grant number: UL1 RR025752; Grant sponsor: National Center for Advancing
   Translational Sciences, the National Institutes of Health; Grant number:
   UL1 TR000073; Grant sponsor: Boston Nutrition Obesity Research Center;
   Grant number: P30DK46200
CR Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C
   Veringa SJE, 2012, PEDIATR BLOOD CANCER, V58, P278, DOI 10.1002/pbc.23251
   Sklar CA, 2000, MED PEDIATR ONCOL, V35, P91, DOI 10.1002/1096-911X(200008)35:2<91::AID-MPO1>3.0.CO;2-G
   Mayer EIE, 2000, HORM RES, V53, P193, DOI 10.1159/000023566
   Brouwer CAJ, 2007, CRIT REV ONCOL HEMAT, V63, P32, DOI 10.1016/j.critrevonc.2007.01.007
   Garmey EG, 2008, J CLIN ONCOL, V26, P4639, DOI 10.1200/JCO.2008.16.3527
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Esbenshade AJ, 2011, PEDIATR BLOOD CANCER, V56, P372, DOI 10.1002/pbc.22782
   Kohler JA, 2011, HORM RES PAEDIAT, V75, P433, DOI 10.1159/000324412
   CRONK C, 1988, PEDIATRICS, V81, P102
   Kourti M, 2005, J PEDIAT HEMATOL ONC, V27, P499, DOI 10.1097/01.mph.0000181428.63552.e9
   Huang TT, 2011, CHEST, V140, P881, DOI 10.1378/chest.10-2133
   Collins L, 2010, J PEDIAT HEMATOL ONC, V32, pE304, DOI 10.1097/MPH.0b013e3181ece2bb
   Nathan PC, 2006, J PEDIATR-US, V149, P518, DOI 10.1016/j.jpeds.2006.06.039
   Withycombe JS, 2009, PEDIATR BLOOD CANCER, V53, P1249, DOI 10.1002/pbc.22237
   Smith M, 1996, J CLIN ONCOL, V14, P18
   ODAME I, 1994, ARCH DIS CHILD, V71, P147
   Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401
   Mariotto AB, 2009, CANCER EPIDEM BIOMAR, V18, P1033, DOI 10.1158/1055-9965.EPI-08-0988
   Love E, 2011, PEDIATR BLOOD CANCER, V57, P1204, DOI 10.1002/pbc.23010
   Tylavsky FA, 2010, PEDIATR BLOOD CANCER, V55, P1362, DOI 10.1002/pbc.22737
   Oeffinger KC, 2008, PEDIATR BLOOD CANCER, V50, P462, DOI 10.1002/pbc.21410
   Mody R, 2008, BLOOD, V111, P5515, DOI 10.1182/blood-2007-10-117150
   Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847
   Reilly JJ, 2000, INT J OBESITY, V24, P1537, DOI 10.1038/sj.ijo.0801403
   Karaman S, 2010, J PEDIATR ENDOCR MET, V23, P669
   Oeffinger KC, 2003, J CLIN ONCOL, V21, P1359, DOI 10.1200/JCO.2003.06.131
   Ness KK, 2007, PEDIATR BLOOD CANCER, V49, P975, DOI 10.1002/pbc.21091
   Centers for Disease Control and Prevention, 2000, CDC GROWTH CHARTS
   Children's Oncology Group, 2008, LONG TERM FOLL UP GU
   Papadia C, 2007, HORM RES, V68, P164, DOI 10.1159/000100781
   Razzouk BI, 2007, J CLIN ONCOL, V25, P1183, DOI 10.1200/JCO.2006.07.8709
   Shaw MP, 2000, PEDIATR HEMAT ONCOL, V17, P231, DOI 10.1080/088800100276406
   Skoczen S, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-64
   van der Sluis IM, 2000, MED PEDIATR ONCOL, V35, P415, DOI 10.1002/1096-911X(20001001)35:4<415::AID-MPO4>3.0.CO;2-9
   VANDONGENMELMAN JEWM, 1995, PEDIATR RES, V38, P86, DOI 10.1203/00006450-199507000-00015
   Warner JT, 2002, MED PEDIATR ONCOL, V38, P165, DOI 10.1002/mpo.1304
NR 37
TC 9
Z9 9
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUL
PY 2014
VL 61
IS 7
BP 1263
EP 1269
DI 10.1002/pbc.24980
PG 7
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA AG1TG
UT WOS:000335198400026
PM 24482072
ER

PT J
AU Khalyfa, A
   Gozal, D
AF Khalyfa, Abdelnaby
   Gozal, David
TI Exosomal miRNAs as potential biomarkers of cardiovascular risk in
   children
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
ID OBSTRUCTIVE SLEEP-APNEA; CELL-DERIVED EXOSOMES; CIRCULATING ENDOTHELIAL
   MICROPARTICLES; ANTIGEN-PRESENTING CELLS; METABOLIC SYNDROME;
   MEMBRANE-VESICLES; PROGENITOR CELLS; DIAGNOSTIC BIOMARKERS; TRANSFERRIN
   RECEPTOR; CHILDHOOD OVERWEIGHT
AB Intercellular interactions are essential for basic cellular activities and errors in either receiving or transferring these signals have shown to cause pathological conditions. These signals are not only regulated by membrane surface molecules but also by soluble secreted proteins, thereby allowing for an exquisite coordination of cell functions. Exosomes are released by cells upon fusion of multivesicular bodies (MVB) with the plasma membrane. Their envelope reflects their cellular origin and their surface and internal contents include important signaling components. Exosomes contain a wide variety of proteins, lipids, RNAs, non-transcribed RNAs, miRNAs and small RNAs that are representative to their cellular origin and shuttle from donor cells to recipient cells. The exosome formation cargo content and delivery is of immense biological interest because exosomes are believed to play major roles in various pathological conditions, and therefore provide unique opportunities for biomarker discovery and development of non-invasive diagnostics when examined in biological fluids such as urine and blood plasma. For example, circulating miRNAs in exosomes have been applied as functional biomarkers for diagnosis and outcomes prediction, while synthetic miRNAs in polymer-based nanoparticles are applicable for therapeutics. This review provides insights into the composition and functional properties of exosomes, and focuses on their potential value as diagnostic markers in the context of cardiovascular disease risk estimates in children who suffer from conditions associated with heightened prevalence of adverse cardiovascular disease, namely obesity and sleep-disordered-breathing.
C1 [Khalyfa, Abdelnaby; Gozal, David] Univ Chicago, Pritzker Sch Med, Dept Pediat, Sect Pediat Sleep Med,Comer Childrens Hosp, Chicago, IL 60637 USA.
   [Khalyfa, Abdelnaby] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.
RP Khalyfa, A (reprint author), Univ Chicago, Pritzker Sch Med, Dept Pediat, Sect Pediat Sleep Med,Comer Childrens Hosp, Chicago, IL 60637 USA.
EM akhalyfa@uchicago.edu
FU National Institutes of Health [HL-065270, HL-086662]
FX DG is supported by National Institutes of Health grants HL-065270 and
   HL-086662.
CR Abi-Rizk G, 2008, COLLOID SURFACE B, V66, P163, DOI 10.1016/j.colsurfb.2008.06.002
   NEEDHAM D, 1990, BIOPHYS J, V58, P997
   Prado N, 2008, J IMMUNOL, V181, P1519
   Priou P, 2010, AM J PATHOL, V177, P974, DOI [10.2353/ajpath.2010.091252, 10.2353/ajpath.2070.091252]
   Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254
   Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7
   Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200
   Piran S, 2012, J AM COLL CARDIOL, V60, P283, DOI 10.1016/j.jacc.2012.05.005
   Jayachandran M, 2012, J IMMUNOL METHODS, V375, P207, DOI 10.1016/j.jim.2011.10.012
   Savina A, 2002, J CELL SCI, V115, P2505
   Scholer N, 2010, EXP HEMATOL, V38, P1126, DOI 10.1016/j.exphem.2010.10.004
   Aharon A, 2008, THROMB HAEMOSTASIS, V100, P878, DOI 10.1160/TH07-11-0691
   Chironi GN, 2009, CELL TISSUE RES, V335, P143, DOI 10.1007/s00441-008-0710-9
   Espinoza-Lewis RA, 2012, CURR TOP DEV BIOL, V100, P279, DOI 10.1016/B978-0-12-387786-4.00009-9
   Amigorena S, 1998, RES IMMUNOL, V149, P661, DOI 10.1016/S0923-2494(99)80035-2
   Thery C, 2001, J IMMUNOL, V166, P7309
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Feng J, 2012, SLEEP BREATH, V16, P283, DOI 10.1007/s11325-011-0519-8
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Laulagnier K, 2004, BIOCHEM J, V380, P161, DOI 10.1042/BJ20031594
   Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004
   Yu X, 2012, J MOL CELL CARDIOL, V53, P848, DOI 10.1016/j.yjmcc.2012.10.002
   Al-Nedawi K, 2005, ARTERIOSCL THROM VAS, V25, P1744, DOI 10.1161/01.ATV.0000172007.86541.76
   Dignat-George F, 2011, ARTERIOSCL THROM VAS, V31, P27, DOI 10.1161/ATVBAHA.110.218123
   Schroen B, 2012, CARDIOVASC RES, V93, P605, DOI 10.1093/cvr/cvr268
   Van Aelst LNL, 2013, J CARDIOVASC TRANSL, V6, P458, DOI 10.1007/s12265-013-9466-z
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Yun CH, 2010, J CLIN NEUROL, V6, P89, DOI 10.3988/jcn.2010.6.2.89
   Aronson JK, 2005, BRIT J CLIN PHARMACO, V59, P491, DOI 10.1111/j.1365-2125.2005.02435.x
   Gunduz Z, 2012, J PEDIATR ENDOCR MET, V25, P1111, DOI 10.1515/jpem-2012-0194
   Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101
   van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jh/mvj128
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Pallet N, 2013, PROTEOMICS, V13, P1108, DOI 10.1002/pmic.201200531
   HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329
   Dursun I, 2009, NEPHROL DIAL TRANSPL, V24, P2511, DOI 10.1093/ndt/gfp066
   Juhola J, 2013, CIRCULATION, V128, P217, DOI 10.1161/CIRCULATIONAHA.113.001614
   Kelishadi R, 2007, EPIDEMIOL REV, V29, P62, DOI 10.1093/epirev/mxm003
   Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   Esposito K, 2006, J CLIN ENDOCR METAB, V91, P3676, DOI 10.1210/jc.2006-0851
   Hulsmans M, 2013, CARDIOVASC RES, V100, P7, DOI 10.1093/cvr/cvt161
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Raposo G, 1997, MOL BIOL CELL, V8, P2631
   Lakkaraju A, 2008, TRENDS CELL BIOL, V18, P199, DOI 10.1016/j.tcb.2008.03.002
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438
   Mathivanan S, 2010, MOL CELL PROTEOMICS, V9, P197, DOI 10.1074/mcp.M900152-MCP200
   Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002
   Gozal D, 2009, AM J RESP CRIT CARE, V180, P1253, DOI 10.1164/rccm.200905-0765OC
   Mocharla P, 2013, BLOOD, V121, P226, DOI 10.1182/blood-2012-01-407106
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Stepanian A, 2013, OBESITY, V21, P2236, DOI 10.1002/oby.20365
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Aggoun Y, 2008, EUR HEART J, V29, P792, DOI 10.1093/eurheartj/ehm633
   Davignon J, 2004, CIRCULATION, V109, P27, DOI 10.1016/01.CIR.0000131515.03336.f8
   DiStefano JK, 2013, CURR DIABETES REP, V13, P582, DOI 10.1007/s11892-013-0386-8
   Keller S, 2007, KIDNEY INT, V72, P1095, DOI 10.1038/sj.ki.5002486
   Hsu DH, 2003, J IMMUNOTHER, V26, P440, DOI 10.1097/00002371-200309000-00007
   VIDAL M, 1989, J CELL PHYSIOL, V140, P455, DOI 10.1002/jcp.1041400308
   Gupta S, 2007, AM J PHYSIOL-HEART C, V292, pH3052, DOI 10.1152/ajpheart.01355.2006
   Abbasi F, 2002, J AM COLL CARDIOL, V40, P937, DOI 10.1016/S0735-1097(02)02051-X
   Hergenreider E, 2012, NAT CELL BIOL, V14, P249, DOI 10.1038/ncb2441
   Mathivanan S, 2009, PROTEOMICS, V9, P4997, DOI 10.1002/pmic.200900351
   Heijnen HFG, 1999, BLOOD, V94, P3791
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Resnick KE, 2009, GYNECOL ONCOL, V112, P55, DOI 10.1016/j.ygyno.2008.08.036
   Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC
   Kelly AS, 2013, CIRCULATION, V128, P1689, DOI 10.1161/CIR.0b013e3182a5cfb3
   Dimov I, 2009, THESCIENTIFICWORLDJO, V9, P1107, DOI 10.1100/tsw.2009.128
   Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Must A, 2012, J PEDIATR-US, V160, P743, DOI 10.1016/j.jpeds.2011.10.037
   Omran A, 2012, MED HYPOTHESES, V79, P889, DOI 10.1016/j.mehy.2012.09.020
   Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033
   Cheng YH, 2012, J MOL CELL CARDIOL, V53, P668, DOI 10.1016/j.yjmcc.2012.08.010
   Masyuk AI, 2013, J HEPATOL, V59, P621, DOI 10.1016/j.jhep.2013.03.028
   LaBaer J, 2005, J PROTEOME RES, V4, P1053, DOI 10.1021/pr01259
   Ayers L, 2009, EUR RESPIR J, V33, P574, DOI 10.1183/09031936.00107408
   Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267
   Ghosh A, 2008, J CLIN INVEST, V118, P1934, DOI 10.1172/JCI34904
   Hristov M, 2004, BLOOD, V104, P2761, DOI 10.1182/blood-2003-10-3614
   Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003
   PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819
   Corsten MF, 2010, CIRC-CARDIOVASC GENE, V3, P499, DOI 10.1161/CIRCGENETICS.110.957415
   Park NJ, 2009, CLIN CANCER RES, V15, P5473, DOI 10.1158/1078-0432.CCR-09-0736
   PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942
   Cho JA, 2005, INT J CANCER, V114, P613, DOI 10.1002/ijc.20757
   Oikonen M, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000244
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061
   Kuwabara Y, 2011, CIRC-CARDIOVASC GENE, V4, P446, DOI 10.1161/CIRCGENETICS.110.958975
   Hirata Y, 2010, INT HEART J, V51, P1
   Gupta SK, 2010, CIRC-CARDIOVASC GENE, V3, P484, DOI 10.1161/CIRCGENETICS.110.958363
   Guillemot L, 2008, BBA-BIOMEMBRANES, V1778, P601, DOI 10.1016/j.bbamem.2007.09.032
   Keller S, 2009, CANCER LETT, V278, P73, DOI 10.1016/j.canlet.2008.12.028
   Morel O, 2011, INT J OBESITY, V35, P1479, DOI 10.1038/ijo.2011.19
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006
   Admyre C, 2007, J IMMUNOL, V179, P1969
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Sheldon H, 2010, BLOOD, V116, P2385, DOI 10.1182/blood-2009-08-239228
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Huang ZH, 2010, INT J CANCER, V127, P118, DOI 10.1002/ijc.25007
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Jansen F, 2012, ARTERIOSCL THROM VAS, V32, P1925, DOI 10.1161/ATVBAHA.112.253229
   Thum T, 2012, CARDIOVASC RES, V93, P543, DOI 10.1093/cvr/cvs085
   Spinale FG, 2013, CIRC RES, V113, P725, DOI 10.1161/CIRCRESAHA.113.300309
   Llorente A, 2007, EUR J CELL BIOL, V86, P405, DOI 10.1016/j.ejcb.2007.05.001
   Mathivanan S, 2012, NUCLEIC ACIDS RES, V40, pD1241, DOI 10.1093/nar/gkr828
   Gozal D, 2012, CURR OPIN PULM MED, V18, P561, DOI 10.1097/MCP.0b013e328358be2d
   Versari D, 2009, DIABETES CARE, V32, pS314, DOI 10.2337/dc09-S330
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Vella LJ, 2008, EUR BIOPHYS J BIOPHY, V37, P323, DOI 10.1007/s00249-007-0246-z
   Yu HR, 2009, PEDIATR ALLERGY IMMU, V20, P699, DOI 10.1111/j.1399-3038.2008.00844.x
   Bhattacharjee R, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-8
   Chugh Shaan, 2010, Curr Cardiol Rev, V6, P124, DOI 10.2174/157340310791162631
   Cosme J, 2013, PROTEOMICS, V13, P1654, DOI 10.1002/pmic.201200441
   de Jong OG, 2012, J EXTRACELL VESICLES, V1, P18396, DOI DOI 10.3402/JEV.V1I0.18396
   Escudier B., 2005, J TRANSL MED, V3, P10, DOI DOI 10.1186/1479-5876-3-10
   Fernandez-Hernando C, 2013, ARTERIOSCL THROM VAS, V33, P178, DOI 10.1161/ATVBAHA.112.300144
   Fomina AF, 2003, EXP CELL RES, V291, P150, DOI 10.1016/S0014-4827(03)00372-0
   Goligorsky MS, 2009, NEPHROLOGY, V14, P291, DOI 10.1111/j.1440-1797.2009.01112.x
   Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8
   Haider BA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089565
   Gozal D, 2008, AM J RESP CRIT CARE, V177, P369, DOI 10.1164/rccm.200608-1190PP
   Kheirandish-Gozal Leila, 2012, Front Neurol, V3, P92, DOI 10.3389/fneur.2012.00092
   Khoury M, 2013, J AM COLL CARDIOL, V62, P742, DOI 10.1016/j.jacc.2013.01.026
   Kim J, 2011, CHEST, V140, P408, DOI 10.1378/chest.10-2161
   Kranendonk MEG, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-37
   Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Morse MA, 2005, J TRANSL MED, V3, P9, DOI DOI 10.1186/1479-5876-3-9
   Müller Günter, 2012, Diabetes Metab Syndr Obes, V5, P247, DOI 10.2147/DMSO.S32923
   Ogawa Y, 2008, TOXICON, V51, P984, DOI 10.1016/j.toxicon.2008.02.003
   Omran A, 2013, CARDIOL YOUNG, V23, P642, DOI 10.1017/S1047951113000048
   Patacchioli FR, 2014, PEDIAT PULMONOL
   Qiu SQ, 2012, ASIAN PAC J ALLERGY, V30, P107
   Reilly J J, 2011, Int J Obes (Lond), V35, P891, DOI 10.1038/ijo.2010.222
   Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068451
   Scholer N, 2011, GENOME MED, V3, DOI 10.1186/gm288
   Sharma D, 2013, J HUM HYPERTENS, V27, P256, DOI 10.1038/jhh.2012.34
   Shtam TA, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-88
   Stiefel P, 2013, ARCH MED RES, V44, P409, DOI 10.1016/j.arcmed.2013.08.005
   Tantawy AAG, 2013, PLATELETS, V24, P605, DOI 10.3109/09537104.2012.749397
   Théry Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3-15
   Tual-Chalot S, 2012, AM J PATHOL, V181, P1473, DOI 10.1016/j.ajpath.2012.06.020
   van Balkom BW, 2013, BLOOD, V121, p[3997, S3991]
   Waldenstrom A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034653
   Zhan R, 2009, BIOCHEM BIOPH RES CO, V387, P229, DOI 10.1016/j.bbrc.2009.06.095
   Zhang Z, 2013, MATERN CHILD HLTH J
NR 157
TC 8
Z9 9
U1 5
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUN 10
PY 2014
VL 12
AR 162
DI 10.1186/1479-5876-12-162
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AK5NY
UT WOS:000338472900001
PM 24912806
ER

PT J
AU Marambio, A
   Watkins, G
   Castro, F
   Riffo, A
   Zuniga, R
   Jans, J
   Villanueva, ME
   Diaz, G
AF Marambio, Andres
   Watkins, Guillermo
   Castro, Fabiola
   Riffo, Andrea
   Zuniga, Roberta
   Jans, Jaime
   Villanueva, Maria E.
   Diaz, Guillermo
TI Changes in iron transporter divalent metal transporter 1 in proximal
   jejunum after gastric bypass
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Roux-en-Y gastric bypass; Bariatric surgery; Divalent metal transporter
   1; Anaemia; Iron
ID NUTRITIONAL DEFICIENCIES; BARIATRIC SURGERY; MORBID-OBESITY; ABSORPTION;
   EXPRESSION; SUPPLEMENTATION; PREVALENCE; PROTEINS; BIOLOGY; ANEMIA
AB AIM: To describe the variation that divalent metal transporter 1 (DMT1) shows in patients after Roux-en-Y gastric bypass (RYGB) surgery.
   METHODS: Prospective and analytical study of DMT1 level at the brush border of proximal jejunum in patients having undergone RYGB surgery. The mucosa of proximal jejunum forming the gastrojejunal anastomosis was biopsied during surgery and after 6 mo later with an endoscopic biopsy. All the patients received precise instructions regarding feeding and nutritional supplementation. Both samples were processed at the same time by immunohistochemistry and western blot. Samples were analysed by a pathologist. For statistical analysis, the. 2 and Wilcoxon tests were used.
   RESULTS: Sixteen patients were recruited, 13 of whom completed the study. Twelve were women. Average age and body mass index (BMI) were 44.1 and 40.4, respectively. Both body weight and BMI decreased significantly during the study period, with an average percent excess weight loss (% EWL) of 60% +/- 13.3% and an average percent excess BMI loss (% EBMIL) of 79.6% +/- 21.6%. Only two patients presented with mild anaemia 6 mo after surgery, but their ferritin levels stayed within normal ranges. Staining for DMT1 showed a significant increase in the cytoplasm of enterocytes located at the tips of the villi (chi(2) = 6.03; p = 0.049). Nevertheless, the total quantity of DMT1 decreased significantly (Z = 2.04; p = 0.04). Associated with these results, we observed a significant increase in goblet cells in the villi 6 mo postoperatively (Z = -2.47; p = 0.013).
   CONCLUSION: Six months after RYGB surgery, patients exhibit an increase in DMT1 expression in the enterocytes of the tips of the villi at the proximal jejunum. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Marambio, Andres; Watkins, Guillermo; Riffo, Andrea; Jans, Jaime] Univ Chile, Clin Hosp, Dept Surg, Santiago 8380456, Chile.
   [Castro, Fabiola] Chilean Air Force Clin Hosp, Dept Gastroenterol, Santiago 7560171, Chile.
   [Zuniga, Roberta; Diaz, Guillermo] Univ Chile, Chem & Pharm Fac, Dept Pharmacol & Toxicol Chem, Santiago 8380492, Chile.
   [Villanueva, Maria E.] Univ Chile, Clin Hosp, Pathol Serv, Santiago 8380456, Chile.
RP Marambio, A (reprint author), Univ Chile, Clin Hosp, Dept Surg, Santos Dumont 999, Santiago 8380456, Chile.
EM amarambio@med.uchile.cl
FU University of Chile Clinical Hospital
FX Supported by "2009 Clinical and Basic Clinical Research Contest" of the
   Bureau for Clinical Research Support from the University of Chile
   Clinical Hospital
CR Frazer DM, 2003, GUT, V52, P340, DOI 10.1136/gut.52.3.340
   Csendes A, 2009, OBES SURG, V19, P269, DOI 10.1007/s11695-008-9625-5
   Vargas-Ruiz AG, 2008, OBES SURG, V18, P288, DOI 10.1007/s11695-007-9310-0
   Dalcanale L, 2010, OBES SURG, V20, P181, DOI 10.1007/s11695-009-9916-5
   Dupic F, 2002, GUT, V51, P648, DOI 10.1136/gut.51.5.648
   Miret S, 2003, ANNU REV NUTR, V23, P283, DOI 10.1146/annurev.nutr.23.011702.073139
   Anderson GJ, 2009, CURR OPIN GASTROEN, V25, P129, DOI 10.1097/MOG.0b013e32831ef1f7
   Kaidar-Person O, 2008, OBES SURG, V18, P1028, DOI 10.1007/s11695-007-9350-5
   SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183
   Simovich M, 2003, AM J HEMATOL, V74, P32, DOI 10.1002/ajh.10383
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Bloomberg RD, 2005, OBES SURG, V15, P145, DOI 10.1381/0960892053268264
   Davies DJ, 2007, OBES SURG, V17, P1150, DOI 10.1007/s11695-007-9208-x
   Ruz M, 2009, AM J CLIN NUTR, V90, P527, DOI 10.3945/ajcn.2009.27699
   Guzman S, 2013, REV MED CHILE, V141, P553, DOI 10.4067/S0034-98872013000500001
   Marinella MA, 2008, SOUTH MED J, V101, P1024, DOI 10.1097/SMJ.0b013e31817cf7b7
   Schweiger C, 2010, OBES SURG, V20, P193, DOI 10.1007/s11695-009-0008-3
   Bavaresco M, 2010, OBES SURG, V20, P716, DOI 10.1007/s11695-008-9721-6
   Gasteyger C, 2008, AM J CLIN NUTR, V87, P1128
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   Stuart KA, 2003, GUT, V52, P953, DOI 10.1136/gut.52.7.953
   Barisani D, 2004, PHYSIOL GENOMICS, V17, P316, DOI 10.1152/physiolgenomics.00211.2003
   Zoller H, 2001, GASTROENTEROLOGY, V120, P1412, DOI 10.1053/gast.2001.24033
   Brolin RE, 1998, ARCH SURG-CHICAGO, V133, P740, DOI 10.1001/archsurg.133.7.740
   Conrad ME, 2000, AM J PHYSIOL-GASTR L, V279, pG767
   Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2
   Papapietro K, 2005, REV MED CHILE, V133, P511, DOI 10.4067/S0034-98872005000500001
   Varma S, 2008, SURG OBES RELAT DIS, V4, P715, DOI [10.1016/j.soard.2008.04.015, 10.1010/j.soard.2008.04.015]
NR 28
TC 2
Z9 2
U1 2
U2 4
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUN 7
PY 2014
VL 20
IS 21
BP 6534
EP 6540
DI 10.3748/wjg.v20.i21.6534
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AK6BS
UT WOS:000338513200018
PM 24914374
ER

PT J
AU Cairo, RCD
   Silva, LR
   Bustani, NC
   Marques, CDF
AF de Andrade Cairo, Romilda Castro
   Silva, Luciana Rodrigues
   Bustani, Nadya Carneiro
   Ferreira Marques, Cibele Dantas
TI Iron deficiency anemia in adolescents; a literature review
SO NUTRICION HOSPITALARIA
LA English
DT Review
DE Iron deficiency anemia; Iron deficiency; Adolescent
ID EAST JAVA; CHILDREN; PREVALENCE; GIRLS; CHILDHOOD; FERRITIN;
   SUPPLEMENTATION; FORTIFICATION; HEMOGLOBIN; OVERWEIGHT
AB Introduction: Anemia is one of the most important nutritional deficiencies affecting various social and socioeconomic strata. It is more common in developing countries, with children and adolescents being at a significantly higher risk for the condition.
   Objective: To perform a literature review on iron deficiency anemia in adolescence as a public health issue and on the risk factors that may contribute towards nutritional deficiencies, stunted growth and development in this age group, emphasizing the physiopathology and causes of anemia, the different diagnostic approaches, and its clinical characteristics, prevention and treatment.
   Methodology: The LILACS-BIREME, SCIELO and PUBMED databases were consulted for the study. Scientific papers published in Spanish, Portuguese or English between 2000 and 2013 on the subject of iron deficiency anemia in adolescents were selected for inclusion. A total of 102 studies published between January 1st, 2000 and June 30th, 2013 were identified and evaluated. Forty-two articles meeting the inclusion criterion (adolescents with anemia) were selected for this review. Finally, an analysis was conducted and the papers were evaluated in accordance with the study objectives. Results and
   Discussion: The studies reviewed revealed a prevalence of iron deficiency anemia of around 20% in adolescents and described the harmful effects of anemia in this age group.
   Conclusion: Preventive action is required with respect to iron deficiency anemia. Healthcare professionals should be aware of the need for early diagnosis, prophylaxis and treatment.
C1 [de Andrade Cairo, Romilda Castro; Bustani, Nadya Carneiro; Ferreira Marques, Cibele Dantas] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [de Andrade Cairo, Romilda Castro; Silva, Luciana Rodrigues; Ferreira Marques, Cibele Dantas] Prof Edgard Santos Teaching Hosp, Dept Pediat Gastroenterol & Hepatol, Brussels, Belgium.
   [de Andrade Cairo, Romilda Castro] Hosp Alianca, Emergency Dept, Salvador, BA, Brazil.
   [Silva, Luciana Rodrigues] Prof Edgard Santos Teaching Hosp, Dept Pediat, Salvador, BA, Brazil.
   [Ferreira Marques, Cibele Dantas] Hosp Cent Roberto Santos, Salvador, BA, Brazil.
RP Cairo, RCD (reprint author), Alameda Anturios 178,Apdo 702, BR-40296530 Salvador, BA, Brazil.
EM romildacairo@terra.com.br
CR Aguiar CD, 2006, MONOGRAFIA U REGIONA
   Andrews NC, 2000, DIGEST LIVER DIS, V32, P56, DOI 10.1016/S1590-8658(00)80045-6
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291
   Tefferi A, 2003, MAYO CLIN PROC, V78, P1274
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Baker RD, 2010, PEDIATRICS, V126, P1040, DOI 10.1542/peds.2010-2576
   OSKI FA, 1993, NEW ENGL J MED, V329, P190
   REEVES JD, 1984, J PEDIATR-US, V105, P874, DOI 10.1016/S0022-3476(84)80069-4
   Worwood M, 1997, CLIN CHIM ACTA, V259, P3, DOI 10.1016/S0009-8981(96)06488-1
   MILMAN N, 1991, EUR J HAEMATOL, V47, P134
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Carter RC, 2010, PEDIATRICS, V126, pE427, DOI 10.1542/peds.2009-2097
   Baker WF, 2000, HEMATOL ONCOL CLIN N, V14, P1061, DOI 10.1016/S0889-8588(05)70171-4
   HERSHKO C, 1993, P NUTR SOC, V52, P165, DOI 10.1079/PNS19930048
   Bruner AB, 1996, LANCET, V348, P992, DOI 10.1016/S0140-6736(96)02341-0
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Mesias M, 2013, CRIT REV FOOD SCI, V53, P1226, DOI 10.1080/10408398.2011.564333
   Assuncao MCF, 2007, CAD SAUDE PUBLICA, V23, P269, DOI 10.1590/S0102-311X2007000200003
   Bagni U. V., 2011, Nutrire - Revista da Sociedade Brasileira de Alimentação e Nutrição, V36, P177
   Ballard L, 2000, SOUTHERN MED J, V93, P571
   Biscegli Terezinha Soares, 2008, Rev. paul. pediatr., V26, P124, DOI 10.1590/S0103-05822008000200005
   Bortolini GA, 2008, ANEMIA FERROPRIVA NU, P243
   Bourroul MLM, 2000, PEDIAT CONSULTORIO
   Braga Josefina A. P., 2010, Rev. Bras. Hematol. Hemoter., V32, P38
   Braga JAP, 2008, PAPEL FERRO CRESCIME, P48
   Braga JAP, 2011, ANEMIAS CARENCIAIS, P197
   Braga JAP, 2007, HEMATOLOGIA PEDIAT, P23
   Brasil - Ministerio da Saude Unicef, 2007, CAD AT BAS A
   Brazil - Ministerio da Saude, 2004, COMPR SOC RED AN CAR
   Brittenham Gary M., 1995, P492
   Caballo Roig N., 1993, AN ESP PEDIATR, V39, P219
   Cancado RD, 2001, ARQUIVOS MED HOSP FA, V46, P10
   Centers for Disease Control and Prevention (CDC), 2002, MMWR-MORBID MORTAL W, V51, P897
   Chiattone CS, 1988, THESIS ESCOLA PAULIS
   Chipkevitch E., 2001, JPED S2, V77, pS135
   COHEN A, 1979, AM J HEMATOL, V7, P69, DOI 10.1002/ajh.2830070109
   Cook JD, 2003, NEWER ASPECTS DIAGNO, P40
   Dallmann PR, 2001, NESTLE NUTR WORKSHOP, V4, P11
   Das Dilip Kumar, 2005, Indian J Public Health, V49, P18
   Gillespie S, 2001, CONTROLLING IRON DEF
   Gottschalk R, 2000, CLIN CHIM ACTA, V293, P127, DOI 10.1016/S0009-8981(99)00242-9
   Green M., 1994, BRIGHT FUTURES NATL
   Hoffbrand AV, 2006, FUNDAMENTOS HEMATOLO
   Iuliano B. A., 2004, Revista de Nutrição, V17, P37, DOI 10.1590/S1415-52732004000100004
   Jordão Regina Esteves, 2009, Rev. paul. pediatr., V27, P90, DOI 10.1590/S0103-05822009000100014
   Kurpad AV, 2013, CURR OPIN CLIN NUTR, V16, P328, DOI 10.1097/MCO.0b013e32835e8d0b
   Lewis SM, 2006, HEMATOLOGIA PRATICA
   Longo KH, 2005, MONOGRAFIA U REGIONA
   Marques MF, 2012, HU REV JUIZ FORA, V38, P78
   Massawe SN, 2002, GYNECOL OBSTET INVES, V54, P137, DOI 10.1159/000067879
   Means RT, 2013, HEMATOLOGY, V18, P305, DOI 10.1179/1024533213Z.000000000197
   Merckel D, 2005, J ADOLESCENT HEALTH, V37, P220
   Michaca VJS, 2012, PEDIATRIA MEXICO, V14, P71
   Moreira ICM, 2010, THESIS U PORTO
   Nathan GD, 1998, NATHAN OSKIS HEMATAL
   NELSON M, 1993, BRIT J NUTR, V70, P147, DOI 10.1079/BJN19930112
   Neuman NA, 2000, REV SAUDE PUBL, V34, P56, DOI 10.1590/S0034-89102000000100011
   Trindade Nunes Sandra Maria, 2008, Acta Amazonica, V38, P263, DOI 10.1590/S0044-59672008000200009
   OLSSON KS, 1995, J INTERN MED, V237, P187
   Orkin SH, 2009, NATHAN OSKIS HEMATOL, P911
   Paiva AA, 2000, REV SAUDE PUBL, V34, P421, DOI 10.1590/S0034-89102000000400019
   Queiroz SS, 2000, J PEDIAT S3, V76, pS298
   Rockey DC, 2005, GASTROENTEROL CLIN N, V34, P699, DOI 10.1016/j.gtc.2005.08.010
   Rybo G, 1985, MECH MENSTRUAL BLEED, P181
   Santos CLA, 2012, REV BRAS CRESCIMENTO, V22, P341
   Schimitz BAS, 1998, PEDIAT MODERNA, V34, P155
   Silva APR, 2006, COMUM CIENC SAUDE, V17, P53
   Silva FC, 2007, REV NUTR, V20, P297
   Silva GD, 2002, REV NUTR, V12, P54
   Sociedade Brasileira de Pediatria - SBP, 2009, AV NUTR CRIANC AD MA
   Soekarjo DD, 2001, EUR J CLIN NUTR, V55, P932, DOI 10.1038/sj.ejcn.1601248
   Soekarjo DD, 2004, EUR J CLIN NUTR, V58, P927, DOI 10.1038/sj.ejcn.1601914
   Temoteo TL, 2012, THESIS U FEDERAL PIA
   Torres MAA, 1996, REV SAUDE PUBL, V30, P350, DOI 10.1590/S0034-89101996000400008
   Tran TN, 1997, BLOOD, V90, P4979
   Vitalle MSS, 2007, ADOLESCENCIA ABORDAG
   Vitalle MSS, 2006, FERRO SAUDE POPULACO, P1
   WHO, GROWTH REF DAT 5 19
   WHO, 2001, IR DEF AN ASS PREV C
   YIP R, 1987, PEDIATRICS, V80, P330
   Zago MA, 2004, HEMATOLOGIA FUNDAMEN
NR 82
TC 0
Z9 0
U1 1
U2 12
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD JUN
PY 2014
VL 29
IS 6
BP 1240
EP 1249
DI 10.3305/nh.2014.29.6.7245
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AM9UT
UT WOS:000340227200004
ER

PT J
AU Oh, S
   Tanaka, K
   Tsujimoto, T
   So, R
   Shida, T
   Shoda, J
AF Oh, Sechang
   Tanaka, Kiyoji
   Tsujimoto, Takehiko
   So, Rina
   Shida, Takashi
   Shoda, Junichi
TI Regular Exercise Coupled to Diet Regimen Accelerates Reduction of
   Hepatic Steatosis and Associated Pathological Conditions in Nonalcoholic
   Fatty Liver Disease
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article
ID INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME;
   OXIDATIVE STRESS; WEIGHT-LOSS; OBESITY; LEPTIN; STEATOHEPATITIS;
   STRATEGIES; PLASMA
AB Background: A diet regimen focusing on weight loss is still the most efficient treatment for nonalcoholic fatty liver disease (NAFLD). Recently, specific benefits of exercise against NAFLD independent of weight loss have been reported. Hence, combining exercise with diet-induced weight loss can be expected to have an additive benefit for NAFLD management. We evaluated the effectiveness of diet in conjunction with exercise (DE) compared with that of diet alone (D) on hepatic steatosis and its underlying pathophysiology.
   Methods: Data obtained from 72 obese, middle-aged men with NAFLD who completed a 3-month program of DE or D in 2011 and 2012 were analyzed. Subjects went through a comprehensive parameters analysis for the pathophysiology of NAFLD.
   Results: Subjects in the DE group, compared with those in the D group, elicited additive effects on the degree of hepatic steatosis (-82.6% vs. -60.0%) and body weight (-13.3% vs. -8.9%) accompanied by an improvement in serum marker levels: inflammation, ferritin (-16.1% vs. -2.1%); oxidative stress, lipid peroxidation (-31.8% vs. +4.8%); adipokine imbalance, adiponectin, and leptin (+27.4% vs. +2.6% and -74.4% vs. -30.2%). Consequently, subjects in the DE group achieved further attenuation of insulin resistance [homeostatsis model assessment of insulin resistance (HOMA-IR) (-63.6% vs. -40.0%)]. These observed additive benefits in the DE group were closely associated with the increased volume of physical activity.
   Conclusions: The addition of exercise to a diet regimen potentiates the benefits in NAFLD management through further improvement of hepatic steatosis, inflammatory and oxidative stress levels, and adipokine imbalance, thereby attenuating insulin resistance independent of detectable weight loss.
C1 [Oh, Sechang] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan.
   [Tanaka, Kiyoji; Tsujimoto, Takehiko; So, Rina] Univ Tsukuba, Fac Hlth & Sport Sci, Tsukuba, Ibaraki 3058575, Japan.
   [Shida, Takashi] Univ Tsukuba, Div Med Sci, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan.
   [Shoda, Junichi] Univ Tsukuba, Fac Med, Div Med Sci, Tsukuba, Ibaraki 3058575, Japan.
RP Shoda, J (reprint author), Univ Tsukuba, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
EM shodaj@md.tsukuba.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [23300250, 24390488]
FX This work was supported in part by Grants-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology,
   Japan (23300250, 24390488).
CR Malaguarnera L, 2005, J HEPATOL, V42, P585, DOI 10.1016/j.jhep.2004.11.040
   Lin H, 2010, AM J PATHOL, V177, P1697, DOI 10.2353/ajpath.2010.090789
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Eguchi E, 2012, EUR HEART J, V33, P467, DOI 10.1093/eurheartj/ehr429
   Okada K, 2012, J GASTROENTEROL, V47, P924, DOI 10.1007/s00535-012-0552-9
   Rector RS, 2011, J APPL PHYSIOL, V111, P1828, DOI 10.1152/japplphysiol.00384.2011
   Madan K, 2006, J CLIN GASTROENTEROL, V40, P930, DOI 10.1097/01.mcg.0000212608.59090.08
   Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929
   Sasso M, 2010, ULTRASOUND MED BIOL, V36, P1825, DOI 10.1016/j.ultrasmedbio.2010.07.005
   Sandrin L, 2003, ULTRASOUND MED BIOL, V29, P1705, DOI 10.1016/j.ultrasmedbio.2003.07.001
   Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129
   Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI 10.1172/JCI200215001
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   Rector RS, 2008, WORLD J GASTROENTERO, V14, P185, DOI 10.3748/wjg.14.185
   Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354
   Leclercq IA, 2002, J HEPATOL, V37, P206, DOI 10.1016/S0168-8278(02)00102-2
   Fabbrini E, 2009, P NATL ACAD SCI USA, V106, P15430, DOI 10.1073/pnas.0904944106
   Day CP, 2006, CLIN MED, V6, P19
   Kanazawa M, 2005, WORLD REV NUTR DIET, V94, P1, DOI 10.1159/000088200
   Shyangdan D, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15380
   Fealy CE, 2012, J APPL PHYSIOL, V113, P1, DOI 10.1152/japplphysiol.00127.2012
   Hallsworth K, 2011, GUT, V60, P1278, DOI 10.1136/gut.2011.242073
   Richter EA, 2009, BIOCHEM J, V418, P261, DOI 10.1042/BJ20082055
   Targher G, 2008, DIABETOLOGIA, V51, P1947, DOI 10.1007/s00125-008-1135-4
   Targher G, 2007, DIABETIC MED, V24, P1, DOI 10.1111/j.1464-5491.2007.02025.x
   Oh S, 2013, MED SCI SPORT EXER, V45, P2214, DOI 10.1249/MSS.0b013e31829afc33
   Brandt C, 2010, J BIOMED BIOTECHNOL
   Chu MP, 2013, OBESITY, V21, P2021, DOI 10.1002/oby.20339
   FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
   Kim SY, 2011, FREE RADIC BIOL S51, pS13
   Lemasters JJ, 2009, LIVER BIOL PATHOBIOL, P511, DOI 10.1002/9780470747919.ch33
   Miyashita M, 2010, J ATHEROSCLER THROMB, V17, P21
   Muthusamy VR, 2012, FREE RADICAL BIO MED, V52, P366, DOI 10.1016/j.freeradbiomed.2011.10.440
   Nagai M, 2012, BMJ OPEN
   Sinn DH, 2011, AM J GASTROENTEROL, V107, P561
   Tobe K, 1999, AM J GASTROENTEROL, V94, P3328, DOI 10.1016/S0002-9270(99)00608-5
   Tomita K, 2008, HEPATOLOGY, V48, P458, DOI 10.1002/hep.22365
   Barba C, 2004, LANCET, V363, P157
NR 38
TC 5
Z9 5
U1 2
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
EI 1557-8518
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD JUN
PY 2014
VL 12
IS 5
BP 290
EP 298
DI 10.1089/met.2013.0143
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AI9JV
UT WOS:000337249800007
PM 24689911
ER

PT J
AU Li, BQ
   Lin, W
   Lin, N
   Dong, XW
   Liu, LB
AF Li, Biqiang
   Lin, Wei
   Lin, Nan
   Dong, Xiaowen
   Liu, Libin
TI Study of the correlation between serum ferritin levels and the
   aggregation of metabolic disorders in non-diabetic elderly patients
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE serum ferritin; metabolic disorder; diabetes; insulin
ID INFLAMMATION; HYPERTENSION; SENSITIVITY; DISEASE; MEN
AB The present study aimed to explore the correlation between serum ferritin (SF) levels and the aggregation of metabolic disorders in non-diabetic elderly patients. A total of 2,600 patients were enrolled in the study. Various parameters, including blood pressure (BP), height, weight, lipid profiles, blood glucose (BG), body mass index (BMI), fasting insulin (FINS), serum uric acid (SUA), the urinary albumin/creatinine ratio (UACR) and SF levels were measured. A homeostatic model was used to evaluate insulin resistance (HOMA-IR) and beta-cell function (HOMA-beta). The quantitative insulin sensitivity check index (QUICKI) and disposition index (DI) were calculated. The QUICKI and DI decreased significantly and other parameters increased significantly when the number of metabolic disorders increased. Patients with high triglycerides (TG), high total cholesterol (TC), high SUA and obesity demonstrated higher SF levels than those with normal TG, normal. TC, normal SUA and normal weight, respectively (P<0.01). Male patients with metabolic disorders (high TG, high TC, high BP, high SUA and obesity) had higher SF levels than female patients with the corresponding disorders (P<0.01). BG, FINS, BMI, TC, TG, SUA, HOMA-IR and HOMA-beta were positively correlated with SF, while DI and QUICKI were negatively correlated with SF (P<0.01). Stepwise regression analysis showed that HOMA-IR, BMI, TC, TG and SUA were risk factors for elevated SF levels. In conclusion, the SF levels in non-diabetic, elderly individuals with metabolic disorders may be significantly related to the clustering of the metabolic disorders. Dyslipidemia, obesity, disorders of purine metabolism and insulin resistance may be important risk factors for higher SF levels in the elderly.
C1 [Li, Biqiang; Lin, Wei; Lin, Nan; Dong, Xiaowen] Fujian Med Univ, Union Hosp, Dept Cadre Ward, Fuzhou 350001, Fujian, Peoples R China.
   [Liu, Libin] Fujian Med Univ, Union Hosp, Dept Endocrinol, Fuzhou 350001, Fujian, Peoples R China.
RP Liu, LB (reprint author), Fujian Med Univ, Union Hosp, Dept Endocrinol, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China.
EM liulibindoctor@yeah.net
CR Jennings JR, 2013, STROKE, V44, P2480, DOI 10.1161/STROKEAHA.113.001716
   Sharifi F, 2008, DIABETES VASC DIS RE, V5, P15, DOI 10.3132/dvdr.2008.003
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Deng X, 2012, CHIN J HEAL MANAG, V6, P271
   El-Gebali HH, 2000, SAUDI MED J, V21, P184
   Ginsberg H, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-S1-S1
   Haraguchi K, 2012, EXP THER MED, V4, P581, DOI 10.3892/etm.2012.663
   Leiva E, 2010, EXP THER MED, V1, P175, DOI 10.3892/etm_000000028
   Lu Y, 2012, CHINESE J HLTH MANAG, V6, P45
   Mainous AG, 2012, BIOMETALS, V25, P563, DOI 10.1007/s10534-012-9536-8
   Warnberg J, 2008, CURR OPIN LIPIDOL, V19, P11, DOI 10.1097/MOL.0b013e3282f4096b
   WOLFF SP, 1993, BRIT MED BULL, V49, P642
   Zhang J, 2006, CHINESE J CHILD HLTH, V14, P231
NR 19
TC 1
Z9 1
U1 1
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUN
PY 2014
VL 7
IS 6
BP 1671
EP 1676
DI 10.3892/etm.2014.1668
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AI0QX
UT WOS:000336555100041
ER

PT J
AU Ndisang, JF
AF Ndisang, Joseph Fomusi
TI Cross-talk between heme oxygenase and peroxisome proliferator-activated
   receptors in the regulation of physiological functions
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Heme oxygenase; Diabetes; Peroxisome proliferator-activated receptor;
   Oxidative stress; Inflammation; Review
ID NF-KAPPA-B; IMPROVES INSULIN SENSITIVITY; PPAR-GAMMA AGONIST;
   ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; DIABETIC FATTY RATS;
   DEOXYCORTICOSTERONE-ACETATE HYPERTENSION; OXYGENASE-1-DERIVED
   CARBON-MONOXIDE; ENDOTHELIAL-CELL ACTIVATION; DIET-INDUCED OBESITY
AB Peroxisome-proliferator-activated-receptors (PPARs) are transcription factors belonging to the superfamily of nuclear receptors. The isoforms of PPAR include PPAR alpha, PPAR gamma and PPAR delta (also known as PPAR beta). Generally, PPARs potentiate insulin sensitivity, improve glucose/lipid metabolism, suppress inflammation/oxidative stress, attenuate excessive immune responses, regulate cell-growth and differentiation. Interestingly, agonists of PPAR gamma and PPAR alpha have been shown to upregulate the heme-oxygenase (HO)-system. Conversely, the HO-system also enhances PPAR alpha, and potentiates the expression and activity of PPAR g. Moreover, the HO-system and related products including bilirubin, biliverdin, carbon monoxide and ferritin have been shown to increase insulin sensitivity, improve glucose/lipid metabolism, suppress inflammation/oxidative stress, abate immune response, and modulate cell-growth/differentiation. Therefore, an intimate, reciprocal, stimulatory and synergistic relationship between PPAR-signaling and the HO-system can be envisaged in the regulation of physiological functions. Thus, both the HO-system and PPARs-signaling participate in fine-tuning similar physiological functions, so novel pharmacological agents capable of optimizing this interaction should be sought. The coordinated regulation of PPAR-signaling and the HO-system may constitute the basis for future drug design.
C1 Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada.
RP Ndisang, JF (reprint author), Univ Saskatchewan, Coll Med, Dept Physiol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
EM joseph.ndisang@usask.ca
FU Heart & Stroke Foundation of Saskatchewan, Canada
FX This work was supported by a grant from the Heart & Stroke Foundation of
   Saskatchewan, Canada to Dr. Joseph Fomusi Ndisang. The author has
   nothing to disclose. The author has no conflict of interest that could
   be perceived as prejudicing the impartiality of the research reported.
CR Adeghate Ernest, 2011, Open Med Chem J, V5, P93, DOI 10.2174/1874104501105010093
   Ali F, 2010, CARDIOVASC RES, V85, P701, DOI 10.1093/cvr/cvp365
   Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   Gaskin FS, 2009, MICROCIRCULATION, V16, P167, DOI 10.1080/10739680802355897
   Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748
   Zabalgoitia M, 2008, FREE RADICAL BIO MED, V44, P284, DOI 10.1016/j.freeradbiomed.2007.08.012
   Lecka-Czernik B, 2010, IDRUGS, V13, P793
   Tata JR, 2002, NAT REV MOL CELL BIO, V3, P702, DOI 10.1038/nrm914
   Lin H, 2010, AM J PATHOL, V177, P1697, DOI 10.2353/ajpath.2010.090789
   Sugawara A, 2010, ENDOCR J, V57, P847
   Hayashi S, 2004, GENE, V336, P241, DOI 10.1016/j.gene.2004.04.002
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987
   Sarafidis PA, 2006, AM J HYPERTENS, V19, P646, DOI 10.1016/j.amjhyper.2005.12.017
   Ndisang JF, 2003, BLOOD, V101, P3893, DOI 10.1182/blood-2002-08-2608
   Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335
   GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Burgess A, 2010, HYPERTENSION, V56, P1124, DOI 10.1161/HYPERTENSIONAHA.110.151423
   RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443
   Ndisang JF, 2010, HYPERTENS RES, V33, P338, DOI 10.1038/hr.2010.1
   Aguilar V, 2010, ENDOCRINOLOGY, V151, P5247, DOI 10.1210/en.2010-0461
   Sun BW, 2008, INT J BIOL SCI, V4, P176
   Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com
   Kronke G, 2007, ARTERIOSCL THROM VAS, V27, P1276, DOI 10.1161/ATVBAHA.107.142638
   Mohri T, 2006, J TRAUMA, V61, P616, DOI 10.1097/01.ta.0000238228.67894.d7
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Cummins NW, 2012, FASEB J, V26, P2911, DOI 10.1096/fj.11-190017
   VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118
   McDaid J, 2005, FASEB J, V19, P458, DOI 10.1096/fj.04-2217fje
   Motani A, 2009, J MOL BIOL, V386, P1301, DOI 10.1016/j.jmb.2009.01.025
   Ndisang JF, 2008, J HYPERTENS, V26, P1188, DOI 10.1097/HJH.0b013e3282fad93d
   Luciani A, 2009, J IMMUNOL, V183, P2775, DOI 10.4049/jimmunol.0900993
   Kwon DY, 2011, J ETHNOPHARMACOL, V135, P455, DOI 10.1016/j.jep.2011.03.037
   Liu DN, 2012, J PHARMACOL SCI, V118, P14, DOI 10.1254/jphs.11071FP
   Zhang HF, 2013, CELL BIOL INT, V37, P430, DOI 10.1002/cbin.10046
   Ndisang JF, 2010, ENDOCRINOLOGY, V151, P549, DOI 10.1210/en.2009-0471
   Tian XY, 2012, DIABETES, V61, P3285, DOI 10.2337/db12-0117
   Benito C, 2012, BRIT J PHARMACOL, V166, P1474, DOI 10.1111/j.1476-5381.2012.01889.x
   Zarzuelo MJ, 2013, CARDIOVASC RES, V99, P622, DOI 10.1093/cvr/cvt152
   Glass CK, 2001, J ENDOCRINOL, V169, P461, DOI 10.1677/joe.0.1690461
   Jun CD, 2006, INFLAMM BOWEL DIS, V12, P619, DOI 10.1097/01.ibd.0000225340.99108.8a
   MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B
   Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200
   Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829
   Ndisang JF, 2013, AM J HYPERTENS, V26, P1123, DOI 10.1093/ajh/hpt082
   Liu F, 2012, MOL BIOL REP, V39, P873, DOI 10.1007/s11033-011-0811-5
   Tsoyi K, 2009, INFLAMMATION, V32, P364, DOI 10.1007/s10753-009-9144-0
   Ndisang JF, 2004, J HYPERTENS, V22, P1057, DOI 10.1097/01.hjh.0000125413.50839.fc
   Kim HJ, 2011, BIOCHEM BIOPH RES CO, V406, P564, DOI 10.1016/j.bbrc.2011.02.091
   Jadhav A, 2009, AM J PHYSIOL-RENAL, V296, pF521, DOI 10.1152/ajprenal.00510.2007
   Bolognesi M, 2007, J PHARMACOL EXP THER, V321, P187, DOI 10.1124/jpet.106.116665
   Balas B, 2007, J HEPATOL, V47, P565, DOI 10.1016/j.jhep.2007.04.013
   Carta AR, 2013, NEUROTOX RES, V23, P112, DOI 10.1007/s12640-012-9342-7
   Shin DW, 2009, BIOCHEM PHARMACOL, V77, P125, DOI 10.1016/j.bcp.2008.09.033
   TUGWOOD JD, 1992, EMBO J, V11, P433
   Dimitrov JD, 2010, BLOOD, V115, P2682, DOI 10.1182/blood-2009-04-216408
   Hoetzel A, 2008, AM J RESP CRIT CARE, V177, P1223, DOI 10.1164/rccm.200708-1265OC
   Elijah IE, 2012, BURNS, V38, P481, DOI 10.1016/j.burns.2011.12.004
   Lebrun V, 2013, CLIN SCI, V125, P501, DOI 10.1042/CS20130064
   Bilban M, 2006, IMMUNITY, V24, P601, DOI 10.1016/j.immuni.2006.03.012
   Abdallah DM, 2010, BRAIN RES, V1351, P246, DOI 10.1016/j.brainres.2010.06.034
   Tsai PS, 2006, ANESTHESIOLOGY, V105, P1201, DOI 10.1097/00000542-200612000-00020
   Miyazaki Y, 2008, DIABETES OBES METAB, V10, P1204, DOI 10.1111/j.1463-1326.2008.00880.x
   Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832
   KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99
   Kilter H, 2009, DIABETES OBES METAB, V11, P1060, DOI 10.1111/j.1463-1326.2009.01097.x
   Yazawa T, 2010, MOL ENDOCRINOL, V24, P485, DOI 10.1210/me.2009-0352
   Oishi Y, 2008, NAT MED, V14, P656, DOI 10.1038/nm1756
   Kinoshita H, 2006, J PHARMACOL EXP THER, V318, P312, DOI 10.1124/jpet.106.100958
   Burns KA, 2007, BBA-MOL CELL BIOL L, V1771, P952, DOI 10.1016/j.bbalip.2007.04.018
   Jonas JC, 2003, DIABETOLOGIA, V46, P1234, DOI 10.1007/s00125-003-1174-9
   Ndisang JF, 2009, ENDOCRINOLOGY, V150, P2627, DOI 10.1210/en.2008-1370
   Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388
   Lu M, 2011, NAT MED, V17, P618, DOI 10.1038/nm.2332
   Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507
   Marx N, 2003, CIRCULATION, V107, P1954, DOI 10.1161/01.CIR.0000069272.06194.91
   Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816
   El-Gowelli HM, 2011, J CARDIOVASC PHARM, V58, P173, DOI 10.1097/FJC.0b013e31821ed803
   Di Paola R, 2010, J LEUKOCYTE BIOL, V88, P291, DOI 10.1189/jlb.0110053
   Chiang N, 2013, J IMMUNOL, V190, P6378, DOI 10.4049/jimmunol.1202969
   Zheng Y, 2010, MOL VIS, V16, P1467
   Li M, 2008, DIABETES, V57, P1526, DOI 10.2337/db07-1764
   Schulz S, 2013, AM J PHYSIOL-GASTR L, V304, pG991, DOI 10.1152/ajpgi.00363.2012
   Reilly SM, 2008, FEBS LETT, V582, P26, DOI 10.1016/j.febslet.2007.11.040
   Kim JW, 2008, BIOCHEM PHARMACOL, V76, P1577, DOI 10.1016/j.bcp.2008.08.007
   Caballero AE, 2003, METABOLISM, V52, P173, DOI 10.1053/meta.2003.50023
   Roberts RA, 1998, CARCINOGENESIS, V19, P43, DOI 10.1093/carcin/19.1.43
   Ndisang JF, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/359732
   Rubenstrunk A, 2007, BBA-MOL CELL BIOL L, V1771, P1065, DOI 10.1016/j.bbalip.2007.02.003
   Ollinger R, 2007, ANTIOXID REDOX SIGN, V9, P2175, DOI 10.1089/ars.2007.1807
   Ferguson HE, 2009, AM J PHYSIOL-LUNG C, V297, pL912, DOI 10.1152/ajplung.00148.2009
   Romano MR, 2012, EUR J PHARMACOL, V683, P197, DOI 10.1016/j.ejphar.2012.02.049
   Ndisang JF, 2010, AM J PHYSIOL-REG I, V298, pR211, DOI 10.1152/ajpregu.91000.2008
   Bionaz M, 2012, BRIT J NUTR, V107, P179, DOI 10.1017/S0007114511002777
   Bain DL, 2007, ANNU REV PHYSIOL, V69, P201, DOI 10.1146/annurev.physiol.69.031905.160308
   Higashiyama H, 2007, HISTOCHEM CELL BIOL, V127, P485, DOI 10.1007/s00418-007-0279-5
   Long GG, 2008, TOXICOL PATHOL, V36, P218, DOI 10.1177/0192623307311757
   Picard F, 2002, ANNU REV NUTR, V22, P167, DOI 10.1146/annurev.nutr.22.010402.102808
   Lin H, 2013, MOL PHARMACOL, V84, P275, DOI 10.1124/mol.112.083964
   MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051
   Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100
   Abraham NG, 2003, CIRC RES, V93, P507, DOI 10.1161/01.RES.0000091828.36599.34
   Kim YS, 2005, FREE RADICAL BIO MED, V38, P85, DOI 10.1016/j.freeradbiomed.2004.09.031
   Ndisang JF, 2003, EXP BIOL MED, V228, P557
   Zhuang H, 2003, ANN NY ACAD SCI, V993, P208
   Donovan C, 2012, PPAR RES, DOI 10.1155/2012/809164
   Seldon MP, 2007, J IMMUNOL, V179, P7840
   Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200
   Jiang CY, 1998, NATURE, V391, P82
   Yu X, 2008, BRAIN RES, V1200, P146, DOI 10.1016/j.brainres.2008.01.047
   Jadhav A, 2009, EXP BIOL MED, V234, P764, DOI 10.3181/0810-RM-302
   Jeong EA, 2011, EXP NEUROL, V232, P195, DOI 10.1016/j.expneurol.2011.09.001
   Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316
   Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216
   Nizamutdinova IT, 2009, ATHEROSCLEROSIS, V207, P405, DOI 10.1016/j.atherosclerosis.2009.05.008
   Rigamonti E, 2008, ARTERIOSCL THROM VAS, V28, P1050, DOI 10.1161/ATVBAHA.107.158998
   Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0
   Ndisang JF, 1999, IMMUNOPHARMACOLOGY, V43, P65, DOI 10.1016/S0162-3109(99)00045-4
   Yang H, 2012, WORLD J GASTROENTERO, V18, P1680, DOI 10.3748/wjg.v18.i14.1680
   Choi YJ, 2012, ATHEROSCLEROSIS, V220, P470, DOI 10.1016/j.atherosclerosis.2011.10.029
   Kobayashi T, 2012, AM J PHYSIOL-ENDOC M, V302, pE1461, DOI 10.1152/ajpendo.00623.2011
   de Groot JC, 2013, J MED CHEM, V56, P1535, DOI 10.1021/jm3013272
   Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955
   Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673
   Hevener AL, 2007, J CLIN INVEST, V117, P1658, DOI 10.1172/JCI31561
   Jimenez R, 2010, J PHARMACOL EXP THER, V332, P554, DOI 10.1124/jpet.109.159806
   Feng XL, 2011, J CELL MOL MED, V15, P1572, DOI 10.1111/j.1582-4934.2010.01085.x
   Marks GS, 2002, ANTIOXID REDOX SIGN, V4, P271, DOI 10.1089/152308602753666325
   Wei Y, 2009, AM J PHYSIOL-CELL PH, V297, pC907, DOI 10.1152/ajpcell.00536.2008
   Vanella L, 2013, BIOCHEM BIOPH RES CO, V432, P606, DOI 10.1016/j.bbrc.2013.02.037
   DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7
   Deeg MA, 2008, PPAR RES, DOI 10.1155/2008/520465
   Ndisang JF, 2009, J CARD FAIL, V15, P616, DOI 10.1016/j.cardfail.2009.02.003
   Ndisang JF, 2009, ENDOCRINOLOGY, V150, P2098, DOI 10.1210/en.2008-0239
   Cheng CF, 2012, J CELL PHYSIOL, V227, P239, DOI 10.1002/jcp.22726
   Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Maruyama K, 2012, THROMB RES, V130, pE188, DOI 10.1016/j.thromres.2012.07.002
   Liu YJ, 2008, J MOL ENDOCRINOL, V41, P53, DOI 10.1677/JME-08-0004
   Woo CH, 2006, J BIOL CHEM, V281, P32164, DOI 10.1074/jbc.M602369200
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198-007-0477-y
   Kim DH, 2013, J BONE MINER METAB, V31, P44, DOI 10.1007/s00774-012-0382-0
   Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003
   Jadhav A, 2008, HYPERTENSION, V52, P910, DOI 10.1161/HYPERTENSIONAHA.108.114801
   Ichihara S, 2006, J MOL CELL CARDIOL, V41, P318, DOI 10.1016/j.yjmcc.2006.05.013
   Kallin A, 2007, J LIPID RES, V48, P1628, DOI 10.1194/jlr.M700136-JLR200
   Wilding JPH, 2012, DIABETES OBES METAB, V14, P973, DOI 10.1111/j.1463-1326.2012.01601.x
   Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23
   Colville-Nash PR, 1998, J IMMUNOL, V161, P978
   Nan YM, 2011, SCAND J GASTROENTERO, V46, P358, DOI 10.3109/00365521.2010.525717
   Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802
   Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200
   Pasceri V, 2000, CIRCULATION, V101, P235
   Mohazab RA, 2012, EPILEPSY RES, V101, P28, DOI 10.1016/j.eplepsyres.2012.02.015
   Lee BH, 2012, FREE RADICAL BIO MED, V53, P2008, DOI 10.1016/j.freeradbiomed.2012.09.025
   Abraham NG, 2003, METH MOLEC MED, V86, P399
   Bilban M, 2009, ENDOCRINOLOGY, V150, P1000, DOI 10.1210/en.2008-0456
   Ndisang JF, 2009, AM J PHYSIOL-ENDOC M, V296, pE1029, DOI 10.1152/ajpendo.90241.2008
   Rosenson RS, 2012, AM HEART J, V164, P672, DOI 10.1016/j.ahj.2012.06.023
   Fan YB, 2008, ARTERIOSCL THROM VAS, V28, P315, DOI 10.1161/ATVBAHA.107.149815
   Bhatti R, 2013, NEUROCHEM RES, V38, P1624, DOI 10.1007/s11064-013-1064-6
   Taira BR, 2009, J BURN CARE RES, V30, P499, DOI 10.1097/BCR.0b013e3181a28e37
   BECK F, 1992, P ROY SOC B-BIOL SCI, V247, P83, DOI 10.1098/rspb.1992.0012
   Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443
   Arlt W, 2004, J MOL ENDOCRINOL, V32, P425, DOI 10.1677/jme.0.0320425
   Bando Y, 1999, J INT MED RES, V27, P53
   Belhaj A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069470
   Bhatia V, 2006, CURR OPIN INVESTIG D, V7, P891
   Boitier E., 2003, COMP HEPATOL, V2, P3, DOI 10.1186/1476-5926-2-3
   Bolten Charles W, 2007, Gene Regul Syst Bio, V1, P73
   Bulger EM, 2003, SURGERY, V134, P146, DOI 10.1067/msy.2003.215
   Bulhak AA, 2009, AM J PHYSIOL-HEART C, V296, pH719, DOI 10.1152/ajpheart.00394.2008
   Charbonnel B, 2005, DIABETOLOGIA, V48, P553, DOI 10.1007/s00125-004-1651-9
   Chen HH, 2010, MOL PHARMACOL, V78, P36, DOI 10.1124/mol.109.061101
   Chen YQE, 2003, VITAM HORM, V66, P157, DOI 10.1016/S0083-6729(03)01005-7
   Chhikara M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008139
   Conde de la Rosa L, 2008, FREE RADICAL BIO MED, V44, P1323, DOI 10.1016/j.freeradbiomed.2007.12.011
   De Ciuceis C, 2007, BRIT J PHARMACOL, V151, P45, DOI 10.1038/sj.bjp.0707215
   DePaoli AM, 2008, DIABETOLOGIA, V51, pS369
   Devey L, 2009, TRANSPLANTATION, V88, P308, DOI 10.1097/TP.0b013e3181ae3067
   Dietz M, 2012, CHEMMEDCHEM, V7, P1101, DOI 10.1002/cmdc.201100598
   Dubrac Sandrine, 2011, Dermatoendocrinol, V3, P23, DOI 10.4161/derm.3.1.14615
   Dumasia Rupal, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P377, DOI 10.2174/156800605774370362
   Eiselt J, 2010, NEPHRON CLIN PRACT, V115, pC147, DOI 10.1159/000312878
   Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-81
   Esposito E, 2010, PPAR RES, DOI 10.1155/2010/917312
   Farret A, 2006, PHARM RES, V23, P2665, DOI 10.1007/s11095-006-9112-4
   Finn AV, 2009, CIRC RES, V105, P1003, DOI 10.1161/CIRCRESAHA.109.200519
   Frederiksen KS, 2004, J LIPID RES, V45, P592, DOI 10.1194/jlr.D300239-JLR200
   Gao DF, 2007, BIOCHEM PHARMACOL, V73, P185, DOI 10.1016/j.bcp.2006.09.019
   George EM, 2012, AM J PHYSIOL-REG I, V302, pR620, DOI 10.1152/ajpregu.00617.2011
   Giaginis C, 2008, PPAR RES, DOI 10.1155/2008/431763
   Hansen BC, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-7
   Hao GH, 2008, BRIT J PHARMACOL, V153, P1409, DOI 10.1038/bjp.2008.21
   Haschemi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026376
   Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200
   Huang JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038626
   Jackson TC, 2007, TRANSPLANT INT, V20, P277, DOI 10.1111/j.1432-2277.2006.00431.x
   Jadhav A, 2012, FREE RADICAL BIO MED, V53, P2277, DOI 10.1016/j.freeradbiomed.2012.10.529
   Jadhav A, 2013, J PHARMACOL EXP THER, V345, P239, DOI 10.1124/jpet.112.200808
   Jadhav A., 2013, J PHARM EXP THER
   Jia YZ, 2005, P NATL ACAD SCI USA, V102, P12531, DOI 10.1073/pnas.0506000102
   Kang Kihwa, 2007, Curr Atheroscler Rep, V9, P72, DOI 10.1007/BF02693931
   Kang K, 2013, SHOCK, V40, P136, DOI 10.1097/SHK.0b013e31829d23f5
   Kim H, 2004, DIABETOLOGIA, V47, P2215, DOI 10.1007/s00125-004-1581-6
   Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5
   Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200
   Krishnaswami Ashok, 2010, Perm J, V14, P64
   Kuroda T, 2007, J MOL CELL CARDIOL, V43, P54, DOI 10.1016/j.yjmcc.2007.04.003
   Lampen A, 2005, MOL PHARMACOL, V68, P193, DOI 10.1124/mol.104.009340
   Li M, 2008, COMP BIOCHEM PHYS B, V150, P263, DOI 10.1016/j.cbpb.2008.03.014
   Li MX, 2010, FEBS J, V277, P1543, DOI 10.1111/j.1742-4658.2010.07581.x
   Liu G, 2013, BIOMED RES INT, DOI [10.1155/2013/903947, DOI 10.1155/2013/903947]
   Mamnoor PK, 2006, PHARMACOL RES, V54, P129, DOI 10.1016/j.phrs.2006.03.020
   McCarthy FP, 2013, BRIT J PHARMACOL, V168, P1074, DOI 10.1111/bph.12069
   McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x
   Meinke PT, 2006, ANNU REP MED CHEM, V41, P99, DOI 10.1016/S0065-7743(06)41006-X
   Mishra M., 2013, CURR PHARM DES
   Miyachi H, 2007, CURR MED CHEM, V14, P2335, DOI 10.2174/092986707781745587
   Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602
   Mori K, 2011, KIDNEY INT, V79, P1274, DOI 10.1038/ki.2011.36
   Nam JS, 2010, DIABETIC MED, V27, P30, DOI 10.1111/j.1464-5491.2009.02897.x
   Ndisang JF, 2009, AM J PHYSIOL-ENDOC M, V296, pE829, DOI 10.1152/ajpendo.90783.2008
   Ndisang J, 2009, HYPERTENSION, V54, pE114
   Ndisang J. F., 2009, FASEB J, V23
   Ndisang J. F., 2011, CIRCULATION, V124
   Ndisang J. F., 2009, AM J PHYSL REGUL INT
   Ndisang J. F., 2013, CURR PHARM DES
   Ndisang Joseph Fomusi, 2007, Int J Angiol, V16, P92
   Ndisang JF, 2002, CARBON MONOXIDE CARD
   Ndisang JF, 2013, DIABETES OBES METAB, V15, P1029, DOI 10.1111/dom.12130
   Ndisang JF, 2011, HYPERTENSION, V58, pE125
   Ndisang JF, 2011, EUR HEART J, V32, P40
   Nie M, 2005, J BIOL CHEM, V280, P2550, DOI 10.1074/jbc.M410616200
   O'Sullivan SE, 2007, BRIT J PHARMACOL, V152, P576, DOI 10.1038/sj.bjp.0707423
   Palozza P, 2006, ANTIOXID REDOX SIGN, V8, P1069, DOI 10.1089/ars.2006.8.1069
   Park SY, 2011, KOREAN J PHYSIOL PHA, V15, P83, DOI 10.4196/kjpp.2011.15.2.83
   Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-20
   Peyton KJ, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00048
   Pingali H, 2010, BIOORG MED CHEM LETT, V20, P1156, DOI 10.1016/j.bmcl.2009.12.022
   Ptasinska A, 2007, FASEB J, V21, P950, DOI 10.1096/fj.06-6822com
   Puligheddu M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064541
   Roberts RA, 2002, TOXICOLOGY, V181, P167, DOI 10.1016/S0300-483X(02)00275-5
   Sacerdoti D, 2006, AM J PHYSIOL-HEART C, V291, pH1999, DOI 10.1152/ajpheart.00082.2006
   Saidi SA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-13
   Sakamoto A., 2012, INT J CARDIOL
   Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5
   Schoonjans K, 1996, EMBO J, V15, P5336
   Shih RH, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-86
   Sodhi K., 2013, INT J OBES LOND
   Song YJ, 2012, BRAIN RES, V1429, P1, DOI 10.1016/j.brainres.2011.10.021
   Sosnowski C., 2007, KARDIOL POL, V65, P216
   Sosnowski C, 2007, KARDIOL POL, V65, P214
   Stringer F, 2013, J CLIN PHARMACOL, V53, P256, DOI 10.1177/0091270012447121
   Stringer F, 2013, EUR J CLIN PHARMACOL, V69, P423, DOI 10.1007/s00228-012-1382-7
   Suliburk JW, 2009, AM J PHYSIOL-GASTR L, V296, pG1360, DOI 10.1152/ajpgi.00038.2009
   Sun BW, 2007, WORLD J GASTROENTERO, V13, P6183, DOI 10.3748/wjg.13.6183
   Takada I., 2010, PPAR RES, V2010
   TAN MH, 2000, INT J CLIN PRACT S, V113, P54
   Tang LM, 2007, TRANSPL P, V39, P1338, DOI 10.1016/j.transproceed.2006.11.032
   Thevis M, 2010, ANAL BIOANAL CHEM, V396, P2479, DOI 10.1007/s00216-009-3283-x
   Tiwari S., 2013, CURR PHARM DES
   Tjalkens RB, 2008, J NEUROSCI RES, V86, P618, DOI 10.1002/jnr.21524
   Tracz MJ, 2007, AM J PATHOL, V170, P1820, DOI 10.2353/ajpath.2007.061093
   Viswakarma N., 2010, PPAR RES, V2010
   von Knethen A, 2011, FREE RADICAL BIO MED, V51, P396, DOI 10.1016/j.freeradbiomed.2011.04.033
   VUDAC N, 1994, J BIOL CHEM, V269, P31012
   Wang HJ, 2012, CELL TRANSPLANT, V21, P2111, DOI 10.3727/096368911X637399
   Werkstrom V, 1997, BRIT J PHARMACOL, V120, P312, DOI 10.1038/sj.bjp.0700893
   Wilding John P H, 2007, Diab Vasc Dis Res, V4, P194
   Xue H, 2007, WORLD J GASTROENTERO, V13, P5384
   Yang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060715
   Yang YH, 2008, PPAR RES, DOI 10.1155/2008/546753
   Yin QQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059313
   Yu J, 2010, GASTROENTEROLOGY, V138, P694, DOI 10.1053/j.gastro.2009.09.058
   Zhang GY, 2010, J PLAST RECONSTR AES, V63, P1209, DOI 10.1016/j.bjps.2009.06.032
   Zhang XM, 2010, J BIOL CHEM, V285, P32869, DOI 10.1074/jbc.M110.135509
   Zhao D, 2012, J PHARMACOL EXP THER, V343, P206, DOI 10.1124/jpet.112.194738
   Zhao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075927
NR 280
TC 5
Z9 5
U1 5
U2 17
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JUN 1
PY 2014
VL 19
BP 916
EP 935
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AI0VK
UT WOS:000336568100007
PM 24896326
ER

PT J
AU Vaz-Tostes, MD
   Viana, ML
   Grancieri, M
   Luz, TCD
   de Paula, H
   Pedrosa, RG
   Costa, NMB
AF Vaz-Tostes, Maria das Gracas
   Viana, Mirelle Lomar
   Grancieri, Mariana
   dos Santos Luz, Tereza Cecilia
   de Paula, Heberth
   Pedrosa, Rogerio Graca
   Brunoro Costa, Neuza Maria
TI Yacon effects in immune response and nutritional status of iron and zinc
   in preschool children
SO NUTRITION
LA English
DT Article
DE Yacon; Prebiotics; Nutritional status; Immune response
ID ATOMIC-ABSORPTION SPECTROPHOTOMETRY; SMALLANTHUS-SONCHIFOLIUS;
   SHORT-CHAIN; CALCIUM-ABSORPTION; PREBIOTICS; FRUCTANS; OLIGOSACCHARIDES;
   PROBIOTICS; LYMPHOCYTES; SYNBIOTICS
AB Objective: The aim of this study was to evaluate the effect of yacon flour on iron and zinc nutritional status and immune response biomarkers in preschool children.
   Methods: Preschool children ages 2 to 5 y were selected from two nurseries and were placed into a control group (n = 58) or a yacon group (n = 59). The yacon group received yacon flour in preparations for 18 wk at a quantity to provide 0.14 g of fructooligosaccharides/kg of body weight daily. Anthropometric parameters were measured before and after the intervention and dietary intake was measured during the intervention. To assess iron and zinc status, erythrograms, serum iron, ferritin, and plasma, and erythrocyte zinc were evaluated. Systemic immune response was assessed by the biomarkers interleukin IL-4, IL-10, IL-6, and tumor necrosis factor-alfa (TNF-alpha). Intestinal immune response was analyzed by secretory IgA (sIgA) levels before and after the intervention. Statistical significance was evaluated using the paired t test (alpha = 5%).
   Results: Before and after the study, the children presented a high prevalence of overweight and an inadequate dietary intake of zinc and fiber. The yacon group presented with lower hemoglobin, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration at the end of the study (P < 0.05). Erythrocyte zinc was reduced in both groups at the end of the study (P < 0.05). Yacon intake increased the serum levels of IL-4 and fecal sIgA (P < 0.05). The control group had lower serum TNF-alpha after the study period (P < 0.05).
   Conclusion: Yacon improved intestinal immune response but demonstrated no effect on the nutritional status of iron and zinc in preschool children. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Vaz-Tostes, Maria das Gracas; Viana, Mirelle Lomar; Grancieri, Mariana; dos Santos Luz, Tereza Cecilia; de Paula, Heberth; Pedrosa, Rogerio Graca; Brunoro Costa, Neuza Maria] Alto Univ, Fed Univ Espirito Santo, Ctr Agr Sci, Dept Pharm & Nutr, Alegre, ES, Brazil.
   [Vaz-Tostes, Maria das Gracas; Brunoro Costa, Neuza Maria] Univ Fed Vicosa, PH Holfs, Dept Nutr, Vicosa, MG, Brazil.
RP Vaz-Tostes, MD (reprint author), Alto Univ, Fed Univ Espirito Santo, Ctr Agr Sci, Dept Pharm & Nutr, Alegre, ES, Brazil.
EM mgvaztostes@gmail.com
FU Fundacao de Amparo a Pesquisa do Espirito Santo (FAPES); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
FX The study was supported by grants from Fundacao de Amparo a Pesquisa do
   Espirito Santo (FAPES) and Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES).
CR Fernandez EC, 2013, LWT-FOOD SCI TECHNOL, V54, P80, DOI 10.1016/j.lwt.2013.05.013
   GIBSON GR, 1995, J NUTR, V125, P1401
   Izcue A, 2009, ANNU REV IMMUNOL, V27, P313, DOI 10.1146/annurev.immunol.021908.132657
   Genta S, 2009, CLIN NUTR, V28, P182, DOI 10.1016/j.clnu.2009.01.013
   Picard C, 2005, ALIMENT PHARM THERAP, V22, P495, DOI 10.1111/j.1365-2036.2005.02615.x
   Abrams SA, 2005, AM J CLIN NUTR, V82, P471
   [Anonymous], 2001, DIET REF INT VIT A V
   Liu B, 2011, GASTROENTEROLOGY, V141, P653, DOI 10.1053/j.gastro.2011.04.053
   Romeo J, 2010, NUTR HOSP, V25, P341, DOI 10.3305/nh.2010.25.3.4517
   HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155
   Ohta A, 1998, J NUTR, V128, P485
   Kelly-Quagliana KA, 2003, NUTR RES, V23, P257, DOI 10.1016/S0271-5317(02)00516-X
   WHITEHOUSE RC, 1982, CLIN CHEM, V28, P475
   Roberfroid MB, 1998, ANNU REV NUTR, V18, P117, DOI 10.1146/annurev.nutr.18.1.117
   Surono IS, 2011, ANAEROBE, V17, P496, DOI 10.1016/j.anaerobe.2011.06.003
   Lobo AR, 2007, BRIT J NUTR, V97, P776, DOI 10.1017/S0007114507336805
   van Hoffen E, 2009, ALLERGY, V64, P484, DOI 10.1111/j.1398-9995.2008.01765.x
   Delgado GTC, 2010, FOOD RES INT, V43, P1231, DOI 10.1016/j.foodres.2010.04.023
   Turroni F, 2014, CELL MOL LIFE SCI, V71, P183, DOI 10.1007/s00018-013-1318-0
   Association of Official Analytical Chemists (AOAC), 1997, OFF METH AN AOAC
   Biancofiore G, 2013, TRANSPL IMMUNOL, V28, P193, DOI 10.1016/j.trim.2013.04.001
   Bonet MEB, 2010, FOOD AGR IMMUNOL, V21, P175, DOI 10.1080/09540100903563589
   Chen Chien-Chang, 2005, Adv Pediatr, V52, P77, DOI 10.1016/j.yapd.2005.03.001
   Ducros V, 2005, J AM COLL NUTR, V24, P30
   FAILACE R, 2003, HEMOGRAMA MANUAL INT
   Filippo DC, 2010, P NATL ACAD SCI USA, V107, P14691
   Griffin IJ, 2002, BRIT J NUTR, V87, pS187, DOI [10.1079/BJN2001503, 10.1079/BJN/2002536]
   HORWITZ W., 2010, OFFICIAL METHODS ANA
   Institute of Medicine Panel on Macronutrients Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, 2005, DIET REF INT EN CARB
   Jellife DB, 1966, ASSESSMENT NUTR STAT
   Lobo AR, 2011, FOOD CHEM, V126, P885, DOI 10.1016/j.foodchem.2010.11.067
   Mafra D., 2004, Revista de Nutrição, V17, P79, DOI 10.1590/S1415-52732004000100009
   Nualkaekul S, 2011, FOOD CHEM, V129, P1037, DOI 10.1016/j.foodchem.2011.05.071
   Ojansivu I., 2011, Trends in Food Science & Technology, V22, P40, DOI 10.1016/j.tifs.2010.11.005
   Rodrigues Fabiana Carvalho, 2011, Revista do Instituto Adolfo Lutz, V70, P290
   RODRIGUEZ MP, 1989, ATOM SPECTROSC, V10, P68
   Scholz-Ahrens KE, 2001, AM J CLIN NUTR, V73, p459S
   Scholz-Ahrens KE, 2007, J NUTR, V137, p838S
   Silva MR, 2008, NUTR RES, V28, P226, DOI 10.1016/j.nutres.2008.02.002
   Thomas DW, 2010, PEDIATRICS, V126, P1217, DOI 10.1542/peds.2010-2548
   Tuma R. C. F. B., 2005, Revista Brasileira de Saúde Materno Infantil, V5, P419, DOI 10.1590/S1519-38292005000400005
   Veereman G., 2007, J NUTR, V137, P2585
   Veereman-Wauters G, 2011, J PEDIATR GASTR NUTR, V52, P763, DOI 10.1097/MPG.0b013e3182139f39
   World Health Organization, 2006, CHILD GROWTH STAND L
   World Health Organization (WHO), 2002, CHILD HLTH RES FDN I
NR 45
TC 1
Z9 1
U1 3
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD JUN
PY 2014
VL 30
IS 6
BP 666
EP 672
DI 10.1016/j.nut.2013.10.016
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AH8WT
UT WOS:000336419600008
PM 24631386
ER

PT J
AU Fagan, KJ
   Irvine, KM
   McWhinney, BC
   Fletcher, LM
   Horsfall, LU
   Johnson, L
   O'Rourke, P
   Martin, J
   Scott, I
   Pretorius, CJ
   Ungerer, JPJ
   Powell, EE
AF Fagan, Kevin J.
   Irvine, Katharine M.
   McWhinney, Brett C.
   Fletcher, Linda M.
   Horsfall, Leigh U.
   Johnson, Lambro
   O'Rourke, Peter
   Martin, Jennifer
   Scott, Ian
   Pretorius, Carel J.
   Ungerer, Jacobus P. J.
   Powell, Elizabeth E.
TI Diagnostic sensitivity of carbohydrate deficient transferrin in heavy
   drinkers
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Alcohol; High performance liquid chromatography; Cirrhosis; Biomarker;
   Obesity
ID GAMMA-GLUTAMYL-TRANSFERASE; ALCOHOL-CONSUMPTION; LIVER-DISEASE; ISOFORM
   DISTRIBUTION; INSULIN SENSITIVITY; DOSE-RESPONSE; HPLC; SERUM; CDT;
   QUANTIFICATION
AB Background and Aim: Carbohydrate deficient transferrin (CDT) is the most specific serum biomarker of heavy alcohol consumption, defined as >= 350-420 g alcohol/week. Despite introduction of a standardized reference measurement technique, widespread use of CDT remains limited due to low sensitivity. The aim of this study was to determine the factors that affect diagnostic sensitivity in patients with sustained heavy alcohol intake.
   Methods: Patients with a self-reported history of sustained heavy alcohol consumption were recruited from the hepatology outpatient department or medical wards. Each patient was interviewed with a validated structured questionnaire of alcohol consumption and CDT analysis using the standardized reference measurement technique with high performance liquid chromatography was performed on serum collected at time of interview.
   Results: 52 patients were recruited: 19 from the hepatology outpatient department and 33 from general medical wards. Median alcohol intake was 1013 (range 366-5880) g/week over the preceding two week period. 26 patients had a diagnostic CDT based on a threshold value of %CDT > 1.7 indicating heavy alcohol consumption, yielding a sensitivity of 50%. Overweight/obesity (defined as body mass index (BMI) >= 25 kg/m(2) in Caucasians and >= 23.0 kg/m(2) in Asians), female gender and presence of cirrhosis were independently associated with non-diagnostic % CDT (<= 1.7).
   Conclusions: CDT has limited sensitivity as a biomarker of heavy alcohol consumption. Caution should be applied when ordering and interpreting %CDT results, particularly in women, patients with cirrhosis and those with an elevated BMI.
C1 [Fagan, Kevin J.; Fletcher, Linda M.; Horsfall, Leigh U.; Powell, Elizabeth E.] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld 4102, Australia.
   [Fagan, Kevin J.; Irvine, Katharine M.; Horsfall, Leigh U.; Powell, Elizabeth E.] Univ Queensland, Sch Med, Ctr Liver Dis Res, Brisbane, Qld, Australia.
   [Fletcher, Linda M.; Martin, Jennifer] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [McWhinney, Brett C.; Johnson, Lambro; Pretorius, Carel J.; Ungerer, Jacobus P. J.] Royal Brisbane & Womens Hosp, Pathol Queensland, Brisbane, Qld, Australia.
   [O'Rourke, Peter] Queensland Inst Med Res, Canc & Populat Studies Grp, Brisbane, Qld 4006, Australia.
   [Martin, Jennifer; Scott, Ian] Princess Alexandra Hosp, Div Med, Brisbane, Qld 4102, Australia.
RP Powell, EE (reprint author), Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld 4102, Australia.
EM e.powell@uq.edu.au
RI Irvine, Katharine/A-5559-2011; Powell, Elizabeth/B-4455-2011
OI Powell, Elizabeth/0000-0001-5008-8061
FU National Health and Medical Research Council of Australia; Queensland
   Government's Smart State Health and Medical Research Fund; Princess
   Alexandra Hospital Research and Development Foundation; Australian Liver
   Foundation
FX This study was funded by the National Health and Medical Research
   Council of Australia, The Queensland Government's Smart State Health and
   Medical Research Fund, The Princess Alexandra Hospital Research and
   Development Foundation and the Australian Liver Foundation.
CR Bianchi V, 2011, ALCOHOL ALCOHOLISM, V46, P123, DOI 10.1093/alcalc/agq092
   Bergstrom JP, 2008, ALCOHOL ALCOHOLISM, V43, P436, DOI 10.1093/alcalc/agn017
   POKORNY AD, 1972, AM J PSYCHIAT, V129, P342
   DiMartini A, 2001, ALCOHOL CLIN EXP RES, V25, P1729
   Petrides AS, 1998, HEPATOLOGY, V28, P141, DOI 10.1002/hep.510280119
   Ridinger M, 2012, EXP MOL PATHOL, V92, P50, DOI 10.1016/j.yexmp.2011.10.005
   Tsochatzis EA, 2011, J HEPATOL, V54, P650, DOI 10.1016/j.jhep.2010.07.033
   Helander A, 2013, ALCOHOL ALCOHOLISM, V48, P478, DOI 10.1093/alcalc/agt045
   Janmahasatian S, 2005, CLIN PHARMACOKINET, V44, P1051, DOI 10.2165/00003088-200544100-00004
   Anton RF, 2002, ALCOHOL CLIN EXP RES, V26, P1215, DOI 10.1097/01.ALC.0000023986.42254.F5
   Fagan KJ, 2013, ALCOHOL CLIN EXP RES, V37, P1771, DOI 10.1111/acer.12143
   Kenan N, 2011, CLIN CHIM ACTA, V412, P129, DOI 10.1016/j.cca.2010.09.022
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Whitfield JB, 2008, CLIN CHEM, V54, P1158, DOI 10.1373/clinchem.2007.101733
   Bakhireva LN, 2012, ALCOHOL ALCOHOLISM, V47, P683, DOI 10.1093/alcalc/ags087
   ANTON RF, 1994, ALCOHOL CLIN EXP RES, V18, P747, DOI 10.1111/j.1530-0277.1994.tb00941.x
   Arndt T, 1997, CLIN CHEM, V43, P344
   Arndt T, 2008, CLIN CHIM ACTA, V394, P42, DOI 10.1016/j.cca.2008.03.033
   Bergstrom J, 2008, LIBR J, V133, P59
   Brathen G, 2001, ALCOHOL CLIN EXP RES, V25, P46, DOI 10.1111/j.1530-0277.2001.tb02126.x
   FAGERBERG B, 1994, J CLIN ENDOCR METAB, V79, P712, DOI 10.1210/jc.79.3.712
   Helander A, 1999, CLIN CHEM, V45, P131
   Helander A, 2010, CLIN CHEM LAB MED, V48, P1585, DOI 10.1515/CCLM.2010.322
   Helander A, 2001, CLIN CHEM, V47, P1225
   Helander A, 2004, CLIN CHEM, V50, P954, DOI 10.1373/clinchem.2003.029629
   Henriksen JH, 1997, J HEPATOL, V26, P287, DOI 10.1016/S0168-8278(97)80043-8
   Kemp W, 2013, AUST FAM PHYSICIAN, V42, P468
   Martensson O, 1998, CLIN CHEM, V44, P2226
   Martensson O, 1997, ALCOHOL CLIN EXP RES, V21, P1710, DOI 10.1111/j.1530-0277.1997.tb04512.x
   Olyslager YS, 2006, CLIN CHIM ACTA, V370, P115
   Piroddi M, 2007, AMINO ACIDS, V32, P573, DOI 10.1007/s00726-006-0433-8
   POTTER BJ, 1985, HEPATOLOGY, V5, P714, DOI 10.1002/hep.1840050503
   Sillanaukee P, 2000, AM J EPIDEMIOL, V152, P747, DOI 10.1093/aje/152.8.747
   Stewart SH, 2010, ALCOHOL CLIN EXP RES, V34, P1956, DOI 10.1111/j.1530-0277.2010.01285.x
   Szegedi A, 2000, ALCOHOL CLIN EXP RES, V24, P497
   Whitfield JB, 1998, CLIN CHEM, V44, P2480
   Wolff F, 2010, CLIN BIOCHEM, V43, P1148, DOI 10.1016/j.clinbiochem.2010.06.003
NR 37
TC 4
Z9 4
U1 3
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD MAY 22
PY 2014
VL 14
AR 97
DI 10.1186/1471-230X-14-97
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AI4RH
UT WOS:000336852000001
PM 24885510
ER

PT J
AU Alfadda, AA
   Turjoman, AA
   Moustafa, AS
   Al-Naami, MY
   Chishti, MA
   Sallam, RM
   Gibson, D
   Duncan, MW
AF Alfadda, Assim A.
   Turjoman, Abdullah Arif
   Moustafa, Amr S.
   Al-Naami, Mohammed Y.
   Chishti, Muhammad A.
   Sallam, Reem M.
   Gibson, David
   Duncan, Mark W.
TI A proteomic analysis of excreted and circulating proteins from obese
   patients following two different weight-loss strategies
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE multiplex biochip array; Obesity; proteomics; low-calorie diet;
   bariatric surgery
ID GASTRIC BYPASS-SURGERY; BARIATRIC SURGERY; INSULIN-RESISTANCE;
   INFLAMMATORY MARKERS; SERINE PROTEASES; REDUCTION; ALBUMIN; URINE;
   TRANSLOCATION; ADIPONECTIN
AB Bariatric surgery is the most successful therapeutic approach to weight loss, but how it leads to weight loss, and how it resolves obesity-related complications, including type-2 diabetes, are poorly understood. This study, comprising two groups of individuals, one on a low-calorie diet (n = 5) and one undergoing bariatric surgery (n = 7), used both targeted and untargeted proteomic approaches to determine changes in protein levels pre- and post-intervention (i.e. 3-6 months later). Changes were observed in both circulating and excreted proteins following weight loss. Targeted multiplexed biochip arrays measured 12 plasma peptides/proteins involved in metabolism and inflammation: C-peptide, ferritin, interleukin-6, interleukin-1 alpha, resistin, insulin, tumor necrosis factor alpha, leptin, plasminogen-activator inhibitor-1, adiponectin, cystatin C, and C-reactive protein. Following a low-calorie diet, plasma insulin and C-reactive protein levels were significantly reduced (P = 0.045 and P = 0.030, respectively); adiponectin increased and leptin decreased following surgery (P = 0.014 and P = 0.005, respectively). Untargeted proteomic analysis employing 2D difference in-gel electrophoresis (DIGE) showed 28 protein spots with >= 1.5-fold changes in expression following weight loss by a low-calorie diet; comparison of pre- and post-intervention urine samples from the bariatric surgery group showed changes in excretion of 110 protein spots.
   The combination of targeted protein analysis by multiplexed arrays and an exploratory (i.e. an unbiased or discovery) proteomic assessment of hundreds of proteins offers valuable insights into the mechanistic differences between alternative weight-loss strategies. This is a powerful hypothesis-generating approach to study complex, multifactorial syndromes such as obesity. The findings that arise from these studies can then be validated in targeted, hypothesis-directed investigations.
C1 [Alfadda, Assim A.; Turjoman, Abdullah Arif; Moustafa, Amr S.; Chishti, Muhammad A.; Sallam, Reem M.; Duncan, Mark W.] King Saud Univ, Coll Med, Obes Res Ctr, Riyadh 11461, Saudi Arabia.
   [Alfadda, Assim A.] King Saud Univ, Dept Med, Coll Med, Riyadh 11461, Saudi Arabia.
   [Turjoman, Abdullah Arif; Moustafa, Amr S.; Chishti, Muhammad A.; Sallam, Reem M.] King Saud Univ, Dept Pathol, Coll Med, Clin Chem Unit, Riyadh 11461, Saudi Arabia.
   [Turjoman, Abdullah Arif; Gibson, David; Duncan, Mark W.] Univ Colorado Denver, Div Endocrinol Diabet & Metab, Dept Med, Sch Med, Aurora, CO 80045 USA.
   [Moustafa, Amr S.; Sallam, Reem M.] Ain Shams Univ, Fac Med, Dept Med Biochem & Mol Biol, Cairo, Egypt.
   [Al-Naami, Mohammed Y.] King Saud Univ, Dept Surg, Coll Med, Riyadh 11461, Saudi Arabia.
   [Gibson, David] Queens Univ Belfast, Arthrit Res Grp, Ctr Infect & Immun, Belfast BT9 7BL, Antrim, North Ireland.
RP Alfadda, AA (reprint author), King Saud Univ, Coll Med, Obes Res Ctr, Riyadh 11461, Saudi Arabia.
EM aalfadda@ksu.edu.sa
RI Gibson, David/L-6155-2015
OI Gibson, David/0000-0003-3547-5551
FU Strategic Technologies Program of the National Plan for Sciences and
   Technology and Innovation, Kingdom of Saudi Arabia [08- MED 513-02]
FX We thank Randox Laboratories Limited, United Kingdom, for assistance
   with aspects of this work. We are also grateful to Professor James O
   Hill, Professor Michael Goran, and Dr Sarit Polsky for advice on drafts
   of this manuscript. We also acknowledge the technical assistance of Dr
   Carmen Deanna O Mendoza, Mrs Ruba Elawad, Mr Shahid Nawaz, and Ms Keri
   Newell. This work was supported by the Strategic Technologies Program of
   the National Plan for Sciences and Technology and Innovation, Kingdom of
   Saudi Arabia (Project no. 08- MED 513-02).
CR Agrawal V, 2009, SURG OBES RELAT DIS, V5, P20, DOI 10.1016/j.soard.2008.07.011
   Alfadda AA, 2013, EXP GERONTOL, V48, P1196, DOI 10.1016/j.exger.2013.07.008
   Schwenk RW, 2012, J BIOL CHEM, V287, P37530, DOI 10.1074/jbc.M112.363630
   Navaneethan SD, 2010, OBES SURG, V20, P308, DOI 10.1007/s11695-009-0026-1
   Zeyda M, 2009, GERONTOLOGY, V55, P379, DOI 10.1159/000212758
   Frauenknecht V, 2013, CLIN EXP IMMUNOL, V173, P112, DOI 10.1111/cei.12093
   Peterli R, 2009, ANN SURG, V250, P234, DOI 10.1097/SLA.0b013e3181ae32e3
   Dalmas E, 2011, AM J CLIN NUTR, V94, P450, DOI 10.3945/ajcn.111.013771
   Woelnerhanssen B, 2011, SURG OBES RELAT DIS, V7, P561, DOI 10.1016/j.soard.2011.01.044
   Alhaider A, 2013, J MASS SPECTROM, V48, P779, DOI 10.1002/jms.3213
   Belza A, 2009, INT J OBESITY, V33, P456, DOI 10.1038/ijo.2009.27
   Forsythe LKS, 2008, NUTR RES REV, V21, P117, DOI 10.1017/S0954422408138732
   Kentsis A, 2009, PROTEOM CLIN APPL, V3, P1052, DOI 10.1002/prca.200900008
   Rao SR, 2012, INFLAMM RES, V61, P789, DOI 10.1007/s00011-012-0473-3
   Olson AL, 1997, MOL CELL BIOL, V17, P2425
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
   Whitson BA, 2007, J SURG RES, V141, P31, DOI 10.1016/j.jss.2007.02.022
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   Damms-Machado A, 2012, OBES SURG, V22, P881, DOI 10.1007/s11695-012-0609-0
   Schauer PR, 2012, NEW ENGL J MED, V366, P1567, DOI 10.1056/NEJMoa1200225
   Tzotzas T, 2010, J CLIN ENDOCR METAB, V95, P4251, DOI 10.1210/jc.2010-0757
   Brethauer SA, 2011, SURG ENDOSC, V25, P2650, DOI 10.1007/s00464-011-1620-6
   Bruschi M, 2013, BBA-GEN SUBJECTS, V1830, P5503, DOI 10.1016/j.bbagen.2013.04.026
   Eldar S, 2011, INT J OBESITY, V35, pS16, DOI 10.1038/ijo.2011.142
   FitzGerald SP, 2005, CLIN CHEM, V51, P1165, DOI 10.1373/clinchem.2005.049429
   Glandt M, 2011, J OBES, V2011
   Greening DW, 2010, J PROTEOMICS, V73, P637, DOI 10.1016/j.jprot.2009.09.013
   Hortin GL, 2008, PROTEOM CLIN APPL, V2, P950, DOI 10.1002/prca.200780145
   Laferrere B, 2011, SCI TRANSL MED, V3, p80re2
   Miller GD, 2011, SURG OBES RELAT DIS, V7, P618, DOI 10.1016/j.soard.2011.03.006
   Mousavinasab F, 2005, ENDOCRINE, V26, P65, DOI 10.1385/ENDO:26:1:065
   Rossi M, 2011, OBES SURG, V21, P87, DOI 10.1007/s11695-010-0286-9
   Santos J, 2013, SCAND J SURG
   Sorensen R, 2005, SPRINGER SEMIN IMMUN, V27, P299, DOI 10.1007/s00281-005-0006-z
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   Yongqing Tang, 2012, Biochim Biophys Acta, V1824, P253, DOI 10.1016/j.bbapap.2011.05.021
   Zhao P, 2009, J CELL SCI, V122, P3472, DOI 10.1242/jcs.047449
NR 37
TC 5
Z9 5
U1 2
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD MAY
PY 2014
VL 239
IS 5
BP 568
EP 580
DI 10.1177/1535370214523894
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AG6EM
UT WOS:000335511500007
PM 24668551
ER

PT J
AU Iwanaga, S
   Sakano, N
   Taketa, K
   Takahashi, N
   Wang, DH
   Takahashi, H
   Kubo, M
   Miyatake, N
   Ogino, K
AF Iwanaga, Suketaka
   Sakano, Noriko
   Taketa, Kazuhisa
   Takahashi, Noriko
   Wang, Da-Hong
   Takahashi, Hidekazu
   Kubo, Masayuki
   Miyatake, Nobuyuki
   Ogino, Keiki
TI Comparison of serum ferritin and oxidative stress biomarkers between
   Japanese workers with and without metabolic syndrome
SO OBESITY RESEARCH & CLINICAL PRACTICE
LA English
DT Article
DE Oxidative stress; Ferritin; 8-Hydroxy-2 '-deoxyguanosine (8-OHdG);
   Hydrogen peroxide (H2O2); Metabolic syndrome
ID C-REACTIVE PROTEIN; BODY IRON STORES; INSULIN-RESISTANCE; HEALTHY
   PEOPLE; DNA-DAMAGE; POPULATION; WOMEN; 8-HYDROXYDEOXYGUANOSINE;
   INFLAMMATION; ASSOCIATION
AB Objective: Metabolic syndrome (MS) is closely associated to life-style and is characterized by central obesity causing severe diseases such as diabetes mellitus (DM) or atherosclerosis. This study investigates the role of oxidative stress and inflammation in MS. Subjects: Total of 685 workers stratified by gender (293 men and 392 women) with a mean age of 41.2 +/- 10.4 in different offices in a city in Japan.
   Methods: Fasting blood and urine tests for MS, oxidative and/or inflammatory biomarker analysis and blood pressure (BP) measurement were performed. MS was defined on the basis of the Japanese criterion.
   Results: Serum ferritin and urinary hydrogen peroxide (H2O2) levels were significantly higher in subjects with MS than those without. Ferritin was positively correlated with 8-hydroxy-2'-deoxyguanosine (8-OHdG) in all subjects and it was negatively correlated with 8-isoprostane and H2O2 in men. In addition, there was a significant positive correlation between ferritin and homeostasis model assessment (HOMA-R) in men. By using multiple regression analysis, ferritin was closely correlated with HOMA-R, gamma-GT, 8-OHdG, smoking value and amount of alcohol ingestion in men, and it was correlated with 8-OHdG, gamma-GT, HOMA-R in women under 50 years old.
   Conclusions: Ferritin is a useful marker of MS including insulin resistance, reflecting the importance of oxidative stress as a cause of MS, especially in men. (C) 2013 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
C1 [Iwanaga, Suketaka] Kyoto Univ, Fac Med, Dept Publ Hlth, Kyoto 6068501, Japan.
   [Sakano, Noriko; Miyatake, Nobuyuki] Kagawa Univ, Dept Hyg, Fac Med, Kagawa 7610793, Japan.
   [Taketa, Kazuhisa] Geriatr Hlth Serv Facil, Mihara, Hiroshima 7291321, Japan.
   [Taketa, Kazuhisa; Takahashi, Noriko; Wang, Da-Hong; Takahashi, Hidekazu; Kubo, Masayuki; Ogino, Keiki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Publ Hlth, Okayama 7008558, Japan.
RP Ogino, K (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Publ Hlth, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
EM kogino@md.okayama-u.ac.jp
FU Junpukai; Health Science Center Foundation
FX This research was supported in part by funding from the Junpukai and in
   part from Health Science Center Foundation. We gratefully acknowledge
   the technical contribution from B. Wang, S. Rani, A. Miura, A. Horii,
   and T. Mitsumune.
CR Ogino K, 2011, FREE RADICAL RES, V45, P147, DOI 10.3109/10715762.2010.520318
   Nakano M, 2003, FREE RADICAL BIO MED, V35, P826, DOI 10.1016/S0891-5849(03)00432-5
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Syrovatka P, 2009, ANN NUTR METAB, V54, P268, DOI 10.1159/000229507
   Banerjee D, 2003, CLIN CHIM ACTA, V334, P205, DOI 10.1016/S0009-8981(03)00236-5
   Kimura S, 2006, BASIC CLIN PHARMACOL, V98, P496
   Sakano N, 2009, J CLIN BIOCHEM NUTR, V44, P185, DOI 10.3164/jcbn.08-252
   Sharifi F, 2008, DIABETES VASC DIS RE, V5, P15, DOI 10.3132/dvdr.2008.003
   Moller P, 2006, FREE RADICAL BIO MED, V41, P388, DOI 10.1016/j.freeradbiomed.2006.04.001
   Ashourpour M, 2010, INT J FOOD SCI NUTR, V61, P316, DOI 10.3109/09637480903555150
   [Anonymous], 2005, NIPPON NAIKA GAKKAI, V94, P794
   Matsuzawa Y, 2002, CIRC J, V66, P987
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Devries MC, 2008, FREE RADICAL BIO MED, V45, P503, DOI 10.1016/j.freeradbiomed.2008.04.039
   Michoulas A, 2006, J PEDIATR-US, V149, P692, DOI 10.1016/j.jpeds.2006.08.015
   Kim CH, 2011, METABOLISM, V60, P414, DOI 10.1016/j.metabol.2010.03.007
   Mojiminiyi OA, 2008, NUTR METAB CARDIOVAS, V18, P559, DOI 10.1016/j.numecd.2007.07.007
   Aso Y, 2010, DIABETES RES CLIN PR, V90, P250, DOI 10.1016/j.diabres.2010.09.008
   Bonassi S, 2002, MUTAT RES-REV MUTAT, V511, P73, DOI 10.1016/S1383-5742(02)00003-0
   Ku BJ, 2009, DIS MARKERS, V27, P303, DOI 10.3233/DMA-2009-0676
   Shibata H, 2004, ARTERIOSCL THROM VAS, V24, P1659, DOI 10.1161/01.ATV.0000137415.67349.3c
   Crist BL, 2009, J WOMENS HEALTH, V18, P795, DOI 10.1089/jwh.2008.0988
   Halliwell B, 1999, FREE RADICAL BIO MED, P246
   Helmersson J, 1999, PROSTAG LEUKOTR ESS, V61, P203
   Hiro H, 1996, Nihon Arukoru Yakubutsu Igakkai Zasshi, V31, P437
   Hofer T, 2006, FREE RADICAL RES, V40, P707, DOI 10.1080/10715760500525807
   Hori A, 2010, CANCER SCI, V101, P517, DOI 10.1111/j.1349-7006.2009.01394.x
   Lee KU, 2008, DIABETES RES CLIN PR, V54, P29
   Matsuzawa Y, 2000, J JAPAN SOC STUDY OB, V6, P18
   Saito S, 2000, RES COMMUN MOL PATH, V107, P39
   Sakano N, 2009, FREE RADICAL RES, V43, P183, DOI 10.1080/10715760802663124
   Sauriasari R, 2010, HYPERTENS RES, V33, P1129, DOI 10.1038/hr.2010.154
   Scudla V, 2001, Vnitr Lek, V47, P400
   Tuomainen TP, 2007, FREE RADICAL RES, V41, P324, DOI 10.1080/10715760601091642
NR 35
TC 0
Z9 0
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1871-403X
EI 1878-0318
J9 OBES RES CLIN PRACT
JI Obes. Res. Clin. Pract.
PD MAY-JUN
PY 2014
VL 8
IS 3
BP E271
EP E282
DI 10.1016/j.orcp.2013.01.003
PG 12
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA AG8JB
UT WOS:000335663500009
ER

PT J
AU Gotardo, EMF
   Ribeiro, GD
   Clemente, TRL
   Moscato, CH
   Tome, RBG
   Rocha, T
   Pedrazzoli, J
   Ribeiro, ML
   Gambero, A
AF Ferreira Gotardo, Erica Martins
   Ribeiro, Gilberto de Almeida
   Leite Clemente, Thayane Rodrigues
   Moscato, Camila Henrique
   Guerra Tome, Renata Bortolin
   Rocha, Thalita
   Pedrazzoli, Jose, Jr.
   Ribeiro, Marcelo Lima
   Gambero, Alessandra
TI Hepcidin expression in colon during trinitrobenzene sulfonic
   acid-induced colitis in rats
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Hepcidin-25; Interleukin-6; Iron; Stat-3; Anemia; Toll-like receptor 4
ID INFLAMMATORY-BOWEL-DISEASE; ADIPOSE-TISSUE ALTERATIONS; IRON-DEFICIENCY;
   ANEMIA; FERROPORTIN; INFECTION; OBESITY; MICE; AXIS
AB AIM: To investigate hepcidin expression, interleukin-6 (IL-6) production and iron levels in the rat colon in the presence of trinitrobenzene sulfonic acid (TNBS)-induced colitis.
   METHODS: In rats, we evaluated the severity of colitis induced by repeated TNBS administration using macroscopic and microscopic scoring systems and myeloperoxidase activity measurements. The colonic levels of hepcidin, tumor necrosis factor alpha (TNF-alpha), IL-10 and IL-6 were measured by Enzyme-Linked Immunosorbent Assay, and hepcidin-25 expression and iron deposition were analyzed by immunohistochemistry and the Prussian blue reaction, respectively. Stat-3 phosphorylation was assessed by Western blot analysis. Hematological parameters, iron and transferrin levels, and transferrin saturation were also measured. Additionally, the ability of iron, pathogen-derived molecules and IL-6 to induce hepcidin expression in HT-29 cells was evaluated.
   RESULTS: Repeated TNBS administration to rats resulted in macroscopically and microscopically detectable colon lesions and elevated colonic myeloperoxidase activity. Hepcidin-25 protein levels were increased in colonic surface epithelia in colitic rats (10.2 +/- 4.0 pg/mg protein vs 71.0 +/- 8.4 pg/mg protein, P < 0.01). Elevated IL-6 levels (8.2 +/- 1.7 pg/mg protein vs 14.7 +/- 0.7 pg/mg protein, P < 0.05), TNF-alpha levels (1.8 +/- 1.2 pg/mg protein vs 7.4 +/- 2.1 pg/mg protein, P < 0.05) and Stat-3 phosphorylation were also observed. Systemic alterations in iron homeostasis, hepcidin levels and anemia were not detected in colitic rats. Iron deposition in the colon was only observed during colitis. Hepcidin gene expression was increased in HT-29 cells after IL-6 and lipopolysaccharide [ a toll-like receptor 4 (TLR-4) ligand] treatment. Deferoxamine, ferric citrate and peptidoglycan (a TLR-2 ligand) were unable to alter the in vitro expression of hepcidin in HT-29 cells.
   CONCLUSION: Colitis increased local hepcidin-25 expression, which was associated with the IL-6/Stat-3 signaling pathway. An increase in local iron sequestration was also observed, but additional studies are needed to determine whether this sequestration is a defensive or pathological response to intestinal inflammation. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 [Ferreira Gotardo, Erica Martins; Ribeiro, Gilberto de Almeida; Leite Clemente, Thayane Rodrigues; Moscato, Camila Henrique; Guerra Tome, Renata Bortolin; Rocha, Thalita; Pedrazzoli, Jose, Jr.; Ribeiro, Marcelo Lima; Gambero, Alessandra] Univ Sao Francisco, Sch Med, Clin Pharmacol & Gastroenterol Unit, BR-12916900 Braganca Paulista, SP, Brazil.
RP Gambero, A (reprint author), Univ Sao Francisco, Sch Med, Clin Pharmacol & Gastroenterol Unit, Av Sao Francisco de Assis 218, BR-12916900 Braganca Paulista, SP, Brazil.
EM alessandra.gambero@usf.edu.br
RI Ribeiro, Marcelo/H-8856-2013; Gambero, Alessandra/G-5792-2013; 
OI Ribeiro, Marcelo/0000-0003-4529-7832; Rocha, Thalita/0000-0002-2731-9586
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP
   2010/02991-6]
FX Supported by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo,
   No. FAPESP 2010/02991-6
CR Qiao B, 2012, CELL METAB, V15, P918, DOI 10.1016/j.cmet.2012.03.018
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Frazer DM, 2007, AM J PHYSIOL-GASTR L, V293, pG525, DOI 10.1152/ajpgi.00579.2006
   Koon HW, 2011, GASTROENTEROLOGY, V141, P1852, DOI 10.1053/j.gastro.2011.06.079
   Schroder O, 2005, AM J GASTROENTEROL, V100, P2503, DOI 10.1111/j.1572-0241.2005.00250.x
   Ho S, 2013, CURR PHARM DESIGN, V19, P40
   Powell JJ, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-9
   Sun CC, 2012, AM J HEMATOL, V87, P392, DOI 10.1002/ajh.23110
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Ward DG, 2008, WORLD J GASTROENTERO, V14, P1339, DOI 10.3748/wjg.14.1339
   Wang LJ, 2008, J IMMUNOL, V181, P2723
   Oustamanolakis P, 2011, EUR J GASTROEN HEPAT, V23, P262, DOI 10.1097/MEG.0b013e328343b885
   Funakoshi T, 2012, J CROHNS COLITIS, V6, P215, DOI 10.1016/j.crohns.2011.08.011
   Ganz T, 2009, SEMIN HEMATOL, V46, P387, DOI 10.1053/j.seminhematol.2009.06.001
   Finberg KE, 2013, CURR OPIN HEMATOL, V20, P208, DOI 10.1097/MOH.0b013e32835f5a47
   Theurl I, 2008, BLOOD, V111, P2392, DOI 10.1182/blood-2007-05-090019
   Recalcati S, 2012, AUTOIMMUN REV, V11, P883, DOI 10.1016/j.autrev.2012.03.003
   Vokurka M, 2010, PHYSIOL RES, V59, P393
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Mullin GE, 2012, NUTR CLIN PRACT, V27, P136, DOI 10.1177/0884533611433436
   Schwarz P, 2012, GUT, V61, P193, DOI 10.1136/gut.2011.241208
   Layoun A, 2012, INFLAMMATION, V35, P1500, DOI 10.1007/s10753-012-9463-4
   Sheikh N, 2007, LAB INVEST, V87, P713, DOI 10.1038/labinvest.3700553
   Gaffney-Stomberg E, 2012, CURR OPIN CLIN NUTR, V15, P605, DOI 10.1097/MCO.0b013e328357f63b
   Arnold J, 2009, EUR J GASTROEN HEPAT, V21, P335, DOI 10.1097/MEG.0b013e32830e2885
   Basseri Robert J, 2013, J Crohns Colitis, V7, pe286, DOI 10.1016/j.crohns.2012.10.013
   Bergamaschi G, 2013, INFLAMM BOWEL DIS, V19, P2166, DOI 10.1097/MIB.0b013e31829a6e43
   Rodriguez-Cabezas ME, 2002, J NUTR, V132, P3263
   Clemente TRL, 2012, SCAND J GASTROENTERO, V47, P943, DOI 10.3109/00365521.2012.688213
   Gambero A, 2007, INFLAMM BOWEL DIS, V13, P1357, DOI 10.1002/ibd.20222
   Kent AJ, 2012, CURR DRUG DELIV, V9, P356
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
NR 32
TC 1
Z9 1
U1 0
U2 4
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD APR 21
PY 2014
VL 20
IS 15
BP 4345
EP 4352
DI 10.3748/wjg.v20.i15.4345
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AF3HQ
UT WOS:000334603000023
PM 24764672
ER

PT J
AU Zelber-Sagi, S
   Buch, A
   Yeshua, H
   Vaisman, N
   Webb, M
   Harari, G
   Kis, O
   Fliss-Isakov, N
   Izkhakov, E
   Halpern, Z
   Santo, E
   Oren, R
   Shibolet, O
AF Zelber-Sagi, Shira
   Buch, Assaf
   Yeshua, Hanny
   Vaisman, Nahum
   Webb, Muriel
   Harari, Gil
   Kis, Ofer
   Fliss-Isakov, Naomi
   Izkhakov, Elena
   Halpern, Zamir
   Santo, Erwin
   Oren, Ran
   Shibolet, Oren
TI Effect of resistance training on non-alcoholic fatty-liver disease a
   randomized-clinical trial
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Resistance exercise; Obesity; Nutrition; Physical activity; Abdominal
   fat
ID AMERICAN-HEART-ASSOCIATION; TIME PHYSICAL-ACTIVITY; X-RAY
   ABSORPTIOMETRY; QUALITY-OF-LIFE; INSULIN-RESISTANCE; SERUM FERRITIN;
   AEROBIC EXERCISE; WEIGHT-LOSS; BODY-COMPOSITION; OLDER-ADULTS
AB AIM: To evaluate the effect of resistance training (RT) on non alcoholic liver disease (NAFLD) patients.
   METHODS: A randomized clinical trial enrolling NAFLD patients without secondary liver disease (e.g., without hepatitis B virus, hepatitis C virus or excessive alcohol consumption). Patients were randomly allocated either to RT, three times weekly, for 3 mo or a control arm consisting of home stretching. The RT included leg press, chest press, seated rowing, latissimus pull down etc. with 8-12 repetitions, 3 sets for each exercise, for a total duration of 40 min. Hepatic ultrasound, fasting blood tests, anthropometrics and body composition by dual energy X-ray absorptiometry were assessed. At baseline and follow-up, patients filled out a detailed semi-quantitative food frequency questionnaire reporting their habitual nutritional intake. Steatosis was quantified by the hepatorenal-ultrasound index (HRI) representing the ratio between the brightness level of the liver and the right kidney. The HRI has been previously demonstrated to be highly reproducible and was validated against liver biopsy and proton magnetic resonance spectroscopy.
   RESULTS: Eighty two patients with primary NAFLD were randomized to receive 3 mo of either RT or stretching. After dropout or exclusion from analysis because of protocol violation (weight change > 3 kg), thirty three patients in the RT arm and 31 in the stretching arm completed the study per protocol. All baseline characteristics were similar for the two treatment groups with respect to demographics, anthropometrics and body composition, blood tests and liver steatosis on imaging. HRI score was reduced significantly in the RT arm as compared to the stretching arm (-0.25 +/- 0.37 vs -0.05 +/- 0.28, P = 0.017). The RT arm had a significantly higher reduction in total, trunk and android fat with increase in lean body mass. There was no correlation between the reduction in HRI in the RT arm and weight change during the study, but it was positively correlated with the change in trunk fat (r = 0.37, P = 0.048). The RT arm had a significant reduction in serum ferritin and total cholesterol. There was no significant difference between arms in dietary changes and these did not correlate with HRI change.
   CONCLUSION: Three months RT improves hepatic fat content accompanied by favorable changes in body composition and ferritin. RT may serve as a complement to treatment of NAFLD. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 [Zelber-Sagi, Shira; Buch, Assaf; Yeshua, Hanny; Vaisman, Nahum; Webb, Muriel; Fliss-Isakov, Naomi; Izkhakov, Elena; Halpern, Zamir; Santo, Erwin; Oren, Ran; Shibolet, Oren] Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol, IL-6423906 Tel Aviv, Israel.
   [Zelber-Sagi, Shira; Harari, Gil] Univ Haifa, Sch Publ Hlth, IL-3498838 Haifa, Israel.
   [Buch, Assaf; Yeshua, Hanny; Vaisman, Nahum; Fliss-Isakov, Naomi; Halpern, Zamir; Santo, Erwin; Oren, Ran; Shibolet, Oren] Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel.
   [Kis, Ofer] Wingate Inst Phys Educ & Sport, IL-4290200 Netanya, Israel.
RP Zelber-Sagi, S (reprint author), Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol, 6 Weizman St, IL-6423906 Tel Aviv, Israel.
EM zelbersagi@bezeqint.net
CR American College of Sports Medicine, 1998, MED SCI SPORTS EXERC, P975, DOI [10.1249/MSS.0b013e318213fefb, DOI 10.1097/00005768-199806000-00032]
   American College of Sports Medicine, 2009, MED SCI SPORTS EXERC, V41, P687, DOI [DOI 10.1249/MSS.0B013E3181915670, 10.1249/MSS.0b013e3181915670]
   Arena R, 2007, CIRCULATION, V116, P329, DOI 10.1161/CIRCULATIONAHA.107.184461
   Orr R, 2006, J GERONTOL A-BIOL, V61, P78
   Hoenig MR, 2010, ATHEROSCLEROSIS, V211, P260, DOI 10.1016/j.atherosclerosis.2010.02.029
   Mancini M, 2009, METABOLISM, V58, P1724, DOI 10.1016/j.metabol.2009.05.032
   de Piano A, 2012, EUR J GASTROEN HEPAT, V24, P1313, DOI 10.1097/MEG.0b013e32835793ac
   Duncan GE, 2003, DIABETES CARE, V26, P557, DOI 10.2337/diacare.26.3.557
   Angulo P, 2011, HEPATOLOGY, V53, P1792, DOI 10.1002/hep.24403
   Simonen P, 2011, J HEPATOL, V54, P153, DOI 10.1016/j.jhep.2010.05.037
   GOING SB, 1993, AM J CLIN NUTR, V57, P845
   Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x
   Wasada T, 2008, METABOLISM, V57, P980, DOI 10.1016/j.metabol.2008.02.015
   Katan MB, 2009, NEW ENGL J MED, V360, P923, DOI 10.1056/NEJMe0810291
   Speliotes EK, 2010, HEPATOLOGY, V51, P1979, DOI 10.1002/hep.23593
   Kelley GA, 2009, PREV MED, V48, P9, DOI 10.1016/j.ypmed.2008.10.010
   Albright A, 2000, MED SCI SPORT EXER, V32, P1345
   Newton JL, 2008, GUT, V57, P807, DOI 10.1136/gut.2007.139303
   Zelber-Sagi S, 2008, HEPATOLOGY, V48, P1791, DOI 10.1002/hep.22525
   Ballestri S, 2012, LIVER INT, V32, P1242, DOI 10.1111/j.1478-3231.2012.02804.x
   Zelber-Sagi S, 2012, J HEPATOL, V56, P1145, DOI 10.1016/j.jhep.2011.12.011
   Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008
   Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129
   Kalantar-Zadeh K, 2004, NEPHROL DIAL TRANSPL, V19, P141, DOI 10.1093/ndt/gfg493
   Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017
   Finucane FM, 2010, DIABETOLOGIA, V53, P624, DOI 10.1007/s00125-009-1641-z
   Zelber-Sagi S, 2006, LIVER INT, V26, P856, DOI 10.1111/j.1478-3231.2006.01311.x
   Van Der Heijden GJ, 2010, MED SCI SPORT EXER, V42, P1973, DOI 10.1249/MSS.0b013e3181df16d9
   Sullivan S, 2012, HEPATOLOGY, V55, P1738, DOI 10.1002/hep.25548
   Banz WJ, 2003, EXP BIOL MED, V228, P434
   Zhao G, 2008, DIABETIC MED, V25, P221, DOI 10.1111/j.1464-5491.2007.02332.x
   Mann S, 2014, SPORTS MED, V44, P211, DOI 10.1007/s40279-013-0110-5
   Peterson JA, 2007, J AM ACAD NURSE PRAC, V19, P349, DOI 10.1111/j.1745-7599.2007.00239.x
   Kraemer WJ, 2004, MED SCI SPORT EXER, V36, P674, DOI 10.1249/01.MSS.0000121945.36635.61
   Valenti L, 2012, WORLD J GASTROENTERO, V18, P3782, DOI 10.3748/wjg.v18.i29.3782
   Zelber-Sagi S, 2013, WORLD J GASTROENTERO, V19, P57, DOI 10.3748/wjg.v19.i1.57
   Flannery C, 2012, DIABETES, V61, P2711, DOI 10.2337/db12-0206
   MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946
   Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335
   Webb M, 2009, AM J ROENTGENOL, V192, P909, DOI 10.2214/AJR.07.4016
   Brovold T, 2012, ARCH GERONTOL GERIAT, V55, P453, DOI 10.1016/j.archger.2012.01.015
   Liu JM, 2003, AM J CLIN NUTR, V78, P1160
   Seguin R, 2003, AM J PREV MED, V25, P141, DOI 10.1016/S0749-3797(03)00177-6
   Pollock ML, 2000, CIRCULATION, V101, P828
   Bugianesi E, 2010, CURR PHARM DESIGN, V16, P1941
   Pettersson J, 2008, BRIT J CLIN PHARMACO, V65, P253, DOI 10.1111/j.1365-2125.2007.03001.x
   LAKKA TA, 1994, AM J EPIDEMIOL, V140, P148
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Williams MA, 2007, CIRCULATION, V116, P572, DOI 10.1161/CIRCULATIONAHA.107.185214
   Hallsworth K, 2011, GUT, V60, P1278, DOI 10.1136/gut.2011.242073
   Pratt M, 1999, MED SCI SPORT EXER, V31, pS526, DOI 10.1097/00005768-199911001-00007
   HAARBO J, 1991, CLIN PHYSIOL, V11, P331, DOI 10.1111/j.1475-097X.1991.tb00662.x
   Bacchi E, 2013, HEPATOLOGY, V58, P1287, DOI 10.1002/hep.26393
   David K, 2009, HEPATOLOGY, V49, P1904, DOI 10.1002/hep.22868
   Bellentani S, 2008, HEPATOLOGY, V47, P746, DOI 10.1002/hep.22009
   Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62
   Ku BJ, 2009, DIS MARKERS, V27, P303, DOI 10.3233/DMA-2009-0676
   van der Heijden GJ, 2010, OBESITY, V18, P384, DOI 10.1038/oby.2009.274
   Zelber-Sagi S, 2007, J HEPATOL, V46, P700, DOI 10.1016/j.jhep.2006.09.018
   Kim LJ, 2011, OBESITY, V19, P1265, DOI 10.1038/oby.2010.291
   Beniamini Y, 1999, J Cardiopulm Rehabil, V19, P8, DOI 10.1097/00008483-199901000-00001
   Brooks Naomi, 2007, Int J Med Sci, V4, P19
   Brudevold R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003547
   Fenicchia LM, 2004, METABOLISM, V53, P284, DOI 10.1016/j.metabol.2003.10.007
   FLUCKEY JD, 1994, J APPL PHYSIOL, V77, P1087
   Frith J, 2010, J HEPATOL, V52, P112, DOI 10.1016/j.jhep.2009.10.010
   Gore RM, 1994, TXB GASTROINTESTINAL, P1968
   Hameed Unaise Abdul, 2012, N Am J Med Sci, V4, P336, DOI 10.4103/1947-2714.99507
   Hevi S, 2003, J BIOL CHEM, V278, P31924, DOI 10.1074/jbc.M303081200
   Kataja-Tuomola M, 2010, EUR J EPIDEMIOL, V25, P333, DOI 10.1007/s10654-010-9444-6
   Ken-Dror Gie, 2005, Harefuah, V144, P200
   Ken- Dror G, 2005, HAREFUAH, V144, P229
   Ken-Dror G, 2005, HAREFUAH, V144, P230
   Manousou P, 2011, LIVER INT, V31, P730, DOI 10.1111/j.1478-3231.2011.02488.x
   Morrato EH, 2007, DIABETES CARE, V30, P203, DOI 10.2337/dc06-1128
   NICHOLS JF, 1993, J AM GERIATR SOC, V41, P205
   St George Alexis, 2009, Hepatology, V50, P68, DOI 10.1002/hep.22940
   St George Alexis, 2009, J Gastroenterol Hepatol, V24, P399, DOI 10.1111/j.1440-1746.2008.05694.x
   Zelber-Sagil S, 2007, J HEPATOL, V47, P711, DOI 10.1016/j.jhep.2007.06.020
NR 79
TC 5
Z9 5
U1 2
U2 19
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD APR 21
PY 2014
VL 20
IS 15
BP 4382
EP 4392
DI 10.3748/wjg.v20.i15.4382
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AF3HQ
UT WOS:000334603000028
PM 24764677
ER

PT J
AU Wong, VWS
   Wong, GLH
   Yeung, DKW
   Abrigo, JM
   Kong, APS
   Chan, RSM
   Chim, AML
   Shen, JY
   Ho, CS
   Woo, J
   Chu, WCW
   Chan, HLY
AF Wong, Vincent Wai-Sun
   Wong, Grace Lai-Hung
   Yeung, David Ka-Wai
   Abrigo, Jill M.
   Kong, Alice Pik-Shan
   Chan, Ruth Suk-Mei
   Chim, Angel Mei-Ling
   Shen, Jiayun
   Ho, Chung-Shun
   Woo, Jean
   Chu, Winnie Chiu-Wing
   Chan, Henry Lik-Yuen
TI Fatty Pancreas, Insulin Resistance, and beta-Cell Function: A Population
   Study Using Fat-Water Magnetic Resonance Imaging
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID LIVER-DISEASE; METABOLIC SYNDROME; RISK-FACTORS; ADVANCED FIBROSIS;
   NATURAL-HISTORY; PREVALENCE; STEATOSIS; CHINESE; MRI; QUANTIFICATION
AB OBJECTIVES: Nonalcoholic fatty liver disease is the most common chronic liver disease. Fatty pancreas has also been described but is difficult to assess. It is now possible to measure pancreatic and liver fat accurately with magnetic resonance imaging (MRI). We aimed to define the normal range of pancreatic fat and identify factors associated with fatty pancreas. In addition, the effect of fatty liver and fatty pancreas on insulin resistance (IR) and pancreatic beta-cell function was studied.
   METHODS: Fat-water MRI and proton-magnetic resonance spectroscopy were performed on 685 healthy volunteers from the general population to measure pancreatic and liver fat, respectively. On the basis of fasting plasma glucose and insulin levels, the IR and beta-cell function were assessed using the homeostasis model assessment (HOMA).
   RESULTS: Among subjects without significant alcohol consumption or any component of metabolic syndrome, 90% had pancreatic fat between 1.8 and 10.4%. Using the upper limit of normal of 10.4%, 110 (16.1%; 95% confidence interval 13.3-18.8%) subjects had fatty pancreas. On multivariable analysis, high serum ferritin, central obesity, and hypertriglyceridemia were independent factors associated with fatty pancreas. Subjects with both fatty pancreas and fatty liver had higher HOMA-IR than did those with either condition alone. Fatty pancreas was not associated with HOMA-beta after adjusting for liver fat and body mass index.
   CONCLUSIONS: In all, 16.1% of this community cohort of adult Hong Kong Chinese volunteers had a fatty pancreas by our definition. Central obesity, hypertriglyceridemia, and hyperferritinemia are associated with fatty pancreas. Individuals with fatty pancreas have increased IR.
C1 [Wong, Vincent Wai-Sun; Wong, Grace Lai-Hung; Chim, Angel Mei-Ling; Shen, Jiayun; Chu, Winnie Chiu-Wing; Chan, Henry Lik-Yuen] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Wong, Vincent Wai-Sun; Wong, Grace Lai-Hung; Kong, Alice Pik-Shan; Chan, Ruth Suk-Mei; Chim, Angel Mei-Ling; Shen, Jiayun; Woo, Jean; Chan, Henry Lik-Yuen] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Yeung, David Ka-Wai] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
   [Abrigo, Jill M.; Chu, Winnie Chiu-Wing] Chinese Univ Hong Kong, Dept Imaging & Intervent Radiol, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Ruth Suk-Mei; Woo, Jean] Chinese Univ Hong Kong, Ctr Nutr Studies, Hong Kong, Hong Kong, Peoples R China.
   [Ho, Chung-Shun] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China.
RP Chan, HLY (reprint author), Prince Wales Hosp, Dept Med & Therapeut, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.
EM winniechu@cuhk.edu.hk; hlychan@cuhk.edu.hk
RI Chan, Ruth/K-4995-2014; Wong, Grace/L-8586-2014; Chu,
   Winnie/F-8449-2014; Chan, Henry Lik-Yuen/B-9636-2008; Wong,
   Vincent/K-3864-2014; Kong, Alice/P-3703-2015; Woo, Jean/K-2625-2014
OI Woo, Jean/0000-0001-7593-3081
FU General Research Fund of the Research Grant Council, Hong Kong SAR
   [476512, SEG CUHK_02]
FX This study was supported by the General Research Fund of the Research
   Grant Council, Hong Kong SAR (Project reference 476512 and SEG CUHK_02).
CR Xu CF, 2013, AM J GASTROENTEROL, V108, P1299, DOI 10.1038/ajg.2013.104
   Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014
   Wong VWS, 2011, GUT, V60, P829, DOI 10.1136/gut.2011.237974
   Guiu B, 2009, RADIOLOGY, V250, P95, DOI 10.1148/radiol.2493080217
   Ma JF, 2008, J MAGN RESON IMAGING, V28, P543, DOI 10.1002/jmri.21492
   Ascha MS, 2010, HEPATOLOGY, V51, P1972, DOI 10.1002/hep.23527
   Farrell GC, 2007, J GASTROEN HEPATOL, V22, P775, DOI 10.1111/j.1440-1746.2007.05002.x
   Rossi AP, 2011, OBESITY, V19, P1747, DOI 10.1038/oby.2011.114
   Hamaguchi M, 2005, ANN INTERN MED, V143, P722
   Reeder SB, 2005, MAGNET RESON MED, V54, P636, DOI 10.1002/mrm.20624
   Bhala N, 2011, HEPATOLOGY, V54, P1208, DOI 10.1002/hep.24491
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Hu HH, 2010, J MAGN RESON IMAGING, V31, P1195, DOI 10.1002/jmri.22162
   Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017
   Wong VWS, 2012, GUT, V61, P409, DOI 10.1136/gutjnl-2011-300342
   Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257
   Hu HH, 2010, OBESITY, V18, P841, DOI 10.1038/oby.2009.352
   Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844
   MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946
   Tushuizen ME, 2007, DIABETES CARE, V30, P2916, DOI 10.2337/dcO7-0326
   Sookoian S, 2011, HEPATOLOGY, V53, P1883, DOI 10.1002/hep.24283
   Heni M, 2010, DIABETES-METAB RES, V26, P200, DOI 10.1002/dmrr.1073
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Mathur A, 2009, J AM COLL SURGEONS, V208, P989, DOI 10.1016/j.jamcollsurg.2008.12.026
   Wong VWS, 2010, GUT, V59, P969, DOI 10.1136/gut.2009.205088
   Patel NS, 2013, ALIMENT PHARM THER, V37, P630, DOI 10.1111/apt.12237
   Mathur A, 2007, ANN SURG, V246, P1058, DOI 10.1097/SLA.0b013e31814a6906
   Hannukainen JC, 2011, J HEPATOL, V54, P545, DOI 10.1016/j.jhep.2010.07.029
   Wong VWS, 2011, GUT, V60, P1721, DOI 10.1136/gut.2011.242016
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Fraulob JC, 2010, J CLIN BIOCHEM NUTR, V46, P212, DOI 10.3164/jcbn.09-83
   STAMM BH, 1984, HUM PATHOL, V15, P677, DOI 10.1016/S0046-8177(84)80294-4
   Wong VWS, 2006, CLIN GASTROENTEROL H, V4, P1154, DOI 10.1016/j.cgh.2006.06.011
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Gaujoux S, 2010, SURGERY, V148, P15, DOI 10.1016/j.surg.2009.12.005
   Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038
   Pietrangelo A, 2007, HEPATOLOGY, V46, P1291, DOI 10.1002/hep.21886
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   Li J, 2011, PANCREAS, V40, P295, DOI 10.1097/MPA.0b013e318201669f
   Manchanayake J, 2011, J GASTROEN HEPATOL, V26, P510, DOI 10.1111/j.1440-1746.2010.06528.x
   Mathur A, 2009, J AM COLL SURGEONS, V208, P994
   Mathur Abhishek, 2007, HPB (Oxford), V9, P312, DOI 10.1080/13651820701504157
   Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052
   Sepe PS, 2011, GASTROINTEST ENDOSC, V73, P987, DOI 10.1016/j.gie.2011.01.015
NR 44
TC 14
Z9 14
U1 3
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD APR
PY 2014
VL 109
IS 4
BP 589
EP 597
DI 10.1038/ajg.2014.1
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AG5HO
UT WOS:000335450300017
PM 24492753
ER

PT J
AU Moreno-Navarrete, JM
   Novelle, MG
   Catalan, V
   Ortega, F
   Moreno, M
   Gomez-Ambrosi, J
   Xifra, G
   Serrano, M
   Guerra, E
   Ricart, W
   Fruhbeck, G
   Dieguez, C
   Fernandez-Real, JM
AF Maria Moreno-Navarrete, Jose
   Novelle, Marta G.
   Catalan, Victoria
   Ortega, Francisco
   Moreno, Maria
   Gomez-Ambrosi, Javier
   Xifra, Gemma
   Serrano, Marta
   Guerra, Ester
   Ricart, Wifredo
   Fruehbeck, Gema
   Dieguez, Carlos
   Manuel Fernandez-Real, Jose
TI Insulin Resistance Modulates Iron-Related Proteins in Adipose Tissue
SO DIABETES CARE
LA English
DT Article
ID DEPENDENT DIABETES-MELLITUS; SERUM FERRITIN; METABOLIC SYNDROME;
   OBESITY; SENSITIVITY; GLUCOSE; RISK; OVERLOAD; STORES; INFLAMMATION
AB OBJECTIVE
   Circulating markers of iron overload are associated with insulin resistance. Less is known about the impact of iron overload on adipose tissue (AT). We hypothesized that gene expression markers of iron metabolism in AT could be associated with insulin action.
   RESEARCH DESIGN AND METHODS
   The AT expression of ferroportin (SLC40A1), transferrin (TF), TF receptor (TFRC), ferritin (FT) heavy polypeptide 1 (FTH1), and FT light polypeptide (FTL) was analyzed cross-sectionally in three independent cohorts and also after weight loss-induced changes in insulin sensitivity (clamp M value) in an independent fourth cohort.
   RESULTS
   In human AT, TF mRNA and protein levels were decreased with obesity and insulin resistance in the three cohorts and were positively associated with adipogenic mRNAs and insulin action. Otherwise, FTL mRNA and protein and SLC40A1 transcripts were positively associated with BMI and negatively linked to adipogenic genes and insulin action. Bariatric surgery-induced weight loss led to increased TF and decreased TFRC, FTH1, FTL, and SLC40A1 in subcutaneous AT in parallel to improved insulin action.
   CONCLUSIONS
   These results suggest that iron overload impacts on AT in association with insulin resistance.
C1 [Maria Moreno-Navarrete, Jose; Ortega, Francisco; Moreno, Maria; Xifra, Gemma; Serrano, Marta; Guerra, Ester; Ricart, Wifredo; Manuel Fernandez-Real, Jose] Inst Salud Carlos III, Dept Diabet Endocrinol & Nutr, Inst Invest Biomed Girona, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Girona, Spain.
   [Novelle, Marta G.; Dieguez, Carlos] Univ Santiago de Compostela, Sch Med, Dept Physiol, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Santiago De Compostela, Spain.
   [Catalan, Victoria; Gomez-Ambrosi, Javier; Fruehbeck, Gema] Inst Salud Carlos III, Dept Endocrinol & Metab Res Lab, Clin Univ Navarra, Pamplona, Spain.
   [Catalan, Victoria; Gomez-Ambrosi, Javier; Fruehbeck, Gema] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Pamplona, Spain.
RP Fernandez-Real, JM (reprint author), Inst Salud Carlos III, Dept Diabet Endocrinol & Nutr, Inst Invest Biomed Girona, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Girona, Spain.
EM jmfreal@idibgi.org
RI Moreno-Navarrete, Jose Maria/H-9772-2015; 
OI Ricart, Wifredo/0000-0002-3452-9098
FU Instituto de Salud Carlos III from Spain [FIS-PI11/00214,
   FIS-PI12/02631, FIS-PI12/00515]
FX This work was partially supported by research grants FIS-PI11/00214,
   FIS-PI12/02631, and FIS-PI12/00515 from the Instituto de Salud Carlos
   III from Spain. CIBER de la Fisiopatologia de la Obesidad y la Nutricion
   is an initiative from the Instituto de Salud Carlos III from Spain.
CR Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Tajima S, 2012, AM J PHYSIOL-ENDOC M, V302, pE77, DOI 10.1152/ajpendo.00033.2011
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Swaminathan S, 2007, DIABETES CARE, V30, P1926, DOI 10.2337/dc06-2625
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825
   DANDONA P, 1983, ANN CLIN BIOCHEM, V20, P77
   Moreno-Navarrete JM, 2013, DIABETOLOGIA, V56, P2524, DOI 10.1007/s00125-013-3015-9
   Haap M, 2003, ANN INTERN MED, V139, P869
   Ascherio A, 2001, CIRCULATION, V103, P52
   Salonen JT, 1998, BRIT MED J, V317, P727
   Ortega FJ, 2010, OBESITY, V18, P13, DOI 10.1038/oby.2009.202
   Dekker LH, 2013, DIABETES CARE, V36, P965, DOI 10.2337/dc12-1243
   Haap M, 2011, J CLIN ENDOCR METAB, V96, pE958, DOI 10.1210/jc.2010-2682
   Kunutsor SK, 2013, DIABETES-METAB RES, V29, P308, DOI 10.1002/dmrr.2394
   Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021
   Dongiovanni P, 2013, AM J PATHOL, V182, P2254, DOI 10.1016/j.ajpath.2013.02.019
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   DAVIS RJ, 1986, J BIOL CHEM, V261, P8708
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Hua NW, 2001, BRIT J NUTR, V86, P515, DOI 10.1079/BJN2001421
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   BOFILL C, 1994, METABOLISM, V43, P614, DOI 10.1016/0026-0495(94)90204-6
   LESNEFSKY EJ, 1994, ADV EXP MED BIOL, V366, P129
   Bourlier V, 2008, CIRCULATION, V117, P806, DOI 10.1161/CIRCULATIONAHA.107.724096
   Lao TT, 2001, DIABETIC MED, V18, P218, DOI 10.1046/j.1464-5491.2001.00453.x
   Nemeth E, 2009, ACTA HAEMATOL-BASEL, V122, P78, DOI 10.1159/000243791
   Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887
   Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62
   Wlazlo N, 2013, DIABETES CARE, V36, P309, DOI 10.2337/dc12-0505
   Festa M, 2000, J BIOL CHEM, V275, P36708, DOI 10.1074/jbc.M004988200
   Arner P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018284
   Bao W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-119
   Facchini FS, 1998, DIABETES CARE, V21, P2190
   Farahani P, 2004, OBES RES, V12, P191, DOI 10.1038/oby.2004.26
   HENRY RR, 1986, DIABETES, V35, P990, DOI 10.2337/diabetes.35.9.990
   Lao TT, 1997, DIABETES CARE, V20, P1368, DOI 10.2337/diacare.20.9.1368
   Moreno-Navarrete JM, 2013, DIABETES, V62, P1923, DOI 10.2337/db12-0977
   Tinkov AA, 2013, BIOMETALS, V26, P447, DOI 10.1007/s10534-013-9630-6
   Virtue S, 2010, BBA-MOL CELL BIOL L, V1801, P338, DOI 10.1016/j.bbalip.2009.12.006
   WING RR, 1987, DIABETES CARE, V10, P563, DOI 10.2337/diacare.10.5.563
   Zhao ZX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041641
   Zheng X, 2011, AM J CLIN NUTR, V94, P1012, DOI 10.3945/ajcn.111.015743
NR 44
TC 8
Z9 8
U1 3
U2 13
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD APR
PY 2014
VL 37
IS 4
BP 1092
EP 1100
DI 10.2337/dc13-1602
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AD7BB
UT WOS:000333414700042
PM 24496804
ER

PT J
AU Batchuluun, B
   Matsumata, T
   Erdenebileg, N
   Tsagaantsooj, G
   Boldbaatar, K
   Khasag, A
AF Batchuluun, B.
   Matsumata, T.
   Erdenebileg, N.
   Tsagaantsooj, G.
   Boldbaatar, K.
   Khasag, A.
TI Serum ferritin level is higher in poorly controlled patients with Type2
   diabetes and people without diabetes, aged over 55years
SO DIABETIC MEDICINE
LA English
DT Article
ID BODY IRON STORES; INSULIN-RESISTANCE; METABOLIC SYNDROME;
   BLOOD-DONATIONS; ADULTS; RISK; MEN; HEMOCHROMATOSIS; MELLITUS;
   HYPERINSULINEMIA
AB Aims
   Diabetes mellitus has been increasing in Mongolia. There is also growing concern about the relationship between iron stores and the severity of Type2 diabetes. In this study, we aimed to evaluate serum ferritin level among Mongolian individuals with and without diabetes.
   Methods
   Of 254 participants, a total of 99 previously diagnosed patients with Type2 diabetes and the same numbers of subjects without diabetes were enrolled and invited to a physical examination (BMI, central obesity, blood pressure) and fasting blood tests (fasting blood glucose, HbA(1c), serum ferritin, C-reactive protein, aspartate aminotransferase, alanine transferase).
   Results
   Serum ferritin was higher in the patients with Type2 diabetes compared with the control group without diabetes, with a significant difference in the female groups (341.6 +/- 67.2 and 159.1 +/- 36.8ng/ml respectively, P=0.019). Of the patients with Type2 diabetes, 43.4% had hyperferritinaemia, and 21.2% of the individuals without diabetes had hyperferritinaemia. In the group with Type2 diabetes, serum ferritin level was significantly higher in the group of women whose HbA(1c) was >= 53mmol/mol (7.0%) compared with the other group of women whose HbA(1c) was <53mmol/mol (7.0%) (562.1 +/- 122.1 and 220.5 +/- 78.7ng/ml respectively, P=0.025). We also found that the subjects without diabetes, aged over 55years, are at risk of increased serum ferritin.
   Conclusion
   Poorly controlled patients with Type2 diabetes and people without diabetes of over 55years of age are likely to be at a higher risk of developing hyperferritinaemia. Thus, regular assessments of serum ferritin might be important for those who are at risk of hyperferritnaemia for prevention and an early intervention.
C1 [Batchuluun, B.; Erdenebileg, N.] Kyushu Univ, Grad Sch Med Sci, Dept Internal Med & Bioregulatory Sci, Fukuoka 812, Japan.
   [Matsumata, T.] Saiseikai Yahata Gen Hosp, Kitakyushu, Fukuoka, Japan.
   [Erdenebileg, N.; Tsagaantsooj, G.; Boldbaatar, K.; Khasag, A.] Hlth Sci Univ Mongolia, Sch Med, Ulaanbaatar, Mongol Peo Rep.
RP Batchuluun, B (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Internal Med & Bioregulatory Sci, Fukuoka 812, Japan.
EM battsetseg.batchuluun@gmail.com
FU Saiseikai Yahata General Hospital, Kitakyushu, Japan
FX This study was supported by Saiseikai Yahata General Hospital,
   Kitakyushu, Japan.
CR Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Jiang R, 2004, AM J CLIN NUTR, V79, P70
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Sharifi F, 2008, DIABETES VASC DIS RE, V5, P15, DOI 10.3132/dvdr.2008.003
   Ascherio A, 2001, CIRCULATION, V103, P52
   Salonen JT, 1998, BRIT MED J, V317, P727
   Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Canturk Z, 2003, ENDOCR RES, V29, P299, DOI 10.1081/ERC-120025037
   DMOCHOWSKI K, 1993, J CLIN ENDOCR METAB, V77, P478, DOI 10.1210/jc.77.2.478
   Luan DC, 2008, DIABETES CARE, V31, P285, DOI 10.2337/dc07-0921
   NIEDERAU C, 1984, DIABETOLOGIA, V26, P441
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Shi ZM, 2006, DIABETES CARE, V29, P1878, DOI 10.2337/dc06-0327
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   CAVALLOPERIN P, 1995, METABOLISM, V44, P281, DOI 10.1016/0026-0495(95)90155-8
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   KAYE TB, 1993, J DIABETES COMPLICAT, V7, P246, DOI 10.1016/0891-6632(93)90008-5
   OBRIEN T, 1990, DIABETES CARE, V13, P532, DOI 10.2337/diacare.13.5.532
   REDMON JB, 1993, DIABETES, V42, P544, DOI 10.2337/diabetes.42.4.544
   Sharifi F, 2004, ACTA MED IRANICA, V42, P142
   Thomas MC, 2004, DIABETIC MED, V21, P798, DOI 10.1111/j.1464-5491.2004.01196.x
   VANOOST BA, 1984, CLIN BIOCHEM, V17, P263, DOI 10.1016/S0009-9120(84)90189-9
   Waalen J, 2008, BLOOD, V111, P3373, DOI 10.1182/blood-2007-07-102673
   WOLFF SP, 1993, BRIT MED BULL, V49, P642
NR 29
TC 3
Z9 3
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD APR
PY 2014
VL 31
IS 4
BP 419
EP 424
DI 10.1111/dme.12343
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AC8BQ
UT WOS:000332758400007
PM 24151864
ER

PT J
AU Gong, LY
   Yuan, FF
   Teng, JH
   Li, X
   Zheng, SN
   Lin, LQ
   Deng, HY
   Ma, GS
   Sun, CH
   Li, Y
AF Gong, Liya
   Yuan, Feifei
   Teng, Jianhua
   Li, Xue
   Zheng, Sining
   Lin, Liqun
   Deng, Haoyuan
   Ma, Guansheng
   Sun, Changhao
   Li, Ying
TI Weight Loss, Inflammatory Markers, and Improvements of Iron Status in
   Overweight and Obese Children
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID SERUM TRANSFERRIN RECEPTOR; BODY-MASS INDEX; CHILDHOOD OBESITY;
   DEFICIENCY; HEPCIDIN; WOMEN; INTERVENTION; ADOLESCENTS; ABSORPTION;
   ANEMIA
AB Objective To assess the effect of aweight-loss program on improving iron status in overweight and obese schoolaged children.
   Study design The data were analyzed in overweight and obese children (7-11 years of age; 114 girls and 212 boys) with body mass index-for-age z-scores (BAZ) >1 from a weight-loss program. Schools were randomly divided into 2 groups: intervention and control. Children in the intervention group underwent a 1-year, nutritionbased comprehensive intervention weight-loss program. Anthropometric, dietary intake, and physical activity data were collected at baseline and follow-up (1 year). Iron status and inflammatory markers were assessed within a month.
   Results In the intervention group, BAZ decreased more than that in the control group (-0.4 +/- 0.7 vs -0.1 +/- 0.6, P < .0001); and iron profiles and inflammation status were improved at follow-up. In multivariable linear regression models, a greater decrease of BAZ and inflammation factors predicted a better improvement of iron status. After adjustment of Delta BAZ, Delta C-reactive protein was significantly associated with Delta serum ferritin (beta: 1.89; 95% CI, 0.70-3.09; P = .002) and Delta soluble transferrin receptor (beta: 0.88; 95% CI, 0.16-0.59; P = .017); Delta interleukin-6 was significantly associated with Delta serum ferritin (beta: 1.22; 95% CI, 0.64-1.79; P < .0001).
   Conclusions Iron status and inflammation were improved by weight reduction. The improvement in inflammatory markers during weight reduction was independently associated with improvements of iron status.
C1 [Gong, Liya; Yuan, Feifei; Teng, Jianhua; Li, Xue; Zheng, Sining; Lin, Liqun; Deng, Haoyuan; Sun, Changhao; Li, Ying] Harbin Med Univ, Sch Publ Hlth, Dept Nutr, Harbin 150081, Peoples R China.
   [Gong, Liya; Yuan, Feifei; Teng, Jianhua; Li, Xue; Zheng, Sining; Lin, Liqun; Deng, Haoyuan; Sun, Changhao; Li, Ying] Harbin Med Univ, Sch Publ Hlth, Dept Food Hyg, Harbin 150081, Peoples R China.
   [Teng, Jianhua] Inst TB Control & Prevent Harbin, Harbin, Peoples R China.
   [Ma, Guansheng] Chinese Ctr Dis Control & Prevent, Natl Inst Nutr & Food Safety, Beijing, Peoples R China.
RP Li, Y (reprint author), Harbin Med Univ, Sch Publ Hlth, Dept Nutr, 157 Baojian Rd, Harbin 150081, Peoples R China.
EM liying_helen@163.com
FU National Science and Technology Pillar Program during the Eleven
   Five-Year Plan Period [2008BAI58B05]; Program for New Century Excellent
   Talents in University of Ministry of Education of China [NCET-10-0148];
   National Institute for Nutrition and Food Safety; China Centers for
   Disease Control and Prevention
FX Supported by National Science and Technology Pillar Program during the
   Eleven Five-Year Plan Period (2008BAI58B05), the Program for New Century
   Excellent Talents in University of Ministry of Education of China
   (NCET-10-0148), National Institute for Nutrition and Food Safety, and
   China Centers for Disease Control and Prevention. The authors declare no
   conflicts of interest.
CR Hamza RT, 2013, HORM RES PAEDIAT, V80, P11, DOI 10.1159/000351941
   Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337
   Punnonen K, 1997, BLOOD, V89, P1052
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Baltussen R, 2004, J NUTR, V134, P2678
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   von Bonsdorff L, 2002, CLIN CHEM, V48, P307
   Baumgartner J, 2013, INT J OBESITY, V37, P24, DOI 10.1038/ijo.2012.145
   Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Ruivard M, 2009, J HEPATOL, V50, P1219, DOI 10.1016/j.jhep.2009.01.029
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Rosenbaum M, 2007, J CLIN ENDOCR METAB, V92, P504, DOI 10.1210/jc.2006-1516
   Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Cade JE, 2005, AM J CLIN NUTR, V82, P813
   COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63
   de Onis M, 2006, WHO CHILD GROWTH STA
   Halle M, 2004, EXERC IMMUNOL REV, V10, P66
   Harris RJ, 2004, ARCH DIS CHILD, V89, P154, DOI 10.1136/adc.2003.019703
   Li YP, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-229
   Liu Ai-Ling, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P901
   Newman BH, 2003, TRANSFUSION, V43, P1084, DOI 10.1046/j.1537-2995.2003.00478.x
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   Schneider JM, 2005, AM J CLIN NUTR, V82, P1269
   Siegrist M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-258
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   World Health Organization, 2004, ASS IR STAT POP INCL, P108
   World Health Organization. Office of the Spokesperson, 2004, WHO CDC EXP CONS AGR
NR 42
TC 6
Z9 7
U1 2
U2 15
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD APR
PY 2014
VL 164
IS 4
BP 795
EP U174
DI 10.1016/j.jpeds.2013.12.004
PG 8
WC Pediatrics
SC Pediatrics
GA AD4YV
UT WOS:000333258900028
PM 24518166
ER

PT J
AU Sano, S
   Izumi, Y
   Yamaguchi, T
   Yamazaki, T
   Tanaka, M
   Shiota, M
   Osada-Oka, M
   Nakamura, Y
   Wei, M
   Wanibuchi, H
   Iwao, H
   Yoshiyama, M
AF Sano, Soichi
   Izumi, Yasukatsu
   Yamaguchi, Takehiro
   Yamazaki, Takanori
   Tanaka, Masako
   Shiota, Masayuki
   Osada-Oka, Mayuko
   Nakamura, Yasuhiro
   Wei, Min
   Wanibuchi, Hideki
   Iwao, Hiroshi
   Yoshiyama, Minoru
TI Lipid synthesis is promoted by hypoxic adipocyte-derived exosomes in
   3T3-L1 cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Adipocytes; Exosome; Hypoxia; Proteomic analysis; De novo lipogenesis
ID MECHANISMS LINKING OBESITY; FATTY-ACID SYNTHASE; ADIPOSE-TISSUE;
   INSULIN-RESISTANCE; TRANSFERRIN RECEPTOR; SHEEP RETICULOCYTES;
   GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; EXTERNALIZATION; LIPOGENESIS; RELEASE
AB Hypoxia occurs within adipose tissues as a result of adipocyte hypertrophy and is associated with adipocyte dysfunction in obesity. Here, we examined whether hypoxia affects the characteristics of adipocyte-derived exosomes. Exosomes are nanovesicles secreted from most cell types as an information carrier between donor and recipient cells, containing a variety of proteins as well as genetic materials. Cultured differentiated 3T3-L1 adipocytes were exposed to hypoxic conditions and the protein content of the exosomes produced from these cells was compared by quantitative proteomic analysis. A total of 231 proteins were identified in the adipocyte-derived exosomes. Some of these proteins showed altered expression levels under hypoxic conditions. These results were confirmed by immunoblot analysis. Especially, hypoxic adipocyte-released exosomes were enriched in enzymes related to de novo lipogenesis such as acetyl-CoA carboxylase, glucose-6-phosphate dehydrogenase, and fatty acid synthase (FASN). The total amount of proteins secreted from exosomes increased by 3-4-fold under hypoxic conditions. Moreover, hypoxia-derived exosomes promoted lipid accumulation in recipient 3T3-L1 adipocytes, compared with those produced under normoxic conditions. FASN levels were increased in undifferentiated 3T3-L1 cells treated with FASN-containing hypoxic adipocytes-derived exosomes. This is a study to characterize the proteomic profiles of adipocyte-derived exosomes. Exosomal proteins derived from hypoxic adipocytes may affect lipogenic activity in neighboring preadipocytes and adipocytes. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Sano, Soichi; Izumi, Yasukatsu; Yamaguchi, Takehiro; Yamazaki, Takanori; Yoshiyama, Minoru] Osaka City Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka 5458585, Japan.
   [Izumi, Yasukatsu; Tanaka, Masako; Shiota, Masayuki; Iwao, Hiroshi] Osaka City Univ, Grad Sch Med, Dept Pharmacol, Osaka 5458585, Japan.
   [Osada-Oka, Mayuko] Kyoto Prefectural Univ, Grad Sch Life & Environm Sci, Kyoto 606, Japan.
   [Nakamura, Yasuhiro] Izumi Municipal Hosp, Dept Cardiol, Izumi Osaka, Japan.
   [Wei, Min; Wanibuchi, Hideki] Osaka City Univ, Grad Sch Med, Dept Pathol, Osaka 5458585, Japan.
RP Izumi, Y (reprint author), Osaka City Univ, Grad Sch Med, Dept Pharmacol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.
EM izumi@msic.med.osaka-cu.ac.jp
FU Ministry of Education, Science, Sports and Culture, and Hoansha
   Foundation [24591101]
FX This study was supported in part by Grant-in-Aid for Scientific Research
   (24591101) from the Ministry of Education, Science, Sports and Culture,
   and Hoansha Foundation.
CR PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049
   Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482
   Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822
   Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110
   Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487
   Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213
   Park J, 2006, DIABETES, V55, P2939, DOI 10.2337/db05-1570
   Park J, 2005, MOL CELL BIOL, V25, P5146, DOI 10.1128/MCB.25.12.5146-5157.2005
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Laliotis GP, 2010, CURR GENOMICS, V11, P168, DOI 10.2174/138920210791110960
   Yu SH, 2007, J IMMUNOL, V178, P6867
   Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9
   Strauss K, 2010, J BIOL CHEM, V285, P26279, DOI 10.1074/jbc.M110.134775
   Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483
   PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942
   PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5
   Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   DUNLOP M, 1978, EARLY HUM DEV, V2, P123, DOI 10.1016/0378-3782(78)90004-X
   Levert KL, 2002, J BIOL CHEM, V277, P16347, DOI 10.1074/jbc.C200113200
   Muller G, 2009, CELL SIGNAL, V21, P324, DOI 10.1016/j.cellsig.2008.10.021
   BJORNTORP P, 1991, INT J OBESITY, V15, P67
   CUSHMAN SW, 1978, J LIPID RES, V19, P269
   de Jong OG, 2012, J EXTRACELL VESICLES, V1
   Eldh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015353
   Fernandez-Real JM, 2010, DIABETES, V59, P1506, DOI 10.2337/db09-1756
   Hashimoto T, 2013, BIOCHEM BIOPH RES CO, V440, P43, DOI 10.1016/j.bbrc.2013.09.034
   King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421
   Marimpietri D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075054
   Muller G, 2011, EUR J PHARMACOL, V656, P1, DOI 10.1016/j.ejphar.2011.01.035
   Takahashi K, 2013, INT J ONCOL, V43, P1985, DOI 10.3892/ijo.2013.2135
   Trayhurn P, 2013, PHYSIOL REV, V93, P1, DOI 10.1152/physrev.00017.2012
   VANDENBO.H, 1974, ANNU REV BIOCHEM, V43, P243
NR 33
TC 9
Z9 9
U1 2
U2 21
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 7
PY 2014
VL 445
IS 2
BP 327
EP 333
DI 10.1016/j.bbrc.2014.01.183
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AD4NV
UT WOS:000333228700011
PM 24513287
ER

PT J
AU Altunoglu, E
   Muderrisoglu, C
   Erdenen, F
   Ulgen, E
   Ar, MC
AF Altunoglu, Esma
   Muderrisoglu, Cuneyt
   Erdenen, Fusun
   Ulgen, Ender
   Ar, M. Cem
TI The Impact of Obesity and Insulin Resistance on Iron and Red Blood Cell
   Parameters: A Single Center, Cross-Sectional Study
SO TURKISH JOURNAL OF HEMATOLOGY
LA English
DT Article
DE Obesity; Insulin resistance; Anemia; Inflammation
ID OVERWEIGHT CHILDREN; SERUM HEPCIDIN; INFLAMMATION; DEFICIENCY;
   METABOLISM; STORES; HYPOFERREMIA; ADOLESCENTS; ANEMIA; ADULTS
AB Objective: Obesity and iron deficiency (ID) are the 2 most common nutritional disorders worldwide causing significant public health implications. Obesity is characterized by the presence of low-grade inflammation, which may lead to a number of diseases including insulin resistance (IR) and type 2 diabetes. Increased levels of acute-phase proteins such as C-reactive protein (CRP) have been reported in obesity-related inflammation. The aim of this study was to investigate the impact of obesity/IR on iron and red blood cell related parameters.
   Materials and Methods: A total of 206 patients and 45 control subjects of normal weight were included in this cross-sectional study. Venous blood samples were taken from each patient to measure hemoglobin (Hb), serum iron (Fe), iron-binding capacity (IBC), ferritin, CRP, fasting blood glucose, and fasting insulin. Body mass index (BMI) and waist-to-hip ratio (WHR) were calculated for each patient. IR was determined using the HOMA-IR formula.
   Results: Subjects were divided into 3 groups according to BMI. There were 152 severely obese (BMI: 42.6 +/- 10.1), 54 mildly obese (BMI: 32.4 +/- 2.1), and 45 normal-weight (BMI: 24.3 +/- 1.3) patients. Hb levels in severely obese patients and normal controls were 12.8 +/- 1.3 g/dL and 13.6 +/- 1.8 g/dL, respectively. We found decreasing Fe levels with increasing weight (14.9 +/- 6.9 mu mol/L, 13.6 +/- 6.3 mu mol/L, and 10.9 +/- 4.6 mu mol/L for normal controls and mildly and severely obese patients, respectively). Hb levels were slightly lower in patients with higher HOMA-IR values (13.1-11.5 g/dL vs. 13.2 +/- 1.2 g/dL; p=0.36). Serum iron levels were significantly higher in the group with low HOMA-IR values (13.6 +/- 5.9 mu mol/L vs. 11.6 +/- 4.9 mu mol/L; p=0.008). IBC was found to be similar in both groups (60.2 +/- 11.4 mu mol/L vs. 61.9 +/- 10.7 mu mol/L; p=0.23). Ferritin was slightly higher in patients with higher HOMA-IR values (156.1 +/- 209.5 mu mol/L vs. 145.3 +/- 131.5 mu mol/L; p=0.62).
   Conclusion: Elevated BMI and IR are associated with lower Fe and hemoglobin levels. These findings may be explained by the chronic inflammation of obesity and may contribute to obesity-related co-morbidities. People with IR may present with ID without anemia.
C1 [Altunoglu, Esma; Muderrisoglu, Cuneyt; Erdenen, Fusun; Ulgen, Ender] Istanbul Training & Res Hosp, Dept Internal Med, Istanbul, Turkey.
   [Ar, M. Cem] Istanbul Univ, Cerrahpasa Med Fac, Dept Internal Med, Div Haematol, Istanbul, Turkey.
RP Altunoglu, E (reprint author), Istanbul Training & Res Hosp, Dept Internal Med, Istanbul, Turkey.
EM esmaaltunoglu@yahoo.com
CR Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Zeyda M, 2009, GERONTOLOGY, V55, P379, DOI 10.1159/000212758
   Kang HT, 2012, CLIN CHIM ACTA, V413, P636, DOI 10.1016/j.cca.2011.12.011
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Chung B, 2007, J NUTR, V137, P2366
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   DANDONA P, 1983, ANN CLIN BIOCHEM, V20, P77
   Roy CN, 2010, HEMATOL-AM SOC HEMAT, P276, DOI 10.1182/asheducation-2010.1.276
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   WENZEL BJ, 1962, LANCET, V2, P327
   Escobar-Morreale HF, 2012, TRENDS ENDOCRIN MET, V23, P509, DOI 10.1016/j.tem.2012.04.003
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Martinez-Garcia MA, 2009, DIABETES CARE, V32, P1525, DOI 10.2337/dc09-0420
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Choudhry VP, 2010, INDIAN J PEDIATR, V77, P787, DOI 10.1007/s12098-010-0098-x
   Fargion S, 2005, ALIMENT PHARM THERAP, V22, P61, DOI 10.1111/j.1365-2036.2005.02599.x
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   Hintze KJ, 2011, BIOL TRACE ELEM RES, V143, P764, DOI 10.1007/s12011-010-8932-6
   Lee Jee-Yon, 2012, Korean J Fam Med, V33, P205, DOI 10.4082/kjfm.2012.33.4.205
   Przybyszewska J, 2011, J NUTR HEALTH AGING, V15, P259, DOI 10.1007/s12603-010-0320-6
   Seltzer CC, 1963, AM J CLIN NUTR, V13, P341
   Senghor A, 2012, INT J BIOL MED RES, V3, P1609
   Suarez-Ortegon MF, 2012, BIOL TRACE ELEM RES, V145, P283, DOI 10.1007/s12011-011-9192-9
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
NR 35
TC 1
Z9 1
U1 2
U2 3
PU GALENOS YAYINCILIK
PI FINDIKZADE
PA ERKAN MOR, MOLLA GURANI CAD 21-1, FINDIKZADE, ISTANBUL 34093, TURKEY
SN 1300-7777
EI 1308-5263
J9 TURK J HEMATOL
JI Turk. J. Hematol.
PD MAR
PY 2014
VL 31
IS 1
BP 61
EP 67
DI 10.4274/Tjh.2012.0187
PG 7
WC Hematology
SC Hematology
GA AY2QX
UT WOS:000347435400009
PM 24764731
ER

PT J
AU Park, SK
   Choi, WJ
   Oh, CM
   Kim, J
   Shin, H
   Ryoo, JH
AF Park, Sung Keun
   Choi, Won Joon
   Oh, Chang-Mo
   Kim, Jongbin
   Shin, Hocheol
   Ryoo, Jae-Hong
TI Association between serum ferritin levels and the incidence of obesity
   in Korean men: A prospective cohort study
SO ENDOCRINE JOURNAL
LA English
DT Article
DE Ferritin; Iron; Obesity; Body mass index; Cohort studies
ID BODY-MASS INDEX; METABOLIC SYNDROME; INSULIN-RESISTANCE; FAT
   DISTRIBUTION; IRON-DEFICIENCY; RISK-FACTORS; INFLAMMATION; WOMEN;
   ADIPONECTIN; DISEASE
AB Elevated serum ferritin levels are associated with insulin resistance, type 2 diabetes, cardiovascular disease, and metabolic syndrome. To date, however, no cohort studies have examined whether serum ferritin levels are an independent risk factor for the obesity. Therefore, we conducted a prospective cohort study to evaluate the temporal relationship between serum ferritin levels and obesity development in Korean men. Total 17,812 healthy Korean men who participated in a medical health check-up program in 2005 were followed-up until 2010. Obesity was defined as a body mass index >= 25 kg/m(2). Cox proportional hazards model was used to measure the hazard ratio of the quartile groups of serum ferritin levels. During 64,446.5 person-years of follow-up carried out, 2,627 patients became obese. After adjusting for multiple covariates, we found that the hazard ratios (95% confidence interval) for incident obesity when we compared the second, third and fourth quartiles of serum ferritin levels with the first quartile were 1.08 (0.95-1.23), 1.14 (1.00-1.30), and 1.24 (1.09-1.41), respectively (p for trend = 0.003). Both severe obesity (body mass index >= 30 kg/m(2)) and abdominal obesity based on waist circumference (>90 cm) showed consistent longitudinal associations (p for trend <0.001). Elevated serum ferritin levels may have been a predictive factor for obesity during the 5-year follow-up in 17,812 Korean men.
C1 [Park, Sung Keun] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Total Healthcare Ctr, Seoul, South Korea.
   [Park, Sung Keun; Oh, Chang-Mo; Ryoo, Jae-Hong] Kyung Hee Univ, Sch Med, Dept Prevent Med, Seoul 130701, South Korea.
   [Choi, Won Joon] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.
   [Oh, Chang-Mo] Natl Canc Ctr, Natl Canc Control Inst, Canc Registrat & Stat Branch, Goyang, South Korea.
   [Kim, Jongbin] Kyung Hee Univ, Grad Sch, Dept Med, Seoul 130701, South Korea.
   [Shin, Hocheol] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Family Med, Seoul, South Korea.
RP Ryoo, JH (reprint author), Kyung Hee Univ, Sch Med, Dept Prevent Med, 1 Hoegi Dong, Seoul 130701, South Korea.
EM armani131@naver.com
CR Brown CD, 2000, OBES RES, V8, P605, DOI 10.1038/oby.2000.79
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Visscher TLS, 2001, INT J OBESITY, V25, P1730, DOI 10.1038/sj.ijo.0801787
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Chung B, 2007, J NUTR, V137, P2366
   Park SK, 2012, DIABETES CARE, V35, P2521, DOI 10.2337/dc12-0543
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Sumida Y, 2011, J GASTROENTEROL, V46, P257, DOI 10.1007/s00535-010-0305-6
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Heeney MM, 2004, HEMATOL ONCOL CLIN N, V18, P1379, DOI 10.1016/j.hoc.2004.06.018
   Bresgen N, 2010, FREE RADICAL BIO MED, V48, P1347, DOI 10.1016/j.freeradbiomed.2010.02.019
   Rizvi AA, 2009, AM J MED SCI, V338, P310, DOI 10.1097/MAJ.0b013e3181a4158c
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Wlazlo N, 2013, DIABETES CARE, V36, P309, DOI 10.2337/dc12-0505
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Greenberg Andrew S, 2006, Am J Clin Nutr, V83, p461S
   Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88
   Rushton DH, 2001, BRIT MED J, V322, P1355, DOI 10.1136/bmj.322.7298.1355
   Tsuchiya H, 2012, METAB CLIN EXP, V62, P62
   Barba C, 2004, LANCET, V363, P157
   Wu HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013316
NR 33
TC 4
Z9 4
U1 1
U2 7
PU JAPAN ENDOCRINE SOC
PI KYOTO
PA 75  YANAGINOBANBA NISHIIRU-MASUYA-CHO, SANJOU-DORI, NAKAGYOU-KU, KYOTO,
   604-8111, JAPAN
SN 0918-8959
EI 1348-4540
J9 ENDOCR J
JI Endocr. J.
PD MAR
PY 2014
VL 61
IS 3
BP 215
EP 224
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AG5UU
UT WOS:000335485000002
PM 24292546
ER

PT J
AU Utzschneider, KM
   Largajolli, A
   Bertoldo, A
   Marcovina, S
   Nelson, JE
   Yeh, MM
   Kowdley, KV
   Kahn, SE
AF Utzschneider, Kristina M.
   Largajolli, Anna
   Bertoldo, Alessandra
   Marcovina, Santica
   Nelson, James E.
   Yeh, Matthew M.
   Kowdley, Kris V.
   Kahn, Steven E.
TI Serum ferritin is associated with non-alcoholic fatty liver disease and
   decreased B-cell function in non-diabetic men and women
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Insulin sensitivity; Ferritin; Insulin secretion in vivo; Fatty liver
ID TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE;
   DIABETES-MELLITUS; HEREDITARY HEMOCHROMATOSIS; MAJOR DETERMINANTS;
   METABOLIC SYNDROME; IRON DEPLETION; HUMAN OBESITY; SENSITIVITY
AB Aims: We sought to determine whether NAFLD is associated with poorer beta-cell function and if any beta-cell dysfunction is associated with abnormal markers of iron or inflammation.
   Methods: This was a cross-sectional study of 15 non-diabetic adults with NAFLD and 15 non-diabetic age and BMI-matched controls. Insulin sensitivity was measured by isotope-labeled hyperinsulinemic-euglycemic clamps and beta-cell function by both oral (OGTT) and intravenous glucose tolerance tests. Liver and abdominal fat composition was evaluated by CT scan. Fasting serum levels of ferritin, transferrin-iron saturation, IL-6, TNF alpha and hsCRP were measured.
   Results: Compared to controls, subjects with NAFLD had lower hepatic and systemic insulin sensitivity and 12,cell function was decreased as measured by the oral disposition index. Fasting serum ferritin and transferrin-iron saturation were higher in NAFLD and were positively associated with liver fat. Serum ferritin was negatively associated with beta-cell function measured by both oral and intravenous tests, but was not associated with insulin sensitivity. IL-6, TNF alpha and hsCRP did not differ between groups and did not correlate with serum ferritin, liver fat or measures of beta-cell function.
   Conclusions: These findings support a potential pathophysiological link between iron metabolism, liver fat and diabetes risk. Published by Elsevier Inc.
C1 [Utzschneider, Kristina M.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Endocrinol & Metab, Seattle, WA USA.
   [Utzschneider, Kristina M.; Kahn, Steven E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA.
   [Largajolli, Anna; Bertoldo, Alessandra] Univ Padua, Padua, Italy.
   [Nelson, James E.; Kowdley, Kris V.] Virginia Mason Med Ctr, Inst Digest Dis, Seattle, WA 98101 USA.
   [Nelson, James E.; Kowdley, Kris V.] Benaroya Res Inst, Seattle, WA USA.
   [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
   [Kowdley, Kris V.] Univ Washington, Dept Med, Div Gastroenterol Hepatol, Seattle, WA USA.
   [Marcovina, Santica] Univ Washington, Dept Med, Seattle, WA USA.
   [Marcovina, Santica] Northwest Lipid Metab & Diabet Res Lab, Seattle, WA USA.
RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst 151, Seattle, WA 98108 USA.
EM kutzschn@u.washington.edu
FU United States Department of Veterans Affairs (Office of Research and
   Development Medical Research Service);  [UL1RR025014];  [P30DK017047]; 
   [P30DK035816];  [T32DK007247]
FX This work was supported by the United States Department of Veterans
   Affairs (Office of Research and Development Medical Research Service)
   and grant numbers UL1RR025014, P30DK017047, P30DK035816 and T32DK007247.
CR Utzschneider KM, 2006, J CLIN ENDOCR METAB, V91, P4753, DOI 10.1210/jc.2006-0587
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Musso G, 2012, HEPATOLOGY, V56, P933, DOI 10.1002/hep.25739
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   [Anonymous], 2011, DIABETES CARE S1, V34, pS62
   Chon CW, 2012, GUT LIVER, V6, P368, DOI 10.5009/gnl.2012.6.3.368
   Licata A, 2009, WORLD J GASTROENTERO, V15, P2132, DOI 10.3748/wjg.15.2132
   Rexrode KM, 2003, ANN EPIDEMIOL, V13, P674, DOI 10.1016/S1047-2797(03)00053-X
   GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142
   Yesilova Z, 2005, AM J GASTROENTEROL, V100, P850, DOI 10.1111/j.1572-0241.2005.41500.x
   Madan K, 2006, J CLIN GASTROENTEROL, V40, P930, DOI 10.1097/01.mcg.0000212608.59090.08
   Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745
   Utzschneider KM, 2010, NAT REV ENDOCRINOL, V6, P26, DOI 10.1038/nrendo.2009.241
   Hui JM, 2004, HEPATOLOGY, V40, P46, DOI 10.1002/hep.20280
   Kelley DE, 2003, AM J PHYSIOL-ENDOC M, V285, pE906, DOI 10.1152/ajpendo.00117.2003
   Facchini FS, 2002, GASTROENTEROLOGY, V122, P931, DOI 10.1053/gast.2002.32403
   Yoneda M, 2007, J GASTROENTEROL, V42, P573, DOI 10.1007/s00535-007-2060-x
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   LONGO R, 1993, INVEST RADIOL, V28, P297, DOI 10.1097/00004424-199304000-00006
   McClain DA, 2006, DIABETOLOGIA, V49, P1661, DOI 10.1007/s00125-006-0200-0
   Bedogni G, 2012, NUTR METAB CARDIOVAS, V22, P120, DOI 10.1016/j.numecd.2010.05.003
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   Kahn SE, 2009, DIABETOLOGIA, V52, P1003, DOI 10.1007/s00125-009-1321-z
   FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417
   Cooksey RC, 2004, ENDOCRINOLOGY, V145, P5305, DOI 10.1210/en.2004-0392
   Sung KC, 2012, DIABETES CARE, V35, P717, DOI 10.2337/dc11-1853
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Valenti L, 2007, AM J GASTROENTEROL, V102, P1251, DOI 10.1111/j.1572-0241.2007.01192.x
   Donath MY, 2008, DIABETES CARE, V31, pS161, DOI 10.2337/dc08-s243
   DMOCHOWSKI K, 1993, J CLIN ENDOCR METAB, V77, P478, DOI 10.1210/jc.77.2.478
   Yarasheski KE, 2011, AM J PHYSIOL-ENDOC M, V300, pE243, DOI 10.1152/ajpendo.00468.2010
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Hsiao TJ, 2004, INT J OBESITY, V28, P167, DOI 10.1038/sj.ijo.0802519
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Utzschneider KM, 2009, DIABETES CARE, V32, P335, DOI 10.2337/dc08-1478
   Kugelmas M, 2003, HEPATOLOGY, V38, P413, DOI 10.1053/jhep.2003.50316
   Zelber-Sagi S, 2007, J HEPATOL, V46, P700, DOI 10.1016/j.jhep.2006.09.018
   Dalla Man C, 2005, DIABETES, V54, P3265, DOI 10.2337/diabetes.54.11.3265
   Gastaldelli A, 2009, OBES SURG, V19, P80, DOI 10.1007/s11695-008-9690-9
   HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936
   Jouihan Hani A, 2008, Mol Med, V14, P98, DOI 10.2119/2007-00114.Jouihan
   Nakashima T, 2000, ANTIOXID REDOX SIGN, V2, P687, DOI 10.1089/ars.2000.2.4-687
   RAHIER J, 1987, DIABETOLOGIA, V30, P5, DOI 10.1007/BF01788899
   Rijkelijkhuizen Josina M, 2009, Metabolism, V58, P196, DOI 10.1016/j.metabol.2008.09.013
   Tushuizen ME, 2008, EUR J ENDOCRINOL, V159, P251, DOI 10.1530/EJE-08-0424
   Warnick G R, 1986, Methods Enzymol, V129, P101
   Wolfe R, 1992, RADIOACTIVE STABLE I
NR 49
TC 3
Z9 4
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAR-APR
PY 2014
VL 28
IS 2
BP 177
EP 184
DI 10.1016/j.jdiacomp.2013.11.007
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AD8VD
UT WOS:000333542900015
PM 24360972
ER

PT J
AU Vuppalanchi, R
   Troutt, JS
   Konrad, RJ
   Ghabril, M
   Saxena, R
   Bell, LN
   Kowdley, KV
   Chalasani, N
AF Vuppalanchi, Raj
   Troutt, Jason S.
   Konrad, Robert J.
   Ghabril, Marwan
   Saxena, Romil
   Bell, Lauren N.
   Kowdley, Kris V.
   Chalasani, Naga
TI Serum Hepcidin Levels Are Associated With Obesity but Not Liver Disease
SO OBESITY
LA English
DT Article
ID IRON-DEFICIENCY; ADIPOSE-TISSUE; CHILDREN; INFLAMMATION; EXPRESSION;
   MEDIATOR; ANEMIA
AB Objective: Hepcidin is regulated by anemia and inflammation. It is primarily expressed in the liver but studies have reported its expression in adipose tissue. The relationship between BMI and serum hepcidin and the relationship between liver histology and serum hepcidin in the morbidly obese was investigated.
   Methods: Serum and liver tissue from patients undergoing bariatric surgery (bariatric cohort, n = 105) and serum from healthy blood donors (n 60) were used to conduct this study. Serum hepcidin was measured using sandwich ELISA, highly specific for hepcidin-25. Serum ferritin, IL-6, IL-1 beta and liver function biochemistries were also measured.
   Results: After controlling for covariates, BMI >= 35 kg/m(2) was significantly associated with higher serum hepcidin level compared to individuals with lower BMI groups (17.7 +/- 11.5 vs. 3.3 +/- 4.7 ng/ml, P = 0.002). The presence of NAFLD was not associated with higher serum levels of hepcidin (multivariate P = 0.37). There was no association between serum hepcidin levels and liver histology (presence of steatohepatitis, advanced fibrosis, or NAFLD activity score) in the bariatric cohort.
   Conclusions: Obesity, but not the presence of NAFLD was associated with serum hepcidin levels. There was no association between serum hepcidin and liver histology in the morbidly obese undergoing bariatric surgery.
C1 [Vuppalanchi, Raj; Ghabril, Marwan; Bell, Lauren N.; Chalasani, Naga] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Troutt, Jason S.; Konrad, Robert J.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.
   [Saxena, Romil] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA.
   [Kowdley, Kris V.] Virginia Mason Med Ctr, Inst Digest Dis, Seattle, WA 98101 USA.
RP Vuppalanchi, R (reprint author), Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
EM rvuppala@iupui.edu
FU  [K24 DK069290]
FX This study was funded in part by K24 DK069290 (NC). Jason S. Troutt and
   Robert J. Konrad are employees of Eli Lilly and Company, Indianapolis,
   IN, USA. Lauren N Bell is currently an employee of Metabolon, Durham, NC
   27560.
CR Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Miura K, 2008, HEPATOLOGY, V48, P1420, DOI 10.1002/hep.22486
   Zhang XL, 2010, BBA-GEN SUBJECTS, V1800, P1262, DOI 10.1016/j.bbagen.2010.08.005
   Butterfield AM, 2010, CLIN CHEM, V56, P1725, DOI 10.1373/clinchem.2010.151522
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Tan TCH, 2012, LIVER INT, V32, P1391, DOI 10.1111/j.1478-3231.2012.02828.x
   Troutt JS, 2012, CLIN CHEM, V58, P1225, DOI 10.1373/clinchem.2012.186866
   Ganz T, 2009, SEMIN HEMATOL, V46, P387, DOI 10.1053/j.seminhematol.2009.06.001
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Ganz T, 2012, BBA-MOL CELL RES, V1823, P1434, DOI 10.1016/j.bbamcr.2012.01.014
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Uysal S, 2011, CLIN BIOCHEM, V44, P1375, DOI 10.1016/j.clinbiochem.2011.09.017
   Nelson JE, 2012, HEPATOLOGY, V56, P1730, DOI 10.1002/hep.25856
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Senates E, 2011, METAB SYNDR RELAT D, V9, P287, DOI 10.1089/met.2010.0121
   Maliken Bryan D, 2011, Hepatology, V53, P1764, DOI 10.1002/hep.24267
   Nemeth Elizabeta, 2010, Expert Rev Hematol, V3, P153, DOI 10.1586/ehm.10.1
   Park KH, 2012, WORLD J SURG, V36, P800, DOI 10.1007/s00268-012-1473-8
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-37
   Tussing-Humphreys L, 2011, THESCIENTIFICWORLDJO, V11, P2197, DOI 10.1100/2011/634861
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Viatte L, 2009, BIOCHIMIE, V91, P1223, DOI 10.1016/j.biochi.2009.06.012
   WHO, 2000, WHO TECHN REP SER, V894
   Zimmermann A, 2011, EUR J INTERN MED, V22, P305, DOI 10.1016/j.ejim.2011.01.011
NR 25
TC 5
Z9 6
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD MAR
PY 2014
VL 22
IS 3
BP 836
EP 841
DI 10.1002/oby.20403
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA AC0ZU
UT WOS:000332224800031
PM 23512600
ER

PT J
AU Tutino, GE
   Tam, WH
   Yang, X
   Chan, JCN
   Lao, TTH
   Ma, RCW
AF Tutino, G. E.
   Tam, W. H.
   Yang, X.
   Chan, J. C. N.
   Lao, T. T. H.
   Ma, R. C. W.
TI Diabetes and pregnancy: perspectives from Asia
SO DIABETIC MEDICINE
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; GLUCOSE CHALLENGE TEST; CHINESE WOMEN;
   RISK-FACTORS; CARDIOMETABOLIC RISK; INSULIN-RESISTANCE; SERUM FERRITIN;
   KOREAN WOMEN; INCREASING PREVALENCE; MATERNAL OBESITY
AB There has been a marked increase in the prevalence of diabetes in Asia over recent years. Diabetes complicating pregnancy, in particular gestational diabetes, has also increased markedly in the region. Multi-ethnic studies have highlighted the increased risk of gestational diabetes mellitus among the different Asian populations. Prevalence of gestational diabetes in Asian countries varies substantially according to the screening strategy and diagnostic criteria applied, and ranges from 1% to 20%, with evidence of an increasing trend over recent years. The International Association for Diabetes in Pregnancy Study group criteria have been adopted by some Asian countries, although they present significant challenges in implementation, especially in low-resource settings. Studies on offspring of mothers with gestational diabetes have reported adverse cardiometabolic profiles and increased risk of diabetes and obesity. Gestational diabetes is likely to be a significant factor contributing to the epidemic of diabetes and other non-communicable diseases in the Asian region. In recognition of this, several large-scale prevention and intervention programmes are currently being implemented in different Asian countries in order to improve glucose control during pregnancy, as well as overall maternal health. Lessons emerging from gestational diabetes studies in Asia may help inform and provide insights on the overall burden and treatment strategies to target gestational diabetes, with the ultimate aim to reduce its adverse short- and long-term consequences.
C1 [Tutino, G. E.; Chan, J. C. N.; Ma, R. C. W.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Tam, W. H.; Lao, T. T. H.] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China.
   [Yang, X.] Tianjin Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Tianjin, Peoples R China.
   [Chan, J. C. N.; Ma, R. C. W.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chan, J. C. N.; Ma, R. C. W.] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Hong Kong, Peoples R China.
RP Ma, RCW (reprint author), Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
EM rcwma@cuhk.edu.hk
RI Ma, Ronald/C-2788-2009; Chan, Juliana /B-7918-2016
OI Ma, Ronald/0000-0002-1227-803X; Chan, Juliana /0000-0003-1325-1194
FU European Foundation for the Study of Diabetes (EFSD)/Chinese Diabetes
   Society (CDS)/Lilly Collaborative Research Programme; General Research
   Fund of the Research Grants Council of Hong Kong [CU471713, CU473408]
FX RCWM received grant support from the European Foundation for the Study
   of Diabetes (EFSD)/Chinese Diabetes Society (CDS)/Lilly Collaborative
   Research Programme, and the General Research Fund of the Research Grants
   Council of Hong Kong (CU471713). WHT received grant support from the
   General Research Fund of the Research Grants Council of Hong Kong
   (CU473408).
CR American College of Obstetricians and Gynecologists, 2013, OBSTET GYNECOL, V122, P406
   American Diabetes Association, 2006, DIABETES CARE S1, V29, pS43
   Anjana RM, 2011, DIABETOLOGIA, V54, P3022, DOI 10.1007/s00125-011-2291-5
   KautzkyWiller A, 1997, DIABETES CARE, V20, P1717, DOI 10.2337/diacare.20.11.1717
   Worda C, 2004, AM J OBSTET GYNECOL, V191, P2120, DOI 10.1016/j.ajog.2004.04.038
   Zhu WW, 2013, DIABETES CARE, V36, pE76, DOI 10.2337/dc12-2624
   Dabelea D, 2005, DIABETES CARE, V28, P579, DOI 10.2337/diacare.28.3.579
   King H, 1998, DIABETES CARE, V21, pB9
   Sacks DA, 2012, DIABETES CARE, V35, P526, DOI 10.2337/dc11-1641
   Tse KY, 2005, J HEPATOL, V43, P771, DOI 10.1016/j.jhep.2005.05.023
   Seshiah V, 2008, J Assoc Physicians India, V56, P329
   Chan KKL, 2009, BJOG-INT J OBSTET GY, V116, P789, DOI 10.1111/j.1471-0528.2008.02014.x
   Wei JN, 2003, DIABETES CARE, V26, P343, DOI 10.2337/diacare.26.2.343
   Lao TT, 2003, DIABETES CARE, V26, P3011, DOI 10.2337/diacare.26.11.3011
   Buchanan TA, 2005, J CLIN INVEST, V115, P485, DOI 10.1172/JCI200524531
   Mauricio D, 1996, DIABETES METAB REV, V12, P275
   Zargar AH, 2004, DIABETES RES CLIN PR, V66, P139, DOI 10.1016/j.diabres.2004.02.023
   Lao TT, 2007, J HEPATOL, V47, P46, DOI 10.1016/j.jhep.2007.02.014
   PETTITT DJ, 1991, DIABETES, V40, P126
   Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808
   Landon MB, 2009, NEW ENGL J MED, V361, P1339, DOI 10.1056/NEJMoa0902430
   Chu SY, 2009, PREV MED, V49, P265, DOI 10.1016/j.ypmed.2009.07.001
   Metzger BE, 2008, NEW ENGL J MED, V358, P1991
   Crowther CA, 2005, NEW ENGL J MED, V352, P2477, DOI 10.1056/NEJMoa042973
   Seshiah V, 2009, INT J GYNECOL OBSTET, V104, pS35, DOI 10.1016/j.ijgo.2008.11.035
   Krishnaveni GV, 2009, DIABETOLOGIA, V52, P2350, DOI 10.1007/s00125-009-1499-0
   Zhu WW, 2013, DIABETES CARE, V36, P2038, DOI 10.2337/dc12-2465
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Marseille E, 2013, J MATERN-FETAL NEO M, V26, P802, DOI 10.3109/14767058.2013.765845
   Ruchat SM, 2013, EPIGENETICS-US, V8, P935, DOI 10.4161/epi.25578
   Lao TT, 2004, DIABETES CARE, V27, P650, DOI 10.2337/diacare.27.3.650
   [Anonymous], 1999, WHONCDNCS992
   Tam WH, 2008, PEDIATRICS, V122, P1229, DOI 10.1542/peds.2008-0158
   Bowers K, 2011, DIABETES CARE, V34, P1557, DOI 10.2337/dc11-0134
   Kwak SH, 2012, DIABETES, V61, P531, DOI 10.2337/db11-1034
   Veeraswamy S, 2012, DIABETES RES CLIN PR, V97, P350, DOI 10.1016/j.diabres.2012.04.024
   Tam WH, 2010, DIABETES CARE, V33, P1382, DOI 10.2337/dc09-2343
   Lao TT, 2001, DIABETIC MED, V18, P218, DOI 10.1046/j.1464-5491.2001.00453.x
   Lappas M, 2011, ANTIOXID REDOX SIGN, V15, P3061, DOI 10.1089/ars.2010.3765
   OSULLIVAN JB, 1964, DIABETES, V13, P278
   Imagawa A, 2003, DIABETES CARE, V26, P2345, DOI 10.2337/diacare.26.8.2345
   Bandyopadhyay M, 2011, AUST NZ J OBSTET GYN, V51, P360, DOI 10.1111/j.1479-828X.2011.01322.x
   Kim C, 2002, DIABETES CARE, V25, P1862, DOI 10.2337/diacare.25.10.1862
   Lim S, 2007, DIABETES CARE, V30, P348, DOI 10.2337/dc06-1405
   Cho YM, 2009, DIABETOLOGIA, V52, P253, DOI 10.1007/s00125-008-1196-4
   Ramachandran A, 2010, LANCET, V375, P408, DOI 10.1016/S0140-6736(09)60937-5
   Morkrid K, 2012, EUR J ENDOCRINOL, V167, P579, DOI 10.1530/EJE-12-0452
   Ma RCW, 2013, CLIN OBSTET GYNECOL, V56, P633, DOI 10.1097/GRF.0b013e31829e5bb0
   Zhang F, 2011, DIABETIC MED, V28, P652, DOI 10.1111/j.1464-5491.2010.03205.x
   Balaji V, 2011, J ASSOC PHYSICIAN I, V59, pS33
   Balaji V, 2012, GYNECOL ENDOCRINOL, V28, P529, DOI 10.3109/09513590.2011.650661
   Ben-Haroush A, 2004, DIABETIC MED, V21, P103, DOI 10.1046/j.1464-5491.2003.00985.x
   Chen XH, 2006, DIABETES CARE, V29, P1077, DOI 10.2337/dc06-0164
   Colom C, 2010, BEST PRACT RES CL EN, V24, P605, DOI 10.1016/j.beem.2010.05.008
   Egeland GM, 2010, DIABETIC MED, V27, P257, DOI 10.1111/j.1464-5491.2010.02944.x
   Hanson MA, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1025
   Hirst JE, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-81
   Hirst JE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001272
   Hu EA, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1454
   Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848
   International Diabetes Federation, 2013, DIABETES ATLAS
   Ko GTC, 1999, AUST NZ J OBSTET GYN, V39, P478
   Korea Diabetes Association, 2013, DIAB FACTSH KOR 2013
   Nielsen KK, 2012, BMC INT HEALTH HUM R, V12, DOI 10.1186/1472-698X-12-33
   Lao TT, 2003, J SOC GYNECOL INVEST, V10, P366, DOI 10.1016/S1071-5576(03)00115-1
   Lao TT, 2001, ACTA OBSTET GYN SCAN, V80, P1003, DOI 10.1034/j.1600-0412.2001.801106.x
   Lao TT, 2001, DIABETOLOGIA, V44, P966, DOI 10.1007/s001250100594
   Lao TT, 2002, OBSTET GYNECOL, V99, P807, DOI 10.1016/S0029-7844(02)01941-5
   Lao TT, 1997, DIABETES CARE, V20, P1368, DOI 10.2337/diacare.20.9.1368
   Lee H, 2007, DIABETES RES CLIN PR, V78, P238, DOI 10.1016/j.diabres.2007.03.023
   Ma RCW, 2009, INT J GYNECOL OBSTET, V104, pS42, DOI 10.1016/j.ijgo.2008.11.032
   Ma RCW, 2013, ELSEV INSIGHT, P193, DOI 10.1016/B978-0-12-416045-3.00014-5
   Maresh M, 2005, SEMIN FETAL NEONAT M, V10, P317, DOI 10.1016/j.siny.2005.04.009
   Miyakoshi K, 2003, DIABETES RES CLIN PR, V60, P63, DOI 10.1016/S0168-8227(02)00274-7
   Morikawa M, 2012, INT J GYNECOL OBSTET, V118, P198, DOI 10.1016/j.ijgo.2012.04.019
   Osgood ND, 2011, AM J PUBLIC HEALTH, V101, P173, DOI 10.2105/AJPH.2009.186890
   Rao Anjali K, 2006, Am J Obstet Gynecol, V194, pe39, DOI 10.1016/j.ajog.2006.01.027
   Ma RCW, 2013, ANN NY ACAD SCI, V1281, P64, DOI 10.1111/nyas.12098
   Shin HD, 2010, J CLIN ENDOCR METAB, V95, P445, DOI 10.1210/jc.2009-1393
   Sibai BM, 2010, J MATERN-FETAL NEO M, V23, P229, DOI 10.3109/14767050903550899
   Tam WH, 2012, DIABETES RES CLIN PR, V95, P169, DOI 10.1016/j.diabres.2011.10.017
   Tam WH, 2012, GYNECOL OBSTET INVES, V73, P168, DOI 10.1159/000329339
   Tan PC, 2007, AUST NZ J OBSTET GYN, V47, P191, DOI 10.1111/j.1479-828X.2007.00717.x
   Teh WT, 2011, AUST NZ J OBSTET GYN, V51, P26, DOI 10.1111/j.1479-828X.2011.01292.x
   Thomson Reuters, EX PERSP WE MUST STA
   TSURUOKA A, 1995, DIABETES RES CLIN PR, V28, P191, DOI 10.1016/0168-8227(95)01101-I
   Wei YM, 2012, CHINESE MED J-PEKING, V125, P1206, DOI 10.3760/cma.j.issn.0366-6999.2012.07.002
   WILKERSON HUGH L. C, 1963, DIABETES, V12, P313
   World Diabetes Foundation, WDF10517
   World Health Organization, 2013, WHONMHMND132ENG
   Yajnik CS, 2009, INT J GYNECOL OBSTET, V104, pS27, DOI 10.1016/j.ijgo.2008.11.034
   Yang H, 2009, DIABETIC MED, V26, P1099, DOI 10.1111/j.1464-5491.2009.02845.x
   杨慧霞, 2013, [中国实用妇科与产科杂志, Chineses Journal of Practical Gynecology and Obstetrics], V29, P241
   Yang X, 2011, WORLD DIAB C DUB UN
   Yu SH, 2009, DIABETES-METAB RES, V25, P329, DOI 10.1002/dmrr.963
   Zhang CL, 2011, AM J CLIN NUTR, V94, p1975S, DOI 10.3945/ajcn.110.001032
NR 96
TC 8
Z9 8
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD MAR
PY 2014
VL 31
IS 3
BP 302
EP 318
DI 10.1111/dme.12396
PG 17
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AA8IC
UT WOS:000331338200010
PM 24417604
ER

PT J
AU Azab, SFA
   Saleh, SH
   Elsaeed, WF
   Elshafie, MA
   Sherief, LM
   Esh, AMH
AF Azab, Seham F. A.
   Saleh, Safaa H.
   Elsaeed, Wafaa F.
   Elshafie, Mona A.
   Sherief, Laila M.
   Esh, Asmaa M. H.
TI Serum trace elements in obese Egyptian children: a case-control study
SO ITALIAN JOURNAL OF PEDIATRICS
LA English
DT Article
DE Trace elements; Obesity; Children
ID ZINC NUTRITIONAL-STATUS; IRON-DEFICIENCY; INSULIN-RESISTANCE;
   ADOLESCENTS; OVERWEIGHT; GLUCOSE; INFLAMMATION; HOMEOSTASIS; PREVENTION
AB Background: To date, only a few studies on child obesity concerned Trace Elements (TE). TE is involved in the pathogenesis of obesity and obesity related diseases. We tried to assess trace elements status [zinc (Zn), copper (Cu), selenium (Se), iron (Fe), and chromium (Cr)] in obese Egyptian children and their relationships with serum leptin and metabolic risk factors of obesity.
   Methods: This was a case-control study performed with 80 obese children (BMI >= 95th centile for age and gender) and 80 healthy non-obese children with comparable age and gender as the control group. For all subjects, serum Zn, Cu, Se, Fe, ferritin and Cr as well as biochemical parameters including lipid profile, serum glucose and homeostasis model assessment of insulin resistance (HOMA-IR) were assessed. Levels of serum leptin were measured by (enzyme-linked immunosorbent assay [ELISA] method), and serum insulin was measured by an electrochemiluminesce immunoassay.
   Results: Compared to the control group, serum Zn, Se, and Fe levels were significantly lower (all P < 0.01) and serum Cu level was significantly higher (P < 0.01) in the obese children. Meanwhile, no significant differences were observed in serum ferritin or Cr levels (P > 0.05). A significant negative correlation was found between serum leptin and zinc levels in the obese children (r = -0.746; P < 0.01). Further, serum Zn showed significant negative correlations with total cholesterol TC levels (P < 0.05) and were positively correlated with high density lipoprotein-cholesterol HDL-C levels (P < 0.01) in the obese children. In addition, serum Se levels showed significant positive correlations with HOMA-IR values in the obese children (P < 0.01).
   Conclusion: The obese children may be at a greater risk of developing imbalance (mainly deficiency) of trace elements which may be playing an important role in the pathogenesis of obesity and related metabolic risk factors.
C1 [Azab, Seham F. A.] Zagazig Univ, Fac Med, Sharkia Governorate, Zagazig, Egypt.
   [Saleh, Safaa H.; Elsaeed, Wafaa F.; Elshafie, Mona A.; Sherief, Laila M.; Esh, Asmaa M. H.] Zagazig Univ, Fac Med, Zagazig, Egypt.
RP Azab, SFA (reprint author), Zagazig Univ, Fac Med, Sharkia Governorate, 18 Omar Bin Elkhattab St, Zagazig, Egypt.
EM Seham_Azab@yahoo.com
OI azab, seham/0000-0002-2299-7986
CR Krebs NF, 2003, PEDIATRICS, V112, P424
   Garcia OP, 2009, NUTR REV, V67, P559, DOI 10.1111/j.1753-4887.2009.00228.x
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Thaler JP, 2010, ENDOCRINOLOGY, V151, P4109, DOI 10.1210/en.2010-0336
   Wijesekara N, 2009, DIABETES OBES METAB, V11, P202, DOI 10.1111/j.1463-1326.2009.01110.x
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Suliburska J, 2013, EUR REV MED PHARMACO, V17, P2396
   Costarelli L, 2010, J NUTR BIOCHEM, V21, P432, DOI 10.1016/j.jnutbio.2009.02.001
   Mantzoros CS, 1998, J AM COLL NUTR, V17, P270
   Ortega RM, 2012, INT J VITAM NUTR RES, V82, P121, DOI 10.1024/0300-9831/a000101
   Lima SCVC, 2006, BIOL TRACE ELEM RES, V114, P19, DOI 10.1385/BTER:114:1:19
   Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747
   Woo KS, 2004, INT J OBESITY, V28, P852, DOI 10.1038/sj.ijo.0802539
   Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75
   Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673
   Balk EM, 2007, DIABETES CARE, V30, P2154, DOI 10.2337/dc06-0996
   Marreiro DD, 2002, BIOL TRACE ELEM RES, V86, P107
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Bougle DL, 2009, E SPEN EUROPEAN J CL, V4, P98
   Chen MD, 2000, OBES RES, V8, P525, DOI 10.1038/oby.2000.65
   CLOUET P, 1986, BIOCHEM J, V239, P103
   Dambal SS, 2011, IJABPT, V2, P280
   DRG International Inc, 2013, DRG LEPTIN SANDWICH
   Group WMGRS, 2006, WHO CHILD GROWTH STA, P312
   Grundy SM, 1998, AM J CLIN NUTR, V67, P563
   Gunasekara Priyanka, 2011, Diabetes Metab Syndr Obes, V4, P53, DOI 10.2147/DMSO.S16691
   Iascilar ME, 2010, BIOL TRACE ELEM RES, V143, P188
   Klevay L. M., 2000, J NUTR, V130, p489s
   Lobo JC, 2010, BIOL TRACE ELEM RES, V135, P16, DOI 10.1007/s12011-009-8504-9
   Mracek T, 2009, CLIN ENDOCRINOL OXF, V72, P334
   NUTTALL KL, 1995, ANN CLIN LAB SCI, V25, P264
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   Stranges S, 2010, BMC PUBLIC HEALTH, V21, P564
   Sunde R. A., 2012, MODERN NUTR HLTH DIS, P225
   Lobstein T, 2004, Obes Rev, V5 Suppl 1, P4, DOI 10.1111/j.1467-789X.2004.00133.x
   World Health Organization, 2000, WHO TECHNICAL REPORT, V894
   World Health Organization, 2009, GLOBAL STRATEGY ON D
   Yerlikaya FH, 2013, INDIAN J MED RES, V137, P339
NR 38
TC 8
Z9 8
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1720-8424
EI 1824-7288
J9 ITAL J PEDIATR
JI Ital. J. Pediatr.
PD FEB 20
PY 2014
VL 40
AR 20
DI 10.1186/1824-7288-40-20
PG 7
WC Pediatrics
SC Pediatrics
GA AB6ME
UT WOS:000331902000001
PM 24555483
ER

PT J
AU Orr, JS
   Kennedy, A
   Anderson-Baucum, EK
   Webb, CD
   Fordahl, SC
   Erikson, KM
   Zhang, YF
   Etzerodt, A
   Moestrup, SK
   Hasty, AH
AF Orr, Jeb S.
   Kennedy, Arion
   Anderson-Baucum, Emily K.
   Webb, Corey D.
   Fordahl, Steve C.
   Erikson, Keith M.
   Zhang, Yaofang
   Etzerodt, Anders
   Moestrup, Soren K.
   Hasty, Alyssa H.
TI Obesity Alters Adipose Tissue Macrophage Iron Content and Tissue Iron
   Distribution
SO DIABETES
LA English
DT Article
ID ALTERNATIVELY ACTIVATED MACROPHAGES; FATTY LIVER-DISEASE; BETA-CELL
   FUNCTION; INSULIN-RESISTANCE; TRANSFERRIN RECEPTORS; METABOLIC SYNDROME;
   ADIPOCYTES; HOMEOSTASIS; POLARIZATION; STRESS
AB Adipose tissue (AT) expansion is accompanied by the infiltration and accumulation of AT macrophages (ATMs), as well as a shift in ATM polarization. Several studies have implicated recruited M1 ATMs in the metabolic consequences of obesity; however, little is known regarding the role of alternatively activated resident M2 ATMs in AT homeostasis or how their function is altered in obesity. Herein, we report the discovery of a population of alternatively activated ATMs with elevated cellular iron content and an iron-recycling gene expression profile. These iron-rich ATMs are referred to as MFehi, and the remaining ATMs are referred to as MFelo. In lean mice, similar to 25% of the ATMs are MFehi; this percentage decreases in obesity owing to the recruitment of MFelo macrophages. Similar to MFelo cells, MFehi ATMs undergo an inflammatory shift in obesity. In vivo, obesity reduces the iron content of MFehi ATMs and the gene expression of iron importers as well as the iron exporter, ferroportin, suggesting an impaired ability to handle iron. In vitro, exposure of primary peritoneal macrophages to saturated fatty acids also alters iron metabolism gene expression. Finally, the impaired MFehi iron handling coincides with adipocyte iron overload in obese mice. In conclusion, in obesity, iron distribution is altered both at the cellular and tissue levels, with AT playing a predominant role in this change. An increased availability of fatty acids during obesity may contribute to the observed changes in MFehi ATM phenotype and their reduced capacity to handle iron.
C1 [Orr, Jeb S.; Kennedy, Arion; Anderson-Baucum, Emily K.; Webb, Corey D.; Hasty, Alyssa H.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA.
   [Fordahl, Steve C.; Erikson, Keith M.] Univ N Carolina, Dept Nutr, Greensboro, NC 27412 USA.
   [Zhang, Yaofang] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA.
   [Etzerodt, Anders; Moestrup, Soren K.] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
RP Hasty, AH (reprint author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA.
EM alyssa.hasty@vanderbilt.edu
RI Moestrup, Soren/A-1403-2014; 
OI Moestrup, Soren/0000-0003-3862-2107; Etzerodt,
   Anders/0000-0002-6757-2068; Hasty, Alyssa/0000-0001-7302-8045
FU Discovery Grant in Innovative Diabetes Research from the Vanderbilt
   Diabetes Center [DK-20593]; National Institutes of Health (NIH) [R21
   DK-095456]; NIH Ruth L. Kirschstein NRSA [F32 DK-091040]; American
   Diabetes Association Mentor-based Postdoctoral Fellowship [7-10-MI-05];
   American Heart Association Pre-doctoral Fellowship [12PRE11910047]; NIH
   [DK-20593, R21 DK-095456, DK-058404, CA-68485, DK-58404, HD-15052,
   DK-59637, EY-08126]; American Heart Association Established Investigator
   Award [12EIA8270000]; NIH Shared Instrumentation grant [S10 RR-026742]; 
   [DK-059637]
FX This project was supported by a Discovery Grant in Innovative Diabetes
   Research from the Vanderbilt Diabetes Center (DK-20593) and National
   Institutes of Health (NIH) R21 DK-095456. The authors were supported by
   the following grants: NIH Ruth L. Kirschstein NRSA F32 DK-091040 (to
   J.S.O.), American Diabetes Association Mentor-based Postdoctoral
   Fellowship 7-10-MI-05 (to A.K.), American Heart Association Pre-doctoral
   Fellowship 12PRE11910047 (to E.K.A.-B.), NIH R21 DK-095456 (to C.D.W.
   and A.H.H.), and American Heart Association Established Investigator
   Award 12EIA8270000 (to A.H.H.). Flow cytometry was performed through
   Vanderbilt University Medical Center (VUMC) Digestive Disease Research
   Center supported by NIH DK-058404 Core Scholarship. Cellular iron
   measurements were performed by the VUMC Mass Spectrometry Research Core
   (supported by NIH Shared Instrumentation grant S10 RR-026742).
   Immunofluorescence imaging was conducted in part through the use of the
   VUMC Cell Imaging Shared Resource (supported by NIH grants CA-68485,
   DK-20593, DK-58404, HD-15052, DK-59637, and EY-08126). Serum iron
   parameter measurements were performed by the Vanderbilt Translational
   Pathology Shared Resource (supported by DK-059637).
CR Tajima S, 2012, AM J PHYSIOL-ENDOC M, V302, pE77, DOI 10.1152/ajpendo.00033.2011
   Boyle JJ, 2012, CIRC RES, V110, P20, DOI 10.1161/CIRCRESAHA.111.247577
   Burgess A, 2010, HYPERTENSION, V56, P1124, DOI 10.1161/HYPERTENSIONAHA.110.151423
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Ganz T, 2012, J INNATE IMMUN, V4, P446, DOI 10.1159/000336423
   Kumar N, 2010, ENDOCRINOLOGY, V151, P3015, DOI 10.1210/en.2009-0800
   Minamiyama Y, 2010, AM J PHYSIOL-ENDOC M, V298, pE1140, DOI 10.1152/ajpendo.00620.2009
   Han J, 2011, DEVELOPMENT, V138, P5027, DOI 10.1242/dev.067686
   Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, pE1236, DOI 10.1152/ajpendo.00022.2010
   Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Corna G, 2010, HAEMATOL-HEMATOL J, V95, P1814, DOI 10.3324/haematol.2010.023879
   Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653
   Luciani N, 2011, OBESITY, V19, P1545, DOI 10.1038/oby.2011.12
   Valenti L, 2007, AM J GASTROENTEROL, V102, P1251, DOI 10.1111/j.1572-0241.2007.01192.x
   DAVIS RJ, 1986, J BIOL CHEM, V261, P8708
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Prieur X, 2011, DIABETES, V60, P797, DOI 10.2337/db10-0705
   Kohyama M, 2009, NATURE, V457, P318, DOI 10.1038/nature07472
   Anderson EK, 2012, ARTERIOSCL THROM VAS, V32, P1687, DOI 10.1161/ATVBAHA.112.250142
   Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887
   Orr JS, 2012, DIABETES, V61, P2718, DOI 10.2337/db11-1595
   Festa M, 2000, J BIOL CHEM, V275, P36708, DOI 10.1074/jbc.M004988200
   Recalcati S, 2010, EUR J IMMUNOL, V40, P824, DOI 10.1002/eji.200939889
   Rumberger JM, 2004, DIABETES, V53, P2535, DOI 10.2337/diabetes.53.10.2535
   Cho CH, 2007, CIRC RES, V100, pE47, DOI 10.1161/01.RES.0000259564.92792.93
   CHEN JJ, 1981, CELL, V26, P117, DOI 10.1016/0092-8674(81)90039-8
   Asano Y, 2006, HISTOCHEM CELL BIOL, V125, P515, DOI 10.1007/s00418-005-0097-6
   Chung J, 2011, NUTR RES, V31, P915, DOI 10.1016/j.nutres.2011.09.014
   DJEHA A, 1993, BLOOD, V81, P1046
   Kotecha N, 2010, CURR PROTOC CYTOM
   Le Guenno G, 2007, DIABETES RES CLIN PR, V77, P363, DOI 10.1016/j.diabres.2007.02.004
   Orr JS, 2013, J VIS EXP
   Sonnweber T, 2012, J NUTR BIOCHEM, V23, P1600, DOI 10.1016/j.jnutbio.2011.10.013
   TANNER LI, 1987, J BIOL CHEM, V262, P8975
   Valenti L, 2011, QJM-INT J MED, V104, P141, DOI 10.1093/qjmed/hcq170
   Virtue S, 2010, BBA-MOL CELL BIOL L, V1801, P338, DOI 10.1016/j.bbalip.2009.12.006
NR 42
TC 15
Z9 15
U1 1
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD FEB
PY 2014
VL 63
IS 2
BP 421
EP 432
DI 10.2337/db13-0213
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AA5BG
UT WOS:000331110000012
PM 24130337
ER

PT J
AU Mujica-Coopman, MF
   Borja, A
   Pizarro, F
   Olivares, M
AF Mujica-Coopman, Maria F.
   Borja, Angelica
   Pizarro, Fernando
   Olivares, Manuel
TI Prevalence of deficiency and dietary intake of iron, zinc and copper in
   Chilean childbearing age women
SO ARCHIVOS LATINOAMERICANOS DE NUTRICION
LA Spanish
DT Article
DE Iron; zinc; copper; anemia; childbearing age women
ID OBESITY; ADULTS; IMPACT
AB The aim of the present study was to evaluate anemia, the biochemical status and dietary adequacy of iron (Fe), zinc (Zn) and copper (Cu), in Chilean childbearing age women. We studied a convenience sample of 86 women aged 18 to 48 years from Santiago, Chile. We determined anemia and the micronutrient status through hemoglobin (Hb) mean corpuscular volume, transferrin saturation, zinc protoporphyrin, serum ferritin (SF), serum Zn and Cu. Dietary adequacy was estimated using a food frequency questionnaire. Of all women, 4.7% had Fe deficiency (ID) anemia, 21 % ID without anemia, 26 % depleted Fe stores and 48.3% normal Fe status. Obese women had higher SF (p<0.01) compared with those classified as having normal BMI. Also, showed higher Hb (p<0.05) concentrations compared with overweight and normal weight women.
   Participants showed 3.5 % and 2.3 % of Zn and Cu deficiency, respectively. Also, 95 %, 94 % and 99 % had adequate intake of Fe, Zn and Cu respectively, according to EAR cut points. There were no significant differences in micronutrients intake across different nutritional status. There was a low prevalence of anemia, Fe, Zn and Cu deficiency. A high percentage of women reached micronutrient adequacy. However, 47% of women had ID without anemia and Fe depleted stores.
C1 [Mujica-Coopman, Maria F.; Borja, Angelica; Pizarro, Fernando; Olivares, Manuel] Univ Chile, Lab Micronutrientes, Inst Nutr & Tecnol Alimentos, Santiago, Chile.
RP Mujica-Coopman, MF (reprint author), Univ Chile, Lab Micronutrientes, Inst Nutr & Tecnol Alimentos, Santiago, Chile.
CR Garcia OP, 2009, NUTR REV, V67, P559, DOI 10.1111/j.1753-4887.2009.00228.x
   [Anonymous], 2001, DIET REF INT VIT A V
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Garmendia ML, 2013, EUR J CLIN NUTR, V67, P513, DOI 10.1038/ejcn.2012.190
   Olivares M, 2004, NUTRITION, V20, P205, DOI 10.1016/j.nut.2003.11.021
   Harvey LJ, 2005, BRIT J NUTR, V94, P557, DOI 10.1079/BJN20051493
   [Anonymous], 2008, WORLDWIDE PREVALENCE
   Azab SF, 2014, ITAL J PEDIATR, V20, P20
   Cediel G Gustavo, 2009, Rev. chil. nutr., V36, P8
   Elin RJ, 2004, CECIL TXB MED, P2496
   Gattas V, 2006, GUIA COMPOSICION NUT
   Gebhardt S, 2002, HOME GARDEN B
   International Zinc Nutrition Consultative Group, 2004, FOOD NUTR BULL, V25, pS91
   Meertens Lesbia, 2002, An Venez Nutr, V15, P5
   Mejia-Rodriguez F, 2013, SALUD PUBLICA MEXICO, V55, P275
   Ministerio da Saude y Centro Brasileiro de Analise e Planejamento, 2006, PESQ NAC DEM SAUD CR
   Ministerio de la proteccion social, 2010, ENC NAC DEM SAL 2010
   Ministerio de Salud, 2003, ENC NAC SAL 2003
   Mora JO, 2010, AN LAT AM CAR 2009 S
   Oficina de Estudios y Politicas Agrarias, 2012, CONS AP PRINC AL CHI
   Pan American Health Organization, 2008, ENC NUTR COST RIC 20
   Rios-Castillo I, 2013, SALUD PUBLICA MEXICO, V55, P478
   United Nations Children's Fund World Health Organization United Nations University, 2001, IR DEF AN ASS PREV C
   WHO, 2000, WHO TECHN REP SER, V894
   WHO, 2011, SER FERR CONC ASS IR
   World Health Organization and Agriculture Organization of the United Nations, 2004, VIT MIN REQ HUM NUTR
NR 26
TC 1
Z9 1
U1 2
U2 6
PU ARCHIVOS LATINOAMERICANOS NUTRICION
PI CARACAS
PA APARTADO 62778 CHACAO, AVENIDA FRANCISCO MIRANDA, CARACAS 1060,
   VENEZUELA
SN 0004-0622
J9 ARCH LATINOAM NUTR
JI Arch. Latinoam. Nutr.
PY 2014
VL 64
IS 1
BP 9
EP 15
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AZ5TS
UT WOS:000348283600002
PM 25796712
ER

PT J
AU Choi, MK
   Lee, SH
   Kim, SK
AF Choi, Mi-Kyeong
   Lee, Sung-Hye
   Kim, Soon-Kyung
TI Relationship between adiposity-related biomarkers and calcium,
   magnesium, iron, copper, and zinc in young adult men with different
   degrees of obesity
SO TRACE ELEMENTS AND ELECTROLYTES
LA English
DT Article
DE calcium; magnesium; iron; copper; zinc; adiposity-related biomarkers
ID C-REACTIVE PROTEIN; SERUM FERRITIN; BLOOD-PRESSURE; US ADULTS; LEPTIN;
   HYPERTENSION; PLASMA; DIETARY; ALPHA; WOMEN
AB Introduction: Several minerals have been reported to be involved in the mechanism of action of biomarkers such as adipokines that have been known to be associated with adiposity. Therefore, the purpose of this study was to identify the correlation between 5 minerals (calcium, magnesium, iron, copper, and zinc) and adiposity-related biomarkers such as blood pressure, blood lipids, C-reactive protein (CRP), adiponectin, and tumor necrosis factor-alpha (TNF-alpha) in young men with different levels of adiposity Methods: A total of 48 male college students aged between 18 and 27 years were classified into three groups, depending on the degree of adiposity: normal group, 17 subjects; overweight group, 14 subjects; and adiposity group, 17 subjects. Anthropometric measurements were obtained and a dietary intake survey to determine the intake levels of the 5 elements was conducted. Blood samples were also collected to analyze the serum levels of the 5 minerals as well as levels of serum lipids, CRP, adiponectin, and TNF-alpha. Results: The mean ages in the normal, overweight, and adiposity groups were 20.47, 21.86, and 22.06 years, respectively; the daily energy intake in each group was 2039.29, 1989.93, and 1919.61 kcal, respectively, with no significant differences among the three groups. In addition, there were no significant differences among the three groups with respect to the intake and serum levels of minerals as well as adiposity-related biomarkers. When the body mass index of all subjects was adjusted while analyzing the correlation between serum minerals and adiposity-related biomarkers, significantly positive correlations between serum calcium and systolic blood pressure, serum iron and high density lipoprotein-cholesterol, and serum zinc and TNF-alpha were found. However, serum copper showed a significantly negative correlation with low density lipoprotein-cholesterol. Conclusion: In young adult men, serum calcium, iron, copper, and zinc were found to be related with adiposity-related biomarkers.
C1 [Choi, Mi-Kyeong] Kongju Natl Univ, Div Food Sci, Yesan, South Korea.
   [Lee, Sung-Hye; Kim, Soon-Kyung] Soonchunhyang Univ, Dept Food Sci & Nutr, Asan 151742, South Korea.
RP Kim, SK (reprint author), Soonchunhyang Univ, Dept Food Sci & Nutr, Asan 151742, South Korea.
EM soon56@sch.ac.kr
FU Soonchunhyang University
FX This study was supported in part by the Soonchunhyang University
   Research Fund.
CR HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   ASCHERIO A, 1992, CIRCULATION, V86, P1475
   Wolf AM, 2004, BIOCHEM BIOPH RES CO, V323, P630, DOI 10.1016/j.bbrc.2004.08.145
   AMINE EK, 1971, J NUTR, V101, P1575
   Chang JS, 2013, ASIA PAC J CLIN NUTR, V22, P400, DOI 10.6133/apjcn.2013.22.3.07
   Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018
   Kengne AP, 2012, DIABETES CARE, V35, P396, DOI 10.2337/dc11-1588
   Mantzoros CS, 1998, J AM COLL NUTR, V17, P270
   Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407
   Pittas AG, 2007, DIABETES CARE, V30, P980, DOI 10.2337/dc06-1994
   Reid IR, 2010, AM J CLIN NUTR, V91, P131, DOI 10.3945/ajcn.2009.28097
   Prasad AS, 2004, FREE RADICAL BIO MED, V37, P1182, DOI 10.1016/j.freeradbiomed.2004.07.007
   Prasad AS, 2008, MOL MED, V14, P353, DOI 10.2119/2008-00033.Prasad
   Cox AJ, 2012, DIABETIC MED, V29, P767, DOI 10.1111/j.1464-5491.2011.03560.x
   Zhao T, 2005, CELL IMMUNOL, V238, P19, DOI 10.1016/j.cellimm.2005.12.002
   DIMARTINO G, 1993, J MED, V24, P177
   Griffith LE, 1999, AM J HYPERTENS, V12, P84, DOI 10.1016/S0895-7061(98)00224-6
   Parikh SJ, 2003, AM J CLIN NUTR, V77, P281
   Sabanayagam C, 2011, J CLIN HYPERTENS, V13, P716, DOI 10.1111/j.1751-7176.2011.00503.x
   Lewis RM, 2001, METABOLISM, V50, P562, DOI 10.1053/meta.2001.22516
   CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531
   Aranha LN, 2012, J TRACE ELEM MED BIO, V26, P238, DOI 10.1016/j.jtemb.2012.02.007
   ENDRE L, 1990, Journal of Trace Elements in Experimental Medicine, V3, P337
   Bureau I, 1998, NUTRITION, V14, P366, DOI 10.1016/S0899-9007(97)00490-5
   Campfield LA, 1999, BEST PRACT RES CL EN, V13, P13, DOI 10.1053/beem.1999.0004
   Chen MD, 2001, EXP BIOL MED, V226, P836
   Chen MD, 2000, BIOL TRACE ELEM RES, V75, P99, DOI 10.1385/BTER:75:1-3:99
   Cunha AR, 2012, INT J HYPERTENS
   Dwyer JH, 1996, AM J EPIDEMIOL, V144, P828
   Feitosa MCP, 2013, REV ASSOC MED BRAS, V59, P429, DOI 10.1016/j.ramb.2013.03.003
   FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
   Gonzalez AJ, 2006, J AM DIET ASSOC, V106, P1066, DOI 10.1016/j.jada.2006.04.024
   Institute National Rural Resources Development, 2006, FOOD COMP TABL
   Klotz LO, 2003, J NUTR, V133, p1448S
   Korean Society for the Study of Obesity, 2000, DIAGN THER OB AS PAC
   Larsson SC, 2011, AM J EPIDEMIOL, V174, P35, DOI 10.1093/aje/kwr051
   MEDEIROS DM, 1991, J NUTR, V121, P815
   Mutakin MA, 2013, J TRACE ELEM MED BIO, V27, P112
   St-Onge MP, 2005, AM J CLIN NUTR, V81, P7
   Sun H, 2013, BIOL TRACE ELEM RES, V155, P344, DOI 10.1007/s12011-013-9805-6
   VLAD M, 1994, J TRACE ELEM ELECT H, V8, P111
   World Health Organization, 2013, OB OV
   Zemel MB, 2005, J AM COLL NUTR, V24, p537S
NR 44
TC 0
Z9 0
U1 2
U2 7
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-2104
J9 TRACE ELEM ELECTROLY
JI Trace Elem. Electrolytes
PY 2014
VL 31
IS 4
BP 148
EP 155
DI 10.5414/TEX01341
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AR8SG
UT WOS:000343844100002
ER

PT J
AU Ondruskova, N
   Honzik, T
   Vondrackova, A
   Tesarova, M
   Zeman, J
   Hansikova, H
AF Ondruskova, Nina
   Honzik, Tomas
   Vondrackova, Alzbeta
   Tesarova, Marketa
   Zeman, Jiri
   Hansikova, Hana
TI Glycogen storage disease-like phenotype with central nervous system
   involvement in a PGM1-CDG patient
SO NEUROENDOCRINOLOGY LETTERS
LA English
DT Article
DE phosphoglucomutase 1; glycoconjugate; congenital disorders of
   glycosylation; glycogen; intellectual disability
ID AMINO-ACID SUBSTITUTIONS; CONGENITAL DISORDERS; GLYCOSYLATION;
   DEFICIENCY; TRANSFERRIN; MUTATIONS; PROTEINS; SERVER; SERUM
AB OBJECTIVES: A 10-year-old boy presented with cleft palate, hepatopathy, cholecystolithiasis, myopathy, coagulopathy, hyperlipidemia, hypoglycemia, hyperuricemia, short stature, obesity, hypothyroidism, microcephaly and mild intellectual disability. The multi-systemic manifestation involving certain distinct clinical features prompted us to search for a subtype of congenital disorders of glycosylation (CDG).
   METHODS: The patient was screened for CDG by examining the distribution of transferrin (TRF) and apolipoprotein C-III (ApoC-III) sialylated isoforms using isoelectric focusing of serum. This was followed by spectrophotometric measurement of phosphoglucomutase 1 (PGM1) activity in fibroblasts and molecular analysis including sequencing and PCR-RFLP of PGM1 gene. Selected bioinformatics tools were used to evaluate the data.
   RESULTS: Increased relative levels of di-, mono-and asialotransferrin reflected a defect of N-glycosylation in the patient. Markedly decreased activity of PGM1 corresponding to less than 5% of control's was found. Sequencing of PGM1 gene revealed the presence of two heterozygous missense mutations c. 1010C>T (p. T337M) and c. 1508G>A (p.R503Q), whose pathogenicity was confirmed by in silico analysis.
   CONCLUSION: We report the first Czech patient with a glycosylation disorder due to PGM1 deficiency. Compared to the described cases, no dilated cardiomyopathy was noted in our patient. However, he suffered from a mild neurological impairment, which is an uncommon feature that extends the phenotype associated with PGM1-CDG. Lactose-rich diet, which was previously reported to have ameliorated the clinical symptoms in some PGM1-CDG patients, did not result in any improvement in our patient.
C1 [Hansikova, Hana] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague 12808, Czech Republic.
   Gen Univ Hosp Prague, Prague, Czech Republic.
RP Hansikova, H (reprint author), Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Ke Karlovu 2, Prague 12808, Czech Republic.
EM hana.hansikova@lf1.cuni.cz
FU Charles University in Prague [GAUK 638512];  [IGA MZ CR NT/12166-5]; 
   [SVV260022];  [PRVOUK P24/LF1/3]
FX We thank the patient and his family for participating in the study. This
   study was supported by the grants GAUK 638512 (Charles University in
   Prague); IGA MZ CR NT/12166-5, SVV260022 and PRVOUK P24/LF1/3.
CR Li B, 2009, BIOINFORMATICS, V25, P2744, DOI 10.1093/bioinformatics/btp528
   Grunewald S, 2002, PEDIATR RES, V52, P618, DOI 10.1203/01.PDR.0000031921.02259.35
   Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118
   Wopereis S, 2007, CLIN CHEM, V53, P180, DOI 10.1373/clinchem.2006.073940
   Honzik T, 2012, MOL GENET METAB, V107, P611, DOI 10.1016/j.ymgme.2012.08.014
   Bao L, 2005, NUCLEIC ACIDS RES, V33, pW480, DOI 10.1093/nar/gki372
   Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539
   Freeze HH, 2013, J BIOL CHEM, V288, P6936, DOI 10.1074/jbc.R112.429274
   Stojkovic T, 2009, NEW ENGL J MED, V361, P425, DOI 10.1056/NEJMc0901158
   Jaeken J, 2010, ANN NY ACAD SCI, V1214, P190, DOI 10.1111/j.1749-6632.2010.05840.x
   Perez B, 2013, J INHERIT METAB DIS, V36, P535, DOI 10.1007/s10545-012-9525-7
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Sturiale L, 2005, GLYCOBIOLOGY, V15, P1268, DOI 10.1093/glycob/cwj021
   Timal S, 2012, HUM MOL GENET, V21, P4151, DOI 10.1093/hmg/dds123
   Calabrese R, 2009, HUM MUTAT, V30, P1237, DOI 10.1002/humu.21047
   JAEKEN J, 1984, CLIN CHIM ACTA, V144, P245, DOI 10.1016/0009-8981(84)90059-7
   Ondruskova N, 2012, MOL GENET METAB, V107, P760, DOI 10.1016/j.ymgme.2012.10.002
   Preisler N, 2013, J CLIN ENDOCR METAB, V98, pE1235, DOI 10.1210/jc.2013-1651
   VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1
NR 20
TC 2
Z9 2
U1 2
U2 6
PU MAGHIRA & MAAS PUBLICATIONS
PI STOCKHOLM
PA PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN
SN 0172-780X
J9 NEUROENDOCRINOL LETT
JI Neuroendocrinol. Lett.
PY 2014
VL 35
IS 2
BP 137
EP 141
PG 5
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA AM8US
UT WOS:000340153900009
PM 24878975
ER

PT J
AU Alvarez, V
   Cuevas, A
   Olivos, C
   Berry, M
   Farias, MM
AF Alvarez, Veronica
   Cuevas, Ada
   Olivos, Cristina
   Berry, Marcos
   Magdalena Farias, Maria
TI MICRONUTRIENT DEFICIENCIES ONE YEAR AFTER SLEEVE GASTRECTOMY
SO NUTRICION HOSPITALARIA
LA Spanish
DT Article
DE Bariatric surgery; Sleeve gastrectomy; Deficiency; Supplementation;
   Obesity; Vitamin
ID VITAMIN-D INSUFFICIENCY; MORBIDLY OBESE-PATIENTS; Y GASTRIC BYPASS;
   BARIATRIC SURGERY; NUTRITIONAL-STATUS; WOMEN; IRON; POPULATION;
   PREVALENCE; EVOLUTION
AB Introduction: Obesity is one of the largest problems in public health worldwide today. For patients with severe obesity and associated comorbidities, surgical treatment is recommended.
   Objective: To analyze the frequency of micronutrient deficiencies and food intake at least 12 months after sleeve gastrectomy (SG).
   Materials and methods: This is a cross sectional study carried out between October and December 2009 with measure of serum levels of vitamin B12, vitamin D, folate, calcium, ferritin, zinc, parathyroid hormone and bone mineral density on patients underwent SG at least 12 months before the study. A food intake questionnaire was also performed. For the statistical analysis, the Pearson or Spearman tests was used.
   Results: Forty patients were evaluated with a mean age of 40 +/- 10 years and mean time post surgery of 26 +/- 6 months. Mean plasma level of 25 OH-vitamin D was 20.9 +/- 10.5 ng/ml. Forty-three percent had low levels of vitamin D (< 20 ng/ml), and 68% showed low levels of calcium (< 1,1 mmol/L) without secondary hyperparathyroidism. Anemia was present in 28% and iron deficiency occurred in 38% of these patients. Deficit of folic acid and vitamin 812 were observed in 13% of the patients. Average daily food intake was 1,256 kcal, 54% of total calories as carbohydrates, 26% as fat and 21% as protein.
   Conclusion: Iron, calcium and vitamin D are the most prevalent micronutrient deficiencies after SG. Long-term Vitamin and mineral supplementation should be considered on every patient. Additional long-term studies are needed to establish specific supplementation recommendations after SG.
C1 [Alvarez, Veronica; Cuevas, Ada; Olivos, Cristina; Magdalena Farias, Maria] Clin Las Condes, Dept Nutr, Santiago, Chile.
   [Berry, Marcos] Clin Las Condes, Dept Cirugia Bariatr, Santiago, Chile.
RP Alvarez, V (reprint author), Clin Las Condes, Dept Nutr, Santiago, Chile.
EM valvarez@clc.cl
CR AMARAL JF, 1985, ANN SURG, V201, P186, DOI 10.1097/00000658-198502000-00009
   Poslusna K, 2009, BRIT J NUTR, V101, pS73, DOI 10.1017/S0007114509990602
   Rhode BM, 1996, AM J CLIN NUTR, V63, P103
   AVINOAH E, 1992, SURGERY, V111, P137
   Buchwald H, 2009, OBES SURG, V19, P1605, DOI 10.1007/s11695-009-0014-5
   Shankar P, 2010, NUTRITION, V26, P1031, DOI 10.1016/j.nut.2009.12.003
   Slater GH, 2004, J GASTROINTEST SURG, V8, P48, DOI 10.1016/j.gassur.2003.09.020
   Goldner WS, 2008, OBES SURG, V18, P145, DOI 10.1007/s11695-007-9315-8
   Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
   BUFFINGTON C, 1993, OBES SURG, V3, P421, DOI 10.1381/096089293765559142
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Salle A, 2010, OBES SURG, V20, P1660, DOI 10.1007/s11695-010-0237-5
   Aills L, 2008, SURG OBES RELAT DIS, V4, pS73, DOI 10.1016/j.soard.2008.03.002
   Vilarrasa N, 2007, J ENDOCRINOL INVEST, V30, P653
   Gehrer S, 2010, OBES SURG, V20, P447, DOI 10.1007/s11695-009-0068-4
   Roa PE, 2006, OBES SURG, V16, P1323, DOI 10.1381/096089206778663869
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604
   Naghshineh N, 2010, PLAST RECONSTR SURG, V126, P602, DOI 10.1097/PRS.0b013e3181de2473
   Bavaresco M, 2010, OBES SURG, V20, P716, DOI 10.1007/s11695-008-9721-6
   Aguirre ME, 2007, ARCH LATINOAM NUTR, V57, P238
   Adams JS, 2010, J CLIN ENDOCR METAB, V95, P471, DOI 10.1210/jc.2009-1773
   Givon-Madhala O, 2007, OBES SURG, V17, P722, DOI 10.1007/s11695-007-9133-z
   Torheim LE, 2010, J NUTR, V140, p2051S, DOI 10.3945/jn.110.123463
   Shah M, 2006, J CLIN ENDOCR METAB, V91, P4223, DOI 10.1210/jc.2006-0557
   Cuevas A, 2011, CURR OPIN ENDOCRINOL, V18, P134, DOI 10.1097/MED.0b013e3283449167
   Balsiger BM, 2000, MAYO CLIN PROC, V75, P673
   Ybarra J, 2005, OBES SURG, V15, P330, DOI 10.1381/0960892053576758
   Bernante P, 2006, OBES SURG, V16, P1327, DOI 10.1381/096089206778663797
   Arts E, 2011, OBES SURG, V21, P207
   Basfi-fer K, 2012, NUTR HOSP, V27, P1527, DOI 10.3305/nh.2012.27.5.5913
   Brolin R E, 1998, J Gastrointest Surg, V2, P436, DOI 10.1016/S1091-255X(98)80034-6
   Casgrain A, 2012, AM J CLIN NUTR, V96, P768, DOI 10.3945/ajcn.112.040626
   CSENDES ATTILA, 2006, Rev Chil Cir, V58, P208, DOI 10.4067/S0718-40262006000300009
   Garcia MJA, 2012, NUTR HOSP, V27, P349, DOI 10.3305/nh.2012.27.2.5670
   HALVERSON JD, 1986, AM SURGEON, V52, P594
   Health implications of obesity, 1985, NAT I HLTH CONS DEV, V5, P1
   Heaney RP, 2004, AM J CLIN NUTR, V80, p1706S
   Hertrampf E, 2004, NUTR REV, V62, pS44, DOI 10.1301/nr.2004.jun.S44-S448
   Martinez-Valls, 2007, REV ESP OBES, V5, P19
   Moize VL, 2010, OBES SURG, V20, P1133, DOI 10.1007/s11695-010-0160-9
   Ocon Breton J, 2005, NUTR HOSP, V20, P409
   Papapietro K, 2013, NUTR HOSP, V28, P631, DOI 10.3305/nh.2013.28.3.6400
   Rebolledo A, 2009, ARCH LATINOAM NUTR, V59, P7
   Valenzuela Andrea A, 2010, Rev Med Chil, V138, P707
   Yetley EA, 2008, AM J CLIN NUTR, V88, p558S
NR 46
TC 2
Z9 2
U1 1
U2 9
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD JAN
PY 2014
VL 29
IS 1
BP 73
EP 79
DI 10.3305/nh.2014.29.1.7039
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AA8IV
UT WOS:000331340100010
PM 24483964
ER

PT J
AU Gartner, A
   El Ati, J
   Traissac, P
   Bour, A
   Berger, J
   Landais, E
   El Hsaini, H
   Ben Rayana, C
   Delpeuch, F
AF Gartner, Agnes
   El Ati, Jalila
   Traissac, Pierre
   Bour, Abdellatif
   Berger, Jacques
   Landais, Edwige
   El Hsaini, Houda
   Ben Rayana, Chiheb
   Delpeuch, Francis
TI A Double Burden of Overall or Central Adiposity and Anemia or Iron
   Deficiency Is Prevalent but with Little Socioeconomic Patterning among
   Moroccan and Tunisian Urban Women
SO JOURNAL OF NUTRITION
LA English
DT Article
ID BODY-MASS INDEX; MIDDLE-INCOME COUNTRIES; NUTRITION TRANSITION; WAIST
   CIRCUMFERENCE; FERRITIN CONCENTRATIONS; MATERNAL OVERWEIGHT; OBESITY
   EPIDEMIC; REPRODUCTIVE AGE; PREGNANT-WOMEN; TIME TRENDS
AB In North Africa, overnutrition has dramatically increased with the nutrition transition while micronutrient deficiencies persist, resulting in clustering of opposite types of malnutrition that can present a unique difficulty for public health interventions. We assessed the magnitude of the double burden of malnutrition among urban Moroccan and Tunisian women, as defined by the coexistence of overall or central adiposity and anemia or iron deficiency (ID), and explored the sociodemographic patterning of individual double burden. In cross-sectional surveys representative of the region around the capital city, we randomly selected 811 and 1689 nonpregnant women aged 20-49 y in Morocco and Tunisia, respectively. Four double burdens were analyzed: overweight (body mass index >= 25 kg/m(2)) or increased risk abdominal obesity (waist circumference >= 80 cm) and anemia (blood hemoglobin <120 g/L) or ID (C-reactive protein-corrected serum ferritin <15 mu g/L). Adjusted associations with 9 sociodemographic factors were estimated by logistic regression. The prevalence of overweight and ID was 67.0% and 45.2% in Morocco, respectively, and 69.5% and 27.0% in Tunisia, respectively, illustrating the population-level double burden. The coexistence of overall or central adiposity with ID was found in 29.8% and 30.1% of women in Morocco, respectively, and in 18.2% and 18.3% of women in Tunisia, respectively, quite evenly distributed across age, economic, or education groups. Generally, the rare, associated sociodemographic factors varied across the 4 subject-level double burdens and the 2 countries and differed from those usually associated with adiposity, anemia, or ID. Any double burden combining adiposity and anemia or ID should therefore be taken into consideration in all women. This trial was registered at clinicaltrials.gov as NCT01844349.
C1 [Gartner, Agnes; Traissac, Pierre; Berger, Jacques; Landais, Edwige; Delpeuch, Francis] Inst Dev Res, Res Unit Nutripass Prevent Malnutr & Associated D, Montpellier, France.
   [El Ati, Jalila] Natl Inst Nutr & Food Technol, Dept Study & Planning, Tunis, Tunisia.
   [Ben Rayana, Chiheb] Natl Inst Nutr & Food Technol, Dept Clin Biol, Res Lab Surven Nutr Surveillance & Epidemiol Tuni, Tunis, Tunisia.
   [Bour, Abdellatif; El Hsaini, Houda] Ibn Tofail Univ, Team Food & Nutr Transit, Kenitra, Morocco.
RP Gartner, A (reprint author), Inst Dev Res, Res Unit Nutripass Prevent Malnutr & Associated D, Montpellier, France.
EM agnes.gartner@ird.fr
FU Cooperation pour la Recherche Universitaire et Scientifique (CORUS)
   program of the French Ministry of Foreign Affairs [6028-2]; Tunisian
   National Institute of Nutrition and Food Technology, Tunis, Tunisia;
   Institute of Research for Development, Marseille, France
FX Supported by the Cooperation pour la Recherche Universitaire et
   Scientifique (CORUS) program of the French Ministry of Foreign Affairs
   (contract Corus 6028-2); the Tunisian National Institute of Nutrition
   and Food Technology, Tunis, Tunisia; and the Institute of Research for
   Development, Marseille, France. H. El Hsaini was a recipient of a
   research allowance from the Institute of Research for Development,
   Marseille, France.
CR Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
   Subramanian SV, 2011, AM J CLIN NUTR, V93, P413, DOI 10.3945/ajcn.110.004820
   Mendez MA, 2005, AM J CLIN NUTR, V81, P714
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Bentley ME, 2003, EUR J CLIN NUTR, V57, P52, DOI 10.1038/sj.ejcn.1601504
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Mei ZG, 2011, AM J CLIN NUTR, V93, P1312, DOI 10.3945/ajcn.110.007195
   Balarajan Y, 2011, LANCET, V378, P2123, DOI 10.1016/S0140-6736(10)62304-5
   Zeba AN, 2012, PUBLIC HEALTH NUTR, V15, P2210, DOI 10.1017/S1368980012000729
   Gartner A, 2013, AM J CLIN NUTR, V98, P821, DOI 10.3945/ajcn.112.054551
   Delisle HF, 2008, ANN NY ACAD SCI, V1136, P172, DOI 10.1196/annals.1425.026
   Monteiro CA, 2004, B WORLD HEALTH ORGAN, V82, P940
   Kim SA, 2007, INT J EPIDEMIOL, V36, P93, DOI 10.1093/ije/dyl252
   Benjelloun S, 2002, PUBLIC HEALTH NUTR, V5, P135, DOI 10.1079/PHN2001285
   Jones-Smith JC, 2012, INT J OBESITY, V36, P1114, DOI 10.1038/ijo.2011.179
   Griffiths P, 2005, EUR J CLIN NUTR, V59, P1217, DOI 10.1038/sj.ejcn.1602228
   Doak CM, 2000, J NUTR, V130, P2965
   Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x
   Eckhardt CL, 2008, EUR J CLIN NUTR, V62, P238, DOI 10.1038/sj.ejcn.1602727
   Kordas K, 2013, J NUTR, V143, P175, DOI 10.3945/jn.112.167767
   Caballero B, 2005, NEW ENGL J MED, V352, P1514, DOI 10.1056/NEJMp048310
   James PT, 2001, OBES RES, V9, p228S, DOI 10.1038/oby.2001.123
   Tazi MA, 2003, J HYPERTENS, V21, P897, DOI 10.1097/01.hjh.0000059034.65882.83
   Rguibi M, 2007, OBES REV, V8, P11, DOI 10.1111/j.1467-789X.2006.00260.x
   Kelly T, 2008, INT J OBESITY, V32, P1431, DOI 10.1038/ijo.2008.102
   Koch E, 2008, J EPIDEMIOL COMMUN H, V62, P461, DOI 10.1136/jech.2007.062240
   Beltaifa L, 2009, OBES REV, V10, P145, DOI 10.1111/j.1467-789X.2008.00543.x
   Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824
   Monteiro CA, 2001, J NUTR, V131, p881S
   Milman N, 2011, ANN HEMATOL, V90, P369, DOI 10.1007/s00277-010-1144-5
   Traissac P, 2012, INT J EPIDEMIOL, V41, P1207, DOI 10.1093/ije/dys122
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   Bobrow KL, 2013, INT J OBESITY, V37, P712, DOI 10.1038/ijo.2012.76
   Jones-Smith JC, 2011, AM J EPIDEMIOL, V173, P667, DOI 10.1093/aje/kwq428
   Lee J, 2012, ECON HUM BIOL, V10, P232, DOI 10.1016/j.ehb.2011.08.002
   Oddo VM, 2012, AM J CLIN NUTR, V95, P951, DOI 10.3945/ajcn.111.026070
   Kanter R, 2012, ADV NUTR, V3, P491, DOI 10.3945/an.112.002063
   Vorster HH, 2011, NUTRIENTS, V3, P429, DOI 10.3390/nu3040429
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   HELIOVAARA M, 1981, J EPIDEMIOL COMMUN H, V35, P197, DOI 10.1136/jech.35.3.197
   Visscher TLS, 2004, INT J OBESITY, V28, P1309, DOI 10.1038/sj.ijo.0802761
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Asfaw A, 2007, ECON HUM BIOL, V5, P471, DOI 10.1016/j.ehb.2007.C3.004
   Bruus M, 2004, EPIDATA VERSION 3 1
   El Ati J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048153
   El Ati J, 2008, PUBLIC HEALTH NUTR, V11, P729, DOI 10.1017/S1368980007001590
   El Rhazi K, 2011, PUBLIC HEALTH NUTR, V14, P160, DOI 10.1017/S1368980010001825
   Garrett J, 2005, MATERN CHILD NUTR, V1, P185, DOI 10.1111/j.1740-8709.2005.00034.x
   Garrett James L., 2005, Food and Nutrition Bulletin, V26, P209
   Kennedy G, 2006, DOUBLE BURDEN MALNUT, P84
   KORN E., 1999, ANAL HLTH SURVEYS
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   Lynch SR, 2011, J NUTR, V141, p763S, DOI 10.3945/jn.110.130609
   Mansour AA, 2009, EAT WEIGHT DISORD-ST, V14, pE50
   Marini A, 2003, POLICY RES WORKING P, P2967
   McLean E., 2008, WORLDWIDE PREVALENCE
   Mokhtar N, 2001, J NUTR, V131, p887S
   Physical Status WHO, 1995, WHO TECH REP SER
   Popkin BM, 2002, PUBLIC HEALTH NUTR, V5, P205, DOI 10.1079/PHN2001295
   Qin Y, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-10
   Rao S, 2011, PUBLIC HEALTH NUTR, V14, P365, DOI 10.1017/S1368980010002776
   Abrahams Z, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-801
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
   UNDP (United Nations Development Programme Ghana Office Accra), 2010, HUM DEV REP 2010
   Vandevijvere S, 2013, J ACAD NUTR DIET, V113, P659, DOI 10.1016/j.jand.2012.10.021
   WHO, 2001, IR DEF AN ASS PREV C
   WHO, 2000, WHO TECHN REP SER, P894
   WHO/CDC, 2007, ASS IR STAT POP REP, V2nd
   WHO/CDC, 2004, ASS IR STAT POP
   World Bank, WORLD DEV IND
NR 70
TC 1
Z9 1
U1 7
U2 15
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD JAN
PY 2014
VL 144
IS 1
BP 87
EP 97
DI 10.3945/jn.113.178285
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 287GU
UT WOS:000329530800015
PM 24198310
ER

PT J
AU McKinnon, EJ
   Rossi, E
   Beilby, JP
   Trinder, D
   Olynyk, JK
AF McKinnon, Elizabeth J.
   Rossi, Enrico
   Beilby, John P.
   Trinder, Debbie
   Olynyk, John K.
TI Factors That Affect Serum Levels of Ferritin in Australian Adults and
   Implications for Follow-up
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Hyperferritinemia; Risk Factor; Population-based Study; Overweight
ID IRON-DEFICIENCY ANEMIA; HEREDITARY HEMOCHROMATOSIS; RISK; DISEASE;
   POPULATION; OVERLOAD; HYPERFERRITINEMIA; PREVALENCE; PREDICTION;
   MANAGEMENT
AB BACKGROUND & AIMS: Serum levels of ferritin are commonly measured to assess iron stores but are affected by factors such as obesity and chronic disease. Published reference ranges have not changed in decades, and the number of patients whose levels exceed the upper limits has been increasing. As a result, more patients are evaluated for iron overload.
   METHODS: We compared serum levels of ferritin in 1188 Australian adults who participated in the 2005 Busselton Population Survey with levels from the 1995 survey. Parametric regression was used to assess the effects of body weight and biochemical parameters on serum level of ferritin to derive contemporary population-appropriate reference ranges.
   RESULTS: In 2005, age-adjusted levels of ferritin were 21% higher in men (P < .0001) and 10% higher in women (P = .01) than in 1995; 31% of men exceeded levels of 300 mu g/L, compared with 23% in 1995. Body mass index (BMI) >= 25 kg/m(2) was associated with higher levels of ferritin in men >= 35 years old and in postmenopausal women (P <= .002). Serum level of g-glutamyltransferase (GGT) correlated with serum level of ferritin (P < .0001). In men, the estimated 95th percentiles ranged from 353 to 495 mu g/L (<35 years), from 350 to 511 mu g/L (>= 35 years, BMI <25 kg/m(2)), and from 413 to 696 mu/L (>= 35 years, BMI >= 25 kg/m(2)) when GGT levels were 10-75 IU/L. In women, the 95th percentiles ranged from 106 to 235 mu g/L (premenopausal), from 222 to 323 mu g/L (postmenopausal, BMI <25 kg/m(2)), and from 249 to 422 mu g/L (postmenopausal, BMI >= 25 kg/m(2)) when GGT levels were 8-45 IU/L.
   CONCLUSION: Serum levels of ferritin increased significantly between 1995 and 2005. Reference ranges that accommodate demographic and biomedical variations will assist clinicians in identifying individuals who require further evaluation for iron overload.
C1 [McKinnon, Elizabeth J.; Olynyk, John K.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia.
   [Rossi, Enrico; Beilby, John P.] PathWest, Perth, WA, Australia.
   [Beilby, John P.] Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA 6009, Australia.
   [Trinder, Debbie] Univ Western Australia, Sch Med & Pharmacol, Fremantle Hosp, Fremantle, WA, Australia.
   [Trinder, Debbie] Western Australian Inst Med Res, Perth, WA, Australia.
   [Olynyk, John K.] Fremantle Hosp, Dept Gastroenterol, Fremantle, WA 6959, Australia.
   [Olynyk, John K.] Curtin Univ Technol, Curtin Hlth Innovat Res Inst, Bentley, WA 6102, Australia.
RP Olynyk, JK (reprint author), Fremantle Hosp, Dept Gastroenterol, POB 480, Fremantle, WA 6959, Australia.
EM john.olynyk@health.wa.gov.au
OI Olynyk, John/0000-0003-0417-3411
FU NHMRC Practitioner Fellowship [APP1042370]; NHMRC Senior Research
   Fellowship [APP1020437]; NHMRC [APP1011319]
FX J.K.O. is the recipient of a NHMRC Practitioner Fellowship (APP1042370).
   D.T. is the recipient of a NHMRC Senior Research Fellowship
   (APP1020437). E.J.M. is supported by an NHMRC project grant
   (APP1011319).
CR Allen KJ, 2010, HEPATOLOGY, V52, P925, DOI 10.1002/hep.23786
   Whitlock EP, 2006, ANN INTERN MED, V145, P209
   Zacharski LR, 2008, J NATL CANCER I, V100, P996, DOI 10.1093/jnci/djn209
   Rossi E, 2001, CLIN CHEM, V47, P202
   Ioannou GN, 2004, GASTROENTEROLOGY, V126, P1293, DOI 10.1053/j.gastro.2004.01.020
   Pasricha SRS, 2010, MED J AUSTRALIA, V193, P525
   Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762
   Clark SF, 2009, CURR OPIN GASTROEN, V25, P122, DOI 10.1097/MOG.0b013e32831ef1cd
   Allen KJ, 2008, NEW ENGL J MED, V358, P221, DOI 10.1056/NEJMoa073286
   Adams PC, 2005, NEW ENGL J MED, V352, P1769, DOI 10.1056/NEJMoa041534
   Olynyk JK, 2008, HEPATOLOGY, V48, P991, DOI 10.1002/hep.22507
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3
   Goot K, 2012, AUST FAM PHYSICIAN, V41, P945
   Bacon BR, 1999, ANN INTERN MED, V130, P953
   Ayonrinde OT, 2008, CRIT REV CL LAB SCI, V45, P451, DOI 10.1080/10408360802335716 
   Beaton MD, 2012, ANN HEPATOL, V11, P294
   Bell B., 2012, AUSTR RED CROSS BLOO
   Houschyar KS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-54
   Hung J, 2008, AM J CARDIOL, V101, P193, DOI 10.1016/j.amjcard.2007.07.061
   Knuiman MW, 1997, J EPIDEMIOL COMMUN H, V51, P515, DOI 10.1136/jech.51.5.515
   KNUIMAN MW, 1995, AUST J PUBLIC HEALTH, V19, P375
   Olynyk JK, 2005, AM J GASTROENTEROL, V100, P837, DOI 10.1111/j.1572-0241.2005.41287.x
   Olynyk JK, 2009, CLIN GASTROENTEROL H, V7, P359, DOI 10.1016/j.cgh.2008.11.010
   Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002
   Pietrangelo A, 2005, SEMIN LIVER DIS, V25, P450, DOI 10.1055/s-2005-923316
   Valenti L, 2011, QJM-INT J MED, V104, P141, DOI 10.1093/qjmed/hcq170
NR 27
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JAN
PY 2014
VL 12
IS 1
BP 101
EP U153
DI 10.1016/j.cgh.2013.07.019
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 276FQ
UT WOS:000328734300019
PM 23906872
ER

PT J
AU Aderibigbe, OR
   Pisa, PT
   Vorster, HH
   Kruger, SH
AF Aderibigbe, Olaide Ruth
   Pisa, Pedro T.
   Vorster, Hester H.
   Kruger, Salome H.
TI The Relationship Between Iron Status and Adiposity in Women from
   Developing Countries: A Review
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE Iron status; adiposity; women; developing countries; review
ID BODY-FAT DISTRIBUTION; INSULIN-RESISTANCE; PREGNANT-WOMEN; DIETARY
   FACTORS; SERUM FERRITIN; RISK-FACTORS; WEIGHT-GAIN; DEFICIENCY; OBESITY;
   ANEMIA
AB Scientific reports have shown that iron deficiency is positively associated with adiposity. With the high prevalence of iron deficiency and obesity in developing countries and women being particularly affected, this review was carried out with the aim of elucidating the link between iron status and adiposity in women from developing countries and to examine factors influencing this relationship. An extensive literature search was conducted using several search engines. A systematic approach with prespecified inclusion criteria was used in selecting relevant literature. Eight studies that met the inclusion criteria were selected for review. The relationship between iron status indices and adiposity in women in developing countries varied widely. While some studies observed negative relationships, some reported positive relationships, and others no significant relationships. Furthermore, other factors such as infection, alcohol consumption, type of diet, and genes were shown to affect the relationship between iron status and adiposity in women in developing countries. In conclusion, the possibility of iron status playing a role in adiposity in women from developing countries is likely, and it may be influenced by several other factors as described in the results. Thus, it is recommended that a special research effort should be directed toward this area.
C1 [Aderibigbe, Olaide Ruth; Pisa, Pedro T.; Vorster, Hester H.; Kruger, Salome H.] North West Univ, Ctr Excellence Nutr, ZA-2520 Potchefstroom, South Africa.
RP Aderibigbe, OR (reprint author), North West Univ, Ctr Excellence Nutr, Hoffman St,Buiding G16, ZA-2520 Potchefstroom, South Africa.
EM connecttolaide@yahoo.com
CR ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x
   Aderibigbe O. R., 2011, S AFR J CLIN NUTR, V22, P1
   Andrew SG, 2006, AM J CLIN NUTR, V83, p461S
   Engstrom G, 2003, DIABETES, V52, P2097, DOI 10.2337/diabetes.52.8.2097
   KENNEDY ML, 1986, J NUTR, V116, P1432
   Barzilay JI, 2006, INT J OBESITY, V30, P1362, DOI 10.1038/sj.ijo.0803306
   Becquey E, 2010, J NUTR, V140, p2079S, DOI 10.3945/jn.110.123356
   Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Ramakrishnan U, 1999, NUTR RES, V19, P103, DOI 10.1016/S0271-5317(98)00178-X
   Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x
   Zimmermann MB, 2005, AM J CLIN NUTR, V81, P115
   Verhoef H, 2002, BLOOD, V100, P3489, DOI 10.1182/blood-2001-12-0228
   Prentice AM, 2006, INT J EPIDEMIOL, V35, P93, DOI 10.1093/ije/dyi272
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Eftekhari MH, 2009, PUBLIC HEALTH NUTR, V12, P2377, DOI 10.1017/S1368980009005187
   Eckhardt CL, 2008, EUR J CLIN NUTR, V62, P238, DOI 10.1038/sj.ejcn.1602727
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Aderibigbe OR, 2011, CARDIOVASC J AFR, V22, P249, DOI 10.5830/CVJA-2011-015
   Tolentino K, 2007, AM J TROP MED HYG, V77, P44
   Killip S, 2007, AM FAM PHYSICIAN, V75, P671
   Chambers EC, 2006, J AM DIET ASSOC, V106, P680, DOI 10.1016/j.jada.2006.02.013
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   FAILLA ML, 1988, J NUTR, V118, P46
   Hattingh Z, 2008, W INDIAN MED J, V57, P431
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Liu JM, 2003, AM J CLIN NUTR, V78, P1160
   Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747
   BERGE LN, 1994, ARTERIOSCLER THROMB, V14, P857
   Newman AB, 2003, J AM GERIATR SOC, V51, P1602, DOI 10.1046/j.1532-5415.2003.51534.x
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Bodnar LM, 2004, OBES RES, V12, P941, DOI 10.1038/oby.2004.115
   Dreyfuss ML, 2000, J NUTR, V130, P2527
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   [Anonymous], 2008, WORLDW PREV AN 1993
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Whitfield JB, 2003, BRIT J HAEMATOL, V120, P860, DOI 10.1046/j.1365-2141.2003.04224.x
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Festa M, 2000, J BIOL CHEM, V275, P36708, DOI 10.1074/jbc.M004988200
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Gunderson EP, 2000, EPIDEMIOL REV, V22, P261
   Lopez MAA, 2004, INT J FOOD SCI NUTR, V55, P597, DOI 10.1080/09637480500085820
   Baynes R. D., 1994, IRON METABOLISM HLTH, P150
   Beard JL, 2000, J NUTR, V130, p440S
   Berki S., 2006, GASTROENTEROLOGY, V131, P788
   Casanueva E, 2000, NUTR RES, V20, P1389, DOI 10.1016/S0271-5317(00)80020-2
   Cook James D., 1992, Nutrition Research Reviews, V5, P189, DOI 10.1079/NRR19920014
   Crist B. L., 2008, J WOMENS HEALTH, V18, P795
   de Monye C, 1999, AIDS, V13, P375, DOI 10.1097/00002030-199902250-00010
   Di P. C., 2009, ADOLESC MED STATE AR, V20, P930
   Ettyang GA, 2003, ANN NUTR METAB, V47, P276, DOI 10.1159/000072400
   Famodu AA, 2009, CLIN HEMORHEOL MICRO, V43, P335, DOI 10.3233/CH-2009-1244
   Flancbaum L., 2006, J GASTROINTEST SURG, V14, P1724
   Ford E. S., 1999, DIABETES CARE, V22, P113
   Frison E., 2004, USING BIODIVERSITY F
   Gopane R. E., 2010, AFR J CLIN NUTR S1, V23, pS16
   Hak E., 2002, THESIS MAASTRICHT U
   Harvey M. G., 1999, HIGH RISK CRITICAL C
   Hurrell RF, 1997, EUR J CLIN NUTR, V51, pS4
   Kasdan T. S., 2000, KRAUSES FOOD NUTR DI, P781
   Kato I, 2000, INT J VITAM NUTR RES, V70, P119, DOI 10.1024/0300-9831.70.3.119
   Kew MC, 2007, LIVER INT, V27, P735, DOI 10.1111/j.1478-3231.2007.01515.x
   Lonnerdal B, 2000, J NUTR, V130, p1378S
   Lyons D, 2000, MAT CULTURE TWINS W
   McClung J. P., 2008, NUTR REV, V60, P100
   McNamara L, 1998, BRIT J HAEMATOL, V102, P1176
   Méthot Julie, 2010, Expert Rev Cardiovasc Ther, V8, P639, DOI 10.1586/erc.10.38
   Montgomery Kristen S, 2005, J Perinat Educ, V14, P26, DOI 10.1624/105812405X44709
   Moyo VM, 1998, BLOOD, V91, P1076
   Nemati A., 2007, Research Journal of Biological Sciences, V2, P263
   Osmani S. R., 1998, Asian Development Review, V16, P31
   Paknahad Z., 2008, Pakistan Journal of Nutrition, V7, P377
   Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6
   Pisa P. T., 2010, S AFR J CLIN NUTR S1, V23, P29
   Quesnel-Valle A., 2011, PREGNANCY RISK FACTO
   Quinion M., 2010, HIDDEN HUNGER WORLDW
   Rohrer James E, 2005, BMC Fam Pract, V6, P17, DOI 10.1186/1471-2296-6-17
   Seshadri S, 2001, BRIT J NUTR, V85, pS87
   Steyn N. P, 2006, DIETARY INTAKE ADULT
   Sukchan P, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-572
   Tomkins A, 2003, J NUTR, V133, p1649S
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   United Nations, 2000, 4 UN ACCSCN COLL INT
   Wenzel B. J., 1962, LANCET, V13, P354
   World Health Organization, 1998, OB PREV MAN GLOB EP
   World Health Organization, 2001, WHO TECHN REP SER, V894
   World Health Organization, 2000, AS PAC PERSP RED OB
   Yip R, 2002, J NUTR, V132, p827S
NR 91
TC 1
Z9 2
U1 2
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PD JAN 1
PY 2014
VL 54
IS 5
BP 553
EP 560
DI 10.1080/10408398.2011.594914
PG 8
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 254RZ
UT WOS:000327186000001
PM 24261530
ER

PT J
AU Westerink, J
   Olijhoek, JK
   Koppen, A
   Faber, DR
   Kalkhoven, E
   Monajemi, H
   van Asbeck, BS
   van der Graaf, Y
   Visseren, FLJ
AF Westerink, Jan
   Olijhoek, Jobien K.
   Koppen, Arjen
   Faber, Daniel R.
   Kalkhoven, Eric
   Monajemi, Houshang
   van Asbeck, B. Sweder
   van der Graaf, Yolanda
   Visseren, Frank L. J.
TI The relation between body iron stores and adipose tissue function in
   patients with manifest vascular disease
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE Adipocytes; adiponectin; adipose tissue function; iron; obesity
ID INSULIN-RESISTANCE; METABOLIC SYNDROME; SERUM FERRITIN;
   ENDOTHELIAL-CELLS; OXIDATIVE STRESS; ADIPONECTIN; OBESITY; INFLAMMATION;
   TRANSFERRIN; RETINOL-BINDING-PROTEIN-4
AB BackgroundWe investigated whether plasma ferritin levels through the pro-inflammatory effects of free iron are associated with adipose tissue dysfunction in a relevant population of patients with manifest vascular disease who would potentially benefit the most from further aetiological insights.
   Materials and methodsIn a cohort of 355 patients with vascular diseases, the association between plasma ferritin and adiponectin levels was quantified using linear regression analysis. Interleukin-6 and adiponectin levels were measured in medium from pre-adipocytes and adipocytes after incubation with increasing concentrations of Fe(III)-citrate and after co-incubation with iron chelators or radical scavengers.
   ResultsIncreasing ferritin plasma concentrations were not related to plasma adiponectin levels in patients without ( -013; 95% CI -030 to 004) or with the metabolic syndrome ( -004; 95% CI -017 to 010). Similar results were found in patients who developed a new cardiovascular event in the follow-up period. In vitro, incubation with increasing concentrations of Fe(III)-citrate-induced inflammation in pre-adipocyte cultures as witnessed by increased IL-6 secretion at 30m Fe(III)-citrate vs. control (50098pg/mL vs. 194 +/- 31pg/mL, P=003). Co-incubation of pre-adipocytes with iron chelators or radical scavengers prevented this inflammatory response. Incubation of adipocytes with 30m Fe(III)-citrate did not influence adiponectin secretion compared with control.
   ConclusionsIn patients with vascular disease, there is no association between plasma ferritin and adiponectin levels. In vitro, free iron induces an inflammatory response in pre-adipocytes, but not in adipocytes. This response was blocked by co-incubation with iron chelators or radical scavengers. Adiponectin secretion by adipocytes was not influenced by free iron.
C1 [Westerink, Jan; Faber, Daniel R.; Monajemi, Houshang; Visseren, Frank L. J.] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands.
   [Olijhoek, Jobien K.] Tweesteden Hosp, Dept Vasc Med, Tilburg, Netherlands.
   [Koppen, Arjen; Kalkhoven, Eric] Univ Med Ctr Utrecht, Dept Metab Dis, NL-3508 GA Utrecht, Netherlands.
   [van Asbeck, B. Sweder] Univ Med Ctr Utrecht, Dept Internal Med, NL-3508 GA Utrecht, Netherlands.
   [van der Graaf, Yolanda] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
RP Visseren, FLJ (reprint author), Univ Med Ctr Utrecht, Dept Vasc Med, POB 85500, NL-3508 GA Utrecht, Netherlands.
EM F.L.J.Visseren@umcutrecht.nl
CR Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Tajima S, 2012, AM J PHYSIOL-ENDOC M, V302, pE77, DOI 10.1152/ajpendo.00033.2011
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862
   Hajer GR, 2008, EUR HEART J, V29, P2959, DOI 10.1093/eurheartj/ehn387
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520
   Fernandez-Real JM, 2008, DIABETES, V57, P1918, DOI 10.2337/db08-0041
   Cook JD, 2005, BEST PRACT RES CL HA, V18, P319, DOI 10.1016/j.beha.2004.08.022
   Despres JP, 2008, ARTERIOSCL THROM VAS, V28, P1039, DOI 10.1161/ATVBAHA.107.159228
   Salonen JT, 1998, BRIT MED J, V317, P727
   Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711
   Devaraj S, 2008, AM J CLIN PATHOL, V129, P815, DOI [10.1309/RN84K51B2JJY1Y0B, 10.1309/BN84K51B2JJY1Y0B]
   Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5
   Munoz M, 2009, WORLD J GASTROENTERO, V15, P4617, DOI 10.3748/wjg.15.4617
   Kartikasari AER, 2004, ARTERIOSCL THROM VAS, V24, P2257, DOI 10.1161/01.ATV.0000147406.00871.b3
   Newell FS, 2006, FASEB J, V20, P2615, DOI 10.1096/fj.05-5710fje
   Simons PCG, 1999, EUR J EPIDEMIOL, V15, P773, DOI 10.1023/A:1007621514757
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   Valenti L, 2007, AM J GASTROENTEROL, V102, P1251, DOI 10.1111/j.1572-0241.2007.01192.x
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Wassink AMJ, 2008, DIABETES VASC DIS RE, V5, P114, DOI 10.3132/dvdr.2008.019
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6
   Rajapurkar MM, 2012, AM J CARDIOL, V109, P438, DOI 10.1016/j.amjcard.2011.09.032
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Aso Y, 2010, DIABETES RES CLIN PR, V90, P250, DOI 10.1016/j.diabres.2010.09.008
   Faber DR, 2010, ATHEROSCLEROSIS, V212, P274, DOI 10.1016/j.atherosclerosis.2010.04.029
   Kohgo Y, 2002, INT J HEMATOL, V76, P213, DOI 10.1007/BF02982790
   Bertelsen M, 2001, DIABETOLOGIA, V44, P605, DOI 10.1007/s001250051667
   Ku BJ, 2009, DIS MARKERS, V27, P303, DOI 10.3233/DMA-2009-0676
   Zimmermann MB, 2008, BRIT J NUTR, V99, pS2, DOI 10.1017/S000711450800679X
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Rumberger JM, 2004, DIABETES, V53, P2535, DOI 10.2337/diabetes.53.10.2535
   Bakker AHF, 2004, OBES RES, V12, P488, DOI 10.1038/oby.2004.55
   Hajer GR, 2009, ATHEROSCLEROSIS, V202, P216, DOI 10.1016/j.atherosclerosis.2008.04.035
   Hajer GR, 2007, AM HEART J, V154, P750
   Hernandez C, 2005, DIABETIC MED, V22, P97, DOI 10.1111/j.1464-5491.2004.01331.x
   Robinson K, 2011, CRIT CARE, V15, DOI 10.1186/cc10021
   Ross R, 1999, NEW ENGL J MED, V340, P115
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
NR 43
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD DEC
PY 2013
VL 43
IS 12
BP 1240
EP 1249
DI 10.1111/eci.12165
PG 10
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 295FL
UT WOS:000330101900002
PM 24245570
ER

PT J
AU Hyogo, H
   Yamagishi, S
   Maeda, S
   Nakahara, T
   Kimura, Y
   Chayama, K
AF Hyogo, Hideyuki
   Yamagishi, Sho-ichi
   Maeda, Sayaka
   Nakahara, Takashi
   Kimura, Yuki
   Chayama, Kazuaki
TI sRAGE is associated with low waist circumference and Hb levels in NAFLD
SO CENTRAL EUROPEAN JOURNAL OF MEDICINE
LA English
DT Article
DE sRAGE; NAFLD; Hemoglobin; Liver; Obesity
ID GLYCATION END-PRODUCTS; LIVER-DISEASE; SOLUBLE FORM; RECEPTOR;
   COMPLICATIONS; CELLS; AGES
AB Advanced glycation end products (AGEs) and the receptor RAGE interaction is involved in nonalcoholic fatty liver disease (NAFLD). Although exogenously administered soluble RAGE (sRAGE) has been shown to block the harmful effects of AGEs in animal models, there is still controversy about the role of sRAGE in humans. We examined here which anthropometric, metabolic and clinical variables were independent correlates of sRAGE levels in NAFLD patients. The study involved 77 biopsy-proven, unmedictaed NAFLD patients (44 male and 33 female) with a mean age of 43.4 +/- 13.0 years old. We examined which anthropometric, metabolic and clinical variables, including liver steatosis and fibrosis markers, are independently associated with serum levels of sRAGE. Mean serum levels of sRAGE were 710.7 +/- 290.2 pg/mL. Univariate analysis revealed that waist circumference (inversely), hemoglobin (inversely), number of white blood cells (inversely), total-bilirubin (inversely), free fatty acid (inversely), ferritin (inversely), and HbA1c (inversely) were significantly correlated with serum levels of sRAGE. In multiple stepwise regression analysis, waist circumference (p < 0.01, inversely) and hemoglobin (p < 0.01, inversely) were independently associated with serum levels of sRAGE (R-2=0.176). The present study reveals that low serum levels of sRAGE are independently associated with waist circumference and hemoglobin in patients with NAFLD.
C1 [Hyogo, Hideyuki; Nakahara, Takashi; Kimura, Yuki; Chayama, Kazuaki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Hiroshima 7348553, Japan.
   [Yamagishi, Sho-ichi; Maeda, Sayaka] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka 8300011, Japan.
RP Yamagishi, S (reprint author), Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka 8300011, Japan.
EM shoichi@med.kurume-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
FX This work was supported in part by Grants of Collaboration with Venture
   Companies Project from the Ministry of Education, Culture, Sports,
   Science and Technology, Japan (S.Y.). The authors declare that they have
   no conflict of interest related to the publication of this manuscript.
CR Iwamoto K, 2008, J GASTROENTEROL, V43, P298, DOI 10.1007/s00535-007-2152-7
   Yamagishi S, 2005, CURR PHARM DESIGN, V11, P2279, DOI 10.2174/1381612054367300
   WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742
   Kimura Y, 2010, J GASTROENTEROL, V45, P750, DOI 10.1007/s00535-010-0203-y
   Yilmaz Y, 2009, CLIN BIOCHEM, V42, P802, DOI 10.1016/j.clinbiochem.2009.02.003
   Hyogo H, 2008, CURR PHARM DESIGN, V14, P969, DOI 10.2174/138161208784139701
   Yamagishi S, 2006, METABOLISM, V55, P1227, DOI 10.1016/j.metabol.2006.05.007
   Iwata H, 2004, BIOCHEM BIOPH RES CO, V321, P700, DOI 10.1016/j.bbrc.2004.07.026
   Nakamura K, 2009, METABOLISM, V58, P421, DOI 10.1016/j.metabol.2008.10.020
   Semba RD, 2009, AGE AGEING, V38, P283, DOI 10.1093/ageing/afp011
   Unoki H, 2007, DIABETES RES CLIN PR, V76, P236, DOI 10.1016/j.diabres.2006.09.016
   Yamagishi S, 2010, FRONT BIOSCI ELITE E, V2, P1184
NR 12
TC 0
Z9 0
U1 1
U2 6
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 1895-1058
EI 1644-3640
J9 CENT EUR J MED
JI Cent. Eur. J. Med.
PD DEC
PY 2013
VL 8
IS 6
BP 830
EP 834
DI 10.2478/s11536-013-0224-z
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268XE
UT WOS:000328203200022
ER

PT J
AU Lin, C
   Chen, PW
   Chen, WY
   Sun, CC
   Mao, FC
AF Lin, Chang
   Chen, Po-Wen
   Chen, Wen-Ying
   Sun, Chi-Ching
   Mao, Frank Chiahung
TI Glucagon and insulin have opposite effects on tissue chromium
   distribution in an obese mouse model
SO JOURNAL OF DIABETES INVESTIGATION
LA English
DT Article
DE Chromium; Glucagon; Insulin
ID RECEPTOR ANTAGONIST; ESSENTIAL NUTRIENT; URINE; MICE; TRANSFERRIN;
   TRANSPORT; PLASMA; BLOOD; DIET; RATS
AB Aims/IntroductionPrevious studies have suggested that chromium (Cr) is an essential cofactor for normal carbohydrate metabolism and affects insulin sensitivity, especially in rodent models. Several factors, such as insulin challenge, high carbohydrate intake, and response to stress (e.g., in obesity), alter Cr excretion or distribution. Glucagon is known to regulate carbohydrate metabolism and hyperglucagonemia plays a role in the development of hyperglycemia in diabetic subjects.
   Materials and MethodsIn the present study we investigated possible modulation of Cr levels by glucagon using an obese mouse model. Mice were kept on a high-fat diet and then used as an obesity model. These obese mice were injected with one dose of glucagon or insulin and Cr levels in their tissues were determined.
   ResultsIn obese mice, glucagon challenge significantly increased Cr levels in bone but decreased them in the fat and liver. In contrast, insulin challenge significantly decreased Cr levels in bone but increased them in the fat, liver and muscle.
   ConclusionsThe results show that glucagon and insulin have opposite effects on Cr levels in bone, fat, liver, and muscle.
C1 [Lin, Chang; Chen, Wen-Ying; Sun, Chi-Ching; Mao, Frank Chiahung] Natl Chung Hsing Univ, Dept Vet Med, Taichung 40227, Taiwan.
   [Mao, Frank Chiahung] Natl Chung Hsing Univ, Agr Biotechnol Ctr, Taichung 40227, Taiwan.
   [Chen, Po-Wen] St Marys Med Nursing & Management Coll, Dept Nursing, Yilan, Taiwan.
RP Mao, FC (reprint author), Natl Chung Hsing Univ, Dept Vet Med, Taichung 40227, Taiwan.
EM fcmao@nchu.edu.tw
FU National Science Council [NSC100-2320-B-562-001, NSC
   100-2313-B-562-001]; St. Mary's Medicine, Nursing and Management College
   [SMC100-I-14, SMC 102-I-04]; Ministry of Education (Taiwan) under the
   Aim for the Top University (ATU) plan
FX This work was supported, in part, by the National Science Council
   (grants NSC100-2320-B-562-001 and NSC 100-2313-B-562-001), grants from
   St. Mary's Medicine, Nursing and Management College (SMC100-I-14 and SMC
   102-I-04), and the Ministry of Education (Taiwan) under the Aim for the
   Top University (ATU) plan. None of the authors has any conflict of
   interest to declare.
CR Polotsky VY, 2003, J PHYSIOL-LONDON, V552, P253, DOI 10.1113/jphysiol.2003.048173
   Cefalu WT, 2004, DIABETES CARE, V27, P2741, DOI 10.2337/diacare.27.11.2741
   Clodfelder BJ, 2005, J BIOL INORG CHEM, V10, P383, DOI 10.1007/s00775-005-0647-3
   MULLER WA, 1970, NEW ENGL J MED, V283, P109, DOI 10.1056/NEJM197007162830301
   Chen WY, 2009, DIABETES OBES METAB, V11, P293, DOI 10.1111/j.1463-1326.2008.00936.x
   Anderson RA, 1997, REGUL TOXICOL PHARM, V26, pS35, DOI 10.1006/rtph.1997.1136
   Qureshi SA, 2004, DIABETES, V53, P3267, DOI 10.2337/diabetes.53.12.3267
   Chen WY, 2009, LIFE SCI, V84, P606, DOI 10.1016/j.lfs.2009.02.003
   Pechova A, 2007, VET MED-CZECH, V52, P1
   Chen WY, 2010, BIOCHEM BIOPH RES CO, V397, P459, DOI 10.1016/j.bbrc.2010.05.129
   Di Bona KR, 2011, J BIOL INORG CHEM, V16, P381, DOI 10.1007/s00775-010-0734-y
   Chen GL, 2006, MOL ENDOCRINOL, V20, P857, DOI 10.1210/me.2005-0255
   JOHNSON DG, 1982, SCIENCE, V215, P1115, DOI 10.1126/science.6278587
   Vincent JB, 2000, J NUTR, V130, P715
   Clodfelder BJ, 2001, J BIOL INORG CHEM, V6, P608, DOI 10.1007/s007750100238
   REAVEN GM, 1987, J CLIN ENDOCR METAB, V64, P106
   BORGUET F, 1990, BIOL TRACE ELEM RES, V26-7, P449, DOI 10.1007/BF02992700
   MORRIS BW, 1988, CLIN CHEM, V34, P1114
   NISHINA PM, 1990, J LIPID RES, V31, P859
   Sun YJ, 2000, J BIOL INORG CHEM, V5, P129, DOI 10.1007/s007750050016
NR 20
TC 2
Z9 2
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2040-1116
EI 2040-1124
J9 J DIABETES INVEST
JI J. Diabetes Investig.
PD NOV
PY 2013
VL 4
IS 6
BP 528
EP 532
DI 10.1111/jdi.12097
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 258EO
UT WOS:000327442200004
PM 24843705
ER

PT J
AU Dao, MC
   Meydani, SN
AF Dao, Maria Carlota
   Meydani, Simin Nikbin
TI Iron Biology, Immunology, Aging, and Obesity: Four Fields Connected by
   the Small Peptide Hormone Hepcidin
SO ADVANCES IN NUTRITION
LA English
DT Review
ID BODY-MASS INDEX; REACTIVE PROTEIN-LEVELS; CELL-MEDIATED-IMMUNITY; WHITE
   ADIPOSE-TISSUE; WEIGHT-LOSS; INTERFERON-GAMMA; POSTMENOPAUSAL WOMEN;
   CHRONIC DISEASE; OLDER-ADULTS; TRANSFERRIN RECEPTOR
AB Iron status and immune response become impaired in situations that involve chronic inflammation, such as obesity or aging. Little is known, however, about the additional burden that obesity may place on the iron status and immune response in the elderly. This question is relevant given the rising numbers of elderly obese (BMI >30 kg/m(2)) individuals and the high prevalence of iron deficiency worldwide. Iron is necessary for proper function of both the innate and adaptive immune system. Hepcidin, a peptide hormone that regulates cellular iron export, is essential for the maintenance of iron homeostasis. Therefore, since immune cells require iron for proper function hepcidin may also play an important role in immune response. In this review, we summarize the evidence for hepcidin as a link between the fields of gerontology, obesity, iron biology, and immunology. We also identify several gaps in knowledge and unanswered questions pertaining to iron homeostasis and immunity in obese populations. Finally, we review studies that have shown the impact of weight loss, focusing on calorie restriction, iron homeostasis, and immunity. These studies are important both in elucidating mechanistic links between obesity and health impairments and identifying possible approaches to target immune impairment and iron deficiency as comorbidities of obesity.
C1 [Dao, Maria Carlota; Meydani, Simin Nikbin] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Immunol Lab, Boston, MA 02111 USA.
RP Dao, MC (reprint author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr Immunol Lab, Boston, MA 02111 USA.
EM simin.meydani@tufts.edu
FU Stanley N. Gershoff Scholarship; National Institutes of Health T32
   Nutrition and Cardiovascular Disease Training Program; USDA
   [58-1950-0-014]
FX Supported by the Stanley N. Gershoff Scholarship, National Institutes of
   Health T32 Nutrition and Cardiovascular Disease Training Program, and
   USDA contract 58-1950-0-014.
CR Peyssonnaux C, 2006, BLOOD, V107, P3727, DOI 10.1182/blood-2005-06-2259
   Clement K, 2004, FASEB J, V18, P1657, DOI 10.1096/fj.04-2204com
   Villareal DT, 2005, AM J CLIN NUTR, V82, P923
   Moschen AR, 2010, GUT, V59, P1259, DOI 10.1136/gut.2010.214577
   Janssen I, 2007, OBES REV, V8, P41, DOI 10.1111/j.1467-789X.2006.00248.x
   Delaby C, 2005, BLOOD, V106, P3979, DOI 10.1182/blood-2005-06-2398
   Karlsson EA, 2010, EXP BIOL MED, V235, P1412, DOI 10.1258/ebm.2010.010227
   Eisenstaedt R, 2006, BLOOD REV, V20, P213, DOI 10.1016/j.blre.2005.12.002
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Lee P, 2004, P NATL ACAD SCI USA, V101, P9263, DOI 10.1073/pnas.0403108101
   McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401
   Houston DK, 2009, J AM DIET ASSOC, V109, P1886, DOI 10.1016/j.jada.2009.08.014
   Chung B, 2007, J NUTR, V137, P2366
   Goswami T, 2006, J BIOL CHEM, V281, P28494, DOI 10.1074/jbc.C600197200
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572
   Witham MD, 2010, AGE AGEING, V39, P176, DOI 10.1093/ageing/afp251
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Pacifico L, 2006, EUR J ENDOCRINOL, V154, P691, DOI 10.1530/eje.1.02138
   Chaston T, 2008, GUT, V57, DOI 10.1136/gut.2007.131722
   Capel F, 2009, DIABETES, V58, P1558, DOI 10.2337/db09-0033
   Ganz T, 2009, CURR OPIN IMMUNOL, V21, P63, DOI 10.1016/j.coi.2009.01.011
   Skikne BS, 2008, AM J HEMATOL, V83, P872, DOI 10.1002/ajh.21279
   Yang H, 2009, BLOOD, V114, P3803, DOI 10.1182/blood-2009-03-213595
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009
   Eckhardt CL, 2008, EUR J CLIN NUTR, V62, P238, DOI 10.1038/sj.ejcn.1602727
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Drakesmith H, 2008, NAT REV MICROBIOL, V6, P541, DOI 10.1038/nrmicro1930
   Khan FA, 2007, INT J INFECT DIS, V11, P482, DOI 10.1016/j.ijid.2007.04.007
   Ahmed T, 2009, J GERONTOL A-BIOL, V64, P1107, DOI 10.1093/gerona/glp101
   Svec P, 2007, EXP CLIN ENDOCR DIAB, V115, P439, DOI 10.1055/s-2007-960494
   Kopp HP, 2003, ARTERIOSCL THROM VAS, V23, P1042, DOI 10.1161/01.ATV.0000073313.16135.21
   Dao MC, 2013, J PERINATOL, V33, P177, DOI 10.1038/jp.2012.81
   Porto G, 2007, WORLD J GASTROENTERO, V13, P4707
   Malyszko J, 2009, CLIN J AM SOC NEPHRO, V4, P1015, DOI 10.2215/CJN.02690409
   Cancello R, 2005, DIABETES, V54, P2277, DOI 10.2337/diabetes.54.8.2277
   Munoz M, 2009, NUTR HOSP, V24, P640, DOI 10.3305/nh.2009.24.6.4547
   Luciani N, 2011, OBESITY, V19, P1545, DOI 10.1038/oby.2011.12
   Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Roy CN, 2004, NAT GENET, V36, P481, DOI 10.1038/ng1350
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   Theurl I, 2009, BLOOD, V113, P5277, DOI 10.1182/blood-2008-12-195651
   Rocha VZ, 2008, CIRC RES, V103, P467, DOI 10.1161/CIRCRESAHA.108.177105
   Doherty CP, 2007, J NUTR, V137, P1341
   Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028
   Ludwiczek S, 2003, BLOOD, V101, P4148, DOI 10.1182/blood-2002-08-2459
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Ward RJ, 2011, J NEURAL TRANSM, V118, P315, DOI 10.1007/s00702-010-0479-3
   Tanaka S, 2001, CLIN ENDOCRINOL, V54, P347, DOI 10.1046/j.1365-2265.2001.1139/cn2155.x
   Nieman DC, 1999, J AM DIET ASSOC, V99, P294, DOI 10.1016/S0002-8223(99)00077-2
   OMARA FO, 1994, BRIT J NUTR, V72, P899, DOI 10.1079/BJN19940094
   Milner JJ, 2012, P NUTR SOC, V71, P298, DOI 10.1017/S0029665112000158
   SPEAR AT, 1992, J NUTR, V122, P46
   Rimon E, 2002, ARCH INTERN MED, V162, P445, DOI 10.1001/archinte.162.4.445
   WENZEL BJ, 1962, LANCET, V2, P327
   JOYNSON DHM, 1972, LANCET, V2, P1058
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Paradkar PN, 2008, BLOOD, V112, P866, DOI 10.1182/blood-2007-12-126854
   Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood-2007-12-077388
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   Nikolich-Zugich J, 2008, NAT REV IMMUNOL, V8, P512, DOI 10.1038/nri2318
   Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70
   Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102
   Collins HL, 2008, EUR J IMMUNOL, V38, P1803, DOI 10.1002/eji.200838505
   Nairz M, 2008, EUR J IMMUNOL, V38, P1923, DOI 10.1002/eji.200738056
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Tchernof A, 2002, CIRCULATION, V105, P564, DOI 10.1161/hc0502.103331
   Brasse-Lagnel C, 2011, GASTROENTEROLOGY, V140, P1261, DOI 10.1053/j.gastro.2010.12.037
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Patel KV, 2008, SEMIN HEMATOL, V45, P210, DOI 10.1053/j.seminhematol.2008.06.006
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   Argyriadou S, 2001, BMC Fam Pract, V2, P5, DOI 10.1186/1471-2296-2-5
   Bougoulia Maria, 2006, Hormones (Athens), V5, P259
   Dao MC, 2009, SIGHT LIFE MAG, V3, P6
   Dao MC, 2011, FASEB J
   de Monye C, 1999, AIDS, V13, P375, DOI 10.1097/00002030-199902250-00010
   Dharmarajan T S, 2004, J Am Med Dir Assoc, V5, P395, DOI 10.1097/01.JAM.0000144734.84172.89
   DiToro A, 1997, BIOL TRACE ELEM RES, V57, P97
   Frazer DM, 2009, AM J CLIN NUTR, V89, P475, DOI 10.3945/ajcn.2008.27232
   Frazier MD, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-100
   Greenberg Andrew S, 2006, Am J Clin Nutr, V83, p461S
   Klimcakova E, 2010, OBES REV, V11, P446, DOI 10.1111/j.1467-789X.2009.00704.x
   Nikolich-Zugich J, 2005, J EXP MED, V201, P837, DOI 10.1084/jem.20050341
   Oppenheimer S. J, 2001, J NUTR, V131, p633S
   Oppenheimer SJ, 2001, J NUTR, V131, p616S
   Pinto JP, 2010, IMMUNOLOGY, V130, P217, DOI 10.1111/j.1365-2567.2009.03226.x
   Prentice AM, 2007, FOOD NUTR BULL, V28, pS524
   Rogers JT, 1996, BLOOD, V87, P2525
   Ross SD, 2003, CLIN THER, V25, P1786, DOI 10.1016/S0149-2918(03)80170-4
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-37
   Schaible Ulrich E., 2004, Nature Reviews Microbiology, V2, P946, DOI 10.1038/nrmicro1046
   Tussing-Humphreys L, 2011, THESCIENTIFICWORLDJO, V11, P2197, DOI 10.1100/2011/634861
   Tussing-Humphreys L, 2011, J AM DIET ASSOC, V111, P528, DOI 10.1016/j.jada.2011.01.006
   Tussing-Humphreys L, 2011, CYTOKINE, V53, P201, DOI 10.1016/j.cyto.2010.11.008
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   Tussing-Humphreys LM, 2010, INT J OBES LOND, V18, P2010
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   WHO, 2001, IR DEF AN ASS PREV C
   World Health Organization, 1968, WHO TECHN REP SER, V405
   Young B., 2006, WHEATERS FUNCTIONAL
   Yudkin JS, 2003, INT J OBESITY, V27, pS25, DOI 10.1038/sj.ijo.0802496
NR 113
TC 5
Z9 6
U1 4
U2 16
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 2161-8313
EI 2156-5376
J9 ADV NUTR
JI Adv. Nutr.
PD NOV
PY 2013
VL 4
IS 6
BP 602
EP 617
DI 10.3945/an.113.004424
PG 16
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 253TT
UT WOS:000327112900002
PM 24228190
ER

PT J
AU Wierdsma, NJ
   van Bokhorst-de van der Schueren, MAE
   Berkenpas, M
   Mulder, CJJ
   van Bodegraven, AA
AF Wierdsma, Nicolette J.
   van Bokhorst-de van der Schueren, Marian A. E.
   Berkenpas, Marijke
   Mulder, Chris J. J.
   van Bodegraven, Ad A.
TI Vitamin and Mineral Deficiencies Are Highly Prevalent in Newly Diagnosed
   Celiac Disease Patients
SO NUTRIENTS
LA English
DT Article
DE vitamins; minerals; celiac disease; deficiency; adult; Body Mass Index
ID GLUTEN-FREE-DIET; BODY-MASS INDEX; NUTRITIONAL-STATUS; VILLOUS ATROPHY;
   HEALTH; SPRUE; RECOGNITION; ASSOCIATION; ENTEROPATHY; SENSITIVITY
AB Malabsorption, weight loss and vitamin/mineral-deficiencies characterize classical celiac disease (CD). This study aimed to assess the nutritional and vitamin/mineral status of current early diagnosed untreated adult CD-patients in the Netherlands. Newly diagnosed adult CD-patients were included (n = 80, 42.8 +/- 15.1 years) and a comparable sample of 24 healthy Dutch subjects was added to compare vitamin concentrations. Nutritional status and serum concentrations of folic acid, vitamin A, B-6, B-12, and (25-hydroxy) D, zinc, haemoglobin (Hb) and ferritin were determined (before prescribing gluten free diet). Almost all CD-patients (87%) had at least one value below the lower limit of reference. Specifically, for vitamin A, 7.5% of patients showed deficient levels, for vitamin B-6 14.5%, folic acid 20%, and vitamin B-12 19%. Likewise, zinc deficiency was observed in 67% of the CD-patients, 46% had decreased iron storage, and 32% had anaemia. Overall, 17% were malnourished (>10% undesired weight loss), 22% of the women were underweight (Body Mass Index (BMI) < 18.5), and 29% of the patients were overweight (BMI > 25). Vitamin deficiencies were barely seen in healthy controls, with the exception of vitamin B-12. Vitamin/mineral deficiencies were counter-intuitively not associated with a (higher) grade of histological intestinal damage or (impaired) nutritional status. In conclusion, vitamin/mineral deficiencies are still common in newly early diagnosed CD-patients, even though the prevalence of obesity at initial diagnosis is rising. Extensive nutritional assessments seem warranted to guide nutritional advices and follow-up in CD treatment.
C1 [Wierdsma, Nicolette J.; van Bokhorst-de van der Schueren, Marian A. E.; Berkenpas, Marijke] Vrije Univ Amsterdam, Dept Nutr & Dietet, Med Ctr, NL-1007 MB Amsterdam, Netherlands.
   [Mulder, Chris J. J.; van Bodegraven, Ad A.] Vrije Univ Amsterdam, Dept Gastroenterol, Celiac Ctr Amsterdam, Med Ctr, NL-1007 MB Amsterdam, Netherlands.
RP Wierdsma, NJ (reprint author), Vrije Univ Amsterdam, Dept Nutr & Dietet, Med Ctr, POB 7057, NL-1007 MB Amsterdam, Netherlands.
EM N.Wierdsma@vumc.nl; m.vanbokhorst@vumc.nl; m.berkenpas@vumc.nl;
   cjmulder@vumc.nl; v.bodegraven@vumc.nl
FU Dutch Society for Gastroenterology (Gastrostart)
FX This study was funded in part by a grant received from the Dutch Society
   for Gastroenterology (Gastrostart). Gastrostart had no involvement in
   any of the study tasks.
CR Addolorato G, 2003, DIGESTION, V68, P9, DOI 10.1159/000073220
   Harper JW, 2007, AM J HEMATOL, V82, P996, DOI 10.1002/ajh.20996
   Tucker E, 2012, J GASTROINTEST LIVER, V21, P11
   Collin P, 2003, AM J CLIN DERMATOL, V4, P13, DOI 10.2165/00128071-200304010-00002
   Dickey W, 2008, SCAND J GASTROENTERO, V43, P682, DOI 10.1080/00365520701881118
   Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600
   vanOverbeek FM, 1997, EUR J GASTROEN HEPAT, V9, P1097
   KEMPPAINEN T, 1995, SCAND J GASTROENTERO, V30, P575, DOI 10.3109/00365529509089792
   Prasad AS, 2013, ADV NUTR, V4, P176, DOI 10.3945/an.112.003210
   Dickey W, 2002, EUR J GASTROEN HEPAT, V14, P425, DOI 10.1097/00042737-200204000-00016
   Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245
   Ukkola A, 2012, EUR J INTERN MED, V23, P384, DOI 10.1016/j.ejim.2011.12.012
   Dahele A, 2001, AM J GASTROENTEROL, V96, P745, DOI 10.1016/S0002-9270(00)02409-6
   Gujral N, 2012, WORLD J GASTROENTERO, V18, P6036, DOI 10.3748/wjg.v18.i42.6036
   Wahab PJ, 2002, AM J CLIN PATHOL, V118, P459
   Tack GJ, 2010, NAT REV GASTRO HEPAT, V7, P204, DOI 10.1038/nrgastro.2010.23
   Cheng JF, 2010, J CLIN GASTROENTEROL, V44, P267, DOI 10.1097/MCG.0b013e3181b7ed58
   Peters JHC, 2008, ALIMENT PHARM THER, V27, P1300, DOI 10.1111/j.1365-2036.2008.03678.x
   McGough N, 2005, P NUTR SOC, V64, P434, DOI 10.1079/PNS2005461
   Bergamaschi G, 2008, HAEMATOL-HEMATOL J, V93, P1785, DOI 10.3324/haematol.13255
   Tikkakoski S, 2007, SCAND J GASTROENTERO, V42, P60, DOI 10.1080/00365520600789974
   Hadithi M, 2007, AM J GASTROENTEROL, V102, P987, DOI 10.1111/j.1572-0241.2007.01122.x
   MARSH MN, 1992, GASTROENTEROLOGY, V102, P330
   Hallert C, 2002, ALIMENT PHARM THERAP, V16, P1333, DOI 10.1046/j.1365-2036.2002.01283.x
   Kabbani TA, 2012, ALIMENT PHARM THER, V35, P723, DOI 10.1111/j.1365-2036.2012.05001.x
   Alwitry A, 2000, BRIT J OPHTHALMOL, V84, P1079
   Rostami K, 1999, AM J GASTROENTEROL, V94, P888
   Sategna-Guidetti C, 2000, ALIMENT PHARM THERAP, V14, P35, DOI 10.1046/j.1365-2036.2000.00671.x
   Hallert C, 2009, ALIMENT PHARM THER, V29, P811, DOI 10.1111/j.1365-2036.2009.03945.x
   Gdynia HJ, 2008, NEUROMUSCULAR DISORD, V18, P156, DOI 10.1016/j.nmd.2007.09.009
   Zanini B, 2013, CLIN GASTROENTEROL H, V11, P253, DOI 10.1016/j.cgh.2012.09.027
   Al-Toma A, 2006, CLIN GASTROENTEROL H, V4, P315, DOI 10.1016/j.cgh.2005.12.011
   Kemppainen TA, 1998, AM J CLIN NUTR, V67, P482
   PARE P, 1988, J CLIN GASTROENTEROL, V10, P395
   SNODGRASS SR, 1992, MOL NEUROBIOL, V6, P41, DOI 10.1007/BF02935566
   Bai JC, 2013, J CLIN GASTROENTEROL, V47, P121, DOI 10.1097/MCG.0b013e31827a6f83
   CORAZZA GR, 1993, J CLIN GASTROENTEROL, V16, P16, DOI 10.1097/00004836-199301000-00006
   CROFTON RW, 1990, AM J CLIN NUTR, V52, P379
   Deressa Evita, 2006, Tidsskr Nor Laegeforen, V126, P1201
   Evans Kate E, 2009, Practitioner, V253, P19
   Fedosov SN, 2007, BIOCHEMISTRY-US, V46, P6446, DOI 10.1021/bi0620631
   Gupta R, 2009, WORLD J GASTROENTERO, V15, P6028, DOI 10.3748/wjg.15.6028
   HALLERT C, 1981, SCAND J GASTROENTERO, V16, P263
   Henri-Bhargava A, 2008, NEUROLOGY, V71, P860, DOI 10.1212/01.wnl.0000325473.13088.18
   Hopper AD, 2008, CLIN GASTROENTEROL H, V6, P314, DOI 10.1016/j.cgh.2007.12.008
   Hozyasz Kamil K, 2003, Med Wieku Rozwoj, V7, P593
   Lerner A., 2013, CLIN REV ALLERG IMMU, V42, P322
   Loche F, 1997, REV MED INTERNE, V18, P975, DOI 10.1016/S0248-8663(97)80118-X
   Nordstrom F., 2011, BMC GASTROENTEROL, V11, P118, DOI 10.1186/1471-230X-11-118
   REINKEN L, 1976, AM J CLIN NUTR, V29, P750
   REINKEN L, 1978, J NUTR, V108, P1562
   Rostami K, 2003, DIGEST LIVER DIS, V35, P758, DOI 10.1016/S1590-8658(03)00460-2
   Nejad MR, 2009, J GASTROINTEST LIVER, V18, P285
   Sinniah R, 2012, ALIMENT PHARM THER, V35, P1483, DOI 10.1111/j.1365-2036.2012.05113.x
   STENELARSEN G, 1988, SCAND J GASTROENTERO, V23, P1105, DOI 10.3109/00365528809090176
   Suitor CW, 1999, J AM DIET ASSOC, V99, P285, DOI 10.1016/S0002-8223(99)00071-1
   Tanumihardjo SA, 2004, J NUTR, V134, p290S
   Tasanen K, 1997, BRIT J DERMATOL, V136, P624, DOI 10.1111/j.1365-2133.1997.tb02157.x
   Wierdsma N. J., 2013, J HUM NUTR DIET, DOI 10.1111/jhn.12113
NR 59
TC 27
Z9 28
U1 6
U2 28
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2013
VL 5
IS 10
BP 3975
EP 3992
DI 10.3390/nu5103975
PG 18
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 274TA
UT WOS:000328627900011
PM 24084055
ER

PT J
AU Sangani, RG
   Ghio, AJ
AF Sangani, Rahul G.
   Ghio, Andrew J.
TI Iron, Human Growth, and the Global Epidemic of Obesity
SO NUTRIENTS
LA English
DT Review
DE ferritin; iron-deficiency anemia; foods; fortified; oxidative stress
ID PYRIDOXAL ISONICOTINOYL HYDRAZONE; CARDIOVASCULAR RISK-FACTORS;
   INSULIN-RESISTANCE SYNDROME; GESTATIONAL DIABETES-MELLITUS; SOLUBLE
   TRANSFERRIN RECEPTOR; INCREASED SERUM FERRITIN; CORONARY-ARTERY-DISEASE;
   ACUTE ISCHEMIC-STROKE; IOWA WOMENS HEALTH; C-REACTIVE PROTEIN
AB Iron is an essential nutrient utilized in almost every aspect of cell function and its availability has previously limited life. Those same properties which allow iron to function as a catalyst in the reactions of life also present a threat via generation of oxygen-based free radicals. Accordingly; life exists at the interface of iron-deficiency and iron-sufficiency. We propose that: (1) human life is no longer positioned at the limits of iron availability following several decades of fortification and supplementation and there is now an overabundance of the metal among individuals of many societies; (2) this increased iron availability exerts a positive effect on growth by targeting molecules critical in regulating the progression of the cell cycle; there is increased growth in humans provided greater amounts of this metal; and indices of obesity can positively correlate with body stores of iron; and (3) diseases of obesity reflect this over-abundance of iron. Testing potential associations between iron availability and both obesity and obesity-related diseases in populations will be difficult since fortification and supplementation is so extensively practiced.
C1 [Sangani, Rahul G.] Geisinger Med Ctr, Danville, PA 17821 USA.
   [Ghio, Andrew J.] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Chapel Hill, NC 27599 USA.
RP Ghio, AJ (reprint author), US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Chapel Hill, NC 27599 USA.
EM rgs4383@gmail.com; ghio.andy@epa.gov
CR Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   RICHARDSON DR, 1995, BLOOD, V86, P4295
   Goldstein SR, 1998, CARCINOGENESIS, V19, P1445, DOI 10.1093/carcin/19.8.1445
   Alissa EM, 2007, J TRACE ELEM MED BIO, V21, P242, DOI 10.1016/j.jtemb.2007.05.002
   KIECHL S, 1994, ARTERIOSCLER THROMB, V14, P1625
   Huang X, 2003, MUTAT RES-FUND MOL M, V533, P153, DOI 10.1016/j.mrfmmm.2003.08.023
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Jiang R, 2004, AM J CLIN NUTR, V79, P70
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Duffy SJ, 2001, CIRCULATION, V103, P2799
   Kalinowski DS, 2007, J MED CHEM, V50, P6212, DOI 10.1021/jm070839q
   NELSON RL, 1994, J NATL CANCER I, V86, P455, DOI 10.1093/jnci/86.6.455
   Swaminathan S, 2007, DIABETES CARE, V30, P1926, DOI 10.2337/dc06-2625
   Hotz C, 2008, FOOD NUTR BULL, V29, P140
   Selim MH, 2004, AGEING RES REV, V3, P345, DOI 10.1016/j.arr.2004.04.001
   Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71
   ASCHERIO A, 1994, CIRCULATION, V89, P969
   Zacharski LR, 2008, J NATL CANCER I, V100, P996, DOI 10.1093/jnci/djn209
   Lee DH, 2004, DIABETOLOGIA, V47, P185, DOI 10.1007/s00125-003-1307-1
   Liu QJ, 2009, CURR MED CHEM, V16, P113
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   SALONEN JT, 1992, CIRCULATION, V86, P803
   Wang JL, 2005, ASIA PAC J CLIN NUTR, V14, P278
   Stoltzfus RJ, 2007, FOOD NUTR BULL, V28, pS572
   MILMAN N, 1991, DAN MED BULL, V38, P471
   KANESHIGE E, 1981, OBSTET GYNECOL, V57, P238
   Pratico D, 1999, CIRCULATION, V99, P3118
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Halle M, 1997, ATHEROSCLEROSIS, V128, P235, DOI 10.1016/S0021-9150(96)05994-1
   Hallberg L, 2000, AM J CLIN NUTR, V71, P1147
   Ascherio A, 2001, CIRCULATION, V103, P52
   Whittaker P, 2001, J AM COLL NUTR, V20, P247
   Pan Y, 2008, EPIDEMIOL INFECT, V136, P421, DOI 10.1017/S095026880700831X
   LEDERMAN HM, 1984, BLOOD, V64, P748
   Salonen JT, 1998, BRIT MED J, V317, P727
   Chaston TB, 2004, CLIN CANCER RES, V10, P7365, DOI 10.1158/1078-0432.CCR-04-0865
   Allen LH, 1997, NUTR REV, V55, P91
   TERADA N, 1991, J IMMUNOL, V147, P698
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Mainous AG, 2005, ANN FAM MED, V3, P131, DOI 10.1370/afm.283
   Bruner AB, 1996, LANCET, V348, P992, DOI 10.1016/S0140-6736(96)02341-0
   Kato J, 2007, J GASTROENTEROL, V42, P830, DOI 10.1007/s00535-007-2095-z
   Lee HS, 2006, EUR J CLIN NUTR, V60, P1130, DOI 10.1038/sj.ejcn.1602429
   Lee DH, 2006, DIABETES CARE, V29, P1090, DOI 10.2337/DC05-2471
   THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Rajpathak S, 2006, DIABETES CARE, V29, P1370, DOI 10.2337/dc06-0119
   Kiechl S, 1997, CIRCULATION, V96, P3300
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   de Valk B, 1999, ARCH INTERN MED, V159, P1542, DOI 10.1001/archinte.159.14.1542
   Stadler N, 2004, ARTERIOSCL THROM VAS, V24, P949, DOI 10.1161/01.ATV.0000124892.90999.cb
   Wurzelmann JI, 1996, CANCER EPIDEM BIOMAR, V5, P503
   Lao TT, 2001, DIABETIC MED, V18, P218, DOI 10.1046/j.1464-5491.2001.00453.x
   KANNEL WB, 1976, ANN INTERN MED, V85, P447
   Asmis R, 2003, CIRC RES, V92, pE20, DOI 10.1161/01.RES.0000051886.43510.90
   Tuomainen TP, 1997, BRIT MED J, V314, P793
   Fleming DJ, 2002, AM J CLIN NUTR, V76, P1375
   Yu Y, 2007, CELL CYCLE, V6, P1982
   Edgren G, 2008, J NATL CANCER I, V100, P572, DOI 10.1093/jnci/djn084
   AUKETT MA, 1986, ARCH DIS CHILD, V61, P849
   Moyo VM, 2009, ANN HEMATOL, V88, P1131, DOI 10.1007/s00277-009-0718-6
   Mainous AG, 2004, AM J CARDIOL, V93, P559, DOI 10.1016/j.amjcard.2003.11.018
   Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62
   Qi L, 2007, DIABETES CARE, V30, P101, DOI 10.2337/dc06-1686
   Carbonell T, 2007, CURR MED CHEM, V14, P857, DOI 10.2174/092986707780363014
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   TURLIN B, 1995, HEPATOLOGY, V22, P446, DOI 10.1016/0270-9139(95)90564-2
   Toyokuni S, 2009, CANCER SCI, V100, P9, DOI 10.1111/j.1349-7006.2008.01001.x
   Gunnarsson BS, 2005, EUR J CLIN NUTR, V59, P761, DOI 10.1038/dj.ejcn.1602137
   Bandhu R, 2003, Indian J Physiol Pharmacol, V47, P59
   Beasley NMR, 2000, TROP MED INT HEALTH, V5, P794, DOI 10.1046/j.1365-3156.2000.00641.x
   Becker EM, 2003, BRIT J PHARMACOL, V138, P819, DOI 10.1038/sj.bjp.0705089
   Bhasin G, 2002, FOOD CHEM TOXICOL, V40, P1105, DOI 10.1016/S0278-6915(02)00056-X
   Bird CL, 1996, AM J EPIDEMIOL, V144, P34
   Bo S, 2009, AM J OBSTET GYNECOL, V201, p158e1
   Bougle D, 2000, EUR J CLIN NUTR, V54, P764, DOI 10.1038/sj.ejcn.1601087
   Campbell S, 2002, DIGEST DIS, V20, P38, DOI 10.1159/000063166
   Castellanos M, 2002, BRAIN RES, V952, P1, DOI 10.1016/S0006-8993(02)03179-7
   Maberly G., 2008, Morbidity and Mortality Weekly Report, V57, P8
   Chen XH, 2006, DIABETES CARE, V29, P1077, DOI 10.2337/dc06-0164
   Choi JW, 2000, ACTA PAEDIATR, V89, P675, DOI 10.1080/080352500750043981
   CHWANG LC, 1988, AM J CLIN NUTR, V47, P496
   Crichton RR, 2003, CURR MED CHEM, V10, P997, DOI 10.2174/0929867033457566
   CUTLER P, 1989, DIABETES, V38, P1207, DOI 10.2337/diabetes.38.10.1207
   DALLMAN PR, 1989, J NUTR, V119, P1852
   DAVALOS A, 1994, STROKE, V25, P1543
   DESANCTIS V, 1994, CLIN ENDOCRINOL, V40, P791
   Deugnier Y, 2003, ALCOHOL, V30, P145, DOI 10.1016/S0741-8329(03)00129-0
   Fan LJ, 2001, CANCER RES, V61, P1073
   Fernandez-Real JM, 1999, DIABETES CARE, V22, P525, DOI 10.2337/diacare.22.3.525
   FUKUCHI K, 1994, FEBS LETT, V350, P139, DOI 10.1016/0014-5793(94)00755-1
   GEORGIEFF MK, 1995, J PEDIATR-US, V127, P308, DOI 10.1016/S0022-3476(95)70317-9
   German A.J., 2006, J NUTR, V136, P1940
   Gibson S, 2003, PUBLIC HEALTH NUTR, V6, P341, DOI 10.1079/PHN2002442
   Gill DG, 1997, ACTA PAEDIATR, V86, P683, DOI 10.1111/j.1651-2227.1997.tb08568.x
   GRAF E, 1985, CANCER, V56, P717, DOI 10.1002/1097-0142(19850815)56:4<717::AID-CNCR2820560402>3.0.CO;2-4
   Grando-Lemaire V, 1999, J HEPATOL, V31, P508, DOI 10.1016/S0168-8278(99)80044-0
   HANN HWL, 1989, INT J CANCER, V43, P376, DOI 10.1002/ijc.2910430304
   Hay G, 2007, AM J CLIN NUTR, V86, P64
   HERSHKO C, 1994, BAIL CL HAE, V7, P965, DOI 10.1016/S0950-3536(05)80133-7
   HILETI D, 1995, BRIT J HAEMATOL, V89, P181
   Hjalgrim H, 2007, J NATL CANCER I, V99, P1864, DOI 10.1093/jnci/djm248
   HOYES KP, 1992, CANCER RES, V52, P4591
   KALTREIDER DF, 1976, AM J OBSTET GYNECOL, V124, P251
   Keenan J, 1996, IN VITRO CELL DEV-AN, V32, P451
   KELLY AM, 1978, BRIT J OBSTET GYNAEC, V85, P338, DOI 10.1111/j.1471-0528.1978.tb14890.x
   Klipstein-Grobusch K, 1999, AM J EPIDEMIOL, V149, P421
   Lao TT, 1997, DIABETES CARE, V20, P1368, DOI 10.2337/diacare.20.9.1368
   LASKEY J, 1988, EXP CELL RES, V176, P87, DOI 10.1016/0014-4827(88)90123-1
   LATHAM MC, 1990, NUTRITION, V6, P159
   Lee DH, 2005, AM J CLIN NUTR, V81, P787
   LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171
   Linet MS, 1999, AM J EPIDEMIOL, V149, P1010
   Mainous AG, 2004, ANN FAM MED, V2, P139, DOI 10.1370/afm.82
   Mainous AG, 2004, ANN FAM MED, V2, P133, DOI 10.1370/afm.25
   Malaviarachchi D, 2002, CAN J PUBLIC HEALTH, V93, P267
   Mallory MA, 2003, ANN INTERN MED, V139, P532
   Matthews AJ, 1997, J SURG RES, V73, P35, DOI 10.1006/jsre.1997.5180
   Mehta SH, 2004, AM J PHYSIOL-REG I, V286, pR283, DOI 10.1152/ajpregu.00446.2002
   MERK K, 1990, INT J EPIDEMIOL, V19, P505, DOI 10.1093/ije/19.3.505
   Meyers DG, 1997, HEART, V78, P188
   Meyers DG, 1996, CLIN CARDIOL, V19, P925
   Millan M, 2007, STROKE, V38, P90, DOI 10.1161/01.STR.0000251798.25803.e0
   MILMAN N, 1994, EUR J HAEMATOL, V53, P16
   Milman N, 2000, ANN HEMATOL, V79, P612, DOI 10.1007/s002770000209
   Milman N, 2003, EUR J HAEMATOL, V71, P51, DOI 10.1034/j.1600-0609.2003.00090.x
   MILMAN N, 1987, ACTA OBSTET GYN SCAN, V66, P205, DOI 10.3109/00016348709020748
   Milman N, 1992, Arctic Med Res, V51, P10
   Milman N, 2002, EUR J HAEMATOL, V68, P332, DOI 10.1034/j.1600-0609.2002.01668.x
   Morais M B, 1993, Rev Paul Med, V111, P439
   OGUCHI S, 1995, BIOL NEONATE, V67, P330
   Palma S, 2008, J EPIDEMIOL COMMUN H, V62, P120, DOI 10.1136/jech.2006.052985
   PONKA P, 1979, BIOCHIM BIOPHYS ACTA, V586, P278, DOI 10.1016/0304-4165(79)90100-4
   PONKA P, 1979, FEBS LETT, V97, P317, DOI 10.1016/0014-5793(79)80111-8
   Puolakka J, 1980, Acta Obstet Gynecol Scand Suppl, V95, P53
   ROSZKOWS.I, 1966, OBSTET GYNECOL, V28, P820
   RUDLAND PS, 1977, BIOCHEM BIOPH RES CO, V75, P556, DOI 10.1016/0006-291X(77)91508-X
   Sullivan JL, 2009, BBA-GEN SUBJECTS, V1790, P718, DOI 10.1016/j.bbagen.2008.06.005
   Sun XS, 2009, J INORG BIOCHEM, V103, P1074, DOI 10.1016/j.jinorgbio.2009.05.004
   Sung KC, 2007, ARCH MED RES, V38, P121, DOI 10.1016/j.arcmed.2006.08.008
   Tarim E, 2004, INT J GYNECOL OBSTET, V84, P259, DOI 10.1016/S0020-7292(03)00341-2
   Thane CW, 2003, PUBLIC HEALTH NUTR, V6, P485, DOI 10.1079/PHN2002455
   Tuomainen TP, 1998, CIRCULATION, V97, P1461
   van der A DL, 2005, STROKE, V36, P1637, DOI 10.1161/01.STR.0000173172.82880.72
   VANLENTEN BJ, 1995, J CLIN INVEST, V95, P2104, DOI 10.1172/JCI117898
   VanNagell J, 1971, Obstet Gynecol Surv, V26, P551, DOI 10.1097/00006254-197108000-00001
NR 148
TC 2
Z9 2
U1 1
U2 13
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2013
VL 5
IS 10
BP 4231
EP 4249
DI 10.3390/nu5104231
PG 19
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 274TA
UT WOS:000328627900027
PM 24152754
ER

PT J
AU ten Broeke, R
   Bravenboer, B
   Smulders, FJF
AF ten Broeke, R.
   Bravenboer, B.
   Smulders, F. J. F.
TI Iron deficiency before and after bariatric surgery: The need for iron
   supplementation
SO NETHERLANDS JOURNAL OF MEDICINE
LA English
DT Review
DE Anaemia; bariatric surgery; hepcidin; intravenous iron supplementation;
   iron deficiency
ID FERRIC CARBOXYMALTOSE; OBESITY; ANEMIA; INFLAMMATION
AB Hepcidin inhibits the iron export from duodenal cells and liver cells into the plasma and therefore plays a key role in controlling iron homeostasis. In obese patients, elevated cytokine production stimulates hepcidin synthesis, causing iron to be retained as ferritin in e. g. macrophages (functional iron deficiency). In addition, patients often develop iron deficiency after bariatric surgery due to malabsorption, which may cause anaemia and thereby lead to complaints such as fatigue. In these patients, the absorption of iron may be disrupted because the reduction of Fe3+ by gastric acid into Fe2+ (the form that is easily absorbed) is not so effective after stomach reduction. Iron absorption is further reduced after malabsorptive interventions as a result of bypassing the duodenum and the proximal part of the small intestine, where the absorption takes place. Oral iron supplements often have little effect after bariatric surgery. Intravenous supplements of iron can restore the iron status rapidly after bariatric surgery, resulting in fewer symptoms such as fatigue.
C1 [ten Broeke, R.] Catharina Hosp, Dept Clin Pharm, Eindhoven, Netherlands.
   [Bravenboer, B.] Univ Hosp Brussels, Brussels, Belgium.
   [Smulders, F. J. F.] Catharina Hosp, Dept Surg, Eindhoven, Netherlands.
RP ten Broeke, R (reprint author), Catharina Hosp, Dept Clin Pharm, Eindhoven, Netherlands.
EM robert.t.broeke@catharinaziekenhuis.nl
CR Aarts EO, 2012, J OBES, V2012, DOI DOI 10.1155/2012/193705
   Ganz T, 2007, J AM SOC NEPHROL, V18, P394, DOI 10.1681/ASN.2006070802
   Avgerinos DV, 2010, WORLD J GASTROENTERO, V16, P1867, DOI 10.3748/wjg.v16.i15.1867
   Fried M, 2008, OBESITY FACTS, V1, P52, DOI 10.1159/000113937
   Geisser P, 2010, ARZNEIMITTEL-FORSCH, V60, P373, DOI 10.1055/s-0031-1296302
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Funk F, 2010, ARZNEIMITTEL-FORSCH, V60, P345, DOI 10.1055/s-0031-1296299
   von Drygalski A, 2011, SURG OBES RELAT DIS, V7, P151, DOI 10.1016/j.soard.2010.04.008
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Munoz M, 2009, NUTR HOSP, V24, P640, DOI 10.3305/nh.2009.24.6.4547
   Gehrer S, 2010, OBES SURG, V20, P447, DOI 10.1007/s11695-009-0068-4
   Evstatiev R, 2012, GUT, V61, P933, DOI 10.1136/gut.2010.214312
   Damms-Machado A, 2012, OBES SURG, V22, P881, DOI 10.1007/s11695-012-0609-0
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   Daansen PF, 2011, RICHTLIJN MORBIDE OB
   Evstatiev R, 2011, GASTROENTEROLOGY, V141
   Gesquiere I, 2013, OBES SURG
   Lynch S., 2012, RATIONAL SELECTING S
   Moore R Andrew, 2011, BMC Blood Disord, V11, P4, DOI 10.1186/1471-2326-11-4
   PREFER studie, 2012, S DIV GEN INT MED DG
   Schigt A, 2013, NETH J MED, V71, P4
   Tussing-Humphreys L, 2011, CYTOKINE, V53, P201, DOI 10.1016/j.cyto.2010.11.008
   van der Linden MW, 2009, GEBU, V43, P13
   Varma S, 2008, SURG OBES RELAT DIS, V4, P715, DOI [10.1016/j.soard.2008.04.015, 10.1010/j.soard.2008.04.015]
NR 24
TC 1
Z9 1
U1 2
U2 4
PU VAN ZUIDEN COMMUNICATIONS
PI ALPHEN AAN DE RIJN
PA HENRY DUNANTWEG 40A, 2402 NR ALPHEN AAN DE RIJN, NETHERLANDS
SN 0300-2977
EI 1872-9061
J9 NETH J MED
JI Neth. J. Med.
PD OCT
PY 2013
VL 71
IS 8
BP 412
EP 417
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268AL
UT WOS:000328140000004
PM 24127501
ER

PT J
AU Gotardo, EMF
   dos Santos, AN
   Miyashiro, RA
   Gambero, S
   Rocha, T
   Ribeiro, ML
   Gambero, A
AF Ferreira Gotardo, Erica Martins
   dos Santos, Aline Noronha
   Miyashiro, Renan Akira
   Gambero, Sheley
   Rocha, Thalita
   Ribeiro, Marcelo Lima
   Gambero, Alessandra
TI Mice That Are Fed a High-Fat Diet Display Increased Hepcidin Expression
   in Adipose Tissue
SO JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY
LA English
DT Article
DE high-fat diet model; IL-6; iron; adipocyte; macrophage
ID IRON-METABOLISM; OXIDATIVE STRESS; MACROPHAGES; TRANSFERRIN; REDUCTION;
   OVERLOAD; OBESITY; LIVER; GENE
AB Since the discovery that hepcidin is expressed in the adipose tissue of obese subjects, attention has been increasingly focused on alterations in iron homeostasis that are associated with adiposity. We examined the production of hepcidin, the expression of hepcidin-related genes and the iron content of the adipose tissue in obesity using Swiss mice fed a high-fat diet (HFD). The mice were maintained on a control diet or HFD for 12 or 24 wk, and body weight, adiposity and glucose homeostasis were evaluated. The expression of several genes (hepcidin, TfR1, TfR2, DMT1, FT-heavy, ferroportin, IRP-1, IRP-2 and HIF-1) and the protein expression of hepcidin and IL-6 were quantified. The iron level was assessed using a Prussian blue reaction in paraffin-embedded tissue. After 24 wk on the HFD, we observed increases in the levels of hepcidin in the serum and the visceral adipose tissue. The IL-6 levels also increased in the visceral adipose tissue. Adipocytes isolated from the visceral adipose tissues of lean and obese mice expressed hepcidin at comparable levels; however, isolated macrophages from the stromal vascular fraction expressed higher hepcidin levels. Adipose tissues from obese mice displayed increased tfR2 expression and the presence of iron. Our results indicate that IL-6 and iron may affect the signaling pathways governing hepcidin expression. Thus, the mice fed HFD for 24 wk represent a suitable model for the study of obesity-linked hepcidin alterations. In addition, hepcidin may play local roles in controlling iron availability and interfering with inflammation in adipose tissue.
C1 [Ferreira Gotardo, Erica Martins; dos Santos, Aline Noronha; Miyashiro, Renan Akira; Gambero, Sheley; Rocha, Thalita; Ribeiro, Marcelo Lima; Gambero, Alessandra] Univ Sao Francisco, Sch Med, Clin Pharmacol & Gastroenterol Unit, BR-12900000 Braganca Paulista, SP, Brazil.
RP Gambero, A (reprint author), Univ Sao Francisco, Sch Med, Clin Pharmacol & Gastroenterol Unit, BR-12900000 Braganca Paulista, SP, Brazil.
EM alessandra.gambero@usf.edu.br
RI Ribeiro, Marcelo/H-8856-2013; Gambero, Alessandra/G-5792-2013; 
OI Ribeiro, Marcelo/0000-0003-4529-7832; Rocha, Thalita/0000-0002-2731-9586
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX A. N. dos Santos received a fellowship from Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP).
CR Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Tajima S, 2012, AM J PHYSIOL-ENDOC M, V302, pE77, DOI 10.1152/ajpendo.00033.2011
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Ilyin G, 2003, FEBS LETT, V542, P22, DOI 10.1016/S0014-5793(03)00329-6
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196
   Zhong SP, 2012, J BIOL CHEM, V287, P32078, DOI 10.1074/jbc.M112.377358
   Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825
   Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631
   Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018
   Gehrke SG, 2003, BLOOD, V102, P371, DOI 10.1182/blood-2002-11-3610
   Zeyda M, 2007, INT J OBESITY, V31, P1420, DOI 10.1038/sj.ijo.0803632
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Recalcati S, 2012, AUTOIMMUN REV, V11, P883, DOI 10.1016/j.autrev.2012.03.003
   Liu XB, 2005, BLOOD CELL MOL DIS, V35, P47, DOI 10.1016/j.bcmd.2005.04.006
   Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Pini M, 2011, CYTOKINE, V56, P708, DOI 10.1016/j.cyto.2011.09.015
   Sonnweber T, 2012, J NUTR BIOCHEM, V23, P1600, DOI 10.1016/j.jnutbio.2011.10.013
NR 23
TC 2
Z9 2
U1 2
U2 7
PU CENTER ACADEMIC PUBL JAPAN
PI TOKYO
PA 2-4-16 YAYOI, BUNKYO-KU, TOKYO, 113-0032, JAPAN
SN 0301-4800
EI 1881-7742
J9 J NUTR SCI VITAMINOL
JI J. Nutr. Sci. Vitaminol.
PD OCT
PY 2013
VL 59
IS 5
BP 454
EP 461
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 245TT
UT WOS:000326487400011
PM 24418880
ER

PT J
AU Manios, Y
   Moschonis, G
   Chrousos, GP
   Lionis, C
   Mougios, V
   Kantilafti, M
   Tzotzola, V
   Skenderi, KP
   Petridou, A
   Tsalis, G
   Sakellaropoulou, A
   Skouli, G
   Katsarou, C
AF Manios, Y.
   Moschonis, G.
   Chrousos, G. P.
   Lionis, C.
   Mougios, V.
   Kantilafti, M.
   Tzotzola, V.
   Skenderi, K. P.
   Petridou, A.
   Tsalis, G.
   Sakellaropoulou, A.
   Skouli, G.
   Katsarou, C.
TI The double burden of obesity and iron deficiency on children and
   adolescents in Greece: the Healthy Growth Study
SO JOURNAL OF HUMAN NUTRITION AND DIETETICS
LA English
DT Article
DE adolescents; children; diet; inflammation; iron deficiency; obesity
ID INTERNATIONAL SURVEY; BODY-FAT; OVERWEIGHT; INFLAMMATION; HEPCIDIN;
   EXPRESSION; CYTOKINES; ACCURACY
AB Background: Some small cohort studies have noted that obesity co-exists with lower serum iron levels. The present study aimed to examine the association between being overweight and iron deficiency (ID) in a large cohort of Greek children and adolescents.
   Methods: A representative sample of 2492 primary schoolchildren aged 9-13 years old was examined. Anthropometric, biochemical, clinical, dietary intake and physical activity data were collected.
   Results: The prevalence of ID and iron deficiency anaemia (IDA) was higher in obese boys and girls compared to their normal-weight peers (P < 0.05). Serum ferritin was higher in obese compared to normal-weight boys (P = 0.024) and higher in obese compared to normal-weight and overweight girls (P = 0.001). By contrast, a negative association was found between transferrin saturation and adiposity in both boys and girls (P = 0.001 and P = 0.005). Furthermore, obese girls had significantly higher fibre intake than normal-weight girls (P = 0.048) and also overweight and obese boys and girls recorded significantly fewer pedometer steps than their normal-weight peers (P < 0.001). Finally, obesity more than doubled the likelihood of ID in both boys (odds ratio = 2.83; 95% confidence inteval = 1.65-4.85) and girls (odds ratio = 2.03; 95% confidence interval = 1.08-3.81) after controlling for certain lifestyle and clinical indices as potential confounders.
   Conclusions: The present study shows that obese children and adolescents were at greater risk for ID and IDA than their normal-weight peers. Low grade inflammation induced by excessive adiposity may be a reason for the observed low iron levels. This is also strengthened by the elevated serum ferritin levels, comprising an acute phase protein that is plausibly increased in inflammation.
C1 [Manios, Y.; Kantilafti, M.; Tzotzola, V.; Skenderi, K. P.; Katsarou, C.] Harokopio Univ Athens, Dept Nutr & Dietet, Athens 17671, Greece.
   [Moschonis, G.; Chrousos, G. P.] Univ Athens, Sch Med, Dept Pediat 1, Aghia Sophia Childrens Hosp, GR-11527 Athens, Greece.
   [Lionis, C.] Univ Crete, Sch Med, Clin Social & Family Med, Iraklion, Greece.
   [Mougios, V.; Petridou, A.; Tsalis, G.; Sakellaropoulou, A.; Skouli, G.] Aristotle Univ Thessaloniki, Dept Phys Educ & Sport Sci, GR-54006 Thessaloniki, Greece.
RP Manios, Y (reprint author), Harokopio Univ Athens, Dept Nutr & Dietet, 70 El Venizelou Ave, Athens 17671, Greece.
EM manios@hua.gr
FU European Union (European Social Fund - ESF); Greek national funds
   through the Operational Program 'Education and Lifelong Learning' of the
   National Strategic Reference Framework (NSRF) - Research Funding
   Program: Heracletus II
FX The authors declare that there are no conflicts of interest. This
   research has been co-financed by the European Union (European Social
   Fund - ESF) and Greek national funds through the Operational Program
   'Education and Lifelong Learning' of the National Strategic Reference
   Framework (NSRF) - Research Funding Program: Heracletus II. Investing in
   knowledge society through the European Social Fund.
CR Aeberli I., 2009, SWISS MED WEEKLY, V140, P13046
   Wisse BE, 2004, J AM SOC NEPHROL, V15, P2792, DOI 10.1097/01.ASN.0000141966.69934.21
   MENTZER WC, 1973, LANCET, V1, P882
   Moschonis G, 2010, PUBLIC HEALTH NUTR, V13, P1693, DOI 10.1017/S1368980010002247
   Chung B, 2007, J NUTR, V137, P2366
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Taylor RW, 2002, AM J CLIN NUTR, V76, P1416
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Duncan JS, 2009, ASIA PAC J CLIN NUTR, V18, P404
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Subramanian V, 2009, NESTLE NUTR WORKS SE, V63, P151, DOI 10.1159/000209979
   Reilly JJ, 2010, OBES REV, V11, P645, DOI 10.1111/j.1467-789X.2009.00709.x
   Munoz M, 2009, WORLD J GASTROENTERO, V15, P4617, DOI 10.3748/wjg.15.4617
   Cole TJ, 2007, BRIT MED J, V335, P194, DOI 10.1136/bmj.39238.399444.55
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   WENZEL BJ, 1962, LANCET, V2, P327
   Peeling P, 2008, EUR J APPL PHYSIOL, V103, P381, DOI 10.1007/s00421-008-0726-6
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Falzacappa MVV, 2007, BLOOD, V109, P353, DOI 10.1182/blood-2006-07-033969
   McNamara E, 2010, BRIT MED BULL, V95, P121, DOI 10.1093/bmb/ldq016
   Sirard JR, 2001, SPORTS MED, V31, P439, DOI 10.2165/00007256-200131060-00004
   Tanner JM, 1955, GROWTH ADOLESCENCE
   Trichopoulou A, 2004, COMPOSITION TABLES F
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   WHO, 2001, IR DEF AN ASS PREV C
   Zafon C, 2009, OBES REV, V11, P322
NR 26
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-3871
EI 1365-277X
J9 J HUM NUTR DIET
JI J. Hum. Nutr. Diet.
PD OCT
PY 2013
VL 26
IS 5
BP 470
EP 478
DI 10.1111/jhn.12025
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 216YZ
UT WOS:000324324400008
PM 23279448
ER

PT J
AU Nguyen, BKL
   Thi, HL
   Do, VAN
   Thuy, NT
   Huu, CN
   Do, TT
   Deurenberg, P
   Khouw, I
AF Bao Khanh Le Nguyen
   Hop Le Thi
   Van Anh Nguyen Do
   Nga Tran Thuy
   Chinh Nguyen Huu
   Tran Thanh Do
   Deurenberg, Paul
   Khouw, Ilse
TI Double burden of undernutrition and overnutrition in Vietnam in 2011:
   results of the SEANUTS study in 0.5-11-year-old children
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Nutrition surveys; Mineral and vitamin deficiencies; Children and
   infants
ID SCHOOL-AGED CHILDREN; GROWTH; MALNUTRITION; ADOLESCENTS; DEFICIENCY;
   COGNITION; SERUM
AB The Vietnamese South East Asian Nutrition Survey (SEANUTS), a cross-sectional study, was undertaken to assess the nutritional status in a nationally representative sample of children aged 0.5-11.9 years. A multi-stage cluster-randomised sampling method was used to recruit 2872 children. Anthropometric measurements included weight, height, mid-upper arm circumference, and waist and hip circumferences. Blood biochemistry involved analyses of Hb, serum ferritin, and vitamins A and D. Dietary intake was assessed using a 24 h recall questionnaire, and nutrient intakes were compared with the Vietnamese RDA. In children aged <5 years, approximately 14% were stunted, 8.6% underweight and 4.4% thin. A higher prevalence of stunting (15.6 %) and underweight (22.2 %) was observed in school-aged children. Undernutrition was more prevalent in rural areas than in urban areas. In contrast, almost 29% of the urban children were either overweight or obese when compared with 4% of the overweight children and 1.6% of the obese children in rural areas. A higher percentage of children in the age group 0.5-1.9 years and residing in rural areas had low Hb levels than those in the age group 2.0-5.9 years and residing in urban areas. In children aged 6-11 years, a small percentage had low Hb (11-14%) and vitamin A (5-10 %) levels, but almost half the children (48-53%) had vitamin D insufficiency. Food consumption data indicated that the children did not meet the RDA for energy, protein, Fe, vitamin A, vitamin B-1 and vitamin C. Results from the SEANUTS highlight the double burden of malnutrition in Vietnam. Information from the SEANUTS can serve as an input for targeted policy development, planning and development of nutrition programmes.
C1 [Bao Khanh Le Nguyen; Hop Le Thi; Van Anh Nguyen Do; Nga Tran Thuy; Chinh Nguyen Huu; Tran Thanh Do] Natl Inst Nutr NIN, Dept Occupat & Sch Nutr, Hanoi, Vietnam.
   [Deurenberg, Paul] Telega Harbour Marina, Langkawi 07000, Malaysia.
   [Khouw, Ilse] FrieslandCampina, Amersfoort, Netherlands.
RP Nguyen, BKL (reprint author), Natl Inst Nutr NIN, Dept Occupat & Sch Nutr, 48B Tang Bat Ho St, Hanoi, Vietnam.
EM bkhanhnin@gmail.com
FU FrieslandCampina; Royal FrieslandCampina
FX The authors thank the staff of the Department of Occupational and School
   Nutrition, the Department of Nutrition Surveillance and Policy and the
   Department of Community Nutrition, who participated in the data
   collection as members of the field team of the Vietnamese SEANUTS. They
   are also grateful to Dr Nguyen Thi Quynh Nga (Dutch Lady Vietnam) and Dr
   Panam Parikh (FrieslandCampina) for their support in the logistics of
   the project. The study was funded by FrieslandCampina.; This paper was
   published as part of a supplement to the British Journal of Nutrition,
   the publication of which was supported by an unrestricted educational
   grant from Royal FrieslandCampina. The papers included in this
   supplement were invited by the Guest Editor and have undergone the
   standard journal formal review process. They may be cited. The Guest
   Editor appointed to this supplement is Dr Panam Parikh. The Guest Editor
   declares no conflict of interest.
CR Poh BK, 2013, BRIT J NUTR, V110, pS21, DOI 10.1017/S0007114513002092
   [Anonymous], 1998, COUNTR REP IAEA, V2
   Best C, 2010, FOOD NUTR BULL, V31, P400
   Crookston BT, 2011, MATERN CHILD NUTR, V7, P397, DOI 10.1111/j.1740-8709.2010.00255.x
   de Pee S, 2002, J NUTR, V132, p2895S
   Schaafsma A, 2013, BRIT J NUTR, V110, pS2, DOI 10.1017/S0007114513002067
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
   Thurnham DI, 2010, AM J CLIN NUTR, V92, P546, DOI 10.3945/ajcn.2010.29284
   Van Nhien N, 2008, ASIA PAC J CLIN NUTR, V17, P48
   Martins VJB, 2011, INT J ENV RES PUB HE, V8, P1817, DOI 10.3390/ijerph8061817
   Bener A, 2009, Minerva Pediatr, V61, P15
   FAO/WHO Expert Consultation on Human Vitamin and Mineral Requirements, 2004, VIT MIN REQ HUM NUTR
   General Statistics Office, 2011, THEM CARD 2 NUTR WAT
   Grantham-McGregor S, 2007, LANCET, V369, P824, DOI 10.1016/S0140-6736(07)60404-8
   Grantham-McGregor S, 2002, LANCET, V359, P542, DOI 10.1016/S0140-6736(02)07719-X
   Greer FR, 2009, CONSULTANT PEDIAT, V8, P323
   Ha Do TP, 2011, BMC PUBLIC HEALTH, V30, P11
   Hong TK, 2007, INT J PEDIATR OBES, V2, P194, DOI 10.1080/17477160701520165
   Hop LT, 1997, EUR J CLIN NUTR, V51, P164, DOI 10.1038/sj.ejcn.1600377
   Ho-Pham LT, 2010, OSTEOPOROSIS INT, V22, P241
   Huard P, 1938, TRAV I ANAT ECOLE SU, P15
   Hunt JM, 2005, ASIA PAC J CLIN NUTR, V14, P10
   Khan NC, 2007, ASIA PAC J CLIN NUTR, V16, P274
   Khan NC, 2008, ASIA PAC J CLIN N S2, V17, P9
   Khan Nguyen Cong, 2010, Public Health Nutr, V13, P1863, DOI 10.1017/S1368980010000571
   Khan NC, 2006, THESIS WAGENINGEN U
   Khan NC, 2008, ASIA PAC J CLIN NUTR, V17, P116
   Khanh LNB, 2010, 4105BYTQD MIN HLTH
   Khanh LNB, 1992, P SCI WORKSH YEAR 19
   Khoi HH, 2001, NUTR PERIOD TRANSITI
   Khoi HH, 1993, P SCI WORKSH YEAR 19
   Khoi HH, 1994, P SCI WORKSH YEAR 19
   Khor GL, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-95
   Laillou A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034906
   Ministry of Health National Institute of Nutrition, 2012, GEN NUTR SURV 2009 2
   Ministry of Health National Institute of Nutrition, 2012, NAT NUTR STRAT 2011
   National Institute of Nutrition General statistics office, 2006, NUTR STAT CHILDR THE
   National Institute of Nutrition-UNICEF, 2003, VIET NAM 2000 2002 R
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   Strain JJ, 2009, INTRO HUMAN NUTR
   Thang NM, 2003, ASIA PAC J CLIN NUTR, V12, P405
   Trang NH, 2012, BMJ OPEN, V15
   Turpeinen U, 2003, CLIN CHEM, V49, P1521, DOI 10.1373/49.9.1521
   WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA
   WHO/UNICEF/UNU, 2001, WHONHD013 UNICEFUNU
NR 46
TC 1
Z9 1
U1 1
U2 15
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD SEP
PY 2013
VL 110
SU 3
BP S45
EP S56
DI 10.1017/S0007114513002080
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 217WH
UT WOS:000324392800006
ER

PT J
AU Poh, BK
   Ng, BK
   Haslinda, MDS
   Shanita, SN
   Wong, JE
   Budin, SB
   Ruzita, A
   Ng, LO
   Khouw, I
   Norimah, AK
AF Poh, Bee Koon
   Ng, Boon Koon
   Haslinda, Mohd Din Siti
   Shanita, Safii Nik
   Wong, Jyh Eiin
   Budin, Siti Balkis
   Ruzita, Abd Talib
   Ng, Lai Oon
   Khouw, Ilse
   Norimah, A. Karim
TI Nutritional status and dietary intakes of children aged 6 months to 12
   years: findings of the Nutrition Survey of Malaysian Children (SEANUTS
   Malaysia)
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Children's nutritional status; Blood biochemistry; Dietary intakes;
   Double burden of malnutrition
ID VITAMIN-D DEFICIENCY; PRIMARY-SCHOOL CHILDREN; IRON-DEFICIENCY;
   DEVELOPING-COUNTRIES; KUALA-LUMPUR; URBAN AREAS; SCHOOLCHILDREN;
   MALNUTRITION; PREVALENCE; PATTERNS
AB The dual burden of malnutrition reportedly coexists in Malaysia; however, existing data are scarce and do not adequately represent the nutritional status of Malaysian children. The Nutrition Survey of Malaysian Children was carried out with the aim of assessing the nutritional status in a sample of nationally representative population of children aged 6 months to 12 years. A total of 3542 children were recruited using a stratified random sampling method. Anthropometric measurements included weight, height, mid-upper arm circumference, and waist and hip circumferences. Blood biochemical assessment involved analyses of Hb, serum ferritin, and vitamins A and D. Dietary intake was assessed using semi-quantitative FFQ, and nutrient intakes were compared with the Malaysian Recommended Nutrient Intakes (RNI). The prevalence of overweight (9.8 %) and obesity (11.8 %) was higher than that of thinness (5.4 %) and stunting (8.4 %). Only a small proportion of children had low levels of Hb (6.6 %), serum ferritin (4.4 %) and vitamin A (4.4 %), but almost half the children (47.5 %) had vitamin D insufficiency. Dietary intake of the children was not compatible with the recommendations, where more than one-third did not achieve the Malaysian RNI for energy, Ca and vitamin D. The present study revealed that overnutrition was more prevalent than undernutrition. The presence of high prevalence of vitamin D insufficiency and the inadequate intake of Ca and vitamin D are of concern. Hence, strategies for improving the nutritional status of Malaysian children need to consider both sides of malnutrition and also put emphasis on approaches for the prevention of overweight and obesity as well as vitamin D insufficiency.
C1 [Poh, Bee Koon; Ng, Boon Koon; Wong, Jyh Eiin; Ruzita, Abd Talib; Norimah, A. Karim] Univ Kebangsaan Malaysia, Sch Healthcare Sci, Fac Hlth Sci, Nutr Sci Programme, Kuala Lumpur 50300, Malaysia.
   [Haslinda, Mohd Din Siti] Dept Stat, Putrajaya, Malaysia.
   [Shanita, Safii Nik] Univ Kebangsaan Malaysia, Sch Healthcare Sci, Fac Hlth Sci, Dietet Programme, Kuala Lumpur 50300, Malaysia.
   [Budin, Siti Balkis] Univ Kebangsaan Malaysia, Sch Diagnost & Appl Hlth, Fac Hlth Sci, Biomed Sci Programme, Kuala Lumpur 50300, Malaysia.
   [Ng, Lai Oon] Univ Kebangsaan Malaysia, Hlth Psychol Programme, Fac Hlth Sci, Kuala Lumpur 50300, Malaysia.
   [Khouw, Ilse] FrieslandCampina, Amersfoort, Netherlands.
RP Poh, BK (reprint author), Univ Kebangsaan Malaysia, Sch Healthcare Sci, Fac Hlth Sci, Nutr Sci Programme, Kuala Lumpur 50300, Malaysia.
EM pbkoon@fsk.ukm.my
OI Wong, Jyh Eiin/0000-0002-9206-3257
FU Royal FrieslandCampina Innovation (UKM-Dutch Lady Project)
   [NN-072-2009]; Royal FrieslandCampina
FX The study was funded by Royal FrieslandCampina Innovation (UKM-Dutch
   Lady Project Code: NN-072-2009). The authors thank all the subjects and
   their parents for their participation and cooperation during the course
   of the present study. They are grateful to the school principals,
   teachers and administrators for their support and assistance. The
   researchers, data collection team, enumerators and all those involved in
   this project are acknowledged and much appreciated for their effort and
   dedication. They are also grateful to Nguyen Thu Ha and Ang Yeow Nyin
   for their assistance in data analysis and, last but not the least, also
   to Paul Deurenberg for his invaluable advice throughout the project.;
   This paper was published as part of a supplement to the British Journal
   of Nutrition, the publication of which was supported by an unrestricted
   educational grant from Royal FrieslandCampina. The papers included in
   this supplement were invited by the Guest Editor and have undergone the
   standard journal formal review process. They may be cited. The Guest
   Editor appointed to this supplement is Dr Panam Parikh. The Guest Editor
   declares no conflict of interest.
CR Aini UN, 2007, ASIA PAC J CLIN NUTR, V16, P724
   ALBERTSON AM, 1993, ANN NY ACAD SCI, V699, P250, DOI 10.1111/j.1749-6632.1993.tb18855.x
   Al-Mekhlafi HM, 2010, AM J TROP MED HYG, V83, P523, DOI 10.4269/ajtmh.2010.09-0371
   Al-Mekhlafi MH, 2008, T ROY SOC TROP MED H, V102, P1046, DOI 10.1016/j.trstmh.2008.05.012
   Misra M, 2008, PEDIATRICS, V122, P398, DOI 10.1542/peds.2007-1894
   Popkin BM, 2001, ASIA PAC J CLIN NUTR, V10, pS13, DOI 10.1046/j.1440-6047.2001.0100s1S13.x
   Klohe DM, 2005, J AM DIET ASSOC, V105, P727, DOI 10.1016/j.jada.2005.02.008
   Gilbert-Diamond D, 2010, AM J CLIN NUTR, V92, P1446, DOI 10.3945/ajcn.2010.29746
   Mei ZG, 2008, J PEDIATR, V153, P622, DOI 10.1016/j.jpeds.2008.05.048
   Hadi H, 2000, AM J CLIN NUTR, V71, P507
   Sherwood NE, 2008, ISSUES CLIN CHILD PS, P73
   Cooke LJ, 2005, BRIT J NUTR, V93, P741, DOI 10.1079/BJN20051389
   Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x
   Du XQ, 2002, BONE, V30, P521, DOI 10.1016/S8756-3282(01)00698-6
   Schaafsma A, 2013, BRIT J NUTR, V110, pS2, DOI 10.1017/S0007114513002067
   Smith LC, 2005, WORLD DEV, V33, P1285, DOI 10.1016/j.worlddev.2005.03.002
   [Anonymous], 2006, WHO CHILD GROWTH STA
   Marwaha RK, 2005, AM J CLIN NUTR, V82, P477
   Gessner BD, 2003, J PEDIATR-US, V143, P434, DOI 10.1067/S00223476(03)00410-4
   Uauy R, 2008, ANN MED, V40, P11, DOI 10.1080/07853890701704683
   [Anonymous], 2008, WORLDWIDE PREVALENCE
   Bener A, 2009, Minerva Pediatr, V61, P15
   Brady LM, 2000, BRIT J NUTR, V84, P361
   Caballero B, 2002, ANN NUTR METAB, V46, P3, DOI 10.1159/00006640
   Chailurkit LO, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-853
   Chong YM, 2011, 26 SCI C NUTR SOC MA, P91
   Department of Nutrition, 2000, COMP FOODS COMM EAT
   Department of Statistics Malaysia, 2010, POP HOUS LIV QUART M
   Elias SM, 2007, ASIA-PAC J PUBLIC HE, V19, P29
   Fatihah F, 2011, 25 SCI C NUTR SOC MA, P117
   Hackett AF, 2002, PUBLIC HEALTH NUTR, V5, P449, DOI 10.1079/PHN2001266
   Hasan I., 2011, Archives of Applied Science Research, V3, P167
   Hazwanie H, 2011, 26 SCI C NUTR SOC MA, P97
   Ho PS, 2011, 26 SCI C NUTR SOC MA, P98
   HOLICK MF, 1995, AM J CLIN NUTR, V61, p638S
   Holick MF, 2008, AM J CLIN NUTR, V87, p1080S
   Institute for Public Health, 2008, NUTR STAT REP 3 NAT
   Institute for Public Health, 2011, NONC DIS REP NAT HLT, VII
   Irma HA, 2011, 26 SCI C NUTR SOC MA, P98
   Ismail MN, 2009, MASO 2009 SCI C OB O
   Ismail MN, 2003, NUTR STATUS DIETARY
   Khambalia AZ, 2012, FOOD NUTR BULL, V33, P31
   Khor Geok Lin, 2005, Food and Nutrition Bulletin, V26, pS281
   Khor GL, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-95
   Khor GL, 2003, ASIA PAC J CLIN NUTR, V12, P427
   Khor GL, 2002, ASIA PAC J CLIN NUTR, V11, pS377, DOI 10.1046/j.1440-6047.11.s1.9.x
   Khor G L Jr, 2009, Malays J Nutr, V15, P121
   Kim SH, 2005, NUTR RES, V25, P349, DOI 10.1016/j.nutres.2005.01.003
   Kuczmarski RJ, 2000, VITAL HLTH STAT, V11, P1
   Mai TT, 2003, ASIA PAC J CLIN NUTR, V12, P178
   Mansour Maha M H K, 2012, Indian J Endocrinol Metab, V16, P263, DOI 10.4103/2230-8210.93746
   Marfell-Jones M, 2006, INT STANDARDS ANTHRO
   Ministry of Education Malaysia, 2010, MAL ED STAT 2010
   Ministry of Health, 2000, HEM SER RET LEV CHIL
   Muhammad Faiz AA, 2012, ASIAN J CLIN NUTR, P116
   National Coordinating Committee on Food and Nutrition, 2005, REC NUTR INT MAL REP
   Ngui R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001550
   Nhien NV, 2008, ASIA PAC J CLIN NUTR, V17, P48
   Nowak M, 1998, J ADOLESCENT HEALTH, V23, P389, DOI 10.1016/S1054-139X(97)00263-2
   Ooi SY, 2010, 25 SCI C NUTR SOC MA, P132
   Popkin BM, 2011, P NUTR SOC, V70, P82, DOI 10.1017/S0029665110003903
   Puwastien P., 2000, ASEAN FOOD COMPOSITI
   Reinaerts E, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-33
   Rokiah D, 2009, MAL J NUTR, V15, pS2
   Ruzita AT, 2009, NUTR STATUS DIETARY
   Taki M, 2010, ACTA PAEDIATR, V99, P61, DOI 10.1111/j.1651-2227.2009.01498.x
   Tee ES, 1997, NUTR COMPOSITION MAL
   Thane CW, 2002, NUTR RES, V22, P423, DOI 10.1016/S0271-5317(02)00355-X
   Thurlow RA, 2005, AM J CLIN NUTR, V82, P380
   UNICEF, 2010, NUTR COUNTR PROF MAL
   W.H. Organization, 2011, HAEM CONC DIAGN AN A
   WHO, 1996, IND ASS VIT A DEF TH
   WHO, 2010, WHO ANTHR PERS COMP
   WHO, 2011, SER FERR CONC ASS IR
   WHO, 2001, IR DEF AN ASS PREV C
   WHO Anthro Plus for personal computers Manual, 2009, WHO ANTHROPLUS PERS
   World Health Organisation (WHO), 2012, WORLD HLTH STAT 2012
   World Health Organization, 2007, GROWTH CHART CHILDR
   World Health Organization, 1986, SAMPL SIZ DET US MAN
   World Health Organization, 2010, WORLD HLTH STAT 2010
   WORLD HEALTH ORGANIZATION, 2009, GLOB PREV VIT A DEF
   World Health Organization, 1966, MONOGRAPH SERIES, V53
NR 82
TC 14
Z9 14
U1 3
U2 21
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD SEP
PY 2013
VL 110
SU 3
BP S21
EP S35
DI 10.1017/S0007114513002092
PG 15
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 217WH
UT WOS:000324392800004
PM 24016764
ER

PT J
AU Rojroongwasinkul, N
   Kijboonchoo, K
   Wimonpeerapattana, W
   Purttiponthanee, S
   Yamborisut, U
   Boonpraderm, A
   Kunapan, P
   Thasanasuwan, W
   Khouw, I
AF Rojroongwasinkul, Nipa
   Kijboonchoo, Kallaya
   Wimonpeerapattana, Wanphen
   Purttiponthanee, Sasiumphai
   Yamborisut, Uruwan
   Boonpraderm, Atitada
   Kunapan, Petcharat
   Thasanasuwan, Wiyada
   Khouw, Ilse
TI SEANUTS: the nutritional status and dietary intakes of 0.5-12-year-old
   Thai children
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Malnutrition; Obesity; Micronutrient deficiencies; Nutrient intakes;
   Thai children
ID SCHOOL-AGED CHILDREN; VITAMIN-D DEFICIENCY; SOLUBLE TRANSFERRIN
   RECEPTOR; FOOD-CONSUMPTION SURVEY; IRON-DEFICIENCY;
   DEVELOPING-COUNTRIES; INTAKE DISTRIBUTIONS; PRESCHOOL-CHILDREN;
   RISK-FACTORS; OBESITY
AB In the present study, we investigated nutritional status and health-related factors in a multistage cluster sample of 3119 Thai urban and rural children aged 0.5-12.9 years. In a subsample, blood samples were collected for the measurement of Hb, transferrin receptor, vitamin A and vitamin D concentrations. The prevalence of stunting and underweight was higher in rural children than in urban children, whereas the wasting rate was similar in both rural and urban areas. Among children aged 3.0-5.9 years, the prevalence of overweight was significantly higher in urban areas than in rural areas and so was the obesity rate in children aged 6.0-12.9 years. Protein intakes of all age groups were relatively high in both the areas. Intakes of Ca, Fe, Zn and vitamin C were significantly higher in urban areas than in rural areas. The prevalence of anaemia in rural areas was twice as high as that in urban areas, particularly in infants and young children. However, the prevalence of Fe-deficiency anaemia was similar in both urban and rural areas. While the prevalence of vitamin A deficiency (by serum retinol cut-off <0.7 mu mol/l) seemed to be very low, vitamin A insufficiency (by serum retinol cut-off <1.05 mu mol/l) was more prevalent (29.4-31.7%) in both the areas. The prevalence of vitamin D insufficiency ranged between 27.7 and 45.6% among the children. The present study indicates that the double burden of malnutrition is still a major public health problem in Thailand. Further studies need to explore the associated risk factors for these nutrient deficiencies. Effective strategies and actions are needed to tackle the nutritional problems in Thai children.
C1 [Rojroongwasinkul, Nipa; Kijboonchoo, Kallaya; Wimonpeerapattana, Wanphen; Purttiponthanee, Sasiumphai; Yamborisut, Uruwan; Boonpraderm, Atitada; Kunapan, Petcharat; Thasanasuwan, Wiyada] Mahidol Univ, Inst Nutr, Nakhon Pathom 73170, Thailand.
   [Khouw, Ilse] FrieslandCampina, Amersfoort, Netherlands.
RP Kijboonchoo, K (reprint author), Mahidol Univ, Inst Nutr, Nakhon Pathom 73170, Thailand.
EM kallaya.kij@mahidol.ac.th
FU FrieslandCampina, The Netherlands; Royal FrieslandCampina
FX The present study was funded by FrieslandCampina, The Netherlands. The
   authors thank Associate Professor Pattanee Winichagoon, Institute of
   Nutrition, Mahidol University, Thailand, for her technical guidance.
   They also thank Ms Jutatip Wangsai and Ms Chumapa Deesudchit
   (FrieslandCampina Thailand) for their guidance and coordination among
   the Thailand research team and other research teams in the SEANUTS
   project. They are grateful to the participants and their parents for
   their time and cooperation. Last but not the least, they also thank the
   enumerators from the Institute of Nutrition, Mahidol University staff
   and local government staff who helped in logistics arrangement and data
   collection. N. R. is the principal investigator, designed the study,
   drafted the paper and carried out the nutrient data analysis. K. K. and
   U. Y. designed the study and drafted the paper. W. W. carried out the
   statistical analyses. S. P. prepared the result tables and was involved
   in the data collection and project coordination. W. T., A. B. and P. K.
   contributed to the design of the survey and data collection. I. K. was
   involved in data management, study monitoring and paper drafting. All
   authors approved the final version of the manuscript. The results of the
   study will be used by FrieslandCampina, but it had no influence on the
   outcome of the study. The authors declare that they have no conflicts of
   interest.; This paper was published as part of a supplement to the
   British Journal of Nutrition, the publication of which was supported by
   an unrestricted educational grant from Royal FrieslandCampina. The
   papers included in this supplement were invited by the Guest Editor and
   have undergone the standard journal formal review process. They may be
   cited. The Guest Editor appointed to this supplement is Dr Panam Parikh.
   The Guest Editor declares no conflict of interest.
CR Aekplakorn W, 2011, REPORT NATL HLTH EXA
   Rosenbloom A, 2000, PEDIATRICS, V105, P671
   Wang YF, 2001, INT J EPIDEMIOL, V30, P1129, DOI 10.1093/ije/30.5.1129
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Poomthavorn P, 2012, INT J OBESITY, V36, P491, DOI 10.1038/ijo.2011.260
   Oner N, 2004, SWISS MED WKLY, V134, P529
   Greer FR, 2009, PEDIATRICS, V124, P1471, DOI 10.1542/peds.2009-2307
   Best C, 2010, FOOD NUTR BULL, V31, P400
   Cook JD, 2005, BEST PRACT RES CL HA, V18, P319, DOI 10.1016/j.beha.2004.08.022
   Nicklas TA, 2003, J AM COLL NUTR, V22, P340
   Halterman JS, 2001, PEDIATRICS, V107, P1381, DOI 10.1542/peds.107.6.1381
   Thurlow RA, 2006, EUR J CLIN NUTR, V60, P623, DOI 10.1038/sj.ejcn.1602361
   de Pee S, 2002, J NUTR, V132, p2895S
   Hossain P, 2007, NEW ENGL J MED, V356, P213, DOI 10.1056/NEJMp068177
   Barr SI, 2002, J AM DIET ASSOC, V102, P780, DOI 10.1016/S0002-8223(02)90177-X
   Aekplakorn W, 2009, OBES REV, V10, P589, DOI 10.1111/j.1467-789X.2009.00626.x
   Doak CM, 2000, J NUTR, V130, P2965
   de Onis M, 2000, AM J CLIN NUTR, V72, P1032
   Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
   Phiri KS, 2009, J CLIN PATHOL, V62, P1103, DOI 10.1136/jcp.2009.066498
   Hollis BW, 2005, J NUTR, V135, P317
   Kosulwat V, 2002, PUBLIC HEALTH NUTR, V5, P183, DOI 10.1079/PHN2001292
   Vieth R, 2007, AM J CLIN NUTR, V85, P649
   Jitnarin N, 2011, EAT WEIGHT DISORD-ST, V16, pE242
   Renzaho AMN, 2011, NUTRITION, V27, P868, DOI 10.1016/j.nut.2010.12.014
   Sungthong R, 2002, ASIA PAC J CLIN NUTR, V11, P117, DOI 10.1046/j.1440-6047.2002.00272.x
   BLACK AE, 1991, EUR J CLIN NUTR, V45, P583
   [Anonymous], 2006, WHO CHILD GROWTH STA
   Pasricha SR, 2010, J PAEDIATR CHILD H, V46, P497, DOI 10.1111/j.1440-1754.2010.01839.x
   Arabi A, 2010, NAT REV ENDOCRINOL, V6, P550, DOI 10.1038/nrendo.2010.146
   Gonzalez-Gross M, 2012, BRIT J NUTR, V107, P755, DOI 10.1017/S0007114511003527
   Thacher TD, 2006, ANN TROP PAEDIATR, V26, P1, DOI 10.1179/146532806X90556
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Murphy SP, 2002, PUBLIC HEALTH NUTR, V5, P843, DOI 10.1079/PHN2002389
   Cook S, 2003, ARCH PEDIAT ADOL MED, V157, P821, DOI 10.1001/archpedi.157.8.821
   Baillie FJ, 2003, CLIN LAB HAEMATOL, V25, P353, DOI 10.1046/j.0141-9854.2003.00548.x
   Behrman RJ, 2004, GLOBAL CRISES GLOBAL, P363
   Brown KH, 1998, WHONUT981
   Carriquiry AL, 2003, J NUTR, V133, p601S
   Cohen B., 2006, TECHNOL SOC, V28, P63, DOI DOI 10.1016/J.TECHS0C.2005.10.005
   Dodd KW, 1996, 96TR31 CARD IOW STAT
   Dodd KW, 1996, 9 IOW STAT U CTR AGR
   Dwyer J, 2003, J NUTR, V133, p609S
   Florentino FR, 2002, ASIA PACIFIC J CLI S, V11, pS676
   Frongillo EA, 1999, J NUTR, V129, p529S
   Gorstein J, 2007, INDICATORS METHODS C
   Grantham-McGregor S, 2001, J NUTR, V131, p649S
   Hirata M, 1998, Environ Health Prev Med, V3, P67, DOI 10.1007/BF02931786
   Hunt JM, 2005, ASIA PAC J CLIN NUTR, V14, P10
   Jahns L, 2005, PUBLIC HEALTH NUTR, V8, P69, DOI 10.1079/PHN2004671
   Jitnarin N, 2010, NUTRIENTS, V2, P60, DOI [10.3390/nu20100060, 10.3390/nu2010060]
   Jones G. W., 2002, J POPULATION RES, V19, P119, DOI DOI 10.1007/BF03031973
   Kalkwarf HJ, 2003, AM J CLIN NUTR, V77, P257
   Khor GL, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-95
   Khor Geok Lin, 2003, Nepal Med Coll J, V5, P113
   Lohman GT, 1988, ANTHROPOMETRIC STAND
   Martorell R, 1992, HUMAN GROWTH BASIC C, P143
   Ministry of Public Health of Thailand, 2010, THAIL HLTH PROF 2005
   Murphy SP, 2003, J NUTR, V133, p585S
   National Consultative Ethics Committee for Health and Life Sciences, 2004, OR COMPL CHEM HEAD N, P1
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   Otero GA, 2008, CLIN NEUROPHYSIOL, V119, P1739, DOI 10.1016/j.clinph.2008.04.015
   Russia U, 1995, ACTA PEDIAT JPN, V38, P455
   Sakamoto N, 2001, INT J OBESITY, V25, P389, DOI 10.1038/sj.ijo.0801477
   WHO, 1996, IND ASS VIT A DEF TH
   WHO. CDC, 2008, WORLDW PREV AN 1993
   WHO/UNICEF/UNU, 2001, IR DEF AN ASS PREV C
   Winichagoon P, 2002, J NUTR, V132, p862S
   World Health Organization, 1995, WHO TECHN REP SER, V854
NR 69
TC 7
Z9 7
U1 4
U2 16
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD SEP
PY 2013
VL 110
SU 3
BP S36
EP S44
DI 10.1017/S0007114513002110
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 217WH
UT WOS:000324392800005
PM 24016765
ER

PT J
AU Gartner, A
   Berger, J
   Bour, A
   El Ati, J
   Traissac, P
   Landais, E
   El Kabbaj, S
   Delpeuch, F
AF Gartner, Agnes
   Berger, Jacques
   Bour, Abdellatif
   El Ati, Jalila
   Traissac, Pierre
   Landais, Edwige
   El Kabbaj, Saad
   Delpeuch, Francis
TI Assessment of iron deficiency in the context of the obesity epidemic:
   importance of correcting serum ferritin concentrations for inflammation
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID NUTRITION TRANSITION; PREVALENCE; MOROCCO; MECHANISMS; CHILDREN; WOMEN;
   RISK
AB Background: The correction of serum ferritin (SF) concentrations for inflammation because of infectious or parasitic diseases was recently proposed, especially in developing countries, but in many countries, adiposity has become the main cause of inflammation
   Objective: We assessed, overall and by adiposity status, the bias in the estimation of iron deficiency (ID) on the basis of uncorrected SF.
   Design: A cross-sectional survey in 2010 in Rabat-Sale, Morocco, used a random sample of 811 women aged 20-49 y. Adiposity was assessed by body mass index (BMI) (in kg/m(2)) (normal: BMI <25; overweight: BMI >= 25 to <30; obese: BMI >= 30), waist circumference, and body fat. Inflammation was indicated by a C-reactive protein (CRP) concentration >2 mg/L. ID was indicated by an SF concentration <15 mu g/L. The correction factor of SF for inflammation was derived from our sample. Differential effects of SF correction on ID status on the basis of adiposity were assessed by models that included adiposity X correction interactions and accounted for the within-subject correlation.
   Results: The prevalence of overweight was 33.0% and of obesity was 34.0%. Inflammation (42.3%) was strongly linked with adiposity (20.1%, 37.6%, and 68.4% in normal, overweight, and obese subjects, respectively; P < 0.0001). SF increased from a CRP concentration >2 mg/L. The correction factor of SF was 0.65. The prevalence of ID (37.2% compared with 45.2%; difference -8.0%, P < 0.0001) was underestimated by not correcting SF, and the difference increased with adiposity (-2.9%, -8.5%, and -12.4% in normal, overweight, and obese subjects, respectively; P-interaction < 0.0001). Analogous results were observed for other adiposity measures.
   Conclusion: In developing countries where ID remains prevalent but rates of obesity are already high, corrected SF should be used when assessing ID status, even if infectious or parasitic diseases are no longer widespread. This trial was registered at clinicaltrials.gov as NCT01844349.
C1 [Gartner, Agnes; Berger, Jacques; Traissac, Pierre; Landais, Edwige; Delpeuch, Francis] IRD, Unite Mixte Rech NutriPass IRD Montpellier Montpe, Montpellier, France.
   [Bour, Abdellatif] Ibn Tofail Univ, Fac Sci, Kenitra, Morocco.
   [El Ati, Jalila] Natl Inst Nutr & Food Technol, Tunis, Tunisia.
   [El Kabbaj, Saad] Fraternelle de la Gendarmerie Royale, Lab Res & Med Anal, Rabat, Morocco.
RP Gartner, A (reprint author), Nutripass, Inst Dev Res, 911 Ave Agropolis, F-34394 Montpellier 5, France.
EM agnes.gartner@ird.fr
FU Corus programme; French Ministry of Foreign and European Affairs
   [6028-2]
FX Supported by the Corus programme (financed by the French Ministry of
   Foreign and European Affairs) as part of the Understanding the
   Nutritional Transition in the Maghreb to Contribute to the Prevention of
   Obesity and Non-communicable Diseases project (Corns contract 6028-2).
CR Amuna Paul, 2008, Proc Nutr Soc, V67, P82, DOI 10.1017/S0029665108006058
   Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
   Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188
   Popkin BM, 2006, AM J CLIN NUTR, V84, P289
   [Anonymous], 2000, WHO TECH REP SER, V894, pi
   Benjelloun S, 2002, PUBLIC HEALTH NUTR, V5, P135, DOI 10.1079/PHN2001285
   Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x
   Rguibi M, 2007, OBES REV, V8, P11, DOI 10.1111/j.1467-789X.2006.00260.x
   Kelly T, 2008, INT J OBESITY, V32, P1431, DOI 10.1038/ijo.2008.102
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4
   Grant FKE, 2012, J NUTR, V142, P105, DOI 10.3945/jn.111.146316
   Akala FA, 2006, LANCET, V367, P961, DOI 10.1016/S0140-6736(06)68402-X
   Johnson AR, 2012, IMMUNOL REV, V249, P218, DOI 10.1111/j.1600-065X.2012.01151.x
   Suganami T, 2012, ENDOCR J, V59, P849, DOI 10.1507/endocrj.EJ12-0271
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   Gallagher D, 2000, AM J CLIN NUTR, V72, P694
   Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Bruus M, 2004, EPIDATA VERSION 3 1
   El Ati J, 2008, PUBLIC HEALTH NUTR, V11, P729, DOI 10.1017/S1368980007001590
   El Rhazi K, 2011, PUBLIC HEALTH NUTR, V14, P160, DOI 10.1017/S1368980010001825
   Greenberg Andrew S, 2006, Am J Clin Nutr, V83, p461S
   Korn E. L., 1999, ANAL HLTH SURVEYS, P159
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   Musaiger Abdulrahman O, 2012, Int J Gen Med, V5, P199, DOI 10.2147/IJGM.S29663
   Stokes ME, 2000, CATEGORICAL DATA ANA
   Thumham DI, 2010, AM J CLIN NUTR, V92, P546
   WHO, 2011, WHONMHNHDMNM112
   WHO CDC, 2007, ASS IR STAT POP REP
   World Health Organization, 1995, WHO TECHN REP SER, V854
   World Health Organization, 2012, 10 FACTS OB
   World Health Organization, 2011, GLOB STAT REP NONC D
   Worwood M, 2007, ASSESSING IRON STATU, P35
NR 37
TC 11
Z9 12
U1 0
U2 10
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD SEP
PY 2013
VL 98
IS 3
BP 821
EP 826
DI 10.3945/ajcn.112.054551
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 206OT
UT WOS:000323532700025
PM 23885047
ER

PT J
AU Catalan, V
   Gomez-Ambrosi, J
   Rodriguez, A
   Ramirez, B
   Rotellar, F
   Valenti, V
   Silva, C
   Gil, MJ
   Salvador, J
   Fruhbeck, G
AF Catalan, Victoria
   Gomez-Ambrosi, Javier
   Rodriguez, Amaia
   Ramirez, Beatriz
   Rotellar, Fernando
   Valenti, Victor
   Silva, Camilo
   Gil, Maria J.
   Salvador, Javier
   Fruehbeck, Gema
TI Six-transmembrane epithelial antigen of prostate 4 and neutrophil
   gelatinase-associated lipocalin expression in visceral adipose tissue is
   related to iron status and inflammation in human obesity
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Iron homeostasis; Ferritin; Obesity; Inflammation; STAMP2; Lipocalin-2
ID MESSENGER-RNA EXPRESSION; TYPE-2 DIABETES-MELLITUS;
   NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; SERUM FERRITIN; STEAP
   PROTEINS; GASTRIC BYPASS; HOMEOSTASIS; STAMP2; ADULTS
AB Six-transmembrane epithelial antigen of prostate (STEAP)-4 and neutrophil gelatinase-associated lipocalin (NGAL) are novel adipokines related to iron homeostasis with potential roles in insulin resistance and inflammation. The aim of the present work was to evaluate the effect of obesity and iron status on gene expression levels of STEAP-4 and NGAL in visceral adipose tissue (VAT) and its implication in inflammation.
   VAT biopsies obtained from 53 subjects were used in the study. Real-time PCR and Western-blot were performed to quantify the levels of STEAP4 and NGAL in VAT as well as the association with other genes implicated in inflammatory pathways. Circulating ferritin and free iron concentrations were also determined.
   Obese patients exhibited significantly increased STEAP4 and NGAL mRNA expression levels (P < 0.001) compared to lean subjects. Protein expression levels of NGAL (P < 0.05) and STEAP4 were also higher in the visceral fat depot of obese patients, although protein levels of STEAP4 did not reach statistical significance. A negative correlation (P < 0.05) between free iron concentrations and gene expression levels of both STEAP4 and NGAL was found, while circulating ferritin concentrations were positively correlated (P < 0.05) with NGAL mRNA after body fat (BF) adjustment. Furthermore, a significant positive association between STEAP4 and NGAL gene expression levels with inflammatory markers was also detected (P < 0.01).
   These findings represent the first observation that STEAP4 and NGAL mRNA and protein levels in human VAT are related to iron status. Moreover, STEAP4 and NGAL are associated with pro-inflammatory markers suggesting their potential involvement in the low-grade chronic inflammation accompanying obesity.
C1 [Catalan, Victoria; Gomez-Ambrosi, Javier; Rodriguez, Amaia; Ramirez, Beatriz; Fruehbeck, Gema] Univ Navarra Clin, Metab Res Lab, Pamplona, Spain.
   [Catalan, Victoria; Gomez-Ambrosi, Javier; Rodriguez, Amaia; Ramirez, Beatriz; Rotellar, Fernando; Valenti, Victor; Silva, Camilo; Gil, Maria J.; Salvador, Javier; Fruehbeck, Gema] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr, Pamplona 31008, Spain.
   [Rotellar, Fernando; Valenti, Victor] Univ Navarra Clin, Dept Surg, Pamplona, Spain.
   [Silva, Camilo; Salvador, Javier; Fruehbeck, Gema] Univ Navarra Clin, Dept Endocrinol & Nutr, Pamplona 31008, Spain.
   [Gil, Maria J.] Univ Navarra Clin, Dept Biochem, Pamplona, Spain.
RP Catalan, V (reprint author), Univ Navarra Clin, Metab Res Lab, Pamplona, Spain.
EM vcatalan@unav.es
OI Rodriguez, Amaia/0000-0002-2180-461X; Rotellar,
   Fernando/0000-0002-6557-0712
FU Fondo de Investigacion Sanitaria (FIS) from the Spanish Instituto de
   Salud Carlos III [PI09/02330, PI08/1146, PI11/02681]; Department of
   Health of the Gobierno de Navarra of Spain [48/2011, 58/2011]; Plan de
   Investigacion de la Universidad de Navarra (PIUNA)
FX This work was supported by Fondo de Investigacion Sanitaria (FIS)
   PI09/02330, PI08/1146, PI11/02681 from the Spanish Instituto de Salud
   Carlos III, by the Department of Health (48/2011 and 58/2011) of the
   Gobierno de Navarra of Spain and by Plan de Investigacion de la
   Universidad de Navarra (PIUNA) (2009-2011).
CR Gygi SP, 1999, MOL CELL BIOL, V19, P1720
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Catalan V, 2012, HISTOL HISTOPATHOL, V27, P1515
   Catalan V, 2007, OBES SURG, V17, P1464, DOI 10.1007/s11695-008-9424-z
   FINCH C, 1994, BLOOD, V84, P1697
   Bao GH, 2010, NAT CHEM BIOL, V6, P602, DOI [10.1038/nchembio.402, 10.1038/NCHEMBIO.402]
   De Domenico I, 2008, NAT REV MOL CELL BIO, V9, P72, DOI 10.1038/nrm2295
   Swaminathan S, 2007, DIABETES CARE, V30, P1926, DOI 10.2337/dc06-2625
   Guo YF, 2008, ACTA BIOCH BIOPH SIN, V40, P426, DOI 10.1111/j.1745-7270.2008.00418.x
   Theil EC, 2009, CHEM REV, V109, P4568, DOI 10.1021/cr900052g
   Ginde SR, 2005, OBES RES, V13, P1232, DOI 10.1038/oby.2005.146
   Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420
   Wang Y, 2007, CLIN CHEM, V53, P34, DOI 10.1373/clinchem.2006.075614
   ten Freyhaus H, 2012, CELL METAB, V16, P81, DOI 10.1016/j.cmet.2012.05.009
   Gkouvatsos K, 2012, BBA-GEN SUBJECTS, V1820, P188, DOI 10.1016/j.bbagen.2011.10.013
   Wellen KE, 2007, CELL, V129, P537, DOI 10.1016/j.cell.2007.02.049
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Moreno-Navarrete JM, 2011, J CLIN ENDOCR METAB, V96, pE1816, DOI 10.1210/jc.2011-0310
   Ohgami RS, 2006, BLOOD, V108, P1388, DOI 10.1182/blood-2006-02-003681
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348
   Catalan V, 2009, J MOL MED, V87, P803, DOI 10.1007/s00109-009-0486-8
   Gomez-Ambrosi J, 2007, J CLIN ENDOCR METAB, V92, P3719, DOI 10.1210/jc.2007-0349
   Gomez-Ambrosi J, 2012, INT J OBESITY, V36, P286, DOI 10.1038/ijo.2011.100
   Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   Guo H, 2010, DIABETES, V59, P1376, DOI 10.2337/db09-1735
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Torti SV, 2011, CANCER RES, V71, P1511, DOI 10.1158/0008-5472.CAN-10-3614
   Menke A, 2012, NUTR METAB CARDIOVAS, V22, P734, DOI 10.1016/j.numecd.2010.11.011
   Arner P, 2008, J CLIN ENDOCR METAB, V93, P2249, DOI 10.1210/jc.2008-0206
   Fruhbeck G, 2003, DIABETOLOGIA, V46, P143, DOI 10.1007/s00125-003-1053-4
   Gomez-Ambrosi J, 2006, OBES SURG, V16, P262, DOI 10.1381/096089206776116525
   Anderson GJ, 2009, CELL MOL LIFE SCI, V66, P3241, DOI 10.1007/s00018-009-0051-1
   Law IKM, 2010, DIABETES, V59, P872, DOI 10.2337/db09-1541
   Anderson GJ, 2007, BIOMETALS, V20, P665, DOI 10.1007/s10534-006-9030-2
   Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200
   Fruhbeck G, 2001, FASEB J, V15, P1996, DOI 10.1096/fj.00-0829hyp
   Knutson MD, 2007, NUTR REV, V65, P335, DOI [10.1301/nr.2007.jul.335-340, 10.1301/nr.2007.jul.335–340]
   Zhang CM, 2008, ACTA PHARMACOL SIN, V29, P587, DOI 10.1111/j.1745-7254.2008.00793.x
   Catalan V, 2009, EXPERT OPIN PHARMACO, V10, P239, DOI [10.1517/14656560802618811 , 10.1517/14656560802618811]
   Catalan V, 2007, HORM METAB RES, V39, P495, DOI 10.1055/s-2007-982502
   Esteve E, 2009, DIABETES CARE, V32, pS362, DOI 10.2337/dc09-S340
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   Freixenet N, 2009, CLIN CHIM ACTA, V400, P111, DOI 10.1016/j.cca.2008.10.019
   Gomez-Ambrosi J, 1999, CELL MOL LIFE SCI, V55, P992, DOI 10.1007/PL00013203
   Guillen C, 1998, ANN RHEUM DIS, V57, P309, DOI 10.1136/ard.57.5.309
   Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9
   Muruzabal FJ, 2002, GEN COMP ENDOCR, V128, P149, DOI 10.1016/S0016-6480(02)00072-2
NR 50
TC 7
Z9 7
U1 2
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
J9 EUR J NUTR
JI Eur. J. Nutr.
PD SEP
PY 2013
VL 52
IS 6
BP 1587
EP 1595
DI 10.1007/s00394-012-0464-8
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 203IS
UT WOS:000323286300004
PM 23179203
ER

PT J
AU Choi, JS
   Koh, IU
   Lee, HJ
   Kim, WH
   Song, J
AF Choi, Joo Sun
   Koh, In-Uk
   Lee, Hyo Jung
   Kim, Won Ho
   Song, Jihyun
TI Effects of excess dietary iron and fat on glucose and lipid metabolism
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE High-fat diet; Iron overload; Insulin resistance; Hepcidin; Hepatic
   steatosis
ID SERUM FERRITIN CONCENTRATION; INSULIN-RESISTANCE; HEREDITARY
   HEMOCHROMATOSIS; REGULATORY PEPTIDE; OXIDATIVE STRESS; HEPATOMA-CELLS;
   ADIPOSE-TISSUE; HEPCIDIN; LIVER; OBESITY
AB Purpose: Diets rich in fat and energy are associated with metabolic syndrome (MS). Increased body iron stores have been recognized as a feature of MS. High-fat diets (HFs), excess iron loading and MS are closely associated, but the mechanism linking them has not been clearly defined. We investigated the interaction between dietary fat and dietary Fe in the context of glucose and lipid metabolism in the body.
   Methods: C57BL6/J mice were divided into four groups and fed the modified AIN-93G low-fat diet (LF) and HF with adequate or excess Fe for 7 weeks. The Fe contents were increased by adding carbonyl iron (2% of diet weight) (LF+Fe and HF+Fe).
   Results: High iron levels increased blood glucose levels but decreased high-density lipoprotein cholesterol levels. The HF group showed increases in plasma levels of glucose and insulin and insulin resistance. HF+Fe mice showed greater changes. Representative indices of iron status, such hepatic and plasma Fe levels, were not altered further by the HF. However, both the HF and excess iron loading changed the hepatic expression of hepcidin and ferroportin. The LF+Fe, HF and HF+Fe groups showed greater hepatic fat accumulation compared with the LF group. These changes were paralleled by alterations in the levels of enzymes related to hepatic gluconeogenesis and lipid synthesis, which could be due to increases in mitochondrial dysfunction and oxidative stress.
   Conclusions: High-fat diets and iron overload are associated with insulin resistance, modified hepatic lipid and iron metabolism and increased mitochondrial dysfunction and oxidative stress. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Choi, Joo Sun; Koh, In-Uk; Lee, Hyo Jung; Kim, Won Ho; Song, Jihyun] Korea Natl Inst Hlth, Ctr Biomed Sci, Div Metab Dis, Chungbuk Do 363951, South Korea.
RP Song, J (reprint author), Korea Natl Inst Hlth, Ctr Biomed Sci, Div Metab Dis, 187 Osongsaengmyeong 2 Ro, Cheongwon Gun 363951, Chungcheongbuk, South Korea.
EM jhsong10@korea.kr
OI song, jihyun/0000-0003-0420-2374
FU Korea National Institute of Health [4845-302-210-13]
FX This work was supported in part by a Korea National Institute of Health
   intramural research grant (4845-302-210-13). No conflicts of interest
   are declared by the authors.
CR Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Dongiovanni P, 2008, AM J PATHOL, V172, P738, DOI 10.2353/ajpath.2008.070097
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Vaithilingam V, 2010, AM J TRANSPLANT, V10, P1961, DOI 10.1111/j.1600-6143.2010.03209.x
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Chung B, 2007, J NUTR, V137, P2366
   Fernandez-Real JM, 2009, J CLIN ENDOCR METAB, V94, P982, DOI 10.1210/jc.2008-1211
   Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839
   Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]
   Haap M, 2003, ANN INTERN MED, V139, P869
   McClain DA, 2006, DIABETOLOGIA, V49, P1661, DOI 10.1007/s00125-006-0200-0
   Munoz M, 2011, J CLIN PATHOL, V64, P281, DOI 10.1136/jcp.2010.079046
   George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Luan DC, 2008, DIABETES CARE, V31, P285, DOI 10.2337/dc07-0921
   Vecchi C, 2009, SCIENCE, V325, P877, DOI 10.1126/science.1176639
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Urakawa H, 2003, J CLIN ENDOCR METAB, V88, P4673, DOI 10.1210/jc.2003-030202
   Valenti L, 2010, GASTROENTEROLOGY, V138, P905, DOI 10.1053/j.gastro.2009.11.013
   Silva M, 2008, NUTR RES, V28, P391, DOI 10.1016/j.nutres.2008.02.009
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Kulaksiz H, 2008, J ENDOCRINOL, V197, P241, DOI 10.1677/JOE-07-0528
   Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, P1236
   FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
   Hramiak IM, 1997, CLIN INVEST MED, V20, P110
   Jouihan Hani A, 2008, Mol Med, V14, P98, DOI 10.2119/2007-00114.Jouihan
   Kim CH, 2010, METABOLISM, V60, P414
   Kishimoto Miyako, 2010, J Med Invest, V57, P345
   Muoio DM, 2004, SCIENCE, V306, P452
   Weiss G, 2009, BBA-GEN SUBJECTS, V1790, P682, DOI 10.1016/j.bbagen.2008.08.006
NR 41
TC 7
Z9 7
U1 3
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD SEP
PY 2013
VL 24
IS 9
BP 1634
EP 1644
DI 10.1016/j.jnutbio.2013.02.004
PG 11
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 204XP
UT WOS:000323404900011
PM 23643521
ER

PT J
AU Sikorska, K
   Stalke, P
   Romanowski, T
   Rzepko, R
   Bielawski, KP
AF Sikorska, Katarzyna
   Stalke, Piotr
   Romanowski, Tomasz
   Rzepko, Robert
   Bielawski, Krzysztof Piotr
TI Liver steatosis correlates with iron overload but not with HFE gene
   mutations in chronic hepatitis C
SO HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
LA English
DT Article
DE hepatitis C virus; iron overload; fatty liver; hemochromatosis;
   metabolic syndrome X
ID VIRUS CORE PROTEIN; INSULIN-RECEPTOR SUBSTRATE-1; AMINOTRANSFERASE
   LEVELS; CYTOKINE SIGNALING-3; OXIDATIVE STRESS; RESISTANCE; DISEASE;
   HEMOCHROMATOSIS; INFECTION; GENOTYPES
AB BACKGROUND: Liver steatosis and iron overload, which are frequently observed in chronic hepatitis C (CHC), may contribute to the progression of liver injury. This study aimed to evaluate the correlation between liver steatosis and iron overload in Polish patients with CHC compared to nonalcoholic fatty liver disease (NAFLD) and HFE-hereditary hemochromatosis (HH) patients.
   METHODS: A total of 191 CHC patients were compared with 67 NAFLD and 21 HH patients. Liver function tests, serum markers of iron metabolism, cholesterol and triglycerides were assayed. The inflammatory activity, fibrosis, iron deposits and steatosis stages were assessed in liver specimens. HFE gene polymorphisms were investigated by PCR-RFLP.
   RESULTS: Liver steatosis was associated with obesity and diabetes mellitus. This disease was confirmed in 76/174 (44%) CHC patients, most of whom were infected with genotype 1. The average grade of steatosis was higher in NAFLD patients. CHC patients had significantly higher iron concentrations and transferrin saturations than NAFLD patients. Compared with CHC patients, HH patients had higher values of serum iron parameters and more intensive hepatocyte iron deposits without differences in the prevalence and intensity of liver steatosis. In the CHC group, lipids accumulation in hepatocytes was significantly associated with the presence of serum markers of iron overload. No correlation between the HFE gene polymorphism and liver steatosis in CHC patients was found.
   CONCLUSIONS: Liver steatosis was diagnosed in nearly half of CHC patients, most of whom were infected with genotype 1. The intensity of steatosis was lower in CHC patients than that in NAFLD patients because of a less frequent diagnosis of metabolic syndrome. Only in CHC patients were biochemical markers of iron accumulation positively correlated with liver steatosis; these findings were independent of HFE gene mutations.
C1 [Sikorska, Katarzyna; Stalke, Piotr] Med Univ Gdansk, Dept Infect Dis, PL-80214 Gdansk, Poland.
   [Romanowski, Tomasz; Bielawski, Krzysztof Piotr] Univ Gdansk, Intercollegiate Fac Biotechnol, Dept Biotechnol, PL-80822 Gdansk, Poland.
   [Romanowski, Tomasz; Bielawski, Krzysztof Piotr] Med Univ Gdansk, PL-80822 Gdansk, Poland.
   [Rzepko, Robert] Med Univ Gdansk, Dept Pathol, PL-80952 Gdansk, Poland.
RP Bielawski, KP (reprint author), Univ Gdansk, Intercollegiate Fac Biotechnol, Dept Biotechnol, Kladki 24, PL-80822 Gdansk, Poland.
EM bielawski@biotech.ug.gda.pl
RI Bielawski, Krzysztof/D-8711-2011; 
OI Stalke, Piotr/0000-0003-2747-6706
FU Medical University of Gdansk [W-175]
FX The study was supported by a grant from Medical University of Gdansk
   (W-175).
CR Miura K, 2008, HEPATOLOGY, V48, P1420, DOI 10.1002/hep.22486
   Ohata K, 2003, CANCER, V97, P3036, DOI 10.1002/cncr.11427
   Koike K, 2005, J GASTROENTEROL, V40, P329, DOI 10.1007/s00535-005-1586-z
   Sebastiani G, 2006, J VIRAL HEPATITIS, V13, P199, DOI 10.1111/j.1365-2893.2005.00662.x
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com
   Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4
   Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1016/S0002-9270(03)00265-X
   Sanyal AJ, 2003, AM J GASTROENTEROL, V98, P2064, DOI 10.1016/S0002-9270(03)00551-3
   Kawaguchi T, 2004, AM J PATHOL, V165, P1499, DOI 10.1016/S0002-9440(10)63408-6
   Cassiman D, 2002, J HEPATOL, V37, P527, DOI 10.1016/S0168-8278(02)00263-5
   Chlabicz S, 2008, J CLIN VIROL, V42, P156, DOI 10.1016/j.jcv.2008.02.001
   Ko C, 2007, LIVER INT, V27, P1394, DOI 10.1111/j.1478-3231.2007.01596.x
   Moirand R, 1997, LANCET, V349, P95, DOI 10.1016/S0140-6736(96)06034-5
   Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
   Pazienza V, 2007, HEPATOLOGY, V45, P1164, DOI 10.1002/hep.21634
   Valenti L, 2007, HAEMATOL-HEMATOL J, V92, P1037, DOI 10.3324/haematol.11281
   Moriya K, 1997, J GEN VIROL, V78, P1527
   Pietrangelo A, 1996, SEMIN LIVER DIS, V16, P13, DOI 10.1055/s-2007-1007215
   Persico M, 2007, HEPATOLOGY, V46, P1009, DOI 10.1002/hep.21782
   Lonardo A, 2004, GASTROENTEROLOGY, V126, P586, DOI 10.1053/j.gastro.2003.11.020
   Rubbia-Brandt L, 2004, GUT, V53, P406, DOI 10.1136/gut.2003.018770
   DAVIS RJ, 1986, J BIOL CHEM, V261, P8708
   Brissot P, 2002, ADV EXP MED BIOL, V509, P45
   Zeuzem S, 2009, J VIRAL HEPATITIS, V16, P75, DOI 10.1111/j.1365-2893.2008.01012.x
   Harrison SA, 2008, CLIN GASTROENTEROL H, V6, P864, DOI 10.1016/j.cgh.2008.03.024
   Nishina S, 2010, LIVER INT, V30, P683, DOI 10.1111/j.1478-3231.2010.02210.x
   Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432
   Isom HC, 2009, BBA-GEN SUBJECTS, V1790, P650, DOI 10.1016/j.bbagen.2009.04.009
   Tung BY, 2003, GASTROENTEROLOGY, V124, P318, DOI 10.1053/gast.2003.50046
   Moriishi K, 2007, P NATL ACAD SCI USA, V104, P1661, DOI 10.1073/pnas.0607312104
   Nishina S, 2008, GASTROENTEROLOGY, V134, P226, DOI 10.1053/j.gastro.2007.10.011
   Bassett ML, 2007, J GASTROEN HEPATOL, V22, P1703, DOI 10.1111/j.1440-1746.2007.05106.x
   Brojer Ewa, 2008, Przegl Epidemiol, V62, P163
   Clouston AD, 2002, BEST PRACT RES CL GA, V16, P767, DOI 10.1053/bega.2002.0329
   Crichton R., 2009, IRON METABOLISM MOL
   DEUGNIER YM, 1992, GASTROENTEROLOGY, V102, P2050
   European Association for the Study of the Liver, 2010, J HEPATOL, V53, P3, DOI DOI 10.1016/J.JHEP.2010.03.001
   Hubscher SG, 2003, J HEPATOL, V38, P521, DOI 10.1016/S0168-8278(03)00078-3
   LESAGE GD, 1983, GASTROENTEROLOGY, V84, P1471
   Machado MV, 2009, ANN HEPATOL, V8, pS67
   MENGHINI G, 1957, Sci Med Ital, V6, P212
   Sikorska K, 2008, HEPATO-GASTROENTEROL, V55, P1024
   Sikorska K, 2010, MED SCI MONITOR, V16, pCR137
   Sikorska K, 2005, INT J MOL MED, V16, P1151
   Yano M, 2004, J GASTROENTEROL, V39, P570, DOI 10.1007/s00535-003-1344-z
NR 46
TC 0
Z9 0
U1 1
U2 5
PU ZHEJIANG UNIV SCH MEDICINE
PI HANGZHOU
PA FIRST AFFILIATED HOSPITAL, 79 QINGCHUN ROAD, HANGZHOU, 310003, PEOPLES R
   CHINA
SN 1499-3872
J9 HEPATOB PANCREAT DIS
JI Hepatob. Pancreatic. Dis. Int.
PD AUG 15
PY 2013
VL 12
IS 4
BP 377
EP 384
DI 10.1016/S1499-3872(13)60059-4
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 198MA
UT WOS:000322925800005
PM 23924495
ER

PT J
AU McLimore, HM
   Phillips, AK
   Blohowiak, SE
   Pham, DQD
   Coe, CL
   Fischer, BA
   Kling, PJ
AF McLimore, Heather M.
   Phillips, Alyssa K.
   Blohowiak, Sharon E.
   Pham, Daphne Q-D.
   Coe, Christopher L.
   Fischer, Beth A.
   Kling, Pamela J.
TI Impact of Multiple Prenatal Risk Factors on Newborn Iron Status at
   Delivery
SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
LA English
DT Article
DE diabetes; minority; obesity; ferritin; iron deficiency
ID ZINC PROTOPORPHYRIN/HEME; TRANSFERRIN RECEPTOR; DEFICIENCY ANEMIA; CORD
   BLOOD; AGE; ASSOCIATIONS; FERRITIN; CHILDREN; INFANTS; BIRTH
AB Background: Maternal anemia and several complications of pregnancy can affect fetal iron acquisition.Aim: Because it is unknown whether the effects of demographic and maternal risk factors (RF) are summative, we examined cord iron status in newborns with multiple RF for acquiring iron deficiency.Methods: Cord blood indices from healthy control newborns with and without RF for newborn or infant iron deficiency were studied.Results: Newborns with greater RF had poorer erythrocyte and storage iron status. Poorest status was seen if mothers with comorbid obesity and diabetes delivered large-for-gestation newborns. Findings highlight the importance of identifying RF.
C1 [McLimore, Heather M.; Phillips, Alyssa K.; Blohowiak, Sharon E.; Kling, Pamela J.] Univ Wisconsin, UW Madison Sch Med & Publ Hlth, Madison, WI 53715 USA.
   [Phillips, Alyssa K.; Blohowiak, Sharon E.; Kling, Pamela J.] Univ Wisconsin, Dept Pediat, Meriter Hosp, Madison, WI 53715 USA.
   [Coe, Christopher L.] Univ Wisconsin, Harlow Ctr Biol Psychol, Madison, WI 53715 USA.
   [Pham, Daphne Q-D.] Univ Wisconsin Parkside, Dept Biol Sci, Kenosha, WI USA.
   [Fischer, Beth A.] Zane State Coll Inst Res, Zanesville, OH USA.
RP Kling, PJ (reprint author), Univ Wisconsin, Dept Pediat, Meriter Hosp, 202 South Pk St, Madison, WI 53715 USA.
EM pkling@pediatrics.wisc.edu
FU NIH UW CTSA Program [1 ULRR026011]; NIH [T32HD048302]; University of
   Wisconsin Shapiro Research Program; University of Wisconsin
   Cardiovascular Research Center; Meriter Foundation; Wisconsin
   Partnership Collaborative Health Sciences Program Grant; Thrasher
   Research Fund; UW Graduate School Competition; Gates Foundation
   [OPP1046203];  [HD057064];  [HD38305]
FX Supported by NIH 1 ULRR026011 UW CTSA Program, NIH T32HD048302 Health
   Disparities Research Scholar (B. A. F.), University of Wisconsin Shapiro
   Research Program (H. M. M.), University of Wisconsin Cardiovascular
   Research Center (H. M. M.), Meriter Foundation (P.J.K.), Wisconsin
   Partnership Collaborative Health Sciences Program Grant (P.J.K., C. L.
   C., D. Q. D. P), Thrasher Research Fund (P.J.K.), UW Graduate School
   Competition (P.J.K.), Salary support (C. L. C.) HD057064, HD38305, Gates
   Foundation OPP1046203).
CR Lozoff B, 2006, AM J CLIN NUTR, V84, P1412
   Baker RD, 2010, PEDIATRICS, V126, P1040, DOI 10.1542/peds.2010-2576
   Schmatz M, 2010, J PERINATOL, V30, P441, DOI 10.1038/jp.2009.182
   Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572
   Ziegler EE, 2009, AM J CLIN NUTR, V89, P525, DOI 10.3945/ajcn.2008.26591
   ARBUCKLE TE, 1993, OBSTET GYNECOL, V81, P39
   Siddappa AM, 2007, NEONATOLOGY, V92, P73, DOI 10.1159/000100805
   Baumann-Blackmore NL, 2008, J PEDIATR-US, V153, P133, DOI 10.1016/j.jpeds.2008.01.032
   Blohowiak SE, 2008, PEDIATR RES, V64, P63, DOI 10.1203/PDR.0b013e31817328e5
   Fomon S, 1993, IRON NUTR NORMAL INF, P239
   Gunnarsson BS, 2004, EUR J CLIN NUTR, V58, P901, DOI 10.1038/sj.ejcn.1601910
   Hay G, 2007, AM J CLIN NUTR, V86, P64
   Hegde NV, 2011, AM J PHYSIOL-GASTR L, V300, pG470, DOI 10.1152/ajpgi.00463.2010
   Kleven KJ, 2007, NEONATOLOGY, V92, P91, DOI 10.1159/000100807
   Lesser KB, 2006, J PERINATOL, V26, P671, DOI 10.1038/sj.jp.7211600
   Lott DG, 2005, PEDIATRICS, V116, P414, DOI 10.1542/peds.2004-1601
   Lozoff Betsy, 2006, Semin Pediatr Neurol, V13, P158, DOI 10.1016/j.spen.2006.08.004
   McClung JP, 2006, J AM COLL NUTR, V25, P64
   PETRY CD, 1994, AM J PHYSIOL-ENDOC M, V267, pE507
NR 19
TC 7
Z9 7
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1077-4114
J9 J PEDIAT HEMATOL ONC
JI J. Pediatr. Hematol. Oncol.
PD AUG
PY 2013
VL 35
IS 6
BP 473
EP 477
DI 10.1097/MPH.0b013e3182707f2e
PG 5
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 202QE
UT WOS:000323232400022
PM 23042017
ER

PT J
AU Tomedi, LE
   Chang, CCH
   Newby, PK
   Evans, RW
   Luther, JF
   Wisner, KL
   Bodnar, LM
AF Tomedi, Laura E.
   Chang, Chung-Chou H.
   Newby, P. K.
   Evans, Rhobert W.
   Luther, James F.
   Wisner, Katherine L.
   Bodnar, Lisa M.
TI Pre-pregnancy obesity and maternal nutritional biomarker status during
   pregnancy: a factor analysis
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Nutrition; Pregnancy; Obesity; Factor analysis
ID BODY-MASS INDEX; FATTY-ACIDS; SERUM CONCENTRATIONS; MAJOR DEPRESSION;
   BETA-CAROTENE; OUTCOMES; RISK; ASSOCIATIONS; IMPACT; DIET
AB Objective: Pre-pregnancy obesity has been associated with adverse birth outcomes. Poor essential fatty acid (EFA) and micronutrient status during pregnancy may contribute to these associations. We assessed the associations between pre-pregnancy BMI and nutritional patterns of maternal micronutrient and EFA status during mid-pregnancy.
   Design: A cross-sectional analysis from a prospective cohort study. Women provided non-fasting blood samples at <= 20 weeks' gestation that were assayed for red cell EFA; plasma folate, homocysteine and ascorbic acid; and serum retinol, 25-hydroxyvitamin D, alpha-tocopherol, soluble transferrin receptors and carotenoids. These nutritional biomarkers were employed in a factor analysis and three patterns were derived: EFA, Micronutrients and Carotenoids.
   Setting: The Antidepressant Use During Pregnancy Study, Pittsburgh, PA, USA.
   Subjects: Pregnant women (n 129).
   Results: After adjustment for parity, race/ethnicity and age, obese pregnant women were 3.0 (95% CI 1.1, 7.7) times more likely to be in the lowest tertile of the EFA pattern and 4.5 (95% CI 1.7, 12.3) times more likely to be in the lowest tertile of the Carotenoid pattern compared with their lean counterparts. We found no association between pre-pregnancy obesity and the Micronutrient pattern after confounder adjustment.
   Conclusions: Our results suggest that obese pregnant women have diminished EFA and carotenoid concentrations.
C1 [Tomedi, Laura E.; Evans, Rhobert W.; Luther, James F.; Wisner, Katherine L.; Bodnar, Lisa M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Chang, Chung-Chou H.] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15261 USA.
   [Newby, P. K.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA.
   [Newby, P. K.] Boston Univ, Sch Med, Program Med Nutr Sci, Boston, MA 02118 USA.
   [Newby, P. K.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Newby, P. K.] Boston Univ, Metropolitan Coll, Program Gastron Culinary Arts & Wine Studies, Boston, MA 02215 USA.
   [Wisner, Katherine L.; Bodnar, Lisa M.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA.
   [Wisner, Katherine L.; Bodnar, Lisa M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA.
RP Bodnar, LM (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 130 DeSoto St, Pittsburgh, PA 15261 USA.
EM bodnar@edc.pitt.edu
FU National Institutes of Health [K01 MH074092, R01 MH060335, R24
   HL076858]; Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (Reproductive, Perinatal and Pediatric Epidemiology)
   [HD 055 162-03 NIH NRSA T32]
FX Sources of funding: Support for this project came from the National
   Institutes of Health (grants K01 MH074092, R01 MH060335 and R24
   HL076858) and the Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (Reproductive, Perinatal and Pediatric
   Epidemiology Grant HD 055 162-03 NIH NRSA T32). Conflicts of interest:
   The authors have no conflicts of interest to declare. Ethics: The study
   was approved by the University of Pittsburgh Institutional Review Board.
   Authors' contributions: L.E.T. analysed the data and wrote the
   manuscript; C.-C.H.C. provided valuable biostatistical assistance;
   P.K.N. provided significant assistance with pattern analysis; R.W.E.
   provided technical assistance for the biomarker assays and critically
   reviewed the manuscript; J.F.L. performed the principal component
   analysis; K.L.W. designed the research and provided the data; L.M.B.
   provided significant analytical assistance and critically edited the
   manuscript; all authors read and approved the final manuscript.
   Acknowledgements: The authors thank Ms Brandi Duffy and Ms Rona de la
   Vega for expert chemical analysis.
CR Wallstrom P, 2001, AM J CLIN NUTR, V73, P777
   Sands SA, 2005, LIPIDS, V40, P343, DOI 10.1007/s11745-006-1392-2
   Cedergren MI, 2004, OBSTET GYNECOL, V103, P219, DOI 10.1097/01.AOG.0000107291.46159.00
   Wisner KL, 2009, AM J PSYCHIAT, V166, P557, DOI 10.1176/appi.ajp.2008.08081170
   Micallef M, 2009, BRIT J NUTR, V102, P1370, DOI 10.1017/S0007114509382173
   Han YS, 2011, INT J OBESITY, V35, P570, DOI 10.1038/ijo.2010.162
   Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302
   Karlsson M, 2006, OBESITY, V14, P1931, DOI 10.1038/oby.2006.225
   Chu SY, 2007, DIABETES CARE, V30, P2070, DOI 10.2337/dc06-2559a
   Galan P, 2005, EUR J CLIN NUTR, V59, P1181, DOI 10.1038/sj.ejcn.1602230
   Kim SY, 2007, OBESITY, V15, P986, DOI 10.1038/oby.2007.621
   Kishino T, 2008, CLIN CHIM ACTA, V398, P57, DOI 10.1016/j.cca.2008.08.010
   Aasheim ET, 2008, AM J CLIN NUTR, V87, P362
   Laraia BA, 2007, PUBLIC HEALTH NUTR, V10, P920, DOI 10.1017/S1368980007657991
   Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1
   Chai WW, 2010, NUTR RES, V30, P227, DOI 10.1016/j.nutres.2010.04.006
   Bodnar LM, 2010, OBESITY, V18, P2184, DOI 10.1038/oby.2010.25
   Bodnar LM, 2007, J NUTR, V137, P2437
   Andersen LF, 2006, BRIT J NUTR, V95, P358, DOI 10.1079/BJN20051638
   Bodnar LM, 2012, PUBLIC HEALTH NUTR, V15, P1078, DOI 10.1017/S1368980011002904
   First M. B., 1997, STRUCTURED CLIN INTE
   Hauger MS, 2008, ACTA OBSTET GYN SCAN, V87, P953, DOI 10.1080/00016340802303349
   Institute of Medicine, 1990, NUTR PREGN 1
   Kimmons Joel E, 2006, MedGenMed, V8, P59
   National Institutes of Health, 1998, OBES RES S2, V6, p51S
   Tomedi LE, 2012, SUBST USE MISUSE, V47, P286, DOI 10.3109/10826084.2011.635324
NR 26
TC 3
Z9 3
U1 0
U2 11
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD AUG
PY 2013
VL 16
IS 8
BP 1414
EP 1418
DI 10.1017/S1368980013000736
PG 5
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 179UL
UT WOS:000321546700009
PM 23522785
ER

PT J
AU Romeu, M
   Aranda, N
   Giralt, M
   Ribot, B
   Nogues, MR
   Arija, V
AF Romeu, Marta
   Aranda, Nuria
   Giralt, Montserrat
   Ribot, Blanca
   Rosa Nogues, Maria
   Arija, Victoria
TI Diet, iron biomarkers and oxidative stress in a representative sample of
   Mediterranean population
SO NUTRITION JOURNAL
LA English
DT Article
DE Diet; Antioxidant status; Oxidative stress; Iron; General population
ID IOWA WOMENS HEALTH; CONSUMPTION; PLASMA; MALONDIALDEHYDE; ANTIOXIDANTS;
   INFLAMMATION; MORTALITY; FERRITIN; OBESITY; LIPIDS
AB Background: The consumption pattern characterized by high consumption of vegetables, fruit, fish, olive oil and red wine has been associated with improvements in the total antioxidant capacity of individuals and reduced incidence of diseases related to oxidation. Also, high body iron levels may contribute to increase the oxidative stress by the generation of reactive oxygen species. The objective of this study is to analyze the relationship between antioxidant and pro-oxidant factors obtained from the diet and iron biomarkers on lipoprotein oxidation and total antioxidant capacity in a representative sample of the Mediterranean population.
   Methods: Cross-sectional prospective study, carried out with 815 randomly selected subjects (425 women and 390 men). Dietary assessment (3-day food records), iron biomarkers (serum ferritin, serum iron and transferrin saturation), biochemical markers of lipoperoxidation (TBARS), antioxidant capacity (ORAC) and CRP (C-Reactive Protein) were determined. Multiple Linear Regression (MLR) models were applied to analyze the association between diet factors and iron biomarkers on TBARS and ORAC levels.
   Results: We observed that lipoperoxidation measured by TBARS increased by age but no differences were observed by sex. Antioxidant capacity measured by ORAC is independent of age and sex. In general, increasing age, tobacco, heme iron intake from meat and fish and transferrin saturation were independently and positively associated with TBARS, while non-heme iron was negatively associated. Vegetables, vitamin C intake and serum ferritin were positively associated with ORAC, whereas saturated fatty acids and meat intake were negatively associated.
   Conclusions: In our general population, we observed that oxidative stress is related to aging, but antioxidant capacity is not. The highest intake of dietary non-heme iron, vegetables and vitamin C intake exerts a protective effect against oxidation while the highest intake of dietary heme iron from meat and fish and saturated fatty acids are associated with increased oxidative stress. High levels of circulating iron measured by transferrin saturation are associated with increased oxidative stress in women however its association with the higher levels of serum ferritin is controversial.
C1 [Romeu, Marta; Giralt, Montserrat; Rosa Nogues, Maria] Univ Rovira & Virgili, Fac Med & Hlth Sci, Pharmacol Unit, E-43201 Reus, Spain.
   [Aranda, Nuria; Ribot, Blanca; Arija, Victoria] Univ Rovira & Virgili, Fac Med & Hlth Sci, Nutr & Publ Hlth Unit, Catalonia, Spain.
   [Aranda, Nuria; Ribot, Blanca; Arija, Victoria] Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Catalonia, Spain.
   [Arija, Victoria] Inst Invest Atencio Primaria Jordi Gol i Gurina, Tarragona, Spain.
RP Arija, V (reprint author), Univ Rovira & Virgili, Fac Med & Hlth Sci, Nutr & Publ Hlth Unit, Catalonia, Spain.
EM victoria.arija@urv.cat
RI ROMEU, MARTA/A-8468-2014; Giralt, Montserrat/I-3905-2015
OI ROMEU, MARTA/0000-0002-2131-1858; Giralt, Montserrat/0000-0002-7073-577X
FU Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria,
   Ministerio de Sanidad y Consumo, Madrid, Spain [PI021131]
FX We thank the volunteers who made the study possible through their
   participation. This study was supported by a grant from the Instituto de
   Salud Carlos III, Fondo de Investigacion Sanitaria, Ministerio de
   Sanidad y Consumo, Madrid, Spain (PI021131).
CR Alvarez E, 2000, REV ESP NUTR COMUNIT, V6, P116
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Ou BX, 2001, J AGR FOOD CHEM, V49, P4619, DOI 10.1021/jf010586o
   RICHARD MJ, 1992, CLIN CHEM, V38, P704
   JUCKETT MB, 1995, AM J PATHOL, V147, P782
   BEATON GH, 1979, AM J CLIN NUTR, V32, P2546
   MONSEN ER, 1982, J AM DIET ASSOC, V80, P307
   Lopez-Uriarte P, 2010, CLIN NUTR, V29, P373, DOI 10.1016/j.clnu.2009.12.008
   Bullo M, 2011, CURR TOP MED CHEM, V11, P1797
   Mutlu-Turkoglu U, 2003, CLIN BIOCHEM, V36, P397, DOI 10.1016/S0009-9120(03)00035-3
   Sies H, 2005, J NUTR, V135, P969
   Yuan XM, 2003, ANN MED, V35, P578, DOI 10.1080/07853890310016342
   Lee DH, 2005, INT J CANCER, V117, P643, DOI 10.1002/ijc.21215
   Blackhurst DM, 2006, NUTR METAB CARDIOVAS, V16, P550, DOI 10.1016/j.numecd.2005.09.006
   Favier JC, 1995, REPERTOIRE GEN ALIME
   Gomez F, 2000, CLIN BIOCHEM, V33, P191, DOI 10.1016/S0009-9120(00)00064-3
   Hodgson JM, 2007, J NUTR, V137, P363
   Hoegel A, 2011, PUBLIC HEALTH NUTR, V14, P2055
   Karaouzene N, 2011, NUTR METAB CARDIOVAS, V21, P792, DOI 10.1016/j.numecd.2010.02.007
   Lee DH, 2005, AM J CLIN NUTR, V81, P787
   Mainous AG, 2004, ANN FAM MED, V2, P139, DOI 10.1370/afm.82
   Mataix J., 2003, TABLA COMPOSICION AL
   Mitjavila MT, 2012, CLIN NUTR IN PRESS
   Nelson M., 1997, DESIGN CONCEPTS NUTR, P123
   Peairs AT, 2008, OBESITY, V16, P1573, DOI 10.1038/oby.2008.252
   Rankin JW, 2008, DIABETES OBES METAB, V10, P1086, DOI 10.1111/j.1463-1326.2008.00867.x
   Sharp PA, 2010, INT J VITAM NUTR RES, V80, P231, DOI 10.1024/0300-9831/a000029
   Tiwari AKM, 2011, CLIN NUTR, V30, P188, DOI 10.1016/j.clnu.2010.08.001
   Trichopoulou A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2337
   Tur JA, 2005, EUR J NUTR, V44, P204, DOI 10.1007/s00394-004-0512-0
   Voss P, 2006, FREE RADICAL RES, V40, P1339, DOI 10.1080/10715760600953859
NR 31
TC 4
Z9 4
U1 2
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PD JUL 16
PY 2013
VL 12
AR 102
DI 10.1186/1475-2891-12-102
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 219TN
UT WOS:000324533100001
PM 23866833
ER

PT J
AU Villarroel, P
   Arredondo, M
   Olivares, M
AF Villarroel H, Pia
   Arredondo O, Miguel
   Olivares G, Manuel
TI Hepcidin as a central mediator of anemia of chronic diseases associated
   with obesity
SO REVISTA MEDICA DE CHILE
LA Spanish
DT Review
DE Anemia; refractory; Antimicrobial cationic peptides; Chronic disease;
   Obesity
ID IRON-DEFICIENCY ANEMIA; ADIPOSE-TISSUE; INSULIN-RESISTANCE; TRANSFERRIN
   RECEPTOR; METABOLIC SYNDROME; SERUM FERRITIN; POTENTIAL ROLE;
   INFLAMMATION; MICE; HOMEOSTASIS
AB Recent evidence suggests that obesity-related inflammation may play a central role in hepcidin regulation. Hepcidin is a key regulator of iron homeostasis and has now been suggested as a central mediator of iron metabolism disorders involved in the pathogenesis of anemia of chronic disease. In this review, we focus on subclinical inflammation in obesity and its effect on hepcidin levels, as the most plausible explanation for the relationship between anemia of chronic disease and obesity.
C1 [Villarroel H, Pia; Arredondo O, Miguel; Olivares G, Manuel] Univ Chile, Inst Nutr & Tecnol Alimentos, Lab Micronutr, Santiago, Chile.
   [Villarroel H, Pia] Univ Chile, Santiago, Chile.
RP Villarroel, P (reprint author), Univ Chile, Inst Nutr & Tecnol Alimentos, Lab Micronutr, Santiago, Chile.
EM pia.villarroel@inta.uchile.cl
CR Zandman-Goddard G, 2007, AUTOIMMUN REV, V6, P457, DOI 10.1016/j.autrev.2007.01.016
   Valore EV, 2008, BLOOD CELL MOL DIS, V40, P132, DOI 10.1016/j.bcmd.2007.07.009
   Ganz T, 2006, PEDIATR BLOOD CANCER, V46, P554, DOI 10.1002/pbc.20656
   Trayhurn P, 2005, ACTA PHYSIOL SCAND, V184, P285, DOI 10.1111/j.1365-201X.2005.01468.x
   Ganz T, 2011, ANNU REV MED, V62, P347, DOI [10.1146/annurev-med-050109-142444, 10.1146/annurev-rned-050109-142444]
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Chung B, 2007, J NUTR, V137, P2366
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   De Domenico I, 2010, J CLIN INVEST, V120, P2395, DOI 10.1172/JCI42011
   Cook JD, 2005, BEST PRACT RES CL HA, V18, P319, DOI 10.1016/j.beha.2004.08.022
   Kemna E, 2005, BLOOD, V106, P3268, DOI 10.1182/blood-2005-05-1873
   Wallace DF, 2009, HEPATOLOGY, V50, P1992, DOI 10.1002/hep.23198
   Skikne BS, 2008, AM J HEMATOL, V83, P872, DOI 10.1002/ajh.21279
   Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499
   Sun CC, 2012, AM J HEMATOL, V87, P392, DOI 10.1002/ajh.23110
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057
   Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Luciani N, 2011, OBESITY, V19, P1545, DOI 10.1038/oby.2011.12
   Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   Theurl I, 2009, BLOOD, V113, P5277, DOI 10.1182/blood-2008-12-195651
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   DAVIS RJ, 1986, J BIOL CHEM, V261, P8708
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Collins JE, 2008, J NUTR, V138, P2284, DOI 10.3945/jn.108.096347
   Truksa J, 2009, BLOOD, V113, P688, DOI 10.1182/blood-2008-05-160184
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   WENZEL BJ, 1962, LANCET, V2, P327
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Zimmermann MB, 2008, BRIT J NUTR, V99, pS2, DOI 10.1017/S000711450800679X
   Roy CN, 2007, BLOOD, V109, P4038, DOI 10.1182/blood-2006-10-051755
   Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413
   Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374
   Cullis JO, 2011, BRIT J HAEMATOL, V154, P289, DOI 10.1111/j.1365-2141.2011.08741.x
   Gabay C, 1999, NEW ENGL J MED, V340, P448
   Ganz Tomas, 2011, Hematology Am Soc Hematol Educ Program, V2011, P538, DOI 10.1182/asheducation-2011.1.538
   Hintze KJ, 2010, BIOL TRACE ELEM RES, V143, P764
   Hugman A, 2006, CLIN LAB HAEMATOL, V28, P75, DOI 10.1111/j.1365-2257.2006.00768.x
   McCarty MF, 2003, MED HYPOTHESES, V61, P567, DOI 10.1016/S0306-9877(03)00231-7
   Nemeth E, 2010, ADV HEMATOL, V2010
   Robson KJ, 2004, GUT, V53, P617, DOI 10.1136/gut.2003.027631
   Roy Cindy N, 2010, Hematology Am Soc Hematol Educ Program, V2010, P276, DOI 10.1182/asheducation-2010.1.276
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-37
   Schrier SL, 2010, ADV HEMATOL, V2010
   Stoian I, 2007, INTERNAL MED, V45, P305
   VERGA F, 2007, BLOOD, V109, P353, DOI DOI 10.1182/BL00D-2006-07-033969)
   Verga Falzacappa Maria Vittoria, 2008, J Mol Med (Berl), V86, P531, DOI 10.1007/s00109-008-0313-7
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Weiss G, 2009, BBA-GEN SUBJECTS, V1790, P682, DOI 10.1016/j.bbagen.2008.08.006
   Ye JP, 2007, AM J PHYSIOL-ENDOC M, V293, pE1118, DOI 10.1152/ajpendo.00435.2007
   Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972
NR 65
TC 0
Z9 0
U1 1
U2 8
PU SOC MEDICA SANTIAGO
PI SANTIAGO 9
PA BERNARDA MORIN 488 PROVIDENCIA, CASILLA 168 CORREO 55, SANTIAGO 9,
   00000, CHILE
SN 0034-9887
J9 REV MED CHILE
JI Rev. Medica Chile
PD JUL
PY 2013
VL 141
IS 7
BP 887
EP 894
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 209ZK
UT WOS:000323798900008
PM 24356737
ER

PT J
AU Bougle, D
   Brouard, J
AF Bougle, Dominique
   Brouard, Jacques
TI Iron in Child Obesity. Relationships with Inflammation and Metabolic
   Risk Factors
SO NUTRIENTS
LA English
DT Article
DE iron; obesity; children; inflammation; metabolic syndrome; non alcoholic
   fatty liver disease (NAFLD)
ID C-REACTIVE PROTEIN; INSULIN-RESISTANCE SYNDROME; SERUM FERRITIN; OBESE
   CHILDREN; MAJOR DETERMINANTS; OXIDATIVE STRESS; LIVER-DISEASE; FATTY
   LIVER; DEFICIENCY; WOMEN
AB Iron (Fe) sequestration is described in overweight and in its associated metabolic complications, i.e., metabolic syndrome (MetS) and non-alcoholic liver fatty disease (NAFLD); however, the interactions between Fe, obesity and inflammation make it difficult to recognize the specific role of each of them in the risk of obesity-induced metabolic diseases. Even the usual surrogate marker of Fe stores, ferritin, is influenced by inflammation; therefore, in obese subjects inflammation parameters must be measured together with those of Fe metabolism. This cross-sectional study in obese youth (502 patients; 57% girls): 11.4 +/- 3.0 years old (x +/- SD); BMI z score 5.5 +/- 2.3), multivariate regression analysis showed associations between Fe storage assessed by serum ferritin with risk factors for MetS and NAFLD, assessed by transaminase levels, which were independent of overweight and the acute phase protein fibrinogen. Further studies incorporating the measurement of complementary parameters of Fe metabolism could improve the comprehension of mechanisms involved.
C1 [Bougle, Dominique; Brouard, Jacques] CHU Caen, Dept Pediat, F-14033 Caen, France.
RP Bougle, D (reprint author), CHU Caen, Dept Pediat, F-14033 Caen, France.
EM dbougle@wanadoo.fr; brouard-jacques@chu-caen.fr
CR Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Valenti L, 2011, NUTR METAB CARDIOVAS, V21, P568, DOI 10.1016/j.numecd.2010.01.003
   Engle-Stone R, 2013, J NUTR, V143, P369, DOI 10.3945/jn.112.167775
   Syrovatka P, 2009, ANN NUTR METAB, V54, P268, DOI 10.1159/000229507
   Moschonis G, 2012, BRIT J NUTR, V108, P710, DOI 10.1017/S0007114511005952
   Skinner AC, 2010, PEDIATRICS, V125, pE801, DOI 10.1542/peds.2009-2182
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Choi KM, 2005, METABOLISM, V54, P1510, DOI 10.1016/j.metabol.2005.05.018
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Whaley-Connell A, 2011, REV CARDIOVASC MED, V12, P21, DOI 10.3909/ricm0555
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   Baumgartner J, 2013, INT J OBESITY, V37, P24, DOI 10.1038/ijo.2012.145
   Ford ES, 2005, DIABETES CARE, V28, P878, DOI 10.2337/diacare.28.4.878
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Ahmed U, 2012, WORLD J GASTROENTERO, V18, P4651, DOI 10.3748/wjg.v18.i34.4651
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Datz C, 2013, EUR J CLIN INVEST, V43, P215, DOI 10.1111/eci.12032
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Dubern B, 2006, INT J PEDIATR OBES, V1, P77, DOI 10.1080/17477160600569594
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Zelber-Sagi S, 2007, J HEPATOL, V46, P700, DOI 10.1016/j.jhep.2006.09.018
   Anses, CHOIX EX MET FER CAS
   Brotanek J. M., 2007, PEDIATRICS, V120, P569
   Brugnara C, 2013, CLIN CHEM, V59, P740, DOI 10.1373/clinchem.2012.182071
   Cooper M., 2012, HLTH REP, V23, P3
   Dongiovanni P., 2011, J HEPATOL, V55, P1120
   Escobar-Morreale HF, 2003, DIABETOLOGIA, V46, P625, DOI 10.1007/s00125-003-1090-z
   Harrison-Findik Duygu D, 2010, World J Hepatol, V2, P302, DOI 10.4254/wjh.v2.i8.302
   Hercberg S, 2001, Public Health Nutr, V4, P537
   Hiura M, 2003, HYPERTENS RES, V26, P541, DOI 10.1291/hypres.26.541
   Houschyar KS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-54
   Mandato C, 2005, J PEDIATR-US, V147, P62, DOI 10.1016/j.jpeds.2005.02.028
   Neuschwander-Tetri BA, 2007, CURR OPIN GASTROEN, V23, P193, DOI 10.1097/MOG.0b013e32801421a9
   Richardson M. W., 2009, INT J PEDIAT ENDOCRI, DOI 10.1155.2009/713269
   Sumida Y, 2006, HEPATOL RES, V36, P315, DOI 10.1016/j.hepres.2006.08.003
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   WHO, 2001, IR DEF AN ASS PREV C
NR 46
TC 1
Z9 1
U1 1
U2 11
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2013
VL 5
IS 6
BP 2222
EP 2230
DI 10.3390/nu5062222
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 169HS
UT WOS:000320771400023
PM 23783556
ER

PT J
AU Griffin, HJ
   Cheng, HL
   O'Connor, HT
   Rooney, KB
   Petocz, P
   Steinbeck, KS
AF Griffin, H. J.
   Cheng, H. L.
   O'Connor, H. T.
   Rooney, K. B.
   Petocz, P.
   Steinbeck, K. S.
TI Higher protein diet for weight management in young overweight women: a
   12-month randomized controlled trial
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE diet composition; high-protein diet; obesity; weight loss; young women
ID OBESE WOMEN; ADULTS
AB Clinical research on weight management in young women is limited. This randomized controlled trial compared the efficacy of two iso-energetically restricted (5600 kJ) diets [higher protein (HP): 32% protein, 41% carbohydrate, 25% fat or higher carbohydrate (HC): 20, 58, 21%, respectively] in 71 (HP: n=36; HC: n=35) young healthy women (1825 years; body mass index27.5kg/m2) for weight (kg; percent weight loss), body composition, metabolic and iron changes assessed at baseline, 6 and 12 months. Data: mean (95% CI). In HP completers at 6 months, percent weight loss was higher [HP: 9.3 (5.613.1); HC: 5.1 (2.37.9)%; p=0.06]; although, this did not reach statistical significance. Absolute weight [HP: 8.9 (5.312.5); HC: 4.6 (2.27.0) kg; p=0.034] and fat loss [HP: 8.0 (4.411.5); HC: 3.4 (1.35.6) kg; p=0.022] were significantly greater. No significant between-diet differences were observed at 12 months. Biochemistry remained within normal ranges with HP showing superior preservation of ferritin at 6 months [HP: 53 (4066); HC: 46 (3061) mu g/l; p=0.029]. Both diets supported clinically meaningful weight loss with HP tending to be more effective in the medium-term.
C1 [Griffin, H. J.; Cheng, H. L.; O'Connor, H. T.; Rooney, K. B.] Univ Sydney, Fac Hlth Sci, Discipline Exercise & Sport Sci, Sydney, NSW 2006, Australia.
   [Petocz, P.] Macquarie Univ, Dept Stat, Sydney, NSW 2109, Australia.
   [Steinbeck, K. S.] Univ Sydney, Acad Dept Adolescent Med, Sydney, NSW 2006, Australia.
RP Griffin, HJ (reprint author), Univ Sydney, Fac Hlth Sci, Discipline Exercise & Sport Sci, POB 170, Lidcombe, NSW 1825, Australia.
EM helen.oconnor@sydney.edu.au
RI O'Connor, Helen/C-1289-2014
FU Meat and Livestock Australia
FX This study was supported by a grant from Meat and Livestock Australia.
   The authors acknowledge Ms Zahra Munas for her clinical contribution to
   this study.
CR Wadden TA, 2003, ENDOCRIN METAB CLIN, V32, P981, DOI 10.1016/S0889-8529(03)00072-0
   BOUCHARD C, 1983, AM J CLIN NUTR, V37, P461
   Grigg M, 1996, PREV MED, V25, P748, DOI 10.1006/pmed.1996.0115
   Noakes M, 2005, AM J CLIN NUTR, V81, P1298
   Gokee-LaRose J, 2009, INT J OBESITY, V33, P1374, DOI 10.1038/ijo.2009.185
   Boschi V, 2010, EAT WEIGHT DISORD-ST, V15, pE60
   Linné Y, 2004, Obes Rev, V5, P137, DOI 10.1111/j.1467-789X.2004.00147.x
   O'Connor H, 2011, ASIA PAC J CLIN NUTR, V20, P206
   Poobalan AS, 2010, OBES REV, V11, P580, DOI 10.1111/j.1467-789X.2009.00673.x
   Popkin BM, 2010, AM J CLIN NUTR, V91, p284S, DOI 10.3945/ajcn.2009.28473C
   Truesdale KP, 2006, INT J OBESITY, V30, P1397, DOI 10.1038/sj.ijo.0803307
   World Health Organization, 2000, TECHNICAL REPORT
NR 12
TC 6
Z9 6
U1 1
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD JUN
PY 2013
VL 15
IS 6
BP 572
EP 575
DI 10.1111/dom.12056
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 137NB
UT WOS:000318441500010
PM 23279557
ER

PT J
AU Zeba, AN
   Delisle, HF
   Rossier, C
   Renier, G
AF Zeba, Augustin N.
   Delisle, Helene F.
   Rossier, Clementine
   Renier, Genevieve
TI Association of high-sensitivity C-reactive protein with cardiometabolic
   risk factors and micronutrient deficiencies in adults of Ouagadougou,
   Burkina Faso
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Micronutrient deficiencies; Cardiometabolic risk factors; Inflammation;
   Adults; Burkina Faso
ID CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; ACUTE-PHASE
   RESPONSE; NUTRITION EXAMINATION SURVEY; LOW-GRADE INFLAMMATION; 3RD
   NATIONAL-HEALTH; BODY-MASS INDEX; CARDIOVASCULAR RISK; METABOLIC
   SYNDROME; INSULIN-RESISTANCE
AB Increasing evidence suggests that high-sensitivity C-reactive protein (hs-CRP) is associated with cardiometabolic risk factors (CMRF) while being also related to micronutrient deficiencies. As part of a project on the double burden of under-and overnutrition in sub-Saharan Africa, we assessed the relationship between hs-CRP and both CMRF and micronutrient deficiencies in a population-based cross-sectional study carried out in the Northern district of Ouagadougou, the capital city of Burkina Faso. We randomly selected 330 households stratified by income tertile. In each income stratum, 110 individuals aged 25-60 years and having lived in Ouagadougou for at least 6 months were randomly selected, and underwent anthropometric measurements and blood sample collection. The prevalence of high hs-CRP was 39.4%, with no sex difference. Vitamin A-deficient subjects (12.7%) exhibited significant risk of elevated hs-CRP (OR 2.5; P = 0.015). Serum ferritin was positively correlated with log hs-CRP (r 0.194; P = 0.002). The risk of elevated hs-CRP was significant in subjects with BMI >= 25 kg/m(2) (OR 6.9; 95% CI 3.6, 13.3), abdominal obesity (OR 4.6; 95% CI 2.2, 7.3) and high body fat (OR 10.2; 95% CI 5.1, 20.3) (P < 0.001, respectively). Independent predictors of hs-CRP in linear regression models were waist circumference (beta = 0.306; P = 0.018) and serum TAG (beta = 0.158; P = 0.027). In this sub-Saharan population, hs-CRP was consistently associated with adiposity. Assuming that plasma hs-CRP reflects future risk of cardiovascular events, intervention which reduces CRP, or chronic and acute nutrition conditions associated with it, could be effective in preventing their occurrence particularly in sub-Saharan Africa.
C1 [Zeba, Augustin N.; Delisle, Helene F.] Univ Montreal, Fac Med, Dept Nutr, Montreal, PQ H3C 3J7, Canada.
   [Rossier, Clementine] Univ Ouagadougou, ISSP, Ouagadougou, Burkina Faso.
   [Renier, Genevieve] Univ Montreal, Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada.
RP Zeba, AN (reprint author), Univ Montreal, Fac Med, Dept Nutr, CP 6128 succ Ctr ville, Montreal, PQ H3C 3J7, Canada.
EM nawidzeb@yahoo.fr
FU Canadian International Development Agency
FX The present study received funding from the Canadian International
   Development Agency. We gratefully acknowledge the technical and field
   support provided by the Institut de Recherche en Sciences de la Sante
   (IRSS) and the Institut Superieur des Sciences de la Population (ISSP).
   We thank Professor Some Issa of Universite de Ouagadougou and Professor
   Jean-Louis Gueant of Universite de Nancy for laboratory analyses. We
   also thank the participants of the 'Population Observatory of
   Ouagadougou' and all field workers involved in the study. A. N. Z.
   developed the study protocol as his PhD project; he collected and
   analysed the data and drafted the manuscript. G. R. was involved in the
   study design and paper revision. H. F. D. designed the study, and
   supervised data analysis and paper revision. C. R. provided the sampling
   database, assisted with statistics and revised the manuscript. The
   authors have no conflicts of interest.
CR Abraham K, 2003, INT J VITAM NUTR RES, V73, P423, DOI 10.1024//0300-9831.73.6.423
   Oliver E, 2010, P NUTR SOC, V69, P232, DOI 10.1017/S0029665110000042
   Niakara A, 2007, T ROY SOC TROP MED H, V101, P1136, DOI 10.1016/j.trstmh.2007.07.002
   Danesh J, 2000, BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199
   Rocha VZ, 2009, NAT REV CARDIOL, V6, P399, DOI 10.1038/nrcardio.2009.55
   Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Misra A, 2008, J CLIN ENDOCR METAB, V93, pS9, DOI 10.1210/jc.2008-1595
   Cesari M, 2003, CIRCULATION, V108, P2317, DOI 10.1161/01.CIR.0000097109.90783.FC
   Zoratti R, 1998, EUR J EPIDEMIOL, V14, P9, DOI 10.1023/A:1007492202045
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15
   Imrie H, 2007, AM J TROP MED HYG, V76, P280
   Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925
   Ridker PM, 2009, J THROMB HAEMOST, V7, P332, DOI 10.1111/j.1538-7836.2009.03404.x
   Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007
   Everett BM, 2006, J AM COLL CARDIOL, V48, P2235, DOI 10.1016/j.jacc.2006.09.030
   Saito M, 2003, ATHEROSCLEROSIS, V167, P73, DOI 10.1016/S0021-9150(02)00380-5
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Hwang JJ, 2008, NUTR METAB CARDIOVAS, V18, P671, DOI 10.1016/j.numecd.2007.11.006
   Aderibigbe OR, 2011, CARDIOVASC J AFR, V22, P249, DOI 10.5830/CVJA-2011-015
   McDade TW, 2008, J NUTR, V138, P2442, DOI 10.3945/jn.108.092700
   Ridker PM, 2004, CIRCULATION, V109, P2818, DOI 10.1161/01.CIR.0000132467.45278.59
   Jackson AS, 2002, INT J OBESITY, V26, P789, DOI 10.1038/sj.ijo.0802006
   Abubakari AR, 2009, PUBLIC HEALTH, V123, P602, DOI 10.1016/j.puhe.2009.07.009
   Han TS, 2002, DIABETES CARE, V25, P2016, DOI 10.2337/diacare.25.11.2016
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Heilbronn LK, 2008, CURR PHARM DESIGN, V14, P1225, DOI 10.2174/138161208784246153
   Blake GJ, 2003, CIRCULATION, V108, P2993, DOI 10.1161/01.CIR.0000104566.10178.AF
   Abubakari AR, 2008, OBES REV, V9, P297, DOI 10.1111/j.1467-789X.2007.00462.x
   Pischon T, 2007, EUR J EPIDEMIOL, V22, P429, DOI 10.1007/s10654-007-9141-2
   Nakamura H, 2008, DIABETES RES CLIN PR, V79, P330, DOI 10.1016/j.diabres.2007.09.004
   Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7
   Brooks GC, 2010, AM J CARDIOL, V106, P56, DOI 10.1016/j.amjcard.2010.02.017
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   Stephensen CB, 2000, AM J CLIN NUTR, V72, P1170
   Santos AC, 2005, INT J OBESITY, V29, P1452, DOI 10.1038/sj.ijo.0803035
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Lapice E, 2009, DIABETES CARE, V32, P1734, DOI 10.2337/dc09-0176
   Goldfine AB, 2011, CLIN CHEM, V57, P162, DOI 10.1373/clinchem.2010.148833
   Sun SS, 2003, AM J CLIN NUTR, V77, P331
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   Benzaquen LR, 2002, CRIT REV CL LAB SCI, V39, P459, DOI 10.1080/10408360290795556
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Brazionis L, 2011, NUTR METAB CARDIOVAS
   City Development Strategy, 2007, ET DIAGN AGGL OUAG
   Direction de la Nutrition, 2006, AN COMPL SIT NUTR BU
   HURT N, 1994, CLIN DIAGN LAB IMMUN, V1, P437
   International Diabetes Federation, 2009, DIABETES ATLAS
   Jeemon P, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-19
   Kao TW, 2009, SAMJ S AFR MED J, V99, P326
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   McLaughlin T, 2002, CIRCULATION, V106, P2908, DOI 10.1161/01.CIR.0000041046.32962.86
   Millán Jesús, 2009, Vasc Health Risk Manag, V5, P757
   Miller M, 2005, ARCH INTERN MED, V165, P2063, DOI 10.1001/archinte.165.18.2063
   Olsen MH, 2006, J HYPERTENS, V24, P655, DOI 10.1097/01.hjh.0000217847.03208.ba
   Pai JK, 2004, NEW ENGL J MED, V351, P2599, DOI 10.1056/NEJMoa040967
   Rosales FJ, 1998, J NUTR, V128, P1681
   Schweigert FJ, 2001, CURR OPIN CLIN NUTR, V4, P477, DOI 10.1097/00075197-200111000-00002
   STEPHENSEN CB, 1994, AM J CLIN NUTR, V60, P388
   Sung KC, 2007, ARCH MED RES, V38, P121, DOI 10.1016/j.arcmed.2006.08.008
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   WHO, 2000, WHO TECHN REP SER, V894
   WHO, 2004, ASS IR STAT POP INCL
   World Health Organization, 2003, WHO TECHN REP SER, V916
   WORLD HEALTH ORGANIZATION, 2009, GLOB PREV VIT A DEF
   World Health Organization, 1999, MET SYNDR DEF DIAG 1
   Xu JW, 2007, MOL ENDOCRINOL, V21, P564, DOI 10.1210/me.2006-0354
   Zeba AN, 2012, PUBLIC HLTH NUTR
NR 75
TC 0
Z9 0
U1 7
U2 20
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD APR 14
PY 2013
VL 109
IS 7
BP 1266
EP 1275
DI 10.1017/S0007114512003182
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 121IM
UT WOS:000317236600011
PM 22914173
ER

PT J
AU Sabuncuoglu, O
AF Sabuncuoglu, Osman
TI Understanding the relationships between breastfeeding, malocclusion,
   ADHD, sleep-disordered breathing and traumatic dental injuries
SO MEDICAL HYPOTHESES
LA English
DT Article
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY
   DISORDER; OF-THE-LITERATURE; NONNUTRITIVE SUCKING HABITS;
   IRON-DEFICIENCY; RISK-FACTORS; MIXED DENTITION; YOUNG-CHILDREN; APNEA
   SYNDROME; ADOLESCENTS
AB Attention-deficit/hyperactivity disorder (ADHD), one of the most common neuropsychiatric disorders that present at young age, may occasionally be associated with physical problems and disorders. Among them exists a group of oral-pharyngeal conditions with considerable clinical morbidity. Previous research that identified absence or short duration of breastfeeding in ADHD children has been reviewed. Essential nutritional factors in breast milk can affect brain development and regulate the manifestation of ADHD symptoms. Low ferritin levels caused by insufficient breastfeeding may contribute to ADHD susceptibility because of the role of iron in dopaminergic activity. Insufficient breast feeding and subsequently excessive bottle-feeding may lead to increased rates of non-nutritive sucking habits, such as pacifier use and thumb-sucking, all of which are associated with the risk of development of malocclusions. Malocclusion refers to an unacceptable deviation from the ideal relationship of the upper and lower teeth and necessitates orthodontic treatment. Sleep-disordered breathing in children may present with neurocognitive symptoms that resemble ADHD and abnormal craniofacial developments, as well as malocclusions, have been cited as part of the syndrome. Obesity, which is an outcome of insufficient breastfeeding, is a shared comorbidity of ADHD and sleep-disordered breathing. The risk of traumatic dental injury is higher in children with ADHD and presence of malocclusions further increases the likelihood of dental injuries.
   In this review, certain oral-pharyngeal conditions relating to ADHD have been reviewed and links among them have been highlighted in a tentative explanatory model. More research that will provide increased awareness and clinical implications is needed. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Sabuncuoglu, Osman] Marmara Univ, Sch Med, Dept Child & Adolescent Psychiat, Istanbul, Turkey.
RP Sabuncuoglu, O (reprint author), Halk Cad Emin Ongan Sok 11-15, TR-34672 Istanbul, Turkey.
EM sabuncuoglu2004@yahoo.com
CR Alonge OK, 2001, DENT TRAUMATOL, V17, P218
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   O'Brien LM, 2003, PEDIATRICS, V111, P554, DOI 10.1542/peds.111.3.554
   Brotanek JM, 2005, ARCH PEDIAT ADOL MED, V159, P1038, DOI 10.1001/archpedi.159.11.1038
   Glendor U, 2009, DENT TRAUMATOL, V25, P19, DOI 10.1111/j.1600-9657.2008.00694.x
   Miano S, 2011, CLIN NEUROPHYSIOL, V122, P311, DOI 10.1016/j.clinph.2010.06.019
   Wei JL, 2007, ARCH OTOLARYNGOL, V133, P974, DOI 10.1001/archotol.133.10.974
   Baker RD, 2010, PEDIATRICS, V126, P1040, DOI 10.1542/peds.2010-2576
   Daley D, 2009, CHILD CARE HLTH DEV, V35, P754, DOI 10.1111/j.1365-2214.2009.00938.x
   Calarge C, 2010, J CHILD ADOL PSYCHOP, V20, P495, DOI 10.1089/cap.2010.0053
   Chervin RD, 2005, SLEEP, V28, P885
   Chervin RD, 2002, PEDIATRICS, V109, P449, DOI 10.1542/peds.109.3.449
   Floet AMW, 2010, PEDIATR REV, V31, P56, DOI 10.1542/pir.31-2-56
   Sever Y, 1997, NEUROPSYCHOBIOLOGY, V35, P178, DOI 10.1159/000119341
   Julvez J, 2007, ACTA PAEDIATR, V96, P842, DOI 10.1111/j.1651-2227.2007.00273.x
   Assis AMO, 2004, REV SAUDE PUBL, V38, P543, DOI [10.1590/S0034-89102004000400010, 10.1590/s0034-89102004000400010]
   Chaparro CM, 2008, J NUTR, V138, P2529
   Howard CR, 2003, PEDIATRICS, V111, P511, DOI 10.1542/peds.111.3.511
   Li HY, 2006, LARYNGOSCOPE, V116, P1142, DOI 10.1097/01.mlg.0000217542.84013.b5
   Guilleminault C, 2005, ARCH PEDIAT ADOL MED, V159, P775, DOI 10.1001/archpedi.159.8.775
   Owens JA, 2009, PEDIATR PULM, V44, P417, DOI 10.1002/ppul.20981
   Sabuncuoglu O, 2005, DENT TRAUMATOL, V21, P249, DOI 10.1111/j.1600-9657.2005.00317.x
   Konofal E, 2008, PEDIATR NEUROL, V38, P20, DOI 10.1016/j.pediatrneurol.2007.08.014
   Davis C, 2010, CURR PSYCHIAT REP, V12, P389, DOI 10.1007/s11920-010-0133-7
   Thapar A, 2012, ARCH DIS CHILD, V97, P260, DOI 10.1136/archdischild-2011-300482
   Cortese S, 2008, CRIT REV FOOD SCI, V48, P524, DOI 10.1080/10408390701540124
   Glendor U, 2008, DENT TRAUMATOL, V24, P603, DOI 10.1111/j.1600-9657.2008.00696.x
   STEVENS LJ, 1995, AM J CLIN NUTR, V62, P761
   Hultcrantz E, 2009, INT J PEDIATR OTORHI, V73, P1234, DOI 10.1016/j.ijporl.2009.05.012
   Kim HW, 2009, PSYCHIAT INVEST, V6, P278, DOI 10.4306/pi.2009.6.4.278
   Viggiano D, 2004, ARCH DIS CHILD, V89, P1121, DOI 10.1136/adc.2003.029728
   Yoon SYR, 2012, SLEEP MED REV, V16, P371, DOI 10.1016/j.smrv.2011.07.001
   Huang YS, 2007, SLEEP MED, V8, P18, DOI 10.1016/j.sleep.2006.05.016
   Cortese S, 2009, J AM ACAD CHILD PSY, V48, P894, DOI 10.1097/CHI.0b013e3181ac09c9
   Atmetlla Gabriela, 2006, J Clin Pediatr Dent, V30, P183
   Banabilh SM, 2010, ANGLE ORTHOD, V80, P37, DOI 10.2319/011509-26.1
   Banerjee Tania Das, 2007, Acta Paediatr, V96, P1269, DOI 10.1111/j.1651-2227.2007.00430.x
   Bimstein Enrique, 2008, Spec Care Dentist, V28, P107, DOI 10.1111/j.1754-4505.2008.00021.x
   Borum M K, 2001, Int J Paediatr Dent, V11, P249, DOI 10.1046/j.1365-263X.2001.00277.x
   Brooks LJ, 2008, ANN ACAD MED SINGAP, V37, P701
   Callen Jennifer, 2005, Adv Neonatal Care, V5, P72, DOI 10.1016/j.adnc.2004.12.003
   Callen J, 2005, ADV NEONATAL CARE, V5, P89
   Camurdan AD, 2008, PUBLIC HEALTH NUTR, V11, P1173, DOI 10.1017/S1368980008001742
   Carrascoza Karina Camillo, 2006, J Pediatr (Rio J), V82, P395, DOI 10.1590/S0021-75572006000600015
   Cazzolla AP, 2010, EUR J PAEDIATR DENT, V11, P189
   Cortese S, 2007, J PSYCHOSOM RES, V63, P587, DOI 10.1016/j.jpsychores.2007.08.005
   Diouf Joseph Samba, 2010, Int Orthod, V8, P372, DOI 10.1016/j.ortho.2010.10.001
   Fewtrell MS, 2011, P NUTR SOC, V70, P472, DOI 10.1017/S0029665111000589
   FRIED I, 1995, J DENT CHILD, V62, P256
   Gelgör Ibrahim Erhan, 2007, Eur J Dent, V1, P125
   Gozal D, 2008, CURR OPIN PEDIATR, V20, P654, DOI 10.1097/MOP.0b013e328316ec2d
   Heasman P, 2003, MASTER DENT RESTORAT
   Kadziela-Olech H, 2005, Rocz Akad Med Bialymst, V50, P302
   Katz-Sagi H, 2010, J CLIN PEDIATR DENT, V34, P287
   Kikuchi Makoto, 2005, Sleep Breath, V9, P146, DOI 10.1007/s11325-005-0028-8
   Lalloo R, 2003, DENT TRAUMATOL, V19, P12, DOI 10.1034/j.1600-9657.2003.00139.x
   Li SH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-144
   Medeiros Ana Paula Magalhães, 2009, Pro Fono, V21, P315, DOI 10.1590/S0104-56872009000400009
   Miyao E, 2008, INTERNAL MED, V47, P1573, DOI 10.2169/internalmedicine.47.0717
   Montaldo L, 2011, INT J PAEDIATR DENT, V21, P68, DOI 10.1111/j.1365-263X.2010.01092.x
   Montgomery-Downs HE, 2007, PEDIATRICS, V120, P1030, DOI 10.1542/peds.2007-0722
   Oddy Wendy H, 2012, Breastfeed Rev, V20, P7
   Oliveira Andréa Silva de, 2010, Cad Saude Publica, V26, P409, DOI 10.1590/S0102-311X2010000200020
   Oliveira Maria A A, 2005, J Pediatr (Rio J), V81, P361, DOI 10.1590/S0021-75572005000600004
   Oner P, 2008, CHILD PSYCHIAT HUM D, V39, P323, DOI 10.1007/s10578-007-0095-0
   Perinetti G, 2008, ORAL HLTH PREV DENT, V6, P119
   Pessah Stéphanie, 2009, Orthod Fr, V80, P331, DOI 10.1051/orthodfr/2009024
   Ray R Mark, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P360, DOI 10.1097/01.moo.0000186076.53986.71
   Rizwanulla T, 2009, THESIS R GANDHI U HL
   Sabuncuoglu O, 2007, DENT TRAUMATOL, V23, P137, DOI 10.1111/j.1600-9657.2005.00431.x
   Sanchez-Molins M, 2010, EUR J PAEDIATR DENT, V11, P87
   Schmied K, 2009, ZWR, V118, P26
   Schutza TCB, 2011, ANGLE ORTHOD, V81, P222, DOI 10.2319/052710-233.1
   Sidlauskas A, 2009, MED LITH, V45, P147
   Stettler N, 2011, NESTLE NUTR WORKSHOP, V68, P222
   Stettler N, 2011, NESTLE NUTR WORKS SE, V68, P215, DOI 10.1159/000325884
   Surman Craig B H, 2006, J Atten Disord, V9, P550, DOI 10.1177/1087054705282121
   Trawitzki Luciana Vitaliano Voi, 2005, Braz J Otorhinolaryngol, V71, P747
   TurgeonOBrien H, 1996, J DENT CHILD, V63, P321
   Vlastos IM, 2010, EUR J PEDIATR, V169, P261, DOI 10.1007/s00431-009-1019-8
   Weber Silke Anna Thereza, 2006, Braz J Otorhinolaryngol, V72, P124
   WHO, 2009, INF YOUNG CHILD FEED
   Yorbik O., 2003, COCUK GENCLIK RUH SA, V10, P115
NR 83
TC 1
Z9 1
U1 4
U2 33
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAR
PY 2013
VL 80
IS 3
BP 315
EP 320
DI 10.1016/j.mehy.2012.12.017
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 102GZ
UT WOS:000315834400023
PM 23306004
ER

PT J
AU Datz, C
   Felder, TK
   Niederseer, D
   Aigner, E
AF Datz, Christian
   Felder, Thomas K.
   Niederseer, David
   Aigner, Elmar
TI Iron homeostasis in the Metabolic Syndrome
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Review
DE FPN - ferroportin-1; hepcidin; iron overload; metabolic syndrome;
   non-alcoholic fatty liver disease
ID NONALCOHOLIC FATTY LIVER; SERUM FERRITIN CONCENTRATION;
   INSULIN-RESISTANCE; HEPATIC IRON; HEREDITARY HEMOCHROMATOSIS; OXIDATIVE
   STRESS; OVERLOAD SYNDROME; HFE MUTATIONS; DISEASE RISK; HEPCIDIN
AB The metabolic syndrome (MetS) affects iron homeostasis in a many-faceted fashion. On the one side, hyperferritinaemia with normal or mildly elevated transferrin saturation is observed in approximately one-third of patients with non-alcoholic fatty liver disease (NAFLD) or the MetS. This constellation has been named the dysmetabolic iron overload syndrome (DIOS). Current evidence suggests that elevated body iron stores exert a detrimental effect on the clinical course of obesity-related conditions and that iron removal improves insulin sensitivity and delays the onset of T2DM. On the other side, iron deficiency is a frequent finding in more progressed stages of obesity. The mechanisms underlying the DIOS and obesity-related iron deficiency appear strikingly similar as elevated hepcidin concentrations, low expression of duodenal ferroportin (FPN) and impaired iron absorption are found in both conditions. This review summarizes the current knowledge about the dysregulation of iron homeostasis in the MetS and particularly in its hepatic manifestation NAFLD.
C1 [Datz, Christian; Niederseer, David] Gen Hosp Oberndorf, Dept Internal Med, A-5110 Oberndorf, Austria.
   [Felder, Thomas K.] Paracelsus Med Univ, Dept Lab Med, A-5020 Salzburg, Austria.
   [Aigner, Elmar] Paracelsus Med Univ, Dept Med 1, A-5020 Salzburg, Austria.
RP Aigner, E (reprint author), Paracelsus Med Univ, Dept Med 1, Mullner Hauptstr 48, A-5020 Salzburg, Austria.
EM c.datz@kh-obdf.salzburg.at; e.aigner@salk.at
CR Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Turlin B, 2001, AM J CLIN PATHOL, V116, P263
   Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274
   Fernandez-Real JM, 2007, DIABETES CARE, V30, P616, DOI 10.2337/dc06-1581
   Dongiovanni P, 2008, AM J PATHOL, V172, P738, DOI 10.2353/ajpath.2008.070097
   Dallalio G, 2006, BLOOD, V107, P2702, DOI 10.1182/blood-2005-07-2854
   Duffy SJ, 2001, CIRCULATION, V103, P2799
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Luque-Ramirez M, 2007, DIABETES CARE, V30, P2309, DOI 10.2337/dc07-0642
   Kawabata H, 2005, BLOOD, V105, P376, DOI 10.1182/blood-2004-04-1416
   Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5
   Chung B, 2007, J NUTR, V137, P2366
   Vulpe CD, 1999, NAT GENET, V21, P195
   Zacharski LR, 2008, J NATL CANCER I, V100, P996, DOI 10.1093/jnci/djn209
   Otogawa K, 2007, AM J PATHOL, V170, P967, DOI 10.2353/ajpath.2007.060441
   Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Wood RJ, 2004, AGEING RES REV, V3, P355, DOI 10.1016/j.arr.2004.04.002
   Du X, 2008, SCIENCE, V320, P1088, DOI 10.1126/science.1157121
   Fernandez-Real JM, 2008, DIABETES, V57, P1918, DOI 10.2337/db08-0041
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]
   De Domenico I, 2007, EMBO J, V26, P2823, DOI 10.1038/sj.emboj.7601735
   Weismuller TJ, 2011, HEPATOLOGY, V54, P2114, DOI 10.1002/hep.24635
   YOKOMORI N, 1991, ENDOCRINOLOGY, V128, P1474
   Sorrentino P, 2009, J HEPATOL, V50, P351, DOI 10.1016/j.jhep.2008.09.011
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Galan P, 2006, PUBLIC HEALTH NUTR, V9, P70, DOI 10.1079/PHN2005826
   Walker NM, 2010, HEPATOLOGY, V51, P1683, DOI 10.1002/hep.23537
   George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Aigner E, 2010, EUR J CLIN INVEST, V40, P155, DOI 10.1111/j.1365-2362.2009.02238.x
   Abraham D, 2006, DIABETOLOGIA, V49, P2546, DOI 10.1007/s00125-006-0445-7
   Valenti L, 2007, AM J GASTROENTEROL, V102, P1251, DOI 10.1111/j.1572-0241.2007.01192.x
   Hernaez R, 2011, J HEPATOL, V55, P1079, DOI 10.1016/j.jhep.2011.02.013
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Valenti L, 2010, J HEPATOL, V53, P927, DOI [10.1016/j.jhep.2010.05.023, 10.1016/j.jhep.2010.06.010]
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Barisani D, 2008, J HEPATOL, V49, P123, DOI 10.1016/j.jhep.2008.03.011
   Bugianesi E, 2004, HEPATOLOGY, V39, P179, DOI 10.1002/hep.20023
   Ruivard M, 2009, J HEPATOL, V50, P1219, DOI 10.1016/j.jhep.2009.01.029
   Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
   Lao TT, 2001, DIABETIC MED, V18, P218, DOI 10.1046/j.1464-5491.2001.00453.x
   Finberg KE, 2008, NAT GENET, V40, P569, DOI 10.1038/ng.130
   Aigner E, 2008, GASTROENTEROLOGY, V135, P680, DOI 10.1053/j.gastro.2008.04.007
   Dubern B, 2006, INT J PEDIATR OBES, V1, P77, DOI 10.1080/17477160600569594
   Nelson JE, 2012, HEPATOLOGY, V56, P1730, DOI 10.1002/hep.25856
   Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Aigner E, 2013, J NUTR BIOCHEM, V24, P112, DOI 10.1016/j.jnutbio.2012.02.017
   Martinez-Garcia MA, 2009, DIABETES CARE, V32, P1525, DOI 10.2337/dc09-0420
   Ku BJ, 2009, DIS MARKERS, V27, P303, DOI 10.3233/DMA-2009-0676
   Valenti L, 2003, DIGEST LIVER DIS, V35, P172, DOI 10.1016/S1590-8658(03)00025-2
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Ramakrishnan U, 2002, AM J CLIN NUTR, V76, P1256
   Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008
   SULLIVAN JL, 1981, LANCET, V1, P1293
   Fargion S, 2001, AM J GASTROENTEROL, V96, P2448
   Chitturi S, 2002, HEPATOLOGY, V36, P142, DOI 10.1053/jhep.2002.33892
   Guillygomarc'h A, 2001, J HEPATOL, V35, P344, DOI 10.1016/S0168-8278(01)00147-7
   Pietrangelo A, 2007, HEPATOLOGY, V46, P1291, DOI 10.1002/hep.21886
   Beaton MD, 2012, ANN HEPATOL, V11, P294
   Facchini FS, 1998, DIABETES CARE, V21, P2190
   Fierbinţeanu-Braticevici Carmen, 2002, Rom J Intern Med, V40, P81
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Piperno A, 2004, LIVER INT, V24, P471, DOI 10.1111/j.1478-3231.2004.0988.x
   Tanno T, 2009, BLOOD, V114, P181, DOI 10.1182/blood-2008-12-195503
   Valenti L, 2003, GASTROENTEROLOGY, V124, P866, DOI 10.1053/gast.2003.50130
NR 72
TC 25
Z9 27
U1 3
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD FEB
PY 2013
VL 43
IS 2
BP 215
EP 224
DI 10.1111/eci.12032
PG 10
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 074NA
UT WOS:000313818000013
PM 23289518
ER

PT J
AU Kordas, K
   Centeno, ZYF
   Pachon, H
   Soto, AZJ
AF Kordas, Katarzyna
   Fonseca Centeno, Zulma Yanira
   Pachon, Helena
   Jimenez Soto, Ana Zulema
TI Being Overweight or Obese Is Associated with Lower Prevalence of Anemia
   among Colombian Women of Reproductive Age
SO JOURNAL OF NUTRITION
LA English
DT Article
ID IRON-DEFICIENCY ANEMIA; DEVELOPING-COUNTRIES; LATIN-AMERICA; PRETERM
   BIRTH; WEIGHT STATUS; CHILDREN; HEPCIDIN; ADOLESCENTS; RISK; ABSORPTION
AB Overweight and micronutrient deficiencies have manifested in the same individuals. This study investigated the association among iron deficiency (ID), anemia, and weight status among nonpregnant Colombian females aged 13-49 y (n = 3267). Data from the 2005 National Survey of the Nutrition Situation were used. The prevalence of ID (plasma ferritin <12.0 mu g/L; individuals with CRP >0.012 g/L excluded) and anemia (altitude-adjusted hemoglobin <120 g/L) was estimated separately. The likelihood of having ID or anemia was tested as a function of overweight (BMI-age Z-score 1-1.9 SD for 13-17 y, BMI 25.0-29.9 kg/m(2) for 18-49 y) and obesity (>= 2 SD for 13-17 y, >= 30 kg/m(2) for 18-49 y) using multivariate logistic regressions accounting for survey design. Additionally, demographic predictors of combined oveweight/obesity with ID or anemia were identified. The prevalence of overweight and obesity was 29.2 and 13.1%, respectively, whereas that of ID and anemia was 16.1 and 32.5%, respectively. Contrary to previous reports, overweight and obese women had a lower likelihood of anemia [OR (95% Cl) = 0.8 (0.7, 0.9) and 0.8 (0.6, 1.0), respectively] than normal-weight women. Overweight/obesity combined with ID or anemia was present among 6.3 and 12.8% of women, respectively. Although overweight and obesity were associated with a lower likelihood of anemia, a sizeable group of women was identified as experiencing both over- and undernutrition. Because of the potential for exacerbated health problems in the presence of over- and undernutrition, these conditions should continue to be monitored. J. Nutr. 143: 175-181, 2013.
C1 [Kordas, Katarzyna] Penn State Univ, Dept Nutr Sci, State Coll, PA USA.
   [Fonseca Centeno, Zulma Yanira] Inst Colombiano Bienestar Familiar, Bogota, Colombia.
   [Pachon, Helena; Jimenez Soto, Ana Zulema] Ctr Int Agr Trop, Cali, Colombia.
   [Jimenez Soto, Ana Zulema] Secretaria Distrital Salud, Bogota, Colombia.
RP Kordas, K (reprint author), Penn State Univ, Dept Nutr Sci, State Coll, PA USA.
EM kxk48@psu.edu
CR Allen LH, 2001, J NUTR, V131, p581S
   Goldfield GS, 2010, J SCHOOL HEALTH, V80, P186, DOI 10.1111/j.1746-1561.2009.00485.x
   Karl JP, 2009, J AM COLL NUTR, V28, P37
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Mendez MA, 2005, AM J CLIN NUTR, V81, P714
   Neymotin F, 2011, OBESITY, V19, P191, DOI 10.1038/oby.2010.112
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Rodriguez A, 2010, J CHILD PSYCHOL PSYC, V51, P134, DOI 10.1111/j.1469-7610.2009.02133.x
   de Wit L, 2010, PSYCHIAT RES, V178, P230, DOI 10.1016/j.psychres.2009.04.015
   Wildman RP, 2008, OBESITY, V16, P1448, DOI 10.1038/oby.2008.208
   Monteiro CA, 2004, B WORLD HEALTH ORGAN, V82, P940
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Doak CM, 2000, J NUTR, V130, P2965
   Eftekhari MH, 2009, PUBLIC HEALTH NUTR, V12, P2377, DOI 10.1017/S1368980009005187
   Eckhardt CL, 2008, EUR J CLIN NUTR, V62, P238, DOI 10.1038/sj.ejcn.1602727
   Chambers EC, 2006, J AM DIET ASSOC, V106, P680, DOI 10.1016/j.jada.2006.02.013
   Fishman SM, 2000, PUBLIC HEALTH NUTR, V3, P125, DOI 10.1017/S1368980000000173
   Aschner P, 2002, DIABETES METAB RES, V18, pS27, DOI 10.1002/dmrr.280
   Neggers YH, 2003, ACTA OBSTET GYN SCAN, V82, P235, DOI 10.1034/j.1600-0412.2003.00090.x
   Fanou-Fogny N, 2011, BRIT J NUTR, V105, P574, DOI 10.1017/S0007114510003776
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Leong WI, 2004, J NUTR, V134, P1
   Lee J, 2012, ECON HUM BIOL, V10, P232, DOI 10.1016/j.ehb.2011.08.002
   Stoltzfus RJ, 1997, AM J CLIN NUTR, V65, P153
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Beard JL, 2006, AM J CLIN NUTR, V84, P1498
   Corwin EJ, 2003, J NUTR, V133, P4139
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Ruager-Martin R, 2010, EARLY HUM DEV, V86, P715, DOI 10.1016/j.earlhumdev.2010.08.007
   DIRREN H, 1994, EUR J CLIN NUTR, V48, P625
   Departamento Administrativo Nacional de Estadistica-DANE, 2005, CENS GEN 2005 NIV NA
   Departamento Nacional de Planeacion, 2001, DOCUMENTO CONPES SOC
   [DNP DDS SPSCV], 2011, IND POBR MULT IPM CO, P1
   Instituto Colombiano de Bienestar Familiar, 2006, ENC NAC SIT NUTR COL
   McDonald SD, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3428
   Murray-Kolb LE, 2009, AM J CLIN NUTR, V89, p946S, DOI 10.3945/ajcn.2008.26692D
   Neufeld LM, 2008, OBESITY, V16, P714, DOI 10.1038/oby.2007.119
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   [PAHO WHO], 2008, AN AD YOUNG AD WOM L
   Perez EM, 2005, J NUTR, V135, P850
   Profamilia, 2005, SAL SEX REPR COL ENC
   Rasmussen KM, 2001, J NUTR, V131, p590S
   Rueda-Clausen CF, 2008, INT J CARDIOL, V125, P111, DOI 10.1016/j.ijcard.2006.12.092
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-37
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   WHO, 2001, IR DEF AN ASS PREV C
NR 51
TC 7
Z9 7
U1 1
U2 12
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD FEB
PY 2013
VL 143
IS 2
BP 175
EP 181
DI 10.3945/jn.112.167767
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 077CC
UT WOS:000314004500009
PM 23236023
ER

PT J
AU Zhou, YP
   Liu, TT
   Jia, CQ
AF Zhou, Yunping
   Liu, Tongtao
   Jia, Chongqi
TI Joint effects of serum ferritin and body mass index on the risk of
   coronary artery disease: a case-control study
SO BMJ OPEN
LA English
DT Article
DE Public Health; Nutrition & Dietetics
ID OXIDATIVE STRESS; HEART-DISEASE; OBESITY; ASSOCIATION; IRON; MORTALITY;
   WOMEN; MEN
AB Objectives Serum ferritin and body mass index (BMI) have been reportedly associated with coronary artery disease (CAD) risk. The aim of the present study was to explore the interaction between serum ferritin and BMI on CAD risk.
   Design Hospital-based case-control study.
   Setting Patients with CAD and the controls were recruited from Qilu Hospital, Shandong University.
   Participants 258 CAD cases and 282 healthy controls.
   Methods Multiplicative interaction was assessed through a cross-product interaction term in a multivariate logistic regression model. The effect of serum ferritin and BMI were evaluated per 50 mu g/L and per 2kg/m(2), respectively. The presence of additive interaction between serum ferritin and BMI was evaluated by calculation of the relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP) and synergy index (S).
   Results The ORs and 95% CI of the serum ferritin-BMI product term on a multiplicative scale in the univariate and multivariate models were 0.943 (0.904 to 0.984) and 1.004 (0.951 to 1.059), respectively. There was also evidence for interaction on an additive scale; the RERI (95% CI), AP (95% CI) and S (95% CI) in the univariate model were 0.314 (0.026 to 1.506), 0.107 (0.017 to 0.241) and 1.194 (1.053 to 1.406), respectively. After adjusting for the potential confounders, the estimates and 95% CIs for the aforementioned three measures were 0.004 (-0.016 to 0.311), 0.004 (-0.016 to 0.191) and 1.039 (0.774 to 1.285), respectively.
   Conclusions Serum ferritin and BMI had an additive interaction on the risk of CAD in Chinese population. Further investigations with big sample size are necessary for confirming this additive interaction.
C1 [Zhou, Yunping; Jia, Chongqi] Shandong Univ, Dept Epidemiol & Hlth Stat, Jinan 250100, Shandong, Peoples R China.
   [Liu, Tongtao] Shandong Univ, Qilu Hosp, Dept Cardiol, Jinan 250100, Shandong, Peoples R China.
RP Jia, CQ (reprint author), Shandong Univ, Dept Epidemiol & Hlth Stat, Jinan 250100, Shandong, Peoples R China.
EM jiachongqi@sdu.edu.cn
FU National Natural Science Foundation of China [81072357]; Ministry of
   Education of China
FX This study was jointly sponsored by a grant from the National Natural
   Science Foundation of China (81072357) and the Scholarship Award for
   Excellent Doctoral Student granted by Ministry of Education of China.
CR Zhou YP, 2012, CLIN BIOCHEM, V45, P1336, DOI 10.1016/j.clinbiochem.2012.06.013
   Manson JE, 2004, ARCH INTERN MED, V164, P249, DOI 10.1001/archinte.164.3.249
   Farkouh ME, 2013, J AM COLL CARDIOL, V61, P1607, DOI 10.1016/j.jacc.2013.01.044
   Coutinho T, 2013, J AM COLL CARDIOL, V61, P553, DOI 10.1016/j.jacc.2012.10.035
   Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]
   Vassalle C, 2008, CLIN BIOCHEM, V41, P1162, DOI 10.1016/j.clinbiochem.2008.07.005
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Assmann SF, 1996, EPIDEMIOLOGY, V7, P286, DOI 10.1097/00001648-199605000-00012
   Basu S, 1998, FEBS LETT, V438, P159, DOI 10.1016/S0014-5793(98)01290-3
   Roberts R, 2012, J AM COLL CARDIOL, V60, P1715, DOI 10.1016/j.jacc.2011.12.062
   Oudit GY, 2004, CIRCULATION, V109, P1877, DOI 10.1161/01.CIR.0000124229.40424.80
   Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   [Anonymous], 1979, CIRCULATION, V59, P607
   Arosio P, 2009, BBA-GEN SUBJECTS, V1790, P589, DOI 10.1016/j.bbagen.2008.09.004
   Eckel RH, 2011, DIABETES CARE, V34, P1424, DOI 10.2337/dc11-0447
   Morrow JD, 2003, ARTERIOSCL THROM VAS, V23, P368, DOI 10.1161/01.ATV.0000063107.86298.FD
   Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935
   SULLIVAN JL, 1981, LANCET, V1, P1293
   Sung KC, 2012, ARTERIOSCL THROM VAS, V32, P2525, DOI 10.1161/ATVBAHA.112.253088
   Crist BL, 2009, J WOMENS HEALTH, V18, P795, DOI 10.1089/jwh.2008.0988
   Canoy D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-87
   Dominguez-Rodriguez A, 2011, INT J CARDIOL, V152, P129, DOI 10.1016/j.ijcard.2011.07.052
   Fernandez-Sanchez A, 2011, INT J MOL SCI, V12, P3117, DOI 10.3390/ijms12053117
   Kalilani Linda, 2006, Epidemiol Perspect Innov, V3, P5, DOI 10.1186/1742-5573-3-5
   Krauss Ronald M., 1998, Circulation, V98, P1472
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   OSHAUG A, 1995, EUR J CLIN NUTR, V49, P430
   Rothman K, 2008, MODERN EPIDEMIOLOGY
NR 29
TC 2
Z9 2
U1 1
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2013
VL 3
IS 11
DI 10.1136/bmjopen-2013-003695
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 293AL
UT WOS:000329943700064
ER

PT J
AU Cheng, HL
   Griffin, HJ
   Bryant, CE
   Rooney, KB
   Steinbeck, KS
   O'Connor, HT
AF Cheng, Hoi Lun
   Griffin, Hayley J.
   Bryant, Christian E.
   Rooney, Kieron B.
   Steinbeck, Katharine S.
   O'Connor, Helen T.
TI Impact of diet and weight loss on iron and zinc status in overweight and
   obese young women
SO ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE obesity; weight loss; young adult; iron; zinc
ID BARIATRIC SURGERY; TRANSFERRIN RECEPTOR; HEPCIDIN LEVELS; SERUM
   HEPCIDIN; DEFICIENCY; DISEASE; PROTEIN; ADULTS; INFLAMMATION;
   MAINTENANCE
AB Young overweight women are at risk of iron and zinc deficiency. This study assessed iron, zinc and inflammatory status during a 12-month weight loss trial in young women (18-25 y; BMI >= 27.5 kg/m(2)) randomised to a higher-protein (HP: 32% protein; 12.2 mg/day iron; 11.7 mg/day zinc) or lower-protein (LP: 20%; 9.9 mg/day; 7.6 mg/day respectively) diet with contrasting haem iron and zinc content. In completers (HP: n=21; LP: n=15), HP participants showed higher median ferritin (52.0 vs 39.0 mu g/L; p=0.021) and lower median soluble transferrin receptor-ferritin index (sTfR-F; 0.89 vs 1.05; p=0.024) although concentrations remained within normal range for both diets. Median C-reactive protein (CRP; HP: 3.54; LP: 4.63 mg/L) and hepcidin (HP: 5.70; LP: 8.25 ng/mL) were not elevated at baseline, and no longitudinal between-diet differences were observed for zinc and CRP. Compared to those with <5% weight loss, HP participants losing >= 10% weight showed lower median sTfR-F (0.76 vs 1.03; p=0.019) at six months. Impact of >= 10% weight loss on iron was more apparent in LP participants who exhibited greater mean serum iron (20.0 vs 13.5 mu mol/L.; p=0.002), transferrin saturation (29.8% vs 19.4%; p=0.001) and lower sTfR (1.24 vs 1.92 mg/L; p=0.034) at 12 months. Results show normal iron and zinc status can be maintained during 12 months of energy restriction. In the absence of elevated baseline inflammation and hepcidin, a more favourable iron profile in those with >= 10% weight loss may reflect stronger compliance or the potential influence of iron regulatory mechanisms unrelated to inflammatory hepcidin reduction.
C1 [Cheng, Hoi Lun; Griffin, Hayley J.; Rooney, Kieron B.; O'Connor, Helen T.] Univ Sydney, Fac Hlth Sci, Discipline Exercise & Sport Sci, Lidcombe, NSW 1825, Australia.
   [Bryant, Christian E.] Univ Sydney, Anzac Res Inst, Sydney, NSW 2006, Australia.
   [Steinbeck, Katharine S.] Univ Sydney, Acad Dept Adolescent Med, Sydney, NSW 2006, Australia.
RP Cheng, HL (reprint author), Univ Sydney, Fac Hlth Sci, Discipline Exercise & Sport Sci, POB 170, Lidcombe, NSW 1825, Australia.
EM hche3056@uni.sydney.edu.au
RI O'Connor, Helen/C-1289-2014
FU Meat and Livestock Australia
FX This study was supported by Meat and Livestock Australia. The authors
   declare that Meat and Livestock Australia did not have any influence on
   the results or conclusions drawn.
CR Garcia OP, 2009, NUTR REV, V67, P559, DOI 10.1111/j.1753-4887.2009.00228.x
   Suominen P, 1998, BLOOD, V92, P2934
   MONSEN ER, 1978, AM J CLIN NUTR, V31, P134
   HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320
   Wadden TA, 2003, ENDOCRIN METAB CLIN, V32, P981, DOI 10.1016/S0889-8529(03)00072-0
   Ball K, 2002, INT J OBESITY, V26, P1570, DOI 10.1038/sj.ijo.0802150
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Monteiro R, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/289645
   Otto MCD, 2012, J NUTR, V142, P526, DOI 10.3945/jn.111.149781
   Ramalho R, 2009, OBES SURG, V19, P915, DOI 10.1007/s11695-009-9848-0
   [Anonymous], 1999, NAT PHYS ACT GUID AD
   Cheng HL, 2012, OBES REV, V13, P150, DOI 10.1111/j.1467-789X.2011.00938.x
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Rosado JL, 2011, J AM DIET ASSOC, V111, P1507, DOI 10.1016/j.jada.2011.07.011
   Noakes M, 2005, AM J CLIN NUTR, V81, P1298
   Bansal SS, 2010, RAPID COMMUN MASS SP, V24, P1251, DOI 10.1002/rcm.4512
   Macdougall IC, 2010, CLIN J AM SOC NEPHRO, V5, P1681, DOI 10.2215/CJN.05990809
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   Ishikawa Y, 2005, IN VIVO, V19, P1035
   Stein CJ, 2004, J CLIN ENDOCR METAB, V89, P2522, DOI 10.1210/jc.2004-0288
   Wortsman J, 2000, AM J CLIN NUTR, V72, P690
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   Astrup A, 2010, INT J OBESITY, V34, P947, DOI 10.1038/ijo.2010.81
   Australian Bureau of Statistics, 1998, NAT NUTR SURV NUTR I
   Betts S, 1999, BODYLINES WEIGHT MAN
   Bialostosky K, 2002, VITAL HLTH STAT, V11
   Brown K.H., 2004, FOOD NUTR BULL, V25, pS99
   Damms-Machado A, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-34
   Franklin M, 2010, CLIN CHEM, V56, pA171
   Griffin HJ, 2013, DIABETES OBES METAB, V15, P572, DOI 10.1111/dom.12056
   Koulaouzidis A, 2009, SCAND J GASTROENTERO, V44, P126, DOI 10.1080/00365520802555983
   LIAO YL, 1994, AM J EPIDEMIOL, V139, P704
   Martinelli N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048250
   National Health and Medical Research Council, 2006, NUTR REF VAL AUSTR N
   Nelson M, 1997, PHOTOGRAPHIC ATLAS F
   O'Connor H, 2011, ASIA PAC J CLIN NUTR, V20, P206
   Pasquali R., 1997, Human Reproduction (Oxford), V12, P82
   Poobalan AS, 2010, OBES REV, V11, P580, DOI 10.1111/j.1467-789X.2009.00673.x
   Popkin BM, 2010, AM J CLIN NUTR, V91, p284S, DOI 10.3945/ajcn.2009.28473C
   Ruxton C. H. S., 2013, Nutrition Bulletin, V38, P178, DOI 10.1111/nbu.12000
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S
   Sullivan S, 2007, INT J OBESITY, V31, P669, DOI 10.1038/sj.ijo.0803464
   Beard J, 2000, AM J CLIN NUTR, V72, p594S
   Tremblay A, 2008, APPL PHYSIOL NUTR ME, V33, P791, DOI 10.1139/H08-038
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   WEBB JL, 1980, J REPROD MED, V25, P150
   WHO, 2001, IR DEF AN ASS PREV C
   Wing RR, 2005, AM J CLIN NUTR, V82, p222S
   World Health Organization, 2011, WAIST CIRC WAIST HIP
   Zive MM, 1996, J ADOLESCENT HEALTH, V19, P39, DOI 10.1016/1054-139X(96)00022-5
NR 50
TC 1
Z9 1
U1 2
U2 8
PU H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI MCKINNON
PA PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
SN 0964-7058
J9 ASIA PAC J CLIN NUTR
JI Asia Pac. J. Clin. Nutr.
PY 2013
VL 22
IS 4
BP 574
EP 582
DI 10.6133/apjcn.2013.22.4.08
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 267KS
UT WOS:000328097100013
PM 24231018
ER

PT J
AU Przybyszewska, J
   Zekanowska, E
   Kedziora-Kornatowska, K
   Boinska, J
   Porzych, K
   Przybyszewski, M
   Cichon, R
AF Przybyszewska, Justyna
   Zekanowska, Ewa
   Kedziora-Kornatowska, Kornelia
   Boinska, Joanna
   Porzych, Katarzyna
   Przybyszewski, Michal
   Cichon, Roman
TI Comparison of serum prohepcidin and iron metabolism parameters in obese
   and non-obese elderly individuals
SO ENDOKRYNOLOGIA POLSKA
LA English
DT Article
DE iron metabolism; obesity; prohepcidin
ID REGULATORY PEPTIDE HEPCIDIN; BODY-MASS INDEX; ANTIMICROBIAL ACTIVITY;
   ADIPOSE-TISSUE; DEFICIENCY; EXPRESSION; ANEMIA; INFLAMMATION; CHILDREN;
   HYPOXIA
AB Introduction: Current knowledge indicates that there is a close connection between being overweight, obesity and iron metabolism disorders, but the underlying mechanism is unclear. Hepcidin could be a major contributor to poor iron status observed in the obese population.
   Material and methods: The study was performed in 58 obese elderly individuals (F/M 34/24) aged 65-91 (78.92 +/- 8.32) years. The control group consisted of 15 non-obese elderly volunteers, age-and sex-matched. Based on the WHO definition, 36 (62%) obese individuals were diagnosed with normo-or microcytic anaemia. The following parameters were determined: prohepcidin, haemoglobin, serum iron, erythropoietin, ferritin and C-reactive protein (CRP).
   Results: Prohepcidin concentrations were significantly increased in obese elderly individuals without anaemia compared to obese and anaemic (p < 0.01) as well as non-obese volunteers (p < 0.01). In obese individuals with anaemia there was a decrease in serum iron, concomitant with increased levels of erythropoietin and CRP compared to two other groups. Ferritin concentration was increased in obese people (with and without anaemia) compared to the non-obese group. Serum prohepcidin levels were positively correlated with fat mass percentage in obese individuals without and with anaemia (r = 0.32; p = 0.02).
   Conclusion: Results of this preliminary study suggest that body fat content does have an impact on prohepcidin concentration, and thereby on iron homeostasis.
C1 [Przybyszewska, Justyna; Cichon, Roman] Nicolaus Copernicus Univ Torun, Dept Nutr & Dietet, Coll Med Bydgoszcz, Torun, Poland.
   [Zekanowska, Ewa; Boinska, Joanna] Nicolaus Copernicus Univ Torun, Dept Pathophysiol, Coll Med Bydgoszcz, Torun, Poland.
   [Kedziora-Kornatowska, Kornelia; Porzych, Katarzyna] Nicolaus Copernicus Univ Torun, Dept & Clin Geriatr, Coll Med Bydgoszcz, Torun, Poland.
   [Przybyszewski, Michal] Nicolaus Copernicus Univ Torun, Clin Allergol Clin Immunol & Internal Dis, Coll Med Bydgoszcz, Torun, Poland.
RP Przybyszewska, J (reprint author), Dept Nutr & Dietet, Debowa St, PL-85626 Bydgoszcz, Poland.
EM j.szwarc@wp.pl
RI Porzych, Katarzyna/G-8603-2014; Boinska, Joanna/H-6707-2014; Zekanowska,
   Ewa/H-2280-2014; Przybyszewska, Justyna/D-7936-2014
OI Przybyszewska, Justyna/0000-0002-0715-3670
CR Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   Villareal DT, 2005, AM J CLIN NUTR, V82, P923
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Chung B, 2007, J NUTR, V137, P2366
   Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260
   Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Rivera S, 2005, BLOOD, V105, P1797, DOI 10.1182/blood-2004-08-3375
   Lago F, 2007, NAT CLIN PRACT RHEUM, V3, P716, DOI 10.1038/ncprheum0674
   Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   Merle U, 2007, ENDOCRINOLOGY, V148, P2663, DOI 10.1210/en.2006-1331
   Vokurka M, 2010, PHYSIOL RES, V59, P393
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Hunter HN, 2002, J BIOL CHEM, V277, P37597, DOI 10.1074/jbc.M205305200
   Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Sorkin JD, 1999, AM J EPIDEMIOL, V150, P969
   Balducci L, 2003, J AM GERIATR SOC, V51, P2, DOI 10.1046/j.1532-5415.51.3s.4.x
   Bekri S, 2006, GASTROENTEROLOGY, V131, P691
   Benedict C, 2007, HAEMATOL-HEMATOL J, V92, P125, DOI 10.3324/haematol.10637
   Farahani P, 2004, OBES RES, V12, P191, DOI 10.1038/oby.2004.26
   Guralnik J. M., 2005, HEMATOL-AM SOC HEMAT, V1, P528
   Hadley KB, 2006, AM J CLIN NUTR, V84, P150
   Heymsfield SB, 1998, MODERN NUTR HLTH DIS, P817
   Laine F, 2005, J HEPATOL, V43, P1055, DOI 10.1016/j.jhep.2005.05.027
   Leung PS, 2005, GUT, V54, P1391, DOI 10.1136/gut.2004.062083
   Przybyszewska J, 2011, J NUTR HEALTH AGING, V15, P259, DOI 10.1007/s12603-010-0320-6
   Ritz P, 2009, J NUTR HEALTH AGING, V13, P168
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-37
   Szczygiel B., 2001, PODSTAWY NAUKOWE YWI, P324
   Tussing-Humphreys L, 2011, THESCIENTIFICWORLDJO, V11, P2197, DOI 10.1100/2011/634861
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   Yamaji S, 2004, BLOOD, V104, P2178, DOI 10.1182/blood-2004-03-0829
   YOUNG VR, 1992, NUTR REV, V50, P454
NR 40
TC 0
Z9 0
U1 0
U2 2
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND
SN 0423-104X
J9 ENDOKRYNOL POL
JI Endokrynol. Pol.
PY 2013
VL 64
IS 4
BP 272
EP 277
DI 10.5603/EP.2013.0005
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 254WL
UT WOS:000327199700007
PM 24002954
ER

PT J
AU Chang, JS
   Lin, SM
   Huang, TC
   Chao, JCJ
   Chen, YC
   Pan, WH
   Bai, CH
AF Chang, Jung-Su
   Lin, Shiue-Ming
   Huang, Tzu-chieh
   Chao, Jane C-J
   Chen, Yi-Chun
   Pan, Wen-Harn
   Bai, Chyi-Huey
TI Serum ferritin and risk of the metabolic syndrome: a population-based
   study
SO ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE metabolic syndrome; serum ferritin; National Nutrition and Health Survey
   in Taiwan; dietary iron intake; obesity
ID INSULIN SENSITIVITY; IRON STORES; GENETIC HEMOCHROMATOSIS;
   DIABETES-MELLITUS; ADIPONECTIN; PREVALENCE; SECRETION; ASIANS; ADULTS;
   CHOLESTEROL
AB Ferritin concentrations in circulation reflect iron stores in healthy individuals. However, elevated serum ferritin (SF) concentrations have recently been implicated in the pathogenesis of the metabolic syndrome (MetS). We aim to investigate factors associated with elevated SF and to evaluate the association between SF and risk of MetS in Taiwanese adults. Data was collected from 2654 healthy individuals aged >= 19 years old, who participated in the Nutrition and Health Survey in Taiwan (NAHSIT Adults 2005-2008). Mean concentrations of SF were 173 +/- 282 ng/mL (men 229 +/- 349 ng/mL and women 119 +/- 180 ng/mL). Prevalence proportion of MetS was 34.6% (men 43.1% and women 26.5%). Prevalence proportion of iron overload was 18.6% (men 21.5% and women 15.8%) and iron deficiency anemia was 5.2% (2.0% for men and 8.3% for women). Individuals with the highest SF tertile (T3) were more likely to consume higher amount of animal protein (p=0.001), betel nuts (p=0.004), and lower amounts of carbohydrates (p<0.0001), compared with the lowest SF group (T1). After adjustments, individuals with the highest SF tertile were associated with risk of MetS compared with those with the lowest (OR=1.724, 95% CI: 1.21-2.45). Serum ferritin concentrations showed a gradient relationship with individual components of MetS (all p<0.0001). Individuals with the highest SF tertile were significantly associated with fasting serum glucose (OR=2.16, 95% CI: 1.75-2.65) and serum triglyceride (OR=2.58, 95% CI: 1.07-3.22) than those with the lowest. In conclusions, our results highlight the crucial role of serum ferritin in the pathogenesis of the MetS in healthy Taiwanese adults.
C1 [Chang, Jung-Su; Huang, Tzu-chieh; Chao, Jane C-J; Chen, Yi-Chun] Taipei Med Univ, Sch Nutr & Hlth Sci, Coll Publ Hlth & Nutr, Taipei, Taiwan.
   [Lin, Shiue-Ming; Bai, Chyi-Huey] Taipei Med Univ, Dept Publ Hlth, Coll Med, Taipei, Taiwan.
   [Pan, Wen-Harn] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
   [Pan, Wen-Harn] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan.
RP Bai, CH (reprint author), Taipei Med Univ, Dept Publ Hlth, Coll Med, Taipei, Taiwan.
EM baich@tmu.edu.tw
RI Pan, Wen-Harn /F-9972-2010
FU Department of Health in Taiwan [DOH94-FS-6-4];  [TMU100-AE1-B09]
FX Data analyzed in this paper were collected by the research project "The
   Third Nutrition and Health Survey in Taiwan (NAHSIT 2005-08, Adults)"
   sponsored by the Department of Health in Taiwan (DOH94-FS-6-4). Dr
   Jung-Su Chang was supported by grant TMU100-AE1-B09.
CR Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421
   Orino K, 2008, VET J, V178, P191, DOI 10.1016/j.tvjl.2007.07.006
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4
   Wu SJ, 2005, ASIA PAC J CLIN NUTR, V14, P211
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   [Anonymous], 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI DOI 10.1001/JAMA.285.19.2486
   McClain DA, 2006, DIABETOLOGIA, V49, P1661, DOI 10.1007/s00125-006-0200-0
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Cohen LA, 2010, BLOOD, V116, P1574, DOI 10.1182/blood-2009-11-253815
   Tan CE, 2004, DIABETES CARE, V27, P1182, DOI 10.2337/diacare.27.5.1182
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505
   Aigner E, 2008, AM J CLIN NUTR, V87, P1374
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17
   Rajpathak S, 2006, DIABETES CARE, V29, P1370, DOI 10.2337/dc06-0119
   Yang WS, 2002, OBES RES, V10, P1104, DOI 10.1038/oby.2002.150
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Pan WH, 2008, OBES REV, V9, P22, DOI 10.1111/j.1467-789X.2007.00434.x
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   Fleming DJ, 1998, AM J CLIN NUTR, V67, P722
   Ku BJ, 2009, DIS MARKERS, V27, P303, DOI 10.3233/DMA-2009-0676
   Barton JC, 2012, CLIN GASTROENTEROL H, V10, P412, DOI 10.1016/j.cgh.2011.11.032
   BENTLEY DP, 1974, J CLIN PATHOL, V27, P786, DOI 10.1136/jcp.27.10.786
   Bingham S., 1987, NUTR ABSTR REV, V7, P706
   Conte D, 1998, ANN INTERN MED, V128, P370
   Fargnoli JL, 2008, AM J CLIN NUTR, V88, P1213, DOI 10.3945/ajcn.2008.26480
   Harris EL, 2007, ARCH INTERN MED, V167, P722, DOI 10.1001/archinte.167.7.722
   Kwan T, 1998, CLIN INVEST MED, V21, P251
   PHELPS G, 1989, LANCET, V2, P233
   Ryoo JH, 2011, DIABETES-METAB RES, V27, P597, DOI 10.1002/dmrr.1211
   Tran TN, 1997, BLOOD, V90, P4979
   WOLFF SP, 1993, BRIT MED BULL, V49, P642
   World Health Organization, 2000, AS PAC PERSP RED OB
   Wu HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013316
NR 38
TC 11
Z9 11
U1 0
U2 3
PU H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI MCKINNON
PA PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
SN 0964-7058
J9 ASIA PAC J CLIN NUTR
JI Asia Pac. J. Clin. Nutr.
PY 2013
VL 22
IS 3
BP 400
EP 407
DI 10.6133/apjcn.2013.22.3.07
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 209YQ
UT WOS:000323796900009
PM 23945410
ER

PT J
AU Fuchs-Tarlovsky, V
   Alvarez-Altamirano, K
   Turquie-Sacal, D
   Alvarez-Flores, C
   Hernandez-Steller, H
AF Fuchs-Tarlovsky, Vanessa
   Alvarez-Altamirano, Karolina
   Turquie-Sacal, Deborah
   Alvarez-Flores, Carolina
   Hernandez-Steller, Hellen
TI Nutritional status and body composition are already affected before
   oncology treatment in ovarian cancer
SO ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE ovarian Cancer; nutritional status; body composition; nutritional
   assessment; bioelectrical impedance analysis
ID FAT DISTRIBUTION; MALNUTRITION; SYMPTOMS; FATNESS; PATIENT; OBESITY;
   WOMEN
AB Poor nutritional status is a common problem among ovarian cancer patients. In order to detect changes in nutritional status and body composition this study investigates anthropometrical and biochemical parameters among these patients. This study included women with ovarian cancer and woman without cancer. Body composition was assessed by bioelectrical impedance analysis (BIA), anthropometrically, and with DXA scan, and total serum protein, albumin, transferrin, hemoglobin, hematocrit levels and total lymphocyte count was also measured. Data from DXA scan and body composition as assessed by BIA was collected from thirty-one women. Student t-test was used to compare differences in means between groups. This study included 120 women, 57 with ovarian cancer and 63 with benign tumors. Both groups of women were overweight. Body fat by skin-fold thickness, arm circumference, serum albumin, total lymphocytes count, as well as transferrin levels were significantly lower in the ovarian cancer group (p<0.05). Ovarian cancer women had lower fat reserves by skin-fold thickness and lower serum proteins even though they were overweight. However, further studies need to use a body composition assessment on all subjects to confirm these results.
C1 [Fuchs-Tarlovsky, Vanessa] Hosp Gen Mexico City, Oncol Ward, Cuauhtemoc, Mexico.
   [Alvarez-Altamirano, Karolina] Nuevo Leon Autonomus Univ, Nuevo Leon, Mexico.
   [Turquie-Sacal, Deborah; Alvarez-Flores, Carolina] Iberoamer Univ, Mexico City, DF, Mexico.
   [Hernandez-Steller, Hellen] San Juan de Dios Hosp, Nutr Support Unit, San Jose, Costa Rica.
RP Fuchs-Tarlovsky, V (reprint author), Hosp Gen Mexico City, Oncol Serv, Doctor Balmis 148, Mexico City 06726, DF, Mexico.
EM vanessafuchs@hotmail.com
CR Vine MF, 2003, GYNECOL ONCOL, V90, P75, DOI 10.1016/S0090-8258(03)00175-6
   Pavelka JC, 2006, CANCER, V107, P1520, DOI 10.1002/cncr.22194
   SELTZER MH, 1979, JPEN-PARENTER ENTER, V3, P157, DOI 10.1177/0148607179003003157
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   Bankhead CR, 2005, BJOG-INT J OBSTET GY, V112, P857, DOI 10.1111/j.1471-0528.2005.00572.x
   Laky B, 2008, AM J CLIN NUTR, V87, P1678
   Goff BA, 2007, CANCER, V109, P221, DOI 10.1002/cncr.22371
   Neovius M, 2006, OBESITY, V14, P1731, DOI 10.1038/oby.2006.199
   Laky B, 2007, EUR J CLIN NUTR, V61, P642, DOI 10.1038/sj.ejcn.1602540
   Parkin DM, 2011, BRIT J CANCER, V105, pS34, DOI 10.1038/bjc.2011.481
   Ottery FD, 1996, NUTRITION, V12, pS15, DOI 10.1016/0899-9007(95)00067-4
   Toth MJ, 2000, INT J OBESITY, V24, P226, DOI 10.1038/sj.ijo.0801118
   Ahmed N, 2005, PROTEOMICS, V5, P4625, DOI 10.1002/pmic.200401321
   Balogun N, 2011, AM I CANC RES ANN RE
   BOLES JM, 1984, RESUSCITATION, V11, P233, DOI 10.1016/0300-9572(84)90020-0
   Cancer Australia, REP NAT OV CANC 2012
   Carlson TH, 2004, KRAUSES FOOD NUTR DI, P440
   Demura Shinichi, 2004, Journal of Physiological Anthropology and Applied Human Science, V23, P93, DOI 10.2114/jpa.23.93
   Fuchs-Tarlovsky V, 2008, RNC, V26, P69
   Fuchs-Tarlovsky V, 2013, SUPPORT CARE CANCER, V21, P1359, DOI 10.1007/s00520-012-1674-6
   Gallardo-Rincón Dolores, 2011, Rev Invest Clin, V63, P665
   Gil KM, 2006, GYNECOL ONCOL, V103, P247, DOI 10.1016/j.ygyno.2006.03.005
   Habicht J P, 1979, NUTR GROWTH, P365
   Lohman TG, 1988, ANTHROPOMETRIC STAND, P55
   Pichard C, 1999, NUTRITION, V15, P676, DOI [10.1016/SO899-9007(99)00122-7, DOI 10.1016/S0899-9007(99)00122-7]
   Ronco DA, 2011, EUR J OBSTET GYN R B, V158, P325, DOI 10.1016/j.ejogrb.2011.05.018
   Shike M, 1996, HEMATOL ONCOL CLIN N, V10, P221, DOI 10.1016/S0889-8588(05)70336-1
   Siri WE, 1961, TECHNIQUE MEASURING, P223
   Tchernof A, 1998, OBES RES, V6, P246
   Van SJ, 2003, CRIT REV ONCOL HEMAT, V47, P1, DOI [10.1016/S1040-8428(03)00093-3, DOI 10.1016/S1040-8428(03)00093-3]
NR 30
TC 2
Z9 2
U1 3
U2 4
PU H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI MCKINNON
PA PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
SN 0964-7058
J9 ASIA PAC J CLIN NUTR
JI Asia Pac. J. Clin. Nutr.
PY 2013
VL 22
IS 3
BP 426
EP 430
DI 10.6133/apjcn.2013.22.3.12
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 209YQ
UT WOS:000323796900012
PM 23945413
ER

PT J
AU Hamza, RT
   Hamed, AI
   Kharshoum, RR
AF Hamza, Rasha T.
   Hamed, Amira I.
   Kharshoum, Reham R.
TI Iron Homeostasis and Serum Hepcidin-25 Levels in Obese Children and
   Adolescents: Relation to Body Mass Index
SO HORMONE RESEARCH IN PAEDIATRICS
LA English
DT Article
DE Body mass index; Hepcidin; Iron deficiency; Obesity
ID TRANSFERRIN RECEPTOR; OVERWEIGHT CHILDREN; HEIGHT VELOCITY; WEIGHT
   VELOCITY; CHRONIC DISEASE; DEFICIENCY; FERRITIN; ANEMIA; PREVALENCE;
   ABSORPTION
AB Background/Aims: The etiology of the hypoferremia of obesity is unclear. Hepcidin is the body's main regulator of systemic iron (Fe) and has been reported to be elevated in obese patients. Thus, we aimed to assess Fe status and serum hepcidin-25 levels and their relationship with body mass index (BMI) in obese Egyptian children and adolescents. Methods: Fifty obese children were compared to 50 age-, sex-and pubertal stage-matched controls. All subjects were subjected to history and anthropometric assessment and measurement of serum Fe, total iron binding capacity (TIBC), ferritin, transferrin saturation (TS), soluble transferrin receptor (sTfR) and hepcidin. Results: Fe, TS and TIBC were lower, while ferritin, sTfR and hepcidin-25 were higher in obese patients than controls. BMI standard deviation score (SDS) correlated negatively with Fe (r = -0.82, p < 0.01), TS (r = -0.79, p = 0.02) and TIBC (r = -0.69, p = 0.02), and positively with ferritin (r = +0.73, p < 0.001), sTfR (r = +0.80, p < 0.01) and hepcidin (r = +0.95, p < 0.001). Higher BMI SDS and hepcidin were risk factors for iron deficiency (ID). Conclusions: Hypoferremia and elevated hepcidin-25 are prevalent in obese children and correlated with BMI SDS. The connection between hepcidin and inflammation could explain the association of ID with obesity. Copyright (C) 2013 S. Karger AG, Basel
C1 [Hamza, Rasha T.; Kharshoum, Reham R.] Ain Shams Univ, Fac Med, Dept Pediat, Cairo, Egypt.
   [Hamed, Amira I.] Ain Shams Univ, Fac Med, Dept Clin Pathol, Cairo, Egypt.
RP Hamza, RT (reprint author), 36 Hisham Labib St,Makram Ebeid St, Cairo 11371, Egypt.
EM rashatarif_2000@hotmail.com
CR Zandman-Goddard G, 2007, AUTOIMMUN REV, V6, P457, DOI 10.1016/j.autrev.2007.01.016
   Ganz T, 2008, BLOOD, V112, P4292, DOI [10.1182/blood-2008-02-139915, 10.1182/blood-2008-02139915]
   TANNER JM, 1976, ARCH DIS CHILD, V51, P170
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Cole TJ, 2002, EUR J CLIN NUTR, V56, P1194, DOI 10.1038/sj.ejcn.1601473
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Phiri KS, 2009, J CLIN PATHOL, V62, P1103, DOI 10.1136/jcp.2009.066498
   FAILLA ML, 1988, J NUTR, V118, P46
   Munoz M, 2009, NUTR HOSP, V24, P640, DOI 10.3305/nh.2009.24.6.4547
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   TANNER JM, 1966, ARCH DIS CHILD, V41, P454
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   WENZEL BJ, 1962, LANCET, V2, P327
   Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood-2007-12-077388
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Wish JB, 2006, CLIN J AM SOC NEPHRO, V1, pS4, DOI 10.2215/CJN.01490506
   FLOWERS CA, 1986, AM J HEMATOL, V23, P141, DOI 10.1002/ajh.2830230209
   FLOWERS CH, 1989, J LAB CLIN MED, V114, P368
   Greenberg AS, 2006, AM J CLIN NUTR, V83, p461S
   GUEST GM, 1957, AMA J DIS CHILD, V93, P486
   Harris RJ, 2004, ARCH DIS CHILD, V89, P154, DOI 10.1136/adc.2003.019703
   National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N
   O'Broin S, 2005, CLIN LAB HAEMATOL, V27, P190, DOI 10.1111/j.1365-2257.2005.00680.x
   Richardson M. W., 2009, INT J PEDIAT ENDOCRI, V2009
   Sanad M, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-34
   Sharma Ajay P, 2009, Adv Pediatr, V56, P135, DOI 10.1016/j.yapd.2009.08.014
   Tussing-Humphreys L, 2012, J ACAD NUTR DIET, V112, P391, DOI 10.1016/j.jada.2011.08.038
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   VERGA F, 2007, BLOOD, V109, P353, DOI DOI 10.1182/BL00D-2006-07-033969)
   World Health Organization, 2001, IR DEF ASS PREV CONT
NR 40
TC 4
Z9 4
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1663-2818
J9 HORM RES PAEDIAT
JI Horm. Res. Paediatr.
PY 2013
VL 80
IS 1
BP 11
EP 17
DI 10.1159/000351941
PG 7
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 219YN
UT WOS:000324547800003
PM 23817203
ER

PT J
AU Pontiroli, AE
   Benetti, A
   Folini, L
   Merlotti, C
   Frige, F
AF Pontiroli, A. E.
   Benetti, A.
   Folini, L.
   Merlotti, C.
   Frige, F.
TI Other aspects of bariatric surgery; liver steatosis, ferritin and
   cholesterol metabolism
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Bariatric surgery; Liver steatosis; Ferritin; Cholesterol metabolism
ID NONALCOHOLIC FATTY LIVER; MORBIDLY OBESE-PATIENTS; BODY IRON STORES;
   INSULIN-RESISTANCE; HEPATIC STEATOSIS; WEIGHT-LOSS; GASTRIC BYPASS;
   SERUM FERRITIN; DISEASE; STEATOHEPATITIS
AB Bariatric surgery developed in the late 1970 to treat severe hyperlipidemias in overweight individuals, not necessarily obese. Several techniques have been developed, and the concept has come first of a surgery for morbid obesity, then of a cure for diabetes in morbid obesity. There are other aspects of bariatric surgery that deserve attention, beyond BMI and diabetes, such as hypertension, poor life expectancy, increased prevalence of cancer, congestive heart failure, social inadequacy. The aim of this presentation is to review some recent development in clinical research, in the fields of liver steatosis, ferritin metabolism, and cholesterol metabolism.
   Liver steatosis, also called fatty liver encompasses a graduation of diseases with different clinical relevance and prognosis. NAFLD correlates with atherosclerosis, insulin resistance and diabetes mellitus. There is now evidence that weight loss, obtained through diet or restrictive surgery, reduces the prevalence (and the severity) of NAFLD.
   An other issue is represented by serum ferritin concentrations, that are strongly associated with fibrosis, portal and lobular inflammation in NAFLD patients, especially in the presence of obesity. Body iron contributes to excess oxidative stress already at non iron overload concentrations. Moreover, serum ferritin is an important and independent predictor of the development of diabetes. Weight loss is accompanied by reduction of ferritin, more after restrictive than malabsorptive surgery.
   Metabolic changes are greater after malabsorptive or mixed surgery than after purely restrictive surgery, and this has been ascribed to a greater weight loss. Studies comparing the two kinds of surgery indicate that, for the same amount of weight loss, decrease of cholesterol is greater with the former than with the latter techniques, and this difference is mainly due to a greater reduction of intestinal absorption of cholesterol. In the choice of surgery for the single patient, among other aspects, malabsorptive surgery seems to be more indicated in subjects with hyperlipidemia, especially with high cholesterol levels. (Nutr Hosp 2013; 28 (Supl. 2):104-108)
C1 [Pontiroli, A. E.; Benetti, A.; Folini, L.; Merlotti, C.; Frige, F.] Univ Milan, Dipartamento Med Chirurg & Odonoiatria, Osped San Paolo, I-20142 Milan, Italy.
RP Pontiroli, AE (reprint author), Univ Milan, Dipartamento Med Chirurg & Odonoiatria, AEP, Osped San Palo, Via A di Rudini 8, I-20142 Milan, Italy.
EM antonio.pontiroli@unimi.it
CR Campos GM, 2008, HEPATOLOGY, V47, P1916, DOI 10.1002/hep.22241
   Gastaldelli A, 2009, HEPATOLOGY, V49, P1537, DOI 10.1002/hep.22845
   Bohte AE, 2011, EUR RADIOL, V21, P87, DOI 10.1007/s00330-010-1905-5
   Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724
   Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x
   Dixon JB, 2006, OBES SURG, V16, P1278, DOI 10.1381/096089206778663805
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   Ramalho R, 2009, OBES SURG, V19, P915, DOI 10.1007/s11695-009-9848-0
   von Drygalski A, 2011, SURG OBES RELAT DIS, V7, P151, DOI 10.1016/j.soard.2010.04.008
   Salonen JT, 1998, BRIT MED J, V317, P727
   Fishbein MH, 1997, MAGN RESON IMAGING, V15, P287, DOI 10.1016/S0730-725X(96)00224-X
   Meisamy S, 2011, RADIOLOGY, V258, P767, DOI 10.1148/radiol.10100708
   Pontiroli AE, 2009, OBES SURG, V19, P745, DOI 10.1007/s11695-008-9626-4
   Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041
   Furuya CK, 2007, J GASTROEN HEPATOL, V22, P510, DOI 10.1111/j.1440-1746.2007.04833.x
   Zhang HS, 2009, P NATL ACAD SCI USA, V106, P2365, DOI 10.1073/pnas.0812600106
   Williamson RM, 2011, DIABETES CARE, V34, P1139, DOI 10.2337/dc10-2229
   Frige F, 2009, NUTR METAB CARDIOVAS, V19, P198, DOI 10.1016/j.numecd.2008.04.005
   McPherson S, 2009, J HEPATOL, V51, P389, DOI 10.1016/j.jhep.2009.04.012
   Bugianesi E, 2004, HEPATOLOGY, V39, P179, DOI 10.1002/hep.20023
   Helling TS, 2008, SURG OBES RELAT DIS, V4, P612, DOI [10.1016/j.soard.2007.11.007, 10.0016/j.soard.2007.11.007]
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Ruhl CE, 2005, CLIN GASTROENTEROL H, V3, P1260, DOI 10.1016/S1542-3565(05)00743-3
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Bays HE, 2004, OBES RES, V12, P1197, DOI 10.1038/oby.2004.151
   Pontiroli AE, 2011, ANN SURG, V253, P484, DOI 10.1097/SLA.0b013e31820d98cb
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Buchwald H, 2010, SURG OBES RELAT DIS, V6, P221, DOI 10.1016/j.soard.2009.09.001
   Forlano R, 2010, GASTROINTEST ENDOSC, V71, P927, DOI 10.1016/j.gie.2009.06.036
   Gastaldelli A, 2009, OBES SURG, V19, P80, DOI 10.1007/s11695-008-9690-9
   Hesp WL, 2011, SURG OBES RELAT DIS
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Machado M, 2006, LIVER INT, V26, P1159, DOI 10.1111/j.1478-3231.2006.01394.x
   Manousou P, 2011, LIVER INT, V31, P730, DOI 10.1111/j.1478-3231.2011.02488.x
   Masci E, CHOLESTEROL LE UNPUB
   Pontiroli AE, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-37
   Pontiroli AE, GLUCOSE CHOLES UNPUB
   Pontiroli AE, 2011, DIABETES S1, V60, pA33
   Pozzato C, 2008, J PEDIATR GASTR NUTR, V47, P493, DOI 10.1097/MPG.0b013e31817b6e10
   Pozzato C, 2007, DIGEST LIVER DIS, V39, P1018, DOI 10.1016/j.dld.2007.06.008
   Prachand VN, 2009, WORLD J SURG, V33, P1989, DOI 10.1007/s00268-009-0101-8
   Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2
   Sessler DI, 2011, OBES SURG
   Tuomainen TP, 2007, FREE RADICAL RES, V41, P324, DOI 10.1080/10715760601091642
   van Werven JR, 2011, AM J ROENTGENOL, V196, pW736, DOI 10.2214/AJR.10.5215
   Weiner RA, 2010, DIGEST DIS, V28, P274, DOI 10.1159/000282102
NR 46
TC 4
Z9 4
U1 0
U2 5
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PY 2013
VL 28
SU 2
BP 104
EP 108
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 127OD
UT WOS:000317707400015
PM 23834053
ER

PT J
AU Bueno, L
   Pizzo, JC
   Marchini, JS
   Dutra-de-Oliveira, JE
   Dos Santos, JE
   Barbosa, F
AF Bueno, Luciana
   Pizzo, Juliana C.
   Marchini, Julio Sergio
   Dutra-de-Oliveira, Jose Eduardo
   Dos Santos, Jose Ernesto
   Barbosa Junior, Fernando
TI Iron (FeSo(4)) bioavailability in obese subjects submitted to bariatric
   surgery
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Iron bioavailability; Nutritional formulation; Obese subjects; Bariatric
   surgery
ID Y GASTRIC BYPASS; NUTRITIONAL-STATUS; MORBID-OBESITY; DEFICIENCY;
   ABSORPTION; HUMANS
AB Background: Iron bioavailability in obese subjects after the ingestion of a nutritional supplement was the aim of this work.
   Methods: Fourteen persons were studied before and after bariatric surgery after the ingestion of a nutritional formulation containing 25 mg iron, 25 g fiber and 800 mg calcium.
   Results: The following ferremia values (median and minimum - maximum) were obtained before and after bariatric surgery, respectively: Fasting, 105 (70 - 364) mu g/dL and 198 (38 - 617) mu g/dL; 1 hour, 103 (63 - 305) mu g/dL and 160 (11 - 207) mu g/dL; 2 hours, 103 (62 - 150) mu g/dL and 141 (10 - 412) mu g/dL; 3 hours. 97 (63 - 190) mu g/dL and 153 (6 - 270) mu g/dL; 4 hours, 91 (58 - 163) mu g/dL and 156 (40 - 251) mu g/dL (p>0.05), with no association of serum iron levels with time. There was a difference in total triglycerides (95 +/- 29 mg/dL and 60 +/- 10 mg/dL) which were correlated with a decrease in serum ferritin levels (r = 0,926, p = 0.008), UIBC (r = 0.910, p = 0.01), total cholesterol (r = 0,918, p = 0.01) and LDL-c fraction (r = 0.830, p = 0.04), with an increase in HDL-c fraction (r = 0,807, p = 0.05).
   Conclusion: Iron bioavailability in obese subjects was affected by the ingestion of the nutritional formulation containing calcium and fiber, a fact that may cause these patients to develop iron deficiency. (Nutr Hosp. 2013;28:100-104) DOI:10.3305/nh.2013.28.1.5974
C1 [Bueno, Luciana; Pizzo, Juliana C.; Marchini, Julio Sergio; Dutra-de-Oliveira, Jose Eduardo; Dos Santos, Jose Ernesto] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, BR-14049 Ribeirao Preto, SP, Brazil.
   [Barbosa Junior, Fernando] Univ Sao Paulo, Fac Pharm Ribeirao Preto, Dept Toxicol, BR-14049 Ribeirao Preto, SP, Brazil.
RP Bueno, L (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Lab Espectrometria Massas Anexo A, Av Bandeirantes 3900, BR-14048900 Monte Alegre Riberao Pre, SP, Brazil.
EM lubuenno@yahoo.com.br
RI Barbosa, Fernando/C-6929-2012; 
OI Barbosa, Fernando/0000-0002-2498-0619; Marchini, Julio
   Sergio/0000-0001-9999-9149
FU Fapesp; SIBAN Foundation
FX We wish to thank the Faculty of Medicine of Ribeirao Preto and the
   University Hospital of Ribeirao Preto for permitting the execution of
   this study. We are grateful to Fapesp and to the SIBAN Foundation for
   financial support. All authors similarly participated in the present
   study. We declare that there are no conflicts of interest.
CR Vargas-Ruiz AG, 2008, OBES SURG, V18, P288, DOI 10.1007/s11695-007-9310-0
   Flancbaum L, 2006, J GASTROINTEST SURG, V10, P1033, DOI 10.1016/j.gassur.2006.03.004
   Lochs H, 2006, CLIN NUTR, V25, P260, DOI 10.1016/j.clnu.2006.01.007
   Palmer CD, 2006, SPECTROCHIM ACTA B, V61, P980, DOI 10.1016/j.sab.2006.09.001
   Cook JD, 1997, AM J CLIN NUTR, V65, P964
   [Anonymous], 1998, STAT GRAPH STAT VERS
   Love AL, 2008, AM J HEMATOL, V83, P403, DOI 10.1002/ajh.21106
   Yoon SJ, 2008, J CLIN BIOCHEM NUTR, V42, P1, DOI 10.3164/jcbn.2008001
   Shah M, 2006, J CLIN ENDOCR METAB, V91, P4223, DOI 10.1210/jc.2006-0557
   Rubio MA, 2007, NUTR HOSP, V22, P124
   Brolin R E, 1998, J Gastrointest Surg, V2, P436, DOI 10.1016/S1091-255X(98)80034-6
   Conway RE, 2006, J NUTR, V136, P1910
   Csendes A, 2005, J GASTROINTEST SURG, V9, P121, DOI 10.1016/j.gassur.2004.05.006
   Dutra-de-Oliveira JE, 1997, ARCH LATINOAM NUT S2, V47, P21
   MATTHEWS JNS, 1990, BRIT MED J, V300, P230
   Reddy MB, 1997, AM J CLIN NUTR, V65, P1805
   Rosa FT, 2007, THESIS UNESP ARARAQU
   SOLOMONS NW, 1983, AM J CLIN NUTR, V37, P566
   Yetley EA, 2007, AM J CLIN NUTR, V85, p269S
NR 19
TC 0
Z9 0
U1 1
U2 6
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD JAN-FEB
PY 2013
VL 28
IS 1
BP 100
EP 104
DI 10.3305/nh.2013.28.1.5974
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 085PJ
UT WOS:000314626400013
PM 23808436
ER

PT J
AU Baumgartner, J
   Smuts, CM
   Aeberli, I
   Malan, L
   Tjalsma, H
   Zimmermann, MB
AF Baumgartner, J.
   Smuts, C. M.
   Aeberli, I.
   Malan, L.
   Tjalsma, H.
   Zimmermann, M. B.
TI Overweight impairs efficacy of iron supplementation in iron-deficient
   South African children: a randomized controlled intervention
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE hepcidin; iron deficiency; nutrition transition; overweight; child
ID OBESE CHILDREN; SERUM HEPCIDIN; UNITED-STATES; ADOLESCENTS; WOMEN;
   INFLAMMATION; EXPRESSION; POPULATION; PREVALENCE; METABOLISM
AB BACKGROUND: Many countries in the nutrition transition have high rates of iron deficiency (ID) and overweight (OW). ID is more common in OW children; this may be due to adiposity-related inflammation reducing iron absorption.
   OBJECTIVE: We investigated whether weight status predicts response to oral iron supplementation in ID South African children.
   DESIGN: A placebo-controlled trial of oral iron supplementation (50 mg, 4 x weeks for 8.5 months) was done in ID 6- to 11-year-old children (n = 321); 28% were OW or obese. BMI-for-age z-scores (BAZ), hepcidin (in a sub-sample), hemoglobin, serum ferritin (SF), transferrin receptor (TfR), zinc protoporphyrin (ZnPP) and C-reactive protein (CRP) were measured; body iron was calculated from the SF to TfR ratio.
   RESULTS: At baseline, BAZ correlated with CRP (r = 0.201, P<0.001) and CRP correlated with hepcidin (r = 0.384, P<0.001). Normal weight children supplemented with iron had significantly lower TfR concentrations at endpoint than the OW children supplemented with iron and the children receiving placebo. Higher BAZ predicted higher TfR (beta = 0.232, P<0.001) and lower body iron (beta = -0.090, P = 0.016) at endpoint, and increased the odds ratio (OR) for remaining ID at endpoint in both the iron and placebo groups (iron: OR 2.31, 95% CI: 1.13, 4.73; placebo: OR 1.78, 95% CI: 1.09, 2.91). In the children supplemented with iron, baseline hepcidin and BAZ were significant predictors of endpoint TfR, with a trend towards a hepcidin x BAZ interaction (P = 0.058).
   CONCLUSION: South African children with high BAZ have a two-fold higher risk of remaining ID after iron supplementation. This may be due to their higher hepcidin concentrations reducing iron absorption. Thus, the current surge in OW in rapidly developing countries may undercut efforts to control anemia in vulnerable groups. The trial is registered at clinicaltrials. gov as NCT01092377. International Journal of Obesity (2013) 37, 24-30; doi: 10.1038/ijo.2012.145; published online 4 September 2012
C1 [Baumgartner, J.; Smuts, C. M.; Malan, L.] North West Univ, CEN, ZA-2520 Potchefstroom, South Africa.
   [Baumgartner, J.; Aeberli, I.; Zimmermann, M. B.] ETH, Lab Human Nutr, Inst Food Nutr & Hlth, Zurich, Switzerland.
   [Tjalsma, H.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Lab Genet Endocrine & Metab Dis, NL-6525 ED Nijmegen, Netherlands.
RP Baumgartner, J (reprint author), North West Univ, CEN, Private Bag X6001,Potchefstroom Campus, ZA-2520 Potchefstroom, South Africa.
EM jeannine.baumgartner@gmail.com
RI Herter-Aeberli, Isabelle/C-8580-2013; Baumgartner, Jeannine/D-2268-2015
OI Herter-Aeberli, Isabelle/0000-0003-0134-6217; Baumgartner,
   Jeannine/0000-0002-9107-4181
FU Unilever Research and Development (Vlaardingen, The Netherlands);
   Medicor Foundation (Vaduz, Principality of Liechtenstein)
FX We thank all the fieldworkers, teachers and principals of the schools
   for their support of the study, the children and parents for their
   participation in the trial, MRC and NWU colleagues and students,
   especially J Greeff, for their assistance during field and laboratory
   work, Anja Fleisch for doing preliminary data analyses and
   interpretation within her Bachelor's thesis, and PL Jooste, and JC
   Jerling for acting as the Safety Monitoring Board. We thank Paul Lohmann
   GmbH (Lomapharm, Emmertal, Germany) for supplying the iron tablets used
   in the trial, and ET Wiegerinck (Hepcidinanalysis.com, Nijmegen, The
   Netherlands) for technical assistance. Financial support for the study
   was provided by Unilever Research and Development (Vlaardingen, The
   Netherlands) and The Medicor Foundation (Vaduz, Principality of
   Liechtenstein).
CR Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
   Chung B, 2007, J NUTR, V137, P2366
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572
   Bourne LT, 2002, PUBLIC HEALTH NUTR, V5, P157, DOI 10.1079/PHN2001288
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631
   Rossi E, 2001, CLIN CHEM, V47, P202
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   [Anonymous], 2001, DIETARY REFERENCE IN, P290
   FAILLA ML, 1988, J NUTR, V118, P46
   Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225
   Li YF, 2008, OBESITY, V16, P1809, DOI 10.1038/oby.2008.296
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   McCann JC, 2007, AM J CLIN NUTR, V85, P931
   WENZEL BJ, 1962, LANCET, V2, P327
   Zimmermann MB, 2005, AM J CLIN NUTR, V82, P1276
   Kroot JJC, 2010, CLIN CHEM, V56, P1570, DOI 10.1373/clinchem.2010.149187
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   Cepeda-Lopez AC, 2011, AM J CLIN NUTR, V93, P975, DOI 10.3945/ajcn.110.005439
   Zimmermann MB, 2008, BRIT J NUTR, V99, pS2, DOI 10.1017/S000711450800679X
   Whitfield JB, 2003, BRIT J HAEMATOL, V120, P860, DOI 10.1046/j.1365-2141.2003.04224.x
   Falzacappa MVV, 2007, BLOOD, V109, P353, DOI 10.1182/blood-2006-07-033969
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Metzgeroth G, 2005, EUR J HAEMATOL, V75, P309, DOI 10.1111/j.1600-0609.2005.00515.x
   Armstrong MEG, 2011, EUR J CLIN NUTR, V65, P835, DOI 10.1038/ejcn.2011.46
   Cepeda-Lopez AC, 2011, INT J VITAM NUTR RES, V80, P263
   Krueger HS, 2005, CONSUMPTION SURVEY F, P121
   Srihari G, 2007, INDIAN PEDIATR, V44, P204
   Swinkels DW, 2008, PLOS ONE, V3, P7
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   Tussing-Humphreys LM, 2009, OBESITY SILVER SPRIN, V18, P1449
   Viatte L, 2009, BIOCHIMIE, V91, P1223, DOI 10.1016/j.biochi.2009.06.012
   WHO, 2001, IR DEF AN ASS PREV C
   World Health Organization, 2010, 10 FACTS OB
NR 39
TC 14
Z9 14
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
J9 INT J OBESITY
JI Int. J. Obes.
PD JAN
PY 2013
VL 37
IS 1
BP 24
EP 30
DI 10.1038/ijo.2012.145
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 068HW
UT WOS:000313358100003
PM 22945607
ER

PT J
AU Leiva, E
   Mujica, V
   Sepulveda, P
   Guzman, L
   Nunez, S
   Orrego, R
   Palomo, I
   Andrews, M
   Arredondo, MA
AF Leiva, Elba
   Mujica, Veronica
   Sepulveda, Pablo
   Guzman, Luis
   Nunez, Sergio
   Orrego, Roxana
   Palomo, Ivan
   Andrews, Monica
   Arredondo, Miguel A.
TI High Levels of Iron Status and Oxidative Stress in Patients with
   Metabolic Syndrome
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Iron; Oxidative stress; oxLDL; TBARS; Insulin; Metabolic syndrome
ID LOW-DENSITY-LIPOPROTEIN; RESISTANCE SYNDROME DESIR; TYPE-2
   DIABETES-MELLITUS; INSULIN-RESISTANCE; BODY IRON; ATHEROSCLEROSIS;
   TRANSFERRIN; FERRITIN; RECEPTOR; OBESITY
AB Studies concerning oxidative stress (OxE) parameters have increased, mainly because of its important role in cardiovascular diseases and diabetes complications. The main objective of this study was to evaluate iron nutrition status and oxidative stress parameters in subjects that had developed metabolic syndrome (MetS). Subjects from the Research Program of Risk Factors for Cardiovascular Disease (n = 155) were studied (ages ranging from 45 to 65 years old) and classified according to the Adult Treatment Panel III criterion. A blood sample was taken after a 12-h fasting period, and basal glucose, insulin, thiobarbituric acid reactive substances (TBARS), oxidized LDL (oxLDL), heme oxygenase (HO) activity, lipid profile, and iron nutrition status were determined. Eighty-five subjects were classified as MetS, and 70 non-MetS. Individuals with MetS showed higher Fe storage (high levels of ferritin, total body iron and low transferrin receptor), oxLDL, TBARS, and homeostatic model assessment for insulin resistance levels. The MetS group showed high levels of oxidative stress parameters (HO activity, oxLDL, and TBARS). The presence of MetS showed an association with LDL oxidation risk (multiple lineal regression according to sex and age, p < 0.001). High levels of triglycerides (p < 0.001) and waist circumference (p < 0.012) were associated with oxLDL levels, as well as an association between TBARS and oxLDL with ferritin levels. Through logistic regression analyses, the highest quartile of ferritin was associated with a threefold risk of developing MetS compared to the lowest quartile; also, TBARS showed a 21-fold risk for the development of MetS. Finally, elevated levels of oxidative stress parameters such us oxLDL, TBARS, HO, and Fe storage were associated to MetS.
C1 [Leiva, Elba; Sepulveda, Pablo; Guzman, Luis; Nunez, Sergio; Orrego, Roxana; Palomo, Ivan] Univ Talca, Res Program Risk Factors Cardiovasc Dis, Dept Clin Biochem & Immunohematol, Fac Hlth Sci, Talca, Chile.
   [Mujica, Veronica] Maule Hlth Serv, Cardiovasc Program, Talca, France.
   [Andrews, Monica; Arredondo, Miguel A.] Univ Chile, Micronutrient Lab, Nutr Inst & Food Technol INTA, Santiago, Chile.
RP Arredondo, MA (reprint author), Univ Chile, Micronutrient Lab, Nutr Inst & Food Technol INTA, Santiago, Chile.
EM marredon@inta.cl
OI Guzman, Luis/0000-0003-1552-7430
FU Research Program of Risk Factors for Cardiovascular Disease at the
   School of Health Science, University of Talca, Chile; Fondecyt [1085173]
FX This research was supported by Research Program of Risk Factors for
   Cardiovascular Disease at the School of Health Science, University of
   Talca, Chile and Fondecyt Grant (#1085173) to MAO.
CR ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   Bonomini F, 2008, HISTOL HISTOPATHOL, V23, P381
   Jo C, 1998, POULTRY SCI, V77, P475
   GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   Holvoet P, 2008, JAMA-J AM MED ASSOC, V299, P2287, DOI 10.1001/jama.299.19.2287
   Soares MP, 2009, TRENDS MOL MED, V15, P50, DOI 10.1016/j.molmed.2008.12.004
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4
   Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0
   HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499
   Covas MI, 2006, FREE RADICAL BIO MED, V40, P608, DOI 10.1016/j.freeradbiomed.2005.09.027
   Weinbrenner T, 2006, AM J CLIN NUTR, V83, P30
   Poulsen HE, 2012, FREE RADICAL BIO MED, V52, P1353, DOI 10.1016/j.freeradbiomed.2012.01.009
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   Dandona P, 2005, CIRCULATION, V111, P1448, DOI 10.1161/01.CIR.0000158483.13093.9D
   Venturini D, 2012, OBESITY, V20, P2361, DOI 10.1038/oby.2012.130
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Bennett BL, 2003, CURR OPIN PHARMACOL, V3, P420, DOI 10.1016/S1471-4892(03)00068-7
   Mashiba S, 2001, ARTERIOSCL THROM VAS, V21, P1801, DOI 10.1161/hq1101.098232
   Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Cederberg J, 2001, PEDIATR RES, V49, P755, DOI 10.1203/00006450-200106000-00007
   Ma ZA, 2012, EXP DIABETES RES, DOI 10.1155/2012/703538
   Itabe H, 2007, J ATHEROSCLER THROMB, V14, P1
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Arredondo M, 2007, AM J CLIN NUTR, V86, P1347
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   HOLVOET P, 1994, FASEB J, V8, P1279
   Hoogeveen RC, 2007, DIABETOLOGIA, V50, P36, DOI 10.1007/s00125-006-0533-8
   Johansen JS, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-5
   Mujica V, 2008, CHIL J NUTR, V7, P14
   National Cholesterol education Program, 2005, NIH PUBL
   Newsholme P, 2007, CLIN SCI, V112, P27, DOI 10.1042/CS20060115
   Palomo I, 2007, REV MED CHILE, V135, P904
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   Tsimikas Sotirios, 2006, Curr Atheroscler Rep, V8, P55, DOI 10.1007/s11883-006-0065-1
   Vasic D, 2012, MEDIAT INFLAMM, DOI 10.1155/2012/858692
   World Health Organization, 2007, ASS IR STAT POP
NR 44
TC 7
Z9 7
U1 1
U2 20
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD JAN
PY 2013
VL 151
IS 1
BP 1
EP 8
DI 10.1007/s12011-012-9525-3
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 061WK
UT WOS:000312880700001
PM 23079936
ER

PT J
AU Varea, A
   Malpeli, A
   Disalvo, L
   Apezteguia, M
   Falivene, M
   Ferrari, G
   Pereyras, S
   Carmuega, E
   Etchegoyen, G
   Vojkovic, M
   Gonzalez, HF
AF Varea, Ana
   Malpeli, Agustina
   Disalvo, Liliana
   Apezteguia, Maria
   Falivene, Mariana
   Ferrari, Guillermina
   Pereyras, Silvia
   Carmuega, Esteban
   Etchegoyen, Graciela
   Vojkovic, Maria
   Gonzalez, Horacio F.
TI Evaluation of the Impact of a Food Program on the Micronutrient
   Nutritional Status of Argentinean Lactating Mothers
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Feeding PROGRAMS; Lactating mothers; Anemia; Micronutrients; Nutritional
   evaluation; Argentina
ID VITAMIN-A STATUS; LOW-INCOME WOMEN; FOLIC-ACID; DEVELOPING-COUNTRIES;
   POSTPARTUM ANEMIA; REPRODUCTIVE AGE; OBESITY; IRON; FORTIFICATION;
   DEFICIENCY
AB This study was conducted to evaluate the impact of a food aid program (Plan Mas Vida, PMV) on the micronutrient nutritional condition of lactating mothers 1 year after its implementation. The food program provided supplementary diets (wheat- and maize-fortified flour, rice or sugar, and fortified soup) to low-income families from the province of Buenos Aires, Argentina. A prospective, non-experimental study was carried out to evaluate the micronutrient nutritional status of lactating mothers (n = 178 at baseline and n = 151 after 1 year). Biochemical tests (hemoglobin, ferritin, zinc, vitamin A, and folic acid), anthropometric assessments (weight and height) and dietary surveys (24-h recall) were performed. We found no significant changes in anthropometric values 1 year after the intervention. The risk for vitamin A (retinol 20-30 mu g/dl) and folate deficiency significantly decreased 1 year after PMV implementation (56.3 vs. 29.9 and 50.3 vs. 3.4 %, respectively; p < 0.001). Anemia was seen in 25.8 % of lactating mothers at baseline, without statistically significant differences 1 year after (p = 0.439). The nutritional data obtained after assessing the early impact of PMV actions may be useful to provincial health authorities to perform periodic evaluations in the future.
C1 [Varea, Ana; Malpeli, Agustina; Disalvo, Liliana; Apezteguia, Maria; Falivene, Mariana; Ferrari, Guillermina; Pereyras, Silvia; Gonzalez, Horacio F.] Hosp Ninos La Plata MS CIC PBA, Inst Desarrollo & Invest Pediat Prof D Fernando E, RA-1900 La Plata, Buenos Aires, Argentina.
   [Etchegoyen, Graciela] Fac Cs Med UNLP, Ctr Interdisciplinario Univ Salud CINUS, Catedra Epidemiol, La Plata, Buenos Aires, Argentina.
   [Carmuega, Esteban; Vojkovic, Maria] Comis Invest Cient Prov Buenos Aires CICPBA, La Plata, Buenos Aires, Argentina.
RP Gonzalez, HF (reprint author), Hosp Ninos La Plata MS CIC PBA, Inst Desarrollo & Invest Pediat Prof D Fernando E, RA-1900 La Plata, Buenos Aires, Argentina.
EM idip01@gmail.com
FU CICPBA; Ministry of Human Development, Province of Buenos Aires
FX This study was funded by CICPBA and the Ministry of Human Development,
   Province of Buenos Aires. The authors are grateful to professionals from
   the Food Program Department of the Ministry of Human Development, Andrea
   Touza for logistics support, and Adriana Di Maggio for manuscript
   edition. Thanks are also due to Prof. Fernando Viteri for a critical
   review of the manuscript.
CR Ahmed F, 2003, PUBLIC HEALTH NUTR, V6, P447, DOI 10.1079/PHN2002454
   Allen LH, 2003, J NUTR, V133, p3875S
   Gibson D, 2003, J NUTR, V133, P2225
   Milman N, 2011, ANN HEMATOL, V90, P1247, DOI 10.1007/s00277-011-1279-z
   Berry RJ, 2010, FOOD NUTR BULL, V31, pS22
   De Wals P, 2007, NEW ENGL J MED, V357, P135, DOI 10.1056/NEJMoa067103
   Frongillo EA, 2003, J NUTR, V133, P2117
   Dijkhuizen MA, 2001, AM J CLIN NUTR, V73, P786
   Hertrampf E, 2003, J NUTR, V133, P3166
   Caballero B, 2005, NEW ENGL J MED, V352, P1514, DOI 10.1056/NEJMp048310
   Singh MB, 2009, PUBLIC HEALTH NUTR, V12, P624, DOI 10.1017/S1368980008002395
   Nakamori M, 2009, J NUTR SCI VITAMINOL, V55, P338, DOI 10.3177/jnsv.55.338
   Olivares M, 2004, NUTRITION, V20, P205, DOI 10.1016/j.nut.2003.11.021
   Huo JS, 2011, ASIA PAC J CLIN NUTR, V20, P118
   Stuetz W, 2012, EUR J NUTR, V51, P425, DOI 10.1007/s00394-011-0226-z
   Gibson D, 2006, J NUTR, V136, P1081
   Jehn M, 2009, ECON HUM BIOL, V7, P28, DOI 10.1016/j.ehb.2009.01.007
   Blanco A, 2003, ARCH LATINOAM NUTR, V53, P28
   Boccio JR, 2003, BIOL TRACE ELEM RES, V94, P1, DOI 10.1385/BTER:94:1:1
   Bodnar LM, 2001, AM J OBSTET GYNECOL, V185, P438, DOI 10.1067/mob.2001.115996
   Brown K. H., 2010, FOOD NUTR BULL, V31, pS62
   Calvo EB, 2008, REV CHIL PEDIATR, V81, P78
   Cavalli-Sforza T, 2005, NUTR REV, V63, pS152
   Correia SAM, 2011, NUTR HOSP, V26, P392
   Dietary Reference Intakes (DRIs), 2002, DIET REF INT EN CARB
   Food and Nutrition Board Institute of Medicine, 1998, DIET REF INT THIAM R
   Hyder SMZ, 2007, J NUTR, V137, P2147
   IVACG, 1993, BRIEF GUID CURR METH
   Klemm RDW, 2010, FOOD NUTR BULL, V31, pS47
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   Ministerio de Desarrollo Social de la Provincia de Buenos Aires, 2004, PLAN MAS VID
   Mitra AK, 2011, PUBLIC HEALTH NUTR, V23, P1
   Portela ML, 1997, APLICACION BIOQUIMIC
   Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1
   Ross Elizabeth M, 2002, Nutr Clin Care, V5, P220, DOI 10.1046/j.1523-5408.2002.05503.x
   Seal A, 2008, PUBLIC HEALTH NUTR, V11, P720, DOI 10.1017/S1368980007001486
   Temple Victor J., 2004, Papua New Guinea Medical Journal, V47, P146
   Uauy R, 2001, J NUTR, V131, p893S
   Uauy R, 2002, PUBLIC HEALTH NUTR, V5, P223, DOI 10.1079/PHN2001297
   WHO, 2009, WEEKL IR FOL SUPPL W
   WHO, OB OV
   Wood J, 1991, CLIN DIAGNOSIS MANAG, P170
NR 42
TC 1
Z9 2
U1 3
U2 12
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD DEC
PY 2012
VL 150
IS 1-3
BP 103
EP 108
DI 10.1007/s12011-012-9512-8
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 050TB
UT WOS:000312075800016
PM 23111948
ER

PT J
AU Goot, K
   Hazeldine, S
   Bentley, P
   Olynyk, J
   Crawford, D
AF Goot, Katie
   Hazeldine, Simon
   Bentley, Peter
   Olynyk, John
   Crawford, Darrell
TI Elevated serum ferritin What should GPs know?
SO AUSTRALIAN FAMILY PHYSICIAN
LA English
DT Article
DE haemochromatosis; venesection; iron
ID METABOLIC SYNDROME; TRANSFERRIN SATURATION; CLINICAL EXPRESSION;
   LIVER-DISEASES; IRON OVERLOAD; FATTY LIVER; HEMOCHROMATOSIS;
   HYPERFERRITINEMIA; POPULATION; REDUCTION
AB Background
   Elevated serum ferritin is commonly encountered in general practice. Ninety percent of elevated serum ferritin is due to noniron overload conditions, where venesection therapy is not the treatment of choice.
   Objective
   This article aims to outline the role of the Australian Red Cross Blood Service Therapeutic Venesection program, to clarify the interpretation of the HFE gene test and iron studies, and to describe the steps in evaluating a patient with elevated serum ferritin.
   Discussion
   After exclusion of hereditary haemochromatosis, investigation of elevated serum ferritin involves identifying alcohol consumption, metabolic syndrome, obesity, diabetes, liver disease, malignancy, infection or inflammation as causative factors. Referral to a gastroenterologist, haematologist or physician with an interest in iron overload is appropriate if serum ferritin is >1000 mu g/L or if the cause of elevated serum ferritin is still unclear.
C1 [Goot, Katie] UQ Rural Clin Sch, Rockhampton, Qld, Australia.
   [Hazeldine, Simon; Olynyk, John] Fremantle Hosp, Dept Gastroenterol, Fremantle, WA, Australia.
   [Bentley, Peter] Australian Red Cross Blood Serv, Med Serv WA, Perth, WA, Australia.
   [Crawford, Darrell] Univ Queensland, Sch Med, Discipline Med, Brisbane, Qld, Australia.
RP Goot, K (reprint author), UQ Rural Clin Sch, Rockhampton, Qld, Australia.
EM k.goot@uq.edu.au
FU Australian governments
FX The authors thank Dr Barbara Bell, National Medical Services Manager,
   Australian Red Cross Blood Service for her assistance in providing
   referral data. Australian governments fully fund the Australian Red
   Cross Blood Service for the provision of blood products and services to
   the Australian community.
CR Trombini P, 2007, J HEPATOL, V46, P549, DOI 10.1016/j.jhep.2007.01.004
   Gurrin LC, 2009, HEPATOLOGY, V50, P94, DOI 10.1002/hep.22972
   Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1053/gast.2002.31903
   Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5
   Zacharski LR, 2008, J NATL CANCER I, V100, P996, DOI 10.1093/jnci/djn209
   LEGGETT BA, 1990, CLIN CHEM, V36, P1350
   Rossi E, 2001, CLIN CHEM, V47, P202
   Allen K, 2010, AUST FAM PHYSICIAN, V39, P938
   Adams PC, 2011, J HEPATOL, V55, P453, DOI 10.1016/j.jhep.2011.02.010
   Wong K, 2006, CAN J GASTROENTEROL, V20, P467
   Dale JC, 2002, AM J CLIN PATHOL, V117, P802, DOI 10.1309/2YT4-CMP3-KYW7-9RK1
   Pietrangelo A, 2007, HEPATOLOGY, V46, P1291, DOI 10.1002/hep.21886
   [Anonymous], 2010, J HEPATOL, V53, P3
   Beaton MD, 2012, ANN HEPATOL, V11, P294
   Bell B, AUSTR RED CROSS BLOO
   Brudevold R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003547
   Centers for Disease Control and Prevention, HEM HLTH CAR PROF
   Chew GT, 2006, MED J AUSTRALIA, V185, P445
   Houschyar KS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-54
   Olynyk JK, 2009, CLIN GASTROENTEROL H, V7, P359, DOI 10.1016/j.cgh.2008.11.010
   Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002
   Pietrangelo A, 2009, J HEPATOL, V50, P249, DOI 10.1016/j.jhep.2008.11.011
   St John AT, 2011, AUST PRESCR, V34, P73
   Valenti L, 2011, QJM-INT J MED, V104, P141, DOI 10.1093/qjmed/hcq170
NR 24
TC 5
Z9 6
U1 1
U2 3
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 0300-8495
J9 AUST FAM PHYSICIAN
JI Aust. Fam. Physician
PD DEC
PY 2012
VL 41
IS 12
BP 945
EP 949
PG 5
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 052WD
UT WOS:000312229700010
PM 23210117
ER

PT J
AU Gan, LX
   Guo, KY
   Cremona, ML
   McGraw, TE
   Leibel, RL
   Zhang, YY
AF Gan, Lixia
   Guo, Kaiying
   Cremona, Maria Laura
   McGraw, Timothy E.
   Leibel, Rudolph L.
   Zhang, Yiying
TI TNF-alpha Up-Regulates Protein Level and Cell Surface Expression of the
   Leptin Receptor by Stimulating Its Export via a PKC-Dependent Mechanism
SO ENDOCRINOLOGY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; SOLUBLE RECEPTOR;
   IMMUNE-RESPONSE; ADIPOSE-TISSUE; SERUM-LEVELS; DB/DB MICE; OBESITY;
   IDENTIFICATION; PATHWAY
AB Increasing evidence suggests that inflammation/cytokines may modulate hypothalamic responses to leptin, which is a key regulator of energy homeostasis and inflammatory/stress responses. We investigated a possible role of TNF-alpha, a key early mediator of inflammation, in regulating the expression and trafficking of the long-isoform leptin receptor (LEPRb), the primary mediator of leptin signaling, in cultured cells. We found that TNF-alpha in a wide range of concentrations up-regulated LEPRb protein level and soluble LEPR (sLEPR) release via ectodomain shedding of LEPRb in multiple cell types, including neuronal cells. TNF-alpha also acutely increased LEPRb cell surface expression and leptin-induced STAT3 phosphorylation. In contrast, TNF-alpha had no significant effects on the protein level or cell surface expression of several other transmembrane proteins, including the transferrin receptor and cadherin. The stimulatory effects of TNF-alpha on LEPRb cell surface expression and sLEPR release were not dependent on de novo protein synthesis or functional lysosomes but were blocked by brefeldin A, suggesting that an intact Golgi or continuous endoplasmic reticulum to Golgi transport of newly synthesized proteins is required for these effects. However, TNF-alpha did not increase the half-life of cell surface LEPRb. Protein kinase C (PKC) inhibitor GF109203X abrogated the effects of TNF-alpha, whereas the pan-PKC activator phorbol 12-myristate 13-acetate mimicked the TNF-alpha effects. Taken together, our results suggest that TNF-alpha, via activation of PKC, regulates anterograde trafficking and/or degradation of LEPRb in the biosynthetic pathway, leading to concomitant increases in LEPRb protein level, cell surface expression, and sLEPR production. The finding that LEPRb cell surface expression and sLEPR production, key modulators of leptin sensitivity and bioavailability, are direct targets of TNF-alpha signaling could have a potentially important implication in the regulation of leptin signaling activity in different pathophysiological conditions as diverse as obesity and sepsis. (Endocrinology 153: 5821-5833, 2012)
C1 [Gan, Lixia; Guo, Kaiying; Cremona, Maria Laura; Leibel, Rudolph L.; Zhang, Yiying] Columbia Univ, Coll Phys & Surg, Div Mol Genet, Dept Pediat, New York, NY 10032 USA.
   [Leibel, Rudolph L.; Zhang, Yiying] Columbia Univ, Coll Phys & Surg, Naomi Berrie Diabet Ctr, New York, NY 10032 USA.
   [Gan, Lixia] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China.
   [McGraw, Timothy E.] Weill Cornell Med Coll, Dept Biochem, New York, NY 10065 USA.
RP Zhang, YY (reprint author), Russ Berrie Pavil,Room 620,1150 St Nicholas Ave, New York, NY 10032 USA.
EM yz84@columbia.edu
FU National Institutes of Health [R01DK063034, R01DK52431, P30 DK26687, P30
   DK63068]; National Natural Science Foundation of China [30971082]
FX This work was supported by grants from the National Institutes of
   Health, R01DK063034 (to Y.Z.), R01DK52431 (to R. L. L.), P30 DK26687,
   and P30 DK63068. L. G. was supported by a grant from the National
   Natural Science Foundation of China (30971082).
CR Cohen P, 2005, J BIOL CHEM, V280, P10034, DOI 10.1074/jbc.M413684200
   Zastrow O, 2003, INT J OBESITY, V27, P1472, DOI 10.1038/sj.ijo.0802432
   Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1
   Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891
   Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962
   de Luca C, 2005, J CLIN INVEST, V115, P3484, DOI 10.1172/jc124059
   Baskin DG, 1999, J HISTOCHEM CYTOCHEM, V47, P353
   Guo KY, 2007, ENDOCRINOLOGY, V148, P3987, DOI 10.1210/en.2007-0261
   DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001
   Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5
   Schulze PC, 2003, EUR J HEART FAIL, V5, P33
   Belouzard S, 2004, J BIOL CHEM, V279, P28499, DOI 10.1074/jbc.M400508200
   Sun Q, 2010, HUM MOL GENET, V19, P1846, DOI 10.1093/hmg/ddq056
   Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0
   Obstfeld AE, 2010, DIABETES, V59, P916, DOI 10.2337/db09-1403
   Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200
   Ge HF, 2002, J BIOL CHEM, V277, P45898, DOI 10.1074/jbc.M205825200
   Myers MG, 2010, TRENDS ENDOCRIN MET, V21, P643, DOI 10.1016/j.tem.2010.08.002
   Clarke CJ, 2008, MOL PHARMACOL, V74, P1022, DOI 10.1124/mol.108.046250
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207
   Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416
   Heiman ML, 1997, ENDOCRINOLOGY, V138, P3859, DOI 10.1210/en.138.9.3859
   Uotani S, 1999, DIABETES, V48, P279, DOI 10.2337/diabetes.48.2.279
   Takahashi N, 1999, J EXP MED, V189, P207, DOI 10.1084/jem.189.1.207
   Guo X, 2011, MUCOSAL IMMUNOL, V4, P294, DOI 10.1038/mi.2010.76
   Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389
   Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660
   Kamikubo Y, 2008, BIOCHEM J, V410, P595, DOI 10.1042/BJ20071137
   Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929
   Diano S, 1998, J NEUROENDOCRINOL, V10, P647, DOI 10.1046/j.1365-2826.1998.00261.x
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388
   Tu H, 2008, J CELL PHYSIOL, V214, P301, DOI 10.1002/jcp.21195
   Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885
   Cohen SE, 2007, J BIOL CHEM, V282, P23672, DOI 10.1074/jbc.M704053200
   Yang GQ, 2004, MOL ENDOCRINOL, V18, P1354, DOI 10.1210/me.2004-0027
   Sethi G, 2008, FRONT BIOSCI, V13, P5094, DOI 10.2741/3066
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596
   Leibel RL, 2008, INT J OBESITY, V32, pS98, DOI 10.1038/ijo.2008.245
   Lehmann W, 2005, BONE, V36, P300, DOI 10.1016/j.bone.2004.10.010
   Seron K, 2011, J BIOL CHEM, V286, P17968, DOI 10.1074/jbc.M111.224857
   Duffy AM, 2005, GENE THER, V12, pS62, DOI 10.1038/sj.gt.3302616
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Loffreda S, 1998, FASEB J, V12, P57
   Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691
   Winkler G, 1999, DIABETIC MED, V16, P207, DOI 10.1046/j.1464-5491.1999.00052.x
   Tschop J, 2010, J NEUROSCI, V30, P6036, DOI 10.1523/JNEUROSCI.4875-09.2010
   Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x
   CALANDRA T, 1990, J INFECT DIS, V161, P982
   Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867
   Lundin A, 2000, BBA-MOL CELL RES, V1499, P130, DOI 10.1016/S0167-4889(00)00114-2
   Olszanecka-Glinianowicz M, 2004, METABOLISM, V53, P1268, DOI 10.1016/j.metabol.2004.07.001
   Orbak Z, 2003, J PEDIATR ENDOCR MET, V16, P727
   Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5
   Voegeling S, 2001, CYTOKINE, V14, P97, DOI 10.1006/cyto.2001.0859
   Wilcke M, 2000, EUR J HISTOCHEM, V44, P325
   Zhang M, 2007, PLACENTA, V28, P779, DOI 10.1016/j.placenta.2007.01.012
NR 59
TC 13
Z9 15
U1 0
U2 12
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD DEC
PY 2012
VL 153
IS 12
BP 5821
EP 5833
DI 10.1210/en.2012-1510
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 046GA
UT WOS:000311752300014
PM 23070544
ER

PT J
AU Insenser, M
   Montes-Nieto, R
   Vilarrasa, N
   Lecube, A
   Simo, R
   Vendrell, J
   Escobar-Morreale, HF
AF Insenser, Maria
   Montes-Nieto, Rafael
   Vilarrasa, Nuria
   Lecube, Albert
   Simo, Rafael
   Vendrell, Joan
   Escobar-Morreale, Hector F.
TI A nontargeted proteomic approach to the study of visceral and
   subcutaneous adipose tissue in human obesity
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Subcutaneous adipose tissue; Visceral adipose tissue; Obesity; Proteome;
   Electrophoresis; Mass spectrometry
ID PRIMARY CULTURES; STEM-CELLS; ADIPOGENESIS; METABOLISM; SECRETOME;
   MODULATION; EXPRESSION; PROTEINS; FRACTION; PLASMA
AB Subcutaneous (SAT) and visceral adipose tissue (VAT) differ in biochemical and metabolic properties, especially when obesity is present. We submitted paired SAT and VAT samples from six morbidly obese patients and six non-obese persons to two-dimensional differential gel electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight mass spectrometry. Compared with non-obese subjects, obese patients presented with increased carboxylesterase-1, zinc finger protein 324A, annexin AS, ubiquitin carboxyl-terminal hydrolase, alpha-crystallin B chain, osteoglycin, retinal dehydrogenase-1 and 14-3-3 protein gamma, and decreased transferrin, complement C3, fibrinogen gamma chain, albumin, alpha 1-antitrypsin and peroxiredoxin-6, irrespective of the adipose tissue depot studied. SAT and VAT differed in protein species of fibrinogen and osteoglycin, whereas adipose tissue depot and obesity interacted on the protein abundance of actin, alpha-actinin 1, one protein species of carboxylesterase-1, retinal dehydrogenase-1 and 14-3-3 protein gamma. Our nontargeted proteomic approach identified novel protein species that may be involved in the development of obesity in humans. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Insenser, Maria; Montes-Nieto, Rafael; Escobar-Morreale, Hector F.] Hosp Univ Ramon y Cajal, E-28034 Madrid, Spain.
   [Insenser, Maria; Montes-Nieto, Rafael; Escobar-Morreale, Hector F.] Univ Alcala De Henares, Diabet Obes & Human Reprod Grp, E-28034 Madrid, Spain.
   [Insenser, Maria; Montes-Nieto, Rafael; Escobar-Morreale, Hector F.] IRYCIS, Madrid, Spain.
   [Vilarrasa, Nuria] Hosp Univ Bellvitge, Dept Endocrinol, Barcelona, Spain.
   [Lecube, Albert; Simo, Rafael] Hosp Univ Vail dHebron, Diabet & Metab Res Grp, Inst Reserca, Barcelona, Spain.
   [Vendrell, Joan] Univ Rovira & Virgili, Diabet & Metab Associated Dis Res Grp, Hosp Univ Tarragona Joan 23, IISPV, Tarragona, Spain.
RP Escobar-Morreale, HF (reprint author), Hosp Univ Ramon y Cajal, Carretera Colmenar Km 91, E-28034 Madrid, Spain.
EM hescobarm.hrc@salud.madrid.org
RI Insenser, Maria/B-9674-2014; Montes Nieto, Rafael/B-9708-2014;
   Escobar-Morreale, Hector/G-5468-2010; 
OI Insenser, Maria/0000-0003-3168-7856; Escobar-Morreale,
   Hector/0000-0003-3025-8996; Vilarrasa, Nuria/0000-0003-3188-1990
FU Instituto de Salud Carlos III, Spanish Ministry of Economy and
   Competitiveness [FIS PI080944, PI110357]; DIA-SOBS from CIBERDEM, an
   initiative of Instituto de Salud Carlos III
FX This study was supported by Grants FIS PI080944 and PI110357 from Fondo
   de Investigacion Sanitaria, Instituto de Salud Carlos III, Spanish
   Ministry of Economy and Competitiveness, and grant DIA-SOBS from
   CIBERDEM, which is also an initiative of Instituto de Salud Carlos III.
   The sponsors had no role in the study design, in the collection,
   analysis and interpretation of data: in the writing of the manuscript:
   and in the decision to submit the manuscript for publication. The
   Authors are grateful to the surgeons that collaborated by obtaining the
   adipose tissue samples used for this study.
CR Ahmed M., 2009, OBESITY, V18, P27
   Klimcakova E, 2011, J CLIN ENDOCR METAB, V96, pE73, DOI 10.1210/jc.2010-1575
   Insenser M, 2010, J CLIN ENDOCR METAB, V95, P3863, DOI 10.1210/jc.2010-0220
   Valverde R, 2008, DERMATOL CLIN, V26, P447, DOI 10.1016/j.det.2008.05.001
   Alvarez-Llamas G, 2007, MOL CELL PROTEOMICS, V6, P589, DOI 10.1074/mcp.M600265-MCP200
   Ramis JM, 2002, CELL MOL LIFE SCI, V59, P1960, DOI 10.1007/PL00012518
   Lefebvre B, 2010, J CLIN INVEST, V120, P1454, DOI 10.1172/JCI38606
   Ramm G, 2006, J BIOL CHEM, V281, P29174, DOI 10.1074/jbc.M603274200
   Molina H, 2009, J PROTEOME RES, V8, P48, DOI 10.1021/pr800650r
   Corton M, 2008, HUM REPROD, V23, P651, DOI 10.1093/humrep/dem380
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   Boden G, 2008, DIABETES, V57, P2438, DOI 10.2337/db08-0604
   Perez-Perez R, 2012, J PROTEOMICS, V75, P783, DOI 10.1016/j.jprot.2011.09.016
   Zhong J, 2010, J PROTEOME RES, V9, P5228, DOI 10.1021/pr100521c
   Faber DR, 2009, OBES REV, V10, P554, DOI 10.1111/j.1467-789X.2009.00593.x
   Jernas M, 2009, BIOCHEM BIOPH RES CO, V383, P63, DOI 10.1016/j.bbrc.2009.03.120
   Peinado JR, 2010, PROTEOMICS, V10, P3356, DOI 10.1002/pmic.201000350
   Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395
   Kampmann A, 2009, MOL CELL BIOCHEM, V322, P15, DOI 10.1007/s11010-008-9935-x
   Zvonic S, 2007, MOL CELL PROTEOMICS, V6, P18, DOI 10.1074/mcp.M600217-MCP200
   Petretto E, 2008, NAT GENET, V40, P546, DOI 10.1038/ng.134
   Escobar-Morreale HF, 2000, FERTIL STERIL, V74, P816, DOI 10.1016/S0015-0282(00)00718-4
   DeLany JP, 2005, MOL CELL PROTEOMICS, V4, P731, DOI 10.1074/mcp.M400198-MCP200
   Suzuki M, 2009, ENDOCRINOLOGY, V150, P5230, DOI 10.1210/en.2009-0332
   Corton M, 2004, PROTEOMICS, V4, P438, DOI 10.1002/pmic.200300644
   Fisher A.B., 2011, ANTIOXID REDOX SIGNA
   Insenser M, 2010, PROTEOM CLIN APPL, V4, P739, DOI 10.1002/prca.201000007
   Kheterpal I, 2011, J PROTEOME RES, V10, P1519, DOI 10.1021/pr100887r
   Nagashima S., 2010, J ATHEROSCLER THROMB, V18, P190
   Perez-Perez R, 2009, J PROTEOME RES, V8, P1682, DOI 10.1021/pr800942k
   Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939
   Siklova-Vitkova M, 2012, J CLIN ENDOCR METAB, V97, pE1176, DOI 10.1210/jc.2011-2380
   Szalowska E, 2007, BIOTECHNOL PROGR, V23, P217, DOI 10.1021/bp0602294
   van Beek EA, 2007, PFLUG ARCH EUR J PHY, V453, P851, DOI 10.1007/s00424-006-0164-4
NR 34
TC 20
Z9 21
U1 1
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD NOV 5
PY 2012
VL 363
IS 1-2
BP 10
EP 19
DI 10.1016/j.mce.2012.07.001
PG 10
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 023MQ
UT WOS:000310039500002
PM 22796336
ER

PT J
AU Soyoral, YU
   Erkoc, R
   Begenik, H
   Aldemir, MN
   Kucukoglu, ME
AF Soyoral, Yasemin Usul
   Erkoc, Reha
   Begenik, Huseyin
   Aldemir, Mehmet Naci
   Kucukoglu, Mehmet Emin
TI Relationship between Visfatin and some clinical and biochemical
   parametres in peritoneal dialysis patients
SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
LA English
DT Article
DE Visfatin; Peritoneal dialysis; Haemodialysis
ID COLONY-ENHANCING FACTOR; TYPE-2 DIABETES-MELLITUS; INSULIN-RESISTANCE;
   SERUM VISFATIN; ASIAN INDIANS; VISCERAL FAT; OBESITY; LEVEL; WOMEN;
   CHOLESTEROL
AB Objective: To characterise the relationship between visfatin levels and various clinical and biochemical parameters in peritoneal dialysis patients.
   Methods: The case-control study was conducted at the Medical Faculty Hospital, Yuzuncu Yil University, Van, Turkey, between May 2007 and December 2008, and involving 41 patients on peritoneal dialysis, 20 haemodialysis patients and 20 healthy controls. Fasting visfatin level was measured with enzyme-linked immunosorpent assay (ELISA) method, and patients on peritoneal dialysis were separated into two groups according to the visfatin levels - high and low. The groups were compared in terms of some clinical (height, weight, body mass index, waist circumference, hip circumference, waist/hip ratio, heart rate, systolic and diastolic blood pressure and the kt/V and CrCl (creatanine clearance) parameters which are indicative of the dialysis adequacy) and biochemical parameters (glucose, triglycerides, cholesterol, low density lipoprotein, high density lipoprotein, aspartate aminotransferase, alanine transminase, blood urea nitrogen, creatinine, total protein, albumin, globulin, sodium, potassium, magnesium, calcium, phosphorus, ferritin, venous blood gas, parathyroid hormone and insulin). SPSS 15 was used for statistcal analysis.
   Results: No statistically significant difference in the visfatin levels was found between the patients and controls (7.71 +/- 4.04, 7.36 +/- 3.71, 7.70 +/- 1.61, respectively, p = 0.63). The triglyceride level of the high-visfatin group was significantly higher than that of the low-visfatin group (243.8 +/- 133.2, 150.8 +/- 65.8, respectively, p < 0.05). However, there was no correlation between visfatin and triglyceride levels. No difference in the other clinical and biochemical parametres was observed between the two groups of peritoneal dialysis patients.
   Conclusions: No significant difference in the serum visfatin levels of peritoneal dialysis patients compared to haemodialysis patients or healthy individuals was noticed. Further studies are needed to confirm the effect of visfatin on triglyceride levels, and, if confirmed, the mechanism of this relation.
C1 [Erkoc, Reha] Bezmi Alem Univ, Dept Nephrol, Istanbul, Turkey.
   [Soyoral, Yasemin Usul; Begenik, Huseyin; Aldemir, Mehmet Naci; Kucukoglu, Mehmet Emin] Yuzuncu Yil Univ, Dept Internal Med, Van, Turkey.
RP Erkoc, R (reprint author), Bezmi Alem Univ, Dept Nephrol, Istanbul, Turkey.
EM rehaerkoc@hotmail.com
CR Johnson DW, 2000, PERITON DIALYSIS INT, V20, P715
   PORSTMANN T, 1992, J IMMUNOL METHODS, V150, P5, DOI 10.1016/0022-1759(92)90061-W
   Sandeep S, 2007, METABOLISM, V56, P565, DOI 10.1016/j.metabol.2006.12.005
   Nordfors L, 2000, KIDNEY INT, V57, P1713, DOI 10.1046/j.1523-1755.2000.00016.x
   Chen MP, 2006, J CLIN ENDOCR METAB, V91, P295, DOI 10.1210/jc.2005-1475
   Ognjanovic S, 2001, J MOL ENDOCRINOL, V26, P107, DOI 10.1677/jme.0.0260107
   Haider DG, 2006, J CLIN ENDOCR METAB, V91, P1578, DOI 10.1210/jc.2005-2248
   Oki K, 2007, CLIN ENDOCRINOL, V67, P796, DOI 10.1111/j.1365-2265.2007.02966.x
   SAMAL B, 1994, MOL CELL BIOL, V14, P1431
   Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243
   Axelsson J, 2007, AM J KIDNEY DIS, V49, P237, DOI 10.1053/j.ajkd.2006.11.021
   Yilmaz MI, 2008, NEPHROL DIAL TRANSPL, V23, P959, DOI 10.1093/ndt/gfm727
   Hug C, 2005, SCIENCE, V307, P366, DOI 10.1126/science.1106933
   Pagano C, 2006, J CLIN ENDOCR METAB, V91, P3165, DOI 10.1210/jc.2006-0361
   Chen CC, 2007, METABOLISM, V56, P1216, DOI 10.1016/j.metabol.2007.04.018
   Erten Y, 2008, RENAL FAILURE, V30, P617, DOI 10.1080/08860220802134573
   Jian WX, 2006, DIABETIC MED, V23, P967, DOI 10.1111/j.1464-5491.2006.01909.x
   Nusken KD, 2007, CLIN CHIM ACTA, V382, P154, DOI 10.1016/j.cca.2007.04.004
   Seo JA, 2008, DIABETES RES CLIN PR, V79, P108, DOI 10.1016/j.diabres.2007.04.016
   Smith J, 2006, CLIN ENDOCRINOL, V65, P667, DOI 10.1111/j.1365-2265.2006.02647.x
   Wang P, 2007, PFLUG ARCH EUR J PHY, V454, P971, DOI 10.1007/s00424-007-0262-y
   Zahorska-Markiewicz B, 2007, METABOLISM, V56, P1131, DOI 10.1016/j.metabol.2007.04.007
NR 22
TC 0
Z9 0
U1 1
U2 4
PU PAKISTAN MEDICAL ASSOC
PI KARACHI
PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
SN 0030-9982
J9 J PAK MED ASSOC
JI J. Pak. Med. Assoc.
PD NOV
PY 2012
VL 62
IS 11
BP 1179
EP 1183
PG 5
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 024RP
UT WOS:000310126600012
PM 23866406
ER

PT J
AU Suliburska, J
   Bogdanski, P
   Szulinska, M
   Pupek-Musialik, D
AF Suliburska, Joanna
   Bogdanski, Pawe
   Szulinska, Monika
   Pupek-Musialik, Danuta
TI Short-Term Effects of Sibutramine on Mineral Status and Selected
   Biochemical Parameters in Obese Women
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Sibutramine; Minerals; Lipid profile; Glucose; Obesity; Women
ID PLACEBO-CONTROLLED TRIAL; WEIGHT-LOSS; DIABETIC-PATIENTS;
   RANDOMIZED-TRIAL; DOUBLE-BLIND; INSULIN-RESISTANCE; OXIDATIVE STRESS;
   COPPER; ZINC; DISEASE
AB The aim of this study was to assess the effect of sibutramine on mineral status and selected biochemical parameters in obese women. The study was conducted on 24 patients who received 15 mg daily doses of sibutramine for 12 weeks, and on 20 patients who received placebo. At the baseline, after the sixth and twelfth weeks of treatment, body weight and blood pressure were measured, the BMI was calculated, and samples of blood and of first morning urine were collected. Serum lipid profiles, glucose levels, and nitric oxide levels were determined. The iron (Fe), copper (Cu), zinc (Zn), calcium (Ca), and magnesium (Mg) present in the serum and urine samples were assessed. The erythrocyte hemolysate of the patients was use to assay the activity of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD). No changes were observed in BMI, blood pressure, or nitric oxide during the study. After 12 weeks of treatment, a decrease was observed in total cholesterol, LDL cholesterol, triglyceride, glucose, and ferritin levels. GSH-Px and SOD activity increased after 12 weeks of sibutramine treatment. The Mg and Cu increases was observed in serum after the sixth and twelfth weeks of treatment. It was found that the Zn level decreased in serum after the twelfth week. The elimination of Ca, Mg, Fe, Zn, and Cu in urine also declined in the twelfth week. No differences were found in the women taking the placebo. In conclusion, we found that sibutramine had a positive effect on lipid and glucose status in obese women. However, the drug disturbed the balance of minerals, especially Zn and Mg, in the subjects.
C1 [Suliburska, Joanna] Poznan Univ Life Sci, Dept Human Nutr & Hyg, PL-60624 Poznan, Poland.
   [Bogdanski, Pawe; Szulinska, Monika; Pupek-Musialik, Danuta] Poznan Univ Med Sci, Dept Internal Med Metab Disorders & Hypertens, PL-60569 Poznan, Poland.
RP Suliburska, J (reprint author), Poznan Univ Life Sci, Dept Human Nutr & Hyg, Wojska Polskiego 31 Str, PL-60624 Poznan, Poland.
EM jsulibur@up.poznan.pl
CR Derosa G, 2005, DIABETES OBES METAB, V7, P47, DOI 10.1111/j.1463-1326.2004.00372.x
   MISRA HP, 1972, J BIOL CHEM, V247, P3170
   Wadden TA, 2005, NEW ENGL J MED, V353, P2111, DOI 10.1056/NEJMoa050156
   Goodpaster BH, 2010, JAMA-J AM MED ASSOC, V304, P1795, DOI 10.1001/jama.2010.1505
   Naziroglu M, 2009, NEUROCHEM RES, V34, P2181, DOI 10.1007/s11064-009-0015-8
   Lima SCVC, 2006, BIOL TRACE ELEM RES, V114, P19, DOI 10.1385/BTER:114:1:19
   Dastych M, 2010, BIOL TRACE ELEM RES, V133, P265, DOI 10.1007/s12011-009-8438-2
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Logue J, 2011, HEART, V97, P564, DOI 10.1136/hrt.2010.211201
   James WPT, 2000, LANCET, V356, P2119, DOI 10.1016/S0140-6736(00)03491-7
   Aguirre ME, 2007, ARCH LATINOAM NUTR, V57, P238
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Cimen B, 2008, CLIN CHIM ACTA, V390, P1
   de Lemos HP, 2008, SAO PAULO MED J, V126, P342, DOI 10.1590/S1516-31802008000600010
   Derosa G, 2010, J PHARM PHARM SCI, V13, P378
   Derosa G, 2010, INTERNAL MED, V49, P1717, DOI 10.2169/internalmedicine.49.3401
   Doggrell SA, 2005, METHOD FIND EXP CLIN, V27, P119, DOI 10.1358/mf.2005.27.2.876281
   Emer E, 2010, TOXICOL LETT, V196, pS238, DOI 10.1016/j.toxlet.2010.03.798
   Finer N, 2000, DIABETES OBES METAB, V2, P105, DOI 10.1046/j.1463-1326.2000.00071.x
   Fujiwara N, 2006, BIOCHEM BIOPH RES CO, V349, P1079, DOI 10.1016/j.bbrc.2006.08.139
   Garcia-Colunga J, 2005, J NEUROSCI RES, V80, P145, DOI 10.1002/jnr.20421
   Gürsoy Alptekin, 2005, Endocr Pract, V11, P308
   Guzman DC, 2012, BASIC CLIN PHARMACOL, V110, P421, DOI 10.1111/j.1742-7843.2011.00829.x
   Konukoglu D, 2004, J NUTR BIOCHEM, V15, P757, DOI 10.1016/j.jnutbio.2004.07.007
   Kovacic P, 2008, CELL MEMBR FREE RADI, V2, P56
   MAHONEY JJ, 1993, CLIN CHEM, V39, P1693
   McMahon FG, 2000, ARCH INTERN MED, V160, P2185, DOI 10.1001/archinte.160.14.2185
   Miles AM, 1996, METHOD ENZYMOL, V268, P105
   National Committee for Clinical Laboratory Standards (NCCLS), 1996, GP2A3 NCCLS
   Naziroğlu Mustafa, 2005, Can J Appl Physiol, V30, P172
   Parmar P, 2001, METAB BRAIN DIS, V16, P199, DOI 10.1023/A:1012545112031
   Pioruńska-Stolzmann M, 2001, Med Sci Monit, V7, P940
   Shechter M, 2006, AM J CARDIOL, V97, P1650, DOI 10.1016/j.amjcard.2005.12.059
   Smith IG, 2001, J FAM PRACTICE, V50, P505
   Suliburska J, 2011, BIOL TRACE ELEM RES, V139, P137, DOI 10.1007/s12011-010-8650-0
   Svacina S, 2007, Prague Med Rep, V108, P333
   Tambascia MA, 2003, DIABETES OBES METAB, V5, P338, DOI 10.1046/j.1463-1326.2003.00285.x
   VIVOLI G, 1995, BIOL TRACE ELEM RES, V49, P97, DOI 10.1007/BF02788959
   Voruganti VS, 2010, J TRACE ELEM MED BIO, V24, P271, DOI 10.1016/j.jtemb.2010.05.001
   Weeke P., 2010, BMC ENDOCR DISORD, V10, P1
NR 40
TC 1
Z9 1
U1 1
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD NOV
PY 2012
VL 149
IS 2
BP 163
EP 170
DI 10.1007/s12011-012-9425-6
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 021BE
UT WOS:000309859500005
PM 22539020
ER

PT J
AU Truthmann, J
   Richter, A
   Thiele, S
   Drescher, L
   Roosen, J
   Mensink, GBM
AF Truthmann, Julia
   Richter, Almut
   Thiele, Silke
   Drescher, Larissa
   Roosen, Jutta
   Mensink, Gert B. M.
TI Associations of dietary indices with biomarkers of dietary exposure and
   cardiovascular status among adolescents in Germany
SO NUTRITION & METABOLISM
LA English
DT Article
DE Dietary indices; Diet quality; Cardiovascular status; Nutritional
   epidemiology; Adolescents; Germany
ID HEALTHY EATING INDEX; BODY-MASS INDEX; FOOD FREQUENCY QUESTIONNAIRE;
   RISK-FACTORS; PHYSICAL-ACTIVITY; MEDITERRANEAN DIET; NUTRIENT INTAKE;
   QUALITY INDEX; CHILDREN; KIGGS
AB Background: Adolescence is an important life stage for the development of dietary preferences and health behaviour. Longitudinal studies indicated that cardiovascular status in adolescence predicts cardiovascular risk marker values in adulthood. Several diet quality indices for adolescents have been developed in the past, but literature concerning associations between indices and biomarkers of dietary exposure and cardiovascular status is rather sparse. Hence, the aim of this study was to analyse associations of dietary indices with biomarkers of dietary exposure and cardiovascular status.
   Methods: For the present analysis, data from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS 2003-2006) were used. The analysis included 5,198 adolescents, aged 12 to 17 years. The Healthy Food Diversity Index (HFD), the Healthy Nutrition Score for Kids and Youth (HuSKY), the Indicator Food Index (IFI) and a simple fruit/vegetable intake index were derived from food frequency questionnaire information to indicate a healthy diet. Adjusted mean values for homocysteine, uric acid, CRP, total cholesterol, HDL-C, ferritin, HbA1c, folate, vitamin B-12 and BMI were calculated using complex-samples general linear models for quintiles of the different indices. Furthermore, the agreement in ranking between the different indices was calculated by weighted kappa. All statistical analyses were conducted for boys and girls separately, and were adjusted for potential confounders.
   Results: Folate was positively associated with the HFD, the HuSKY, and fruit/vegetable intake for both boys and girls and with IFI for boys. Among girls, positive associations were seen between vitamin B-12 and the IFI and between diastolic blood pressure and the IFI as well as fruit/vegetable intake. A negative association was found between homocysteine and the HFD, the HuSKY, and the IFI for both boys and girls and with fruit/vegetable intake for boys. Among boys, uric acid and HbA1c were negatively and prevalence of obesity positively associated with the IFI.
   Conclusions: Overall, the indices, even the simpler ones, seem to have a similar general capability in predicting biomarkers of dietary exposure. To predict risk of cardiovascular disease dietary indices may have to be more specific.
C1 [Truthmann, Julia; Richter, Almut; Mensink, Gert B. M.] Robert Koch Inst, Dept Epidemiol & Hlth Reporting, D-13302 Berlin, Germany.
   [Thiele, Silke] Univ Kiel, Dept Food Econ & Consumpt Studies, D-24098 Kiel, Germany.
   [Drescher, Larissa; Roosen, Jutta] Tech Univ Munich, Sch Management Mkt & Consumer Res, D-85350 Freising Weihenstephan, Germany.
RP Truthmann, J (reprint author), Robert Koch Inst, Dept Epidemiol & Hlth Reporting, Postbox 65 02 61, D-13302 Berlin, Germany.
EM TruthmannJ@rki.de
RI Mensink, Gert/B-2447-2009; 
OI Mensink, Gert/0000-0001-6268-5998; Roosen, Jutta/0000-0002-3032-399X
FU German Research Foundation; German Ministry of Health; Ministry of
   Education and Research; Robert Koch Institute
FX The study was supported by the German Research Foundation. KiGGS was
   funded by the German Ministry of Health, the Ministry of Education and
   Research, and the Robert Koch Institute. Analyses were performed while
   JT was a member of the School of Management, TU Munchen. We would like
   to thank Christina Kleiser for sharing the syntax of the HuSKY and the
   IFI. Further, we would like to thank the families that participated in
   KiGGS.
CR Angelopoulos P, 2009, EUR J CLIN NUTR, V63, P964, DOI 10.1038/ejcn.2009.10
   Livingstone MBE, 2000, P NUTR SOC, V59, P279, DOI 10.1017/S0029665100000318
   Rosario AS, 2010, EUR J CLIN NUTR, V64, P341, DOI 10.1038/ejcn.2010.8
   Golley RK, 2011, J NUTR, V141, P1340, DOI 10.3945/jn.110.136879
   Arvaniti F, 2008, CRIT REV FOOD SCI, V48, P317, DOI 10.1080/10408390701326268
   [Anonymous], 2001, DIET REF INT VIT A V
   Centritto F, 2009, NUTR METAB CARDIOVAS, V19, P697, DOI 10.1016/j.numecd.2008.11.009
   Bach-Faig A, 2006, PUBLIC HEALTH NUTR, V9, P1110, DOI 10.1017/S1368980007668499
   McCullough ML, 2002, AM J CLIN NUTR, V76, P1261
   Huybrechts I, 2010, BRIT J NUTR, V104, P135, DOI 10.1017/S0007114510000231
   Kristal AR, 2005, CANCER EPIDEM BIOMAR, V14, P2826, DOI 10.1158/1055-9965.EPI-editorial
   Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002
   Kant AK, 1996, J AM DIET ASSOC, V96, P785, DOI 10.1016/S0002-8223(96)00217-9
   Hoebeeck LI, 2011, EUR J CLIN NUTR, V65, P606, DOI 10.1038/ejcn.2010.286
   Bland JM, 1997, BRIT MED J, V314, P572
   Drewnowski A, 2009, J AM COLL NUTR, V28, P22
   Shannon J, 1997, CANCER EPIDEM BIOMAR, V6, P355
   BERRY CH, 1971, J LAW ECON, V14, P371, DOI 10.1086/466714
   Weinstein SJ, 2004, J AM DIET ASSOC, V104, P576, DOI 10.1016/j.jada.2004.01.005
   Kant AK, 2005, J AM COLL NUTR, V24, P294
   Feskanich D, 2004, J AM DIET ASSOC, V104, P1375, DOI 10.1016/j.jada.2004.06.020
   Togo P, 2001, INT J OBESITY, V25, P1741, DOI 10.1038/sj.ijo.0801819
   KELDER SH, 1994, AM J PUBLIC HEALTH, V84, P1121, DOI 10.2105/AJPH.84.7.1121
   Lazarou C, 2010, CLIN NUTR, V29, P779, DOI 10.1016/j.clnu.2010.05.001
   McNulty H, 2008, P NUTR SOC, V67, P232, DOI 10.1017/S0029665108007076
   Kamtsiuris P, 2007, BUNDESGESUNDHEITSBLA, V50, P547, DOI 10.1007/s00103-007-0215-9
   Hann CS, 2001, AM J CLIN NUTR, V74, P479
   Hurley KM, 2009, J NUTR, V139, P359, DOI 10.3945/jn.108.097113
   Steinberger J, 2009, CIRCULATION, V119, P628, DOI 10.1161/CIRCULATIONAHA.108.191394
   Kahl H, 2007, BUNDESGESUNDHEITSBLA, V50, P677, DOI 10.1007/s00103-007-0229-3
   Serra-Majem L, 2004, PUBLIC HEALTH NUTR, V7, P931, DOI 10.1079/PHN2004556
   Kleiser C, 2009, BRIT J NUTR, V102, P610, DOI 10.1017/S0007114509222689
   Hedrick VE, 2012, J ACAD NUTR DIET, V112, P840, DOI 10.1016/j.jand.2012.01.023
   Lake AA, 2006, J PUBLIC HEALTH, V28, P10, DOI 10.1093/pubmed/fdi082
   Drescher LS, 2007, J NUTR, V137, P647
   Inzucchi SE, 2012, NEW ENGL J MED, V367, P542, DOI 10.1056/NEJMcp1103643
   Tek NA, 2011, NUTR RES PRACT, V5, P322, DOI 10.4162/nrp.2011.5.4.322
   Kersting M, 2005, J PEDIATR GASTR NUTR, V40, P301, DOI 10.1097/01.MPG.0000153887.19429.70
   Knopf H, 2007, BUNDESGESUNDHEITSBLA, V50, P863, DOI 10.1007/s00103-007-0249-z
   Bassler K-H, 2002, VITAMIN LEXIKON ARZT
   Berenson GS, 2005, NEUROBIOL AGING, V26, P303, DOI 10.1016/j.neurobiolaging.2004.05.009
   Bundesinstitut fur Risikobewertung (BfR), 2009, STUD FLEISCHV STERBL
   Day RS, 2009, AM J PREV MED, V37, pS25, DOI 10.1016/j.amepre.2009.04.006
   Fink A, 2007, HDB EPIDEMIOLOGY
   George CG, 2004, NUTR RES, V24, P29
   Hidaka H, 2012, ANN NUTR METAB, V61, P111, DOI 10.1159/000339261
   Hunter D., 1998, NUTR EPIDEMIOLOGY, P174
   Institute of Medicine, 1998, DIET REF INT THIAM R
   Kleiser C., 2007, ERNAHRUNGSVERHALTEN
   Kromeyer-Hauschild K, 2001, MONATSSCHR KINDERH, V149, P807, DOI 10.1007/s001120170107
   Kurth BM, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-196
   Kurth BM, 2009, BUNDESGESUNDHEITSBLA, V52, P557, DOI 10.1007/s00103-009-0843-3
   KUSHI LH, 1995, AM J CLIN NUTR, V61, p1416S
   LaRosa J C, 1992, Womens Health Issues, V2, P102, DOI 10.1016/S1049-3867(05)80278-6
   Lazarou C, 2009, J AM DIET ASSOC, V109, P1070, DOI 10.1016/j.jada.2009.03.010
   Mensink G B M, 2004, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V47, P219, DOI 10.1007/s00103-003-0794-z
   Mirmiran P, 2005, INT J VITAM NUTR RES, V75, P195, DOI 10.1024/0300-9831.75.3.195
   Rabenberg M, 2011, GBE KOMPAKT, V2, P6
   Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472
   Thierfelder W, 2008, LABORATORIUMSMEDIZIN, V32
   Truthmann J, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-133
   Vaccarino V, 1999, ANN INTERN MED, V131, P62
   Willett W., 1998, NUTR EPIDEMIOLOGY, V2nd, P3
   Winkler J., 1999, GESUNDHEITSWESEN, V61, P178
   World Health Organization, 2003, DIET NUTR PREV CHRON, V916
NR 65
TC 9
Z9 9
U1 4
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-7075
J9 NUTR METAB
JI Nutr. Metab.
PD OCT 24
PY 2012
VL 9
AR 92
DI 10.1186/1743-7075-9-92
PG 14
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 084KD
UT WOS:000314537000001
PM 23095712
ER

PT J
AU Nikolic, J
   Nickovic, V
   Acimovic, D
AF Nikolic, Jelenka
   Nickovic, Vanja
   Acimovic, Danilo
TI Contemporary aspects of the diagnostics of alcoholic liver disease
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE liver diseases, alcoholic; diagnosis; biological markers; ethanol;
   alcohol drinking; alcoholism
ID CARBOHYDRATE-DEFICIENT TRANSFERRIN; GAMMA-GLUTAMYL-TRANSFERASE;
   REFERENCE INTERVALS; OXIDATIVE STRESS; PREDNISOLONE; CONSUMPTION;
   BIOMARKERS; ENZYMES; OBESITY; COFFEE
C1 [Nikolic, Jelenka; Nickovic, Vanja] Univ Nis, Fac Med, Nish 18000, Serbia.
   [Acimovic, Danilo] Univ Novi Pazar, Dept Biochem & Med Sci, Novi Pazar, Serbia.
RP Nikolic, J (reprint author), Univ Nis, Fac Med, Bulevar Dr Zorana Djindjica 81, Nish 18000, Serbia.
EM jelenka.nikolic@gmail.com
CR Mathurin P, 1996, GASTROENTEROLOGY, V110, P1847, DOI 10.1053/gast.1996.v110.pm8964410
   Susse S, 2010, FORENSIC SCI INT, V196, P111, DOI 10.1016/j.forsciint.2009.12.029
   Conigrave KM, 2003, ADDICTION, V98, P31, DOI 10.1046/j.1359-6357.2003.00581.x
   Bergstrom JP, 2008, ALCOHOL ALCOHOLISM, V43, P436, DOI 10.1093/alcalc/agn017
   Sillanaukee P, 2001, CLIN CHEM, V47, P681
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]
   Anton RF, 2002, ALCOHOL CLIN EXP RES, V26, P1215, DOI 10.1097/01.ALC.0000023986.42254.F5
   Gelatti U, 2005, J HEPATOL, V42, P528, DOI 10.1016/j.jhep.2004.11.039
   Lee DH, 2004, FREE RADICAL RES, V38, P535, DOI 10.1080/10715760410001694026
   Mathurin P, 2003, HEPATOLOGY, V38, P1363, DOI 10.1016/j.hep.2003.09.038
   Klatsky AL, 2006, ARCH INTERN MED, V166, P1190, DOI 10.1001/archinte.166.11.1190
   Butura A, 2008, DRUG ALCOHOL INDUCED
   Carithers RL, 2010, FELDMAN SLEISINGER F
   Dahl H, 2011, EVALUATION CLIN APPL
   Djordjevic D, 1998, PATHOL BIOL, V46, P760
   Elshorbagy AK, 2009, OBESITY, V17, P1435, DOI 10.1038/oby.2008.671
   Everitt H, 2010, THESIS U WESTMINSTER
   Fairbanks K, 2010, CURRENT CLIN MED, P506
   Ferruzzi G, ASIALOTRANSFERRIN
   Hietala J, 2005, ALCOHOL ALCOHOLISM, V40, P511, DOI 10.1093/alcalc/agh201
   Leusink GL, 2000, ALCOHOL CLIN EXP RES, V24, P172, DOI 10.1097/00000374-200002000-00006
   Mancinelli R, 2009, ALCOHOL ALCOHOLISM, V44, P177, DOI 10.1093/alcalc/agn117
   Nikolic J, 2007, ALCOHOL ALCOHOL S1, V42, pi65
   Nikolic J, 2007, ALCOHOL ALCOHOL S1, V42, P65
   NIKOLIC J, 1998, PROGR HPLC, V7, P193
   Nomura Fumio, 2004, Nihon Rinsho, V62 Suppl 11, P240
   Puukka K, 2006, ALCOHOL ALCOHOLISM, V41, P522, DOI 10.1093/alcalc/agl052
   Sharpe PC, 2001, ANN CLIN BIOCHEM, V38, P652, DOI 10.1258/0004563011901064
   Skipper GE, 2004, J MED LICENS DISCIPL, V90, P14
   Stromme JH, 2004, SCAND J CLIN LAB INV, V64, P371, DOI 10.1080/00365510410002742
   Tyulina OV, 2006, BBA-MOL BASIS DIS, V1762, P558, DOI 10.1016/j.bbadis.2006.03.003
   Vlahović Predrag, 2007, Nephron Exp Nephrol, V106, pe73, DOI 10.1159/000103019
NR 32
TC 0
Z9 0
U1 0
U2 9
PU MILITARY MEDICAL ACAD-INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33-35, BELGRADE, 11040, SERBIA
SN 0042-8450
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PD OCT
PY 2012
VL 69
IS 10
BP 874
EP 879
DI 10.2298/VSP110405015N
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 028JQ
UT WOS:000310419000009
PM 23155609
ER

PT J
AU Andrews, M
   Arredondo, M
AF Andrews, M.
   Arredondo, M.
TI Ferritin Levels and Hepcidin mRNA Expression in Peripheral Mononuclear
   Cells from Anemic Type 2 Diabetic Patients
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Anemia; Chronic disease; Hepcidin; Type 2 diabetes
ID IRON-METABOLISM; OBESITY
AB This study aims to measure iron nutrition parameters and to determine the presence of anemia in obese type 2 diabetic patients and to analyze the mRNA relative abundance of genes related to inflammation, immune system, iron metabolism, and mitochondrial activity. Obese type 2 diabetic (OBDM, n = 30) and healthy subjects (Cn, n = 30) were studied. Biochemical, anthropometric, and iron nutrition parameters were determined. Peripheral mononuclear cells from type 2 diabetic and control group were challenged with high concentrations of iron (Fe) and glucose and total mRNA was isolated. The frequency of anemia among diabetic patients was 4/30. OBDM patients with or without anemia had higher levels of ferritin and high-sensitivity C-reactive protein than the Cn group. mRNA relative abundance of nuclear factor kappa-light-chain-enhancer of activated B cells was elevated in OBDM with anemia, and mRNA expression of interleukin-6 and toll-like receptor (TLR) 2 was increased in OBDM group in basal high Fe and high glucose concentrations. The expression of tumor necrosis factor alpha and TLR-4 was increased in OBDM with anemia in all experimental conditions. Hepcidin mRNA expression was increased in OBDM with anemia even in basal Fe concentration, and mitofusin 2 was decreased in all experimental conditions. This study shows that obese type 2 diabetic patients have iron distribution disorders associated to their proinflammatory state, and anemic subjects have a marked elevation of hepcidin mRNA expression.
C1 [Andrews, M.; Arredondo, M.] Univ Chile, Micronutr Lab, Inst Nutr & Food Technol, Santiago 5524, Chile.
RP Andrews, M (reprint author), Univ Chile, Micronutr Lab, Inst Nutr & Food Technol, Santiago 5524, Chile.
EM monica.andrews@gmail.com
FU Chilean Diabetes and Endocrinology Society (SOCHED); FONDECYT [1085173,
   1110080]
FX This research was supported by grants from the Chilean Diabetes and
   Endocrinology Society (SOCHED) and FONDECYT with numbers 1085173 and
   1110080.
CR Ganz T, 2011, ANNU REV MED, V62, P347, DOI [10.1146/annurev-med-050109-142444, 10.1146/annurev-rned-050109-142444]
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898
   You SA, 2005, CLIN CHIM ACTA, V357, P1, DOI 10.1016/j.cccn.2005.02.001
   Bach D, 2005, DIABETES, V54, P2685, DOI 10.2337/diabetes.54.9.2685
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Dasu MR, 2008, DIABETES, V57, P3090, DOI 10.2337/db08-0564
   Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Jiang H, 2011, DIAB RES CLIN PRAC, V93, P43
   Kovacs Ferenc, 2006, Orvosi Hetilap, V147, P345
NR 13
TC 2
Z9 2
U1 0
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD OCT
PY 2012
VL 149
IS 1
BP 1
EP 4
DI 10.1007/s12011-012-9389-6
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 002NE
UT WOS:000308538100001
PM 22426798
ER

PT J
AU Hamalainen, P
   Saltevo, J
   Kautiainen, H
   Mantyselka, P
   Vanhala, M
AF Hamalainen, Paivi
   Saltevo, Juha
   Kautiainen, Hannu
   Mantyselka, Pekka
   Vanhala, Mauno
TI Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin
   receptor in metabolic syndrome: a case control study
SO CARDIOVASCULAR DIABETOLOGY
LA English
DT Article
DE Erythropoietin; Ferritin; Hemoglobin; Metabolic syndrome
ID C-REACTIVE PROTEIN; ADIPOSE-TISSUE; ABDOMINAL OBESITY; IRON-DEFICIENCY;
   SLEEP-APNEA; INFLAMMATION; HYPOXIA; POPULATION; HEPCIDIN; RISK
AB Background: Increased ferritin concentrations are associated with metabolic syndrome (MetS). The association between ferritin as well as hemoglobin level and individual MetS components is unclear. Erythropoietin levels in subjects with MetS have not been determined previously. The aim of this study was to compare serum erythropoietin, ferritin, haptoglobin, hemoglobin, and transferrin receptor (sTFR) levels between subjects with and without MetS and subjects with individual MetS components.
   Methods: A population based cross-sectional study of 766 Caucasian, middle-aged subjects (341 men and 425 women) from five age groups born in Pieksamaki, Finland who were invited to a health check-up in 2004 with no exclusion criteria. Laboratory analyzes of blood samples collected in 2004 were done during year 2010. MetS was defined by National Cholesterol Education Program criteria.
   Results: 159 (53%) men and 170 (40%) women of study population met MetS criteria. Hemoglobin and ferritin levels as well as erythropoietin and haptoglobin levels were higher in subjects with MetS (p < 0.001, p = 0.018). sTFR level did not differ significantly between subjects with or without MetS. Hemoglobin level was significantly higher in subjects with any of the MetS components (p < 0.001, p = 0.002). Ferritin level was significantly higher in subjects with abdominal obesity or high TG or elevated glucose or low high density cholesterol component (p < 0.001, p = 0.002, p = 0.02). Erythropoietin level was significantly higher in subjects with abdominal obesity component (p = 0.015) but did not differ significantly between subjects with or without other MetS components. Haptoglobin level was significantly higher in subjects with blood pressure or elevated glucose component o MetS (p = 0.028, p = 0.025).
   Conclusion: Subjects with MetS have elevated hemoglobin, ferritin, erythropoietin and haptoglobin concentrations. Higher hemoglobin levels are related to all components of MetS. Higher ferritin levels associate with TG, abdominal obesity, elevated glucose or low high density cholesterol. Haptoglobin levels associate with blood pressure or elevated glucose. However, erythropoietin levels are related only with abdominal obesity. Higher serum erythropoietin concentrations may suggest underlying adipose tissue hypoxemia in MetS.
C1 [Hamalainen, Paivi] Tampere Univ Hosp, Dept Internal Med, Tampere 33521, Finland.
   [Saltevo, Juha] Cent Finland Cent Hosp, Dept Med, Jyvaskyla, Finland.
   [Kautiainen, Hannu; Vanhala, Mauno] Cent Finland Cent Hosp, Unit Family Practice, Jyvaskyla, Finland.
   [Kautiainen, Hannu] Kuopio Univ Hosp, Unit Primary Hlth Care, SF-70210 Kuopio, Finland.
   [Mantyselka, Pekka] Univ Eastern Finland, Unit Primary Hlth Care, Kuopio, Finland.
RP Hamalainen, P (reprint author), Tampere Univ Hosp, Dept Internal Med, Teiskontie 35, Tampere 33521, Finland.
EM Paivi.O.Hamalainen@uta.fi
CR Ahluwalia N, 1997, AM J KIDNEY DIS, V30, P532, DOI 10.1016/S0272-6386(97)90313-9
   Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   Pasarica M, 2009, DIABETES, V58, P718, DOI 10.2337/db08-1098
   Kang HT, 2012, CLIN CHIM ACTA, V413, P636, DOI 10.1016/j.cca.2011.12.011
   Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Wood IS, 2009, P NUTR SOC, V68, P370, DOI 10.1017/S0029665109990206
   Frohlich M, 2000, DIABETES CARE, V23, P1835, DOI 10.2337/diacare.23.12.1835
   Vanhala M, 2012, AM J EPIDEMIOL, V176, P253, DOI 10.1093/aje/kwr504
   Jehn ML, 2007, AM J EPIDEMIOL, V165, P1047, DOI 10.1093/aje/kwk093
   Cancello R, 2005, DIABETES, V54, P2277, DOI 10.2337/diabetes.54.8.2277
   JELKMANN W, 1992, PHYSIOL REV, V72, P449
   Quaye IK, 2008, T ROY SOC TROP MED H, V102, P735, DOI 10.1016/j.trstmh.2008.04.010
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   Regazzetti C, 2009, DIABETES, V58, P95, DOI 10.2337/db08-0457
   Muraki I, 2010, J ATHEROSCLER THROMB, V17, P369
   Calvin AD, 2010, EUR J HEART FAIL, V12, P354, DOI 10.1093/eurjhf/hfq005
   Bozzini C, 2005, DIABETES CARE, V28, P2061, DOI 10.2337/diacare.28.8.2061
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   SKIKNE BS, 1990, BLOOD, V75, P1870
   Chiellini C, 2004, J CLIN ENDOCR METAB, V89, P2678, DOI 10.1210/hc.2003-031965
   CAHAN C, 1995, J APPL PHYSIOL, V79, P1278
   den Engelsen C, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-25
   Gabay C, 1999, NEW ENGL J MED, V340, P448
   He MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040919
   Hermans MP, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-88
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Lohsoonthorn V, 2007, DIABETES METAB SYNDR, V1, P143, DOI 10.1016/j.dsx.2007.05.002
   Lu B, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-92
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Zuliani G, 2009, ATHEROSCLEROSIS, V203, P626, DOI 10.1016/j.atherosclerosis.2008.07.038
NR 33
TC 13
Z9 14
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2840
J9 CARDIOVASC DIABETOL
JI Cardiovasc. Diabetol.
PD SEP 27
PY 2012
VL 11
AR 116
DI 10.1186/1475-2840-11-116
PG 8
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism
GA 026TW
UT WOS:000310305600001
PM 23016887
ER

PT J
AU Moschonis, G
   Chrousos, GP
   Lionis, C
   Mougios, V
   Manios, Y
AF Moschonis, George
   Chrousos, George P.
   Lionis, Christos
   Mougios, Vassilis
   Manios, Yannis
CA Healthy Growth Study Grp
TI Association of total body and visceral fat mass with iron deficiency in
   preadolescents: the Healthy Growth Study
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Iron deficiency; Obesity; Children; Adipose tissue
ID SERUM FERRITIN; BIOELECTRICAL-IMPEDANCE; INTERNATIONAL SURVEY; OBESE
   CHILDREN; UNITED-STATES; ADOLESCENTS; OVERWEIGHT; HEPCIDIN; RISK;
   POPULATION
AB The aim of the present study was to examine the associations of obesity, percentage body fat and visceral fat mass with body Fe status in a representative sample of 1493 schoolchildren aged 9-13 years. Anthropometric, body composition, biochemical, clinical (Tanner stage, age of menarche) and dietary intake data were collected. Fe deficiency (ID) was defined as transferrin saturation (TS), 16 %; and Fe-deficiency anaemia (IDA) as ID with Hb <120 g/l. Obese boys and girls and those in the highest quartiles of percentage body fat mass had significantly higher levels of serum ferritin (P <= 0.05) compared to their normal-weight peers and those in the corresponding lowest quartiles. Similarly, obese boys and girls and those in the highest quartiles of percentage body fat and visceral fat mass had significantly lower levels of TS (P <= 0.05) compared to normal-weight children and those in the corresponding lowest quartiles. The prevalence of ID and IDA was significantly higher in boys and girls in the highest quartiles of percentage body fat than in peers in the lowest quartile. Higher quartiles of percentage body fat and visceral fat mass were the main significant predictors of ID in boys, after controlling for other important confounders, with OR of 2.48 (95% CI, 1.26, 4.88) and 2.12 (95% CI, 1.07, 4.19), respectively. Similar significant associations were observed for girls. In conclusion, percentage body fat and visceral fat mass were positively associated with ID in both sexes of preadolescents. These associations might be attributed to the chronic inflammation induced by excess adiposity.
C1 [Moschonis, George; Manios, Yannis] Harokopio Univ Athens, Dept Nutr & Dietet, Kallithea Athenes 17671, Greece.
   [Chrousos, George P.] Univ Athens, Sch Med, Dept Pediat 1, Aghia Sophia Childrens Hosp, GR-11527 Athens, Greece.
   [Lionis, Christos] Univ Crete, Clin Social & Family Med, Sch Med, Iraklion, Crete, Greece.
   [Mougios, Vassilis] Aristotle Univ Thessaloniki, Dept Phys Educ & Sport Sci, GR-54006 Thessaloniki, Greece.
RP Manios, Y (reprint author), Harokopio Univ Athens, Dept Nutr & Dietet, 70 El Venizelou Ave, Kallithea Athenes 17671, Greece.
EM manios@hua.gr
RI Charmandari, Evangelia/B-6701-2011; 
OI PAPADOPOULOU, ELENI/0000-0001-7034-5897
FU European Union (European Social Fund - ESF); Greek national funds
   through the Operational Programme 'Education and Lifelong Learning' of
   the National Strategic Reference Framework (NSRF) - Research Funding
   Programme: Heracleitus II
FX The present research has been co-financed by the European Union
   (European Social Fund - ESF) and Greek national funds through the
   Operational Programme 'Education and Lifelong Learning' of the National
   Strategic Reference Framework (NSRF) - Research Funding Programme:
   Heracleitus II. Investing in knowledge society through the European
   Social Fund. None of the authors has any conflict of interest to
   declare. All authors contributed to the study design, writing and
   revising of the manuscript. G. M., V. M. and Y. M. were responsible for
   the data collection, management and statistical analyses. The authors
   thank the 'Healthy Growth Study' group for the valuable contribution to
   the completion of the study.
CR Aeberli I, 2009, SWISS MED WEEKLY, V140
   Ahmed F, 2008, ASIA PAC J CLIN NUTR, V17, P40
   Wisse BE, 2004, J AM SOC NEPHROL, V15, P2792, DOI 10.1097/01.ASN.0000141966.69934.21
   MENTZER WC, 1973, LANCET, V1, P882
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Halterman JS, 2001, PEDIATRICS, V107, P1381, DOI 10.1542/peds.107.6.1381
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Cattaneo A, 2010, OBES REV, V11, P389, DOI 10.1111/j.1467-789X.2009.00639.x
   Taylor RW, 2002, AM J CLIN NUTR, V76, P1416
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Subramanian V, 2009, NESTLE NUTR WORKS SE, V63, P151, DOI 10.1159/000209979
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747
   Hassapidou M, 2006, OBESITY, V14, P855, DOI 10.1038/oby.2006.99
   Ryo M, 2005, DIABETES CARE, V28, P451, DOI 10.2337/diacare.28.2.451
   Cole TJ, 2007, BRIT MED J, V335, P194, DOI 10.1136/bmj.39238.399444.55
   Nielsen BM, 2007, DIABETES OBES METAB, V9, P521, DOI 10.1111/j.1463-1326.2006.00634.x
   Kaidar-Person O, 2008, OBES SURG, V18, P870, DOI 10.1007/s11695-007-9349-y
   WENZEL BJ, 1962, LANCET, V2, P327
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Fernandez JR, 2004, J PEDIATR-US, V145, P439, DOI 10.1016/j.jpeds.2004.06.044
   Falzacappa MVV, 2007, BLOOD, V109, P353, DOI 10.1182/blood-2006-07-033969
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Gade Wayne, 2010, Clin Lab Sci, V23, P51
   Gade W, 2010, CLIN LAB SCI, V23, P62
   Jean-Claude D, 2006, DRUG DEVELOP RES, V67, P602
   Kimmons Joel E, 2006, MedGenMed, V8, P59
   Lozoff B, 2004, PEDIATR RES, V55, p23A
   LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004
   Manios Y, 2005, ACTA PAEDIATR, V94, P859, DOI 10.1080/08035250510025734
   Ogden CL, 2009, JAMA-J AM MED ASSOC, V303, P242
   Pollitt E, 2001, J NUTR, V131, p669S
   Tanner JM, 1955, GROWTH ADOLESCENCE
   Trichopoulou A, 2004, COMPOSITION TABLES F
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   WHO, 2001, IR DEF AN ASS PREV C
   Zafon C, 2009, OBES REV, V11, P322
NR 43
TC 10
Z9 11
U1 2
U2 4
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD AUG 28
PY 2012
VL 108
IS 4
BP 710
EP 719
DI 10.1017/S0007114511005952
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 000CT
UT WOS:000308364800019
PM 22088365
ER

PT J
AU Yoo, KD
   Ko, SH
   Park, JE
   Ahn, YB
   Yim, HW
   Lee, WC
   Park, YM
AF Yoo, Ki-Dong
   Ko, Seung-Hyun
   Park, Ji-Eun
   Ahn, Yu-Bae
   Yim, Hyeon Woo
   Lee, Won-Chul
   Park, Yong-Moon
TI High serum ferritin levels are associated with metabolic risk factors in
   non-obese Korean young adults: Korean National Health and Nutrition
   Examination Survey (KNHANES) IV
SO CLINICAL ENDOCRINOLOGY
LA English
DT Article
ID INSULIN-RESISTANCE SYNDROME; CARDIOVASCULAR RISK; IRON-METABOLISM;
   DISEASE; OBESITY; MEN; ADOLESCENTS; TRANSFERRIN; POPULATION; PREVALENCE
AB Objective The purpose of this study is to investigate the relationship between serum ferritin levels and metabolic risk factors in nonobese Korean young adults. Design and Subjects We analysed the fourth annual Korea National Health and Nutrition Examination Survey (KNHANES) in young adults (aged 1939 years), conducted between 2007 and 2008. A total of 1542 nonobese [body mass index (BMI) <25 kg/m2] young adults (684 men and 858 women) were enrolled. Using blood pressure and levels of serum triglycerides, plasma glucose and high-density lipoprotein (HDL) cholesterol, the Asian criteria for abdominal obesity (Waist circumference =90 cm in men or =80 cm in women) was used to identify individuals with metabolic syndrome. Measurements Data on anthropometry, fasting plasma glucose, insulin, lipid profile and ferritin levels were analysed. Results The prevalence of metabolic syndrome was 4.1% for men and 2.7% for women. High fasting glucose and the prevalence of metabolic syndrome increased progressively across three different tertiles of ferritin levels in men. However, high ferritin levels were associated with high triglycerides, low HDL cholesterol and metabolic syndrome in women. After adjustment for age, smoking, alcohol consumption, BMI and ALT levels, low HDL cholesterol (OR 1.66, 95% confidence interval (CI) 1.162.36) and the presence of metabolic syndrome (OR 3.87, 95% CI 1.3411.2) were independently associated with high serum ferritin levels in Korean nonobese young women. Conclusions Our results suggest that elevated serum ferritin levels may be employed as a marker of metabolic syndrome in nonobese young adult women.
C1 [Park, Ji-Eun; Yim, Hyeon Woo; Lee, Won-Chul; Park, Yong-Moon] Catholic Univ Korea, Dept Prevent Med, Seoul 137701, South Korea.
   [Yoo, Ki-Dong] Catholic Univ Korea, Div Cardiol, Seoul 137701, South Korea.
   [Ko, Seung-Hyun; Ahn, Yu-Bae] Catholic Univ Korea, Div Endocrinol & Metab, Dept Internal Med, Seoul 137701, South Korea.
RP Park, YM (reprint author), Catholic Univ Korea, Dept Prevent Med, 505 Banpo Dong, Seoul 137701, South Korea.
EM markYMpark@gmail.com
OI PARK, YONG-MOON/0000-0002-5879-6879
FU Catholic Medical Center Research Foundation
FX The authors wish to acknowledge the financial support of the Catholic
   Medical Center Research Foundation made in the programme year of 2011.
CR Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709
   Rajpathak SN, 2009, BBA-GEN SUBJECTS, V1790, P671, DOI 10.1016/j.bbagen.2008.04.005
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Agarwal DP, 2002, ALCOHOL ALCOHOLISM, V37, P409, DOI 10.1093/alcalc/37.5.409
   Tzou WS, 2005, J AM COLL CARDIOL, V46, P457, DOI 10.1016/j.jacc.2005.04.046
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Lim S, 2011, DIABETES CARE, V34, P1323, DOI 10.2337/dc10-2109
   Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Halle M, 1997, ATHEROSCLEROSIS, V128, P235, DOI 10.1016/S0021-9150(96)05994-1
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505
   Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   Balkau B, 2007, DIABETES METAB, V33, P405, DOI 10.1016/j.diabet.2007.08.001
   Kim CH, 2011, METABOLISM, V60, P414, DOI 10.1016/j.metabol.2010.03.007
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   NIEDERAU C, 1984, DIABETOLOGIA, V26, P441
   Dekker JM, 2005, CIRCULATION, V112, P666, DOI 10.1161/CIRCULATIONAHA.104.516948
   Mottillo S, 2010, J AM COLL CARDIOL, V56, P1113, DOI 10.1016/j.jacc.2010.05.034
   Park HS, 2004, INT J EPIDEMIOL, V33, P328, DOI 10.1093/ije/dyh032
   Jang M, 2011, CLIN NURS RES, V20, P276, DOI 10.1177/1054773811406111
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   KCDC, KOR NAT HLTH NUTR EX
   Kim D.J, 2011, DIABETES METAB, V35, P317
   Kim HM, 2007, DIABETES RES CLIN PR, V75, P111, DOI 10.1016/j.diabres.2006.04.009
   Kim SJ, 2011, YONSEI MED J, V52, P746, DOI 10.3349/ymj.2011.52.5.746
   Puntarulo Susana, 2005, Molecular Aspects of Medicine, V26, P299, DOI 10.1016/j.mam.2005.07.001
   Third report of the National Cholesterol Education Program (NCEP), 2002, CIRCULATION, V106, P3143
   WOLFF SP, 1993, BRIT MED BULL, V49, P642
NR 36
TC 6
Z9 6
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-0664
J9 CLIN ENDOCRINOL
JI Clin. Endocrinol.
PD AUG
PY 2012
VL 77
IS 2
BP 233
EP 240
DI 10.1111/j.1365-2265.2011.04248.x
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 971SF
UT WOS:000306223400010
PM 21977991
ER

PT J
AU Le Blanc, S
   Villarroel, P
   Candia, V
   Gavilan, N
   Soto, N
   Perez-Bravo, F
   Arredondo, M
AF Le Blanc, Solange
   Villarroel, Pia
   Candia, Valeria
   Gavilan, Natalia
   Soto, Nestor
   Perez-Bravo, Francisco
   Arredondo, Miguel
TI Type 2 diabetic patients and their offspring show altered parameters of
   iron status, oxidative stress and genes related to mitochondrial
   activity
SO BIOMETALS
LA English
DT Article
DE Iron; Oxidative stress; Bcl2/Bax ratio; Mitofusin; Diabetes mellitus
ID LOW-DENSITY-LIPOPROTEIN; METABOLIC SYNDROME; HEME OXYGENASE-1;
   CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; CELL APOPTOSIS; BODY IRON;
   OBESITY; MELLITUS; DYSFUNCTION
AB Type 2 diabetes (T2D) is directly related to alterations in iron status, oxidative stress and decreased mitochondrial activity, but the possible interaction of these parameters among T2D patients and their offspring is unclear. The whole study included 301 subjects: 77 T2D patients and one of their offspring and 51 control subjects with one of their offspring. The offspring were older than 20 years old. We measured parameters of iron status (serum iron, ferritin and transferrin receptor), diabetes (pre and post-prandial glucose, insulin, lipids), oxidative stress (Heme oxygenase activity, TBARS, SOD, GSH, Vitamin E), as well as the expression of genes in blood leukocytes related to mitochondrial apopotosis (mitofusin and Bcl/Bax ratios). The offspring of T2D patients had increased levels of serum ferritin (P < 0.01) and lower transferrin receptor (P < 0.008); higher insulin (P < 0.03) and total and LDL cholesterol; higher heme oxygenase and SOD activities increased TBARS and lower GSH; decreased mitofusin and Bcl/Bax expression ratios compared to offspring of normal subjects. These results suggest that the offspring of T2D patients could have an increased metabolic risk of develop a cardiovascular disease mediated by oxidative stress and iron status.
C1 [Le Blanc, Solange; Villarroel, Pia; Candia, Valeria; Arredondo, Miguel] Univ Chile, Lab Micronutrientes, INTA, Santiago, Chile.
   [Gavilan, Natalia] Consultorio Eduardo Frei Montalva, Santiago, Chile.
   [Soto, Nestor] Hosp San Borja Arriaran, SSMC, Unidad Endocrinol & Diabet, Santiago, Chile.
   [Perez-Bravo, Francisco] Univ Chile, Fac Med, Dept Nutr, Santiago 7, Chile.
RP Arredondo, M (reprint author), Univ Chile, Lab Micronutrientes, INTA, El Libano 5524, Santiago, Chile.
EM marredon@inta.uchile.cl
FU Fondo Nacional de Ciencia y Tecnologia (FONDECYT), Chile [1085173]
FX We thank the staff from the Diabetic Program, Nutrition Unit, of San
   Juan de Dios Hospital, for their teamwork and persistent efforts in this
   project. This work was supported by Grant 1085173 from Fondo Nacional de
   Ciencia y Tecnologia (FONDECYT), Chile to M. Arredondo.
CR Alemany M, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-74
   Wang XD, 2001, GENE DEV, V15, P2922
   Acosta AM, 2002, REV MED CHILE, V130, P1227, DOI 10.4067/S0034-98872002001100004
   Bonomini F, 2008, HISTOL HISTOPATHOL, V23, P381
   Guo XM, 2007, CIRC RES, V101, P1113, DOI 10.1161/CIRCRESAHA.107.157644
   Imamura M, 2011, ENDOCR J, V58, P723
   Praveen EP, 2010, DIABETES TECHNOL THE, V12, P723, DOI 10.1089/dia.2009.0163
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Sumida Y, 2009, HEPATOL RES, V39, P213, DOI 10.1111/j.1872-034X.2008.00442.x
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Loboda A, 2008, ANTIOXID REDOX SIGN, V10, P1767, DOI 10.1089/ars.2008.2043
   Sheftel AD, 2007, J BIOL CHEM, V282, P10480, DOI 10.1074/jbc.M700240200
   Bach D, 2005, DIABETES, V54, P2685, DOI 10.2337/diabetes.54.9.2685
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348
   Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb/1161
   Jin YX, 2011, CHEMOSPHERE, V82, P398, DOI 10.1016/j.chemosphere.2010.09.072
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Dandona P, 2005, CIRCULATION, V111, P1448, DOI 10.1161/01.CIR.0000158483.13093.9D
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Ong SB, 2010, CARDIOVASC RES, V88, P16, DOI 10.1093/cvr/cvq237
   NIEDERAU C, 1984, DIABETOLOGIA, V26, P441
   MERKEL PA, 1988, NEW ENGL J MED, V318, P809, DOI 10.1056/NEJM198803313181303
   Mojiminiyi OA, 2008, NUTR METAB CARDIOVAS, V18, P559, DOI 10.1016/j.numecd.2007.07.007
   Rocha M, 2010, CURR MED CHEM, V17, P3827
   Kalra N, 2008, LIFE SCI, V82, P348, DOI 10.1016/j.lfs.2007.11.006
   Khera T, 2006, LAB INVEST, V86, P566, DOI 10.1038/labinvest.3700418
   Metukuri MR, 2010, INFLAMMATION, V33, P235, DOI 10.1007/s10753-009-9177-4
   Marcovecchio M, 2005, J ENDOCRINOL INVEST, V28, P853
   Cepeda-Lopez AC, 2010, INT J VITAM NUTR RES, V80, P263, DOI 10.1024/0300-9831/a000033
   Bacha F, 2010, DIABETES CARE, V33, P2225, DOI 10.2337/dc10-0004
   Crist BL, 2009, J WOMENS HEALTH, V18, P795, DOI 10.1089/jwh.2008.0988
   Arredondo M, 2007, AM J CLIN NUTR, V86, P1347
   Callahan ST, 2000, CURR OPIN PEDIATR, V12, P310, DOI 10.1097/00008480-200008000-00004
   Celis-Morales CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024690
   Center for the Evaluation of Risks to Human Reproduction NTP, 2005, NIH PUBL, P05
   Chang Jui-Chih, 2010, World J Cardiol, V2, P150, DOI 10.4330/wjc.v2.i6.150
   Cleland MM, 2011, CELL DEATH DIFFER, V18, P235, DOI 10.1038/cdd.2010.89
   Halpern A, 2010, DIABETOL METAB SYNDR, V2, DOI 10.1186/1758-5996-2-55
   Hoogeveen RC, 2007, DIABETOLOGIA, V50, P36, DOI 10.1007/s00125-006-0533-8
   Jiamsripong Panupong, 2008, Prev Cardiol, V11, P155
   Johansen JS, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-5
   Mendiburo MJ, 2011, EUR J NUTR, V50, P363, DOI 10.1007/s00394-010-0144-5
   Munoz C, 2005, EUR CYTOKINE NETW, V16, P261
   Reusens Brigitte, 2011, World J Diabetes, V2, P149, DOI 10.4239/wjd.v2.i9.149
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   World Health Organization, 2007, ASS IR STAT POP
   Zhai L, 2011, MOL ENDOCRINOL, V25, P492, DOI 10.1210/me.2010-0224
   Zheng M, 2010, J MOL MED, V88, P987, DOI 10.1007/s00109-010-0675-5
   Zorzano A, 2009, INT J BIOCHEM CELL B, V41, P1846, DOI 10.1016/j.biocel.2009.02.004
NR 50
TC 7
Z9 7
U1 2
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0966-0844
J9 BIOMETALS
JI Biometals
PD AUG
PY 2012
VL 25
IS 4
BP 725
EP 735
DI 10.1007/s10534-012-9540-z
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 964XX
UT WOS:000305731100009
PM 22450556
ER

PT J
AU Velasco-Rodriguez, R
   Perez-Hernandez, MG
   Mora-Brambila, AB
   Bazan-Arellano, DA
   Vasquez, C
AF Velasco-Rodriguez, R.
   Perez-Hernandez, M. G.
   Mora-Brambila, A. B.
   Bazan-Arellano, D. A.
   Vasquez, C.
TI Serum ferritin and nutritional status in older adults at eldercare
   facilities
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Older adult; aging; ferritin; nutritional status; body mass index
ID ANEMIA
AB To identify serum ferritin levels and their association with nutritional status determined by Body Mass Index in older adults at four eldercare facilities.
   An exploratory, cross-sectional study was carried out on 100 older adults residing at eldercare facilities in Colima, Mexico. Association between blood serum ferritin levels and nutritional status determined by Body Mass Index was evaluated. Ferritin levels were determined by means of chemiluminescence of blood samples obtained from subjects under control conditions. Descriptive statistics were used to analyze demographic characteristics. Student's t test and chi-square test were used to compare ferritin levels and Body Mass Index, respectively, between sexes. Statistical significance was considered to exist when P a parts per thousand currency sign 0.05. Pearson's correlation was used to establish the relation between Body Mass Index and serum ferritin levels.
   Mean serum ferritin levels were 59.9489 ng/mL in women and 86.9266 ng/mL in men (P= 0.12). In regard to Body Mass Index there was statistical significance between normal vs overweight/obesity (P = 0.008), but not between normal vs underweight (P = 0.34). Body Mass Index/serum ferritin correlation was not statistically significant (Pearson's r = 0.003).
   The quantification of a single serum indicator is insufficient for determining nutritional status in the older adult.
C1 [Velasco-Rodriguez, R.; Perez-Hernandez, M. G.; Bazan-Arellano, D. A.] Univ Colima, Fac Nursing, Colima 28040, Mexico.
   [Mora-Brambila, A. B.] Univ Colima, Biomed Res Ctr, Colima 28040, Mexico.
RP Velasco-Rodriguez, R (reprint author), Univ Colima, Fac Enfermeria, Av Univ 333, Colima 28040, Mexico.
EM rayvel@ucol.mx
CR Smith DL, 2000, AM FAM PHYSICIAN, V62, P1565
   [Anonymous], NOM167SSA11997 SECR
   Han YH, 2009, PUBLIC HEALTH NUTR, V12, P1189, DOI 10.1017/S1368980008003686
   [Anonymous], 2005, REACTIVOS DETERMINAC, P1
   Timpini A, 2011, J NUTR HEALTH AGING, V15, P233, DOI 10.1007/s12603-010-0286-4
   O'Meara A, 2011, TRANSFUSION, V51, P2183, DOI 10.1111/j.1537-2995.2011.03148.x
   [Anonymous], NOM003SSA21993 SECR
   [Anonymous], NOM043SSA22005 SECR
   Becerra Bulla F., 2006, REV FAC MED UNAL, V54, P283
   Burke M., 2000, ENFERMERIA GERONTOLO
   Casanueva E, 2001, NUTRIOLOGIA MED
   Cuervo M, 2009, PUBLIC HEALTH NUTR, V12, P82
   Cuervo M, 2009, ARCH GERONTOL GERIAT, V49, P69, DOI 10.1016/j.archger.2008.05.003
   Dupuy AM, 2009, CLIN LAB, V55, P207
   Forster S, 2005, NUTR J, V4, P1
   Guillen F, 2003, MANUAL GERIATRIA
   Guyton AC, 2001, ERITROCITOS ANEMIA P, P465
   Joosten E, 2004, GERONTOLOGY, V50, P49, DOI 10.1159/000075555
   Konig B, 1999, ANTICANCER RES, V19, P2739
   LIPSCHITZ DA, 1981, AM J CLIN NUTR, V34, P951
   MACPHAIL AP, 1981, S AFR MED J, V59, P939
   Martinez J, 1998, FUNDAMENTOS TEORICO
   Monterrey P, 2001, REV CUBANA ALIMENT N, V15, P62
   Organizacion Mundial de la Salud, 2011, OB SOBR
   Ramirez C, 2004, MED CLIN-BARCELONA, V122, P532, DOI 10.1157/13060470
NR 25
TC 1
Z9 1
U1 4
U2 5
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD JUN
PY 2012
VL 16
IS 6
BP 525
EP 528
DI 10.1007/s12603-012-0013-4
PG 4
WC Geriatrics & Gerontology; Nutrition & Dietetics
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA 959XF
UT WOS:000305350800003
PM 22659990
ER

PT J
AU Sarmiento, OL
   Ramirez, A
   Kutschbach, BS
   Pinzon, PL
   Garcia, S
   Olarte, AC
   Mosquera, T
   Atalah, E
   Ojeda, G
   Forero, Y
AF Sarmiento, Olga L.
   Ramirez, Andrea
   Samper Kutschbach, Belen
   Pinzon, Paula L.
   Garcia, Sandra
   Olarte, Angie C.
   Mosquera, Tatiana
   Atalah, Eduardo
   Ojeda, Gabriel
   Forero, Yibby
TI Nutrition in Colombian pregnant women
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Nutrition; Pregnancy; Health statistics; Public health policy; Maternal
   disease
ID BODY-MASS INDEX; DEVELOPING-COUNTRIES; BIRTH-WEIGHT; MATERNAL
   OVERWEIGHT; OBESITY; TRANSITION; OUTCOMES; TRENDS; UNDERNUTRITION;
   PERSPECTIVES
AB Objective: The present study aimed to evaluate the nutritional status of pregnant women in Colombia and the associations between gestational BMI and sociodemographic and gestational characteristics.
   Design: Cross-sectional study. A secondary analysis was made of data from the 2005 Demographic and Health Survey of Colombia.
   Setting: Bogota, Colombia.
   Subjects: Pregnant adolescents aged 13-19 years (n 430) and pregnant women aged 20-49 years (n 1272).
   Results: The gestational BMI and sociodemographic characteristics of the adolescents differed from those of the pregnant adult women. Thirty-one per cent of the adolescents were underweight for gestational age, compared with 14.5% of the adult women. Eighteen per cent of adolescents were overweight for gestational age, in contrast to 37.3% of adult women. The overall prevalence of anaemia was 44.7% and the prevalence of low serum ferritin was 38.8%. Women within the high quintiles of the wealth index (prevalence odds ratio (POR) = 0.56; 95% CI 0.34, 0.91, P < 0.02) had lower odds of being underweight. Women who received prenatal care (POR = 2.17; 95% CI 1.48, 3.09, P < 0.001) and were multiparous (POR = 2.10; 95% CI 1.43, 3.15, P < 0.0 0 1) had higher odds of being overweight. Women in extended families (POR = 0.63; 95% CI 0.50, 0.95, P < 0.025) had lower odds of being overweight.
   Conclusions: Underweight in pregnant adolescents and overweight in adult women coexist as a double burden in Colombia. Factors associated with malnutrition among pregnant women and adolescents should be considered for future interventions in countries experiencing nutritional transition.
C1 [Sarmiento, Olga L.; Ramirez, Andrea; Pinzon, Paula L.; Olarte, Angie C.; Mosquera, Tatiana] Univ Los Andes, Sch Med, Dept Publ Hlth, Bogota, Colombia.
   [Samper Kutschbach, Belen] Profamilia, Dept Res & Evaluat, Bogota, Colombia.
   [Garcia, Sandra; Ojeda, Gabriel] Univ Los Andes, Sch Govt, Bogota, Colombia.
   [Atalah, Eduardo] Univ Chile, Fac Med, Dept Nutr, Santiago 7, Chile.
   [Forero, Yibby] Natl Inst Hlth, Bogota, Colombia.
RP Sarmiento, OL (reprint author), Univ Los Andes, Sch Med, Dept Publ Hlth, Carrera 1 18A-10, Bogota, Colombia.
EM osarmien@uniandes.edu.co
FU US Agency for International Development (USAID); United Nations
   Population Fund (UNFPA); Colombian Institute of Family Welfare (ICBF);
   Colombia's Ministry of Social Protection; Epidemiology Group at
   Universidad de los Andes [1808]
FX The Demographic and Health Survey of Colombia 2005 was funded by the US
   Agency for International Development (USAID), the United Nations
   Population Fund (UNFPA), the Colombian Institute of Family Welfare
   (ICBF) and Colombia's Ministry of Social Protection. O.L.S., A.C.O.,
   P.L.P. and A.R. received funding from the Epidemiology Group at
   Universidad de los Andes #1808. The authors declare that they have no
   conflict of interests. All authors were involved with data
   interpretation, critical revisions of the paper and provided approval
   for its publication.
CR Mendez MA, 2005, AM J CLIN NUTR, V81, P714
   Muller O, 2005, CAN MED ASSOC J, V173, P279, DOI 10.1503/cmaj.050342
   Gale CR, 2007, J CLIN ENDOCR METAB, V92, P3904, DOI 10.1210/jc.2007-0088
   Reece EA, 2008, AM J OBSTET GYNECOL, V198, P23, DOI 10.1016/j.ajog.2007.06.076
   Poston L, 2011, PEDIATR RES, V69, P175, DOI 10.1203/PDR.0b013e3182055ede
   Anderson JL, 2005, EPIDEMIOLOGY, V16, P87, DOI 10.1097/01.ede.0000147122.97061.bb
   Abenhaim Haim A., 2007, Archives of Gynecology and Obstetrics, V275, P39, DOI 10.1007/s00404-006-0219-y
   Lee AI, 2011, HEMATOL ONCOL CLIN N, V25, P241, DOI 10.1016/j.hoc.2011.02.001
   Siega-Riz AM, 2006, MATERN CHILD HLTH J, V10, pS153, DOI 10.1007/s10995-006-0115-x
   Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824
   Atalah E, 1997, REV MED CHILE, V125, P1429
   Oken E, 2009, OBSTET GYN CLIN N AM, V36, P361, DOI 10.1016/j.ogc.2009.03.007
   Ramakrishnan U, 2004, AM J CLIN NUTR, V79, P17
   Yogev Y, 2009, OBSTET GYN CLIN N AM, V36, P285, DOI 10.1016/j.ogc.2009.03.003
   Seligman LC, 2006, REV SAUDE PUBL, V40, P457, DOI 10.1590/s0034-89102006000300014
   Davies AA, 2006, HYPERTENSION, V48, P431, DOI 10.1161/01.HYP.0000236551.00191.61
   Sullivan KM, 2008, TROP MED INT HEALTH, V13, P1267, DOI 10.1111/j.1365-3156.2008.02143.x
   Ehrenberg HM, 2002, AM J OBSTET GYNECOL, V187, P1189, DOI 10.1067/mob.2002.127125
   Gore SA, 2003, ANN BEHAV MED, V26, P149, DOI 10.1207/S15324796ABM2602_07
   LaCoursiere DY, 2005, AM J OBSTET GYNECOL, V192, P832, DOI 10.1016/j.ajog.2004.11.034
   Rached-Paoli I, 2005, ARCH LATINOAM NUTR, V55, P42
   Martorell R, 2000, EUR J CLIN NUTR, V54, P247, DOI 10.1038/sj.ejcn.1600931
   Popkin BM, 2004, INT J OBESITY, V28, pS2, DOI [10.1038/sj.ijo.0802804, 10.1038/sj.ijo.0802557]
   ATALAH E, 1980, REV MED CHILE, V108, P351
   Atalah E, 1995, REV MED CHILE, V123, P1531
   Atalah E, 2004, REV MED CHILE, V132, P923, DOI 10.4067/S0034-98872004000800003
   Barria RM, 2006, ARCH LATINOAM NUTR, V56, P3
   Benjumea MV, 2007, BIOMEDICA, V27, P42
   THOMSON AM, 1957, BRIT MED J, V1, P243
   Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0
   Ciok J, 1999, Ginekol Pol, V70, P573
   Demographic and Health Survey, 2002, DHS DIMENSIONS, V4
   Departamento Administrativo Nacional de Estadistica, 2005, CENS GEN COL 2005
   Grandi C, 2007, MEDICINA-BUENOS AIRE, V67, P677
   Ha do TP, 2011, BMC PUBLIC HEALTH, V11, P62
   Haider BA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S19
   International Anemia Consultative Group, 2002, ADJ HEM VAL PROGR SU
   Leddy Meaghan A, 2008, Rev Obstet Gynecol, V1, P170
   Linné Y, 2004, Obes Rev, V5, P137, DOI 10.1111/j.1467-789X.2004.00147.x
   Mardones F, 1997, REV MED CHILE, V125, P1437
   Mundial Banco, 2009, RES COL
   Organization WH, 2006, GLOB DAT BOD MASS IN
   PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086
   Profamilia, 2005, ENC NAC DEM SAL 2005
   Rached-Paoli I, 2010, ARCH LATINOAM NUTR, V60, P141
   Rayis Duria A, 2010, BMC Res Notes, V3, P327, DOI 10.1186/1756-0500-3-327
   Santos IS, 2008, CAD SAUDE PUBLICA, V24, pS381, DOI 10.1590/S0102-311X2008001500003
   Siega-Riz A. M., 2009, Journal of the American Dietetic Association, V109, P918, DOI 10.1016/j.jada.2009.03.020
   Stoltzfus Rebecca J., 2003, Food and Nutrition Bulletin, V24, pS99
   Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1
   Uauy R., 2001, Journal of Nutrition, V131, P893
   Van EP, 2011, 4650 S D MED
   Villamor E, 2006, AM J CLIN NUTR, V83, P1387
   WHO/UNICEF/United Nations University, 2001, IR DEF AN ASS PREV C
   World Health Organization, 2007, AD PREGN UNM NEEDS U
NR 55
TC 4
Z9 4
U1 1
U2 6
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD JUN
PY 2012
VL 15
IS 6
BP 955
EP 963
DI 10.1017/S1368980011003399
PG 9
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 951TF
UT WOS:000304742200003
PM 22217728
ER

PT J
AU Houschyar, KS
   Ludtke, R
   Dobos, GJ
   Kalus, U
   Broecker-Preuss, M
   Rampp, T
   Brinkhaus, B
   Michalsen, A
AF Houschyar, Khosrow S.
   Luedtke, Rainer
   Dobos, Gustav J.
   Kalus, Ulrich
   Broecker-Preuss, Martina
   Rampp, Thomas
   Brinkhaus, Benno
   Michalsen, Andreas
TI Effects of phlebotomy-induced reduction of body iron stores on metabolic
   syndrome: results from a randomized clinical trial
SO BMC MEDICINE
LA English
DT Article
ID INSULIN-RESISTANCE SYNDROME; SERUM FERRITIN; BLOOD-PRESSURE; SYNDROME
   DESIR; US ADULTS; DISEASE; HYPERTENSION; MEN; POPULATION; PREVALENCE
AB Background: Metabolic syndrome (METS) is an increasingly prevalent but poorly understood clinical condition characterized by insulin resistance, glucose intolerance, dyslipidemia, hypertension, and obesity. Increased oxidative stress catalyzed by accumulation of iron in excess of physiologic requirements has been implicated in the pathogenesis of METS, but the relationships between cause and effect remain uncertain. We tested the hypothesis that phlebotomy-induced reduction of body iron stores would alter the clinical presentation of METS, using a randomized trial.
   Methods: In a randomized, controlled, single-blind clinical trial, 64 patients with METS were randomly assigned to iron reduction by phlebotomy (n = 33) or to a control group (n = 31), which was offered phlebotomy at the end of the study (waiting-list design). The iron-reduction patients had 300 ml of blood removed at entry and between 250 and 500 ml removed after 4 weeks, depending on ferritin levels at study entry. Primary outcomes were change in systolic blood pressure (SBP) and insulin sensitivity as measured by Homeostatic Model Assessment (HOMA) index after 6 weeks. Secondary outcomes included HbA1c, plasma glucose, blood lipids, and heart rate (HR).
   Results: SBP decreased from 148.5 +/- 12.3 mmHg to 130.5 +/- 11.8 mmHg in the phlebotomy group, and from 144.7 +/- 14.4 mmHg to 143.8 +/- 11.9 mmHg in the control group (difference -16.6 mmHg; 95% CI -20.7 to -12.5; P < 0.001). No significant effect on HOMA index was seen. With regard to secondary outcomes, blood glucose, HbA1c, low-density lipoprotein/high-density lipoprotein ratio, and HR were significantly decreased by phlebotomy. Changes in BP and HOMA index correlated with ferritin reduction.
   Conclusions: In patients with METS, phlebotomy, with consecutive reduction of body iron stores, lowered BP and resulted in improvements in markers of cardiovascular risk and glycemic control. Blood donation may have beneficial effects for blood donors with METS.
C1 [Brinkhaus, Benno; Michalsen, Andreas] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.
   [Houschyar, Khosrow S.; Dobos, Gustav J.; Rampp, Thomas] Univ Duisburg Essen, Kliniken Essen Mitte, Dept Internal Med, Essen, Germany.
   [Luedtke, Rainer] Karl & Veronica Carstens Fdn, Dept Biometry, Essen, Germany.
   [Kalus, Ulrich] Charite Univ Med Ctr, Inst Transfus Med, Berlin, Germany.
   [Broecker-Preuss, Martina] Univ Hosp Essen, Dept Endocrinol, Essen, Germany.
   [Broecker-Preuss, Martina] Univ Hosp Essen, Div Lab Res, Essen, Germany.
   [Michalsen, Andreas] Immanuel Hosp Berlin, Dept Internal & Integrat Med, D-14109 Berlin, Germany.
RP Michalsen, A (reprint author), Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.
EM a.michalsen@immanuel.de
FU Karl and Veronica Carstens Foundation, Essen, Germany
FX The study was funded by a grant from the Karl and Veronica Carstens
   Foundation, Essen, Germany.
CR Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Valenti L, 2011, NUTR METAB CARDIOVAS, V21, P568, DOI 10.1016/j.numecd.2010.01.003
   Fleming DJ, 2001, AM J CLIN NUTR, V73, P638
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Cinar Y, 1999, AM J HYPERTENS, V12, P739, DOI 10.1016/S0895-7061(99)00011-4
   Facchini FS, 2002, GASTROENTEROLOGY, V122, P931, DOI 10.1053/gast.2002.32403
   Vari IS, 2007, DIABETES CARE, V30, P1795, DOI 10.2337/dc-2342
   Whaley-Connell A, 2011, REV CARDIOVASC MED, V12, P21, DOI 10.3909/ricm0555
   Salonen JT, 1998, BRIT MED J, V317, P727
   Zacharski LR, 2007, JAMA-J AM MED ASSOC, V297, P603, DOI 10.1001/jama.297.6.603
   Coban E, 2010, MED SCI MONITOR, V16, pCR92
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Wrede CE, 2006, EUR J ENDOCRINOL, V154, P333, DOI 10.1530/eje.1.02083
   HOLM S, 1979, SCAND J STAT, V6, P65
   DMOCHOWSKI K, 1993, J CLIN ENDOCR METAB, V77, P478, DOI 10.1210/jc.77.2.478
   Hu G, 2004, ARCH INTERN MED, V164, P1066, DOI 10.1001/archinte.164.10.1066
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Cai H, 2005, CARDIOVASC RES, V68, P26, DOI 10.1016/j.cardiores.2005.06.021
   BOFILL C, 1994, METABOLISM, V43, P614, DOI 10.1016/0026-0495(94)90204-6
   Cho GJ, 2011, MENOPAUSE, V18, P1120, DOI 10.1097/gme.0b013e318217e172
   Olivieri NF, 1997, BLOOD, V89, P739
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   BARENBROCK M, 1993, CLIN NEPHROL, V40, P241
   CHALLONER T, 1986, BRIT J HAEMATOL, V62, P671, DOI 10.1111/j.1365-2141.1986.tb04090.x
   Dongiovanni P., 2011, J HEPATOL, V55, P1120
   Ellervik C, 2010, J INTERN MED, V268, P252, DOI 10.1111/j.1365-2796.2010.02217.x
   Equitani F, 2008, DIABETES CARE, V31, P3, DOI 10.2337/dc07-0939
   Facchini FS, 2003, DIABETES, V52, P1204, DOI 10.2337/diabetes.52.5.1204
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665
   Pelot D, 1998, DIGEST DIS SCI, V43, P2411, DOI 10.1023/A:1026669829121
   Rubin DB, 1987, MULTIPLE IMPUTATION
   Valenti L, 2010, ARTERIOSCLER THROMB, V31, P683
   Zacharski LR, 2010, J INTERN MED, V268, P246, DOI 10.1111/j.1365-2796.2010.02233.x
   ZIDEK W, 1985, KLIN WOCHENSCHR, V63, P762, DOI 10.1007/BF01733828
NR 37
TC 30
Z9 30
U1 4
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD MAY 30
PY 2012
VL 10
AR 54
DI 10.1186/1741-7015-10-54
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 967OG
UT WOS:000305917100001
PM 22647517
ER

PT J
AU Cymerys, M
   Bogdanski, P
   Pupek-Musialik, D
   Jablecka, A
   Lacki, J
   Korczowska, I
   Dytfeld, J
AF Cymerys, Maciej
   Bogdanski, Pawel
   Pupek-Musialik, Danuta
   Jablecka, Anna
   Lacki, Jan
   Korczowska, Izabela
   Dytfeld, Joanna
TI Influence of hypertension, obesity and nicotine abuse on quantitative
   and qualitative changes in acute-phase proteins in patients with
   essential hypertension
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE arterial hypertension; obesity; nicotine; acute-phase proteins
ID C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION;
   OXIDATIVE STRESS; RISK-FACTORS; TNF-ALPHA; ATHEROSCLEROSIS;
   INFLAMMATION; COMPLEMENT; SMOKING
AB Background: Hypertension is a powerful risk factor for cardiovascular disease and frequently occurs in conjunction with obesity. Accumulative evidence suggests a link between inflammation and hypertension. The aim of study was to evaluate whether blood pressure, obesity and smoking may influence acute-phase response.
   Material/Methods: Ninety-two patients with essential hypertension and 75 healthy volunteers as a control group were studied. In all subjects assessment of hsCRP, alpha 1-acid glycoprotein (AGP), alpha 1-antichymotrypsin, transferrin, alpha 1-antitrypsin, and C3 and C4 complement were performed. Evaluation of glycosylation profile and reactivity coefficient (RC) for AGP was done by means of affinity immunoelectrophoresis with concanavalin A as a ligand.
   Results: When compared to the controls, hypertensive subjects presented significantly higher hsCRP concentrations and lower transferrin level. Hypertensive patients had elevated AGP-AC. The intensification of the inflammatory reaction was greater in the subgroup of hypertensive patients smoking cigarettes. In obese hypertensives, elevated serum C3 complement level was found.
   Conclusions: We conclude that arterial hypertension may evoke the acute-phase response in humans. Markers of acute-phase response are particularly strongly expressed in smokers. Serum C 3 complement, but not other APPs, is elevated in hypertension coexisting with obesity.
C1 [Cymerys, Maciej; Bogdanski, Pawel; Pupek-Musialik, Danuta; Dytfeld, Joanna] Univ Med Sci, Dept Internal Med Metab Disorders & Hypertens, Poznan, Poland.
   [Jablecka, Anna] Univ Med Sci, Dept Clin Pharmacol, Poznan, Poland.
   [Lacki, Jan; Korczowska, Izabela] Poznan Univ Med Sci, Dept Rheumatol & Clin Immunol, Poznan, Poland.
RP Bogdanski, P (reprint author), Szamarzewskiego 84 St, PL-60569 Poznan, Poland.
EM pawelbogdanski@wp.pl
CR MacLaren R, 2008, ADV EXP MED BIOL, V632, P1, DOI 10.1007/978-0-387-78952-1_1
   Rocha VZ, 2009, NAT REV CARDIOL, V6, P399, DOI 10.1038/nrcardio.2009.55
   Das Arghya, 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P23
   Vallianou NG, 2010, MED SCI MONITOR, V16, pCR56
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Basu A, 2006, ARTERIOSCL THROM VAS, V26, P995, DOI 10.1161/01.ATV.0000214295.86079.d1
   Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007
   Mizuno Y, 2011, J ATHEROSCLER THROMB, V18, P351
   May A, 2007, EXPERT REV MOL DIAGN, V7, P793, DOI 10.1586/14737159.7.6.793
   Dehnavi RA, 2008, ATHEROSCLEROSIS, V200, P417, DOI 10.1016/j.atherosclerosis.2007.12.050
   Cao YL, 2008, DIABETES RES CLIN PR, V79, P214, DOI 10.1016/j.diabres.2007.08.030
   Mancia G, 2009, BLOOD PRESSURE, V18, P308, DOI 10.3109/08037050903450468
   Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119
   Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10
   Eder K, 2009, INFLAMM RES, V58, P727, DOI 10.1007/s00011-009-0060-4
   Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P2167
   Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179
   Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029
   Bogdanski P, 2008, BIOMED PHARMACOTHER, V62, P360, DOI 10.1016/j.biopha.2007.10.019
   Brunetti ND, 2009, J THROMB THROMBOLYS, V28, P50, DOI 10.1007/s11239-008-0248-4
   Carter AM, 2009, ATHEROSCLEROSIS, V203, P538, DOI 10.1016/j.atherosclerosis.2008.07.007
   Fernandez-Sanchez A, 2011, INT J MOL SCI, V12, P3117, DOI 10.3390/ijms12053117
   Haskard DO, 2008, CURR OPIN LIPIDOL, V19, P478, DOI 10.1097/MOL.0b013e32830f4a06
   Jimenez-Gomez Y., 2009, ATHEROSCLEROSIS, V204, P70, DOI DOI 10.1016/J.ATHEROSCLEROSIS.2008.09.011
   Koj A, 1998, GEN PHARMACOL, V31, P9, DOI 10.1016/S0306-3623(97)00435-7
   Kones Richard, 2009, Ther Adv Cardiovasc Dis, V3, P309, DOI 10.1177/1753944709337056
   Lind P, 2004, ARTERIOSCL THROM VAS, V24, P577, DOI 10.1161/01.ATV.0000116863.37311.82
   Lonnberg M, 2000, J IMMUNOL METHODS, V246, P25, DOI 10.1016/S0022-1759(00)00287-8
   Muscari A, 2002, INT J CARDIOL, V83, P63, DOI 10.1016/S0167-5273(02)00017-7
   NICULESCU F, 1987, CLIN EXP IMMUNOL, V69, P477
   Nishimura Satoshi, 2009, Discov Med, V8, P55
   Ross R, 1999, NEW ENGL J MED, V340, P115
   Sauer WH, 2002, ARCH INTERN MED, V162, P300, DOI 10.1001/archinte.162.3.300
   Stumpf C, 2009, J HYPERTENS, V27, P1748, DOI 10.1097/HJH.0b013e32832f4c64
   Szeplaki G, 2009, MOL IMMUNOL, V46, P2784, DOI 10.1016/j.molimm.2009.04.028
   Ueno T, 2009, MED SCI MONITOR, V15, pCR341
   Yang R.Z., 2006, PLOS MED, V3, P287
NR 38
TC 3
Z9 3
U1 3
U2 5
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1234-1010
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAY
PY 2012
VL 18
IS 5
BP CR330
EP CR336
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 948XE
UT WOS:000304535900018
PM 22534714
ER

PT J
AU Oliva, K
   Barker, G
   Riley, C
   Bailey, MJ
   Permezel, M
   Rice, GE
   Lappas, M
AF Oliva, Karen
   Barker, Gillian
   Riley, Clyde
   Bailey, Mark J.
   Permezel, Michael
   Rice, Gregory E.
   Lappas, Martha
TI The effect of pre-existing maternal obesity on the placental proteome:
   two-dimensional difference gel electrophoresis coupled with mass
   spectrometry
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID GESTATIONAL DIABETES-MELLITUS; INTRAUTERINE GROWTH RESTRICTION;
   PREGNANCY OUTCOMES; FETAL MEMBRANES; IRON-DEFICIENCY; POTENTIAL ROLE;
   EXPRESSION; ACCUMULATION; STRESS; INFLAMMATION
AB Our aim was to study the protein expression profiles of placenta obtained from lean and obese pregnant women with normal glucose tolerance at the time of term Caesarean section. We used two-dimensional difference gel electrophoresis (2D-DIGE), utilising narrow-range immobilised pH gradient strips that encompassed the broad pH range of 4-5 and 5-6, followed by MALDI-TOF mass spectrometry of selected protein spots. Western blot and quantitative RT-PCR (qRT-PCR) analyses were performed to validate representative findings from the 2D-DIGE analysis. Eight proteins were altered (six down-regulated and two up-regulated on obese placentas). Annexin A5 (ANXA5), ATP synthase subunit beta, mitochondria (ATPB), brain acid soluble protein 1 (BASP1), ferritin light chain (FTL), heterogeneous nuclear ribonucleoprotein C (HNRPC) and vimentin (VIME) were all lower in obese patients. Alpha-1-antitrypsin (A1AT) and stress-70 protein, mitochondrial (GRP75) were higher in obese patients. Western blot analysis of ANXA5, ATPB, FTL, VIME, A1AT and GRP75 confirmed the findings from the 2D-DIGE analysis. For brain acid soluble protein 1 and HNRPC, qRT-PCR analysis also confirmed the findings from the 2D-DIGE analysis. Immunohistochemical analysis was also used to determine the localisation of the proteins in human placenta. In conclusion, proteomic analysis of placenta reveals differential expression of several proteins in patients with pre-existing obesity. These proteins are implicated in a variety of cellular functions such as regulation of growth, cytoskeletal structure, oxidative stress, inflammation, coagulation and apoptosis. These disturbances may have significant implications for fetal growth and development. Journal of Molecular Endocrinology (2012) 48, 139-149
C1 [Oliva, Karen; Barker, Gillian; Riley, Clyde; Permezel, Michael; Lappas, Martha] Univ Melbourne, Mercy Hosp Women, Dept Obstet & Gynaecol, Heidelberg, Vic 3084, Australia.
   [Oliva, Karen; Barker, Gillian; Riley, Clyde; Permezel, Michael; Lappas, Martha] Univ Melbourne, Mercy Hosp Women, Mercy Perinatal Res Ctr, Heidelberg, Vic 3084, Australia.
   [Oliva, Karen; Barker, Gillian; Bailey, Mark J.; Rice, Gregory E.] Univ Queensland, UQ Ctr Clin Res, Brisbane, Qld, Australia.
RP Lappas, M (reprint author), Univ Melbourne, Mercy Hosp Women, Dept Obstet & Gynaecol, Level 4-163 Studley Rd, Heidelberg, Vic 3084, Australia.
EM mlappas@unimelb.edu.au
RI RICE, GREGORY/F-2412-2010
OI RICE, GREGORY/0000-0001-7177-0246
FU National Health and Medical Research Council (NHMRC) [454777, 454310];
   Medical Research Foundation for Women and Babies; Australian Proteomics
   Computational Facility; Australian NHMRC [381413]
FX Dr M L was a recipient of a National Health and Medical Research Council
   (NHMRC) RD Wright Fellowship (grant number 454777). The work described
   in this manuscript was funded, in part, by a project grant from NHMRC
   (grant number 454310). Funding for the Chemi-Doc system, xMark
   Microplate Absorbance Spectrophotometer and Leica Qwin Image Analysis
   System was provided by the Medical Research Foundation for Women and
   Babies. Proteomic data analysis described in this work was supported by
   the use of the Australian Proteomics Computational Facility funded by
   the Australian NHMRC (grant number 381413).
CR Ewing MM, 2011, ARTERIOSCL THROM VAS, V31, P95, DOI 10.1161/ATVBAHA.110.216747
   Chu SY, 2008, NEW ENGL J MED, V358, P1444, DOI 10.1056/NEJMoa0706786
   Zhang HH, 2011, BIOL REPROD, V84, P966, DOI 10.1095/biolreprod.110.090688
   THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289
   Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+
   Prohaszka Z, 2004, MOL IMMUNOL, V41, P29, DOI 10.1016/j.molimm.2004.02.001
   Drake AJ, 2010, REPRODUCTION, V140, P387, DOI 10.1530/REP-10-0077
   Challier JC, 2008, PLACENTA, V29, P274, DOI 10.1016/j.placenta.2007.12.010
   Surkan PJ, 2004, OBSTET GYNECOL, V104, P720, DOI 10.1097/01.AOG.0000141442.59573.ed
   Dexlin-Mellby L, 2010, PROTEOM CLIN APPL, V4, P794, DOI 10.1002/prca.201000001
   Subramaniyam D, 2010, INFLAMM RES, V59, P571, DOI 10.1007/s00011-010-0164-x
   Siddappa AM, 2004, PEDIATR RES, V55, P1034, DOI 10.1203/01.pdr.0000127021.38207.62
   Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8
   Colagiuri S, 2010, MED J AUSTRALIA, V192, P260
   Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808
   CASTELLUCCI M, 1994, CELL TISSUE RES, V278, P283, DOI 10.1007/BF00414172
   Bhattacharya S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-168
   Struwe E, 2010, CLIN ENDOCRINOL, V72, P241, DOI 10.1111/j.1365-2265.2009.03659.x
   Schepens B, 2007, EMBO J, V26, P158, DOI 10.1038/sj.emboj.7601468
   Taylor PD, 2007, EXP PHYSIOL, V92, P287, DOI 10.1113/expphysiol.2005.032854
   Vankoningsloo S, 2006, J CELL SCI, V119, P1266, DOI 10.1242/jcs.02848
   Sebire NJ, 2001, INT J OBESITY, V25, P1175, DOI 10.1038/sj.ijo.0801670
   Colomiere M, 2009, EUR J ENDOCRINOL, V160, P567, DOI 10.1530/EJE-09-0031
   Wadhwa R, 2002, CELL STRESS CHAPERON, V7, P309, DOI 10.1379/1466-1268(2002)007<0309:AHFCMM>2.0.CO;2
   Heslehurst N, 2008, OBES REV, V9, P635, DOI 10.1111/j.1467-789X.2008.00511.x
   Jarvie E, 2010, CLIN SCI, V119, P123, DOI 10.1042/CS20090640
   Izumi-Yoneda N, 2009, MOL HUM REPROD, V15, P49, DOI 10.1093/molehr/gan071
   Stothard KJ, 2009, JAMA-J AM MED ASSOC, V301, P636, DOI 10.1001/jama.2009.113
   Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003
   Radaelli T, 2003, DIABETES, V52, P2951, DOI 10.2337/diabetes.52.12.2951
   Heslehurst N, 2010, INT J OBESITY, V34, P420, DOI 10.1038/ijo.2009.250
   Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020
   Korshunova I, 2008, J NEUROSCI RES, V86, P2201, DOI 10.1002/jnr.21678
   Ehrenberg HM, 2004, AM J OBSTET GYNECOL, V191, P964, DOI 10.1016/j.ajog.2004.05.052
   Lappas M, 2011, ANTIOXID REDOX SIGN, V15, P3061, DOI 10.1089/ars.2010.3765
   Mailloux R, 2007, CELL PHYSIOL BIOCHEM, V20, P627, DOI 10.1159/000107546
   Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971
   Hojlund K, 2003, J BIOL CHEM, V278, P10436, DOI 10.1074/jbc.M212881200
   Mackenzie EL, 2008, ANTIOXID REDOX SIGN, V10, P997, DOI [10.1089/ars.2007.1893, 10.1089/ars.007.1893]
   Bacic G, 2008, SPECTROCHIM ACTA A, V69, P1354, DOI 10.1016/j.saa.2007.09.047
   Lappas M, 2003, J CLIN ENDOCR METAB, V88, P1723, DOI 10.1210/jc.2002-021677
   Dichtl Wolfgang, 2000, Molecular Cell Biology Research Communications, V4, P50, DOI 10.1006/mcbr.2000.0256
   El Baky AM, 2010, INT J FOOD SAFETY NU, V3, P57, DOI [10.1504/IJFSNPH.2010.032035, DOI 10.1504/IJFSNPH.2010.032035]
   Hache S, 2011, J CELL MOL MED, V15, P654, DOI 10.1111/j.1582-4934.2010.01039.x
   Hass R, 2006, SIGNAL TRANSDUCTION, V6, P190, DOI [10.1002/sita.200500072, DOI 10.1002/SITA.200500072]
   Higgins L, 2010, REPROD SCI, V17, p194A
   Hull HR, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.10.796
   Leon C, 2006, J IMMUNOL, V176, P5934
   LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004
   Ma Y, 2010, AM J PHYSIOL-REG I, V299, pR249, DOI 10.1152/ajpregu.00498.2009
   McCarthy C, 2007, AM J OBSTET GYNECOL, V196, P70, DOI 10.1016/j.ajog.2006.08.027
   Roy SC, 2009, PEDIATR RES, V66, P480
   Shu F, 2000, GYNECOL OBSTET INVES, V49, P17, DOI 10.1159/000010206
   Sifakis S, 2010, THROMB RES, V125, P326, DOI 10.1016/j.thromres.2009.11.033
   Zhao YH, 2011, DIABETIC MED, V28, P237, DOI 10.1111/j.1464-5491.2010.03140.x
NR 55
TC 18
Z9 19
U1 2
U2 12
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0952-5041
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD APR
PY 2012
VL 48
IS 2
BP 139
EP 149
DI 10.1530/JME-11-0123
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 938VS
UT WOS:000303762100006
PM 22301947
ER

PT J
AU Tarantino, G
   Finelli, C
   Colao, A
   Capone, D
   Tarantino, M
   Grimaldi, E
   Chianese, D
   Gioia, S
   Pasanisi, F
   Contaldo, F
   Scopacasa, F
   Savastano, S
AF Tarantino, Giovanni
   Finelli, Carmine
   Colao, Annamaria
   Capone, Domenico
   Tarantino, Marianna
   Grimaldi, Ernesto
   Chianese, Donato
   Gioia, Saverio
   Pasanisi, Fabrizio
   Contaldo, Franco
   Scopacasa, Francesco
   Savastano, Silvia
TI Are hepatic steatosis and carotid intima media thickness associated in
   obese patients with normal or slightly elevated
   gamma-glutamyltransferase?
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE NAFLD; Atherosclerosis; Metabolic syndrome
ID FATTY LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN
   RESPONSE; HEAT-SHOCK PROTEINS; C-REACTIVE PROTEIN; INSULIN-RESISTANCE;
   METABOLIC SYNDROME; INFLAMMATORY MARKERS; ATHEROSCLEROSIS; CELLS
AB Background: Hepatic steatosis (HS) has been associated with obesity and metabolic syndrome (MS), conditions carrying a high risk of coronary artery disease. We aimed to determine whether HS was an independent factor of atherogenic risk beyond its association with MS and its components.
   Methods: We assessed the circulating levels of the heat shock protein-70 (HSP-70), a chaperone involved in inflammation, endoplasmic reticulum stress and apoptosis at liver and endothelial level and the gamma-glutamyl transferase activity (gamma-GT) correlating them to carotid intima-media thickness (IMT), along with lipid profile, HOMA, C-reactive protein, fibrinogen, ferritin, adiposity type as well as spleen volume in 52 obese pts with grade 1, 128 with grade 2, and 20 with grade 3 of HS evaluated by sonography.
   Results: Patients with different grade of HS demonstrated overlapping HSP-70 levels; similarly performed obese subjects regarding IMT. Using multiple regression analysis, IMT was predicted by age, visceral adiposity and by HOMA (beta = 0.50, rho < 0.0001, beta = 0.30, rho = 0.01 and beta = 0.18, rho = 0.048 respectively, while the severity of HS was predicted by visceral and subcutaneous adiposity and HOMA (beta = 0.50, rho < 0.0001 and beta = 0.27, rho = 0.001 and beta = 0.18, rho = 0.024, respectively).
   Conclusion: In our series of patients with normal or mild elevation of gamma-GT, the severity of HS does not entail higher IMT, which may be linked to MS stigmata.
C1 [Tarantino, Giovanni; Pasanisi, Fabrizio; Contaldo, Franco] Federico II Univ Med Sch Naples, Dept Clin & Expt Med, Naples, Italy.
   [Finelli, Carmine; Gioia, Saverio] Fdn Stella Maris Mediterraneo, Ctr Riferimento Reg Disturbi & Comportamenti Alim, Chiaromonte, PZ, Italy.
   [Colao, Annamaria; Savastano, Silvia] Federico II Univ Med Sch Naples, Endocrinol Sect, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy.
   [Capone, Domenico] Federico II Univ Med Sch Naples, Clin Pharmacol Unit, Dept Neurosci, Naples, Italy.
   [Tarantino, Marianna] Federico II Univ Med Sch Naples, Dept Biomorphol & Funct Sci, Naples, Italy.
   [Grimaldi, Ernesto; Chianese, Donato; Scopacasa, Francesco] Federico II Univ Med Sch Naples, Dept Biochem & Med Biotechnol, Naples, Italy.
RP Tarantino, G (reprint author), Federico II Univ Med Sch Naples, Dept Clin & Expt Med, Naples, Italy.
EM tarantin@unina.it
RI Pasanisi, Fabrizio/L-7437-2015; 
OI Pasanisi, Fabrizio/0000-0003-4224-7821; Contaldo,
   Franco/0000-0002-3657-3922; Savastano, Silvia/0000-0002-3211-4307
FU Federico II University Medical School
FX This research was supported by departmental funds of Federico II
   University Medical School
CR Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137
   Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI200523621
   Pockley AG, 2009, CELL STRESS CHAPERON, V14, P545, DOI 10.1007/s12192-009-0113-1
   Tsan MF, 2009, J LEUKOCYTE BIOL, V85, P905, DOI 10.1189/jlb.0109005
   Han S, 2009, J CLIN INVEST, V119, P1029, DOI 10.1172/JCI36523
   Ribas V, 2010, AM J PHYSIOL-ENDOC M, V298, pE304, DOI 10.1152/ajpendo.00504.2009
   Magyar MT, 2003, STROKE, V34, P58, DOI 10.1161/01.STR.0000048845.83285.AC
   Ghayour-Mobarhan M, 2007, INT J EXP PATHOL, V88, P249, DOI 10.1111/j.1365-2613.2007.00542.x
   McKimmie RL, 2008, AM J GASTROENTEROL, V103, P3029, DOI 10.1111/j.1572-0241.2008.02188.x
   Njemini R, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-24
   Assmann G, 2004, CIRCULATION, V109, P8, DOI 10.1161/01.CIR.0000131512.50667.46
   Webb M, 2009, AM J ROENTGENOL, V192, P909, DOI 10.2214/AJR.07.4016
   Stefan N, 2008, ENDOCR REV, V29, P939, DOI 10.1210/er.2008-0009
   Tarantino G, 2009, EUR J GASTROEN HEPAT, V21, P504, DOI 10.1097/MEG.0b013e3283229b40
   Petit JM, 2009, J CLIN ENDOCR METAB, V94, P4103, DOI 10.1210/jc.2009-0541
   Marotta F, 2007, ANN NY ACAD SCI, V1119, P196, DOI 10.1196/annals.1404.011
   Wei Y, 2007, MOL CELL BIOCHEM, V303, P105, DOI 10.1007/s11010-007-9461-2
   Tarantino G, 2007, J GASTROEN HEPATOL, V22, P293, DOI 10.1111/j.1440-1746.2007.04824.x
   Kim HC, 2009, ATHEROSCLEROSIS, V204, P521, DOI 10.1016/j.atherosclerosis.2008.09.012
   Lee DH, 2004, FREE RADICAL RES, V38, P535, DOI 10.1080/10715760410001694026
   Sookoian S, 2008, J HEPATOL, V49, P600, DOI 10.1016/j.jhep.2008.06.012
   Civelek M, 2009, CIRC RES, V105, P453, DOI 10.1161/CIRCRESAHA.109.203711
   Kapoor A, 2009, CLIN LIVER DIS, V13, P581, DOI 10.1016/j.cld.2009.07.004
   Andre P, 2007, DIABETES CARE, V30, P2355, DOI 10.2337/dc07-0440
   Ludwig M, 2003, ULTRASCHALL MED, V24, P162
   Wunderlich FT, 2010, CELL METAB, V12, P237, DOI 10.1016/j.cmet.2010.06.011
   Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038
   Chiang CH, 2010, CLIN BIOCHEM, V43, P1399, DOI 10.1016/j.clinbiochem.2010.09.003
   FREEMAN ML, 1993, RADIAT RES, V135, P387, DOI 10.2307/3578879
   Gastaldelli A, 2007, GASTROENTEROLOGY, V133, P490
   Haring R, 2009, HEPATOLOGY, V59, P1403
   Hodge A M, 1996, J Cardiovasc Risk, V3, P263, DOI 10.1097/00043798-199606000-00001
   Massip-Salcedo M, 2006, AM J PATHOL, V168, P1474, DOI 10.2353/ajpath.2006.050645
   Meisinger C, 2006, ATHEROSCLEROSIS, V189, P297, DOI 10.1016/j.atherosclerosis.2006.01.010
   Merchant S, 2010, CELL STRESS CHAPERON
   Perseghin G, 2009, DIABETES CARE, V32, pS164, DOI 10.2337/dc09-S303
   Savastano S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-136
   Singh SK, 2008, ANN MED, V40, P110, DOI 10.1080/07853890701749225
   Wong VW, 2011, GUT
   Yamagami Kazuhiko, 2003, Transpl Int, V16, P456
   Zhang LH, 2008, METABOLISM, V57, P1115, DOI 10.1016/j.metabol.2008.03.017
NR 41
TC 26
Z9 26
U1 2
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAR 16
PY 2012
VL 10
AR 50
DI 10.1186/1479-5876-10-50
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 934BV
UT WOS:000303416200001
PM 22424154
ER

PT J
AU Tussing-Humphreys, L
   Pustacioglu, C
   Nemeth, E
   Braunschweig, C
AF Tussing-Humphreys, Lisa
   Pustacioglu, Cenk
   Nemeth, Elizabeta
   Braunschweig, Carol
TI Rethinking Iron Regulation and Assessment in Iron Deficiency, Anemia of
   Chronic Disease, and Obesity: Introducing Hepcidin
SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS
LA English
DT Review
DE Iron; Hepcidin; Obesity; Anemia of chronic disease; Iron deficiency
ID SERUM TRANSFERRIN RECEPTOR; Y GASTRIC BYPASS; NUTRITIONAL-STATUS;
   MORBID-OBESITY; BARIATRIC SURGERY; OVERWEIGHT CHILDREN; MENSTRUATING
   WOMEN; FERRITIN INDEX; DIETARY IRON; HEALTHY-MEN
AB Adequate iron availability is essential to human development and overall health. Iron is a key component of oxygen-carrying proteins, has a pivotal role in cellular metabolism, and is essential to cell growth and differentiation. Inadequate dietary iron intake, chronic and acute inflammatory conditions, and obesity are each associated with alterations in iron homeostasis. Tight regulation of iron is necessary because iron. is highly toxic and human beings can only excrete small amounts through sweat, skin and enterocyte sloughing, and fecal and menstrual blood loss. Hepcidin, a small peptide hormone produced mainly by the liver, acts as the key regulator of systemic iron homeostasis. Hepcidin controls movement of iron into plasma by regulating the activity of the sole known iron exporter ferroportin-1. Downregulation of the ferroportin-1 exporter results in sequestration of iron within intestinal enterocytes, hepatocytes, and iron-storing macrophages reducing iron bioavailability. Hepcidin expression is increased by higher body iron levels and inflammation and decreased by anemia and hypoxia. Importantly, existing data illustrate that hepcidin may play a significant role in the development of several iron-related disorders, including the anemia of chronic disease and the iron dysregulation observed in obesity. Therefore, the purpose of this article is to discuss iron regulation, with specific emphasis on systemic regulation by hepcidin, and examine the role of hepcidin within several disease states, including iron deficiency, anemia of chronic disease, and obesity. The relationship between obesity and iron depletion and the clinical assessment of iron status will also be reviewed. J Acad Nutr Diet. 2012;112:391-400.
C1 [Tussing-Humphreys, Lisa] USDA ARS, Baton Rouge, LA 70803 USA.
   [Pustacioglu, Cenk; Braunschweig, Carol] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA.
   [Nemeth, Elizabeta] Univ Calif Los Angeles, Div Pulm & Crit Care Med, Los Angeles, CA USA.
RP Tussing-Humphreys, L (reprint author), USDA ARS, 282 Knapp Hall, Baton Rouge, LA 70803 USA.
EM lisa.tussing@ars.usda.gov
FU National Institutes of Health [R01 DK082717]
FX Dr Nemeth's effort was supported by National Institutes of Health grant
   no. R01 DK082717.
CR Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020
   Ganz T, 2008, BLOOD, V112, P4292, DOI [10.1182/blood-2008-02-139915, 10.1182/blood-2008-02139915]
   Suominen P, 1998, BLOOD, V92, P2934
   Young MF, 2009, AM J CLIN NUTR, V89, P533, DOI 10.3945/ajcn.2008.26589
   FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385
   UPDEGRAFF TA, 1981, J AM DIET ASSOC, V78, P135
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Suominen P, 2000, ARTHRITIS RHEUM, V43, P1016, DOI 10.1002/1529-0131(200005)43:5<1016::AID-ANR9>3.0.CO;2-3
   Flancbaum L, 2006, J GASTROINTEST SURG, V10, P1033, DOI 10.1016/j.gassur.2006.03.004
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Wians FH, 2001, AM J CLIN PATHOL, V115, P112
   AVINOAH E, 1992, SURGERY, V111, P137
   Zimmermann MB, 2005, AM J CLIN NUTR, V81, P115
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Amato A, 2010, INT J OBESITY, V34, P1772, DOI 10.1038/ijo.2010.204
   Wolmarans P, 2003, PUBLIC HEALTH NUTR, V6, P439, DOI 10.1079/PHN2003460
   MARTINI A, 1994, LANCET, V344, P1052, DOI 10.1016/S0140-6736(94)91710-8
   Shankar P, 2010, NUTRITION, V26, P1031, DOI 10.1016/j.nut.2009.12.003
   Ramalho R, 2009, OBES SURG, V19, P915, DOI 10.1007/s11695-009-9848-0
   Weiss G, 2002, BLOOD REV, V16, P87, DOI 10.1054/blre.2002.0193
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Pak M, 2006, BLOOD, V108, P3730, DOI 10.1182/blood-2006-06-028787
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Ozata M, 2002, CLIN BIOCHEM, V35, P627, DOI 10.1016/S0009-9120(02)00363-6
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Steele TM, 2005, IUBMB LIFE, V57, P499, DOI 10.1080/15216540500149904
   Clark SF, 2009, CURR OPIN GASTROEN, V25, P122, DOI 10.1097/MOG.0b013e32831ef1cd
   Chambers EC, 2006, J AM DIET ASSOC, V106, P680, DOI 10.1016/j.jada.2006.02.013
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   GUYATT GH, 1992, J GEN INTERN MED, V7, P145, DOI 10.1007/BF02598003
   Toh SY, 2009, NUTRITION, V25, P1150, DOI 10.1016/j.nut.2009.03.012
   FRICKER J, 1990, AM J CLIN NUTR, V52, P863
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Fitzsimons EJ, 2001, BRIT MED J, V322, P811, DOI 10.1136/bmj.322.7290.811
   Annibale B, 1999, ANN INTERN MED, V131, P668
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Collins JE, 2008, J NUTR, V138, P2284, DOI 10.3945/jn.108.096347
   Leong WI, 2004, J NUTR, V134, P1
   Jensen NM, 1999, EUR J HAEMATOL, V63, P103
   Roe MA, 2009, AM J CLIN NUTR, V89, P1088, DOI 10.3945/ajcn.2008.27297
   Hallberg L, 2000, EUR J CLIN NUTR, V54, P650, DOI 10.1038/sj.ejcn.1601069
   Ruz M, 2009, AM J CLIN NUTR, V90, P527, DOI 10.3945/ajcn.2009.27699
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   Darshan D, 2009, BIOMETALS, V22, P77, DOI 10.1007/s10534-008-9187-y
   WENZEL BJ, 1962, LANCET, V2, P327
   Nemeth E, 2009, ACTA HAEMATOL-BASEL, V122, P78, DOI 10.1159/000243791
   Das Gupta A, 2003, AM J HEMATOL, V72, P158, DOI 10.1002/ajh.10260
   Schweiger C, 2010, OBES SURG, V20, P193, DOI 10.1007/s11695-009-0008-3
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549
   Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   AHLUWALIA N, 1995, AM J CLIN NUTR, V61, P590
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   BAINTON DF, 1964, AM J MED, V37, P62, DOI 10.1016/0002-9343(64)90212-8
   BASTA SS, 1979, AM J CLIN NUTR, V32, P916
   Beard J, 1997, AM J CLIN NUTR, V66, P104
   Bothwell TH, 2000, AM J CLIN NUTR, V72, p257S
   CARR ND, 1989, GUT, V30, P1048, DOI 10.1136/gut.30.8.1048
   CARTWRIGHT G. E., 1966, SEMINARS HEMATOL, V3, P351
   Cavill I, 1999, AM J KIDNEY DIS, V34, pS12, DOI 10.1053/ajkd.1999.v34.aajkd0344b0012
   COOK JD, 1989, J INTERN MED, V226, P349
   Cook JD, 1998, BLOOD, V92, P1807
   COOK JD, 1990, BRIT J HAEMATOL, V75, P603, DOI 10.1111/j.1365-2141.1990.tb07806.x
   Coupaye M, 2009, OBES SURG, V19, P56, DOI 10.1007/s11695-008-9571-2
   Dallalio G, 2003, BRIT J HAEMATOL, V122, P996, DOI 10.1046/j.1365-2141.2003.04516.x
   DiToro A, 1997, BIOL TRACE ELEM RES, V57, P97
   Freixenet N, 2009, CLIN CHIM ACTA, V400, P111, DOI 10.1016/j.cca.2008.10.019
   Gasteyger C, 2006, OBES SURG, V16, P243, DOI 10.1381/096089206776116381
   Hassan EO, 1999, CONTRACEPTION, V60, P93, DOI 10.1016/S0010-7824(99)00066-9
   Hunt JR, 2009, AM J CLIN NUTR, V89, P1792, DOI 10.3945/ajcn.2009.27439
   JOHNSON MA, 1990, J NUTR, V120, P1486
   Kretsch MJ, 1998, EUR J CLIN NUTR, V52, P512, DOI 10.1038/sj.ejcn.1600598
   Looker AC, 1999, CLIN CHEM, V45, P2191
   Means RT, 2004, BLOOD REV, V18, P219, DOI 10.1016/S0268-960X9(03)00066-3
   Rodriguez-Rodriguez E, 2007, ANN NUTR METAB, V51, P367, DOI 10.1159/000107680
   Shi ZM, 2005, J ADOLESCENT HEALTH, V37, P313, DOI 10.1016/j.jadohealth.2004.10.013
   Skroubis G, 2002, OBES SURG, V12, P551, DOI 10.1381/096089202762252334
   Tussing-Humphreys LM, 2009, J AM DIET ASSOC, V109, P297, DOI 10.1016/j.jada.2008.10.044
   Tussing-Humphreys LM, 2010, OBESITY, V18, P2010, DOI 10.1038/oby.2009.490
   Tussing-Humphreys LM, 2009, OBESITY SILVER SPRIN, V18, P1449
   WEINSIER RL, 1983, INT J OBESITY, V7, P539
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   World Health Organization,Centers for Disease Control and Prevention, ASS IR STAT POP REP
NR 91
TC 31
Z9 32
U1 3
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-2672
J9 J ACAD NUTR DIET
JI J. Acad. Nutr. Diet.
PD MAR
PY 2012
VL 112
IS 3
BP 391
EP 400
DI 10.1016/j.jada.2011.08.038
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 905VU
UT WOS:000301305100007
PM 22717199
ER

PT J
AU Gilbert-Diamond, D
   Baylin, A
   Mora-Plazas, M
   Villamor, E
AF Gilbert-Diamond, D.
   Baylin, A.
   Mora-Plazas, M.
   Villamor, E.
TI Chronic inflammation is associated with overweight in Colombian school
   children
SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
LA English
DT Article
DE CRP; Ferritin; Leukocytes; Overweight; Skinfold thickness; Child;
   Colombia
ID C-REACTIVE PROTEIN; CARDIOVASCULAR RISK-FACTORS; BODY-FAT DISTRIBUTION;
   NUTRITION EXAMINATION SURVEY; IRON-DEFICIENCY; METABOLIC SYNDROME;
   ADIPOSE-TISSUE; OBESE CHILDREN; INSULIN-RESISTANCE; NATIONAL-HEALTH
AB Background and Aims: To examine the cross-sectional associations of inflammatory markers in plasma including C-reactive protein (CRP) and ferritin, and white blood cell (WBC) count, with overweight, skinfold sum (subscapular + triceps), and skinfold ratio (subscapular/triceps) among children from Bogota, Colombia.
   Methods and Results: The sample (n = 2614) represented low-and middle-income children, aged 5-12 years, from Bogota. We assessed their anthropometry, sociodemographic characteristics, and circulating inflammatory markers. We defined overweight, including obesity, according to the International Obesity Task Force BMI criteria. After adjustment for potential confounders, children in the fourth quartile of the CRP distribution had a 37% higher prevalence of overweight compared to those in the first quartile (P for trend = 0.03); and children in the fourth quartile of ferritin had a 67% greater prevalence of overweight compared to children in the first quartile (P for trend < 0.001). Children in the highest 3 quartiles of the WBC distribution had a 35% higher prevalence of overweight than those in the first quartile (P = 0.03). Ferritin was significantly and positively associated with skinfold sum (P for trend < 0.001), while WBC was significantly and positively associated with skinfold ratio (P for trend < 0.001). There was a significant interaction between CRP and ferritin; children in the highest quartiles of CRP and ferritin had twice the prevalence of overweight compared to those below the highest quartiles (P = 0.001).
   Conclusion: Biomarkers of chronic inflammation are positively associated with child overweight. WBC is positively related to skinfold ratio, a proxy for truncal adiposity. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Villamor, E.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
   [Gilbert-Diamond, D.; Villamor, E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Baylin, A.; Villamor, E.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Mora-Plazas, M.] Univ Nacl Colombia, Dept Nutr, Bogota, Colombia.
RP Villamor, E (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
EM dgilbert@hsph.harvard.edu; abaylin@umich.edu; mmorap@unal.edu.co;
   villamor@umich.edu
FU Secretary of Education of Bogota; National University of Colombia; David
   Rockefeller Center for Latin American Studies at Harvard University
FX Funding for the study was provided by the Secretary of Education of
   Bogota, the National University of Colombia, and the David Rockefeller
   Center for Latin American Studies at Harvard University.
CR Acevedoa M, 2007, REV ESP CARDIOL, V60, P1051, DOI 10.1157/13111237
   Alcaldia Mayor de Bogota Secretaria de Educacion, 2006, EST SECT ED BOG 2005
   Li SX, 2003, JAMA-J AM MED ASSOC, V290, P2271, DOI 10.1001/jama.290.17.2271
   Engstrom G, 2003, DIABETES, V52, P2097, DOI 10.2337/diabetes.52.8.2097
   Barzilay JI, 2006, INT J OBESITY, V30, P1362, DOI 10.1038/sj.ijo.0803306
   Arsenault JE, 2009, J NUTR, V139, P1744, DOI 10.3945/jn.109.108662
   Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29
   Caballero AE, 2008, DIABETES CARE, V31, P576, DOI 10.2337/dc07-1540
   Hsieh CH, 2007, PEDIATR INT, V49, P827, DOI 10.1111/j.1442-200X.2007.02450.x
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Gillum RF, 2003, J NATL MED ASSOC, V95, P545
   Brotanek JM, 2007, PEDIATRICS, V120, P568, DOI 10.1542/peds.2007-0572
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Ford ES, 2003, CIRCULATION, V108, P1053, DOI 10.1161/01.CIR.0000080913.81393.B8
   WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934
   Ulijaszek SJ, 1999, BRIT J NUTR, V82, P165
   Popkin BM, 2008, HEALTH AFFAIR, V27, P1064, DOI [10.1377/hlthaff.27.4.1064, 10.1377/hlthaff.274.1064]
   Kelishadi R, 2008, CLIN CHEM, V54, P147, DOI 10.1373/clinchem.2007.089953
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   McDonald CM, 2009, J NUTR, V139, P370, DOI 10.3945/jn.108.098111
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   McVean JJF, 2009, J PEDIATR ENDOCR MET, V22, P153
   Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   Lambert M, 2004, CLIN CHEM, V50, P1762, DOI 10.1373/clinchem.2004.036418
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Jaye DL, 1997, PEDIATR INFECT DIS J, V16, P735, DOI 10.1097/00006454-199708000-00003
   Haas JD, 2001, J NUTR, V131, p676S
   Brownlie T., 2001, J NUTR, V131, p688S
   FINCH CA, 1986, WESTERN J MED, V145, P657
   Fogarty AW, 2008, AM J CLIN NUTR, V87, P30
   Gabay C, 1999, NEW ENGL J MED, V340, P448
   Geiss HC, 2001, INT J OBESITY, V25, P830, DOI 10.1038/sj.ijo.0801594
   Li Cheng-Wan, 2010, Zhongguo Dang Dai Er Ke Za Zhi, V12, P40
   Liu Chiu-Shong, 1999, Acta Paediatrica Sinica, V40, P319
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   Lopez-Jarami P, 2008, AM J HYPERTENS, V21, P527, DOI 10.1038/ajh.2007.86
   Moreno LA, 1997, J PEDIATR GASTR NUTR, V25, P175, DOI 10.1097/00005176-199708000-00008
   Oliveira AC, 2008, OBESITY, V16, P1094, DOI 10.1038/oby.2008.43
   de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497
   Richardson M. W., 2009, INT J PEDIAT ENDOCRI, DOI 10.1155.2009/713269
   Skinner AC, 2010, PEDIATRICS      0301
   Tresaco B, 2009, OBESITY, V17, P1086, DOI 10.1038/oby.2008.626
   WHO, 1995, PHYS STAT US INT ANT
   YJ Lee, 2009, NUTR METAB CARD 0717
   Zieske AW, 2005, ARTERIOSCL THROM VAS, V25, P1237, DOI 10.1161/01.ATV.0000164625.93129.64
NR 56
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0939-4753
EI 1590-3729
J9 NUTR METAB CARDIOVAS
JI Nutr. Metab. Carbiovasc. Dis.
PD MAR
PY 2012
VL 22
IS 3
BP 244
EP 251
DI 10.1016/j.numecd.2010.06.001
PG 8
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition
   & Dietetics
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism;
   Nutrition & Dietetics
GA 905QZ
UT WOS:000301288800012
PM 20705440
ER

PT J
AU Cheng, HL
   Bryant, C
   Cook, R
   O'Connor, H
   Rooney, K
   Steinbeck, K
AF Cheng, H. L.
   Bryant, C.
   Cook, R.
   O'Connor, H.
   Rooney, K.
   Steinbeck, K.
TI The relationship between obesity and hypoferraemia in adults: a
   systematic review
SO OBESITY REVIEWS
LA English
DT Review
DE Hepcidin; inflammation; iron deficiency; obesity
ID SERUM TRANSFERRIN RECEPTOR; Y GASTRIC BYPASS; IRON-DEFICIENCY;
   BILIOPANCREATIC DIVERSION; NUTRITIONAL CONSEQUENCES; CHRONIC
   INFLAMMATION; BARIATRIC SURGERY; UNITED-STATES; WEIGHT-LOSS; WOMEN
AB A growing number of studies suggest a potential link between obesity and altered iron metabolism. The purpose of this systematic review was to examine existing literature on iron status in obese populations. A comprehensive literature search was conducted. Included studies recruited participants = 18 years with a body mass index = 30 kg m-2 and provided descriptive statistics for haemoglobin or ferritin at a minimum. There were 25 studies meeting all eligibility criteria, of these 10 examined iron status in free-living obese individuals and 15 reported baseline iron biomarkers from bariatric surgery candidates. Non-obese comparison groups were used by 10 (40%) articles. In these, seven obese groups reported higher mean haemoglobin concentration; six reported significantly higher ferritin concentration; and four significantly lower transferrin saturation. Due to insufficient data, it was not possible to make conclusions regarding mean differences for soluble transferrin receptor (sTfR), hepcidin or C-reactive protein. Existing evidence suggests a tendency for higher haemoglobin and ferritin concentration and lower transferrin saturation in obesity. Alternation of iron biomarkers in obese populations may be a result of obesity-related inflammation and/or related comorbidities. Further research incorporating measurement of inflammatory cytokines, sTfR and hepcidin is required to confirm the impact of obesity on iron status.
C1 [Cheng, H. L.; Cook, R.; O'Connor, H.; Rooney, K.] Univ Sydney, Fac Hlth Sci, Discipline Exercise & Sport Sci, Lidcombe, NSW 1825, Australia.
   [Bryant, C.] Royal Prince Alfred Hosp, Inst Haematol, Sydney, NSW, Australia.
   [Steinbeck, K.] Univ Sydney, Acad Dept Adolescent Med, Sydney, NSW 2006, Australia.
RP Cheng, HL (reprint author), Univ Sydney, Fac Hlth Sci, Discipline Exercise & Sport Sci, POB 170, Lidcombe, NSW 1825, Australia.
EM hche3056@uni.sydney.edu.au
FU Meat and Live-stock Australia
FX This systematic review was supported by Meat and Live-stock Australia.
   The authors declare that Meat and Live-stock Australia had no influence
   on any part of the review process, including the conclusions drawn.
CR Ahmed F, 2008, ASIA PAC J CLIN NUTR, V17, P40
   AMARAL JF, 1985, ANN SURG, V201, P186, DOI 10.1097/00000658-198502000-00009
   Anna K, 2009, AM J GASTROENTEROL, V104, pS114
   Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
   Ernst B, 2009, OBES SURG, V19, P66, DOI 10.1007/s11695-008-9545-4
   Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020
   Heinemann F, 2007, RESP MED, V101, P1229, DOI 10.1016/j.rmed.2006.10.027
   Suominen P, 1998, BLOOD, V92, P2934
   Punnonen K, 1997, BLOOD, V89, P1052
   Brownlie T, 2002, AM J CLIN NUTR, V75, P734
   De Domenico I, 2008, NAT REV MOL CELL BIO, V9, P72, DOI 10.1038/nrm2295
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Mast AE, 1998, CLIN CHEM, V44, P45
   Pocock SJ, 2004, BRIT MED J, V329, P883, DOI 10.1136/bmj.38250.571088.55
   Chung B, 2007, J NUTR, V137, P2366
   Aasheim ET, 2009, AM J CLIN NUTR, V90, P15, DOI 10.3945/ajcn.2009.27583
   Schwartz Alan R, 2008, Proc Am Thorac Soc, V5, P185, DOI 10.1513/pats.200708-137MG
   Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007
   Brutsaert TD, 2003, AM J CLIN NUTR, V77, P441
   Moayeri H, 2006, EUR J PEDIATR, V165, P813, DOI 10.1007/s00431-006-0178-0
   Roy CN, 2010, HEMATOL-AM SOC HEMAT, P276, DOI 10.1182/asheducation-2010.1.276
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Toh SY, 2009, NUTRITION, V25, P1150, DOI 10.1016/j.nut.2009.03.012
   FRICKER J, 1990, AM J CLIN NUTR, V52, P863
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Shariatpanaahi MV, 2007, EUR J CLIN NUTR, V61, P532, DOI 10.1038/sj.ejcn.1602542
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Zafon C, 2010, OBES REV, V11, P322, DOI 10.1111/j.1467-789X.2009.00638.x
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Panagiotakos DB, 2005, ATHEROSCLEROSIS, V183, P308, DOI 10.1016/j.atherosclerosis.2005.03.010
   WENZEL BJ, 1962, LANCET, V2, P327
   Hensrud DD, 2006, MAYO CLIN PROC, V81, pS5
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   MICOZZI MS, 1989, AM J CLIN NUTR, V50, P1276
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Wessling-Resnick M, 2010, ANNU REV NUTR, V30, P105, DOI 10.1146/annurev.nutr.012809.104804
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   Beard J, 1997, AM J CLIN NUTR, V66, P104
   Brolin RE, 1998, ARCH SURG-CHICAGO, V133, P740, DOI 10.1001/archsurg.133.7.740
   Cooper PL, 1999, INT J OBESITY, V23, P382, DOI 10.1038/sj.ijo.0800830
   Coupaye M, 2009, OBES SURG, V19, P56, DOI 10.1007/s11695-008-9571-2
   de Luis DA, 2008, ANN NUTR METAB, V53, P234, DOI 10.1159/000185641
   ENGLAND JM, 1976, BRIT J HAEMATOL, V34, P589, DOI 10.1111/j.1365-2141.1976.tb03605.x
   Gasteyger C, 2006, OBES SURG, V16, P243, DOI 10.1381/096089206776116381
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Jensen JT, 2000, OBSTET GYN CLIN N AM, V27, P705, DOI 10.1016/S0889-8545(05)70169-8
   Kepczyk T, 1999, AM J GASTROENTEROL, V94, P109
   Koulaouzidis A, 2009, SCAND J GASTROENTERO, V44, P126, DOI 10.1080/00365520802555983
   Kretsch MJ, 1998, EUR J CLIN NUTR, V52, P512, DOI 10.1038/sj.ejcn.1600598
   O'Connor H, 2011, ASIA PAC J CLIN NUTR, V20, P206
   Palomar R, 2005, OBES SURG, V15, P794, DOI 10.1381/0960892054222687
   Parajes S, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-110
   PAYNE JH, 1969, AM J SURG, V118, P141, DOI 10.1016/0002-9610(69)90113-5
   Rowlett R, SI UNITS CLIN DATA
   Skroubis G, 2002, OBES SURG, V12, P551, DOI 10.1381/096089202762252334
   Switoniak T, 1992, Przegl Epidemiol, V46, P379
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   Zaccai JH, 2004, POSTGRAD MED J, V80, P140, DOI 10.1136/pgmj.2003.012633
   Zhang An-Sheng, 2009, Hematology Am Soc Hematol Educ Program, P207, DOI 10.1182/asheducation-2009.1.207
NR 63
TC 40
Z9 42
U1 1
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1467-7881
J9 OBES REV
JI Obes. Rev.
PD FEB
PY 2012
VL 13
IS 2
BP 150
EP 161
DI 10.1111/j.1467-789X.2011.00938.x
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 872WB
UT WOS:000298839800004
PM 21981048
ER

PT J
AU Karbownik-Lewinska, M
   Szosland, J
   Kokoszko-Bilska, A
   Stepniak, J
   Zasada, K
   Gesing, A
   Lewinski, A
AF Karbownik-Lewinska, Malgorzata
   Szosland, Janusz
   Kokoszko-Bilska, Agnieszka
   Stepniak, Jan
   Zasada, Krzysztof
   Gesing, Adam
   Lewinski, Andrzej
TI Direct contribution of obesity to oxidative damage to macromolecules
SO NEUROENDOCRINOLOGY LETTERS
LA English
DT Article
DE obesity; oxidative damage; lipid peroxidation; 8-oxo-7,8-dihydro-2
   '-deoxyguanosine; non-communicable diseases
ID INCREASED LIPID-PEROXIDATION; METABOLIC SYNDROME; INSULIN-RESISTANCE;
   DNA-DAMAGE; FENTON REACTION; GROWTH-HORMONE; HIGH-FAT; STRESS; CANCER;
   MELATONIN
AB BACKGROUND: Obesity constitutes a common modifiable risk factor for certain non-communicable diseases (NCDs) associated with enhanced oxidative stress.
   OBJECTIVES AND METHODS: The aim of the study was to examine serum concentrations of malondialdehyde + 4-hydroxyalkenals (MDA+4-HDA), as an index of lipid peroxidation (LPO), and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) concentration in peripheral blood lymphocytes, as an index of nuclear DNA damage, in overweight and obese adult patients. LPO and 8-oxodG, as well as clinical and laboratory parameters, which are frequently affected by obesity, were evaluated in 58 overweight and obese adult patients, and in 20 healthy volunteers.
   RESULTS: Both LPO and 8-oxodG levels were increased in overweight and obese patients, with further increase observed with the increasing body mass index (BMI). LPO correlated positively with body mass, BMI, waist circumference, hip circumference, waist:hip ratio, systolic or diastolic blood pressure, glucose, C-reactive protein and ferritin concentrations. 8-oxodG correlated positively with body mass, BMI, hip circumference and triglyceride concentration, whereas it correlated negatively with iron concentration. Expectedly, positive correlation between LPO and 8-oxodG was also found.
   CONCLUSIONS: BMI constituted the only independent determinant (predictor) of LPO in overweight and obese patients. Consistently, LPO did constitute the only independent determinant of obesity. Overweight and obesity in adults are directly associated with increased oxidative damage to macromolecules.
C1 [Karbownik-Lewinska, Malgorzata; Szosland, Janusz; Kokoszko-Bilska, Agnieszka; Stepniak, Jan; Zasada, Krzysztof; Gesing, Adam] Med Univ Lodz, Dept Oncol Endocrinol, PL-90752 Lodz, Poland.
   [Lewinski, Andrzej] Med Univ Lodz, Dept Endocrinol & Metab Dis, PL-90752 Lodz, Poland.
   [Karbownik-Lewinska, Malgorzata; Kokoszko-Bilska, Agnieszka; Zasada, Krzysztof; Lewinski, Andrzej] Polish Mothers Mem Hosp, Res Inst, Lodz, Poland.
RP Karbownik-Lewinska, M (reprint author), Med Univ Lodz, Dept Oncol Endocrinol, 7-9 Zeligowski St, PL-90752 Lodz, Poland.
EM MKarbownik@hotmail.com
RI Lewinski, Andrzej/N-3971-2014; Kokoszko-Bilska, Agnieszka/O-2307-2014
FU Medical University of Lodz [503-1107-5]
FX The research was supported by the Medical University of Lodz (grant
   number 503-1107-5).
CR Chrissobolis S, 2011, FRONT BIOSCI-LANDMRK, V16, P1733, DOI 10.2741/3816
   Zeyda M, 2009, GERONTOLOGY, V55, P379, DOI 10.1159/000212758
   Paz G, 2011, FRONT BIOSCI-LANDMRK, V16, P1634, DOI 10.2741/3810
   Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5
   Flegal KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/jama.298.17.2028
   Karbownik M, 2000, P SOC EXP BIOL MED, V225, P9, DOI 10.1046/j.1525-1373.2000.22502.x
   Dalle-Donne I, 2006, CLIN CHEM, V52, P601, DOI 10.1373/clinchem.2005.061408
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Stasiak M, 2010, NEUROENDOCRINOL LETT, V31, P363
   Ando K, 2009, FREE RADICAL BIO MED, V47, P213, DOI 10.1016/j.freeradbiomed.2009.04.030
   Demirbag R, 2006, INT J CLIN PRACT, V60, P1187, DOI 10.1111/j.1742-1241.2006.01042.x
   Harrison DG, 2009, MED CLIN N AM, V93, P621, DOI 10.1016/j.mcna.2009.02.015
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Ceschi M, 2007, SWISS MED WKLY, V137, P50
   Pischon T, 2008, P NUTR SOC, V67, P128, DOI 10.1017/S0029665108006976
   Karbownik M, 2003, J CELL BIOCHEM, V90, P806, DOI 10.1002/jcb.10689
   Akamine EH, 2010, J ENDOCRINOL, V206, P65, DOI 10.1677/JOE-09-0461
   Maes M, 2009, NEUROENDOCRINOL LETT, V30, P715
   Vincent HK, 2006, INT J OBESITY, V30, P400, DOI 10.1038/sj.ijo.0803177
   Misra MK, 2009, MED SCI MONITOR, V15, pRA209
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Yan RT, 2009, ATHEROSCLEROSIS, V207, P232, DOI 10.1016/j.atherosclerosis.2009.03.053
   Ausk KJ, 2008, OBESITY, V16, P2356, DOI 10.1038/oby.2008.353
   Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0
   Ford ES, 2003, DIABETES, V52, P2346, DOI 10.2337/diabetes.52.9.2346
   de Assis AM, 2009, EXP BIOL MED, V234, P1296, DOI 10.3181/0904-RM-126
   Roberts CK, 2006, METABOLISM, V55, P928, DOI 10.1016/j.metabol.2006.02.022
   Cardona F, 2008, EUR J CLIN INVEST, V38, P510, DOI 10.1111/j.1365-2362.2008.01959.x
   Cortes DF, 2011, FREE RADICAL BIO MED, V50, P1565, DOI 10.1016/j.freeradbiomed.2011.03.002
   Dobrian AD, 2001, HYPERTENSION, V37, P554
   Gosmanov AR, 2010, AM J PHYSIOL-ENDOC M, V299, pE953, DOI 10.1152/ajpendo.00469.2010
   Kalisz M, 2012, NEUROENDOCRINOL LETT, V33, P11
   Karbownik-Lewinska M, 2010, NEUROENDOCRINOL LETT, V31, P343
   Karbownik-Lewinska M, 2008, CLIN ENDOCRINOL, V68, P957, DOI 10.1111/j.1365-2265.2007.03142.x
   Kokoszko A, 2010, NEUROENDOCRINOL LETT, V31, P517
   Kokoszko A, 2006, NEUROENDOCRINOL LETT, V27, P225
   Pelclova D, 2011, NEUROENDOCRINOL LETT, V32, P71
   Podborska M, 2009, NEUROENDOCRINOL LETT, V30, P116
   Szosland J, 2010, PRZ MENOPAUZALNY, V9, P159
NR 39
TC 7
Z9 7
U1 2
U2 6
PU MAGHIRA & MAAS PUBLICATIONS
PI STOCKHOLM
PA PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN
SN 0172-780X
J9 NEUROENDOCRINOL LETT
JI Neuroendocrinol. Lett.
PY 2012
VL 33
IS 4
BP 453
EP 461
PG 9
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 026FH
UT WOS:000310259500016
PM 22936256
ER

PT J
AU Hosick, PA
   Stec, DE
AF Hosick, Peter A.
   Stec, David E.
TI Heme oxygenase, a novel target for the treatment of hypertension and
   obesity?
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
   PHYSIOLOGY
LA English
DT Review
DE carbon monoxide; bilirubin; biliverdin; adiponectin; kidney;
   inflammation
ID MESENCHYMAL STEM-CELLS; IMPROVES INSULIN SENSITIVITY; INCREASES
   ADIPONECTIN LEVELS; II-DEPENDENT HYPERTENSION; LOWERS BLOOD-PRESSURE;
   ACUTE-RENAL-FAILURE; ANGIOTENSIN-II; COBALT-PROTOPORPHYRIN;
   CARBON-MONOXIDE; WEIGHT-LOSS
AB Hosick PA, Stec DE. Heme oxygenase, a novel target for the treatment of hypertension and obesity? Am J Physiol Regul Integr Comp Physiol 302: R207-R214, 2012. First published November 9, 2011; doi:10.1152/ajpregu.00517.2011.-Heme oxygenase (HO) is the rate-limiting enzyme in the metabolism of heme-releasing bioactive molecules carbon monoxide (CO), biliverdin, and iron, each with beneficial cardiovascular actions. Biliverdin is rapidly reduced to bilirubin, a potent antioxidant, by the enzyme biliverdin reductase, and iron is rapidly sequestered by ferritin in the cell. Several studies have demonstrated that HO-1 induction can attenuate the development of hypertension as well as lower blood pressure in established hypertension in both genetic and experimental models. HO-1 induction can also reduce target organ injury and can be beneficial in cardiovascular diseases, such as heart attack and stroke. Recent studies have also identified a beneficial role for HO-1 in the regulation of body weight and metabolism in diabetes and obesity. Chronic HO-1 induction lowers body weight and corrects hyperglycemia and hyperinsulinemia. Chronic HO-1 induction also modifies the phenotype of adipocytes in obesity from one of large, cytokine producing to smaller, adiponectin producing. Finally, chronic induction of HO-1 increases oxygen consumption, CO(2), and heat production and activity in obese mice. This review will discuss the current understanding of the actions of the HO system to lower blood pressure and body weight and how HO or its metabolites may be ideal candidates for the development of drugs that can both reduce blood pressure and lower body weight.
C1 [Hosick, Peter A.; Stec, David E.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Ctr Excellence Cardiovasc Renal Res, Jackson, MS 39216 USA.
RP Stec, DE (reprint author), Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Ctr Excellence Cardiovasc Renal Res, Jackson, MS 39216 USA.
EM dstec@umc.edu
FU National Heart, Lung and Blood Institute [HL-088421, 1T32-HL-105324]
FX The authors acknowledge the support of National Heart, Lung and Blood
   Institute Grants HL-088421 (to D. E. Stec) and 1T32-HL-105324 (to P. A.
   Hosick).
CR Sacerdoti D, 2005, CELL MOL BIOL, V51, P363, DOI 10.1170/T639
   Kim DH, 2010, STEM CELLS DEV, V19, P1863, DOI 10.1089/scd.2010.0098
   Tsubokawa T, 2010, AM J PHYSIOL-HEART C, V298, pH1320, DOI 10.1152/ajpheart.01330.2008
   Murali NS, 2007, AM J PHYSIOL-RENAL, V292, pF837, DOI 10.1152/ajprenal.00254.2006
   Burgess A, 2010, HYPERTENSION, V56, P1124, DOI 10.1161/HYPERTENSIONAHA.110.151423
   Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103
   Mathieu P, 2009, HYPERTENSION, V53, P577, DOI 10.1161/HYPERTENSIONAHA.108.110320
   Vera T, 2009, AM J PHYSIOL-REG I, V297, pR738, DOI 10.1152/ajpregu.90889.2008
   GALBRAITH RA, 1989, P NATL ACAD SCI USA, V86, P7653, DOI 10.1073/pnas.86.19.7653
   Li NJ, 2007, HYPERTENSION, V49, P148, DOI 10.1161/01.HYP.0000250086.06137.fb
   Han SS, 2010, TOHOKU J EXP MED, V221, P133, DOI 10.1620/tjem.221.133
   Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34
   Christmas AB, 2007, AM SURGEON, V73, P1122
   Shibata R, 2009, CIRC J, V73, P608
   Polednak AP, 2008, CANCER DETECT PREV, V32, P190, DOI 10.1016/j.cdp.2008.08.004
   Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250
   Ndisang JF, 2009, ENDOCRINOLOGY, V150, P2627, DOI 10.1210/en.2008-1370
   Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014
   GALBRAITH RA, 1991, AM J PHYSIOL, V261, pR1388
   Liang OD, 2011, STEM CELLS, V29, P99, DOI 10.1002/stem.548
   Converso DP, 2006, FASEB J, V20, P1236, DOI 10.1096/fj.05-4204fje
   Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484
   Garvin JL, 2003, ACTA PHYSIOL SCAND, V179, P225, DOI 10.1046/j.0001-6772.2003.01203.x
   Piantadosi CA, 2008, CIRC RES, V103, P1232, DOI 10.1161/01.RES.0000338597.71702.ad
   Li M, 2008, DIABETES, V57, P1526, DOI 10.2337/db07-1764
   Engeli S, 2003, DIABETES, V52, P942, DOI 10.2337/diabetes.52.4.942
   MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475
   Zarjou A, 2011, AM J PHYSIOL-RENAL, V300, pF254, DOI 10.1152/ajprenal.00594.2010
   Kobayashi A, 2007, HYPERTENSION, V50, P1040, DOI 10.1161/HYPERTENSIONAHA.107.097006
   Surh YJ, 2009, ARCH PHARM RES, V32, P1163, DOI 10.1007/s12272-009-1807-8
   Mathieu P, 2010, CLIN PHARMACOL THER, V87, P407, DOI 10.1038/clpt.2009.311
   Suliman HB, 2007, J CLIN INVEST, V117, P3730, DOI 10.1172/JCI32967
   Botros FT, 2005, KIDNEY INT, V68, P2745, DOI 10.1111/j.1523-1755.2005.00745.x
   Beckman JD, 2011, J BIOL CHEM, V286, P3194, DOI 10.1074/jbc.M110.148726
   MARTASEK P, 1991, J AM SOC NEPHROL, V2, P1078
   Peterson SJ, 2008, J LIPID RES, V49, P1658, DOI 10.1194/jlr.M800046-JLR200
   Tayem Y, 2006, AM J PHYSIOL-RENAL, V290, pF789, DOI 10.1152/ajprenal.00363.2005
   Yang LM, 2004, HYPERTENSION, V43, P1221, DOI 10.1161/01.HYP.0000126287.62060.e6
   Vera T, 2005, J AM SOC NEPHROL, V16, P950, DOI 10.1681/ASN.2004090736
   Sabaawy HE, 2001, HYPERTENSION, V38, P210
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Slebos DJ, 2007, AM J RESP CELL MOL, V36, P409, DOI 10.1165/rcmb.2006-0214OC
   Ndisang JF, 2009, ENDOCRINOLOGY, V150, P2098, DOI 10.1210/en.2008-0239
   Kaide JI, 2004, HYPERTENSION, V44, P210, DOI 10.1161/01.HYP.0000135658.57547.bb
   Pflueger A, 2005, AM J PHYSIOL-RENAL, V288, pF552, DOI 10.1152/ajprenal.00278.2004
   Sharma K, 2008, J CLIN INVEST, V118, P1645, DOI 10.1172/JCI32691
   Abraham NG, 2005, FREE RADICAL BIO MED, V39, P1, DOI 10.1016/j.freeadbiomed.2005.03.010
   Rhodes MA, 2009, AM J PHYSIOL-HEART C, V297, pH392, DOI 10.1152/ajpheart.00164.2009
   Mori T, 2007, HYPERTENSION, V49, P1336, DOI 10.1161/HYPERTENSIONAHA.106.085811
   Peterson SJ, 2009, J LIPID RES, V50, P1293, DOI 10.1194/jlr.M800610-JLR200
   GUYTON AC, 1990, HYPERTENSION, V16, P725
   Tagliaferri F, 2009, J TRAUMA, V66, P727, DOI 10.1097/TA.0b013e31815edefd
   Ndisang JF, 2010, J PHARMACOL EXP THER, V334, P87, DOI 10.1124/jpet.109.164871
   Wiesel P, 2001, CIRC RES, V88, P1088, DOI 10.1161/hh1001.091521
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Chin HJ, 2009, J KOREAN MED SCI, V24, pS50, DOI 10.3346/jkms.2009.24.S1.S50
   Chin HJ, 2009, J KOREAN MED SCI, V24, pS22, DOI 10.3346/jkms.2009.24.S1.S22
   Csongradi E, 2011, INT J OBES LOND
   Di Noia MA, 2006, J BIOL CHEM, V281, P15687, DOI 10.1074/jbc.M510595200
   DRUMMOND GS, 1982, P NATL ACAD SCI-BIOL, V79, P2384, DOI 10.1073/pnas.79.7.2384
   GALBRAITH RA, 1992, MOL BRAIN RES, V15, P298, DOI 10.1016/0169-328X(92)90121-Q
   GALBRAITH RA, 1987, PHARMACOLOGY, V34, P241, DOI 10.1159/000138275
   GALBRAITH RA, 1991, AM J PHYSIOL, V261, pR1395
   GALBRAITH RA, 1992, AM J PHYSIOL, V263, pR805
   GUYTON AC, 1990, AM J PHYSIOL, V259, pR865
   Jin XH, 2001, HYPERTENSION, V38, P309
   Kelsen S, 2008, AM J PHYSIOL-RENAL, V295, pF1158, DOI 10.1152/ajprenal.00057.2008
   LEVERE RD, 1990, J CLIN INVEST, V86, P213, DOI 10.1172/JCI114686
   Li MY, 2006, J APPL PHYSIOL, V100, P1983, DOI 10.1152/japplphysiol.01169.2005
   Mangge H, 2010, CURR MED CHEM, V17, P4511, DOI 10.2174/092986710794183006
   Nath KA, 2007, AM J PHYSIOL-HEART C, V293, pH333, DOI 10.1152/ajpheart.00870.2006
   SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116
   Sakoda E, 2008, NEUROSCI LETT, V440, P160, DOI 10.1016/j.neulet.2008.04.082
   Tuzcu M, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-28
   Vecoli C, 2011, J CELL BIOCH
   Vera T, 2007, AM J PHYSIOL-REG I, V292, pR1472, DOI 10.1152/ajpregu.00601.2006
   Vera T, 2008, HYPERTENSION, V52, P660, DOI 10.1161/HYPERTENSIONAHA.108.114884
   Vera T, 2010, AM J PHYSIOL-REG I, V299, pR1044, DOI 10.1152/ajpregu.00316.2010
   Wang R, 2006, HYPERTENSION, V48, P685, DOI 10.1161/01.HYP.0000239673.80332.2f
   Young SC, 2009, AM J PHYSIOL-REG I, V297, pR1546, DOI 10.1152/ajpregu.90933.2008
   Zeng B, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-80
   Zou AP, 2000, HYPERTENSION, V35, P342
NR 82
TC 15
Z9 15
U1 2
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD JAN
PY 2012
VL 302
IS 2
BP R207
EP R214
DI 10.1152/ajpregu.00517.2011
PG 8
WC Physiology
SC Physiology
GA 877FP
UT WOS:000299163000001
PM 22071158
ER

PT J
AU Tajima, S
   Ikeda, Y
   Sawada, K
   Yamano, N
   Horinouchi, Y
   Kihira, Y
   Ishizawa, K
   Izawa-Ishizawa, Y
   Kawazoe, K
   Tomita, S
   Minakuchi, K
   Tsuchiya, K
   Tamaki, T
AF Tajima, Soichiro
   Ikeda, Yasumasa
   Sawada, Kaori
   Yamano, Noriko
   Horinouchi, Yuya
   Kihira, Yoshitaka
   Ishizawa, Keisuke
   Izawa-Ishizawa, Yuki
   Kawazoe, Kazuyoshi
   Tomita, Shuhei
   Minakuchi, Kazuo
   Tsuchiya, Koichiro
   Tamaki, Toshiaki
TI Iron reduction by deferoxamine leads to amelioration of adiposity via
   the regulation of oxidative stress and inflammation in obese and type 2
   diabetes KKAy mice
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE iron; adipose tissue; obesity; type 2 diabetes; oxidative stress
ID SERUM AMINOTRANSFERASE LEVELS; NADPH OXIDASE ACTIVITY; BETA-CELL
   FUNCTION; INSULIN-RESISTANCE; LABILE IRON; PROTEIN EXPRESSION;
   ENDOTHELIAL-CELLS; ANGIOTENSIN-II; HEPATITIS-C; FERRITIN
AB Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, Kihira Y, Ishizawa K, Izawa-Ishizawa Y, Kawazoe K, Tomita S, Minakuchi K, Tsuchiya K, Tamaki T. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab 302: E77-E86, 2012. First published September 13, 2011; doi:10.1152/ajpendo.00033.2011.-Iron is an essential trace metal for most organisms. However, excess iron causes oxidative stress through production of highly toxic hydroxyl radicals via the Fenton/Haber-Weiss reaction. Iron storage in the body is reported to be associated with fat accumulation and type 2 diabetes mellitus. We investigated the role of iron in adiposity by using KKAy mice and obese and diabetic model mice. Eight-week-old KKAy mice were divided into two groups and treated with deferoxamine (DFO), an iron chelator agent, or a vehicle for 2 wk. DFO treatment diminished fat iron concentration and serum ferritin levels in KKAy mice. Fat weight and adipocyte size were reduced significantly in DFO-treated mice compared with vehicle-treated mice. Macrophage infiltration into fat was also decreased in DFO-treated mice compared with vehicle-treated mice. Superoxide production and NADPH oxidase activity in fat, as well as urinary 8-hydroxy-2'-deoxyguanosine excretion, were decreased in KKAy mice after DFO treatment while p22(phox) expression in adipose tissue was diminished in such mice. Ferritin expression in the fat of DFO-treated KKAy mice was decreased. In addition, F4/80-positive cells also presented through both p22(phox) and ferritin expression. The mRNA expression levels of inflammatory cytokines were also reduced in fat tissue of DFO-treated mice. These findings suggest that reduction of iron levels ameliorates adipocyte hypertrophy via suppression of oxidative stress, inflammatory cytokines, and macrophage infiltration, thereby breaking a vicious cycle in obesity.
C1 [Tajima, Soichiro; Ikeda, Yasumasa; Sawada, Kaori; Yamano, Noriko; Horinouchi, Yuya; Kihira, Yoshitaka; Izawa-Ishizawa, Yuki; Tomita, Shuhei; Tamaki, Toshiaki] Univ Tokushima, Grad Sch Hlth Biosci, Dept Pharmacol, Tokushima 7708503, Japan.
   [Tajima, Soichiro; Horinouchi, Yuya; Kawazoe, Kazuyoshi; Minakuchi, Kazuo] Tokushima Univ Hosp, Dept Pharm, Tokushima, Japan.
   [Sawada, Kaori] Univ Tokushima, Fac Med, Student Lab, Tokushima 7708503, Japan.
   [Ishizawa, Keisuke; Tsuchiya, Koichiro] Univ Tokushima, Grad Sch Hlth Biosci, Dept Med Pharmacol, Tokushima 7708503, Japan.
RP Ikeda, Y (reprint author), Univ Tokushima, Grad Sch Hlth Biosci, Dept Pharmacol, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
EM yasuike@basic.med.tokushima-u.ac.jp
FU Grants for the Regional Innovation Cluster Program; Houansha Foundation
FX This work was supported by Grants for the Regional Innovation Cluster
   Program and Houansha Foundation (T. Tamaki), Grants-in-Aid for Young
   Scientist B, the Uehara Memorial Foundation, Takeda Science Foundation,
   and Tokushima Shinbun Foundation (Y. Ikeda).
CR Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Dongiovanni P, 2008, AM J PATHOL, V172, P738, DOI 10.2353/ajpath.2008.070097
   Ejiri J, 2003, CARDIOVASC RES, V59, P988, DOI 10.1016/S0008-6363(03)00523-6
   Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292
   Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   Minamiyama Y, 2010, AM J PHYSIOL-ENDOC M, V298, pE1140, DOI 10.1152/ajpendo.00620.2009
   Kruszewski M, 2003, MUTAT RES-FUND MOL M, V531, P81, DOI 10.1016/j.mrfmmm.2003.08.004
   Rosen P, 2001, DIABETES METAB RES, V17, P189, DOI 10.1002/dmrr.196
   Shoham S, 2000, CELL MOL BIOL, V46, P743
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI200421625]
   Azumi H, 1999, CIRCULATION, V100, P1494
   Cooksey RC, 2010, AM J PHYSIOL-ENDOC M, V298, pE1236, DOI 10.1152/ajpendo.00022.2010
   Li LX, 2009, ARTERIOSCL THROM VAS, V29, P732, DOI 10.1161/ATVBAHA.108.183210
   Mihara M, 2010, ENDOCRINOLOGY, V151, P513, DOI 10.1210/en.2009-0661
   Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216
   Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Li LX, 2006, ARTERIOSCL THROM VAS, V26, P2638, DOI 10.1161/01.ATV.0000245820.34238.da
   Rains JL, 2011, FREE RADICAL BIO MED, V50, P567, DOI 10.1016/j.freeradbiomed.2010.12.006
   Galaris D, 2008, CANCER LETT, V266, P21, DOI 10.1016/j.canlet.2008.02.038
   Rajpathak SN, 2009, DIABETES OBES METAB, V11, P472, DOI 10.1111/j.1463-1326.2008.00985.x
   Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288
   Green A, 2006, METABOLISM, V55, P1042, DOI 10.1016/j.metabol.2006.03.015
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   Camaschella C, 2005, BLOOD, V106, P3710, DOI 10.1182/blood-2005-05-1857
   Pou KM, 2007, CIRCULATION, V116, P1234, DOI 10.1161/CIRCULATIONAHA.107.710509
   HAYASHI H, 1994, AM J GASTROENTEROL, V89, P986
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Cairo G, 2002, FREE RADICAL BIO MED, V32, P1237, DOI 10.1016/S0891-5849(02)00825-0
   CUTLER P, 1989, DIABETES, V38, P1207, DOI 10.2337/diabetes.38.10.1207
   Hagiwara S, 2009, METABOLISM, V58, P934, DOI 10.1016/j.metabol.2009.02.033
   HAYASHI H, 1995, J HEPATOL, V22, P268, DOI 10.1016/0168-8278(95)80278-9
   Ikeda Y, 2010, MOL ENDOCRINOL, V24, P1338, DOI 10.1210/me.2009-0402
   Korac A, 2003, EUR J HISTOCHEM, V47, P241
   KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641
   Meshkinpour H, 1996, DIGEST DIS SCI, V41, P984, DOI 10.1007/BF02091541
   Tajima S, 2010, HYPERTENS RES, V33, P713, DOI 10.1038/hr.2010.63
   Thethi TK, 2011, CLIN CHEM, V57, P272, DOI 10.1373/clinchem.2010.154757
   Tsukamoto H, 1999, AM J PHYSIOL-GASTR L, V277, pG1240
   Yuan XL, 2004, J MOL BIOL, V339, P131, DOI 10.1016/j.jmb.2004.03.027
NR 44
TC 27
Z9 28
U1 0
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JAN
PY 2012
VL 302
IS 1
BP E77
EP E86
DI 10.1152/ajpendo.00033.2011
PG 10
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 866JU
UT WOS:000298377600009
PM 21917632
ER

PT J
AU Ramaraj, R
   Roberts, SA
   Clarke, G
   Williams, G
   Thomas, GA
AF Ramaraj, Rajeswari
   Roberts, Stuart Ashley
   Clarke, Geoffrey
   Williams, Geraint
   Thomas, Gareth A.
TI A rare case of iron deficiency
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE benign tumours of the stomach; gastric lipoma; iron deficiency
ID GASTRIC LIPOMA
AB Giant lipomas of the stomach are very rare, accounting for less than 3% of all benign tumors of the stomach. A clear-cut endoscopic differentiation between gastric lipomas and other submucosal neoplasms is not feasible, because routine endoscopic gastric biopsies do not reach the submucosal layer. Gastric submucosal lipomas can cause gastric ulceration as in the case presented below and in rare instances this may in turn promote gastric cancer. Therefore, complete pretreatment diagnostic evaluation is needed. We present a 52-year-old man with a 6-month history of epigastric discomfort, early satiety, decreased appetite, and dyspepsia. His weight was noted to be stable and he was iron deficient ( hemoglobin 11.5 g/dl and ferritin of 5 g/dl). His past history included a gastric ulcer found on endoscopy 5 years ago for which he was on omeprazole 40mg once a day, hypertension, hypercholesterolemia, and diabetes. Clinical examination revealed central obesity with divarification of recti muscles. He underwent a colonoscopy that was normal, and an oesophago-gastro-duodenoscopy that revealed a smooth extrinsic indentation of the anterior aspect of the distal stomach at around 50 cm. Biopsies of this were normal. A computed tomography scan was obtained (Fig. 1) that demonstrated a 14 by 15-cm fatty tumor arising from the distal stomach with a couple of 5-mm nodes adjacent to tumor and no distant metastasis representing either a lipoma, liposarcoma or gastrointestinal stromal tumours. He subsequently underwent a subtotal gastrectomy. Macroscopically, the antrum was distorted by a huge submucosal intramural tumor mass. The antral mucosa was stretched over its surface and bore a central 15-mm ulcer surrounded by a raised border ( Fig. 2). Microscopic examination confirmed an ulcerated benign submucosal lipoma. Our patient was symptomatic with a large gastric lipoma that necessitated surgical excision. Following surgery his postoperative recovery was uneventful, and he was asymptomatic when reviewed 4 weeks later. This case demonstrates a rare case of gastric lipoma causing gastric epithelial ulceration leading to iron deficiency. Eur J Gastroenterol Hepatol 24: 82- 83 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Ramaraj, Rajeswari] Univ Wales Hosp, Dept Gastroenterol, Cardiff CF14 4XW, S Glam, Wales.
RP Ramaraj, R (reprint author), Univ Wales Hosp, Dept Gastroenterol, Heath Pk, Cardiff CF14 4XW, S Glam, Wales.
EM jeswaram@doctors.net.uk
CR Alberti D, 1999, AM J GASTROENTEROL, V94, P3634
   CHU AG, 1983, AM J GASTROENTEROL, V78, P615
   Yamamoto T, 2004, INTERNAL MED, V43, P1039, DOI 10.2169/internalmedicine.43.1039
NR 3
TC 0
Z9 0
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0954-691X
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD JAN
PY 2012
VL 24
IS 1
BP 82
EP 83
DI 10.1097/MEG.0b013e328348d642
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 862UH
UT WOS:000298119100014
PM 22008628
ER

PT J
AU Varea, A
   Malpeli, A
   Etchegoyen, G
   Vojkovic, M
   Disalvo, L
   Apezteguia, M
   Pereyras, S
   Pattin, J
   Ortale, S
   Carmuega, E
   Gonzalez, HF
AF Varea, Ana
   Malpeli, Agustina
   Etchegoyen, Graciela
   Vojkovic, Maria
   Disalvo, Liliana
   Apezteguia, Maria
   Pereyras, Silvia
   Pattin, Jorgelina
   Ortale, Susana
   Carmuega, Esteban
   Gonzalez, Horacio F.
TI Short-Term Evaluation of the Impact of a Food Program on the
   Micronutrient Nutritional Status of Argentinean Children Under the Age
   of Six
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Feeding programs; Children; Anemia; Micronutrients; Nutritional
   evaluation; Argentina
ID DEVELOPING-COUNTRIES; FORTIFICATION; GROWTH; SUPPLEMENTATION;
   PREVALENCE; DEFICIENCY; TRANSITION; OVERWEIGHT; OBESITY; ANEMIA
AB This study was undertaken to evaluate the impact of Plan Mas Vida (PMV) on the micronutrient nutritional condition of children aged 1 to 6 years 1 year after PMV implementation. The food program was intended for low-income families from the province of Buenos Aires, Argentina and provided supplementary diets. A prospective, nonexperimental study was carried out. Children (472 at baseline and 474 after 1 year) were divided into two groups (1-2 and 2-6 years of age). Biochemical tests (hemogram, ferritin, zinc, vitamin A, and folic acid), anthropometric assessments (weight and height), and dietary surveys (24-h recall) were performed. Chronic growth retardation (-2 height/age Z-score) was present in 2.8% and 8.7% of 1-2- and 2-6-year-old children, respectively; 14.4% in the former and 8.8% in the latter group had overweight/obesity. No significant changes were recorded 1 year after PMV implementation. Whereas anemia values decreased (55.3% to 39.1%, p = 0.003) and serum zinc values increased in 1-2-year-old children, the risk for vitamin A deficiency decreased significantly in both age groups. The evaluation of the early impact of PMV actions provided important nutritional data that should be used by provincial health authorities to conduct future evaluations.
C1 [Varea, Ana; Malpeli, Agustina; Disalvo, Liliana; Apezteguia, Maria; Pereyras, Silvia; Pattin, Jorgelina; Gonzalez, Horacio F.] Hosp Ninos La Plata, Inst Desarrollo Invest Pediat Prof Dr Fernando E, RA-1900 La Plata, Buenos Aires, Argentina.
   [Etchegoyen, Graciela] Ctr Interdisciplinario Univ Salud CINUS, Fac Cs Med UNLP, Catedra Epidemiol, La Plata, Argentina.
   [Vojkovic, Maria; Ortale, Susana; Carmuega, Esteban] Comis Invest Cient Prov Buenos Aires, La Plata, Buenos Aires, Argentina.
RP Gonzalez, HF (reprint author), Hosp Ninos La Plata, Inst Desarrollo Invest Pediat Prof Dr Fernando E, RA-1900 La Plata, Buenos Aires, Argentina.
EM horaciofgonzalez@gmail.com
FU CICPBA; Ministry of Human Development, Province of Buenos Aires
FX This study was funded by CICPBA and Ministry of Human Development,
   Province of Buenos Aires. The authors are grateful to professionals from
   the Food Program Department of the Ministry of Human Development, Andrea
   Touza for logistics support, and Adriana Di Maggio for manuscript
   edition. Special thanks are due to Prof. Fernando Viteri for a careful
   review of this manuscript.
CR Orden Alicia B., 2005, Arch. argent. pediatr., V103, P205
   Lutter CK, 2008, J NUTR, V138, P379, DOI 10.3945/jn.108.095406
   Brown KH, 2002, AM J CLIN NUTR, V75, P1062
   Adu-Afarwuah S, 2008, AM J CLIN NUTR, V87, P929
   Allen LH, 2000, AM J CLIN NUTR, V71, P1485
   Caballero B, 2005, NEW ENGL J MED, V352, P1514, DOI 10.1056/NEJMp048310
   de Onis M, 2000, AM J CLIN NUTR, V72, P1032
   Popkin BM, 1996, J NUTR, V126, P3009
   BIERI JG, 1979, AM J CLIN NUTR, V32, P2143
   de Onis M, 2006, PUBLIC HEALTH NUTR, V9, P942, DOI 10.1017/PHS20062005
   Beard JL, 2006, AM J CLIN NUTR, V84, P1498
   Bolzán Andrés, 2005, Arch. argent. pediatr., V103, P545
   Hess SY, 2009, FOOD NUTR BULL, V30, pS79
   Comite Nacional de Crecimiento y Desarrollo, 2001, GUIAS EV CREC
   Duran P, 2009, ARCH ARGENT PEDIATR, V107, P397, DOI 10.1590/S0325-00752009000500005
   Food and Nutrition Board Institute of Medicine, 2002, DIET REF INT 1997 20
   Food and Nutrition Board Subcommittee on Upper Reference Levels of Nutrients, 1998, DIET REF INT THIAM R
   Galvan M, 2007, ARCH LATINOAM NUTR, V57, P316
   Klemm RDW, 2010, FOOD NUTR BULL, V31, pS47
   Kuczmarski RJ, 2000, ADV DATA, V314, P1
   Layrisse Miguel, 2002, Food and Nutrition Bulletin, V23, P384
   Layrisse M, 1996, AM J CLIN NUTR, V64, P903
   Le Thi H, 2006, NUTR J, V5, P32
   Ministerio de Desarrollo Social de la Provincia de Buenos Aires, 2004, PLAN MAS VID
   NUTRIABA, 1999, ENC NUTR NIN NON MEN
   Oyhenart EE, 2007, REV PANAM SALUD PUBL, V22, P194, DOI 10.1590/S1020-49892007000800006
   Pehuen, 2005, NUTR DES CLAV EX MOD
   Poletti O H, 2001, An Esp Pediatr, V55, P300
   Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1
   Repetto F, 2001, INVENTARIO PROGRAMAS
   Smuts CM, 2005, J NUTR, V135, p653S
   Sommer A, 2002, J NUTR, V132, p2845S
   Uauy R., 2001, Journal of Nutrition, V131, P893
   Uauy R, 2002, PUBLIC HEALTH NUTR, V5, P223, DOI 10.1079/PHN2001297
   UN ACC/SCN, 2004, 5 UN ACCSCN
   YIP R, 1988, AM J CLIN NUTR, V48, P1295
NR 36
TC 3
Z9 3
U1 0
U2 5
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD DEC
PY 2011
VL 143
IS 3
BP 1337
EP 1348
DI 10.1007/s12011-011-8978-0
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 852HR
UT WOS:000297348900014
PM 21301990
ER

PT J
AU Sankaralingam, S
   Jiang, YY
   Davidge, ST
   Yeo, S
AF Sankaralingam, Sowndramalingam
   Jiang, Yanyan
   Davidge, Sandra T.
   Yeo, SeonAe
TI Effect of Exercise on Vascular Superoxide Dismutase Expression in
   High-Risk Pregnancy
SO AMERICAN JOURNAL OF PERINATOLOGY
LA English
DT Article
DE Preeclampsia; superoxide dismutase; oxidative stress; transferrin;
   endothelial dysfunction
ID INDUCED OXIDATIVE STRESS; TIME PHYSICAL-ACTIVITY; ANTIOXIDANT SYSTEMS;
   PREECLAMPSIA; WOMEN; OBESITY; DYSFUNCTION; PLASMA; SEDENTARY; WALKING
AB Endothelial dysfunction of the maternal vasculature induced by pro-oxidants may contribute to the development of preeclampsia. Obesity results in vascular inflammation and oxidative stress and is therefore a risk factor for preeclampsia. Regular exercise is known to induce antioxidants. We recently demonstrated that stretchers (subjects who performed low-intensity exercises) had a lower incidence of preeclampsia as opposed to walkers (moderate-intensity exercise; 2.6% versus 14.6%). We now seek to determine the possible protective mechanisms. We hypothesized that stretchers will have higher vascular levels of the antioxidant superoxide dismutase (SOD) and plasma transferrin levels, an antioxidant marker. We conducted immunohistochemical analyses of blood vessels embedded in fat biopsy samples obtained during cesarean sections from women who were randomized to either stretching (n = 6) or walking (n = 5) exercises. In addition, levels of plasma transferrin were measured. SOD expression was increased (p < 0.05) in stretchers [106.3 (interquartile range 84.2 to 127.8 arbitrary units (AU)] when compared with that of walkers [56.92 (interquartile range 46.35 to 82.32 AU)]. Transferrin levels continued to increase throughout gestation only among the stretchers. There appears to be a higher antioxidant protective effect in subjects who performed low-intensity exercise during pregnancy.
C1 [Yeo, SeonAe] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
   [Sankaralingam, Sowndramalingam; Jiang, Yanyan; Davidge, Sandra T.] Univ Alberta, Dept Physiol, Cardiovasc Res Ctr, Mazankowski Alberta Heart Inst, Edmonton, AB T6G 2M7, Canada.
   [Davidge, Sandra T.] Univ Alberta, Dept Obstet & Gynecol, Cardiovasc Res Ctr, Mazankowski Alberta Heart Inst, Edmonton, AB T6G 2M7, Canada.
   [Davidge, Sandra T.] Univ Alberta, Women & Childrens Hlth Res Inst, Cardiovasc Res Ctr, Mazankowski Alberta Heart Inst, Edmonton, AB T6G 2M7, Canada.
RP Yeo, S (reprint author), Univ N Carolina, Sch Nursing, Carrington Hall, Chapel Hill, NC 27599 USA.
EM syeo@email.unc.edu
FU Canadian Institutes for Health Research (CIHR); Alberta Heritage
   Foundation for Medical Research (AHFMR); Heart and Stroke Foundation of
   Canada; National Institute of Health in the United States [R01-NR05005]
FX This work was supported by grants from the Canadian Institutes for
   Health Research (CIHR). S. Sankaralingam was supported by the Alberta
   Heritage Foundation for Medical Research (AHFMR) and the Junior
   Personnel Award from the Heart and Stroke Foundation of Canada. S.T.
   Davidge is an AHFMR Scientist and a Canada Research Chair in Women's
   Cardiovascular Health. S. Yeo conducted the parent study (R01-NR05005),
   which was funded by National Institute of Health in the United States.
CR Yeo S, 2009, RES NURS HEALTH, V32, P379, DOI 10.1002/nur.20328
   GUTTERIDGE JMC, 1993, BIOCHIM BIOPHYS ACTA, V1156, P144, DOI 10.1016/0304-4165(93)90129-V
   Kopelman PG, 2000, NATURE, V404, P635
   Sankaralingam Sowndramalingam, 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010465
   Kaiser PS, 2001, OBSTET GYNECOL, V97, P39, DOI 10.1016/S0029-7844(00)01078-4
   Yeo S, 2008, HYPERTENS PREGNANCY, V27, P113, DOI 10.1080/10641950701826778
   Granger JP, 2002, MICROCIRCULATION, V9, P147, DOI 10.1038/sj.mn.7800137
   Redman CWG, 2010, AM J REPROD IMMUNOL, V63, P534, DOI 10.1111/j.1600-0897.2010.00831.x
   Sorensen TK, 2003, HYPERTENSION, V41, P1273, DOI 10.1161/01.HYP.0000072270.82815.91
   Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248
   Hubel CA, 1996, AM J OBSTET GYNECOL, V175, P692
   Roggensack AM, 1999, HYPERTENSION, V33, P83
   Saftlas AF, 2004, AM J EPIDEMIOL, V160, P758, DOI 10.1093/aje/kwh277
   Friedman JM, 2000, NATURE, V404, P632
   Ji LL, 1998, ANN NY ACAD SCI, V854, P102, DOI 10.1111/j.1749-6632.1998.tb09896.x
   Avery M D, 2001, J Matern Fetal Med, V10, P52, DOI 10.1080/714904296
   Carlsohn A, 2008, ANN NUTR METAB, V53, P96, DOI 10.1159/000165357
   Crane Joan, 2008, J Obstet Gynaecol Can, V30, P561
   Fisher-Wellman Kelsey, 2009, Dyn Med, V8, P1, DOI 10.1186/1476-5918-8-1
   Hernandez R, 1999, ENDOCR RES, V25, P153
   Leaf DA, 1999, AM J MED SCI, V317, P295, DOI 10.1097/00000441-199905000-00005
   Manders RJF, 2010, MED SCI SPORT EXER, V42, P219, DOI 10.1249/MSS.0b013e3181b3b16d
   Meijer EP, 2002, J AM GERIATR SOC, V50, P349, DOI 10.1046/j.1532-5415.2002.50069.x
   Osterdal ML, 2009, BJOG-INT J OBSTET GY, V116, P98, DOI 10.1111/j.1471-0528.2008.02001.x
   Sankaralingam S, 2009, HYPERTENSION, V54, P897, DOI 10.1161/HYPERTENSIONAHA.109.135228
   Sankaralingam S, 2010, CARDIOVASC RES, V85, P194, DOI 10.1093/cvr/cvp277
   Sankaralingam S, 2009, HYPERTENSION, V53, P270, DOI 10.1161/HYPERTENSIONAHA.108.122630
   Senturk UK, 2005, J APPL PHYSIOL, V99, P1434, DOI 10.1152/japplphysiol.01392.2004
   Stepan H, 2006, OBESITY, V14, P770, DOI 10.1038/oby.2006.88
   Yeo S, 2001, J WOMEN HEALTH GEN-B, V10, P983, DOI 10.1089/152460901317193558
   Yeo S, 2006, CONTEMP CLIN TRIALS, V27, P531, DOI 10.1016/j.cct.2006.06.005
NR 31
TC 3
Z9 3
U1 1
U2 5
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0735-1631
J9 AM J PERINAT
JI Am. J. Perinatol.
PD NOV
PY 2011
VL 28
IS 10
BP 803
EP 810
DI 10.1055/s-0031-1284230
PG 8
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 863XB
UT WOS:000298200500009
PM 21815126
ER

PT J
AU Olah, M
   Koncz, A
   Feher, J
   Kalmanczhey, J
   Olah, C
   Nagy, G
   Bender, T
AF Olah, Mihaly
   Koncz, Agnes
   Feher, Judit
   Kalmanczhey, Judit
   Olah, Csaba
   Nagy, Gyoergy
   Bender, Tamas
TI The effect of balneotherapy on antioxidant, inflammatory, and metabolic
   indices in patients with cardiovascular risk factors (hypertension and
   obesity)-A randomised, controlled, follow-up study
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Balneotherapy; Arteriosclerosis; Hypertension; Obesity
ID C-REACTIVE PROTEIN; SPA THERAPY; ATHEROSCLEROSIS; DISEASE; WATER;
   PERSPECTIVES; IMMERSION
AB Introduction: The primary objective of our study was to explore the changes of antioxidant, inflammatory, and metabolic parameters in obese and hypertension people patients during balneotherapy and to evaluate the safety of balneotherapy in these participants.
   Methods: Following randomisation, 22 obese and 20 hypertensive patients underwent balneotherapy with thermal water of 38 degrees C temperature, in 15 sessions of 30 minutes. An additional 22 obese and 20 hypertensive patients served as controls. Antioxidant, inflammatory, and metabolic parameters were determined at baseline, as well as post-treatment and at the end of follow-up (at 15 weeks).
   Results: As regards changes observed in hypertensive patients subjected to balneotherapy, differences could be detected between baseline and post-treatment albumin and haemoglobin A(1C) levels only; however, these were no longer significant after 3 months. Although the difference between transferrin levels determined at the end of balneotherapy and 3 months later was significant, it remained within the physiological range, as well as it was accompanied by normal serum iron level and therefore, it was considered irrelevant. c-reactive protein levels of balneotherapy patients decreased significantly after treatment.
   In obese patients, haemoglobin A(1C) level decreased after balneotherapy, but this difference was not observed either after 3 months. Similarly, both transferrin and C-reactive protein levels changed from baseline, but not between groups.
   Conclusions: This study contributes important information regarding the safety of balneotherapy in hypertensive and obese diabetics by showing no alterations of antioxidant, inflammatory, or metabolic indices. The findings of this study confirm that balneotherapy is not contraindicated for hypertensive or obese patients. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Olah, Mihaly; Feher, Judit; Kalmanczhey, Judit] Hungarospa Hajduszoboszlo Private Ltd Co, Budapest, Hungary.
   [Olah, Csaba] BAZ Cty Hosp, Dept Neurosurg, Miskolc, Hungary.
   [Koncz, Agnes] Heim Pal Paediat Hosp, Budapest, Hungary.
   [Nagy, Gyoergy; Bender, Tamas] Hosp Hospitaller Bros St John God Buda, Budapest, Hungary.
   [Nagy, Gyoergy; Bender, Tamas] Polyclin Hospitaller Bros St John God Buda, Budapest, Hungary.
RP Bender, T (reprint author), Budai Irgalmasrendi Korhaz, Arpad Fejedelem U 7, H-1023 Budapest, Hungary.
EM bender@mail.datanet.hu
CR Bender T, 2005, RHEUMATOL INT, V25, P220, DOI 10.1007/s00296-004-0487-4
   Bender T, 2007, ARCH MED RES, V38, P86, DOI 10.1016/j.arcmed.2006.08.007
   Hooper PL, 1999, NEW ENGL J MED, V341, P924, DOI 10.1056/NEJM199909163411216
   Anand SS, 2010, EUR HEART J, V31, P2092, DOI [10.1093/eurheartj/ehq242, 10.1093/eurheartj/ehq238]
   Shi GP, 2010, EUR J VASC ENDOVASC, V39, P485, DOI 10.1016/j.ejvs.2010.01.028
   West IC, 2000, DIABETIC MED, V17, P171, DOI 10.1046/j.1464-5491.2000.00259.x
   Sukenik S, 1999, RHEUM DIS CLIN N AM, V25, P883, DOI 10.1016/S0889-857X(05)70108-3
   Biasucci LM, 2010, CLIN CHEM LAB MED, V48, P1685, DOI 10.1515/CCLM.2010.277
   Montecucco F, 2008, J LEUKOCYTE BIOL, V84, P1109, DOI 10.1189/jlb.0208123
   Forestier R, 2010, ANN RHEUM DIS, V69, P660, DOI 10.1136/ard.2009.113209
   Levonen AL, 2008, CIRCULATION, V117, P2142, DOI 10.1161/CIRCULATIONAHA.107.718585
   Libby P, 2010, CIRC J, V74, P213, DOI 10.1253/circj.CJ-09-0706
   Apostolakis S, 2010, ACTA PHARMACOL SIN, V31, P1103, DOI 10.1038/aps.2010.131
   Cider A, 2006, EUR J HEART FAIL, V8, P308, DOI 10.1016/j.ejheart.2005.08.001
   Costantino M, 2009, AMINO ACIDS, V36, P161, DOI 10.1007/s00726-008-0032-y
   Ekmekcioglu C, 2000, ALTERN THER HEALTH M, V6, P46
   Fatehi-Hassanabad Z, 2010, EUR J PHARMACOL, V636, P8, DOI 10.1016/j.ejphar.2010.03.048
   Guo SJ, 2011, DNA CELL BIOL, V30, P157, DOI 10.1089/dna.2010.1093
   Leibetseder V, 2004, CLIN CHIM ACTA, V343, P105, DOI 10.1016/j.cccn.2003.12.024
   Matsuura E, 2009, J CLIN IMMUNOL, V29, P714, DOI 10.1007/s10875-009-9333-5
   Ohtsuka Y, 1996, INT J BIOMETEOROL, V39, P156, DOI 10.1007/BF01211230
   Olah M, 2010, INT J BIOMETEOROL, V54, P249, DOI 10.1007/s00484-009-0276-6
   Schega L, 2007, J CARDIOPULM REHABIL, V27, P76
   SVEALV BG, 2009, CARDIOVASC ULTRASOUN, V6, P33
NR 24
TC 6
Z9 7
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD NOV
PY 2011
VL 32
IS 6
BP 793
EP 801
DI 10.1016/j.cct.2011.06.003
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 841CE
UT WOS:000296489100004
PM 21763463
ER

PT J
AU Lee, BK
   Kim, Y
   Kim, YI
AF Lee, Byung-Kook
   Kim, Yangho
   Kim, Young-Il
TI Association of serum ferritin with metabolic syndrome and diabetes
   mellitus in the South Korean general population according to the Korean
   National Health and Nutrition Examination Survey 2008
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID BODY IRON STORES; INSULIN-RESISTANCE SYNDROME; CARDIOVASCULAR
   RISK-FACTORS; POLYCYSTIC-OVARY-SYNDROME; GLUCOSE-INTOLERANCE; OXIDATIVE
   STRESS; FATTY LIVER; MEN; WOMEN; OVERLOAD
AB We examined the association of serum ferritin levels with metabolic syndrome (MS) and diabetes mellitus in a representative sample of the adult South Korean population using data from the 2008 Korean National Health and Nutrition Examination Survey. We conducted a cross-sectional study of 6311 adults older than 20 years who participated in the 2008 Korean National Health and Nutrition Examination Survey. Metabolic syndrome was defined as the presence of at least 3 of the following: elevated blood pressure, low high-density lipoprotein cholesterol, elevated serum triglycerides, elevated plasma glucose, and abdominal obesity. Diabetes mellitus was defined as fasting glucose of at least 126 mg/dL. Insulin resistance was determined using the homeostasis model assessment estimate of insulin resistance. In a representative sample of the adult Korean population, MS was more prevalent in the highest quartile compared with the lowest quartile of serum ferritin concentrations in women following adjustments for age, education, smoking, alcohol intake, body mass index, aspartate aminotransferase, and alanine aminotransferase. Diabetes mellitus was more prevalent in the highest quartile compared with the lowest quartile of serum ferritin concentrations in premenopausal women and men. The geometric means of fasting insulin and insulin resistance determined using the homeostasis model assessment of insulin resistance in the fourth serum ferritin quartiles of postmenopausal women and men were significantly higher compared with those in the first quartile of the respective groups. The present study demonstrates that elevated serum ferritin concentrations are associated with an increased risk of MS and diabetes mellitus in a representative sample of the adult South Korean population. (C) 2011 Published by Elsevier Inc.
C1 [Kim, Yangho] Univ Ulsan Coll Med, Dept Occupat & Environm Med, Ulsan Univ Hosp, Ulsan 682060, South Korea.
   [Lee, Byung-Kook] Soonchunhyang Univ 646 Eupnae Ri, Inst Environm & Occupat Med, Asan 336745, Choongnam, South Korea.
   [Kim, Young-Il] Univ Ulsan Coll Med, Div Endocrinol & Metab, Dept Internal Med, Ulsan Univ Hosp, Ulsan 682060, South Korea.
RP Kim, Y (reprint author), Univ Ulsan Coll Med, Dept Occupat & Environm Med, Ulsan Univ Hosp, Ulsan 682060, South Korea.
EM yanghokm@nuri.net
CR Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Fernandez-Real JM, 2005, CLIN CHEM, V51, P1201, DOI 10.1373/clinchem.2004.046847
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Alissa EM, 2007, J TRACE ELEM MED BIO, V21, P242, DOI 10.1016/j.jtemb.2007.05.002
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Pasquali R, 2011, CLIN ENDOCRINOL, V74, P424, DOI 10.1111/j.1365-2265.2010.03956.x
   Trombini P, 2007, J HEPATOL, V46, P549, DOI 10.1016/j.jhep.2007.01.004
   Mateo-Gallego R, 2010, METABOLISM, V59, P154, DOI 10.1016/j.metabol.2009.06.021
   Fumeron F, 2006, DIABETES CARE, V29, P2090, DOI 10.2337/dc06-0093
   Sun L, 2008, J CLIN ENDOCR METAB, V93, P4690, DOI 10.1210/jc.2008-1159
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Halle M, 1997, ATHEROSCLEROSIS, V128, P235, DOI 10.1016/S0021-9150(96)05994-1
   Haap M, 2003, ANN INTERN MED, V139, P869
   Salonen JT, 1998, BRIT MED J, V317, P727
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Cooksey RC, 2004, ENDOCRINOLOGY, V145, P5305, DOI 10.1210/en.2004-0392
   Kim CH, 2011, METABOLISM, V60, P414, DOI 10.1016/j.metabol.2010.03.007
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Valenti L, 2007, AM J GASTROENTEROL, V102, P1251, DOI 10.1111/j.1572-0241.2007.01192.x
   Fernandez-Real JM, 2002, DIABETES, V51, P1000, DOI 10.2337/diabetes.51.4.1000
   NIEDERAU C, 1984, DIABETOLOGIA, V26, P441
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   MERKEL PA, 1988, NEW ENGL J MED, V318, P809, DOI 10.1056/NEJM198803313181303
   Lecube A, 2008, INT J OBESITY, V32, P1665, DOI 10.1038/ijo.2008.154
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Ren Y, 2004, DIABETES CARE, V27, P622, DOI 10.2337/diacare.27.2.622
   Aso Y, 2010, DIABETES RES CLIN PR, V90, P250, DOI 10.1016/j.diabres.2010.09.008
   Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62
   Martinez-Garcia MA, 2009, DIABETES CARE, V32, P1525, DOI 10.2337/dc09-0420
   Acton RT, 2006, DIABETES CARE, V29, P2084, DOI 10.2337/dc05-1592
   Shi ZM, 2006, DIABETES CARE, V29, P1878, DOI 10.2337/dc06-0327
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Zelber-Sagi S, 2007, J HEPATOL, V46, P700, DOI 10.1016/j.jhep.2006.09.018
   Lee SY, 2007, DIABETES RES CLIN PR, V75, P72, DOI 10.1016/j.diabres.2006.04.013
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Beard JL, 2001, J NUTR, V131, P568
   Brudevold R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003547
   Franks S, 2011, CLIN ENDOCRINOL, V74, P148, DOI 10.1111/j.1365-2265.2010.03934.x
   Gabay C, 1999, NEW ENGL J MED, V340, P448
   Gastaldelli A, 2009, OBES SURG, V19, P80, DOI 10.1007/s11695-008-9690-9
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Korean Ministry of Health and Welfare, 2007, 4 KOR NAT HLTH NUTR
   Le Guenno G, 2007, DIABETES RES CLIN PR, V77, P363, DOI 10.1016/j.diabres.2007.02.004
   McCarty MF, 2003, MED HYPOTHESES, V61, P567, DOI 10.1016/S0306-9877(03)00231-7
   Milman N, 2003, EUR J HAEMATOL, V71, P51, DOI 10.1034/j.1600-0609.2003.00090.x
   Milman N, 2002, EUR J HAEMATOL, V68, P332, DOI 10.1034/j.1600-0609.2002.01668.x
   Swanson CA, 2003, ALCOHOL, V30, P99, DOI 10.1016/S0741-8329(03)00103-4
   The Korean Ministry of Health and Welfare, 2010, 4 KOR NAT HLTH NUTR
   Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2
   WOLFF SP, 1993, BRIT MED BULL, V49, P642
NR 55
TC 35
Z9 35
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
J9 METABOLISM
JI Metab.-Clin. Exp.
PD OCT
PY 2011
VL 60
IS 10
BP 1416
EP 1424
DI 10.1016/j.metabol.2011.02.008
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 826IN
UT WOS:000295347900010
PM 21489582
ER

PT J
AU Ryoo, JH
   Kim, MG
   Lee, DW
   Shin, JY
AF Ryoo, Jae-Hong
   Kim, Min-Gi
   Lee, Da-Woon
   Shin, Ju-Young
TI The relationship between serum ferritin and metabolic syndrome in
   healthy Korean men
SO DIABETES-METABOLISM RESEARCH AND REVIEWS
LA English
DT Article
DE ferritin; metabolic syndrome; iron
ID CARDIOVASCULAR RISK-FACTORS; BODY IRON STORES; INSULIN-RESISTANCE;
   DIABETES-MELLITUS; ASSOCIATION; ADULTS; OBESITY; WOMEN; INFLAMMATION;
   HOMEOSTASIS
AB Background and objective Elevated serum ferritin levels have been reported to be associated with several metabolic disorders. We investigated the relationship between serum ferritin level and metabolic syndrome and its components in healthy Korean men.
   Methods In this cross-sectional study, serum ferritin level and metabolic syndrome and its components were measured from 18 581 men from January to December in 2008. The presence of metabolic syndrome was determined according to the most recent consensus report of the National Cholesterol Education Program's Third Adult Treatment Panel. Logistic regression models were applied to examine the relationship between the serum ferritin level and the metabolic syndrome and its components.
   Results After adjusting for clinical covariates, the odds ratio and 95% confidence intervals of metabolic syndrome with respect to Q2, Q3 and Q4 were 1.34 (1.14-1.57), 1.49 (1.24-1.70) and 1.99 (1.70-2.33), respectively (p for trend < 0.001). The multivariable-adjusted model also showed a significantly graded relationship between individual components of metabolic syndrome and the quartile groups of serum ferritin.
   Conclusions In this study, elevated ferritin concentration is independently associated with metabolic syndrome and its components among healthy Korean men. Copyright. (C) 2011 John Wiley & Sons, Ltd.
C1 [Kim, Min-Gi] Dongguk Univ, Gyeongju Hosp, Dept Occupat & Environm Med, Gyeongju Si 780350, Kyungsang Bukdo, South Korea.
   [Ryoo, Jae-Hong] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Occupat Med, Seoul, South Korea.
   [Lee, Da-Woon] Chung Ang Univ, Sch Med, Dept Family Med, Seoul 156756, South Korea.
   [Shin, Ju-Young] Seoul Natl Univ, Coll Med, Dept Prevent Med, Pharmacoepidemiol Res Lab, Seoul, South Korea.
RP Kim, MG (reprint author), Dongguk Univ, Gyeongju Hosp, Dept Occupat & Environm Med, 1090-1 Sukjang Dong, Gyeongju Si 780350, Kyungsang Bukdo, South Korea.
EM searchthing@naver.com
CR Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Heeney MM, 2004, HEMATOL ONCOL CLIN N, V18, P1379, DOI 10.1016/j.hoc.2004.06.018
   Williams MJA, 2002, ATHEROSCLEROSIS, V165, P179, DOI 10.1016/S0021-9150(02)00233-2
   Halle M, 1997, ATHEROSCLEROSIS, V128, P235, DOI 10.1016/S0021-9150(96)05994-1
   Han TS, 2002, OBES RES, V10, P923, DOI 10.1038/oby.2002.126
   Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872-200208000-00013
   Jehn M, 2004, DIABETES CARE, V27, P2422, DOI 10.2337/diacare.27.10.2422
   Dandona P, 2005, CIRCULATION, V111, P1448, DOI 10.1161/01.CIR.0000158483.13093.9D
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   [Anonymous], 2004, LANCET, V363, P157
   Shi ZM, 2006, DIABETES CARE, V29, P1878, DOI 10.2337/dc06-0327
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426
   Chen XH, 2006, DIABETES CARE, V29, P1077, DOI 10.2337/dc06-0164
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Gabay C, 1999, NEW ENGL J MED, V340, P448
   Haidari M, 2001, CLIN CHEM, V47, P1666
   Harris EL, 2007, ARCH INTERN MED, V167, P722, DOI 10.1001/archinte.167.7.722
   Rushton DH, 2001, BRIT MED J, V322, P1355, DOI 10.1136/bmj.322.7298.1355
   Wen CP, 2009, PUBLIC HEALTH NUTR, V12, P497, DOI 10.1017/S1368980008002802
   WOLFF SP, 1993, BRIT MED BULL, V49, P642
NR 26
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1520-7552
J9 DIABETES-METAB RES
JI Diabetes-Metab. Res. Rev.
PD SEP
PY 2011
VL 27
IS 6
BP 597
EP 603
DI 10.1002/dmrr.1211
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 824BZ
UT WOS:000295176500010
PM 21538776
ER

PT J
AU Marin, AS
   Graupera, JMX
AF Soler Marin, A.
   Xandri Graupera, J. Ma
TI Nutritional status of intellectual disabled persons with Down syndrome
SO NUTRICION HOSPITALARIA
LA English
DT Article
DE Down syndrome; Intellectual disability; Obesity; Nutritional status;
   Body composition
ID BODY-MASS INDEX; MENTAL-RETARDATION; METABOLIC-RATE; PHYSICAL-FITNESS;
   ADULTS; OVERWEIGHT; CHILDREN; OBESITY; ADOLESCENTS; PREVALENCE
AB Background: To evaluate the nutritional status in young adults with Down syndrome (DS).
   Methods: 38 persons, 15 (39.5%) women and 23 (60.5%) men (age range 16-38 years) with DS. Body composition was analyzed from anthropometric parameters according to standard protocols, levels of physical activity and nutrient intake was determined using validated questionnaires: a 72 h recall and consumption food frequency questionnaire (recorded by the tutors of the participants). The following biochemical parameters were estimated: blood lipids profile (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides), glucose, uric acid, proteins (ferritin and transferrin), minerals (Fe, Zn, Cu, Mg and Se) and vitamins (B12, B9, E, C and beta-carotene). The data were statistically analysed with Student t tests.
   Results: From the 38 participants, 36.8% were over-weight (BMI: 25-29.9 kg/m(2)) and 36.8% were obese (BMI >= 30 kg/m(2)). The BMI differed from women to men (P < 0.001) (29.1 +/- 4.3 and 27.9 +/- 4.6 kg/m(2), respectively). The average values of the biochemical parameters, except for uric acid, both in women and men were within normal ranges. The average energy intake was 1,909 +/- 337 and 2,260 +/- 284 kcal/day for women and men, respectively. The contribution of proteins to total caloric intake was 18.8 and 16.3% for women and men, respectively, while carbohydrates contributed 43.3 and 45.6%, and lipids 37.9 and 38.1%. All participants were sedentary.
   Conclusion: In this group presented a high prevalence of overweight and obesity. Further research is required in the development and evaluation of appropriate intervention programs to improve their nutritional status and quality of life.
C1 [Soler Marin, A.] Univ Catolica San Antonio Murcia, Dept Tecnol Alimentac & Nutr, Murcia, Spain.
   [Xandri Graupera, J. Ma] Hosp Univ Virgen de la Arrixaca Murcia, Unidad Nutr & Dietet, Murcia, Spain.
RP Marin, AS (reprint author), Care of Lesiak T, 113 Zeromskiego St, PL-90549 Lodz, Poland.
FU CEOM; ASSIDO; San Antonio Catholic University; Seneca Foundation of
   Murcia, Spain
FX The authors would like to acknowledge the support from two occupational
   centres for the intellectual disabled (CEOM and ASSIDO) in the province
   of Murcia (Spain). This study was made possible by the financial support
   of the San Antonio Catholic University and Seneca Foundation of Murcia,
   Spain. No conflict of interest was declared.
CR ALLISON DB, 1995, INT J OBESITY, V19, P858
   Brown CD, 2000, OBES RES, V8, P605, DOI 10.1038/oby.2000.79
   Rubin SS, 1998, MENT RETARD, V36, P175, DOI 10.1352/0047-6765(1998)036<0175:OPIPWD>2.0.CO;2
   [Anonymous], 2008, SPSS SCI COMP SCI PR
   Garaulet M, 2000, J PEDIATR GASTR NUTR, V30, P253, DOI 10.1097/00005176-200003000-00008
   Fujiura GT, 1997, RES DEV DISABIL, V18, P261, DOI 10.1016/S0891-4222(97)00008-5
   WADDEN TA, 1985, ANN INTERN MED, V103, P1062
   CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   LUKE A, 1994, J PEDIATR-US, V125, P829, DOI 10.1016/S0022-3476(94)70087-7
   DORNER K, 1984, CLIN CHIM ACTA, V142, P307, DOI 10.1016/0009-8981(84)90267-5
   BROZEK J, 1963, ANN NY ACAD SCI, V110, P113, DOI 10.1111/j.1749-6632.1963.tb17079.x
   PUESCHEL SM, 1992, J INTELL DISABIL RES, V36, P365
   Roizen NJ, 2003, LANCET, V361, P1281, DOI 10.1016/S0140-6736(03)12987-X
   CHUMLEA WC, 1981, J MENT DEFIC RES, V25, P275
   PITETTI KH, 1993, SPORTS MED, V16, P23, DOI 10.2165/00007256-199316010-00004
   JACKSON AS, 1980, MED SCI SPORT EXER, V12, P175
   Moreno LA, 2006, EUR J CLIN NUTR, V60, P191, DOI 10.1038/sj.ejcn.1602285
   BELL AJ, 1992, J INTELL DISABIL RES, V36, P359
   BRONKS R, 1985, AM J MENT DEF, V90, P110
   Bruininks RH, 1986, ICAP INVENTARY CLIEN
   CHAD K, 1990, AM J MENT RETARD, V95, P228
   Colombo M L, 1992, Minerva Pediatr, V44, P11
   Departamento de Nutricion, 1998, TABL ING REC EN NUTR
   Domenech JM, 2004, FDN DESIGN STAT
   Draheim CC, 2002, AM J MENT RETARD, V107, P201, DOI 10.1352/0895-8017(2002)107<0201:DICDRB>2.0.CO;2
   FERNHALL B, 1993, MED SCI SPORT EXER, V25, P442
   FORT P, 1984, J PEDIATR-US, V104, P545, DOI 10.1016/S0022-3476(84)80544-2
   Franz MJ, 1998, J AM DIET ASSOC, V89, pS39
   Gil-Campos M, 2009, NUTR HOSP, V24, P607, DOI 10.3305/nh.2009.24.5.4491
   Gonzalvo MC, 1992, REV DIAGN BIOL, V5, P22
   GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406
   Guerra M, 2000, THESIS U BARCELONA
   Gutierrez A, 2000, REV DIAGN BIOL, V49, P165
   Jung RT, 1997, OBESITY, P307
   Lennox N, 2002, HLTH GUIDELINES ADUL
   Martinez-Victoria E, 2002, ALIMENTACION SALUD S
   McCubbin J. A, 1995, SPORTS MED TRAINING, V6, P15, DOI DOI 10.1080/15438629509512032
   Medlen JG, 2002, DOWN SYNDROME NUTR H
   Melville CA, 2005, J INTELL DISABIL RES, V49, P125, DOI 10.1111/j.1365-2788.2004.00616.x
   MURPHY CM, 1992, INT J OBESITY, V16, P633
   Patterson B, 1993, PEDIAT NUTRITION CHR, P59
   PERCY ME, 1990, AM J MED GENET, V36, P148, DOI 10.1002/ajmg.1320360205
   PITETTI KH, 1992, MED SCI SPORT EXER, V24, P13
   PRASHER VP, 1995, J INTELL DISABIL RES, V39, P437
   Pueschel SM, 1988, YOUNG PERSON DOWN SY, P23
   Pueschel SM, 1992, BIOMEDICAL CONCERNS
   Pueschel SM, 1982, ADV BIOMEDICINE BEHA, P241
   Purice M, 1988, Endocrinologie, V26, P113
   Rimmer JH, 1993, BROWN COMMUNICATIONS, P247
   RIMMER JH, 1987, AM J MENT RETARD, V91, P626
   Salas-Salvado J, 2007, MED CLIN-BARCELONA, V128, P184, DOI 10.1016/S0025-7753(07)72531-9
   SALO MK, 1979, SCAND J CLIN LAB INV, V39, P485, DOI 10.3109/00365517909106135
   Sarria A, 2001, ACTA PAEDIATR, V90, P387, DOI 10.1080/080352501750126195
   SENC. Sociedad Espanola de Nutricion Comunitaria, 2001, OBJ NUTR POBL ESP
   SHARAV T, 1992, CLIN PEDIATR, V31, P341, DOI 10.1177/000992289203100605
   SIMILA S, 1991, J MENT DEFIC RES, V35, P160
   West P, 1984, THERAPEUTIC REACREAT, V19, P40
   WHO, 2003, TECHN REP SER WHO
   World Health Organization, 1997, OB PREV MAN
NR 60
TC 5
Z9 6
U1 2
U2 6
PU AULA MEDICA EDICIONES
PI MADRID
PA C/ISABEL COLBRAND, 10-12 NAVE 78 S PLANTA CIUDAD INDUSTRIAL
   VENECIA-EDIFICIO ALFA, MADRID, 28050, SPAIN
SN 0212-1611
J9 NUTR HOSP
JI Nutr. Hosp.
PD SEP-OCT
PY 2011
VL 26
IS 5
BP 1059
EP 1066
DI 10.3305/nh.2011.26.5.5233
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 817SC
UT WOS:000294694100021
ER

PT J
AU Botero-Lopez, JE
   Araya, M
   Parada, A
   Mendez, MA
   Pizarro, F
   Espinosa, N
   Canales, P
   Alarcon, T
AF Botero-Lopez, Jorge E.
   Araya, Magdalena
   Parada, Alejandra
   Mendez, Marco A.
   Pizarro, Fernando
   Espinosa, Nelly
   Canales, Paulina
   Alarcon, Teresa
TI Micronutrient Deficiencies in Patients With Typical and Atypical Celiac
   Disease
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE atypical celiac disease; copper; iron; typical celiac disease; zinc
ID GLUTEN-FREE DIET; COPPER DEFICIENCY; CHILDREN; ANEMIA; PREVALENCE;
   POPULATION; MECHANISM; OBESITY; ZINC
AB Objective: The extent of the digestive/absorptive involvement in atypical presentation of celiac disease (CD) is not always clear. The aim of the study was to assess nutritional status of iron (Fe), copper (Cu), and zinc (Zn) in patients with typical CD (TCD) and atypical CD (ACD).
   Patients and Methods: A cross-sectional study was done in patients with TCD, ACD, and healthy controls (HC). Hemoglobin, serum ferritin, free erythrocyte protoporphyrin, Fe, Cu, ceruloplasmin, Zn, anti-endomysial antibodies, and anti-tissue transglutaminase antibodies were measured. Data were analyzed by Kruskal-Wallis, principal component analysis, and linear discriminant analysis.
   Results: One hundred nine individuals were studied (54 TCD, 19 ACD, 36 HC); mean age +/- standard deviation was 23 +/- 15.8 (range 1.6-75.4) years. Median and range of hemoglobin were 12.8 g/dL (8.1-17.6) in TCD, 12.4 g/dL (10.5-14.5) in ACD, and 13.6 g/dL (11.1-16.7) in HC (P<0.0001); serum ferritin was 17.7 mu g/L (2.9-157), 10.8 mu g/L (2.7-39.8), and 28.7 mu g/L (4.5-127.2), respectively (P<0.01). Cu was 105 mu g/dL (60-185), 97.5 mu g/dL (40-130), and 125 mu g/dL (80-205), respectively (P<0.05). Ceruloplasmin was 21.6 mg/dL (14.2-73.2), 22.6 mg/dL (0.9-34.3), and 32.1 mg/dL (5.8-72.6), respectively (P<0.01). There were no differences in Fe, free erythrocyte protoporphyrin, and Zn. Principal component analysis showed that 58% of observed variability was explained by Fe and Cu indicators. Linear discriminant analysis revealed differences between CD and HC (P<0.0001), with high values of correct classification for TCD (73%) and HC (72%), but not ACD (16%), which were mostly classified as TCD (79%).
   Conclusions: Deficiency of micronutrients was found both in typical as well as in atypical cases.
C1 [Botero-Lopez, Jorge E.; Araya, Magdalena; Parada, Alejandra; Mendez, Marco A.; Pizarro, Fernando] Univ Chile, Inst Nutr & Food Technol INTA, Santiago 11, Chile.
RP Araya, M (reprint author), Univ Chile, Inst Nutr & Food Technol INTA, Macul 5540, Santiago 11, Chile.
EM maraya@inta.cl
RI Mendez, Marco/B-1912-2014; Pizarro, Fernando/K-5266-2012
OI Pizarro, Fernando/0000-0001-6088-1119
FU Fondecyt [1070595]
FX The study was partially funded by projects Fondecyt 1070595.
CR American Association of Clinical Endocrinologists, 2003, ENDOCR PRACT, V9, P64
   Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600
   Griffith DP, 2009, OBESITY, V17, P827, DOI 10.1038/oby.2008.614
   Fasano A, 2005, BEST PRACT RES CL GA, V19, P467, DOI 10.1016/j.bpg.2005.01.008
   Kemppainen T, 1999, BONE, V25, P355, DOI 10.1016/S8756-3282(99)00171-4
   Kagnoff MF, 2005, GASTROENTEROLOGY, V128, pS10, DOI 10.1053/j.gastro.2005.02.008
   Dickey W, 2006, AM J GASTROENTEROL, V101, P2356, DOI 10.1111/j.1572-0241.2006.00750.x
   Hogberg L, 2009, ACTA PAEDIATR, V98, P343, DOI 10.1111/j.1651-2227.2008.01085.x
   Bergamaschi G, 2008, HAEMATOL-HEMATOL J, V93, P1785, DOI 10.3324/haematol.13255
   Dewar DH, 2005, GASTROENTEROLOGY, V128, pS19, DOI 10.1053/j.gastro.2005.02.010
   Catassi C, 2008, CURR OPIN GASTROEN, V24, P687, DOI 10.1097/MOG.0b013e32830edc1e
   Halfdanarson TR, 2007, BLOOD, V109, P412, DOI 10.1182/blood-2006-07-031104
   Telega G, 2008, ARCH PEDIAT ADOL MED, V162, P164, DOI 10.1001/archpediatrics.2007.38
   Fasano A, 2005, GASTROENTEROLOGY, V128, pS68, DOI 10.1053/j.gastro.2005.02.015
   Abu-Zekry M, 2008, J PEDIATR GASTR NUTR, V47, P136, DOI 10.1097/MPG.0b013e31815ce5d1
   Arslan N, 2009, J PAEDIATR CHILD H, V45, P317, DOI 10.1111/j.1440-1754.2009.01512.x
   Bilic E, 2009, CLIN NEUROL NEUROSUR, V111, P644, DOI 10.1016/j.clineuro.2009.04.006
   BONOMO RP, 1995, J INORG BIOCHEM, V59, P773, DOI 10.1016/0162-0134(94)00063-G
   Elin RJ, 2004, CECIL TXB MED, P2496
   Furse RM, 2005, BRIT MED J, V330, P773, DOI 10.1136/bmj.330.7494.773
   Gleason G., 2007, NUTR ANEMIA, P45
   GOYENS P, 1985, J PEDIATR GASTR NUTR, V4, P677, DOI 10.1097/00005176-198508000-00033
   GREBE G, 1984, REV MED CHILE, V112, P884
   Halfdanarson TR, 2009, J CLIN GASTROENTEROL, V43, P162, DOI 10.1097/MCG.0b013e3181354294
   Henri-Bhargava A, 2008, NEUROLOGY, V71, P860, DOI 10.1212/01.wnl.0000325473.13088.18
   Hershko C, 2008, HAEMATOL-HEMATOL J, V93, P1761, DOI 10.3324/haematol.2008.000828
   HERTRAMPF E, 2001, ANN NUTR METAB, V45, P117
   Ince AT, 2008, DIGEST DIS SCI, V53, P1564, DOI 10.1007/s10620-007-0043-7
   *INT AN CONS GROUP, 1985, MEAS IR STAT
   International Zinc Nutrition Consultative Group, 2004, FOOD NUTR BULL, V25, pS91
   MANOHARAN PT, 1989, BIOCHEMISTRY-US, V28, P7148, DOI 10.1021/bi00444a003
   Mearin M Luisa, 2007, Curr Probl Pediatr Adolesc Health Care, V37, P86, DOI 10.1016/j.cppeds.2007.01.001
   *MIN SAL CHIL PUC, 2003, ENC NAC SAL CHIL 200
   OLIVARES M, 1990, ARCH LATINOAM NUTR, V40, P209
   Olivares M, 2000, EUR J CLIN NUTR, V54, P834, DOI 10.1038/sj.ejcn.1601099
   Oso O, 2006, ACTA PAEDIATR, V95, P618, DOI 10.1080/08035250500421576
   Puri Amrinder Singh, 2004, Indian Pediatr, V41, P822
   RODRIGUEZ A, 1985, ACTA PAEDIATR SCAND, V74, P770, DOI 10.1111/j.1651-2227.1985.tb10029.x
   *WHO, 1998, WHONUTNCD9811998
   World Health Organization, WHO CHILD GROWTH STA
   World Health Organization, 2001, WHONHD0132001
NR 41
TC 11
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD SEP
PY 2011
VL 53
IS 3
BP 265
EP 270
DI 10.1097/MPG.0b013e3181f988fc
PG 6
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 811WH
UT WOS:000294247000006
PM 21865972
ER

PT J
AU Sanad, M
   Osman, M
   Gharib, A
AF Sanad, Mohammed
   Osman, Mohammed
   Gharib, Amal
TI Obesity modulate serum hepcidin and treatment outcome of iron deficiency
   anemia in children: A case control study
SO ITALIAN JOURNAL OF PEDIATRICS
LA English
DT Article
DE Obesity; Hepcidin; Iron deficiency; Children
ID INSULIN-RESISTANCE; INFLAMMATION; EXPRESSION; PROTEIN; WOMEN;
   HYPOFERREMIA; ADOLESCENTS; ABSORPTION; MICE; ASSOCIATION
AB Background: Recently, hepcidin expression in adipose tissue has been described and shown to be increased in patients with severe obesity. We tried to assess the effect of obesity on hepcidin serum levels and treatment outcome of iron deficiency anemia in children.
   Methods: This was a case control study included 70 children with iron deficiency anemia "IDA" (35 obese and 35 non-obese) and 30 healthy non-obese children with comparable age and sex(control group). Parameters of iron status (Serum iron, ferritin, transferrin, total iron binding capacity and transferrin saturation) and serum hepcidin levels were assessed initially and after 3 months of oral iron therapy for IDA.
   Results: Compared to the control group, serum hepcidin was significantly lower in non-obese children with IDA(p < 0.01) and significantly higher in obese children with IDA (p < 0.01). Hepcidin increased significantly in non-obese children with IDA after 3 months of iron therapy (P < 0.01). On the other hand, obese children showed nonsignificant change in hepcidin level after iron therapy (p > 0.05). Although hepcidin showed significant positive correlations with Hb, serum iron and transferrin saturation in non-obese children with IDA, it showed significant negative correlations with Hb, serum iron and transferrin saturation in obese children with IDA (P < 0.05).
   Conclusions: Obesity increased hepcidin levels and was associated with diminished response to oral iron therapy in childhood iron deficiency anemia.
C1 [Sanad, Mohammed; Osman, Mohammed] Zagazig Univ, Dept Pediat, Fac Med, Zagazig, Egypt.
   [Gharib, Amal] Zagazig Univ, Dept Biochem, Fac Med, Zagazig, Egypt.
RP Sanad, M (reprint author), Zagazig Univ, Dept Pediat, Fac Med, Zagazig, Egypt.
EM zanad_zanad2005@yahoo.com
CR Ganz T, 2008, BLOOD, V112, P4292, DOI [10.1182/blood-2008-02-139915, 10.1182/blood-2008-02139915]
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Goswami T, 2006, J BIOL CHEM, V281, P28494, DOI 10.1074/jbc.C600197200
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   Kemna E, 2005, BLOOD, V106, P3268, DOI 10.1182/blood-2005-05-1873
   Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   FAILLA ML, 1988, J NUTR, V118, P46
   Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   Fitzsimons EJ, 2001, BRIT MED J, V322, P811, DOI 10.1136/bmj.322.7290.811
   Vokurka M, 2010, PHYSIOL RES, V59, P393
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   WENZEL BJ, 1962, LANCET, V2, P327
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102
   Whitfield JB, 2003, BRIT J HAEMATOL, V120, P860, DOI 10.1046/j.1365-2141.2003.04224.x
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Gillum RF, 2001, INT J OBESITY, V25, P639, DOI 10.1038/sj.ijo.0801561
   Metzgeroth G, 2005, EUR J HAEMATOL, V75, P309, DOI 10.1111/j.1600-0609.2005.00515.x
   Anty R, 2008, OBES SURG, V18, P709, DOI 10.1007/s11695-007-9276-y
   Cherian S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004030
   Greenberg AS, 2006, AM J CLIN NUTR, V83, p461S
   Haluzik M, 2004, PHYSIOL RES, V53, P123
   Lin L, 2005, BLOOD, V106, P2884, DOI 10.1182/blood-2005-05-1845
   Nemeth E., 2010, ADV HEMATOL, DOI DOI 10.1155/2010/750643
   Rogers JT, 1996, BLOOD, V87, P2525
   VERGA F, 2007, BLOOD, V109, P353, DOI DOI 10.1182/BL00D-2006-07-033969)
   Weizer-Stern O, 2006, BRIT J HAEMATOL, V135, P129, DOI 10.1111/j.1365-2141.2006.06258.x
NR 35
TC 18
Z9 18
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1720-8424
J9 ITAL J PEDIATR
JI Ital. J. Pediatr.
PD JUL 19
PY 2011
VL 37
AR 34
DI 10.1186/1824-7288-37-34
PG 6
WC Pediatrics
SC Pediatrics
GA 805BH
UT WOS:000293700700001
PM 21771327
ER

PT J
AU Herman, WA
   Lacka, K
   Kaufman, E
   Wojcicka, M
   Kramer, L
   Losy, J
AF Herman, W. A.
   Lacka, K.
   Kaufman, E.
   Wojcicka, M.
   Kramer, L.
   Losy, J.
TI The Associations Between IL-18 Serum Levels and the Prevalence of
   Metabolic Syndrome in Polish Men Over the Age of 40 According to Other
   Selected Inflammatory Indices and Androgens: Comparison of NCEP with IDF
   Criteria
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article
DE IL-18; metabolic syndrome; androgen deficiency; ageing men
ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; BODY-MASS INDEX;
   INTERLEUKIN-18 LEVELS; INSULIN-RESISTANCE; ADIPOSE-TISSUE;
   BLOOD-PRESSURE; WEIGHT-LOSS; RISK; OBESITY
AB Background: The frequency of MS increases with age and augments the cardiovascular risk. The criteria for distinguishing MS constantly evolve. The aim of the study was to estimate the reciprocal links between low-grade inflammation, selected serum androgens and prevalence of MS, according to NCEP and IDF criteria, in Polish men over the age of 40.
   Materials and Methods: A sample of 160 men was randomly selected from men at the age of 40, 50, 60 and 70, residing in the rural south-western region of Poland. IL-18 and CRP, transferrin, alpha(1)-antichymotrypsin, dehydroepiandrosterone and its sulfate as well as free-testosterone levels were evaluated.
   Results: The prevalence of MS was 37.5% using NCEP criteria and 46.25% employing IDF indices. Patients with MS diagnosed according to criteria proposed by NCEP and IDF exhibit a similar hormonal and immunological profile. Age was positively correlated with CRP (r = 0.231; p<0.0005), and alpha(1)-ACT (r = 0.191 p<0.05) and negatively with transferrin (r=-0.27; p<0.001), but not with IL-18 plasma levels. Both adrenal androgens were negatively correlated with age: DHEA r=-0.489; p<0.001 and DHEAS: r=-0.553; p<0.001 respectively, in contrast to free-testosterone. People suffering from MS have shown a significantly higher level of IL-18 and CRP. The number of MS components identified (according to NCEP) is positively correlated only with IL-18 serum levels (r=0.226; p=0.043).
   Conclusions: Inflammatory parameters were better than a deficit of androgens in identifying men suffering from MS. However, the best correlation with the number of MS components was revealed by IL-18 plasma levels.
C1 [Herman, W. A.] Outpatients Unit Endocrine Dis, Poznan, Poland.
   [Lacka, K.] Univ Med Sci, Dept Endocrinol Metab & Internal Med, Poznan, Poland.
   [Kaufman, E.; Wojcicka, M.; Losy, J.] Univ Med Sci, Dept Clin Neuroimmunol, Poznan, Poland.
   [Kramer, L.] Univ Med Sci, Dept Comp Sci & Stat, Poznan, Poland.
   [Losy, J.] Polish Acad Sci, Inst Expt & Clin Med, Neuroimmunol Unit, Poznan, Poland.
RP Herman, WA (reprint author), Outpatients Unit Endocrine Dis HERMED, Wolsztynska 21 A, PL-67400 Wschowa, Poland.
EM wherman@wschowa.com.pl
CR Brown CD, 2000, OBES RES, V8, P605, DOI 10.1038/oby.2000.79
   Skurk T, 2005, EUR J ENDOCRINOL, V152, P863, DOI 10.1530/eje.1.01897
   Chae CU, 2001, HYPERTENSION, V38, P399
   Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336
   Troseid M, 2009, DIABETES CARE, V32, P486, DOI 10.2337/dc08-1710
   Sugama S, 2008, BRAIN RES REV, V58, P85, DOI 10.1016/j.brainresrev.2007.11.003
   Blankenberg S, 2003, CIRCULATION, V108, P2453, DOI 10.1161/01.CIR.0000099509.76044.A2
   Olusi SO, 2003, HORM RES, V60, P29, DOI 10.1159/000070824
   Miles EA, 2008, ATHEROSCLEROSIS, V196, P298, DOI 10.1016/j.atherosclerosis.2006.11.002
   Zirlik A, 2007, ARTERIOSCL THROM VAS, V27, P2043, DOI 10.1161/ATVBAHA.107.149484
   NAKAMURA K, 1993, INFECT IMMUN, V61, P64
   Dinarello CA, 2007, SEMIN NEPHROL, V27, P98, DOI 10.1016/j.semnephrol.2006.09.013
   Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8
   Krogh-Madsen R, 2006, AM J PHYSIOL-ENDOC M, V291, pE108, DOI 10.1152/ajpendo.00471.2005
   Hung J, 2005, ARTERIOSCL THROM VAS, V25, P1268, DOI 10.1161/01.ATV.0000163843.70369.12
   Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7
   Thorand B, 2005, DIABETES, V54, P2932, DOI 10.2337/diabetes.54.10.2932
   Lechleitner M, 2008, GERONTOLOGY, V54, P253, DOI 10.1159/000161734
   Herder C, 2006, DIABETES CARE, V29, P174, DOI 10.2337/diacare.29.01.06.dc05-1963
   Bruun JM, 2007, EUR J ENDOCRINOL, V157, P465, DOI 10.1530/EJE-07-0206
   Kahn R, 2005, DIABETOLOGIA, V48, P1684, DOI 10.1007/s00125-005-1876-2
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Phillips AC, 2010, EUR J ENDOCRINOL, V162, P919, DOI 10.1530/EJE-09-1078
   Esposito K, 2002, J CLIN ENDOCR METAB, V87, P3864, DOI 10.1210/jc.2002-????
   Janssen I, 2002, ARCH INTERN MED, V162, P2074, DOI 10.1001/archinte.162.18.2074
   Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211
   Hemingway H, 2003, AM J CARDIOL, V92, P984, DOI 10.1016/S0002-9149(03)00985-8
   Berneis K, 2010, EUR J CLIN INVEST, V40, P54, DOI 10.1111/j.1365-2362.2009.02228.x
   Chapman CML, 2006, ATHEROSCLEROSIS, V189, P414, DOI 10.1016/j.atherosclerosis.2005.12.026
   CHEN YC, 2010, EUR J CLIN INVEST, V40, P22
   Grundy S.M., 2004, ARTERIOSCLER THROMB, V24, P13
   Hung J, 2008, HEART LUNG CIRC, V17, P90, DOI 10.1016/j.hlc.2007.07.002
   KOENIG W, 2006, ARTERIOSCLER THROMB, V26, P275
   Mamcarz A, 2010, KARDIOL POL, V68, P121
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   Ruotsalainen E, 2010, ATHEROSCLEROSIS, V210, P536, DOI 10.1016/j.atherosclerosis.2009.11.036
   STENHOLM S, 2009, CLIN ENDOCRINOL, V73, P55
   Tannenbaum C, 2004, EUR J ENDOCRINOL, V151, P717, DOI 10.1530/eje.0.1510717
   Welsh P, 2008, BRIT J HAEMATOL, V141, P852, DOI 10.1111/j.1365-2141.2008.07133.x
   2005, IDF CONSENSUS WORLDW
NR 40
TC 3
Z9 3
U1 0
U2 4
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0947-7349
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PD JUL
PY 2011
VL 119
IS 7
BP 423
EP 430
DI 10.1055/s-0030-1270467
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 817CX
UT WOS:000294649600007
PM 21264805
ER

PT J
AU Sanvisens, A
   Rivas, I
   Bolao, F
   Tor, J
   Roson, B
   Rey-Joly, C
   Muga, R
AF Sanvisens, Arantza
   Rivas, Inmaculada
   Bolao, Ferran
   Tor, Jordi
   Roson, Beatriz
   Rey-Joly, Celestino
   Muga, Roberto
TI Gender and liver, nutritional and metabolic alterations of severe
   alcoholism: a study of 480 patients
SO MEDICINA CLINICA
LA Spanish
DT Article
DE Alcoholism; Biomarkers; Comorbidity
ID HEPATITIS-C; ETHANOL; DISEASES; WOMEN; RISK; MEN
AB Background and objective: To analyze gender differences in the hepatic. nutritional and metabolic complications associated with alcoholism.
   Patients and methods: Cross-sectional study in alcoholic patients admitted to detoxification in two university hospitals of Barcelona between 1999 and 2006. During admission, co-morbidity prior to admission was assessed and blood samples to analyze biological markers were collected. Demographic and anthropometric data, daily alcohol consumption and other drug use characteristics were also obtained at admission.
   Results: There were 566 admissions in 480 patients (375 males). Age at admission was 43 years (IQR: 36.3-49.0 years). Overall, 68.4% showed macrocytosis (MCV > 95 fl), 81.7% GGT > 40 U/L and 57.7% AST > 37 U/L Regarding liver function tests, frequency of alkaline phosphatase > 120 U/L was significantly higher in women (18.5 vs 10.5%, p = 0.037). However, the prevalence of hyperferritinemia (> 90 ng/mL) was significantly higher in alcoholic men (85.7% vs 62.2%) (p = 0.000). Having multiple liver function test alterations was significantly higher in men (OR: 1.64, 95% CI: 1.01-2.65) (p = 0.043). Women showed significant differences regarding the prevalence of macrocytosis (77.5% vs 65.8%, p = 0.026), low serum creatinine (< 0.7 mg/100 mL) (28.2 vs 14.6%, p = 0.001), low serum ferritin (< 30 ng/mL) (10.8 vs 3.9%, p = 0.020), as well as of multiple nutritional alterations (OR: 1.59, 95% CI: 1.02-2.48) (p = 0.040). However, men had higher prevalence of anemia than women (32.3 vs 21.4%, p = 0.032). Prevalence of type I obesity (BMI > 30 kg/m(2)) was significantly higher in alcoholic women (29.2 vs 7.9%, p = 0.007).
   Conclusions: Hepatic, nutritional and metabolic complications of alcoholism in women are frequent, thus increasing the risk of developing adverse clinical outcomes. (C) 2010 Elsevier Espana, S.L. All rights reserved.
C1 [Sanvisens, Arantza; Rivas, Inmaculada; Tor, Jordi; Rey-Joly, Celestino; Muga, Roberto] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Serv Med Interna, E-08193 Barcelona, Spain.
   [Bolao, Ferran; Roson, Beatriz] Univ Autonoma Barcelona, Hosp Univ Bellvitge, Serv Med Interna, E-08193 Barcelona, Spain.
RP Sanvisens, A (reprint author), Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Serv Med Interna, E-08193 Barcelona, Spain.
EM asanvisens.igtp.germanstrias@gencat.cat
OI Muga, Roberto/0000-0001-6301-431X; Sanvisens,
   Arantza/0000-0001-6269-5491
CR RANDALL B, 1980, HUM PATHOL, V11, P147
   FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205
   Li TK, 2001, ALCOHOL CLIN EXP RES, V25, P136, DOI 10.1111/j.1530-0277.2001.tb02138.x
   Killip S, 2007, AM FAM PHYSICIAN, V75, P671
   Singal AK, 2007, J CLIN GASTROENTEROL, V41, P761, DOI 10.1097/MCG.0b013e3180381584
   Alte D, 2004, ALCOHOL CLIN EXP RES, V28, P931, DOI 10.1097/01.ALC.0000128383.34605.16
   Zakhari S, 2007, HEPATOLOGY, V46, P2032, DOI 10.1002/hep.22010
   ESTRUCH R, 1993, ALCOHOL ALCOHOLISM, V28, P543
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Niemela O, 2007, CLIN CHIM ACTA, V377, P39, DOI 10.1016/j.cca.2006.08.035
   CHALMERS I, 1978, BRIT MED J, V6145, P1119
   De la Feunte J. R., 1992, AUDIT ALCOHOL USE DI
   EDENBERG HJ, 2007, ALCOHOL RES HEALTH, V1, P5
   EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905
   Gual A, 1999, ALCOHOL ALCOHOLISM, V34, P183, DOI 10.1093/alcalc/34.2.183
   GUAL A, 2004, MED CLIN-BARCELONA, V10, P364
   JOSEPH H, 1985, AM J DRUG ALCOHOL AB, V11, P37, DOI 10.3109/00952998509016848
   LEE MH, 1995, AM J MED, V98, P566, DOI 10.1016/S0002-9343(99)80015-1
   LIEBER CS, 2005, CLIN LIVER DIS, V1, P1
   LIEBER CS, 1984, ALCOHOL CLIN EXP RES, V8, P409, DOI 10.1111/j.1530-0277.1984.tb05689.x
   Lieber CS, 2000, ALCOHOL CLIN EXP RES, V24, P417
   LIEBER CS, 1991, AM J CLIN NUTR, V54, P976
   LIEBER CS, 1995, NEW ENGL J MED, V333, P1058
   MEZEY E, 1984, METABOLISM NUTR LIVE, P5
   *MIN SAN CONS, ENC NAC SAL ESP
   Monras M, 2003, MED CLIN-BARCELONA, V121, P733
   Moroney Joan T, 2002, Adv Neurol, V90, P295
   Müller Christian, 2006, Wien Med Wochenschr, V156, P523, DOI 10.1007/s10354-006-0348-8
   URBANOMARQUEZ A, 1995, JAMA-J AM MED ASSOC, V274, P149, DOI 10.1001/jama.274.2.149
   WARNET JM, 1984, CAN J PUBLIC HLTH, V4, P285
   2008, PLAN NACL DROGAS INF
NR 31
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER DOYMA SL
PI BARCELONA
PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN
SN 0025-7753
J9 MED CLIN-BARCELONA
JI Med. Clin.
PD JUN 18
PY 2011
VL 137
IS 2
BP 49
EP 54
DI 10.1016/j.medcli.2010.11.030
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 779FH
UT WOS:000291763000001
PM 21419462
ER

PT J
AU Fracanzani, AL
   Valenti, L
   Bugianesi, E
   Vanni, E
   Grieco, A
   Miele, L
   Consonni, D
   Fatta, E
   Lombardi, R
   Marchesini, G
   Fargion, S
AF Fracanzani, Anna Ludovica
   Valenti, Luca
   Bugianesi, Elisabetta
   Vanni, Ester
   Grieco, Antonio
   Miele, Luca
   Consonni, Dario
   Fatta, Erika
   Lombardi, Rosa
   Marchesini, Giulio
   Fargion, Silvia
TI Risk of nonalcoholic steatohepatitis and fibrosis in patients with
   nonalcoholic fatty liver disease and low visceral adiposity
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE NASH; Waist circumference; NAFLD; Abdominal obesity; Glucose metabolism
ID WAIST CIRCUMFERENCE; METABOLIC SYNDROME; INSULIN-RESISTANCE; NONINVASIVE
   MARKERS; ABDOMINAL OBESITY; POPULATION; NAFLD; THICKNESS; VARIANTS;
   SEVERITY
AB Background & Aims: Increased visceral adiposity is considered the hallmark of the metabolic syndrome, whose hepatic manifestation is nonalcoholic fatty liver disease (NAFLD), although a subset of patients does not have visceral obesity. Our study aimed to compare metabolic alterations and liver damage in patients with NAFLD with and without visceral obesity.
   Methods: Four hundred and thirty one consecutive patients with liver biopsy-confirmed NAFLD were divided in three groups according to waist circumference, the simplest surrogate marker of visceral obesity. One hundred and thirty three patients (31%) had a waist circumference <= 94 (males) and <= 80 cm (females) (group A), 157 (36%) between 94 and 102, and 80 and 88 (B), and the remaining 141(33%) had values higher than 102 and 88 cm (C).
   Results: Significant trends for older age, higher prevalence of female gender, lower HDL, higher triglycerides, altered glucose metabolism, hypertension, and metabolic syndrome were observed with increasing visceral adiposity. In contrast, non-alcoholic steato-hepatitis (NASH) detected in 55% and 72% of patients with normal and increased waist circumference, respectively, and the presence of fibrosis >= 2 were not associated with visceral adiposity. Alanine aminotransferase (ALT), ferritin, HOMA-IR >4, and severe steatosis were independently associated with NASH, whereas ferritin and impaired glucose tolerance were associated with fibrosis >= 2.
   Conclusions: Patients with normal waist circumference, despite milder metabolic alterations, may have NASH and are at risk of developing fibrosis, suggesting that once NAFLD is present, visceral obesity is not a major determinant of liver damage severity. (C) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 [Fracanzani, Anna Ludovica; Valenti, Luca; Fatta, Erika; Lombardi, Rosa; Fargion, Silvia] Univ Milan, Dipartimento Med Interna, Ctr Malattie Metabol Fegato, Osped Maggiore Policlin,IRCCS,Fdn Ca Granda, Milan, Italy.
   [Bugianesi, Elisabetta; Vanni, Ester] Univ Turin, Unita Gastroenterol, Osped S Giovanni Battista, Turin, Italy.
   [Grieco, Antonio; Miele, Luca] Univ Cattolica, Dipartimento Med Interna, Rome, Italy.
   [Consonni, Dario] Univ Milan, Unita Epidemiol, Osped Maggiore Policlin, IRCCS,Fdn Ca Granda, Milan, Italy.
   [Marchesini, Giulio] Univ Alma Mater Studiorum, Dipartimento Med Interna, Bologna, Italy.
RP Fargion, S (reprint author), Fdn Osped Policlin IRCCS, Dipartimento Med Interna, Via F Sforza 35, I-20122 Milan, Italy.
EM silvia.fargion@unimi.it
RI Valenti, Luca/B-3695-2009; Miele, Luca/C-2255-2015; 
OI Valenti, Luca/0000-0001-8909-0345; Miele, Luca/0000-0003-3464-0068;
   Fracanzani, Anna Ludovica/0000-0001-5918-0171
FU FIRST Universita di Milano; Ricerca Corrente Ospedale Maggiore
   Policlinico; Centro Studi Malattie Metaboliche del Fegato; European
   Community [HEALTH-F2-2009-241762]
FX The work was supported by the following grants:; FIRST Universita di
   Milano 2007-2008 (ALF, SF) Ricerca Corrente Ospedale Maggiore
   Policlinico 2006-2008 and Centro Studi Malattie Metaboliche del Fegato.;
   European Community's Seventh Framework Programme (FP7/2007-2013) under
   grant agreement No. HEALTH-F2-2009-241762 for the project "Fatty Liver:
   Inhibition of Progression" (FLIP) (EB, GM).
CR Adams Leon A, 2007, Clin Liver Dis, V11, P25, DOI 10.1016/j.cld.2007.02.004
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kim HJ, 2004, ARCH INTERN MED, V164, P2169, DOI 10.1001/archinte.164.19.2169
   Westerbacka J, 2007, DIABETES, V56, P2759, DOI 10.2337/db07-0156
   Konishi M, 2010, ATHEROSCLEROSIS, V209, P573, DOI 10.1016/j.atherosclerosis.2009.10.008
   Bosy-Westphal A, 2010, J NUTR, V140, P954, DOI 10.3945/jn.109.118737
   Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
   Guldiken S, 2006, INT J CLIN PRACT, V60, P1576, DOI 10.1111/j.1742-1241.2005.00803.x
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   Wasada T, 2008, METABOLISM, V57, P980, DOI 10.1016/j.metabol.2008.02.015
   Dongiovanni P, 2010, GUT, V59, P267, DOI 10.1136/gut.2009.190801
   Lear SA, 2007, OBESITY, V15, P2817, DOI 10.1038/oby.2007.334
   Mathurin P, 2009, GASTROENTEROLOGY, V137, P532, DOI 10.1053/j.gastro.2009.04.052
   Valenti L, 2008, DIABETES, V57, P1355, DOI [10.2337/db07-0714, 10.2337/dbO7-0714]
   Guha IN, 2008, HEPATOLOGY, V47, P455, DOI 10.1002/hep.21984
   Despres JP, 2008, ARTERIOSCL THROM VAS, V28, P1039, DOI 10.1161/ATVBAHA.107.159228
   Das K, 2010, HEPATOLOGY, V51, P1593, DOI 10.1002/hep.23567
   Nelson JE, 2007, HEPATOLOGY, V46, P723, DOI 10.1002/hep.21742
   Lirussi F, 2009, J GASTROINTEST LIVER, V18, P61
   Valenti L, 2010, HEPATOLOGY, V51, P1209, DOI 10.1002/hep.23622
   Gastaldelli A, 2009, HEPATOLOGY, V50, P1087, DOI 10.1002/hep.23116
   Fracanzani AL, 2008, HEPATOLOGY, V48, P792, DOI 10.1002/hep.22429
   Carter-Kent C, 2009, HEPATOLOGY, V50, P1113, DOI 10.1002/hep.23133
   Stepanova M, 2010, ALIMENT PHARM THER, V31, P1085, DOI 10.1111/j.1365-2036.2010.04266.x
   Cheung O, 2007, HEPATOLOGY, V46, P1091, DOI 10.1002/hep.21803
   Karelis AD, 2004, J CLIN ENDOCR METAB, V89, P2569, DOI 10.1210/jc.2004-0165
   Petersen KF, 2010, NEW ENGL J MED, V362, P1082, DOI 10.1056/NEJMoa0907295
   Malaguarnera M, 2009, J MOL MED-JMM, V87, P679, DOI 10.1007/s00109-009-0464-1
   Adams LA, 2009, AM J GASTROENTEROL, V104, P861, DOI 10.1038/ajg.2009.67
   Haffner SM, 1997, DIABETES CARE, V20, P1087, DOI 10.2337/diacare.20.7.1087
   Manco M, 2008, GUT, V57, P1283, DOI 10.1136/gut.2007.142919
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Rocha R, 2005, J HUM NUTR DIET, V18, P365, DOI 10.1111/j.1365-277X.2005.00634.x
   Alberti KGMM, 2007, DIABETIC MED, V24, P451, DOI 10.1111/j.1464-5491.2007.02157.x
   Valenti L, 2010, GASTROENTEROLOGY, V138, P905, DOI 10.1053/j.gastro.2009.11.013
   Farrell GC, 2009, J GASTROEN HEPATOL, V24, pS105, DOI 10.1111/j.1440-1746.2009.06080.x
   Guha IN, 2006, GUT, V55, P1650, DOI 10.1136/gut.2006.091454
   Gus M, 2009, NUTR METAB CARDIOVAS, V19, P15, DOI 10.1016/j.numecd.2008.03.007
   NOBILI V, 2009, BMC MED, V1, P7
   Rubio A, 2007, J HEPATOL, V46, P708, DOI 10.1016/j.jhep.2006.10.021
   StataCorp, 2009, STAT REL 11 STAT SOF
NR 41
TC 23
Z9 23
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD JUN
PY 2011
VL 54
IS 6
BP 1244
EP 1249
DI 10.1016/j.jhep.2010.09.037
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 776GR
UT WOS:000291523000023
PM 21145841
ER

PT J
AU Arsenault, JE
   Mora-Plazas, M
   Forero, Y
   Lopez-Arana, S
   Jauregui, G
   Baylin, A
   Gordon, PM
   Villamor, E
AF Arsenault, Joanne E.
   Mora-Plazas, Mercedes
   Forero, Yibby
   Lopez-Arana, Sandra
   Jauregui, German
   Baylin, Ana
   Gordon, Paul M.
   Villamor, Eduardo
TI Micronutrient and anthropometric status indicators are associated with
   physical fitness in Colombian schoolchildren
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Anaerobic performance; Micronutrients; Stunting; Overweight
ID DISEASE RISK-FACTORS; SCHOOL-AGE-CHILDREN; INTERNATIONAL SURVEY;
   HOMOCYSTEINE LEVELS; AEROBIC FITNESS; ADOLESCENTS; OVERWEIGHT;
   PERFORMANCE; GROWTH; IRON
AB Poor physical fitness is associated with increased health-related risks in children. The association of nutritional status indicators and physical fitness in children residing in developing countries is not well characterised. We conducted a cross-sectional study among 1945 children of age 5-12 years in Bogota, Colombia, to assess whether anthropometric and micronutrient status indicators were associated with performance in the shuttle run and standing long jump tests. Stunted children scored significantly lower in the run (0.4 s; P=0.0002) and jump (6 cm; boys only; P=0.003) tests than non-stunted children, after adjustment for age and other factors. Children who were thin, overweight or obese ran slower than normal-weight children (P<0.01). Lower jump scores were associated with overweight or obesity and greater arm fat area in boys only (P<0.0001). Girls with low ferritin concentrations ran 0.6 s slower than girls with normal ferritin concentrations (P=0.02). Erythrocyte folate concentrations were linearly related to higher run (P<0.0001) and long jump scores (P=0.0001). Boys with marginal or low vitamin B-12 status had 4 cm lower long jump scores than children with normal status (P=0.01). Suboptimal anthropometric and micronutrient status are related to poorer performance in fitness tests. The effects of improving nutritional status on physical fitness of children warrant investigation.
C1 [Arsenault, Joanne E.; Villamor, Eduardo] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Mora-Plazas, Mercedes; Lopez-Arana, Sandra] Univ Nacl Colombia, Dept Nutr, Bogota, Colombia.
   [Forero, Yibby] Natl Inst Hlth, Nutr Grp, Bogota, Colombia.
   [Jauregui, German] INCCA Univ Colombia, Dept Phys Educ, Bogota, Colombia.
   [Baylin, Ana; Villamor, Eduardo] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Gordon, Paul M.] Univ Michigan, Lab Phys Activ & Exercise Intervent Res, Ann Arbor, MI 48109 USA.
   [Villamor, Eduardo] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
RP Villamor, E (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM villamor@umich.edu
FU Secretary of Education of Bogota; David Rockefeller Center for Latin
   American Studies at Harvard University; National University of Colombia;
   National Institute of Health of Colombia; National Institutes of Health
   [T32DK07703]
FX The present study was supported by the Secretary of Education of Bogota,
   the David Rockefeller Center for Latin American Studies at Harvard
   University, the National University of Colombia and the National
   Institute of Health of Colombia. J. E. A. was supported by training
   grant T32DK07703 from the National Institutes of Health. None of the
   authors has any conflicts of interest. The authors' contributions were
   as follows: J. E. A. was involved in the data analyses, interpretation
   of the results and writing of the first draft of the manuscript; M.
   M.-P. contributed to the study design and implementation of tests in the
   field; Y. F. contributed to the study implementation and laboratory
   analyses; S. L.-A. contributed to the study implementation and data
   management; G. J. was responsible for the implementation of physical
   performance tests in the field; A. B. participated in the study design
   and interpretation of the data; P. M. G. contributed to the
   interpretation of the data; E. V. contributed to the study design, data
   analyses, interpretation of the results and preparation of the
   manuscript. All authors critically reviewed the manuscript.
CR Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140-6736(07)61235-5
   Arsenault JE, 2009, J NUTR, V139, P1744, DOI 10.3945/jn.109.108662
   Hinton PS, 2000, J APPL PHYSIOL, V88, P1103
   Sallis JF, 2000, MED SCI SPORT EXER, V32, P963
   Cole TJ, 2000, P NUTR SOC, V59, P317, DOI 10.1017/S0029665100000355
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Doak CM, 2000, J NUTR, V130, P2965
   Twisk JWR, 2002, INT J SPORTS MED, V23, pS8
   ROWLAND TW, 1988, AM J DIS CHILD, V142, P165
   Deforche B, 2003, EUR J PEDIATR, V162, P616, DOI 10.1007/s00431-003-1247-2
   McDonald CM, 2009, J NUTR, V139, P370, DOI 10.3945/jn.108.098111
   Tomkinson GR, 2007, SCAND J MED SCI SPOR, V17, P497, DOI 10.1111/j.1600-0838.2006.00569.x
   Dekker LH, 2010, FOOD NUTR BULL, V31, P242
   Cole TJ, 2007, BRIT MED J, V335, P194, DOI 10.1136/bmj.39238.399444.55
   Konig D, 2003, ANN NUTR METAB, V47, P114, DOI 10.1159/000070032
   Jones KM, 2007, J NUTR, V137, P1307
   MATTER M, 1987, CLIN SCI, V72, P415
   Malina RM, 2006, FOOD NUTR BULL, V27, pS295
   Benefice E, 1999, ANN HUM BIOL, V26, P443, DOI 10.1080/030144699282561
   Cleland V, 2008, INT J OBESITY, V32, P1685, DOI 10.1038/ijo.2008.171
   Dao HH, 2004, INT J OBESITY, V28, P870, DOI 10.1038/sj.ijo.0802535
   Prista A, 2003, AM J CLIN NUTR, V77, P952
   Arsenault JE, 2009, EUR J CLIN NUTR, V63, P842, DOI 10.1038/ejcn.2008.50
   Beard J., 2000, AM J CLIN NUTR, V72, p594S
   Bovet P, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-24
   Cairney J, 2008, AM J HUM BIOL, V20, P132, DOI 10.1002/ajhb.20690
   Council of Europe Committee for the Development of Sport, 1988, EUROFIT EUR TEST PHY
   DAVIES BN, 1990, EUR J APPL PHYSIOL O, V60, P139, DOI 10.1007/BF00846034
   Duran P, 2006, FOOD NUTR BULL, V27, P300
   Food and Nutrition Board - Institute of Medicine, 1998, DIET REF INT THIAM R
   Froberg K, 2005, INT J OBESITY, V29, pS34, DOI 10.1038/sj.ijo.0803096
   Gibson R., 2005, PRINCIPLES NUTR ASSE
   Knopfli BH, 2008, J ADOLESCENT HEALTH, V42, P119, DOI 10.1016/j.jadohealth.2007.08.015
   Lohman TG, 1988, ANTHROPOMETRIC STAND
   MALINA RM, 1995, OBES RES, V3, P221
   Maslova E, 2009, FOOD NUTR BULL, V30, P103
   MONTOYE HJ, 1955, J APPL PHYSIOL, V7, P589
   NESTLE P, 2002, ADJUSTING HEMOGLOBIN
   Ruiz JR, 2007, ARCH PEDIAT ADOL MED, V161, P166, DOI 10.1001/archpedi.161.2.166
   SOLON FS, 2003, FOOD NUTR B S4, V4, pS129
   TIN-MAY-THAN, 1978, British Journal of Nutrition, V40, P269, DOI 10.1079/BJN19780122
   Tomkinson Grant R, 2007, Med Sport Sci, V50, P46
   World Health Organization, 1983, MEAS CHANG NUTR STAT
NR 43
TC 2
Z9 2
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUN
PY 2011
VL 105
IS 12
BP 1832
EP 1842
DI 10.1017/S0007114510005647
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 782CH
UT WOS:000291984700017
PM 21281544
ER

PT J
AU Broderstad, AR
   Melhus, M
   Brustad, M
   Lund, E
AF Broderstad, Ann R.
   Melhus, Marita
   Brustad, Magritt
   Lund, Eiliv
TI Iron stores in relation to dietary patterns in a multiethnic population:
   the SAMINOR study
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Ferritin; Iron status; Traditional food; SAMINOR
ID C-REACTIVE PROTEIN; AGED 40-70 YEARS; METABOLIC SYNDROME;
   BLOOD-DONATION; NORWEGIAN POPULATIONS; INSULIN-RESISTANCE; SERUM
   FERRITIN; ALCOHOL INTAKE; LIFE-STYLE; PREVALENCE
AB Objective: We evaluated the association between serum ferritin (s-ferritin), transferrin saturation and dietary patterns, in connection with ethnicity, geographical settlement and lifestyle factors.
   Design: In 2003-2004, a cross-sectional study of health and living conditions was carried out in northern Norway.
   Setting: A questionnaire explored, among other factors, ethnicity and food consumption habits. Principal component analysis was used to assess the association between variables. Seven principal components were then used as input to a cluster analysis. To characterise food consumptions, five dietary patterns were identified and used to assess the effect of food consumption habits on Fe stores.
   Subjects: A total of 16 323 men and women between the ages of 36 and 79 years participated.
   Results: Participants who frequently consumed reindeer meat had higher levels of s-ferritin (P<0.0001) than did individuals with other dietary patterns. This pattern was highly represented by subjects with three generations of Sami language (Sami I). Further, mean transferrin saturation in the reindeer group was higher compared with the other dietary clusters for men (P<0.04) and women (P<0.02). However, the reindeer pattern individuals also had the highest proportion of subjects with overweight and obesity. Obesity was positively associated with s-ferritin in both men and women (P<0.0001).
   Conclusions: The differences in Fe status described earlier between inland Sami and non-Sami can be explained by several factors such as food habits, age and obesity. High level of s-ferritin may reflect high intake of reindeer meat. Being overweight and obese is also associated with s-ferritin levels.
C1 [Broderstad, Ann R.; Melhus, Marita; Brustad, Magritt; Lund, Eiliv] Univ Tromso, Ctr Sami Hlth Res, Inst Community Med, Fac Hlth Sci, N-9037 Tromso, Norway.
RP Broderstad, AR (reprint author), Univ Tromso, Ctr Sami Hlth Res, Inst Community Med, Fac Hlth Sci, N-9037 Tromso, Norway.
EM Ann.Ragnhild.Broderstad@uit.no
FU Norwegian Ministry of Health
FX Funding for this project was provided by the Norwegian Ministry of
   Health. The authors have no conflict of interest to declare. E. L. and
   A. R. B. designed and conducted the research; A. R. B. and M. M.
   analysed the data; A. R. B., M. B., M. M. and E. L. wrote the paper; A.
   R. B. had primary responsibility for the final content. All authors read
   and approved the final manuscript. The authors are indebted to the
   participants in the SAMINOR study who made this research possible. They
   also thank the staff at the Department of Clinical Chemistry, University
   Hospital of Northern Norway, for technical assistance and careful
   evaluation of the blood tests.
CR Broderstad AR, 2007, EUR J HAEMATOL, V79, P447, DOI 10.1111/j.1600-0609.2007.00929.x
   Jacques PF, 2001, AM J CLIN NUTR, V73, P1
   Newby PK, 2004, NUTR REV, V62, P177, DOI [10.1301/rn.2004.may.177-203, 10.1301/nr.2004.may.177-203]
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   Gonzalez AS, 2006, EUR J CLIN NUTR, V60, P802, DOI 10.1038/sj.ejcn.1602384
   Wilsgaard T, 2007, DIABETES RES CLIN PR, V78, P217, DOI 10.1016/j.diabres.2007.03.006
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Forouhi NG, 2007, DIABETOLOGIA, V50, P949, DOI 10.1007/s00125-007-0604-5
   Mainous AG, 2004, AM J CARDIOL, V93, P559, DOI 10.1016/j.amjcard.2003.11.018
   Whitfield JB, 2003, BRIT J HAEMATOL, V120, P860, DOI 10.1046/j.1365-2141.2003.04224.x
   Hjartaker A, 1998, EUR J CLIN NUTR, V52, P565, DOI 10.1038/sj.ejcn.1600608
   Kuhnlein HV, 2004, J NUTR, V134, P1447
   Aubert Vilhelm, 1978, SAMISKE BEFOLKNING N
   BRUSTAD M, 2007, PUBLIC HEALTH NUTR, V5, P1
   BRUSTAD M, 2008, INT J CIRCUMPOL HEAL, V67, P1
   Johansson L., 1997, Scandinavian Journal of Nutrition, V41, P63
   LUND E, 2007, INT J CIRCUMPOL HEAL, V66, P89
   Milman N, 2000, ANN HEMATOL, V79, P612, DOI 10.1007/s002770000209
   Milman N, 1999, ANN HEMATOL, V78, P393, DOI 10.1007/s002770050537
   Milman N, 2001, EUR J HAEMATOL, V66, P115, DOI 10.1034/j.1600-0609.2001.00312.x
   Milman N, 1996, INT J HEMATOL, V63, P103
   Nilsen H, 1999, Int J Circumpolar Health, V58, P120
   Njolstad I, 1998, EPIDEMIOLOGY, V9, P550, DOI 10.1097/00001648-199809000-00014
   Nystad T, 2010, SCAND J PUBLIC HEALT, V38, P17, DOI 10.1177/1403494809354791
   Nystad T, 2010, PUBLIC HEALTH NUTR, V13, P1818, DOI 10.1017/S1368980010000376
   Skikne B, 1994, IRON METABOLISM HLTH, P151
   The Norwegian Food Safety Authority, 2006, NORW FOOD COMP TABL
   WHO, 2000, WHO TECHN REP SER, V894
   World Health Organization/UNICEF/United Nations University, 2001, WHONHD013
NR 29
TC 4
Z9 4
U1 4
U2 6
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD JUN
PY 2011
VL 14
IS 6
BP 1039
EP 1046
DI 10.1017/S1368980010003289
PG 8
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 763CF
UT WOS:000290530400015
PM 21208473
ER

PT J
AU Manousou, P
   Kalambokis, G
   Grillo, F
   Watkins, J
   Xirouchakis, E
   Pleguezuelo, M
   Leandro, G
   Arvaniti, V
   Germani, G
   Patch, D
   Calvaruso, V
   Mikhailidis, DP
   Dhillon, AP
   Burroughs, AK
AF Manousou, Pinelopi
   Kalambokis, George
   Grillo, Federica
   Watkins, Jennifer
   Xirouchakis, Elias
   Pleguezuelo, Maria
   Leandro, Gioacchino
   Arvaniti, Vasiliki
   Germani, Giacomo
   Patch, David
   Calvaruso, Vincenza
   Mikhailidis, Dimitri P.
   Dhillon, Amar P.
   Burroughs, Andrew K.
TI Serum ferritin is a discriminant marker for both fibrosis and
   inflammation in histologically proven non-alcoholic fatty liver disease
   patients
SO LIVER INTERNATIONAL
LA English
DT Article
DE ferritin; fibrosis; inflammation; NAFLD; NASH
ID INSULIN-RESISTANCE SYNDROME; NATURAL-HISTORY; HEPATOCELLULAR-CARCINOMA;
   AMINOTRANSFERASE LEVELS; CRYPTOGENIC CIRRHOSIS; MAJOR DETERMINANTS;
   METABOLIC SYNDROME; SCORING SYSTEM; IRON OVERLOAD; RISK-FACTORS
AB Introduction: Differentiation between steatosis and non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver disease (NAFLD) is important as NASH progress to cirrhosis. No specific laboratory/imaging technique exists either to diagnose NASH or to select patients for liver biopsy. Patients and methods: We evaluated serum ferritin and the features of metabolic syndrome with respect to histological inflammation and/or fibrosis in NAFLD patients. The Kleiner scoring system was used to classify NAFLD in consecutive liver biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity 62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia 40%. Results: Histologically, 40.7 had fatty liver, 30.6% had borderline NASH, 28.7% had NASH and 11% had cirrhosis. Multivariate regression showed that diabetes, serum ferritin concentrations, body mass index (BMI) and AST were independently associated with NASH: together, the areas under the receiver operating characteristic (AUROC) was 0.91 (95% confidence interval 0.86-0.96); fibrosis was associated with ferritin concentrations and BMI: AUROC 0.87, portal inflammation with ferritin and DM: AUROC 0.82, while lobular inflammation was associated with BMI, DM and ferritin: AUROC 0.85. Conclusion: Serum ferritin concentrations and BMI are strongly associated with fibrosis, portal and lobular inflammation in NAFLD patients. Both ferritin and BMI are potential discriminant markers to select patients for liver biopsy and are associated with inflammation and fibrosis.
C1 [Manousou, Pinelopi; Kalambokis, George; Xirouchakis, Elias; Pleguezuelo, Maria; Leandro, Gioacchino; Arvaniti, Vasiliki; Germani, Giacomo; Patch, David; Calvaruso, Vincenza; Burroughs, Andrew K.] UCL, Royal Free Sheila Sherlock Liver Ctr, Div Surg & Intervent Sci, London NW3 2QG, England.
   [Grillo, Federica; Watkins, Jennifer; Dhillon, Amar P.] Royal Free Hosp, Dept Histopathol, London NW3 2QG, England.
   [Mikhailidis, Dimitri P.] Royal Free Hosp, Dept Clin Biochem, London NW3 2QG, England.
RP Burroughs, AK (reprint author), UCL, Royal Free Sheila Sherlock Liver Ctr, Div Surg & Intervent Sci, Pond St, London NW3 2QG, England.
EM andrew.burroughs@royalfree.nhs.uk
RI Burroughs, Andrew/C-5645-2009; Germani, Giacomo/D-7140-2011;
   Mikhailidis, Dimitri/A-1869-2013; 
OI Burroughs, Andrew/0000-0001-6527-457X; Leandro,
   Gioacchino/0000-0001-6624-4532; Calvaruso, Vincenza/0000-0002-0287-1059
CR Brunt EM, 2001, SEMIN LIVER DIS, V21, P3, DOI 10.1055/s-2001-12925
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Turlin B, 2001, AM J CLIN PATHOL, V116, P263
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168
   Skelly MM, 2001, J HEPATOL, V35, P195, DOI 10.1016/S0168-8278(01)00094-0
   Loguercio C, 2004, DIGEST LIVER DIS, V36, P398, DOI 10.1016/j.dld.2004.01.022
   BACON BR, 1994, GASTROENTEROLOGY, V107, P1103
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/hep.1840120505
   Ludwig J, 1997, J GASTROEN HEPATOL, V12, P398, DOI 10.1111/j.1440-1746.1997.tb00450.x
   Lonardo A, 1997, ITAL J GASTROENTEROL, V29, P351
   Bugianesi E, 2006, HEPATOLOGY, V44, P1648, DOI 10.1002/hep.21429
   Tsochatzis E, 2006, AM J GASTROENTEROL, V101, P2629, DOI 10.1111/j.1572-0241.2006.00848.x
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1016/0270-9139(95)90196-5
   George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2
   Albano E, 2005, GUT, V54, P987, DOI 10.1136/gut.2004.057968
   Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844
   Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984
   Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604
   Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
   Harrison SA, 2008, GUT, V57, P1441, DOI 10.1136/gut.2007.146019
   Fracanzani AL, 2008, HEPATOLOGY, V48, P792, DOI 10.1002/hep.22429
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Brunt EM, 2005, HEPATOL RES, V33, P68, DOI 10.1016/j.hepres.2005.09.006
   Bonkovsky HL, 1999, J HEPATOL, V31, P421, DOI 10.1016/S0168-8278(99)80032-4
   Chitturi S, 2002, HEPATOLOGY, V35, P373, DOI 10.1053/jhep.2002.30692
   Prati D, 2002, ANN INTERN MED, V137, P1
   LUDWIG J, 1980, MAYO CLIN PROC, V55, P434
   Bugianesi E, 2004, HEPATOLOGY, V39, P179, DOI 10.1002/hep.20023
   Hsiao TJ, 2004, INT J OBESITY, V28, P167, DOI 10.1038/sj.ijo.0802519
   BELL H, 1994, J INTERN MED, V236, P315
   Wieckowska A, 2007, HEPATOLOGY, V46, P582, DOI 10.1002/hep.21768
   James OFW, 1998, J HEPATOL, V29, P495, DOI 10.1016/S0168-8278(98)80073-1
   Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5
   Bedogni G, 2007, HEPATOLOGY, V46, P1387, DOI 10.1002/hep.21827
   Ratziu V, 2002, HEPATOLOGY, V35, P1485, DOI 10.1053/jhep.2002.33324
   Garcia-Monzon C, 2000, J HEPATOL, V33, P716, DOI 10.1016/S0168-8278(00)80301-3
   Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62
   Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540
   Zelber-Sagi S, 2007, J HEPATOL, V46, P700, DOI 10.1016/j.jhep.2006.09.018
   Fargion S, 2001, AM J GASTROENTEROL, V96, P2448
   Canbakan B, 2007, ACTA GASTRO-ENT BELG, V70, P277
   Chavez-Tapia NC, 2008, GUT, V57, P1351, DOI 10.1136/gut.2008.154435
   de Ledinghen V, 2004, EUR J GASTROEN HEPAT, V16, P879
   FIERBINTEANUBRA.C, 2002, J INTERN MED, V40, P81
   Giostra Emiliano, 2007, Rev Med Suisse, V3, P1939
   ITOH S, 1987, AM J GASTROENTEROL, V82, P650
   Koruk Mehmet, 2003, Turk J Gastroenterol, V14, P12
   Moon Joon Ho, 2006, Korean J Gastroenterol, V47, P432
   Shimada M, 2002, HEPATOL RES, V24, P429, DOI 10.1016/S1386-6346(02)00246-2
   SIBILLE JC, 1988, HEPATOLOGY, V8, P296, DOI 10.1002/hep.1840080218
   Turnbull AJ, 1997, QJM-MON J ASSOC PHYS, V90, P271, DOI 10.1093/qjmed/90.4.271
   Yajima Yosiaki, 2006, Nihon Shokakibyo Gakkai Zasshi, V103, P515
NR 55
TC 31
Z9 32
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
PD MAY
PY 2011
VL 31
IS 5
BP 730
EP 739
DI 10.1111/j.1478-3231.2011.02488.x
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 745HY
UT WOS:000289157700018
PM 21457446
ER

PT J
AU Przybyszewska, J
   Zekanowska, E
   Kedziora-Kornatowska, K
   Boinska, J
   Cichon, R
   Porzych, K
AF Przybyszewska, J.
   Zekanowska, E.
   Kedziora-Kornatowska, K.
   Boinska, J.
   Cichon, R.
   Porzych, K.
TI PROHEPCIDIN AND IRON METABOLISM PARAMETERS IN THE OBESE ELDERLY PATIENTS
   WITH ANEMIA
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Prohepcidin; obesity; iron metabolism; anemia; elderly
ID REGULATORY PEPTIDE HEPCIDIN; ANTIMICROBIAL ACTIVITY; DEFICIENCY;
   INFLAMMATION; EXPRESSION; HYPOXIA; CHILDREN; WOMEN; MICE; HYPOFERREMIA
AB Objective: To examine the impact of a body fat content on the concentration of a serum prohepcidin, iron metabolism parameters and inflammation markers in elderly patients with microcytic or normocytic anemia. Design: Clinical study with biochemical and anthropometric measurements. Subjects: Fifty two elderly patients (19 male, 33 female) with anemia, 65-91 years of age. Measurements: Prohepcidin, ferritin, soluble transferrin receptor, erythropoietin and interleukin-6 were measured using commercially available ELISA kits. Iron, TIBC, transferrin, C-reactive protein and complete blood count were assayed using standard laboratory methods. Body fat content, fat distribution and protein nutrition state parameters were assessed by means of anthropometry. Results: Mean serum prohepcidin levels were significantly higher in patients with high body fat content in comparison to patients with normal body fat content (224,85 vs 176,6 ng/ml). Prohepcidin levels of the elderly patients with anemia were positively correlated with biceps, subscapular and suprailiac skinfold thickness or body fat mass percentage. In our study serum prohepcidin levels do not correlate with any iron parameters or inflammation markers. Conclusion: Summing up, the results of this study indicate that increased prohepcidin concentration, observed in obese elderly patients with anemia, may play an important role in iron deficiency development.
C1 [Przybyszewska, J.; Cichon, R.] Nicolaus Copernicus Univ Torun, Dept Nutr & Dietet, Coll Med, PL-85626 Bydgoszcz, Poland.
   [Zekanowska, E.; Boinska, J.] Nicolaus Copernicus Univ Torun, Dept Pathophysiol, Coll Med, PL-85626 Bydgoszcz, Poland.
   [Kedziora-Kornatowska, K.; Porzych, K.] Nicolaus Copernicus Univ Torun, Dept & Clin Geriatr, Coll Med, PL-85626 Bydgoszcz, Poland.
RP Przybyszewska, J (reprint author), Nicolaus Copernicus Univ Torun, Dept Nutr & Dietet, Coll Med, Ul Debowa 3, PL-85626 Bydgoszcz, Poland.
EM j.szwarc@wp.pl
RI Porzych, Katarzyna/G-8603-2014; Boinska, Joanna/H-6707-2014; Zekanowska,
   Ewa/H-2280-2014; Przybyszewska, Justyna/D-7936-2014
OI Przybyszewska, Justyna/0000-0002-0715-3670
CR Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Chung B, 2007, J NUTR, V137, P2366
   Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260
   Rivera S, 2005, BLOOD, V106, P2196, DOI 10.1182/blood-2005-04-1766
   Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499
   Nead KG, 2004, PEDIATRICS, V114, P104, DOI 10.1542/peds.114.1.104
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Rivera S, 2005, BLOOD, V105, P1797, DOI 10.1182/blood-2004-08-3375
   Lago F, 2007, NAT CLIN PRACT RHEUM, V3, P716, DOI 10.1038/ncprheum0674
   Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   Merle U, 2007, ENDOCRINOLOGY, V148, P2663, DOI 10.1210/en.2006-1331
   del Giudice EM, 2009, J CLIN ENDOCR METAB, V94, P5102, DOI 10.1210/jc.2009-1361
   Hunter HN, 2002, J BIOL CHEM, V277, P37597, DOI 10.1074/jbc.M205305200
   Lago F, 2007, CYTOKINE GROWTH F R, V18, P313, DOI 10.1016/j.cytogfr.2007.04.007
   Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483
   Pinhas-Hamiel O, 2003, INT J OBESITY, V27, P416, DOI 10.1038/sj.ijo.802224
   Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Balducci L, 2003, J AM GERIATR SOC, V51, P2, DOI 10.1046/j.1532-5415.51.3s.4.x
   Bekri S, 2006, GASTROENTEROLOGY, V131, P691
   Benedict C, 2007, HAEMATOL-HEMATOL J, V92, P125, DOI 10.3324/haematol.10637
   Farahani P, 2004, OBES RES, V12, P191, DOI 10.1038/oby.2004.26
   GIBSON RS, 2003, PRINCIPLES NUTR ASSE
   Guralnik J. M., 2005, HEMATOL-AM SOC HEMAT, V1, P528
   Hadley KB, 2006, AM J CLIN NUTR, V84, P150
   Heymsfield SB, 1998, MODERN NUTR HLTH DIS, P817
   Laine F, 2005, J HEPATOL, V43, P1055, DOI 10.1016/j.jhep.2005.05.027
   Leung PS, 2005, GUT, V54, P1391, DOI 10.1136/gut.2004.062083
   Malinowski A, 1997, PODSTAWY ANTROPOMETR
   Olivares M, 2000, EUR J CLIN NUTR, V54, P834, DOI 10.1038/sj.ejcn.1601099
   Richardson M. W., 2009, INT J PEDIAT ENDOCRI, DOI 10.1155.2009/713269
   Szczygiel B., 2001, PODSTAWY NAUKOWE YWI, P324
   Tussing-Humphreys LM, 2010, OBESITY, V18, P1449, DOI 10.1038/oby.2009.319
   World Health Organization, 1995, TECHN REP SER WHO, V854
   World Health Organization, 1972, NUTR AN REP WHO GROU
   Yamaji S, 2004, BLOOD, V104, P2178, DOI 10.1182/blood-2004-03-0829
NR 38
TC 5
Z9 5
U1 1
U2 1
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD APR
PY 2011
VL 15
IS 4
BP 259
EP 264
DI 10.1007/s12603-010-0320-6
PG 6
WC Geriatrics & Gerontology; Nutrition & Dietetics
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA 766PE
UT WOS:000290796900003
PM 21437556
ER

PT J
AU Lim, SS
   Norman, RJ
   Clifton, PM
   Noakes, M
AF Lim, S. S.
   Norman, R. J.
   Clifton, P. M.
   Noakes, M.
TI The effect of comprehensive lifestyle intervention or metformin on
   obesity in young women
SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
LA English
DT Article
DE Lifestyle modifications; Women; Weight loss; Clinical trials; Drug
   treatment
ID POLYCYSTIC-OVARY-SYNDROME; WEIGHT-GAIN; PHYSICAL-ACTIVITY; METAANALYSIS;
   PREVENTION; OVERWEIGHT; REDUCTION; PROGRAM; PLASMA
AB Background and aim: Young women are at high risk of weight gain but few weight management interventions have been investigated in this group. This study aimed to determine the effect of metformin on body weight, body composition, metabolic risk factors and reproductive hormone levels in overweight or obese young women compared to placebo and comprehensive lifestyle intervention.
   Methods and results: 203 overweight or obese young women (BMI 33.2+/-0.3 kg/m2, age 28+/-0.3 years) were randomised to 1500 mg/day metformin (M) plus general lifestyle advice, placebo (P) plus general lifestyle advice or comprehensive lifestyle intervention including structured diet, exercise and behavioural therapy (L) for 12-weeks. At 12-weeks, linear mixed models found that L group had greater weight loss (-4.2+/-0.4 kg) compared to M (-1.0+/-0.4 kg) and P groups (-0.2+/-0.3 kg) (P < 0.0001). Weight loss between M and P groups were not significantly different. Attrition rate was 48% for L, 34% for M and 29% for P (P = 0.08). Intention-to-treat analysis showed that 10% (8/79) of the subjects in P group had gained weight (> 3%), compared to 3% (2/65) from M group and none (0/59) from L group (P < 0.001). The L group had the greatest decrease in waist circumference (-5.2+/-0.7 cm) and fat mass (-5.4+/-0.7 kg) compared to the other groups (P < 0.05). No significant time-by-group effects were seen in plasma lipids, SHBG, testosterone, blood pressure, serum folate, serum ferritin and serum vitamin B12. Conclusion: Lifestyle intervention was more effective in reducing body weight and improving body composition compared to metformin among healthy overweight or obese young women. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Lim, S. S.; Clifton, P. M.; Noakes, M.] CSIRO Human Nutr, Adelaide, SA 5000, Australia.
   [Lim, S. S.] Univ Adelaide, Sch Mol & Biomed Sci, Discipline Physiol, Adelaide, SA 5000, Australia.
   [Norman, R. J.] Univ Adelaide, Discipline Obstet & Gynaecol, Adelaide, SA 5000, Australia.
RP Lim, SS (reprint author), CSIRO Human Nutr, POB 10041, Adelaide, SA 5000, Australia.
EM siew.seen.lim@gmail.com
RI Perez , Claudio Alejandro/F-8310-2010; noakes, manny/H-2813-2013;
   Clifton, Peter/F-4446-2013
OI Perez , Claudio Alejandro/0000-0001-9688-184X; Clifton,
   Peter/0000-0002-6411-626X
FU CSIRO Human Nutrition, Adelaide, Australia; CSIRO Human Nutrition
FX This work was supported by CSIRO Human Nutrition, Adelaide, Australia.
   This trial was registered with the Australian Clinical Trials Registry
   (ACTRN012607000213448).; We gratefully acknowledge Julia Weaver, Kathryn
   Baastians, Grant Brinkworth, Rosemary McArthur, Lindy Lawson, David
   Jesudason, Xenia Cleanthous, Gemma Williams, Lynn Field, and Vanessa
   Courage for assistance in performing this study, Julie Syrette for data
   management, and Kylie Lange for statistical advice. This study was
   funded by CSIRO Human Nutrition.
CR Franz MJ, 2007, J AM DIET ASSOC, V107, P1755, DOI 10.1016/j.jada.2007.07.017
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Lachin JM, 2007, DIABETES, V56, P1153, DOI 10.2337/db06-0918
   Fairfield KM, 2002, OBSTET GYNECOL, V100, P288, DOI 10.1016/S0029-7844(02)02053-7
   Salpeter SR, 2008, AM J MED, V121, P149, DOI 10.1016/j.amjmed.2007.09.016
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Wu RR, 2008, JAMA-J AM MED ASSOC, V299, P185, DOI 10.1001/jama.2007.56-b
   Knowler WC, 2002, NEW ENGL J MED, V346, P393
   Stevens J, 2006, INT J OBESITY, V30, P391, DOI 10.1038/sj.ijo.0803175
   Welch N, 2009, PUBLIC HEALTH NUTR, V12, P888, DOI 10.1017/S1368980008003066
   Honas JJ, 2003, OBES RES, V11, P888, DOI 10.1038/oby.2003.122
   Moran LJ, 2003, J CLIN ENDOCR METAB, V88, P812, DOI 10.1210/jc.2002-020815
   Lord JM, 2003, BRIT MED J, V327, P951, DOI 10.1136/bmj.327.7421.951
   McTigue KM, 2002, ANN INTERN MED, V136, P857
   *AUSTR GOV DOHAA, AUSTR GUID HLTH EAT
   *AUSTR GOV DOHAA, NAT PHYS ACT GUID AD
   COLDITZ GA, 1997, INT J SPORTS MED S, V3, pS70
   Crandall J, 2006, J GERONTOL A-BIOL, V61, P1075
   DATTILO AM, 1992, AM J CLIN NUTR, V56, P320
   FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
   Hill JO, 2005, J APPL PHYSIOL, V99, P765, DOI 10.1152/japplphysiol.00137.2005
   Huber-Buchholz MM, 1999, J CLIN ENDOCR METAB, V84, P1470, DOI 10.1210/jc.84.4.1470
   KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S
   Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194
   *NIH, 2002, AD TREAT PAN NIH PUB
NR 25
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0939-4753
J9 NUTR METAB CARDIOVAS
JI Nutr. Metab. Carbiovasc. Dis.
PD APR
PY 2011
VL 21
IS 4
BP 261
EP 268
DI 10.1016/j.numecd.2009.10.006
PG 8
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition
   & Dietetics
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism;
   Nutrition & Dietetics
GA 736YQ
UT WOS:000288531400005
PM 20163941
ER

PT J
AU Fanou-Fogny, N
   Saronga, NJ
   Koreissi, Y
   Dossa, RAM
   Melse-Boonstra, A
   Brouwer, ID
AF Fanou-Fogny, Nadia
   Saronga, Naomi J.
   Koreissi, Yara
   Dossa, Romain A. M.
   Melse-Boonstra, Alida
   Brouwer, Inge D.
TI Weight status and iron deficiency among urban Malian women of
   reproductive age
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Overweight and iron deficiency; Mali; Women of reproductive age; Urban
   areas; West Africa
ID OBESITY; ABSORPTION; HEPCIDIN; OVERWEIGHT; HYPOFERREMIA; INFLAMMATION;
   TRANSITION; EXPRESSION; CHILDREN
AB The present study investigated the association between weight status and Fe deficiency (ID) among urban Malian women of reproductive age. Height, weight, serum ferritin (SF), soluble transferrin receptor (sTfR) and C-reactive protein (CRP) concentrations were measured in sixty apparently healthy women aged 15-49 years old in Bamako, Mali. Prevalences of overweight and obese were 19 and 9%, respectively. SF was non-significantly different between overweight (84 mu g/l) and normal-weight women (52 mu g/l). The prevalence of ID (SF < 12 mu g/l) was 9% in the overweight group and no true ID (sTfR > 8.3 mg/l) cases were recorded in the overweight and obese groups. The prevalence OR of ID (SF < 12 mu g/l) in the overweight group was NS (OR = 0.3; P=0.363). Conversely, the chronic energy deficiency group was at a significantly higher risk of ID than the normal-weight group, adjusting or not for CRP (OR = 7.7; 95% CI 1.49, 39.96; P=0.015). The lack of association between overweight and ID in the present study could be due to the fact that the excess of body fat of the women might not be critical to induce chronic inflammation related to reduced Fe absorption. Future research based on a larger convenience sample should be designed to further investigate associations between overweight, obesity and ID in developing countries.
C1 [Fanou-Fogny, Nadia; Dossa, Romain A. M.] Univ Abomey Calavi, Fac Agron Sci, Dept Nutr & Food Sci, Cotonou, Benin.
   [Fanou-Fogny, Nadia; Saronga, Naomi J.; Koreissi, Yara; Melse-Boonstra, Alida; Brouwer, Inge D.] Wageningen Univ, Div Human Nutr, NL-6700 EV Wageningen, Netherlands.
   [Koreissi, Yara] Reg Agron Res Ctr Sotuba, Inst Rural Econ, Food Technol Lab, Bamako, Mali.
RP Fanou-Fogny, N (reprint author), Univ Abomey Calavi, Fac Agron Sci, Dept Nutr & Food Sci, 01 BP 526, Cotonou, Benin.
EM nadia.fanou@gmail.com
RI Brouwer, Inge/K-8455-2013; 
OI Melse-Boonstra, Alida/0000-0001-8406-7592
FU European Union [0015043]
FX This work was supported by the European Union under the project EU/INCO
   no. 0015043. We acknowledge Lucy Okma and Joke Barendse (Wageningen
   University) for the help with blood sample collection and handling; the
   authors also thank all the women for their willingness to participate
   and their important contribution to the study. N. F.-F. was responsible
   for the proposal writing, data collection and analysis, and article
   writing; N. J. S. collaborated in proposal writing and analysed data. Y.
   K. collaborated in data collection and article refining; R. A. M. D.
   collaborated in refining the article; A. M.-B. and I. D. B. refined
   methodologies and the article; all authors read and approved the final
   content. The authors declare no conflict of interest.
CR Karl JP, 2009, J AM COLL NUTR, V28, P37
   Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973
   Flegal KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/jama.298.17.2028
   Lecube A, 2006, OBESITY, V14, P1724, DOI 10.1038/oby.2006.198
   Chung B, 2007, J NUTR, V137, P2366
   Zimmermann MB, 2008, INT J OBESITY, V32, P1098, DOI 10.1038/ijo.2008.43
   McClung JP, 2009, NUTR REV, V67, P100, DOI 10.1111/j.1753-4887.2008.00145.x
   Menzie CM, 2008, J AM DIET ASSOC, V108, P145, DOI 10.1016/j.jada.2007.10.034
   Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953
   Fitzsimons EJ, 2001, BRIT MED J, V322, P811, DOI 10.1136/bmj.322.7290.811
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   Black AE, 2000, INT J OBESITY, V24, P1119, DOI 10.1038/sj.ijo.0801376
   McClung JP, 2008, J NUTR, V138, P1293
   Siervo M, 2006, EUR J CLIN NUTR, V60, P455, DOI 10.1038/sj.ejcn.1602337
   LOOKER AC, 1995, NUTR REV, V53, P246
   Aeberli I, 2009, INT J OBESITY, V33, P1111, DOI 10.1038/ijo.2009.146
   Murphy SP, 2008, ASIA PAC J CLIN NUTR, V17, P299
   SELTZER CC, 1963, AM J CLIN NUTR, V13, P354
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Baillie FJ, 2003, CLIN LAB HAEMATOL, V25, P353, DOI 10.1046/j.0141-9854.2003.00548.x
   DIARRA M, 2001, DEMOGRAPHIC HLTH SUR, P137
   Geissler CA, 2005, HUMAN NUTR
   Gibson RS, 2008, HARVEST PLUS TECHNIC, V8
   Greenberg AS, 2006, AM J CLIN NUTR, V83, p461S
   INSTITUTE OF MEDICINE-IOM, 2001, DIET REF INT VIT A V
   Kennedy G., 2009, DIETARY DIVERSITY ME
   McLean E, 2007, NUTR ANEMIA, P1
   SHINE B, 1981, CLIN CHIM ACTA, V117, P13, DOI 10.1016/0009-8981(81)90005-X
   Sodjinou R, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-84
   United Nations Children's Fund (UNICEF), 2006, MON SIT CHILDR WOM M
   WHO, 1995, PHYS STAT US INT ANT
   WHO/UNICEF/UNU, 2001, IR DEF AN ASS PREV C
NR 32
TC 8
Z9 8
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD FEB
PY 2011
VL 105
IS 4
BP 574
EP 579
DI 10.1017/S0007114510003776
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 724VY
UT WOS:000287605500010
PM 20875192
ER

PT J
AU Francque, S
   Verrijken, A
   Mertens, I
   Hubens, G
   Van Marck, E
   Pelckmans, P
   Michielsen, P
   Van Gaal, L
AF Francque, S.
   Verrijken, A.
   Mertens, I.
   Hubens, G.
   Van Marck, E.
   Pelckmans, P.
   Michielsen, P.
   Van Gaal, L.
TI Visceral adiposity and insulin resistance are independent predictors of
   the presence of non-cirrhotic NAFLD-related portal hypertension
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE non-alcoholic fatty liver; visceral fat; insulin resistance; metabolic
   syndrome; portal hypertension
ID NONALCOHOLIC FATTY LIVER; METABOLIC SYNDROME; HEPATIC STEATOSIS;
   OBESE-PATIENTS; IN-VIVO; DISEASE; STEATOHEPATITIS; BIOPSY; TISSUE;
   COMPLICATIONS
AB Introduction: We previously demonstrated in an animal model that steatosis, in the absence of fibrosis, induces a significant rise in portal pressure, indicating substantial changes in liver hemodynamics. As assessment of portal pressure is an invasive procedure, non-invasive parameters are needed to identify patients at risk.
   Aims: To study the portal pressure in nonalcoholic fatty liver disease patients and to identify factors that are possibly related to steatosis-induced changes in liver hemodynamics.
   Materials and methods: Patients presenting with a problem of overweight or obesity, and in whom non-invasive investigations showed signs of liver involvement, were proposed for transjugular hepatic vein catheterization and liver biopsy. The biopsy was scored according to the Nonalcoholic Steatohepatitis Clinical Research Network Scoring System.
   Results: A total of 50 consecutive patients were studied. Their mean age was 47.9 +/- 1.8 years; 31 (62%) were female. Hepatic venous pressure gradient was normal in 36 (72%) and elevated in 14 (28%) patients. The degree of steatosis was the only histological parameter that differed significantly between the two groups (P = 0.016), and was a predictor of the presence of portal hypertension (PHT) in regression analysis (P = 0.010). Comparing normal versus portal hypertensive patients, waist circumference (117 +/- 2 versus 128 +/- 4 cm, P = 0.005), waist-hip ratio (0.96 +/- 0.06 versus 1.04 +/- 0.03, P = 0.003), visceral fat (229 +/- 15 versus 292 +/- 35cm(2), P = 0.022), fasting insulin (15.4 +/- 1.7 versus 21.8 +/- 2.4 mu U ml(-1), P = 0.032), fasting c-peptide (1.22 +/- 0.06 versus 1.49 +/- 0.09 nmol l(-1), P = 0.035) and homeostasis model assessment-insulin resistance (HOMA IR) (3.28 +/- 0.29 versus 4.81 +/- 0.57, P = 0.019) were significantly higher. Age, gender, liver enzymes, ferritin and high-sensitive C-reactive protein were not significantly different. In regression analysis, waist circumference (P = 0.008) and HOMA IR (P = 0.043) were independent predictors of PHT.
   Conclusions: Estimates of both visceral adiposity and IR are predictors for the presence of PHT, related to the degree of steatosis, and may help in identifying patients who are at risk of developing steatosis-related complications. International Journal of Obesity (2011) 35, 270-278; doi: 10.1038/ijo.2010.134; published online 27 July 2010
C1 [Francque, S.; Pelckmans, P.; Michielsen, P.] Univ Antwerp Hosp, Dept Gastroenterol & Hepatol, B-2650 Antwerp, Belgium.
   [Verrijken, A.; Mertens, I.; Van Gaal, L.] Univ Antwerp Hosp, Dept Endocrinol Diabetol & Metab, B-2650 Antwerp, Belgium.
   [Hubens, G.] Univ Antwerp Hosp, Dept Abdominal Surg, B-2650 Antwerp, Belgium.
   [Van Marck, E.] Univ Antwerp Hosp, Dept Pathol, B-2650 Antwerp, Belgium.
RP Francque, S (reprint author), Univ Antwerp Hosp, Dept Gastroenterol & Hepatol, Wilrijkstr 10, B-2650 Antwerp, Belgium.
EM sven.francque@uza.be
FU European Commission [LSHM-CT-2005-018734]
FX This work is part of the project 'Hepatic and adipose tissue and
   functions in the metabolic syndrome' (HEPADIP), which is supported by
   the European Commission as an Integrated Project under the 6th Framework
   Program (Contract LSHM-CT-2005-018734).
CR Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   MERKEL C, 1992, GUT, V33, P836, DOI 10.1136/gut.33.6.836
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   Selzner M, 2001, SEMIN LIVER DIS, V21, P105, DOI 10.1055/s-2001-12933
   Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168
   Stranges S, 2004, HEPATOLOGY, V39, P754, DOI 10.1002/hep.20149
   Bellentani S, 2000, ANN INTERN MED, V132, P112
   Choi S, 2005, CURR OPIN GASTROEN, V21, P702, DOI 10.1097/01.mog.0000182863.96421.47
   McCuskey RS, 2004, HEPATOLOGY, V40, P386, DOI 10.1002/hep.20302
   Bosch J, 2006, SEMIN LIVER DIS, V26, P348, DOI 10.1055/s-2006-951603
   Kalambokis G, 2007, J HEPATOL, V47, P284, DOI 10.1016/j.jhep.2007.05.001
   DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270
   Abrams GA, 2004, HEPATOLOGY, V40, P475, DOI 10.1002/hep.20323
   Jarrar MH, 2008, ALIMENT PHARM THERAP, V27, P412, DOI 10.1111/j.1365-2036.2007.03586.x
   Joy D, 2003, EUR J GASTROEN HEPAT, V15, P539, DOI 10.1097/01.meg.0000059112.41030.2e
   LEBREC D, 1982, GASTROENTEROLOGY, V83, P338
   Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Clark JM, 2002, GASTROENTEROLOGY, V122, P1649, DOI 10.1053/gast.2002.33573
   Campbell MS, 2004, ALIMENT PHARM THERAP, V20, P249, DOI 10.1111/j.1365-2036.2004.02071.x
   Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5
   Prati D, 2002, ANN INTERN MED, V137, P1
   Seifalian AM, 1998, LIVER TRANSPLANT SUR, V4, P71, DOI 10.1002/lt.500040110
   de Marco R, 1999, DIABETES CARE, V22, P756, DOI 10.2337/diacare.22.5.756
   Despres JP, 2001, BMJ-BRIT MED J, V322, P716, DOI 10.1136/bmj.322.7288.716
   Francque S, 2010, LIVER INT, V30, P365, DOI 10.1111/j.1478-3231.2009.02136.x
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Verrijken A, 2010, INT J OBESITY, V34, P899, DOI 10.1038/ijo.2010.4
   Behrns K E, 1998, J Gastrointest Surg, V2, P292, DOI 10.1016/S1091-255X(98)80025-5
   BUCOMBE JR, 1999, OXFORD TXB CLIN HEPA, P579
   COSGROVE DO, 1994, ABDOMINAL GEN ULTRAS, V1, P227
   DARDENNE AN, 1994, ABDOMINAL GEN ULTRAS, V1, P351
   EGUSHI Y, 2006, J GASTROENTEROL, V41, P462
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Farrell GC, 2005, FATTY LIVER DIS NASH, P1
   FRANCQUE S, 2009, CHRONIC HEPATITIS OT, V16, P1249
   Groszmann Roberto, 2006, Clin Liver Dis, V10, P499, DOI 10.1016/j.cld.2006.08.005
   Kichian K, 2003, CAN J GASTROENTEROL, V17, P38
   Laleman W., 2005, LIVER INT, V25, P1070
   Lebrec D, 2001, EUR J GASTROEN HEPAT, V13, P309, DOI 10.1097/00042737-200104000-00002
   Neuschwander-Tetri BA, 2007, CURR OPIN GASTROEN, V23, P193, DOI 10.1097/MOG.0b013e32801421a9
   Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707
   Puoti C, 2005, Eur Rev Med Pharmacol Sci, V9, P285
   Rao MS, 2001, DIGEST DIS SCI, V46, P1821, DOI 10.1023/A:1010654908938
   Rinella ME, 2001, LIVER TRANSPLANT, V7, P409, DOI 10.1053/jlts.2001.23787
   Selzner M, 2000, HEPATOLOGY, V32, P1281
   TAWALKAR JA, 2002, CAN J GASTROENTEROL, V16, P718
   VANDERKOOY K, 1993, INT J OBESITY, V17, P187
   WHO, 2000, WHO TECHN REP SER, V894
NR 52
TC 13
Z9 13
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
J9 INT J OBESITY
JI Int. J. Obes.
PD FEB
PY 2011
VL 35
IS 2
BP 270
EP 278
DI 10.1038/ijo.2010.134
PG 9
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 721LD
UT WOS:000287355000012
PM 20661251
ER

PT J
AU Tussing-Humphreys, L
   Pini, M
   Ponemone, V
   Braunschweig, C
   Fantuzzi, G
AF Tussing-Humphreys, Lisa
   Pini, Maria
   Ponemone, Venkatesh
   Braunschweig, Carol
   Fantuzzi, Giamila
TI Suppressed cytokine production in whole blood cultures may be related to
   iron status and hepcidin and is partially corrected following weight
   reduction in morbidly obese pre-menopausal women
SO CYTOKINE
LA English
DT Article
DE Obesity; Ex vivo LPS and ZY stimulated cytokine; production; Immunity;
   Hepcidin; Iron status
ID DIET-INDUCED OBESITY; ADIPOSE-TISSUE; IMMUNE-RESPONSES; INFLAMMATION;
   METABOLISM; MICE; LIPOPOLYSACCHARIDE; INTERLEUKIN-18; MACROPHAGES;
   DEFICIENCY
AB Objective: Assess ex vivo whole-blood (WB) cytokine production and its association with iron status and serum hepcidin in obese versus non-obese women. Determine the change in ex vivo WB cytokine production 6 months after restrictive bariatric surgery in the obese group. Subjects: Seventeen obese (BMI: 46.6 +/- 7.9 kg/m(2)) and 19 non-obese (BMI: 22.5 +/- 3.0 kg/m(2)), pre-menopausal women: frequency matched for hemoglobin, age and race. Measurements: At baseline control and ex vivo stimulated IL-6, IL-10, IL-22, IFN gamma, and TNF alpha from heparinized WB cultures, hemoglobin from finger-stick and transferrin receptor, hepcidin, CRP, IL-6, HOMA-IR from fasted serum samples and anthropometric parameters were assessed in the women. All parameters were reassessed 6-months following restrictive bariatric surgery in the obese women only. Results: Whole blood ex vivo LPS and ZY stimulated production of IL-6, TNF alpha, and IFN gamma was reduced, IL-22 increased, and IL-10 was unaffected in obese compared with the non-obese women. Furthermore, ex vivo stimulated production of IL-6 and TNF alpha normalized, but IFN gamma production remained unchanged with weight loss following restrictive bariatric surgery. In the obese women, serum transferrin receptor (a marker of iron status) and serum hepcidin were correlated with ex vivo stimulated IFN gamma production at baseline. Conclusion: Ex vivo LPS and ZY stimulated cytokine production from WB cultures was altered in pre-menopausal women with morbid obesity. Significant weight loss resulted in normalization of some but not all observed alterations. Furthermore, iron status and serum hepcidin were associated with ex vivo LPS and ZY stimulated IFN gamma in obesity. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Pini, Maria; Ponemone, Venkatesh; Braunschweig, Carol; Fantuzzi, Giamila] Univ Illinois, Dept Kinesiol & Nutr, Coll Appl Hlth Sci, Chicago, IL 60612 USA.
   [Tussing-Humphreys, Lisa] ARS, USDA, So Reg Res Ctr, Baton Rouge, LA 70803 USA.
RP Fantuzzi, G (reprint author), Univ Illinois, Dept Kinesiol & Nutr, Coll Appl Hlth Sci, 1919 W Taylor St,Room 650,M-C 517, Chicago, IL 60612 USA.
EM giamila@uic.edu
RI Fantuzzi, Giamila/A-1758-2009
OI Fantuzzi, Giamila/0000-0001-5334-0082
CR Ahluwalia N, 2004, AM J CLIN NUTR, V79, P516
   Benson S, 2008, BRAIN BEHAV IMMUN, V22, P177, DOI 10.1016/j.bbi.2007.07.003
   Fain JN, 2006, VITAM HORM, V74, P443, DOI 10.1016/S0083-6729(06)74018-3
   Ganz T, 2008, BLOOD, V112, P4292, DOI [10.1182/blood-2008-02-139915, 10.1182/blood-2008-02139915]
   Raymond NC, 2000, INT J EAT DISORDER, V28, P293, DOI 10.1002/1098-108X(200011)28:3<293::AID-EAT6>3.0.CO;2-F
   Weiss G, 2002, EUR J CLIN INVEST, V32, P70, DOI 10.1046/j.1365-2362.2002.0320s1070.x
   BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B
   Lagrelius M, 2006, CYTOKINE, V33, P156, DOI 10.1016/j.cyto.2006.01.005
   De Domenico I, 2010, J CLIN INVEST, V120, P2395, DOI 10.1172/JCI42011
   Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008
   Yang H, 2009, BLOOD, V114, P3803, DOI 10.1182/blood-2009-03-213595
   Karalis KP, 2009, FEBS J, V276, P5747, DOI 10.1111/j.1742-4658.2009.07304.x
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   Zilverschoon GRC, 2008, INT J OBESITY, V32, P1407, DOI 10.1038/ijo.2008.109
   WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969
   SELIGMAN PA, 1992, PATHOBIOLOGY, V60, P19, DOI 10.1159/000163692
   Goldberg RB, 2009, J CLIN ENDOCR METAB, V94, P3171, DOI 10.1210/jc.2008-2534
   Nijhuis J, 2009, OBESITY, V17, P2014, DOI 10.1038/oby.2009.113
   Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200
   Zhou QD, 2009, P NATL ACAD SCI USA, V106, P10740, DOI 10.1073/pnas.0904412106
   Yang JF, 2010, IMMUNOLOGY, V131, P174, DOI 10.1111/j.1365-2567.2010.03286.x
   Winer S, 2009, EUR J IMMUNOL, V39, P2629, DOI 10.1002/eji.200838893
   Ganz T, 2004, CURR OPIN HEMATOL, V11, P251, DOI 10.1097/00062752-200407000-00004
   Bekri S, 2006, GASTROENTEROLOGY, V131, P788, DOI 10.1053/j.gastro.2006.07.007
   JOYNSON DHM, 1972, LANCET, V2, P1058
   Fontana L, 2007, REJUV RES, V10, P41, DOI 10.1089/rej.2006.0504
   Ainsworth BE, 2000, MED SCI SPORT EXER, V32, P1327, DOI 10.1097/00005768-200007000-00022
   Strissel KJ, 2010, OBESITY, V18, P1918, DOI 10.1038/oby.2010.1
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Kueht ML, 2009, OBESITY, V17, P447, DOI 10.1038/oby.2008.552
   Weiss G, 2005, BEST PRACT RES CL HA, V18, P183, DOI 10.1016/j.beha.2004.09.001
   Fritsche G, 2001, J INFECT DIS, V183, P1388, DOI 10.1086/319860
   GORDEUK VR, 1992, BLOOD, V79, P308
   Karlsson Erik A, 2010, J Immunol, V184, P3127, DOI 10.4049/jimmunol.0903220
   Miehsler Wolfgang, 2010, Wien Med Wochenschr, V160, P124, DOI 10.1007/s10354-010-0767-4
   O'Shea D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008660
   Oppenheimer SJ, 2001, J NUTR, V131, p616S
   Pini M, 2010, OBESITY, V18, P476, DOI 10.1038/oby.2009.263
   Pini M, 2009, J LEUKOCYTE BIOL, V87, P51
   Poniachik J, 2006, CYTOKINE, V33, P252, DOI 10.1016/j.cyto.2006.02.006
   TUSSINGHUMPHREY.LM, 2010, OBESITY SILVER SPRIN, V18, P2020
   Tussing-Humphreys LM, 2009, OBESITY SILVER SPRIN, V18, P1449
   Weiss G, 1997, J INFECT DIS, V175, P226
NR 43
TC 10
Z9 10
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
J9 CYTOKINE
JI Cytokine
PD FEB
PY 2011
VL 53
IS 2
BP 201
EP 206
DI 10.1016/j.cyto.2010.11.008
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 720HX
UT WOS:000287272700013
PM 21145254
ER

PT J
AU Scaglioni, F
   Ciccia, S
   Marino, M
   Bedogni, G
   Bellentani, S
AF Scaglioni, F.
   Ciccia, S.
   Marino, M.
   Bedogni, G.
   Bellentani, S.
TI ASH and NASH
SO DIGESTIVE DISEASES
LA English
DT Article
DE Alcoholic fatty liver disease; Alcoholic steatohepatitis; Non-alcoholic
   fatty liver disease; Non-alcoholic steatohepatitis
ID NONALCOHOLIC FATTY LIVER; CARBOHYDRATE-DEFICIENT TRANSFERRIN; ASSESSING
   INSULIN SENSITIVITY; CLINICAL SCORING SYSTEM; CHRONIC HEPATITIS-C;
   GENERAL-POPULATION; METABOLIC SYNDROME; PHYSICAL-ACTIVITY; DISEASE
   NAFLD; RISK-FACTORS
AB Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). NAFLD is characterized by excessive fat accumulation in the liver (steatosis), without any other evident causes of chronic liver diseases (viral, autoimmune, genetic, etc.), and with an alcohol consumption <= 20-30 g/day. On the contrary, AFLD is defined as the presence of steatosis and alcohol consumption 1 20-30 g/day. The most common phenotypic manifestations of primary NAFLD/NASH are overweight/obesity, visceral adiposity, type 2 diabetes, hypertriglyceridemia and hypertension. The prevalence of NAFLD in the general population in Western countries is estimated to be 25-30%. The prevalence and incidence of NASH and ASH are not known because of the impossibility of performing liver biopsy in the general population. Up to 90% of alcoholics have fatty liver, and 5-15% of these subjects will develop cirrhosis over 20 years. The risk of cirrhosis increases to 30-40% in those who continue to drink alcohol. About 10-35% of alcoholics exhibit changes on liver biopsy consistent with alcoholic hepatitis. Natural histories of NASH and ASH are not completely defined, even if patients with NASH have a reduced life expectancy due to liver-related death and cardiovascular diseases. The best treatment of AFLD/ASH is to stop drinking, and the most effective first-line therapeutic option for NAFLD/NASH is non-pharmacologic lifestyle interventions through a multidisciplinary approach including weight loss, dietary changes, physical exercise, and cognitive-behavior therapy. Copyright (C) 2011 S. Karger AG, Basel
C1 [Scaglioni, F.; Ciccia, S.; Marino, M.; Bellentani, S.] Azienda USL Modena, Ctr Liver, Carpi, Italy.
   [Bedogni, G.] Liver Res Ctr, Trieste, Italy.
RP Bellentani, S (reprint author), Poliambulatori Osped Ramazzini, Ctr Studi Fegato, Azienda USL Modena, Ple Donatori di Sangue 3, IT-41012 Carpi Modena, Italy.
EM liversb@unimore.it
CR Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   NAKANO M, 1982, GASTROENTEROLOGY, V83, P777
   Mancini M, 2009, METABOLISM, V58, P1724, DOI 10.1016/j.metabol.2009.05.032
   Pan MH, 2004, J CLIN INVEST, V113, P1277, DOI 10.1172/JCI200419197
   Campos GM, 2008, HEPATOLOGY, V47, P1916, DOI 10.1002/hep.22241
   Gastaldelli A, 2009, HEPATOLOGY, V49, P1537, DOI 10.1002/hep.22845
   Conigrave KM, 2002, ALCOHOL CLIN EXP RES, V26, P332, DOI 10.1111/j.1530-0277.2002.tb02542.x
   Kechagias S, 2008, GUT, V57, P649, DOI 10.1136/gut.2007.131797
   KELLY JP, 1995, AM J GASTROENTEROL, V90, P1058
   Ratziu V, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-6
   Ibanez J, 2005, DIABETES CARE, V28, P662, DOI 10.2337/diacare.28.3.662
   Ji C, 2006, J HEPATOL, V45, P321, DOI 10.1016/j.jhep.2006.06.004
   Tiikkainen M, 2003, DIABETES, V52, P701, DOI 10.2337/diabetes.52.3.701
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Loria P, 2010, DIGEST LIVER DIS, V42, P272, DOI 10.1016/j.dld.2010.01.021
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   Sougioultzis S, 2005, CURR MED RES OPIN, V21, P1337, DOI 10.1185/030079905X56493
   Younossi ZM, 2008, ALIMENT PHARM THER, V28, P2, DOI 10.1111/j.1365-2036.2008.03710.x
   Pessione F, 2003, LIVER INT, V23, P45, DOI 10.1034/j.1600-0676.2003.01804.x
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   BOROWSKY SA, 1981, GASTROENTEROLOGY, V80, P1405
   Hamaguchi M, 2005, ANN INTERN MED, V143, P722
   BACON BR, 1994, GASTROENTEROLOGY, V107, P1103
   POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114
   Bellentani S, 2000, ANN INTERN MED, V132, P112
   PALMER M, 1990, GASTROENTEROLOGY, V99, P1408
   Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748
   Machado M, 2006, J HEPATOL, V45, P600, DOI 10.1016/j.jhep.2006.06.013
   Newton JL, 2008, GUT, V57, P807, DOI 10.1136/gut.2007.139303
   Zelber-Sagi S, 2008, HEPATOLOGY, V48, P1791, DOI 10.1002/hep.22525
   Harrison SA, 2009, HEPATOLOGY, V49, P80, DOI 10.1002/hep.22575
   Nyblom H, 2004, ALCOHOL ALCOHOLISM, V39, P336, DOI 10.1093/alcalc/agh074
   Ryan CK, 2002, LIVER TRANSPLANT, V8, P1114, DOI 10.1053/jlts.2002.36740
   Kotronen A, 2009, GASTROENTEROLOGY, V137, P865, DOI 10.1053/j.gastro.2009.06.005
   Tran TT, 2006, J GASTROEN HEPATOL, V21, P381, DOI 10.1111/j.1440-1746.2005.03968.x
   Frith J, 2009, GERONTOLOGY, V55, P607, DOI 10.1159/000235677
   Marra F, 2008, TRENDS MOL MED, V14, P72, DOI 10.1016/j.molmed.2007.12.003
   Abrams GA, 2004, HEPATOLOGY, V40, P475, DOI 10.1002/hep.20323
   ELHASSAN AY, 1992, BRIT J RADIOL, V65, P774
   Church TS, 2006, GASTROENTEROLOGY, V130, P2023, DOI 10.1053/j.gastro.2006.03.019
   Lebray P, 2008, HEPATOLOGY, V48, P2089, DOI 10.1002/hep.22594
   BRUNT PW, 1974, GUT, V15, P52, DOI 10.1136/gut.15.1.52
   Hui JM, 2004, HEPATOLOGY, V40, P46, DOI 10.1002/hep.20280
   TELI MR, 1995, LANCET, V346, P987, DOI 10.1016/S0140-6736(95)91685-7
   Ratziu V, 2010, J HEPATOL, V53, P372, DOI 10.1016/j.jhep.2010.04.008
   Nobili V, 2008, HEPATOLOGY, V48, P442, DOI 10.1002/hep.22376
   Guha IN, 2008, HEPATOLOGY, V47, P455, DOI 10.1002/hep.21984
   Lieber CS, 2000, ANNU REV NUTR, V20, P395, DOI 10.1146/annurev.nutr.20.1.395
   Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055
   Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126
   Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129
   d'Assignies G, 2009, EUR RADIOL, V19, P2033, DOI 10.1007/s00330-009-1351-4
   Thiele GM, 2004, SEMIN LIVER DIS, V24, P273, DOI 10.1055/s-2004-832940
   Arena U, 2008, HEPATOLOGY, V47, P380, DOI 10.1002/hep.22007
   Hannuksela ML, 2007, CLIN CHEM LAB MED, V45, P953, DOI 10.1515/CCLM.2007.190
   Wagenknecht LE, 2009, OBESITY, V17, P1240, DOI 10.1038/oby.2009.4
   Araya J, 2004, CLIN SCI, V106, P635, DOI 10.1042/CS20030326
   Powell EE, 2005, GASTROENTEROLOGY, V129, P1937, DOI 10.1053/j.gastro.2005.09.015
   Cortez-Pinto H, 2006, CLIN NUTR, V25, P816, DOI 10.1016/j.clnu.2006.01.027
   Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920
   Ratziu V, 2000, GASTROENTEROLOGY, V118, P1117, DOI 10.1016/S0016-5085(00)70364-7
   Bellentani S, 1997, GUT, V41, P845
   Zelber-Sagi S, 2006, LIVER INT, V26, P856, DOI 10.1111/j.1478-3231.2006.01311.x
   Vuppalanchi R, 2009, CLIN GASTROENTEROL H, V7, P481, DOI 10.1016/j.cgh.2008.12.015
   Lee S, 2007, HEPATOLOGY, V45, P841, DOI 10.1002/hep.21645
   Younossi ZM, 2008, OBES SURG, V18, P1430, DOI 10.1007/s11695-008-9506-y
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   Suzuki A, 2005, HEPATOLOGY, V41, P64, DOI 10.1002/hep.20543
   Bedogni G, 2005, HEPATOLOGY, V42, P44, DOI 10.1002/hep.20734
   Roulot D, 2008, J HEPATOL, V48, P606, DOI 10.1016/j.jhep.2007.11.020
   Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028
   Minervini MI, 2009, J HEPATOL, V50, P501, DOI 10.1016/j.jhep.2008.10.030
   Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844
   Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984
   Baumeister SE, 2008, GASTROENTEROLOGY, V134, P85, DOI 10.1053/j.gastro.2007.10.024
   Fan JG, 2005, J HEPATOL, V43, P508, DOI 10.1016/j.jhep.2005.02.042
   Day CP, 1998, HEPATOLOGY, V27, P1463, DOI 10.1002/hep.510270601
   Ouyang X, 2008, J HEPATOL, V48, P993, DOI 10.1016/j.jhep.2008.02.011
   Suzuki A, 2005, J HEPATOL, V43, P1060, DOI 10.1016/j.jhep.2005.06.008
   LEEVY CM, 1962, MEDICINE, V41, P249, DOI 10.1097/00005792-196209000-00003
   Millonig G, 2008, HEPATOLOGY, V48, P1718, DOI 10.1002/hep.22577
   Helmerhorst HJF, 2009, DIABETES, V58, P1776, DOI 10.2337/db08-1773
   Harrison SA, 2008, GUT, V57, P1441, DOI 10.1136/gut.2007.146019
   Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354
   HILDEN M, 1977, SCAND J GASTROENTERO, V12, P593
   Levitsky J, 2004, SEMIN LIVER DIS, V24, P233, DOI 10.1055/s-2004-832937
   Levy JR, 2004, HEPATOLOGY, V39, P608, DOI 10.1002/hep.20093
   Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Ratziu V, 2005, GASTROENTEROLOGY, V128, P1898, DOI 10.1053/j.gastro.2005.03.084
   Perseghin G, 2007, DIABETES CARE, V30, P683, DOI 10.2337/dc06-2032
   McPherson S, 2009, J HEPATOL, V51, P389, DOI 10.1016/j.jhep.2009.04.012
   Luca A, 1997, GASTROENTEROLOGY, V112, P1284, DOI 10.1016/S0016-5085(97)70142-2
   Bortolotti F, 2006, J CHROMATOGR B, V841, P96, DOI 10.1016/j.jchromb.2006.05.005
   Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120
   Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283
   NOMURA H, 1988, JPN J MED, V27, P142
   McLaughlin T, 2005, AM J CARDIOL, V96, P399, DOI 10.1016/j.amjcard.2005.03.085
   Capanni M, 2006, ALIMENT PHARM THERAP, V23, P1143, DOI 10.1111/j.1365-2036.2006.02885.x
   Zou CB, 2007, NAT MED, V13, P1078, DOI 10.1038/nm1625
   Mari A, 2001, DIABETES CARE, V24, P539, DOI 10.2337/diacare.24.3.539
   Yoneda M, 2008, DIGEST LIVER DIS, V40, P371, DOI 10.1016/j.dld.2007.10.019
   Schwimmer JB, 2009, GASTROENTEROLOGY, V136, P1585, DOI 10.1053/j.gastro.2009.01.050
   Brunt EM, 2009, HEPATOLOGY, V49, P809, DOI 10.1002/hep.22724
   Stickel F, 2003, ALIMENT PHARM THERAP, V18, P357, DOI 10.1046/j.0269-2813.2003.01660.x
   Weston SR, 2005, HEPATOLOGY, V41, P372, DOI 10.1002/hep.20554
   Feldstein AE, 2009, HEPATOLOGY, V50, P1072, DOI 10.1002/hep.23050
   Soderberg C, 2010, HEPATOLOGY, V51, P595, DOI 10.1002/hep.23314
   Cales P, 2009, J HEPATOL, V50, P165, DOI 10.1016/j.jhep.2008.07.035
   Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5
   Bedogni G, 2007, HEPATOLOGY, V46, P1387, DOI 10.1002/hep.21827
   Fehrenbach H, 2001, HEPATOLOGY, V34, P943, DOI 10.1053/jhep.2001.28788
   Moucari R, 2008, GASTROENTEROLOGY, V134, P416, DOI 10.1053/j.gastro.2007.11.010
   Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402
   Brunt EM, 2009, CLIN LIVER DIS, V13, P533, DOI 10.1016/j.cld.2009.07.008
   YERSIN B, 1995, ARCH INTERN MED, V155, P1907, DOI 10.1001/archinte.155.17.1907
   Poynard T, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-34
   Bellentani S, 2008, HEPATOLOGY, V47, P746, DOI 10.1002/hep.22009
   Tetri LH, 2008, AM J PHYSIOL-GASTR L, V295, pG987, DOI 10.1152/ajpgi.90272.2008
   Tanaka N, 2008, J CLIN GASTROENTEROL, V42, P413, DOI 10.1097/MCG.0b013e31815591aa
   Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540
   Marra F, 2009, HEPATOLOGY, V50, P957, DOI 10.1002/hep.23046
   Krasnoff JB, 2008, HEPATOLOGY, V47, P1158, DOI 10.1002/hep.22137
   Kim KM, 2007, J GASTROENTEROL, V42, P382, DOI 10.1007/s00535-007-2016-1
   Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022
   SORENSEN TIA, 1984, LANCET, V2, P241
   GROUND KEU, 1982, AVIAT SPACE ENVIR MD, V53, P14
   Bedogni G, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-33
   Bedogni G, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-98
   Bruno S, 2005, BRIT MED J, V330, P932, DOI 10.1136/bmj.38391.663287.E0
   Corrao G, 1997, J STUD ALCOHOL, V58, P486
   de Ledinghen V, 2006, J HEPATOL, V45, P592, DOI 10.1016/j.jhep.2006.05.008
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   Frith J, 2010, J HEPATOL, V52, P112, DOI 10.1016/j.jhep.2009.10.010
   HALSTED CH, 1999, CURR OPIN CLIN NUTR, V2, P345
   Lakshman M. Raj, 2004, Alcohol, V34, P45, DOI 10.1016/j.alcohol.2004.08.004
   Lieber Charles S, 2004, Curr Gastroenterol Rep, V6, P60, DOI 10.1007/s11894-004-0027-0
   MACSWEEN RN, 1973, J CLIN PATHOL, V26, P936, DOI 10.1136/jcp.26.12.936
   MENDENHA.CL, 1968, AM J DIG DIS, V13, P783, DOI 10.1007/BF02233094
   Mikines K J, 1992, Acta Physiol Scand Suppl, V609, P1
   Nadalin S, 2005, LIVER TRANSPLANT, V11, P980, DOI 10.1002/lt.20462
   Neuschwander-Tetri BA, 2009, CLIN LIVER DIS, V13, P649, DOI 10.1016/j.cld.2009.07.006
   O'Shea R. S, AM J GASTROENTEROL, V105, P33
   O'Shea R.S., AM J GASTROENTEROL, V105, P14
   Powell EE, 2005, HEPATOLOGY, V42, P5, DOI 10.1002/hep.20750
   Poynard Thierry, 2005, Comp Hepatol, V4, P10, DOI 10.1186/1476-5926-4-10
   Poynard T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003857
   Ratziu V, 2009, BIOMARK MED, V3, P353, DOI [10.2217/bmm.09.36, 10.2217/BMM.09.36]
   SAVOLAINEN V, 1995, J HEPATOL, V23, P524, DOI 10.1016/0168-8278(95)80057-3
   Schwinnner JB, 2005, HEPATOLOGY, V42, P641, DOI 10.1002/hep.20842
   St George Alexis, 2009, Hepatology, V50, P68, DOI 10.1002/hep.22940
   UCHIDA T, 1983, GASTROENTEROLOGY, V84, P683
   Wahrenberg H, 2005, BRIT MED J, V330, P1363, DOI 10.1136/bmj.38429.473310.AE
   WORNER TM, 1985, JAMA-J AM MED ASSOC, V254, P627, DOI 10.1001/jama.254.5.627
   Zelber-Sagil S, 2007, J HEPATOL, V47, P711, DOI 10.1016/j.jhep.2007.06.020
NR 156
TC 28
Z9 28
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0257-2753
J9 DIGEST DIS
JI Dig. Dis.
PY 2011
VL 29
IS 2
BP 202
EP 210
DI 10.1159/000323886
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 789FI
UT WOS:000292499500011
PM 21734385
ER

EF